

# EXHIBIT 1

**EXHIBIT 1**

**JOINT STATEMENT OF ADMITTED FACTS**

1. Masimo Corporation is organized and exists under the laws of the state of Delaware, and has a principal place of business at 52 Discovery, Irvine, California 92618.

2. Sound United is organized and exists under the laws of the state Delaware, and has a principal place of business at 5541 Fermi Court, Carlsbad, CA 92008.

3. Cercacor Laboratories, Inc., is organized and exists under the laws of the state of Delaware, and has a principal place of business at 15750 Alton Parkway, Irvine, California 92618.

4. Apple Inc. is organized and exists under the laws of the state of California, and has a principal place of business at One Apple Park Way, Cupertino, California, 95014.

5. Apple owns all right, title, and interest in each of the Asserted Utility Patents.<sup>1</sup>

6. Apple owns all title in each of the Asserted Design Patents.<sup>2</sup>

7. The differences between the Masimo W1 Original Design and the Masimo W1 Wave Design are not material to evaluating infringement or noninfringement of the '783, '491, '054, '352, and '483 Patents.

8. The '783 Patent was issued by the USPTO on April 21, 2020 and, for purposes of this litigation, its priority date is September 2, 2014.

9. The '491 Patent was issued by the USPTO on March 9, 2021 and, for purposes of this litigation, its priority date is September 2, 2014.

10. The '054 Patent was issued by the USPTO on April 27, 2021, and, for purposes of this litigation, its priority date is September 5, 2017.

---

<sup>1</sup>The Asserted Utility Patents are U.S. Patent Nos. 10,627,783 (the "'783 Patent"); 10,942,491 (the "'491 Patent"); 10,987,054 (the "'054 Patent"); 11,106,352 (the "'352 Patent"); and 11,474,483 (the "'483 Patent").

<sup>2</sup>The Asserted Design Patents are U.S. Patent Nos. D883,279 (the "D'279 Patent"); D947,842 (the "D'842 Patent"); D962,936 (the "D'936 Patent"); and D735,131 (the "D'131 Patent").

11. The '352 Patent was issued by the USPTO on August 31, 2021 and, for purposes of this litigation, its priority date is May 16, 2017.

12. The '483 Patent was issued by the USPTO on October 18, 2022 and, for purposes of this litigation, its priority date is September 2, 2014.

13. The D'279 Patent was issued by the USPTO on May 5, 2020 and, for purposes of this litigation, its priority date is July 27, 2018.

14. The D'842 Patent was issued by the USPTO on April 5, 2022.

15. The D'936 Patent was issued by the USPTO on September 6, 2022.

16. The D'131 Patent was issued by the USPTO on July 28, 2015 and, for purposes of this litigation, its priority date is July 28, 2015.

17. Masimo made, used, offered to sell, and sold the Masimo W1 Original Design in the United States.

18. Masimo made, used, offered to sell, and sold the Masimo W1 Wave Design in the United States.

19. Masimo made, used, and/or offered to sell the Masimo Freedom Original Design in the United States.

20. Masimo made, used, and/or offered to sell the Masimo Freedom Wave Design in the United States.

21. Masimo made, used, offered to sell, and/or sold the original Masimo Charger in the United States.

22. Masimo made, used, and/or offered to sell the Masimo Health Module in the United States.



# **EXHIBIT 2**

**EXHIBIT 2**

**APPLE'S STATEMENT OF CONTESTED FACTS**

1. Whether Apple owns all right, title, and interest in each of U.S. Patent Nos. D883,279 (the “D’279 Patent”); D947,842 (the “D’842 Patent”); D962,936 (the “D’936 Patent”); and D735,131 (the “D’131 Patent”).<sup>1</sup>

2. Whether Apple owns all rights to recover damages for past, present, and future infringement of Apple’s Utility Patents and Apple’s Design Patents.

3. Whether Defendants directly infringed each claim of Apple’s Design Patents, literally and/or under the doctrine of equivalents.

4. Whether Defendants directly infringed each of the asserted claims of Apple’s Utility Patents, literally and/or under the doctrine of equivalents.

5. Whether Defendants’ infringement of any asserted claim of any Apple Utility Patent or Apple Design Patent was willful.

6. Whether any asserted claim of any of Apple’s Utility Patents is invalid.

7. Whether any asserted claim of any of Apple’s Design Patents is invalid.<sup>2</sup>

8. If Defendants infringed any asserted claim of any Apple Utility Patent that is not invalid, what damages should be awarded to Apple for Defendants’ infringement.

9. If Defendants infringed any asserted claim of any Apple Design Patent that is not invalid, what damages should be awarded to Apple for Defendants’ infringement.

10. If Defendants infringed any asserted claim of an Apple Patent that is not invalid, whether Defendants’ infringement has caused and will continue to cause Apple irreparable harm;

---

<sup>1</sup> Masimo refused to admit that Apple owns all right, title, and interest in the Asserted Patents in the Parties’ Joint Statement of Admitted Facts (Ex. 1). Apple’s ownership of the Asserted Patents, however, is not properly disputed. Masimo has never raised an ownership defense or previously disputed ownership, and has no basis to dispute ownership now.

<sup>2</sup> Apple reserves the right to object to any or all of Masimo’s functionality arguments to the extent the same arguments were raised and are disposed of through claim construction.

whether remedies available at law are inadequate to compensate for the injury caused by Defendants' infringement; whether, considering the balance of hardships, a remedy in equity is warranted; and whether the public interest would be served by a permanent injunction.

11. Whether this case is exceptional under 35 U.S.C. § 285, and, if so, whether Plaintiff or Defendants are entitled to attorneys' fees or costs.

12. Whether all documents with a PININFARINA production stamp in this case are authentic business records of Pininfarina of America.<sup>3</sup>

---

<sup>3</sup> During the November 17, 2023 deposition of Claudio Da Soller, counsel for Pininfarina stipulated to the authenticity of documents bearing PININFARINA Bates stamps. Counsel for Masimo stated they had no objection to this stipulation. (23:13-24.)

# **EXHIBIT 3**

**EXHIBIT 3**

**MASIMO'S STATEMENT OF CONTESTED FACTS**

1. Whether Masimo directly infringed each of Apple's Design Patents.
2. Whether Masimo directly infringed each of the asserted claims of Apple's Utility Patents, literally and/or, for some claims, under the doctrine of equivalents.
3. Whether any asserted claim of any of Apple's Utility Patents is invalid.
4. Whether any of Apple's Design Patents is invalid.
5. Whether Apple committed fraud in procuring any of Apple's Design Patents.

# **EXHIBIT 4**



**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

APPLE INC.,

Plaintiff,

v.

MASIMO CORPORATION AND SOUND  
UNITED, LLC,

Defendants.

---

MASIMO CORPORATION AND CERCACOR  
LABORATORIES, INC.,

Counterclaim-Plaintiffs,

v.

APPLE INC.,

Counterclaim-Defendant.

---

C.A. No. 1:22-cv-1377-JLH

C.A. No. 1:22-cv-1378-JLH

**HIGHLY CONFIDENTIAL – ATTORNEYS  
EYES’ ONLY**

**FILED UNDER SEAL**

**APPLE’S STATEMENT OF ISSUES OF LAW**

**I. APPLE’S STATEMENT OF ISSUES OF LAW**

1. This Statement is based on Apple’s current understanding of the arguments Masimo is likely to advance in this case, based upon the pleadings and discovery in the action to date. To the extent that Masimo attempts to introduce different or additional facts or legal theories, Apple reserves the right to rely on other legal authorities to counter those facts or theories. Apple reserves the right to rely on additional authority.

2. Masimo’s Statement of Issues of Law (Exhibit 5) advances procedural positions and other issues that are not issues of law and/or not properly raised here. The fact that Apple may not respond to Masimo’s various positions here is not waiver or indication that Apple agrees with Masimo. Apple reserves the right to further address Masimo’s positions, including by relying on additional authority, at a later time.

**A. Invalidity Under 35 U.S.C. § 101**

3. Whether Masimo has shown that claims 1, 6, 9, 14, 17, and 22 of the ’352 Patent are directed to patent ineligible subject matter under 35 U.S.C. § 101.

Relevant Authority: In the first step of the *Alice* inquiry, the court must “determine whether the claims at issue are directed to a patent-ineligible concept.” *Alice Corp. Pty. v. CLS Bank Int’l*, 134 S. Ct. 2347, 2355 (2014). This inquiry does not ask whether the claims simply involve a patent-eligible concept, as “all inventions at some level embody, use, reflect, rest upon, or apply laws of nature, natural phenomena, or abstract ideas.” *Mayo Collaborative Servs. v. Prometheus Lab’ys, Inc.*, 132 S. Ct. 1289, 1293, (2012). Rather, the Step One inquiry looks at the “focus of the claimed advance over the prior art” to determine if the claim’s “character as a whole” is directed to excluded subject matter. *Affinity Labs of Texas, LLC v. DIRECTV, LLC*, 838 F.3d 1253, 1257 (Fed. Cir. 2016).

Step Two of the *Alice* inquiry asks “whether the additional elements ‘transform the nature of the claim’ into a patent eligible application.” *Alice Corp.*, 134 S. Ct. at 2355. This inquiry requires a determination of “whether a claim element or combination of elements is well-understood, routine and conventional to a skilled artisan in the relevant field[, which] is a question of fact.” *Berkheimer v. HP Inc.*, 881 F.3d 1360, 1368 (Fed. Cir. 2018). A particular technology is not well-understood, routine, and conventional merely because it was disclosed in prior art. *Id.* at 1369. “[A]n inventive concept can be found in the non-conventional and non-generic arrangement of known, conventional pieces.” *Bascom Glob. Internet Servs., Inc. v. AT&T Mobility LLC*, 827 F.3d 1341, 1350 (Fed. Cir. 2016). Claims that “overcome[] a problem specifically arising in a particular technological realm . . . may likely contain an inventive concept.” *ART+COM Innovationpool GmbH v. Google Inc.*, 183 F. Supp. 3d 552 (D. Del. 2016).

**B. Indefiniteness Under 35 U.S.C. § 112**

4. Whether the D’936, D’842, D’279, and D’131 Patents are indefinite under 35 U.S.C. § 112.

Relevant Authority: “[A] design patent is indefinite under § 112 if one skilled in the art, viewing the design as would an ordinary observer, would not understand the scope of the design with reasonable certainty based on the claim and visual disclosure.” *In re Maatita*, 900 F.3d 1369, 1377 (Fed. Cir. 2018). Design patent drawings are not materially inconsistent merely if some features are obscured in one view but are visible in other views. *Deckers Outdoor Corp. v. Romeo & Juliette, Inc.*, 2016 WL 7017219, at \*4 (C.D. Cal. Dec. 1, 2016); *see also Antonious v. Spalding & Evenflo Companies, Inc.*, 217 F.3d 849 (Fed. Cir. 1999) (finding a design not indefinite where some figures provided clear views and alleged inconsistencies could be blamed on a shift in perspective).

**C. Inequitable Conduct**

5. Whether the Asserted Design Patents are unenforceable because of inequitable conduct.

Relevant Authority: Inequitable conduct by omission requires establishing by clear and convincing evidence that one with a duty of candor (1) knew of information material to patentability, (2) knew that the information was material, and (3) deliberately withheld that information from the PTO with specific intent to deceive. *Therasense, Inc. v. Becton, Dickinson & Co.*, 649 F.3d 1276, 1290 (Fed. Cir. 2011). To meet the clear and convincing evidence standard, the specific intent to deceive must be “the single most reasonable inference able to be drawn from the evidence” and the evidence “must be sufficient to require a finding of deceitful intent in the light of all the circumstances.” *Id.* (emphasis in original). A “should have known” standard does not satisfy this intent requirement. *Id.*

“When an alleged omitted co-inventor does not claim to be such, it can hardly be inequitable conduct not to identify that person to the PTO as an inventor.” *Pro-Mold & Tool Co. v. Great Lakes Plastics, Inc.*, 75 F.3d 1568, 1576 (Fed. Cir. 1996). *DeCurtis LLC v. Carnival Corp.*, 2023 WL 2071915, at \*8 (S.D. Fla. Feb. 8, 2023) (no inequitable conduct where patentee omitted an individual “because it was actually believed he was not, in fact, an inventor,” and “without any evidence in the record showing that these inventors were lying, the most that can be inferred is a mistake”); *Mformation Techs., Inc. v. Rsch. in Motion Ltd.*, 830 F. Supp. 2d 815, 829-830 (N.D. Cal. 2011) (no inequitable conduct where the allegedly omitted inventor never indicated that he believed he should be named).

Inequitable conduct requires specificity and timely-pled notice. *Exergen Corp. v. Wal-Mart Stores, Inc.*, 575 F.3d 1312, 1326–27 (Fed. Cir. 2009) (“A pleading that simply avers the substantive elements of inequitable conduct, without setting forth the particularized factual bases

for the allegation, does not satisfy Rule 9(b).”); *see also California Inst. of Tech. v. Broadcom Ltd.*, 2019 WL 8807748, at \*3 (C.D. Cal. July 1, 2019), *affd*, 25 F.4th 976 (Fed. Cir. 2022) (finding “it was not appropriate for Defendants to bypass their pleading obligations under Rule 9(b) by incorporating new inequitable conduct theories into an interrogatory response served on the fact discovery deadline”). Among other requirements, a pleading of inequitable conduct must sufficiently “identify the ‘who’ of the material omissions and misrepresentation.” *Exergen*, 575 F.3d at 1329 (emphasis added). To plead the specific “who,” the allegations must “name the specific individual” who committed the alleged inequitable conduct. *Id.*

#### **D. Doctrine of Equivalents**

6. Whether legal limitations on the Doctrine of Equivalents preclude a finding of infringement under that doctrine for Apple’s utility-patent claims.

Relevant Authority: The doctrine of equivalents allows patent holders to claim infringement even if an accused product does not meet every claim limitation exactly. “Under this doctrine, a product or process that does not literally infringe upon the express terms of a patent claim may nonetheless be found to infringe if there is ‘equivalence’ between the elements of the accused product or process and the claimed elements of the patented invention.” *Warner-Jenkinson Co., Inc. v. Hilton Davis Chemical Co.*, 520 U.S. 17, 21, 29 (1997). The doctrine of equivalents allows the patentee to claim those insubstantial alterations that were not captured in drafting the original patent claim but which could be created through trivial changes. *Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co.*, 535 U.S. 722, 733 (2002). “The doctrine of equivalents prevents an accused infringer from avoiding infringement by changing only minor or insubstantial details of a claimed invention while retaining their essential functionality.” *Sage Products, Inc. v. Devon Industries, Inc.*, 126 F.3d 1420, 1424 (Fed. Cir. 1997).

For there to be infringement under the doctrine of equivalents, the accused product or process must embody every limitation of a claim, either literally or by an equivalent. *Warner-Jenkinson*, 520 U.S. at 41. An element is equivalent if the differences between the element and the claim limitation are “insubstantial.” *Zelinski v. Brunswick Corp.*, 185 F.3d 1311, 1316 (Fed. Cir. 1999). One test used to determine “insubstantiality” is whether the element performs substantially the same function in substantially the same way to obtain substantially the same result as the claim limitation. *See Graver Tank & Mfg. Co. v. Linde Air Products Co.*, 339 U.S. 605, 608 (1950). This test is commonly referred to as the “function-way-result” test. The doctrine of equivalents function-way-result test “requires the evidence to establish what the function, way, and result of both the claimed device and the accused device are, and why those functions, ways, and results are substantially the same.” *Malta v. Schulmerich Carillons, Inc.*, 952 F.2d 1320, 1327 n.5 (Fed. Cir. 1991) (emphasis omitted).

Courts will not consider prosecution history estoppel and the doctrine of equivalents until after the claims have been properly interpreted and no literal infringement has been found. *Southwall Techs., Inc. v. Cardinal IG Co.*, 54 F.3d 1570, 1578 (Fed. Cir. 1995) (citation omitted). “There is a clear line of distinction between using the contents of the prosecution history to reach an understanding about disputed claim language and the doctrine of prosecution history estoppel which ‘estops’ or limits later expansion of the protection accorded by the claim to the patent owner under the doctrine of equivalents when the claims have been purposefully amended or distinguished over relevant prior art to give up scope.” *Biodex Corp. v. Loredan Biomedical, Inc.*, 946 F.2d 850, 862 (Fed. Cir. 1991) (citation omitted). “The limit on the range of equivalents that may be accorded a claim due to prosecution history estoppel is simply irrelevant to the interpretation of those claims.” *Southwall Techs., Inc.*, 54 F.3d at 1578.

Prosecution history estoppel argument-based disavowals will only be found if they constitute clear and unmistakable surrenders of subject matter. *Cordis Corp. v. Medtronic Ave, Inc.*, 511 F.3d 1157, 1177 (Fed. Cir. 2008). “The party seeking to invoke prosecution history disclaimer bears the burden of proving the existence of a ‘clear and unmistakable’ disclaimer that would have been evident to one skilled in the art.” *Trivascular, Inc. v. Samuels*, 812 F.3d 1056, 1063–64 (Fed. Cir. 2016).

The claim-vitiation rule is best understood as part of the initial determination whether there is a substantial difference between an element of the accused device and the patent claim at issue. *E.g., Nystrom v. Trex Co.*, 580 F.3d 1281, 1287 (Fed. Cir. 2009) (Rader, J., expressing additional views). “[T]he rule [of claim vitiation] is simply a circular application of the doctrine of equivalents.” *Id.*, *accord, e.g., DePuy Spine*, 469 F.3d at 1018-19 (“A holding that the doctrine of equivalents cannot be applied to an accused device because it ‘vitiates’ a claim is nothing more than a conclusion that the evidence is such that no reasonable jury could conclude that an element of an accused device is equivalent to an element called for in the claim.”). A finding of insubstantial difference to show equivalency obviates any further vitiation analysis because the wholly insignificant equivalent, by definition, would not vitiate the claim, whereas a substantial difference renders vitiation unnecessary. *Id.* “Vitiation is not an exception or threshold determination that forecloses resort to the doctrine of equivalents, but is instead a legal conclusion of a lack of equivalence based on the evidence presented and the theory of equivalence asserted.” *Bio-Rad Lab’ys, Inc. v. 10X Genomics Inc.*, 967 F.3d 1353, 1367 (Fed. Cir. 2020) (cleaned up).

A literal failure to meet a claim limitation does not necessarily constitute a “specific exclusion.” *See Ethicon Endo-Surgery, Inc. v. U.S. Surgical Corp.*, 149 F.3d 1309, 1317

(Fed.Cir.1998). Such subject matter is not necessarily “specifically excluded” from coverage under the doctrine unless its inclusion is somehow inconsistent with the language of the claim. *Id.*

#### **E. Enhanced Damages**

7. Whether Apple should be awarded enhanced damages.

Relevant Authority: Section 289 states that “[n]othing in this section shall prevent, lessen, or impeach any other remedy which an owner of an infringed patent has under the provisions of this title.” 35 U.S.C. § 289.

This Court may “increase the damages up to three times” under 35 U.S.C. § 284. Enhancement is a flexible tool to “punish the full range of culpable behavior,” particularly in cases involving conduct that is “willful, wanton, malicious, bad-faith, deliberate, consciously wrongful, flagrant, or—indeed—characteristic of a pirate.” *Halo Elecs., Inc. v. Pulse Elecs., Inc.*, 579 U.S. 93, 103-04, 106 (2016). “The subjective willfulness of a patent infringer, intentional or knowing, may warrant enhanced damages, without regard to whether his infringement was objectively reckless.” *Id.* at 105. Enhanced damages are “designed as a ‘punitive’ or ‘vindictive’ sanction for egregious infringement behavior.” *Id.* at 103.

After *Halo*, the Federal Circuit continues to encourage district courts to use the *Read* factors to explain why they are awarding enhancement. *See e.g., WCM Indus., Inc. v. IPS Corp. (WCM II)*, 809 F.App’x 957, 959-60 (Fed. Cir. 2020) (affirming district court’s enhancement order that applied *Read* factors, after prior vacatur and remand of enhancement order that did not completely analyze the *Read* factors). The nine *Read* factors are: (1) whether the infringer deliberately copied the ideas of another; (2) whether the infringer investigated the scope of the patent and formed a good-faith belief that it was invalid or that it was not infringed; (3) the infringer’s behavior as a party to the litigation; (4) the defendant’s size and financial condition; (5) the closeness of the case; (6) the duration of the defendant’s misconduct; (7) remedial action by



the defendant; (8) the defendant's motivation for harm; and (9) whether the defendant attempted to conceal its misconduct. *Read Corp. v. Portec, Inc.*, 970 F.2d 816, 827 (Fed. Cir. 1992).

**F. Attorney's Fees**

8. Whether any party should be awarded attorney's fees under 35 U.S.C. § 285.

Relevant Authority: Section 285 of the Patent Act authorizes a district court to award attorney's fees in patent litigation. It provides, in its entirety, that "[t]he court in exceptional cases may award reasonable attorney fees to the prevailing party." 35 U.S.C. § 285. "[A]n 'exceptional' case is simply one that stands out from others with respect to the substantive strength of a party's litigating position (considering both the governing law and the facts of the case) or the unreasonable manner in which the case was litigated." *Octane Fitness, LLC v. ICON Health & Fitness, Inc.*, 572 U.S. 545, 554 (2014). Whether a case is "exceptional" depends on the totality of the circumstances in that individual case. *Id.* However, only limited circumstances warrant a finding of exceptionality in a patent case: "inequitable conduct before the PTO; litigation misconduct; vexatious, unjustified, and otherwise bad faith litigation; [or] a frivolous suit or willful infringement." *Wedgetail Ltd. v. Huddleston Deluxe, Inc.*, 576 F.3d 1302, 1304–05 (Fed. Cir. 2009). Even so, a finding of the circumstances above does not always make a case exceptional. *See, e.g., Argus Chemical Corp. v. Fibre Glass-Evercoat Co., Inc.*, 812 F.2d 1381, 1387 (Fed. Cir. 1987) (J. Nies, concurring) (denying attorney's fees to accused infringer even though patent was found unenforceable due to inequitable conduct where the district court found that the patentee brought the litigation in good faith and believed that its claims were legitimate). The Federal Circuit has permitted a finding of exceptionality other than the circumstances listed above "*only* if both (1) the litigation is brought in subjective bad faith, and (2) the litigation is objectively baseless." *Id.*

**G. Injunctive Relief**

9. Whether Apple should be granted injunctive relief.

Relevant Authority: A court may enjoin ongoing patent infringement after considering traditional principles of equity. *See* 35 U.S.C. § 283. “A party seeking a permanent injunction must demonstrate: (1) that it has suffered an irreparable injury; (2) that remedies available at law, such as monetary damages, are inadequate to compensate for that injury; (3) that, considering the balance of hardships between the plaintiff and defendant, a remedy in equity is warranted; and (4) that the public interest would not be disserved by a permanent injunction.” *Apple Inc. v. Samsung Elecs. Co.*, 809 F.3d 633, 639 (Fed. Cir. 2015) (citing *eBay Inc. v. MercExchange, L.L.C.*, 547 U.S. 388, 391 (2006)).

# **EXHIBIT 5**

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

APPLE INC.,

Plaintiff,

v.

MASIMO CORPORATION AND SOUND  
UNITED, LLC,

Defendants.

---

MASIMO CORPORATION AND CERCACOR  
LABORATORIES, INC.,

Counterclaim-Plaintiffs,

v.

APPLE INC.,

Counterclaim-Defendant.

---

C.A. No. 1:22-cv-1377-JLH

C.A. No. 1:22-cv-1378-JLH

**HIGHLY CONFIDENTIAL – ATTORNEYS  
EYES’ ONLY**

**FILED UNDER SEAL**

**MASIMO’S STATEMENT OF ISSUES OF LAW**

Pursuant to Local Rule 16.3(c)(5), Masimo submits the following Statement of Issues of Law. This Statement is based on Masimo's current understanding of the arguments Plaintiff and Counterclaim Defendant Apple is likely to advance in this case, based upon the pleadings and discovery in the action to date. To the extent that Apple attempts to introduce different or additional facts or legal theories, Masimo reserves the right to rely on other legal authorities to counter those facts or theories.

If any issue of law identified below is more properly considered an issue of fact, then such statement should be considered part of the parties' Issues of Fact in Exhibit \*\*\*. Masimo reserves the right to rely on additional authority.

**A. Invalidity Under 35 U.S.C. § 101**

1. Whether Masimo has shown that claims 1, 6, 9, 14, 17, and 22 of the '352 Patent are directed to patent ineligible subject matter under 35 U.S.C. § 101.

Relevant Authority: Patent eligibility under § 101 is a question of law. *OIP Techs., Inc. v. Amazon.com, Inc.*, 788 F.3d 1359, 1362 (Fed. Cir. 2015). The Supreme Court's two-step *Alice* framework governs whether computer-based patent claims are impermissibly abstract under § 101. *Alice Corp. v. CLS Bank Int'l*, 573 U.S. 208, 217-227 (2014). At step one, the Court determines whether claims are directed to an abstract idea. *Id.* at 217-18. To determine whether a claim is "directed to" an abstract idea, courts "look at the 'focus of the claimed advance over the prior art.'" *Hawk Tech. Sys. v. Castle Retail, LLC*, 60 F.4th 1349, 1356 (Fed. Cir. 2023). Claims that focus on "organizing information" and "displaying the information" on user interfaces are abstract. *E.g., Interval Licensing LLC v. AOL, Inc.*, 896 F.3d 1335, 1345 (Fed. Cir. 2018). Such claims are

abstract even when the information is “limited to particular content.” *Elec. Power Grp., LLC v. Alstom S.A.*, 830 F.3d 1350, 1353 (Fed. Cir. 2016).

At step two, the Court determines whether other claim elements beyond the abstract idea add something “inventive” that transforms the idea “into a patent-eligible application.” *Alice*, 573 U.S. at 217-22. Conventional computer functionality is not inventive. *Id.*

**B. Indefiniteness Under 35 U.S.C. § 112**

2. Whether the D’936, D’842, D’279, and D’131 Patents are indefinite under 35 U.S.C. § 112.

Relevant Authority: “[T]he standard for indefiniteness is connected to the standard for infringement,” and “one skilled in the art would look to the perspective of the ordinary observer since that is the perspective from which infringement is judged.” *In re Maatita*, 900 F.3d 1369, 1376 (Fed. Cir. 2018). A design patent is indefinite “if one skilled in the art, viewing the design as would an ordinary observer, would not understand the scope of the design with reasonable certainty based on the claim and visual disclosure.” *Id.* at 1377. In particular, “[a] visual disclosure may be inadequate—and its associated claim indefinite—if it includes multiple, internally inconsistent drawings.” *Id.* at 1375; *Masonite Corp. v. Craftmaster Mfg., Inc.*, 2011 WL 13327344, at \*3-\*7 (N.D. Ill. Apr. 28, 2011) (design patent indefinite because “[t]he drawings are plainly irreconcilably inconsistent”).

**C. Inequitable Conduct**

3. Whether the Asserted Design Patents are unenforceable because of inequitable conduct.

Relevant Authority: “Inequitable conduct is a defense to patent infringement that, if proven, renders the asserted patent unenforceable.” *Belcher Pharms., LLC v. Hospira, Inc.*, 11 F.4th 1345, 1352 (Fed. Cir. 2021) (citing *Therasense, Inc. v. Becton, Dickinson & Co.*, 649 F.3d

1276, 1285 (Fed. Cir. 2011) (en banc)). A finding of inequitable conduct as to “any single claim renders the entire patent unenforceable” and may “render unenforceable other related patents and applications in the same technology family.” *Therasense*, 649 F.3d at 1288 (citations omitted).

“Patent applicants are required to prosecute patent applications with candor, good faith, and honesty.” *Semiconductor Energy Lab. Co. v. Samsung Elecs. Co.*, 204 F.3d 1368, 1373 (Fed. Cir. 2000) (citing *Molins PLC v. Textron, Inc.*, 48 F.3d 1172, 1178 (Fed. Cir. 1995)); *see also Bruno Indep. Living Aids, Inc. v. Acorn Mobility Servs., Ltd.*, 394 F.3d 1348, 1351 (Fed. Cir. 2005) (“Patent applicants owe a ‘duty of candor and good faith’ to the PTO.” (quoting 37 C.F.R. § 1.56)). “A breach of this duty may constitute inequitable conduct . . . .” *Bruno*, 394 F.3d at 1351; *see also Ferring B.V. v. Barr Labs., Inc.*, 437 F.3d 1181, 1186 (Fed. Cir. 2006) (“Inequitable conduct occurs when a patentee breaches his or her duty to the PTO of candor, good faith, and honesty.” (internal quotations and citations omitted)).

“The duty of candor includes a duty to disclose to the PTO all information known to each individual that is material to the issue of patentability.” *Avid Identification Sys., Inc. v. Crystal Import Corp.*, 603 F.3d 967, 973 (Fed. Cir. 2010) (citing 37 C.F.R. § 1.56); *Brasseler, U.S.A. I, L.P. v. Stryker Sales Corp.*, 267 F.3d 1370, 1383 (Fed. Cir. 2001) (“Once an attorney, or an applicant has notice that information exists that appears material and questionable, that person cannot ignore that notice in an effort to avoid his or her duty to disclose.”); *Belcher*, 450 F. Supp. 3d at 548 (“[The duty of candor] includes the duty to inform the Patent Office of any information material to patentability.”). The duty of candor also includes a duty to refrain from submitting “unmistakably false” affidavits to the Patent Office or committing other “affirmative acts of egregious misconduct[.]” *Therasense, Inc. v. Becton, Dickinson & Co.*, 649 F.3d 1276, 1293 (Fed. Cir. 2011).

Information regarding functionality is material. If a claimed design “is essential to the use of an article” or is “‘dictated by’ the use or purpose of the article,” the design is “primarily functional rather than ornamental” and invalid for functionality or lack of ornamentality. *Ethicon Endo-Surgery, Inc. v. Covidien, Inc.*, 796 F.3d 1312, 1328 (Fed. Cir. 2015). The Patent Office instructs examiners to reject design patent applications under 35 U.S.C. § 171 for lack of ornamentality. MPEP § 1504.01(c). The Patent Office identifies a related utility application as a specific “[e]xample[] of proper evidentiary basis for a rejection under 35 U.S.C. 171 that a claim is lacking in ornamentality.” MPEP § 1504.01(c)(II).

Information regarding inventorship is also material. *See, e.g., Frank’s Casing Crew & Rental Tools, Inc. v. PMR Techs., Inc.*, 292 F.3d 1363, 1376 (Fed. Cir. 2002) (affirming finding of inequitable conduct where the named inventors failed to disclose the omitted inventor’s involvement in the invention); *PerSeptive Biosystems, Inc. v. Pharmacia Biotech, Inc.*, 225 F.3d 1315, 1319-21 (Fed. Cir. 2000) (affirming finding of inequitable conduct where the named inventors misrepresented the relationship between themselves and omitted inventors for the purpose of concealing the issue of inventorship).

“Because direct evidence of deceptive intent is rare, a district court may infer intent from indirect and circumstantial evidence.” *Therasense*, 649 F.3d at 1290; *Paragon Podiatry Lab., Inc. v. KLM Labs., Inc.*, 984 F.2d 1182, 1189-90 (Fed. Cir. 1993) (“However, ‘smoking gun’ evidence is not required in order to establish an intent to deceive. Rather, this element of inequitable conduct, must generally be inferred from the facts and circumstances surrounding the applicant’s overall conduct.” (citations omitted)).

In evaluating intent, it is improper to consider “individual acts of misconduct in isolation” without addressing the collective weight of the evidence regarding each person's misconduct as a



whole.” *Luv n’ Care, Ltd. v. Laurain*, 98 F.4th 1081, 1098 (Fed. Cir. 2024). “Acts which are not ‘per se unreasonable when considered in isolation’ may still demonstrate ‘repeated attempts to avoid playing fair and square with the patent system’ and, collectively, support a finding of deceptive intent.” *Id.* (quoting *Nilssen v. Osram Sylvania, Inc.*, 504 F.3d 1223, 1235 (Fed. Cir. 2007)). “When a person having a duty of candor and good faith has engaged in serial misconduct during the prosecution of the same or related patents, it is not enough for a court to consider each individual act of misconduct without also considering the collective whole.” *Id.* “Because an intent to deceive the PTO can be inferred from a person’s ‘pattern of lack of candor,’ a district court must consider the person’s multiple acts of misconduct ‘[i]n the aggregate.’” *Id.* (quoting *Apotex Inc. v. UCB, Inc.*, 763 F.3d 1354, 1362 (Fed. Cir. 2014)). In particular, “a conscious choice to misrepresent” facts to the Patent Office should not be discounted “as merely gross negligence.” *Id.* at 1099.

Under *Beacon Theatres*, “when legal claims involve factual issues that are ‘common with those upon which [the] claim to equitable relief is based, the legal claims involved in the action must be determined prior to any final court determination of [the] equitable claims.’” *Shum v. Intel Corp.*, 499 F.3d 1272, 1276 (Fed. Cir. 2007); see *Beacon Theatres, Inc. v. Westover*, 359 U.S. 500, 510–511 (1959). Thus, the Court may not resolve “an equitable claim (the inequitable conduct defenses) prior to a legal claim (the *Walker Process* counterclaims)” without violating the Seventh Amendment. See *Schering Corp. v. Mylan Pharms., Inc.*, 2010 WL 11474547 (D.N.J. June 10, 2010); see also *Celgene Corp. v. Barr Labs., Inc.*, 2008 WL 2447354 (D.N.J. June 13, 2008). Because the fraud element of Masimo’s *Walker Process* claim overlaps with Masimo’s inequitable conduct defense, the jury must decide the fraud element of Masimo’s *Walker Process* claim before the Court decides inequitable conduct. The Court’s decision on inequitable conduct

must be consistent with the jury's decision on the fraud element of Masimo's *Walker Process* claim.

**D. Doctrine of Equivalents**

4. Whether the following legal limitations preclude a finding of infringement under the doctrine of equivalents of the following Apple utility-patent claims:

a. Prosecution History Estoppel

i. Claims 1-4, 8, 11, 12, and 14 of the '257 Patent

b. Vitiating

i. Claims 1-4, 8, 11, 12, and 14 of the '257 Patent

ii. Claims 6, 9, 10, 12, and 14-17 of the '783 Patent

iii. Claims 7, 9, 10, 11, and 13 (for the Masimo Freedom) and 17 (for the Masimo W1 and Freedom) of the '491 Patent

c. Specific Exclusion

i. Claims 1-4, 8, 11, 12, and 14 of the '257 Patent

ii. Claims 9, 10, 12, and 14-17 of the '783 Patent

iii. Claims 7, 9, 10, 11, and 13 (for the Masimo Freedom) and 17 (for the Masimo W1 and Freedom) of the '491 Patent

Relevant Authority: The Court must determine whether legal limitations bar application of the doctrine of equivalents for a claim limitation. *Warner-Jenkinson Co. v. Hilton Davis Chem. Co.*, 520 U.S. 17, 39, 117 S. Ct. 1040, 1053, 137 L. Ed. 2d 146 (1997). Prosecution history estoppel is one such limitation. *Bio-Rad Labs., Inc. v. 10X Genomics Inc.*, 967 F.3d 1353, 1364 (Fed. Cir. 2020). Prosecution history estoppel arises when a patent applicant narrows the scope of his claims during prosecution for a reason substantially relating to patentability. *See generally Festo Corp.*

*v. Shoketsu Kinzoku Kogyo Kabushiki Co.*, 344 F.3d 1359, 1366–67 (Fed. Cir. 2003) (*en banc*). A narrowing amendment is presumed to be a surrender of all equivalents within the territory between the original claim and the amended claim. *Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co.*, 535 U.S. 722, 740 (2002). This presumption can be overcome if the patentee can show that one of the following “exceptions” to prosecution history estoppel applies: (1) the rationale underlying the amendment bears no more than a tangential relation to the equivalent in question; (2) the equivalent was unforeseeable at the time of the application; or (3) there was some other reason suggesting that the patentee could not reasonably be expected to have described the equivalent. *Id.* at 740–41.

Another limitation on the doctrine of equivalents is claim vitiation. *Bio-Rad Labs.*, 967 F.3d at 1366. Vitiation is a legal conclusion of a lack of equivalence based on the evidence presented and the theory of equivalence asserted. *Cadence Pharms. Inc. v. Exela PharmSci Inc.*, 780 F.3d 1364, 1371 (Fed. Cir. 2015). A court should find vitiation when the evidence is such that no reasonable jury could conclude that an element of an accused device is equivalent to an element called for in the claim, or that the theory of equivalence to support the conclusion of infringement otherwise lacks legal sufficiency. *DePuy Spine, Inc. v. Medtronic Sofamor Danek, Inc.*, 469 F.3d 1005, 1018–19 (Fed. Cir. 2006).

Another limitation on the doctrine of equivalents is that a patentee cannot invoke the doctrine “to embrace a structure that was specifically excluded from the claims.” *SciMed Life Sys., Inc. v. Advanced Cardiovascular Sys., Inc.*, 242 F.3d 1337, 1345 (Fed. Cir. 2001). A “particular structure can be deemed outside the reach of the doctrine of equivalents because that structure is clearly excluded from the claims whether the exclusion is express or implied.” *Id.* “By defining the claim in a way that clearly excluded certain subject matter, the patent implicitly disclaimed the

subject matter that was excluded and thereby barred the patentee from asserting infringement under the doctrine of equivalents.” *Id.* at 1346.

### **E. Enhanced Damages**

5. Whether Apple should be awarded enhanced damages.<sup>1</sup>

Relevant Authority: A monetary recovery under Section 289, in contrast to Section 284, does not constitute “damages” that may be enhanced. *Braun Inc. v. Dynamics Corp. of Am.*, 975 F.2d 815, 823-24 (Fed. Cir. 1992); *Catalina Lighting, Inc. v. Lamps Plus, Inc.*, 295 F. 3d 1277, 1291 (Fed. Cir. 2002) (“Section 289, however, has no provision for enhanced damages”).

Damages under Section 284 may be enhanced due to “willful misconduct,” but such enhanced damages are “generally reserved for egregious cases of culpable behavior,” for example, “the ‘wanton and malicious pirate’ who intentionally infringes another’s patent—with no doubts about its validity or any notion of a defense—for no purpose other than to steal the patentee’s business.” *Halo Elec., Inc. v. Pulse Elecs., Inc.*, 579 U.S. 93, 104 (2016). The question for the Court to consider when deciding whether to enhance damages is whether the circumstances of the case present an “egregious case[] of culpable behavior.” *See Halo*, 589 at 104; *see also Trustees of Boston Univ. v. Everlight Elecs. Co.*, 212 F. Supp. 3d 254, 257 (D. Mass. 2016) (“[T]he touchstone for awarding enhanced damages after *Halo* is egregiousness.”); *Sociedad Espanola de Electromedicina y Calidad, S.A. v. Blue Ridge X-Ray Co.*, 226 F. Supp. 3d 520, 531 (W.D.N.C. 2016) (“enhanced damages are designed to punish ‘egregious infringement behavior’ and should not be imposed in the run-of-the-mill case”).

---

<sup>1</sup> Enhanced damages are not available for any monetary award under 35 U.S.C. § 289. And as explained in Masimo’s Motion *in limine* No. 1, Apple cannot seek damages under 35 U.S.C. § 284. Nevertheless, Apple included this issue in its portion of the Pretrial Conference Order. Masimo therefore addresses the issue here.

**F. Attorney's Fees**

6. Whether any party should be awarded attorney's fees under 35 U.S.C. § 285.

Relevant Authority: Section 285 provides that “[t]he court in exceptional cases may award reasonable attorney fees to the prevailing party.” An “‘exceptional’ case is simply one that stands out from others with respect to the substantive strength of a party's litigating position ... or the unreasonable manner in which the case was litigated,” to be determined at the district court’s discretion under the totality of the circumstances based on a preponderance of the evidence. *Octane Fitness, LLC v. ICON Health & Fitness, Inc.*, 134 S. Ct. 1749, 1756, 1758 (2014). Whether a case is exceptional cannot be determined unless there is final judgment substantially favoring one party and thus is not appropriate for review until after the entirety of the case is complete including Masimo’s case. *See, e.g., DH Tech., Inc. v. Synergystex Int’l, Inc.*, 154 F.3d 1333, 1344 (Fed. Cir. 1998) (“Because the case is not yet complete, any analysis of exceptional case status would be premature.”); *Shum v. Intel Corp.*, 629 F.3d 1360, 1367 (Fed. Cir. 2010) (“For the purposes of costs and fees, there can be only one winner. A court must choose one, and only one, ‘prevailing party’ to receive any costs award”); *Intellectual Ventures I LLC v. Capital One Fin. Corp.*, No. 1:13CV0740 (AJT/TCB), 2015 WL 7283108, at \*2 (E.D. Va. Nov. 17, 2015) (“There can be, however, only one ‘prevailing party,’ even in cases involving mixed judgments”).

**G. Injunctive Relief**

7. Whether Apple should be granted injunctive relief.

Relevant Authority: To obtain a permanent injunction, a patent holder must show “(1) that it has suffered an irreparable injury; (2) that remedies available at law . . . are inadequate to compensate for that injury; (3) that, considering the balance of hardships between the plaintiff and defendant, a remedy in equity is warranted; and (4) that the public interest would not be disserved by a permanent injunction.” *eBay Inc. v. MercExchange, L.L.C.*, 547 U.S. 388, 391 (2006). “An

injunction should not be granted lightly . . . because it is a ‘drastic and extraordinary remedy.’” *Riverbed Tech., Inc. v. Silver Peak Sys., Inc.*, C.A. No. 11-484-RGA, 2014 WL 4695765, at \*3 (D. Del. Sept. 12, 2014) (quoting *Monsanto Co. v. Geertson Seed Farms*, 561 U.S. 139, 165 (2010)). “Indeed, if the plaintiff’s injury can be adequately redressed with a less severe remedy, ‘recourse to the additional and extraordinary relief of an injunction’ is not warranted.” *Id.* (quoting *Monsanto*, 561 U.S. at 166); *see also id.* at \*14 (denying request for injunctive relief despite three of the four *eBay* factors weighing in favor of an injunction, finding that “the final three factors do not outweigh the absence of irreparable harm”). Likewise, a patentee’s general “assertion that the public interest favors a strong patent system . . . is insufficient to compel an injunction.” *XpertUniverse, Inc. v. Cisco Sys., Inc.*, C.A. No. 09-157-RGA, 2013 WL 6118447, at \*13 (D. Del. Nov. 20, 2013) (citing *ActiveVideo Networks, Inc. v. Verizon Commc’ns, Inc.*, 694 F.3d 1312, 1341 (Fed. Cir. 2012)).

## **EXHIBIT 6**

**FILED UNDER SEAL**

APPLE INC.

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-0001	Certified copy of U.S. Patent No. 10,076,257	APL DEL00002995	APL DEL00003011	
PTX-0002	Certified copy of U.S. Patent No. 10,627,783	APL DEL00005158	APL DEL00005221	
PTX-0003	Certified copy of U.S. Patent No. 10,942,491	APL DEL00006854	APL DEL00006917	
PTX-0004	Certified copy of U.S. Patent No. 10,987,054	APL DEL00008353	APL DEL00008426	
PTX-0005	Certified copy of U.S. Patent No. 11,106,352	APL DEL00008906	APL DEL00009208	
PTX-0006	Certified copy of U.S. Patent No. 11,474,483	APL DEL00010259	APL DEL00010324	
PTX-0007	Certified copy of U.S. Patent No. D735,131	APL_DEL000002505	APL_DEL000002513	
PTX-0008	Certified copy of U.S. Patent No. D883,279	APL DEL000002564	APL DEL000002575	
PTX-0009	Certified copy of U.S. Patent No. D947,842	APL DEL000002576	APL DEL000002586	
PTX-0010	Certified copy of U.S. Patent No. D962,936	APL_DEL000002587	APL_DEL000002597	
PTX-0011	Certified copy of File History for U.S. Patent No. 10,076,257 - Appl. No. 14/136,658	APL_DEL000002610	APL_DEL000002994	
PTX-0012	Certified copy of File History for U.S. Patent No. 10,627,783 - Appl. No. 15/261,917	APL_DEL000003012	APL_DEL000005157	
PTX-0013	Certified copy of File History for U.S. Patent No. 10,942,491 - Appl No. 16/826,130	APL_DEL000005222	APL_DEL000006853	
PTX-0014	Certified copy of File History for U.S. Patent No. 10,987,054 - Appl. No. 16/841,543	APL_DEL000006918	APL_DEL000008352	
PTX-0015	Certified copy of File History for U.S. Patent No. 11,106,352 - Appl. No. 16/915,971	APL_DEL000008427	APL_DEL000008905	
PTX-0016	Certified copy of File History for U.S. Patent No. 11,474,483 - Appl. No. 17/672,653	APL_DEL000009209	APL_DEL000010258	
PTX-0017	Certified copy of File History for U.S. Patent No. D735,131 - Appl. No. 29/498,998	APL_DEL000000001	APL_DEL000000161	
PTX-0018	Certified copy of File History for U.S. Patent No. D883,279 - Appl. No. 29/684,822	APL_DEL000000162	APL_DEL000000454	
PTX-0019	Certified copy of File History for U.S. Patent No. D947,842 - Appl No. 29/816,024	APL_DEL000000455	APL_DEL000000835	ID
PTX-0020	Certified copy of File History for U.S. Patent No. D962,936 - Appl. No. 29/816,025	APL_DEL000000836	APL_DEL000001216	
PTX-0021	Certified copy of File History for U.S. Provisional Appl. No. 61/111,498	APL DEL00010336	APL DEL00010395	
PTX-0022	Certified copy of File History for U.S. Provisional Appl. No. 62/044,974	APL_DEL00010433	APL_DEL00010558	
PTX-0023	Certified copy of File History for U.S. Provisional Appl. No. 62/507,181	APL DEL00010574	APL DEL00011019	
PTX-0024	Certified copy of File History for U.S. Provisional Appl. No. 62/554,196	APL DEL00011033	APL DEL00011106	
PTX-0025	Certified copy of File History for U.S. Provisional Appl. No. 62/644,886	APL_DEL00011127	APL_DEL00011233	
PTX-0026	Certified copy of Patent Assignment Abstract of Title for U.S. Patent No. D735,131	APL_DEL000002457	APL_DEL000002459	
PTX-0027	Certified copy of Assignment between Akana et al. and Apple Inc. (02-05-2015)	APL_DEL000002460	APL_DEL000002504	
PTX-0028	Certified copy of Patent Assignment Abstract of Title for U.S. Patent No. D882,563	APL_DEL000002514	APL_DEL000002516	



APPLE INC.

## FOURTH AMENDED TRIAL EXHIBIT LIST



PTX No.	Description	Beg Bates	End Bates	Objections
PTX-0029	Certified copy of Assignment between Anderson et al. and Apple Inc. (2018-11-17)	APL_DEL00002517	APL_DEL00002563	
PTX-0030	Certified copy of Patent Assignment Abstract of Title for U.S. Provisional Appl. No. 61/111,498	APL_DEL00010325	APL_DEL00010327	
PTX-0031	Certified copy of Assignment between Lin et al. and Apple Inc. (01-21-2009)	APL_DEL00010328	APL_DEL00010335	
PTX-0032	Certified copy of Patent Assignment Abstract of Title for U.S. Provisional Appl. No. 62/044,974	APL_DEL00010396	APL_DEL00010399	
PTX-0033	Certified copy of Assignment between Rothkopf and Apple Inc. (10-15-2015)	APL_DEL00010400	APL_DEL00010404	
PTX-0034	Certified copy of Assignment between Rothkopf and Apple Inc. (11-22-2019)	APL_DEL00010405	APL_DEL00010411	
PTX-0035	Certified copy of Assignment between Ive and Apple Inc. (01-05-2020)	APL_DEL00010412	APL_DEL00010418	
PTX-0036	Certified copy of Assignment between Hoenig and Apple Inc. (02-11-2020)	APL_DEL00010419	APL_DEL00010425	
PTX-0037	Certified copy of Assignment between Zorkendorfer and Apple Inc. (02-11-2020)	APL_DEL00010426	APL_DEL00010432	
PTX-0038	Certified copy of Patent Assignment Abstract of Title for U.S. Provisional Appl. No. 62/507,181	APL_DEL00010559	APL_DEL00010561	
PTX-0039	Certified copy of Assignment between Karunamuni et al. and Apple Inc. (02-28-2018)	APL_DEL00010562	APL_DEL00010573	
PTX-0040	Certified copy of Patent Assignment Abstract of Title for U.S. Provisional Appl. No. 62/554,196	APL_DEL00011020	APL_DEL00011022	
PTX-0041	Certified copy of Assignment between Clavelle et al. and Apple Inc. (10-14-2017)	APL_DEL00011023	APL_DEL00011032	ID
PTX-0042	Certified copy of Patent Assignment Abstract of Title for U.S. Provisional Appl. No. 62/644,886	APL_DEL00011107	APL_DEL00011109	
PTX-0043	Certified copy of Assignment between Clavelle et al. and Apple Inc. (05-10-2018)	APL_DEL00011110	APL_DEL00011121	
PTX-0044	Certified copy of Assignment between Pandya et al. and Apple Inc. (10-11-2018)	APL_DEL00011122	APL_DEL00011126	
PTX-0045	Certified copy of Patent Assignment Abstract of Title for U.S. Patent No. 10,466,889	APL_DEL00011234	APL_DEL00011236	
PTX-0046	Certified copy of Assignment between Tyler and Apple Inc. (02-28-2018)	APL_DEL00011237	APL_DEL00011240	
PTX-0047	Certified copy of Patent Assignment Abstract of Title for U.S. Patent No. 10,599,101	APL_DEL00011241	APL_DEL00011244	
PTX-0048	Certified copy of Patent Assignment Abstract of Title for U.S. Patent No. 10,613,485	APL_DEL00011245	APL_DEL00011248	
PTX-0049	Certified copy of Patent Assignment Abstract of Title for U.S. Patent No. 10/620,591	APL_DEL00011249	APL_DEL00011252	

APPLE INC.

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-0050	Certified copy of Patent Assignment Abstract of Title for U.S. Patent No. 10,627,783	APL_DEL00011253	APL_DEL00011256	
PTX-0051	Certified copy of Patent Assignment Abstract of Title for U.S. Patent No. 11,432,766	APL_DEL00011257	APL_DEL00011258	
PTX-0052	Certified copy of Assignment between Pandya et al. and Apple Inc. (08-29-2018)	APL_DEL00011260	APL_DEL00011264	
PTX-0053	Certified copy of Assignment between Clavelle et al. and Apple Inc. (09-26-2018)	APL_DEL00011265	APL_DEL00011276	
PTX-0054	Certified copy of Patent Assignment Abstract of Title for U.S. Patent No. 8,615,290	APL_DEL00011277	APL_DEL00011279	
PTX-0055	Certified copy of Assignment between Lin et al. and Apple Inc. (01-21-2009)	APL_DEL00011280	APL_DEL00011287	
PTX-0056		APL_DEL00037757	APL_DEL00037763	
PTX-0057		APL_DEL00037764	APL_DEL00037771	
PTX-0058		APL_DEL00037755	APL_DEL00037756	
PTX-0059				
PTX-0060				
PTX-0061		APL_DEL00037474	APL_DEL00037498	
PTX-0062		APL_DEL00034347	APL_DEL00034424	
PTX-0063				F
PTX-0064				
PTX-0065				UK
PTX-0066		MASA03078747	MASA03078787	
PTX-0067	INTENTIONALLY OMITTED			
PTX-0068	INTENTIONALLY OMITTED			
PTX-0069	INTENTIONALLY OMITTED			
PTX-0070	INTENTIONALLY OMITTED			
PTX-0071	INTENTIONALLY OMITTED			
PTX-0072	INTENTIONALLY OMITTED			
PTX-0073	INTENTIONALLY OMITTED			
PTX-0074		MASAD03749526	MASAD03749526	402; 403
PTX-0075		MASAD02992234	MASAD02992240	F; 402; 403
PTX-0076		MASITC_00908110	MASITC_00908112	
PTX-0077		MASAD02463583	MASAD02463584	
PTX-0078				
PTX-0079				

APPLE INC.  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-0080		MASA00159627	MASA00159627	402; 403
PTX-0081		MASAD02865699	MASAD02865699	402; 403
PTX-0082		MASITC_01127176	MASITC_01127177	
PTX-0083				402; 403
PTX-0084		MASA03114330	MASA03114331	
PTX-0085		MASA03114332	MASA03114336	
PTX-0086				402; 403
PTX-0087		MASITC_01378907	MASITC_01378908	
PTX-0088		MASAD00814906	MASAD00814908	F
PTX-0089		MASAD00814909	MASAD00814914	
PTX-0090		MASA03186880	MASA03186889	F
PTX-0091				402; 403
PTX-0092		MASITC_01250598	MASITC_01250598	
PTX-0093				
PTX-0094				402; 403
PTX-0095		MASAD00012267	MASAD00012267	
PTX-0096		MASAD00006405	MASAD00006405	402; 403
PTX-0097		MASAD00014300	MASAD00014300	
PTX-0098	INTENTIONALLY OMITTED			
PTX-0099	INTENTIONALLY OMITTED			
PTX-0100		MASA00604826	MASA00604827	
PTX-0101		MASITC_01165811	MASITC_01165813	F
PTX-0102				F; 403; 403
PTX-0103		MASAD02515977	MASAD02515978	F
PTX-0104		MASAD02515976	MASAD02515976	F; IC
PTX-0105		MASA01934098	MASA01934098	F
PTX-0106		MASA01934099	MASA01934101	F
PTX-0107				
PTX-0108				

APPLE INC.

87922

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-0109		MASAD00227962	MASAD00228016	
PTX-0110		MASAD00985383	MASAD00985387	
PTX-0111		MASAD00253467	MASAD00253478	
PTX-0112	INTENTIONALLY OMITTED			
PTX-0113	Excerpt to an Interrogatory Response, Interrogatory 46 (09-25-2023)			F; H
PTX-0114	Responses and Objections to Apple Inc.'s Notice of Deposition of Masimo Corporation, Sound United, LLC, and Cercacor Laboratories, Inc. Pursuant to Federal Rule of Civil Procedure 30 (B)(6) (09-26-2023)			F; H; 402, 403
PTX-0115	INTENTIONALLY OMITTED			
PTX-0116	INTENTIONALLY OMITTED			
PTX-0117	INTENTIONALLY OMITTED			
PTX-0118	INTENTIONALLY OMITTED			
PTX-0119	INTENTIONALLY OMITTED			
PTX-0120	INTENTIONALLY OMITTED			
PTX-0121		MASAD01285463	MASAD01285519	F
PTX-0122		MASAD01186294	MASAD01186295	F
PTX-0123		MASAD02993349	MASAD02993351	F
PTX-0124		MASAD02160161	MASAD02160162	F
PTX-0125		MASAD02080045	MASAD02080046	
PTX-0126		MASAD03959430	MASAD03959432	F
PTX-0127		MASAD02155668	MASAD02155673	F
PTX-0128		MASAD02154634	MASAD02154635	F
PTX-0129		MASAD03927899	MASAD03927899	F
PTX-0130		MASAD03086452	MASAD03086452	F
PTX-0131		MASAD03008276	MASAD03008278	F
PTX-0132	Reply Expert Report of Alan D. Ball on Masimo's Infringement of Apple's Asserted Design Patents (01-05-2024)			E
PTX-0133	Resume Nicholas Barker			F
PTX-0134	U.S. Patent No. 9,241,055			402; 403
PTX-0135	U.S. Patent No. D746,262			402; 403
PTX-0136		MASITC_01218359	MASITC_01218359	F; H; 402; 403
PTX-0137	Apple Snags Patent for Embedded Heart Rate Monitor ( <a href="https://web.archive.org/web/20140106041128/http://www.qmed.com/news/apple-snags-patent-embedded-heart-rate-monitor">https://web.archive.org/web/20140106041128/http://www.qmed.com/news/apple-snags-patent-embedded-heart-rate-monitor</a> )			F; H; 402; 403

APPLE INC.

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-0138	Plaintiff Apple INC.'s Fourth Set of Requests for Admission (NOS. 89-114)			F; H
PTX-0139		MASA03079922	MASA03079922	
PTX-0140		MASA03079923	MASA03079936	
PTX-0141				
PTX-0142		MASITC_01127131	MASITC_01127131	F; H; 402; 403
PTX-0143				F; H; 402; 403
PTX-0144		MASITC 01388367	MASITC 01388368	
PTX-0145		MASTIC 01388369	MASTIC 01388384	
PTX-0146		MASITC_01078226	MASITC_01078283	
PTX-0147		MASITC_01148548	MASITC_01148548	
PTX-0148		MASITC 01148549	MASITC 01148550	
PTX-0149		MASA00688648	MASA00688650	
PTX-0150		MASITC 01359966	MASITC 01359966	
PTX-0151				F
PTX-0152				402; 403
PTX-0153		MASA03475385	MASA03475410	
PTX-0154		MASA11266642	MASA11266693	
PTX-0155		MASA11270082	MASA11270083	
PTX-0156		MASA03474978	MASA03474982	
PTX-0157		MASA03583915	MASA03583921	
PTX-0158		MASAD00797976	MASAD00797976	
PTX-0159		MASAD02194368	MASAD02194369	F
PTX-0160		MASAD03749526 MASAD02992238	MASAD03749526 MASAD02992240	

APPLE INC.

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-0161		MASAD02043467	MASAD02043476	
PTX-0162		MASAD03759189	MASAD03759195	F
PTX-0163				
PTX-0164				
PTX-0165				F
PTX-0166		APL-MAS_00230527	APL-MAS_00230528	F
PTX-0167		APL-MAS_00639005	APL-MAS_00639011	F
PTX-0168		APL-MAS_00972250	APL-MAS_00972288	F
PTX-0169		MASA03583102	MASA03583103	F
PTX-0170		MASA03582651	MASA03582652	F
PTX-0171		MASAD00638778	MASAD00638778	F
PTX-0172		MASA03582709	MASA03582710	F
PTX-0173		MASAD03064885	MASAD03064886	F
PTX-0174		MASA03583010	MASA03583016	F
PTX-0175		MASA03582989	MASA03582992	F
PTX-0176		MASAD03070496	MASAD03070497	F
PTX-0177		MASA03582958	MASA03582962	F
PTX-0178		MASA03583589	MASA03583589	F; 402; 403
PTX-0179		MASAD00502155	MASAD00502155	F
PTX-0180		MASAD03740445	MASAD03740449	F
PTX-0181		MASAD01254444	MASAD01254446	F
PTX-0182		MASAD03759436	MASAD03759445	F
PTX-0183		MASAD00502087	MASAD00502089	F
PTX-0184		MASAD01248178	MASAD01248182	F

APPLE INC.

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-0185		PININFARINA0004262	PININFARINA0004281	
PTX-0186		PININFARINA0013668	PININFARINA0013668	F
PTX-0187		PININFARINA0000777	PININFARINA0000788	402; 403
PTX-0188		MASAD01001288	MASAD01001289	F; H; 402; 403
PTX-0189		PININFARINA009264	PININFARINA009278	402; 403
PTX-0190		PININFARINA0000246	PININFARINA0000248	F; H
PTX-0191		PININFARINA0003460	PININFARINA0003490	
PTX-0192		PININFARINA0000391	PININFARINA0000400	F; H
PTX-0193		MASA02984613	MASA02984800	F; 402; 403
PTX-0194		MASA00419270	MASA00419270	402; 403
PTX-0195		MASA00419271	MASA00419289	402; 403
PTX-0196				
PTX-0197		MASITC_01250508	MASITC_01250508	IC
PTX-0198		MASITC_01250511	MASITC_01250511	402; 403
PTX-0199		MASA03213188	MASA03213189	402
PTX-0200		MASITC_01126853	MASITC_01126856	
PTX-0201	Webpage: Masimo W1 - Advanced Health Tracking Watch (www.masimopersonalhealth.com/products/masimo-w1) (Captured 09-27-2023)			
PTX-0202	Webpage: Web Capture of Masimo video at 0:07 seconds (09-27-2023) (https://cdn.shopify.com/videos/c/vp/112c72b865c243ffadccc6ce352492e9/112c72b865c243ffadccc6ce35249e9.HD-1080p-7.2Mbps-15636006.mp4)			
PTX-0203		MASAD03440097	MASAD03440100	402; 403
PTX-0204				
PTX-0205		APL_DEL00089454	APL_DEL00089463	F

APPLE INC.

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-0206		APL_DEL00095888	APL_DEL00096059	F; H
PTX-0207		APL-MAS_00591948	APL-MAS_00591955	F; H
PTX-0208		APL_DEL00090739	APL_DEL00090763	F; H
PTX-0209	U.S. Patent No. 9,632,537			
PTX-0210	Photograph of Masimo W1			
PTX-0211	Photograph of Masimo W1			
PTX-0212	Photograph of Masimo W1			
PTX-0213	Reply Expert Report of Joel Delman (01-05-2024)			
PTX-0214	Rebuttal Expert Report of Joel Delman (12-15-2023)			
PTX-0215	Physical: Masimo W1			UK
PTX-0216	Fitbit - Fitbit Charge 5 User Manual, Version 1.8 (2023)			F; H; 402; 403
PTX-0217	Physical: Fitbit Charge 5			UK; 402; 403
PTX-0218	Physical: Fitbit Charge 5 charger			UK; 402; 403
PTX-0219	Webpage: Fitbit Help Center - What is the Fitbit ECG app? (support.google.com/fitbit/answer/14236718#zippy=%2Cwhere-can-i-find-the-fitbit-ecg-app)			F; H; 402; 403
PTX-0220	Webpage: Garmin Technology - Garmin ECG App (www.garmin.com/en-US/garmin-technology/health-science/ecg/)			F; H; 402; 403
PTX-0221	Webpage: Garmin Technology - Venu 2 Plus (www.garmin.com/en-US/p/730659/pn/010-02496-02)			F; H; 402; 403
PTX-0222	Physical: Garmin Venu 2 Plus			UK; 402; 403
PTX-0223	Physical: Garmin Venu 2 Plus charger			UK; 402; 403
PTX-0224	International Publication No. WO 2017/165532 (Paulke)			
PTX-0225	Comparison chart between D'842 Patent and Prior Art References			402, 403, E
PTX-0226	Masimo v. Apple, PTAB Case No. IPR2023-00831, Declaration of Joel Delman (04-10-2023)			
PTX-0227	Masimo v. Apple, PTAB Case No. IPR2023-00774, Declaration of Joel Delman (03-23-2023)			
PTX-0228	U.S. Patent No. D557,338 (Delman)			402; 403
PTX-0229	Webpage: Teachers Paradise - Learning Resources Radius Audio Learning System LER6910			F; H
PTX-0230	Amended Rebuttal Expert Report of Christian M. Dippon, Ph.D. on behalf of Apple Inc. (12-20-2023)			E
PTX-0231	Document showing Docket Number, Patent Number, Title, and Client Contact	STERNE000000001	STERNE000000001	
PTX-0232				402, 403; F; H
PTX-0233	Notice of 30(b)(1) Deposition of Rick Fishel (08-31-2023)			402, 403
PTX-0234	Rick Fishel LinkedIn			F; H



APPLE INC.

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-0235	Rick Fishel LinkedIn - Experience			F; H
PTX-0236	Masimo v. Apple, C.D. Cal. Case No. 8:20-cv-00048-JVS, Video-Recorded Deposition of Rick Fishel (07-28-2022)			402, 403, H, F
PTX-0237	U.S. Patent No. 8,626,255 (Al-Ali)	MASA00057727	MASA00057764	
PTX-0238		MASA00439326	MASA00439327	F; H; 402; 403
PTX-0239		MASA002759700	MASA002759700	F; H; 402; 403
PTX-0240		MASA002759701	MASA002759702	F; H; 402; 403
PTX-0241				402; 403
PTX-0242				
PTX-0243				
PTX-0244				
PTX-0245				
PTX-0246				
PTX-0247				
PTX-0248		MASA00573617	MASA00573617	F; H
PTX-0249		MASAD00438070	MASAD00438076	
PTX-0250		MASA00186101	MASA00186120	
PTX-0251		MASA00081231	MASA00081272	
PTX-0252		APL_DEL01571391	APL_DEL01571396	
PTX-0253		MASA002439916	MASA002439929	
PTX-0254				
PTX-0255		APL_DEL01378954	APL_DEL01378956	
PTX-0256		APL-MAS_00634347	APL-MAS_00634348	
PTX-0257		APL-MAS_00625926	APL-MAS_00625927	
PTX-0258		APL_DEL01428916	APL_DEL01428917	
PTX-0259		APL-MAS_00647879	APL-MAS_00647881	
PTX-0260		APL-MAS_00637532	APL-MAS_00637541	
PTX-0261		APL-MAS_01135120	APL-MAS_01135122	

APPLE INC.  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-0262		APL-MAS_00653965	APL-MAS_00653972	
PTX-0263		APL_DEL01534226	APL_DEL01534231	
PTX-0264		APL_DEL01367285	APL_DEL01367286	
PTX-0265		APL-MAS_01808114	APL-MAS_01808119	
PTX-0266		APL-MAS_00499741	APL-MAS_00499742	
PTX-0267		APL_DEL01424966	APL_DEL01424975	
PTX-0268		APL-MAS_00652165	APL-MAS_00652171	
PTX-0269		APL_DEL01521475	APL_DEL01521494	
PTX-0270		APL_DEL01902110	APL_DEL01902125	
PTX-0271		APL_DEL01535192	APL_DEL01535203	
PTX-0272		APL_DEL01423109	APL_DEL01423115	
PTX-0273		APL_DEL02419009	APL_DEL02419020	
PTX-0274		APL_DEL01472712	APL_DEL01472713	
PTX-0275				
PTX-0276				
PTX-0277		APL_DEL02842414	APL_DEL02842421	F; H
PTX-0278				402; F; H
PTX-0279				402, 403; F; H
PTX-0280				F; H
PTX-0281		APL MAS ITC 00366722	APL MAS ITC 00366754	
PTX-0282		MASAD00017965	MASAD00017996	
PTX-0283		KMMASD_00104696	KMMASD_00104731	
PTX-0284		MASAD00018067	MASAD00018098	
PTX-0285		APL_DEL00008353	APL_DEL00008426	
PTX-0286		BROWNSTEIN000001	BROWNSTEIN000001	F; H
PTX-0287				F; H
PTX-0288		APL-MAS 00083085	APL-MAS 00083104	F; H
PTX-0289		APL-MAS 00083940	APL-MAS 00083940	F; H


APPLE INC.

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-0290	INTENTIONALLY OMITTED			
PTX-0291	INTENTIONALLY OMITTED			
PTX-0292	INTENTIONALLY OMITTED			
PTX-0293	INTENTIONALLY OMITTED			
PTX-0294	INTENTIONALLY OMITTED			
PTX-0295	INTENTIONALLY OMITTED			
PTX-0296	INTENTIONALLY OMITTED			
PTX-0297	INTENTIONALLY OMITTED			
PTX-0298	INTENTIONALLY OMITTED			
PTX-0299	INTENTIONALLY OMITTED			
PTX-0300		APL-MAS_00180353	APL-MAS_00180355	
PTX-0301		APL-MAS_00230191	APL-MAS_00230195	F; H
PTX-0302		APL-MAS_00249195	APL-MAS_00249195	
PTX-0303		APL-MAS_00230843	APL-MAS_00230851	F; H
PTX-0304		APL-MAS_00230910	APL-MAS_00230910	
PTX-0305				F; H
PTX-0306		MASA00377441	MASA00377441	
PTX-0307		MASA01152928	MASA01152962	
PTX-0308		MASAD00235560	MASAD00235560	
PTX-0309		MASAD00438203	MASAD00438215	
PTX-0310		MASAD00438219	MASAD00438386	
PTX-0311				E
PTX-0312				E
PTX-0313				
PTX-0314				
PTX-0315				
PTX-0316				E; 402; 403
PTX-0317				
PTX-0318				

APPLE INC.

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-0319	Isaacson Expert Report, Exhibit 8: Cross Tabulation Tables for the Materiality Survey			
PTX-0320	Isaacson Expert Report, Exhibit 10: Cross Tabulation Tables for the Advertising Communications Survey			
PTX-0321	Diamond - Control Foundations: Rationales and Approaches (Excerpt) (2022)			106; 402; 403; F; H
PTX-0322	Doud - Mobvoi TicWatch GTH Pro Hands-on Review: Monitor the Plumbing (03-09-2022)			F, H; 402; 403
PTX-0323	Halliday - Mobvoi Ticwatch GTH Pro review: An Apple alternative with a worse screen and a better price (04-21-2022)			F, H; 402; 403
PTX-0324	Table Showing Isaacson Association Survey Images and Unobscured Images of the Masimo W1 and Apple Watch			
PTX-0325	Physical: Masimo W1 Watch (retained by counsel)			UK
PTX-0326	Physical: Apple Watch Series 4 (retained by counsel)			UK
PTX-0327	Physical: Masimo W1 Charger (retained by counsel)			UK
PTX-0328	INTENTIONALLY OMITTED			
PTX-0329	INTENTIONALLY OMITTED			
PTX-0330	INTENTIONALLY OMITTED			
PTX-0331	INTENTIONALLY OMITTED			
PTX-0332	INTENTIONALLY OMITTED			
PTX-0333	INTENTIONALLY OMITTED			
PTX-0334	U.S. Patent No. D359,546 (Savage)	APL-MAS 02068308	APL-MAS 02068312	402; 403
PTX-0335	Webpage: Knobbe Martens - Jarom D. Kesler Overview ( <a href="https://www.knobbe.com/attorneys/jarom-kesler">https://www.knobbe.com/attorneys/jarom-kesler</a> )			402; 403; H; F
PTX-0336				402, 403; F; H
PTX-0337				402, 403; F; H
PTX-0338		MASITC_00454376	MASITC_00454388	402; 403
PTX-0339		MASAD03439319	MASAD03439320	402; 403
PTX-0340		MASAD03712845	MASAD03712845	402; 403
PTX-0341		MASITC_01132065	MASITC_01132069	402, 403, ID, F, H
PTX-0342		MASAD03715284	MASAD03715289	402; 403
PTX-0343		MASAD02463376	MASAD02463376	402; 403
PTX-0344		MASAD00006925	MASAD00006948	

APPLE INC.

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-0345	INTENTIONALLY OMITTED			
PTX-0346		MASITC_01148528	MASITC_01148530	
PTX-0347	Complaint for Patent Infringement (-1378) (10-20-2022)			402, 403, F; H
PTX-0348		MASAD02879830	MASAD02879832	
PTX-0349		APL_DEL00002374	APL_DEL00002380	
PTX-0350				
PTX-0351		MASAD03849398	MASAD03849398	106
PTX-0352		MASITC_01128316	MASITC_01128316	
PTX-0353		MASA00678787	MASA00678798	402, 403
PTX-0354		MASITC_01147258	MASITC_01147273	
PTX-0355		MASITC_01226958	MASITC_01226958	
PTX-0356		MASAD00904699	MASAD00904858	
PTX-0357		MASAD00899339	MASAD00899341	
PTX-0358		MASAD02496984	MASAD02496984	106
PTX-0359		MASAD00043982	MASAD00043983	
PTX-0360		MASAD03164869	MASAD03164902	
PTX-0361		MASAD01000960	MASAD01000963	402; 403
PTX-0362		MASAD03308515	MASAD03308515	402, 403
PTX-0363		MASAD03730518	MASAD03730518	402, 403
PTX-0364		MASAD02884676	MASAD02884676	402, 403
PTX-0365		MASAD00034786	MASAD00034918	
PTX-0366		MASAD00034172	MASAD00034231	
PTX-0367		MASA01114929	MASA01114930	
PTX-0368				402, 403

APPLE INC.

87932

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-0369	Photograph: Apple AirPods			402, 403
PTX-0370	Photograph of Masimo and Apple Product Comparisons			402, 403
PTX-0371	Photograph of Masimo and Apple Product Comparisons			402, 403
PTX-0372	Photograph of Masimo and Apple Product Comparisons			402, 403
PTX-0373	Webpage: Sound United Enters into Agreement to Be Acquired by Masimo Corporation (02-15-2022) (www.soundunited.com/news/sound-united-enters-into-agreement-to-be-acquired-by-masimo-corporation)			
PTX-0374	Webpage: Masimo stock falls as The Street ponders \$1B Sound United acquisition (02-16-2022) (www.massdevice.com/masimo-stock-falls-as-the-street-ponders-1b-sound-united-acquisition/)			402, 403, H, F
PTX-0375	Webpage: Koffey's Politan takes 9% stake in Masimo, to push for change (08-16-2022) (www.reuters.com/business/healthcare-pharmaceuticals/activist-investor-politan-reports-84-stake-masimo-corp-2022-08-16/)			402, 403, H, F
PTX-0376		MASAD01094513	MASAD01094514	402, 403
PTX-0377				402, 403, H, F
PTX-0378				402, 403, H, F
PTX-0379		MASAD01059128	MASAD01059130	402; 403
PTX-0380		MASAD01339520	MASAD01339521	402; 403
PTX-0381		MASAD01339522	MASAD01339556	402, 403, H
PTX-0382		MASAD01127592	MASAD01127594	402, 403
PTX-0383		MASAD01057333	MASAD01057341	402, 403
PTX-0384				
PTX-0385				
PTX-0386		MASA002737666	MASA002737666	
PTX-0387		MASA002737665	MASA002737665	
PTX-0388		MASITC 00503412	MASITC 00503413	402; 403
PTX-0389		MASA03198084	MASA03198088	
PTX-0390		MASAD00831422	MASAD00831422	

APPLE INC.  
87933

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-0391		MASA03103622	MASA03103624	
PTX-0392	U.S. Patent No. 11,234,602 (Kinast)			402; 403
PTX-0393	Physical: Masimo W1 Watch			ID
PTX-0394		MASAD00694308	MASAD00694308	106
PTX-0395		MASAD00694352	MASAD00694358	402; 403
PTX-0396		MASAD00694327	MASAD00694338	402; 403
PTX-0397				
PTX-0398		MASAD00727847	MASAD00727855	
PTX-0399		MASA11356021	MASA11356021	
PTX-0400		MASA03583509	MASA03583510	F; 402; 403
PTX-0401		MASAD03414233	MASAD03414234	402; 403
PTX-0402				F; H; 402; 403
PTX-0403		MASAD00639822	MASAD00639824	F; H
PTX-0404		MASAD02421722	MASAD02421723	F; H
PTX-0405		MASAD03593395	MASAD03593395	402; 403
PTX-0406		MASA03008870	MASA03008870	F; H
PTX-0407		MASA03007380	MASA03007381	
PTX-0408		MASITC_01225674	MASITC_01225674	F; H; 402; 403
PTX-0409		MASA11250345	MASA11250355	
PTX-0410		MASA11251252	MASA11251253	F
PTX-0411		MASITC_01253789	MASITC_01253790	
PTX-0412		MASITC_01147256	MASITC_01147274	
PTX-0413		MASITC_01254226	MASITC_01254227	402; 403
PTX-0414		MASA02123686	MASA02123885	
PTX-0415		MASAD00489961	MASAD00489985	
PTX-0416		MASA11356102	MASA11356102	F

APPLE INC.

87934

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-0417		MASAD00982531	MASAD00982548	402; 403
PTX-0418		MASAD00745176	MASAD00745180	
PTX-0419		MASA03583571	MASA03583574	
PTX-0420		MASA11250896	MASA11250907	
PTX-0421		MASAD00678122	MASAD00678123	F
PTX-0422		MASA03472536	MASA03472542	
PTX-0423		MASA03475033	MASA03475034	
PTX-0424		MASA03476083	MASA03476084	
PTX-0425		MASAD03724291	MASAD03724293	
PTX-0426		MASAD00677704	MASAD00677704	F; 402; 403
PTX-0427		MASAD00725202	MASAD00725300	
PTX-0428		MASA03104643	MASA03104663	F
PTX-0429		MASAD00721231	MASAD00721234	F
PTX-0430		MASAD03583084	MASAD03583086	
PTX-0431		MASAD00502077	MASAD00502077	
PTX-0432		MASAD01386138	MASAD01386162	
PTX-0433		MASAD00502147	MASAD00502152	
PTX-0434		MASAD01386003	MASAD01386036	
PTX-0435		MASAD03428005	MASAD03428005	F; 402; 403
PTX-0436		MASITC 01254596	MASITC 01254596	402; 403
PTX-0437		MASAD00035370	MASAD00035429	F; 402; 403
PTX-0438		MASAD00035619	MASAD00035715	F; 402; 403
PTX-0439		MASAD00465562	MASAD00465564	F; 402; 403
PTX-0440		MASAD02646500	MASAD02646500	F; 402; 403
PTX-0441				F
PTX-0442	INTENTIONALLY OMITTED			
PTX-0443	INTENTIONALLY OMITTED			




APPLE INC.  
FOURTH AMENDED TRIAL EXHIBIT LIST


PTX No.	Description	Beg Bates	End Bates	Objections
PTX-0444		MASA03109106	MASA03109109	
PTX-0445		MASAD03073193	MASAD03073194	
PTX-0446				
PTX-0447		MASAD00896440	MASAD00896444	F
PTX-0448				F
PTX-0449		MASAD02687957	MASAD02687973	F
PTX-0450		MASITC_1078228	MASITC_1078283	
PTX-0451		MASITC_01126859	MASITC_01126867	
PTX-0452		MASA00688648	MASA00688650	
PTX-0453		MASA03164869	MASA03164902	
PTX-0454		MASA03167004	MASA03167058	402; 403
PTX-0455		MASA11250972	MASA11250974	402; 403
PTX-0456		MASAD02868581	MASAD02868582	402; 403
PTX-0457		MASAD02885210	MASAD02885211	402; 403
PTX-0458		MASAD03730975	MASAD03730977	402; 403
PTX-0459		MASA03078900	MASA03078901	F
PTX-0460				
PTX-0461				
PTX-0462				
PTX-0463				
PTX-0464				
PTX-0465				
PTX-0466				F, H; 402; 403
PTX-0467				402; 403
PTX-0468				E
PTX-0469	Opening Expert Report of Joseph Matal (11-22-2023)			E; 402; 403

APPLE INC.

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-0470	Rebuttal Expert Report of Joseph Matal (12-15-2023)			E
PTX-0471	Tom McClenahan LinkedIn			F
PTX-0472	U.S. Application No. 15/880,071 Address and Attorney/Agent Information			402; 403
PTX-0473	U.S. Application No. 16/791,955 Address and Attorney/Agent Information			402; 403
PTX-0474	U.S. Application No. 16/791,963 Address and Attorney/Agent Information			402; 403
PTX-0475	INTENTIONALLY OMITTED			
PTX-0476		MASA002745867	MASA002745867	F; 402; 403
PTX-0477		MASA03474641	MASA03474646	
PTX-0478		MASAD03849353	MASAD03849354	
PTX-0479				402, 403, F, H
PTX-0480				402, 403, F, H
PTX-0481		MASAD00234421	MASAD00234421	F; 402; 403
PTX-0482		MASAD00234422	MASAD00234422	F; 402; 403
PTX-0483		MASAD00234465	MASAD00234465	F; 402; 403
PTX-0484		MASAD00234464	MASAD00234464	F; 402; 403
PTX-0485				402, 403, F, H
PTX-0486		MASAD01983038	MASAD01983059	F
PTX-0487		MASAD02452431	MASAD02452433	F
PTX-0488		MASAD00725302	MASAD00725361	

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-0489		MASAD00681585	MASAD00681587	
PTX-0490		MASAD04143010	MASAD04143021	F
PTX-0491		MASAD00016542	MASAD00016561	F
PTX-0492		MASAD04143037	MASAD04143054	F
PTX-0493		MASAD04142991	MASAD04143009	F
PTX-0494				
PTX-0495		MASAD01984659	MASAD01984660	
PTX-0496				
PTX-0497		MASA02278117	MASA02278117	F; 402; 403
PTX-0498		MASA02278118	MASA02278128	H, F; 402; 403
PTX-0499		MASITC_01159778 MASA11156343	MASITC_01159778 MASA11156343	F; 402; 403
PTX-0500		MASITC_01159777 MASA11156344	MASITC_01159778 MASA11156345	H, F; 402; 403
PTX-0501				
PTX-0502				
PTX-0503				F
PTX-0504	Image of a product (MASITC_P_058) (back)	MASITC_01077023 MASA11073596	MASITC_01077023 MASA11073596	
PTX-0505	Image of a product (MASITC_P_058) (front)	MASITC_01077022 MASA11073595	MASITC_01077022 MASA11073595	
PTX-0506	Webpage: Masimo Sensor Module ( <a href="https://www.masimo.com/search/?q=Masimo+Sensor+Module">https://www.masimo.com/search/?q=Masimo+Sensor+Module</a> )			F
PTX-0507	Webpage: Sensor Module ( <a href="https://www.masimo.com/search/?q=Sensor+Module">https://www.masimo.com/search/?q=Sensor+Module</a> )			F

APPLE INC.


87938

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-0508				F
PTX-0509		MASAD00690172	MASAD00690178	F
PTX-0510	Letter from J. Shih to S. Penubarthi re K232512 (11-17-2023)			
PTX-0511	Letter from J. Shih to D. Xavier re K201456 (10-05-2021)			F, H, 402, 403
PTX-0512	Webpage: Why The Chips Are Down: Navigating the Global Chip Shortages and Beyond ( <a href="https://www/jabil.com/blog/global-chip-shortages.html">https://www/jabil.com/blog/global-chip-shortages.html</a> )			F, H, 402, 403
PTX-0513	Webpage: TSMC Says a Shortage of Commodity Chips Is Disrupting Trillion-Dollar Industries ( <a href="https://www.tomshardware.com/news/tsmc-shortage-of-commodity-chips-disrupt-trillion-dollar-industries">https://www.tomshardware.com/news/tsmc-shortage-of-commodity-chips-disrupt-trillion-dollar-industries</a> )			F, H, 402, 403
PTX-0514	Video	MASAD04143078	MASAD04143078	F
PTX-0515				F; 402; 403
PTX-0516				402, 403, F, H
PTX-0517				
PTX-0518				402, 403, F, H
PTX-0519				F
PTX-0520		MASITC_01385131 MASA11381270	MASITC_01385133 MASA11381272	
PTX-0521		MASAD00866046	MASAD00866047	F
PTX-0522		MASAD00438082	MASAD00438084	
PTX-0523		MASAD00430290	MASAD00430352	
PTX-0524		MASITC_01159868 MASA11156435	MASITC_01159868 MASA11156435	
PTX-0525		MASITC_01159869 MASA11156438	MASITC_01159870 MASA11156437	
PTX-0526		MASA00592101	MASA00592101	
PTX-0527		MASITC_00169027 MASA10168991	MASITC_00169078 MASA10169042	
PTX-0528				402, 403, E
PTX-0529				
PTX-0530				
PTX-0531				402, 403

APPLE INC.

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-0532	Order Granting In Part Plaintiff's Motion To Strike The New And Untimely Non-infringement Opinions Of Alan L. Oslan (10-05-2021)			402, 403
PTX-0533	Opening Expert Report of Alan L. Oslan On Invalidity Of. U.S. Patent NO. 10,076,257 And U.S. Patent NO. 10,987,054 almost any (11-22-2023)			
PTX-0534	Rebuttal Expert Report of Alan L. Oslan on Noninfringement of U.S. Patent No. 10,076,257 and U.S. Patent No. 10,987,054 (12-15-2023)			
PTX-0535	Image of a watch			
PTX-0536	Declaration Of Alan L. Oslan In Support Of Defendants' Responsive Claim Construction Brief (08-10-2023)			
PTX-0537	Appendix D-1 Non-Infringement Claim Chart for U.S. Patent No. 10,987,054			
PTX-0538		MASAD00053444	MASAD00053444	
PTX-0539				H, F
PTX-0540				
PTX-0541				
PTX-0542				402; 403; F; H; A
PTX-0543				402; 403; F; H; A
PTX-0544		MASA00104216	MASA00104220	
PTX-0545				
PTX-0546		MASA03271342	MASA03271355	
PTX-0547		MASA002701068	MASA002701134	F; 402; 403
PTX-0548		MASA01802042	MASA01802062	F
PTX-0549				
PTX-0550		APL_DEL03853320	APL_DEL03853324	
PTX-0551		MASAD02992806	MASAD02992808	F; 402; 403
PTX-0552		MASA00590052	MASA00590080	F; 402; 403
PTX-0553		MASA0224990	MASA02247002	F; 402; 403
PTX-0554		MASITC_01147102 MASA11143669	MASITC_01147106 MASA11143673	F; 402; 403
PTX-0555		MASA03136151	MASA03136152	F; 402; 403
PTX-0556		MASA002494713	MASA002494728	F; 402; 403
PTX-0557		MASAD01248094	MASAD01248102	

APPLE INC.

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-0558	Expert Rebuttal Report Of Marco Perez, M.D. (12-15-2023)			E
PTX-0559		MASAD00985191	MASAD00985290	
PTX-0560				E
PTX-0561		APL-MAS_01875507	APL-MAS_01875513	H, F
PTX-0562				
PTX-0563				
PTX-0564		MASAD02472588	MASAD02472590	F
PTX-0565		MASA03100681	MASA03100682	
PTX-0566		MASITC 00620761	MASITC 00620762	
PTX-0567		MASITC_01374109/MASA11370248	MASITC_01374110/MASA11370249	
PTX-0568		MASAD00012161	MASAD00012161	
PTX-0569		MASAD00237000	MASAD00237000	
PTX-0570		MASA03073980	MASA03073982	H, F
PTX-0571				
PTX-0572				
PTX-0573				
PTX-0574				
PTX-0575		MASA03073896	MASA03073898	
PTX-0576		MASA03084550	MASA03084551	
PTX-0577		MASITC_01289569 MASA11286127	MASITC_01289570 MASA11286128	
PTX-0578		MASAD00692066	MASAD00692071	
PTX-0579		MASAD01015779	MASAD01015786	
PTX-0580		MASA03081057	MASA03081058	
PTX-0581		MASAD00681573	MASAD00681578	
PTX-0582		MASAD03738082	MASAD03738083	
PTX-0583		MASAD00681579	MASAD00681584	F

APPLE INC.  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-0584		MASAD03724512	MASAD03724512	
PTX-0585		MASAD01020990	MASAD01020994	
PTX-0586		MASAD02876238	MASAD02876239	F
PTX-0587				
PTX-0588		MASAD00716843	MASAD00716851	F; 402; 403
PTX-0589		MASAD00639370	MASAD00639483	
PTX-0590		MASITC_01132950 MASA11129519	MASITC_01132952 MASA11129521	F
PTX-0591		MASITC_01376070 MASA11372209	MASITC_01376072 MASA11372211	F
PTX-0592		MASAD02894782	MASAD02894788	402; 403
PTX-0593		MASAD02894947	MASAD02894948	F
PTX-0594		MASAD02890954	MASAD02890955	F
PTX-0595		MASAD01025466	MASAD01025466	F
PTX-0596				
PTX-0597				
PTX-0598				402; 403
PTX-0599				
PTX-0600				
PTX-0601				
PTX-0602				
PTX-0603		PL_DELO1466431	APL_DELO1466433	
PTX-0604		PL_DELO1470432	APL_DELO1470441	
PTX-0605		PL-MAS_00976389	APL-MAS_00976397	
PTX-0606		PL-MAS_00671609	APL-MAS_00671611	
PTX-0607		PL-MAS_00273328	APL-MAS_00273345	

APPLE INC.

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-0608		APL_DEL01468322	APL_DEL01468326	
PTX-0609		APL_MAS_ITC_01191634	APL_MAS_ITC_01191636	
PTX-0610		APL_DEL01470664	APL_DEL01470670	
PTX-0611	Masimo v. Apple, C.D. Cal. Case No. 8:20-cv-00048-JVS, Certified copy of Reporter's Transcript of Proceedings, Jury Trial, Day 11, Volume I (04-19-2023)			402, 403, H, F
PTX-0612	INTENTIONALLY OMITTED			
PTX-0613	INTENTIONALLY OMITTED			
PTX-0614	INTENTIONALLY OMITTED			
PTX-0615	INTENTIONALLY OMITTED			
PTX-0616	Stephen Scruggs LinkedIn			
PTX-0617	INTENTIONALLY OMITTED			
PTX-0618	INTENTIONALLY OMITTED			
PTX-0619		MASAD00043943	MASAD00044204	402; 403
PTX-0620		MASAD00968035	MASAD00968035	
PTX-0621		MASA00159626	MASA00159626	UK
PTX-0622				402; 403
PTX-0623		MASAD03461554	MASAD03461554	
PTX-0624		MASAD00816062	MASAD00816085	
PTX-0625		MASAD00650278	MASAD00650322	
PTX-0626	INTENTIONALLY OMITTED			
PTX-0627	INTENTIONALLY OMITTED			
PTX-0628	INTENTIONALLY OMITTED			
PTX-0629		ASAD00995548	MASAD00995548	106
PTX-0630		ASAD00995550	MASAD00995550	
PTX-0631		ASAD00995551	MASAD00995551	
PTX-0632		ASAD00051056	MASAD00051059	
PTX-0633		ASAD00500463	MASAD00500478	402; 403
PTX-0634		ASAD00500463	MASAD00500478	402; 403
PTX-0635		ASAD00053277	MASAD00053280	



APPLE INC.

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-0636				
PTX-0637				
PTX-0638				
PTX-0639		MASAD00006405	MASAD00006405	
PTX-0640		MASAD00081725	MASAD00081742	
PTX-0641		MASAD00069492	MASAD00069504	
PTX-0642		MASAD00016182	MASAD00016184	
PTX-0643		MASAD00014301	MASAD00014301	
PTX-0644		MASAD00014301	MASAD00014301	
PTX-0645		MASAD00071298	MASAD00071298	
PTX-0646		MASAD00071298	MASAD00071298	
PTX-0647		MASAD00112870	MASAD00112870	
PTX-0648				
PTX-0649		MASITC_01126796	MASITC_01126797	
PTX-0650		MASA03006137	MASA03006137	UK; 402; 403
PTX-0651		MASAD01031628	MASAD01031629	
PTX-0652		MASAD01031630	MASAD01031649	
PTX-0653		MASAD01969654	MASAD01969656	
PTX-0654				
PTX-0655		MASA03074109	MASA03074114	
PTX-0656	Apple Inc. Subpoena to Harnik Shukla (08-22-2023)			402, 403, H, F
PTX-0657	Webpage: Knobbe Martens - Harnik Shukla (www.knobbe.com/attorneys/harnik-shukla)			402, 403, H, F
PTX-0658	Certified copy of File History of U.S. Patent No. 10,736,507	MASAD00022148	MASAD00022401	
PTX-0659	Mendselson - A Wearable Reflectance Pulse Oximeter for Remote Physiological Monitoring, Proceedings of the 28th IEEE (2006)	APL-MAS_00031387	APL-MAS_00031390	H, F
PTX-0660	INTENTIONALLY OMITTED			
PTX-0661	INTENTIONALLY OMITTED			
PTX-0662	INTENTIONALLY OMITTED			
PTX-0663	INTENTIONALLY OMITTED			
PTX-0664	INTENTIONALLY OMITTED			
PTX-0665	INTENTIONALLY OMITTED			
PTX-0666	INTENTIONALLY OMITTED			

APPLE INC.

87944

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-0667	INTENTIONALLY OMITTED			
PTX-0668	INTENTIONALLY OMITTED			
PTX-0669	INTENTIONALLY OMITTED			
PTX-0670	INTENTIONALLY OMITTED			
PTX-0671	Opening Expert Report of Robert L. Stoll (11-22-2023)			
PTX-0672	Rebuttal Expert Report of Robert L. Stoll (12-15-2023)			
PTX-0673	Reply Expert Report of Robert L. Stoll (01-05-2024)			
PTX-0674		PL-MAS_00587611	APL-MAS_00587614	F
PTX-0675				
PTX-0676		ASITC_01146962	MASITC_01146964	F; 402; 403
PTX-0677		ASITC_01146569	MASITC_01146572	F; 402; 403
PTX-0678		ASITC_01146562	MASITC_01146568	F; 402; 403
PTX-0679				E
PTX-0680				E
PTX-0681				E
PTX-0682				F; 402; 403
PTX-0683		ASAD00438090	MASAD00438202	F
PTX-0684		ASITC_01160218	MASITC_01160218	F; 402; 403
PTX-0685		ASITC_01160331	MASITC_01160331	F; 402; 404
PTX-0686		ASITC_01392812	MASITC_01392816	F; 402; 405
PTX-0687		ASAD00255648	MASAD00255651	F; 402; 406
PTX-0688		ASA002487346	MASA002487353	F; 402; 407
PTX-0689		ASA00850374	MASA00850391	F; 402; 408
PTX-0690		ASAD00316776	MASAD00316778	F; 402; 409

APPLE INC.

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-0691	Premarket Notification, Special 510(k): Change to an Existing Device, Masimo SET uSpO2 Pulse Oximetry Cable (K121914) (10-11-2012)	MASA01185697	MASA01186081	F; 402; 410
PTX-0692	Letter from M. Thomlinson to the United States Food and Drug Administration re Response to FDA's Request for Additional Information Letter dated December 11, 2012 (06-03-2013)	MASA03507438	MASA03507742	F; 402; 411
PTX-0693		MASITC_01137812	MASITC_01137813	F; 402; 412
PTX-0694		MASAD00003695	MASAD00003935	
PTX-0695		MASAD02400394	MASAD02400395	
PTX-0696		MASAD00727828	MASAD00727842	
PTX-0697		MASAD00769088	MASAD00769091	F
PTX-0698		MASAD00640895	MASAD00641070	
PTX-0699				E
PTX-0700				F
PTX-0701		MASA00399471	MASA00399474	F
PTX-0702		MASA03099950	MASA03099950	
PTX-0703		MASAD03896100	MASAD03896100	402; 403
PTX-0704		MASITC_01078284	MASITC_01078284	F
PTX-0705		MASAD03641515	MASAD03641516	F
PTX-0706		MASAD00608602	MASAD00608609	F; 402; 403; H
PTX-0707		MASAD03054993	MASAD03054995	402; 403
PTX-0708		MASAD04057901	MASAD04057901	F
PTX-0709		MASAD02143058	MASAD02143059	F
PTX-0710		MASAD03001634	MASAD03001635	F; 402; 403
PTX-0711		MASAD02046661	MASAD02046663	F; 402; 403
PTX-0712		MASAD00237018	MASAD00237019	
PTX-0713		MASAD00237020	MASAD00237021	
PTX-0714				

APPLE INC.  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-0715		ASA03206438	MASA03206451	F
PTX-0716		ASAD03204960	MASAD03204969	
PTX-0717		ASAD00040198	MASAD00040302	F
PTX-0718		ASAD00007358	MASAD00007358	
PTX-0719		ASAD00007358	MASAD00007358	
PTX-0720		ASAD00014028	MASAD00014032	
PTX-0721		ASAD02013548	MASAD02013552	F
PTX-0722		ASAD03856963	MASAD03856967	F
PTX-0723		ASAD03747372	MASAD03747373	
PTX-0724		ASAD02916608	MASAD02916622	F
PTX-0725				F
PTX-0726		ASAD02153362	MASAD02153362	
PTX-0727		ASAD00253917	MASAD00253921	
PTX-0728		ASAD00225655	MASAD00225686	
PTX-0729		ASAD00253427	MASAD00253429	
PTX-0730		ASAD00225802	MASAD00225808	
PTX-0731		ASAD00237745	MASAD00237760	
PTX-0732		ASAD00221078	MASAD00221097	
PTX-0733		ASAD01064262	MASAD01064265	F
PTX-0734		ASAD01982959	MASAD01982960	F
PTX-0735		ASAD03761171	MASAD03761171	F
PTX-0736		ASAD03761172	MASAD03761172	F
PTX-0737		ASAD00253466	MASAD00253466	F
PTX-0738				F, H
PTX-0739				F

APPLE INC.

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-0740				F
PTX-0741		ASA00016943	MASA00017094	
PTX-0742		ASA002747892	MASA002747965	
PTX-0743				
PTX-0744		ASAD00025622	MASAD00025626	402; F
PTX-0745				
PTX-0746				
PTX-0747				
PTX-0748				
PTX-0749				
PTX-0750				
PTX-0751				
PTX-0752		ASAD00014301	MASAD00014301	F, 402, 403
PTX-0753		ASAD00071331	MASAD00071331	F, 402, 403
PTX-0754		ASAD00071331	MASAD00071331	F, 402, 403
PTX-0755				
PTX-0756				F, H, 403, 403
PTX-0757				
PTX-0758				402, 403, F, H
PTX-0759		ASAD00430236	MASAD00430236	402; 403
PTX-0760				402; 403
PTX-0761		ASAD01168853	MASAD01168853	F
PTX-0762		ASAD00785704	MASAD00785704	F

APPLE INC.  
87948

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-0763	INTENTIONALLY OMITTED			
PTX-0764	INTENTIONALLY OMITTED			
PTX-0765	INTENTIONALLY OMITTED			
PTX-0766	INTENTIONALLY OMITTED			
PTX-0767	INTENTIONALLY OMITTED			
PTX-0768	INTENTIONALLY OMITTED			
PTX-0769	INTENTIONALLY OMITTED			
PTX-0770		ASAD00737504		UK, F
PTX-0771		ASAD00644134	MASAD00644134	F
PTX-0772		ASAD00792304	MASAD00792304	F
PTX-0773		ASAD01140690	MASAD01140697	F
PTX-0774		ASAD02030558	MASAD02030558	F
PTX-0775				
PTX-0776		ASAD00506297	MASAD00506297	F; 402; 403
PTX-0777		ASAD03749554	MASAD03749557	F
PTX-0778				
PTX-0779				
PTX-0780				
PTX-0781				
PTX-0782				
PTX-0783				
PTX-0784				
PTX-0785				
PTX-0786				
PTX-0787				H; F, 402, 403
PTX-0788				
PTX-0789				
PTX-0790				402; 403; H; F
PTX-0791		PL DEL00000304	APL DEL00000304	
PTX-0792		PL DEL00000122	APL DEL00000122	
PTX-0793		PL-MAS_00187821	APL-MAS_00187826	
PTX-0794		PL-MAS_00972913	APL-MAS_00972920	

APPLE INC.  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-0795		PL-MAS_00980152	APL-MAS_00980169	
PTX-0796				402; 403
PTX-0797				
PTX-0798		MASAD00018594	MASAD00018605	
PTX-0799		MASAD00016237	MASAD00016241	
PTX-0800		MASITC 00974350	MASITC 00974350	
PTX-0801		MASITC 00974339	MASITC 00974348	
PTX-0802		MASITC_01078052	MASITC_01078054	F
PTX-0803		MASITC 01078056	MASITC 01078056	F
PTX-0804		MASITC_01140637	MASITC_01140637	402; 403; H; F
PTX-0805		MASITC_01122382	MASITC_01122382	
PTX-0806				402; 403; F, H
PTX-0807				F
PTX-0808				
PTX-0809				
PTX-0810				
PTX-0811		MASITC 01078357	MASITC 01078360	
PTX-0812		MASITC 01078487	MASITC 01078494	
PTX-0813		MASITC_01279993	MASITC_01280012	
PTX-0814		PL MAS ITC 00252094	APL MAS ITC 00252105	402; 403
PTX-0815		PL MAS ITC 00353012	APL MAS ITC 00353062	402; 403
PTX-0816		PL MAS ITC 00026059	APL MAS ITC 00026078	402; 403
PTX-0817		MASITC 01153579	MASITC 01153579	402; 403, H, F
PTX-0818				402; 403; H; F
PTX-0819		MASITC_01152226	MASITC_01152226	402; 403; H; F
PTX-0820		MASITC_01126821	MASITC_01126822	
PTX-0821		MASITC_01126823	MASITC_01126852	402; 403

APPLE INC.  
87950

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-0822		MASA11218767	MASA11218767	
PTX-0823		MASA00699502	MASA00699503	402; 403; F
PTX-0824				402; 403; F
PTX-0825		MASA11143776	MASA11143776	402; 403
PTX-0826		MASA03476016	MASA03476017	402; 403; H; F
PTX-0827		MASA03474629	MASA03474631	
PTX-0828		MASA03474632	MASA03474634	
PTX-0829				402; 403; F; H
PTX-0830				F
PTX-0831				F, H
PTX-0832				
PTX-0833				F, H
PTX-0834		MASA00085639	MASA00085876	F
PTX-0835		MASA00086120	MASA00086339	F
PTX-0836		MASA02983559	MASA02983726	F
PTX-0837		MASA00565470	MASA00565472	F
PTX-0838		MASA002706958	MASA002706959	
PTX-0839		MASA00085877	MASA00086119	F
PTX-0840		MASA002748560	MASA002748568	F
PTX-0841		MASA03578124	MASA03578129	F



APPLE INC.

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-0842		ASA01444610	MASA01444611	F
PTX-0843		ASA00053937	MASA00054002	
PTX-0844				F; H
PTX-0845				F; H
PTX-0846		ASA00595302	MASA00595302	402; 403; F
PTX-0847				
PTX-0848		ASA11076665	MASA11076665	
PTX-0849		ASA002877467	MASA002877468	402; 403; F
PTX-0850		ASA03320940	MASA03320941	402; 403; F
PTX-0851		ASA03320794	MASA03320819	402; 403; F
PTX-0852		ASA03583153	MASA03583155	402; 403
PTX-0853		ASA03583176	MASA03583185	
PTX-0854		ASA03582578	MASA03582587	
PTX-0855		ASA03582456	MASA03582460	
PTX-0856		ASA03583594	MASA03583599	
PTX-0857		ASA03583619	MASA03583619	F; 402; 403
PTX-0858		ASA03583622	MASA03583622	F; 402; 403
PTX-0859		ASA03583611	MASA03583611	F; 402; 403
PTX-0860		ASA03583618	MASA03583618	F; 402; 403
PTX-0861		ASA002456919	MASA002456966	
PTX-0862		ASA11236564	MASA11236585	
PTX-0863		ASA03583519	MASA03583570	F; H
PTX-0864		ASA11251510	MASA11251510	402; 403
PTX-0865				402; 403; F; H
PTX-0866		ASITC_01078312	MASITC_01078312	F

APPLE INC.

87952

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-0867				F
PTX-0868		MASITC 01078315	MASITC 01078325	F
PTX-0869		MASITC_01078314	MASITC_01078314	F; 106
PTX-0870		MASITC_01079373	MASITC_01079375	F
PTX-0871				
PTX-0872		MASITC_01080001	MASITC_01080001	F
PTX-0873		MASITC_01234058	MASITC_01234058	F
PTX-0874		MASITC_01078328	MASITC_01078328	F
PTX-0875		MASITC_01079383	MASITC_01079387	F
PTX-0876		MASITC 01079443	MASITC 01079454	F
PTX-0877		MASITC 01079458	MASITC 01079458	F
PTX-0878		MASITC_01079776	MASITC_01079777	F
PTX-0879		MASITC 01065590	MASITC 01065624	
PTX-0880				
PTX-0881				
PTX-0882		MASITC 01076806	MASITC 01076806	
PTX-0883		MASITC 00345680	MASITC 00345705	
PTX-0884		APL-MAS_00648680	APL-MAS_00648682	H; F
PTX-0885		APL-MAS_00273691	APL-MAS_00273701	
PTX-0886		MASA11128490	MASA11128490	402; 403
PTX-0887		MASA11250356	MASA11250356	402; 403
PTX-0888		MASA11250357	MASA11250357	402; 403
PTX-0889		MASA11250363	MASA11250363	402; 403
PTX-0890		MASA11250364	MASA11250364	402; 403
PTX-0891		MASA11074858	MASA11074860	402; 403
PTX-0892		MASA03213057	MASA03213057	402; 403; F

APPLE INC.

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-0893		MASA03142893	MASA03142894	402; 403; F
PTX-0894		MASA03103257	MASA03103263	402; 403; F
PTX-0895		MASA11145230	MASA11145237	
PTX-0896				F; H
PTX-0897				F; H
PTX-0898				F
PTX-0899		MASA00131617	MASA00131617	402; 403; F
PTX-0900		MASA00131574	MASA00131574	402; 403; F
PTX-0901		MASA00131620	MASA00131620	402; 403; F
PTX-0902		MASA00131626	MASA00131626	402; 403; F
PTX-0903		MASA00186020	MASA00186020	402; 403; F
PTX-0904		MASA03116196	MASA03116196	402; 403; F
PTX-0905		MASA00123971	MASA00124005	
PTX-0906		MASA00103182	MASA00103188	402; 403; F
PTX-0907				
PTX-0908				
PTX-0909				
PTX-0910		MASITC_01076908	MASITC_01076908	402; 403; F
PTX-0911		MASITC_01076914	MASITC_01076914	402; 403; F
PTX-0912		MASITC_01076903	MASITC_01076903	402; 403; F
PTX-0913		MASITC_01076902	MASITC_01076902	402; 403; F
PTX-0914		MASITC_01076925	MASITC_01076925	402; 403; F
PTX-0915		MASITC_01076911	MASITC_01076911	402; 403; F
PTX-0916		MASITC_01076907	MASITC_01076907	402; 403; F
PTX-0917		MASITC_01076919	MASITC_01076919	402; 403; F
PTX-0918		MASITC_01076921	MASITC_01076921	402; 403; F

APPLE INC.

879534

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-0919				402; 403; F
PTX-0920		MASITC_00974413	MASITC_00974413	402; 403; F
PTX-0921		MASITC_00974433	MASITC_00974433	402; 403; F
PTX-0922		MASITC_01072905	MASITC_01072905	402; 403; F
PTX-0923		MASITC_01076915	MASITC_01076915	402; 403; F
PTX-0924		MASITC_00974486	MASITC_00974486	402; 403; F
PTX-0925		MASITC_00538087	MASITC_00538087	402; 403; F
PTX-0926		MASITC_01076909	MASITC_01076909	402; 403; F
PTX-0927				402; 403; F
PTX-0928		MASITC_01080004	MASITC_01080004	
PTX-0929				
PTX-0930	Video: Apple Special Event, Steve Jobs Theater, Cupertino (2018)			402; 403; F
PTX-0931	Joint Claim Construction Chart for Asserted Apple Patents (07-13-2023)			402; 403; F; H
PTX-0932	Joint Claim Construction Brief for Apple Asserted Patents (08-31-2023)			402; 403; F; H
PTX-0933	Masimo Corporation and Sound United, LLC's Final Non-Infringement Contentions (08-31-2023)			
PTX-0934	Webpage: 25 Things to Know About Apple Watch (www.pcmag.com/news/25-things-to-know-about-apple-watch)			402; 403; H; F
PTX-0935	Photograph: Masimo W1 "Redesign" (07-20-2023)	APL_DEL00300789	APL_DEL00300789	ID
PTX-0936	Photograph: Masimo Health Module (07-20-2023)	APL_DEL00300846	APL_DEL00300846	
PTX-0937	Photograph: Masimo Health Module (07-20-2023)	APL_DEL00300847	APL_DEL00300847	
PTX-0938	Webpage: Masimo W1 - Advanced Health Tracking Watch (www.masimopersonalhealth.com/products/masimo-w1) (Captured 10-12-2023)	APL_DEL03994735	APL_DEL03994739	
PTX-0939	Webpage: Masimo W1 - Advanced Health Tracking Watch (www.masimopersonalhealth.com/products/masimo-w1) (Captured 11-07-2023)	APL_DEL03994837	APL_DEL03994841	
PTX-0940	Webpage: Apple Watch Series 1 - Technical Specifications (support.apple.com/kb/sp745?locale=en_US)			402; 403
PTX-0941	Webpage: Apple Watch Series 4   D&AD Awards 2019 Pencil Winner (www.dandad.org/awards/professional/2019/product-design/231063/apple-watch-series-4/)			402; 403; H; F
PTX-0942	Webpage: Apple Watch Review: A Day in the Life (www.theverge.com/a/apple-watch-review)			402; 403; H; F


APPLE INC.  
87953

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-0943	Webpage: Google Patents search results for assignee:(apple inc) (patents.google.com/?assignee=apple+inc)			402; 403; F; H
PTX-0944	CN Design Registration No. 304481666	MASAD00019163	MASAD00019165	
PTX-0945	Declaration of Joel Delman in Support of Masimo's Answering Claim Construction Brief (08-10-2023)			
PTX-0946	Masimo v. Apple, PTAB Case No. IPR2023-00774, Decision Denying Institution of Inter Partes Review (09-27-2023)			
PTX-0947	Masimo v. Apple, PTAB Case No. IPR2023-00702, Decision Denying Institution of Inter Partes Review (09-27-2023)			
PTX-0948	Masimo v. Apple, PTAB Case No. IPR2023-00728, Decision Denying Institution of Inter Partes Review (09-18-2023)			
PTX-0949	E-mail from C. de Jong to A. Al-Ali re Smart watch back graphics (07-31-2020)	MASA00159626	MASA00159626	F; 402; 403
PTX-0950		MASAD00073612	MASAD00073612	
PTX-0951	Webpage: Masimo Freedom Smart Health Watch and Band – Masimo Consumer (https://www.masimoconsumer.com)			
PTX-0952	Webpage: Masimo W1 - Advanced Health Tracking Watch (www.masimopersonalhealth.com/products/masimo-w1)			
PTX-0953	U.S. Patent Application Publication No. 2019/0072912 (Pandya)	MASITC 01379393	MASITC 01379465	
PTX-0954	INTENTIONALLY OMITTED			
PTX-0955	Webpage: Fowler - Apple Watch Review: The Smartwatch Finally Makes Sense, Wall Street Journal (04-08-2015) (https://www.wsj.com/articles/apple-watch-review-the-smartwatch-finally-makes-sense-1428494495)			H; F; 402; 403
PTX-0956	Webpage: Apple Watch Series 4 (www.red-dot.org/project/apple-watch-series-4-37071)			H; F; 402; 403
PTX-0957	Webpage: 29/498,998   2607.7350000(P22721US1): CHARGER (patentcenter.uspto.gov/applications/29498998/supplementalContent?application=)			F
PTX-0958	Webpage: Design number 4032616 (www.registered-design-service.gov.uk/find/4032616)			
PTX-0959	U.S. Patent Application Publication No. 2015/0296963 (Byun)			
PTX-0960	U.S. Patent No. 7,004,469 (von Goeben)			
PTX-0961	U.S. Patent No. D287,471 (Sato)			
PTX-0962	U.S. Patent No. D513,195 (Gruosi)			
PTX-0963	U.S. Patent No. D584,170 (Morrison)			
PTX-0964	U.S. Patent No. D620,884 (Lee)			
PTX-0965	U.S. Patent No. D706,212 (Zwierstra)			
PTX-0966	U.S. Patent No. D718,712 (Aumiller)			
PTX-0967	U.S. Patent No. D725,034 (Chen)			
PTX-0968	U.S. Patent No. D728,624 (Akana)			
PTX-0969	U.S. Patent No. D883,279, Replacement Sheet, Fig. 9			

APPLE INC.  
879538

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-0970	U.S. Patent No. D883,279, Figs. 1 through 135			
PTX-0971	U.S. Patent No. D883,279, Replacement Sheet, Figs. 1 through 9			
PTX-0972	U.S. Patent No. D947,842, Amendments to the Drawings			
PTX-0973	U.S. Patent No. D947,842, Figs. 1 through 135			
PTX-0974	U.S. Patent No. D947,842, Replacement Sheet, Figs. 1 through 9			
PTX-0975	U.S. Patent No. D962,936, Amendments to the Drawings			
PTX-0976	U.S. Patent No. D962,936, Figs. 1 through 135			
PTX-0977	U.S. Patent No. D962,936, Replacement Sheet, Figs. 1 through 9			
PTX-0978	WO Application Publication No. 2017/165532 (Paulke)	MASAD00018640	MASAD00018740	
PTX-0979	Masimo v. Apple, PTAB Case No. IPR2023-00702, Petition for Inter Partes Review of U.S. Patent No. D947,842 (03-09-2023)			
PTX-0980	Masimo v. Apple, PTAB Case No. IPR2023-00728, Petition for Inter Partes Review of US Patent No. D962,936 (03-16-2023)			
PTX-0981	Masimo v. Apple, PTAB Case No. IPR2023-00774, Petition for Inter Partes Review of U.S. Patent No. D883,279 (03-24-2023)			
PTX-0982	Masimo v. Apple, PTAB Case No. IPR2023-00831, Petition for Inter Partes Review of U.S. Patent No. D735,131 (04-11-2023)			
PTX-0983	Webpage: Apple Watch Leads Customer Preferences in the USA - Counterpoint Research (www.counterpointresearch.com/apple-watch-leads-customer-preference-usa/)	APL_DEL00038390	APL_DEL00038393	H; F; 402; 403
PTX-0984				F; 402; 403
PTX-0985				F; 402; 403
PTX-0986		APL-MAS_00158504	APL-MAS_00158638	402; 403
PTX-0987		APL-MAS_02905499	APL-MAS_02905620	402; 403
PTX-0988		APL-MAS_02906408	APL-MAS_02906571	402; 403
PTX-0989	(www.dandad.org/awards/professional/2019/product-design/231063/apple-watch-series-4/)			402; 403; H; F
PTX-0990	Webpage: Inside Apple Park: first look at the design team shaping the feature of tech (www.wallpaper.com/design/apple-park-behind-the-scenes-design-team-interview)			402; 403; H; F
PTX-0991	U.S. Patent Application Publication No. 2017/0086743 (Bushnell)	MASA00034885	MASA00034902	

APPLE INC.

87957

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-0992	U.S. Patent No. 6,801,799 (Mendelson)	MASA00048431	MASA00048446	
PTX-0993	U.S. Patent Application Publication No. 2019/0196411 (Yuen)	MASAD00019433	MASAD00019451	
PTX-0994	U.S. Patent Application Publication No. 2019/0324593 (Chung)	MASAD00019452	MASAD00019479	
PTX-0995	U.S. Patent No. D816,524 (Akana)	MASAD00019515	MASAD00019523	
PTX-0996	U.S. Patent No. D827,831 (Fong)	MASAD00019524	MASAD00019527	
PTX-0997	U.S. Patent No. D718,236 (Murray)	MASAD00020376	MASAD00020379	
PTX-0998	U.S. Patent No. D720,289 (Chiang)	MASAD00020380	MASAD00020385	
PTX-0999	Webpage: GMYLE® Qi Wireless Charger Review (Nexus 5) (www.youtube.com/watch?v=EvJ4Jkvj R8)	MASAD00028594	MASAD00028599	
PTX-1000	Masimo v. Apple, PTAB Case No. IPR2023-00774, Patent Owner's Preliminary Response (07-12-2023)			
PTX-1001	Webpage: Coin Specifications   U.S. Mint (www.usmint.gov/learn/coin-and-medal-programs/coin-specifications)			402; 403
PTX-1002	Covves v. Dillard's, C.D. Cal. Case. No. 2:18-cv-08518-RGK, Expert Report of Joel Delman Regarding Infringement of US Patents D787,617 and D783,370 (10-15-2019)			E; 402; 403
PTX-1003	Masimo v. Apple, PTAB Case No. IPR2023-00774, Declaration of Lance Gordon Rake (07-11-2023)			403; F; H
PTX-1004	Panasonic v. Getac, C.D. Cal. Case No. 8:19-cv-01118-DOC, Reporter's Transcript of Proceedings, Jury Trial Day 5, Volume I (06-06-2022)			402; 403; F; H
PTX-1005	Shure v. ClearOne, D. Del. Case No. 1:19-cv-01343-RGA, Reporter's Transcript of Proceedings, Jury Trial, Day 3 (11-03-2021)			402; 403; F; H
PTX-1006	U.S. Patent No. D865,723 (Cho)			402; 403
PTX-1007	Defendants Masimo Corporation and Sound United, LLC's Responses and Objections to Apple's Second Set of Interrogatories (2-4) (-1377) (03-17-2023)			F; H
PTX-1008	Plaintiff Apple Inc.'s Third Set of Interrogatories (Nos. 15-34) (07-21-2023)			402; 403; F; H
PTX-1009	Transcript of Markman Hearing (09-14-2023)			402; 403; F; H
PTX-1010		PL DEL00029953	APL DEL00029994	402; 403
PTX-1011		PL DEL00211157	APL DEL00211158	402; 403
PTX-1012		PL DEL00248715	APL DEL00248758	402; 403
PTX-1013		PL DEL00678424	APL DEL00678535	402; 403
PTX-1014		PL DEL00723768	APL DEL00723771	
PTX-1015		PL DEL00723772	APL DEL00723791	
PTX-1016		PL DEL00723792	APL DEL00723793	

APPLE INC.

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1017	Whitepaper: Masimo - Masimo W1 Hospital-Grade Continuous Monitoring of SpO2 and Other Parameters in a Consumer Watch	APL_DEL00723799	APL_DEL00723814	
PTX-1018		APL_DEL01346727	APL_DEL01346750	402; 403
PTX-1019		APL_DEL01922643	APL_DEL01922689	402; 403
PTX-1020		APL_DEL01923594	APL_DEL01923642	402; 403
PTX-1021		APL_DEL01989135	APL_DEL01989166	402; 403
PTX-1022		APL_DEL02420136	APL_DEL02420161	402; 403
PTX-1023		APL_DEL03851022	APL_DEL03851052	402; 403
PTX-1024		APL_DEL04014868	APL_DEL04014884	H; F
PTX-1025		APL_MAS_01145816	APL-MAS_01145865	
PTX-1026	Ed. (2003)			H; F; 402; 403
PTX-1027	Webpage: Masimo - Governance - Executive Management (investor.masimo.com/governance/executive-management/default.aspx)			
PTX-1028	Webpage: Medical Pioneer Masimo Announces the Full Market Consumer Release of the Masimo W1™, the First Watch to Offer Accurate, Continuous Health Data   Masimo (08-31-2022) (investor.masimo.com/news/news-details/2022/Medical-Pioneer-Masimo-Announces-the-Full-Market-Consumer-Release-of-the-Masimo-W1-the-First-Watch-to-Offer-Accurate-Continuous-Health-Data/default.aspx)			
PTX-1029		ASA00176554	MASA00176554	
PTX-1030		ASA03074104	MASA03074108	
PTX-1031		ASA03163747	MASA03163749	
PTX-1032		ASA03228642	MASA03228649	
PTX-1033		ASA03352097	MASA03352104	
PTX-1034		ASA03581258	MASA03581260	
PTX-1035		ASA03581317	MASA03581325	



APPLE INC.

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1036	Webpage: Medical Pioneer Masimo Announces the Full Market Consumer Release of the Masimo W1, the First Watch to Offer Accurate, Continuous Health Data (www.businesswire.com/news/home/20220831005074/en/Medical-Pioneer-Masimo-Announces-the-Full-Market-Consumer-Release-of-the-Masimo-W1%E2%84%A2-the-First-Watch-to-Offer-Accurate-Continuous-Health-Data)	MASA03583912	MASA03583914	
PTX-1037		MASA03585382	MASA03585412	
PTX-1038		MASAD00006405	MASAD00006405	
PTX-1039		MASAD00006427	MASAD00006427	
PTX-1040		MASAD00006443	MASAD00006443	
PTX-1041		MASAD00006445	MASAD00006445	
PTX-1042		MASAD00006616	MASAD00006622	
PTX-1043		MASAD00006639	MASAD00006639	
PTX-1044		MASAD00006645	MASAD00006645	
PTX-1045		MASAD00006646	MASAD00006646	
PTX-1046		MASAD00006810	MASAD00006816	
PTX-1047		MASAD00006999	MASAD00007002	
PTX-1048		MASAD00007202	MASAD00007202	
PTX-1049		MASAD00007358	MASAD00007358	
PTX-1050		MASAD00007367	MASAD00007367	
PTX-1051		MASAD00007376	MASAD00007376	
PTX-1052		MASAD00008134	MASAD00008136	
PTX-1053		MASAD00008159	MASAD00008162	
PTX-1054		MASAD00008205	MASAD00008208	
PTX-1055		MASAD00008243	MASAD00008248	
PTX-1056		MASAD00008407	MASAD00008417	
PTX-1057		MASAD00008614	MASAD00008615	
PTX-1058		MASAD00009174	MASAD00009178	
PTX-1059		MASAD00010737	MASAD00010756	
PTX-1060		MASAD00010879	MASAD00010910	
PTX-1061		MASAD00010972	MASAD00010977	
PTX-1062		MASAD00010982	MASAD00010982	

APPLE INC.

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1063		ASAD00010987	MASAD00010988	
PTX-1064		ASAD00010989	MASAD00010992	
PTX-1065		ASAD00011249	MASAD00011280	
PTX-1066		ASAD00012046	MASAD00012079	
PTX-1067		ASAD00012155	MASAD00012155	
PTX-1068		ASAD00012267	MASAD00012267	
PTX-1069		ASAD00012325	MASAD00012326	
PTX-1070		ASAD00012385	MASAD00012391	
PTX-1071		ASAD00013476	MASAD00013490	
PTX-1072		ASAD00014131	MASAD00014134	
PTX-1073		ASAD00014255	MASAD00014259	
PTX-1074		ASAD00014300	MASAD00014300	
PTX-1075		ASAD00014301	MASAD00014301	
PTX-1076		ASAD00014304	MASAD00014304	
PTX-1077		ASAD00014323	MASAD00014323	
PTX-1078		ASAD00014399	MASAD00014399	
PTX-1079		ASAD00014429	MASAD00014430	
PTX-1080		ASAD00014497	MASAD00014497	
PTX-1081		ASAD00016586	MASAD00016586	402; 403; F
PTX-1082		ASAD00016590	MASAD00016597	F
PTX-1083		ASAD00032917	MASAD00032946	F; H
PTX-1084		ASAD00033048	MASAD00033069	F; H
PTX-1085		ASAD00033139	MASAD00033179	F; H
PTX-1086		ASAD00033524	MASAD00033524	402; 403
PTX-1087		ASAD00033533	MASAD00033541	
PTX-1088		ASAD00036816	MASAD00036825	
PTX-1089		ASAD00039694	MASAD00039803	F
PTX-1090		ASAD00040063	MASAD00040158	F
PTX-1091		ASAD00043172	MASAD00043179	F
PTX-1092		ASAD00044998	MASAD00045023	
PTX-1093		ASAD00045143	MASAD00045191	

APPLE INC.

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1094		ASAD00048481	MASAD00048481	402; 403
PTX-1095		ASAD00051594	MASAD00051594	402; 403
PTX-1096		ASAD00051598	MASAD00051598	402; 403
PTX-1097		ASAD00051600	MASAD00051602	402; 403; F
PTX-1098		ASAD00053444	MASAD00053444	
PTX-1099		ASAD00059684	MASAD00059689	
PTX-1100		ASAD00070856	MASAD00070868	
PTX-1101		ASAD00070882	MASAD00070882	
PTX-1102		ASAD00071280	MASAD00071280	
PTX-1103		ASAD00071298	MASAD00071298	
PTX-1104		ASAD00071331	MASAD00071331	
PTX-1105		ASAD00073612	MASAD00073612	
PTX-1106		ASAD00081610	MASAD00081617	
PTX-1107		ASAD00081859	MASAD00081866	
PTX-1108				
PTX-1109		ASAD00116642	MASAD00116642	
PTX-1110		ASAD00124013	MASAD00124013	
PTX-1111		ASAD00183722	MASAD00183777	
PTX-1112		ASAD00183838	MASAD00183907	
PTX-1113		ASAD00184338	MASAD00184343	
PTX-1114		ASAD00233544	MASAD00233583	
PTX-1115		ASAD00237172	MASAD00237228	
PTX-1116		ASAD00237465	MASAD00237510	
PTX-1117		ASAD00507213	MASAD00507214	F
PTX-1118		ASAD00667448	MASAD00667474	
PTX-1119		ASAD00684831	MASAD00684837	F
PTX-1120		ASAD00694309	MASAD00694326	
PTX-1121		ASAD00694339	MASAD00694351	
PTX-1122		ASAD01188095	MASAD01188102	F; 106
PTX-1123		ASAD01188103	MASAD01188103	F; 106

APPLE INC.

87982

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1124		MASAD03004245	MASAD03004252	
PTX-1125		MASAD03585382	MASAD03585386	402; 403; F
PTX-1126		MASITC 00464308	MASITC 00464308	
PTX-1127		MASITC 00465602	MASITC 00465603	
PTX-1128		MASITC_00958744	MASITC_00958750	
PTX-1129		MASITC_01081766	MASITC_01081770	
PTX-1130		MASITC 01250599	MASITC 01250599	
PTX-1131		MASITC_01299351	MASITC_01299355	F
PTX-1132		MASITC_01379391	MASITC_01379391	402; 403
PTX-1133	Shim et al. (2021), Fundamental Limits to the Refractive Index of Transparent Optical Materials, Advanced Materials			F; H
PTX-1134	File History for US Patent No. 10,448,871			402; 403; F
PTX-1135	Certified copy of U.S. Patent No. 11,474,483	APL DEL00010259	APL DEL00010324	
PTX-1136	U.S. Patent No. 10,448,871 (Al-Ali)			402; 403
PTX-1137	U.S. Patent No. 11,432,766 (Pandya)			
PTX-1138	U.S. Patent Application Publication No. 2016/0378069 (Rothkopf)			402; 403
PTX-1139	U.S. Patent Application Publication No. 2016/0378071			402; 403
PTX-1140	U.S. Patent Application Publication No. 2019/0072912 (Pandya)			
PTX-1141	M. Hutin & M. Leblanc Transformer System For Electric Railways Patent No. 527,857 (10-23-1894)			402; 403
PTX-1142	U.S. Patent No. 8,615,290 (Lin)			
PTX-1143	Webpage: Masimo W1 - Advanced Health Tracking Watch (www.masimopersonalhealth.com/products/masimo-w1) (Redesign) (Captured 12-06-2023)			
PTX-1144	Merriam-Webster - Array Definition & Meaning (www.merriam-webster.com)			402; 403; F; H
PTX-1145	Merriam-Webster Thesaurus - WATER-RESISTANT Synonyms_ 14 Similar and Opposite Words (www.merriam-webster.com)			402; 403; F; H
PTX-1146	ROHM - Electromagnetic induction I Electronics Basics (www.rohm.com)			402; 403; F; H
PTX-1147		APL DEL00196708	APL DEL00196750	402; 403
PTX-1148		APL_DEL01460418	APL_DEL01460429	402; 403; H; F

APPLE INC.

87963

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1149	Webpage: Apple Watch 4 Adds ECG, EKG and More Heart-Monitoring Capabilities   WIRED (09-12-2018) (www.wired.com/story/apple-watch-series-4/)	APL_DEL01460430	APL_DEL01460440	402; 403; H; F
PTX-1150	Webpage: Apple Watch Series 4 Named Wearable of the Year   Forbes (12-13-2018) (www.forbes.com/sites/paullamkin/2018/12/13/apple-watch-series-4-named-wearable-of-the-year/?sh=30baae3e7b3e)	APL_DEL01460441	APL_DEL01460443	402; 403; H; F
PTX-1151	Webpage: Apple Watch Series 4 review   Tom's Guide (09-17-2021) (www.tomsguide.com/us/apple-watch-series-4,review-5764.html)	APL_DEL01460444	APL_DEL01460450	402; 403; H; F
PTX-1152	Webpage: Asus ZenWatch review   The Verge (12-10-2014) (www.theverge.com/2014/12/10/7369247/asus-zenwatch-review)	APL_DEL01460462	APL_DEL01460467	402; 403; H; F
PTX-1153	Webpage: Asus Zen Watch review   Wareable (01-19-2015) (www.wareable.com/android-wear/asus-zenwatch-smartwatch-review)	APL_DEL01460468	APL_DEL01460472	402; 403; H; F
PTX-1154	Webpage: Qualcomm Toq: The Good, the Bad & the Ugly [Review] (01-03-2014) (www.readwrite.com/qualcomm-toq-smartwatch-review/)	APL_DEL01460473	APL_DEL01460477	402; 403; H; F
PTX-1155	Webpage: Withings Pulse O2 Review   PC Mag (04-30-2014) (www.pcmag.com/reviews/withings-pulse-o2)	APL_DEL01460484	APL_DEL01460490	402; 403; H; F
PTX-1156	Webpage: Apple awarded stocking full of patents, including heart monitor (12-24-2013) (www.cnet.com/tech/tech-industry/apple-awarded-stocking-full-of-patents-including-heart-monitor/)	APL_DEL03850995	APL_DEL03850995	402; 403; H; F
PTX-1157	Webpage: Apple's Seamlessly Embedded Heart Rate Monitor could turn the iPhone into a new-age mood ring (07-19-2019) (www.engadget.com/2010-05-06-apples-seamlessly-embedded-heart-rate-monitor-could-turn-the-up.html)	APL_DEL03850996	APL_DEL03850996	402; 403; H; F
PTX-1158	Webpage: Apple Patents 'Touch and Hover' Sensing, Embedded Heart Rate Monitoring (12-24-2013) (www.hothardware.com/news/apple-patents-touch-and-hover-sensing-embedded-heart-rate-monitoring)	APL_DEL03850997	APL_DEL03850997	402; 403; H; F
PTX-1159	Webpage: Apple patents "seamless" heart rate sensor for authentication, personalization (01-02-2014) (www.mobihealthnews.com/28349/apple-patents-seamless-heart-rate-sensor-for-authentication-personalization)	APL_DEL03851002	APL_DEL03851002	402; 403; H; F
PTX-1160	Webpage: Apple's latest patents cover heart rate monitors and hover touch displays (12-24-2013) (www.techradar.com/news/phone-and-communications/mobile-phones/apple-s-new-patents-cover-heart-rate-monitors-and-hover-touch-displays-1210845)	APL_DEL03851011	APL_DEL03851011	402; 403; H; F
PTX-1161	Bruning et al. - Acquisition and analysis of cardiovascular signals on smartphones: potential, pitfalls and perspectives - European Journal of Preventive Cardiology, Vol. 21 (09-03-2014)	APL_DEL03851012	APL_DEL03851021	402; 403; H; F

APPLE INC.

87984

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1162	Photograph: Polar Pacer Heart Monitor with Chest Band, User's Guide and packaging produced by Masimo bearing tags MASAD_P_020-A through MASAD_P_20-C (APL_DELO4028334 - APL_DELO4028366; MASAD04145202 - MASAD04145235) (67 native documents)			
PTX-1163	Photograph: Mio Fuse smartwatch with packaging produced by Masimo bearing tags MASAD_P_021-A through MASAD_P_021-B (APL_DELO4028367 - APL_DELO4028407) (35 native documents)			
PTX-1164	Photograph: Fossil Abacus AU4002 with packaging and charger produced by Masimo bearing tags MASAD_P_022A through MASAD_P_022C (APL_DELO4028408 - APL_DELO4028427) (19 native documents)			
PTX-1165	Photograph: Polar Pacer Heart Rate Monitor produced by Masimo bearing tag MASAD_P_041 (APL_DELO4028429 - APL_DELO4028611) (18 native documents)			
PTX-1166	Photograph: Qualcomm Toq smartwatch produced by Masimo bearing tag MASAD_P_024 (APL_DELO4028445 - APL_DELO4028457) (13 native documents)			
PTX-1167	Photograph: Epson Pulsense PS-100 produced by Masimo bearing tag MASAD_P_027 (APL_DELO4028488 - APL_DELO4028501) (14 native documents)			
PTX-1168	Photograph: Epson Pulsense PS-100 produced by Masimo bearing tag MASAD_P_028 (APL_DELO4028502 - APL_DELO4028523) (22 native documents)			
PTX-1169	Photograph: Epson Pulsense PS-100 produced by Masimo bearing tag MASAD_P_029 (APL_DELO4028524 - APL_DELO4028539) (16 native documents)			
PTX-1170	Photograph: Contec CMS50K Wearable SpO2/ECG Monitor produced by Masimo bearing tag MASAD_P_038 (APL_DELO4028547 - APL_DELO4028572) (26 native documents)			
PTX-1171	Photograph: Mio Shape smartwatch produced by Masimo bearing tag MASAD_P_040 (APL_DELO4028573 - APL_DELO4028595) (23 native documents)			
PTX-1172	Photograph: Qualcomm Toq smartwatch and charger produced by Masimo bearing tag MASAD_P_052 (APL_DELO4028612 - APL_DELO4028656) (45 native documents)			
PTX-1173	Photograph: Fossil Abacus AU4005 produced by Masimo bearing tag MASAD_P_053 (APL_DELO4028657 - APL_DELO4028691) (35 native documents)			
PTX-1174	Wrist Net Reference guide front	APL DELO4028666	APL DELO4028666	
PTX-1175	Wrist Net Reference guide back	APL DELO4028667	APL DELO4028667	
PTX-1176	The Oxford American Dictionary	APL DELO4028846	APL DELO4028848	402; 403; H; F
PTX-1177	The Merriam-webster Dictionary	APL DELO4029526	APL DELO4029528	402; 403; H; F

APPLE INC.

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1178		ONTEC00005	CONTEC00005	
PTX-1179	Masimo Ex. 1009 EP14163114 Patent Application			
PTX-1180		EPSON0001	EPSON0041	
PTX-1181		EPSON0042	EPSON0042	
PTX-1182		EPSON0043	EPSON0046	
PTX-1183		EPSON0047	EPSON0047	
PTX-1184	Webpage: Si PIN photodiode S5821-03 ( <a href="https://www.hamamatsu.com/us/en/product/optical-sensors/photodiodes/si-photodiodes/S5821-03.html">https://www.hamamatsu.com/us/en/product/optical-sensors/photodiodes/si-photodiodes/S5821-03.html</a> )			402; 403; H; F; UK
PTX-1185				402; 403; H; F; UK
PTX-1186		INNOMINDS 000028	INNOMINDS 000039	
PTX-1187	(09-18-2023)			
PTX-1188	Masimo v. Apple, PTAB Case No. IPR2023-00807, Petition for Inter Partes Review of U.S. Patent No. 11,474,483 (04-04-2023)			
PTX-1189	Masimo v. Apple, PTAB Case No. IPR2023-00831, Decision Denying Institution of Inter Partes Review (11-21-2023)			
PTX-1190	Japanese Patent Application Publication No. 2005-270543 (Japanese) (Tanagi)			
PTX-1191		MASA02215050	MASA02215056	402; 403; F
PTX-1192	U.S. Patent No. 9,583,256 (Lapetina)	MASAD00017839	MASAD00017862	
PTX-1193	U.S. Patent Application Publication No. 2015/0135310 (Lee)	MASAD00017903	MASAD00017928	
PTX-1194	WO Application Publication No. 2005/092182 (Paulke)	MASAD00017965	MASAD00017996	
PTX-1195	PCT/EP2015/056482 Application (03-26-2015)	MASAD00018410	MASAD00018440	
PTX-1196	WO Application Publication No. 2015/150199 (Koninklijke)	MASAD00018441	MASAD00018471	
PTX-1197	Francis, ECG monitoring leads and special leads, Indian Pacing and Electrophysiology Journal 16, 92-95 (2016)	MASAD00018881	MASAD00018884	
PTX-1198	Quick Start Guide for the Fossil Abacus Wrist Net, Version 3 (05-2014)	MASAD00251160	MASAD00251177	
PTX-1199	DC Rainmaker, Hands-On with Epsoms new Pulsense Optical heart rate activity tracker (08-11-2014)	MASAD00251180	MASAD00251217	
PTX-1200	CN Patent No. 205041396 (Hu)	MASAD00251218	MASAD00251232	
PTX-1201	Japanese Unexamined Patent Application S57-37438 (Yoshihisa)	MASAD00251323	MASAD00251326	
PTX-1202	Mio Introduces Its Next Breakthrough Product: The Most Accurate Wrist-Based Heart Rate Monitoring without a Chest Strap Now Paired with Daily Activity Tracking - "Your Day. In Action!" (07-31-2014)	MASAD00251552	MASAD00251556	
PTX-1203	Lee, Review: Qualcomm's Tog smartwatch lasts an extra, extra, extra long time (12-11-2013)	MASAD00251602	MASAD00251620	
PTX-1204	Shuhai, Oranger Releases Overall Solution for Sleep and Breathing	MASAD00253864	MASAD00253868	

APPLE INC.

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1205	Oranger Dr Watch 2.0: A Doctor's Care for Her Snoring Mother by Sleep Health (09-18-2016)	MASAD00253888	MASAD00253904	
PTX-1206	Care for your loved one by your side with the Oranger Snore Monitor 2.0 by Hao Xi Intelligent (07-27-2015)	MASAD00253905	MASAD00253916	
PTX-1207		MASAD04060866	MASAD04060872	
PTX-1208		MASAD04144843	MASAD04144845	402; 403; F; H
PTX-1209				
PTX-1210				402; 403; H; F
PTX-1211		PEI SUBPOENA 000001	PEI SUBPOENA 000019	
PTX-1212		PEI SUBPOENA 000020	PEI SUBPOENA 000021	
PTX-1213		PEI SUBPOENA 000022	PEI SUBPOENA 000027	
PTX-1214		PEI SUBPOENA 000028	PEI SUBPOENA 000040	
PTX-1215		PEI SUBPOENA 000041	PEI SUBPOENA 000046	
PTX-1216		PEI SUBPOENA 000047	PEI SUBPOENA 000047	
PTX-1217				
PTX-1218	File History for U.S. Prov. Appl. No. 61/886,930			
PTX-1219	File History for U.S. Prov. Appl. No. 62/044,974			
PTX-1220	Certified copy of File History for U.S. Patent No. 10,627,783 - Appl. No. 15/261,917	APL_DEL00003012	APL_DEL00005157	
PTX-1221	U.S. Patent Application Publication No. 2007/0021677 (Markel)			
PTX-1222	U.S. Patent Application Publication No. 2020/0336019			
PTX-1223	U.S. Patent No. 5,351,695 (Mills)			
PTX-1224	U.S. Patent No. 6,982,930 (Hung)			
PTX-1225	U.S. Patent Application Publication No. 2016/0058375 (Rothkopf)	MASAD00018767	MASAD00018825	
PTX-1226	U.S. Patent Application Publication No. 2014/0107493 (Yuen)			
PTX-1227	U.S. Patent Application Publication No. 2014/0275852 (Hong)			
PTX-1228	U.S. Patent Application Publication No. 2019/0072912 (Pandya)	MASITC 01379393	MASITC 01379465	
PTX-1229	Patent WO 2005 092182 (Kotanagi)			
PTX-1230	Patent WO 2012-140559A1 (Shmueli)			
PTX-1231	Photograph: February 2021 Masimo W1 Sensor with "Circle Design"	APL_DEL00261798	APL_DEL00261798	
PTX-1232		MASA03073322	MASA03073324	
PTX-1233		MASAD00045192	MASAD00045211	402; 403
PTX-1234		MASAD00445598	MASAD00445599	
PTX-1235		MASAD00835219	MASAD00835221	F
PTX-1236		MASAD02496985	MASAD02496991	
PTX-1237		MASAD03461553	MASAD03461553	
PTX-1238				F; H



APPLE INC.

87987

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1239	Declaration of Peter Russell-Clarke in Support of Apple Inc.'s Motion for an Expedited Trial (-1377) (01-12-2023)			402; 403; F; H
PTX-1240		PL_DELO1525964	APL_DELO1525967	
PTX-1241	Declaration of Alan D. Ball in support of Apple Inc's Opening Claim Construction Brief with exhibits			402; 403; E
PTX-1242	Masimo's Final Noninfringement Contentions and Appendix A-F (1378) (2023-08-31 )			
PTX-1243	Webpage: Lens   Meaning, Principles, Manufacture, & Facts   Britannica ( <a href="https://www.britannica.com/technology/lens-optics">https://www.britannica.com/technology/lens-optics</a> )			402; 403; F; H
PTX-1244	Webpage: Lens Definition & Meaning - Merriam-Webster ( <a href="https://www.merriam-webster.com/dictionary/lens">https://www.merriam-webster.com/dictionary/lens</a> )			402; 403; F; H
PTX-1245	Webpage: LENS Definition & Usage Examples   Dictionary.com			402; 403; F; H
PTX-1246		MASAD00006403	MASAD00006403	
PTX-1247		MASAD00006957	MASAD00006957	
PTX-1248		MASAD00012159	MASAD00012162	
PTX-1249		MASAD00033167	MASAD00033167	
PTX-1250		MASAD00037078	MASAD00037078	
PTX-1251		MASAD00051056	MASAD00051059	
PTX-1252		MASAD00071221	MASAD00071275	
PTX-1253		MASAD00079667	MASAD00079688	
PTX-1254		MASAD01001288	MASAD01001289	F
PTX-1255		MASAD03738106	MASAD03738168	
PTX-1256	Webpage: Masimo - The Future of Wearables Technology Masimo Freedom Smart Health Watch & Band ( <a href="https://www.masimoconsumer.com">https://www.masimoconsumer.com</a> )			
PTX-1257	Webpage: Structure Definition & Meaning - Merriam-Webster ( <a href="https://www.merriam-webster.com/dictionary/structure">https://www.merriam-webster.com/dictionary/structure</a> )			402; 403; F; H
PTX-1258	Webpage: Structure Definition & Meaning   Britannica Dictionary ( <a href="https://www.britannica.com/dictionary/structure">https://www.britannica.com/dictionary/structure</a> )			402; 403; F; H
PTX-1259	U.S. Patent No. 9,413,191			402; 403; F
PTX-1260	U.S. Patent No. 5,738,104			
PTX-1261	U.S. Patent No. 5,802,467			402; 403; F
PTX-1262	Webpage: WYC - 20 Dual Time and GMT Watches You Will Surely Love ( <a href="https://watchesyoucanafford.com/dual-time-and-gmt-watches/">https://watchesyoucanafford.com/dual-time-and-gmt-watches/</a> )			402; 403; H; F
PTX-1263	Webpage: Amazon.com: Masimo W1™ Advanced Fitness Tracker Smart Watch ( <a href="https://www.amazon.com/Masimo-Advanced-Smartwatch-Continuous-Activity/dp/B0C5JY26W2">https://www.amazon.com/Masimo-Advanced-Smartwatch-Continuous-Activity/dp/B0C5JY26W2</a> )			

APPLE INC.

87968

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1264	Webpage: Amazon.com: Smartwatches - Wearable Technology: Electronics ( <a href="https://www.amazon.com/smart-watches/b?ie=UTF8&amp;node=7939901011">https://www.amazon.com/smart-watches/b?ie=UTF8&amp;node=7939901011</a> )			402; 403; H; F
PTX-1265	Simonson - Choice Based on Reasons: The Case of Attraction and Compromise Effects, Journal Of Consumer Research Vol. 16 (09-1998)			402; 403
PTX-1266	Webpage: Garmin Forerunner   Premium Running Watch ( <a href="https://www.garmin.com/en-US/p/777655#specs">https://www.garmin.com/en-US/p/777655#specs</a> )			402; 403; H; F
PTX-1267	Jim Cramer on CNBC's Mad Money to Discuss Masimo and the W1 Smartwatch.mp4			
PTX-1268	S. Frederick et al. - Limits of Attraction, American Marketing Association (2014)			402; 403; H; F
PTX-1269	Video of Masimo CEO Joe Kiani Interview with Jim Cramer on CNBC's Mad Money on WI Product			
PTX-1270	Webpage: Masimo W1 - Advanced Health Tracking Watch ( <a href="http://www.masimopersonalhealth.com/products/masimo-w1">www.masimopersonalhealth.com/products/masimo-w1</a> )			
PTX-1271	G. Kolb - Mobvoi TicWatch Pro 3 Ultra GPS Smartwatch Review - Making Your Wrist the Smartest Part of Your Body, The Gadgeteer (09-11-2022)			402; 403; H; F
PTX-1272	Webpage: Multi Time Zone Digital   Garmin Connect IQ ( <a href="https://apps.garmin.com/en-US/apps/230667a0-e5a6-49bc-aeed-856806870d7a#0">https://apps.garmin.com/en-US/apps/230667a0-e5a6-49bc-aeed-856806870d7a#0</a> )			402; 403; H; F
PTX-1273	D. Gal et al. - Predicting Consumers' Choices in The Age of The Internet, AI, and Almost Perfect Tracking: Some Things Change, The Key, Challenges Do Not (11-19-2020)			402; 403
PTX-1274	M. DeGroot et al. - Probability and Statistic, Fourth Edition, Pearson Education, Inc. (2012)			402; 403; H; F
PTX-1275	R. Dawes - The Robust Beauty of Improper Linear Models in Decision Making, American Psychological Association, Inc. (07-1979)			402; 403; H; F
PTX-1276	R. Leedham - The TicWatch Pro 3 Was Made With Speed In Mind, GQ Magazine (11-20-2020)			402; 403; H; F
PTX-1277	I. Simonson - Will I Like a "Medium" Pillow? Another Look at Constructed and Inherent Preferences, Journal of Consumer Psychology (06-03-2008)			402; 403
PTX-1278	Webpage: Apple Watch Series 8 [ GPS + Cellular, 45mm] - Midnight Aluminum Case with Midnight Sport Band, M/L (Renewed) ( <a href="https://www.amazon.com/Apple-Watch-GPS-Cellular-45mm/dp/B0BNFGKSNF/ref=sr_1_3?crd=2BCVH1RM4498Y&amp;keywords=apple+smartwatch+series+8&amp;qid=1702819597&amp;srefix=apple+smartwatch+series+8,aps,205&amp;sr=8-3&amp;th=1">https://www.amazon.com/Apple-Watch-GPS-Cellular-45mm/dp/B0BNFGKSNF/ref=sr_1_3?crd=2BCVH1RM4498Y&amp;keywords=apple+smartwatch+series+8&amp;qid=1702819597&amp;srefix=apple+smartwatch+series+8,aps,205&amp;sr=8-3&amp;th=1</a> )			402; 403; H; F

APPLE INC.  
87969

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1279	Webpage: Masimo W1 Sport Advanced Health Tracking Wearable Now Including FDA-Cleared Module ( <a href="https://www.amazon.com/Masimo-Advanced-Smartwatch-ContinuousActivity/dp/B0C5JY26W2/ref=sr_1_1?crid=1IRQI7HVRVT33&amp;keywords=masimo+w1&amp;qid=1702819344&amp;srefix=masimo+w1,aps,191&amp;sr=8-1&amp;ufe=app_do:amzn1.fos.17d9e15d-4e43-4581-b373-0e5c1a776d5d">https://www.amazon.com/Masimo-Advanced-Smartwatch-ContinuousActivity/dp/B0C5JY26W2/ref=sr_1_1?crid=1IRQI7HVRVT33&amp;keywords=masimo+w1&amp;qid=1702819344&amp;srefix=masimo+w1,aps,191&amp;sr=8-1&amp;ufe=app_do:amzn1.fos.17d9e15d-4e43-4581-b373-0e5c1a776d5d</a> )			
PTX-1280	Webpage: Masimo W1 Medical Watch ( <a href="https://www.masimo.com/products/monitors/masimo-w1-medical-watch">https://www.masimo.com/products/monitors/masimo-w1-medical-watch</a> )			
PTX-1281	S. Diamond - Reference Guide on Survey Research, Reference Manual on Scientific Evidence (n/a)			402; 403; H; F
PTX-1282	J. Krosnick - Survey Research, Annual Review of Psychology (1999)			402; 403; H; F
PTX-1283	Masimo v. Apple, PTAB Case No. IPR2023-00664, Petition for Inter Partes Review of U.S. Patent No. 11,106,352 (03-06-2023)			
PTX-1284	Appendix E Non-Infringement Claim Chart for U.S. Patent No. 11, 106,352 to Masimo Corporation and Sound United, LLC's Final Non-Infringement Contentions (08-31-2023)			
PTX-1285	Webpage: iPhone 15 and iPhone 15 Plus - Technical Specifications - Apple ( <a href="https://www.apple.com/iphone-15/specs/">https://www.apple.com/iphone-15/specs/</a> )			402; 403; H; F
PTX-1286		MASA03083556	MASA03083557	F
PTX-1287		MASA03187572	MASA03187580	
PTX-1288		MASA03188242	MASA03188247	
PTX-1289		MASAD00007252	MASAD00007253	
PTX-1290		MASAD00231638	MASAD00231642	
PTX-1291		MASAD00451510	MASAD00451511	
PTX-1292		MASAD02178654	MASAD02178661	
PTX-1293		MASAD02463376	MASAD02463376	402; 403; F
PTX-1294		MASAD02463583	MASAD02463584	F
PTX-1295				402; 403; H; F
PTX-1296	2018)			
PTX-1296	Video File (File Name: VID_20231213_105208421.mp4)	APL_DEL04028306	APL_DEL04028306	F
PTX-1297	Inspection Video (12-12-2023) (File Name: MVI_3332.MOV)	APL_DEL04028700	APL_DEL04028700	F
PTX-1298	Inspection Video (12-12-2023) (File Name: MVI_3334.MOV)	APL_DEL04028702	APL_DEL04028702	F
PTX-1299	Inspection Video (12-12-2023) (File Name: MVI_3335.MOV)	APL_DEL04028703	APL_DEL04028703	F
PTX-1300	Inspection Video (12-12-2023) (File Name: MVI_3337.MOV)	APL_DEL04028705	APL_DEL04028705	F
PTX-1301	Inspection Video (12-12-2023) (File Name: MVI_3338.MOV)	APL_DEL04028706	APL_DEL04028706	F
PTX-1302	Inspection Video (12-12-2023) (File Name: MVI_3341.MOV)	APL_DEL04028708	APL_DEL04028708	F

APPLE INC.  
87970

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1303	Inspection Video (12-12-2023) (File Name: MVI_3343.MOV)	APL_DEL04028710	APL_DEL04028710	F
PTX-1304	M. Belvedere - Apple's Tim Cook: If We Unveiled iPhone X after iPhone 8, People Would Have Said, 'You Hosed Me.', CNBC (11-03-2017)			H; F; 402; 403
PTX-1305	V. Savov - Asus Adds Zen to The Android Wear Smartwatch, The Verge (09-03-2014)			
PTX-1306	[REDACTED]	SUS_00000001	ASUS_00000001	
PTX-1307	Gadget Hacks Shop (09-13-2018)			H; F
PTX-1308	J. Centers - Early iPhone X Reviews Praise Screen, Face ID, TidBITS (11-06-2017)			H; F
PTX-1309	W. Nicol - Here are Five Things We Like About the iPhone X (And Two We Don't) DigitalTrends (09-12-2017)			H; F
PTX-1310	L. Eadicicco - The 2024 iPhone SE 4 May Already Be Canceled, CNET (01-29-2023)			H; F
PTX-1311	D. Seifert - Every Phone Should Copy the iPhone X's Gestures, The Verge (01-31-2018)			H; F
PTX-1312	A. Hern - iPhone X: Most Expensive Apple Smartphone Sells Out In Minutes, The Guardian (10-28-2017)			H; F
PTX-1313	S. Vazharov - Apple's iPhone X is The Future of Smartphone Technology, Best Products (11-01-2017)			H; F
PTX-1314	U.S. Patent Application Publication No. 2012/0129495 (Chae)	MASAD00017374	MASAD00017414	
PTX-1315	Video File	MASAD00017740	MASAD00017740	
PTX-1316	B. Chester - ASUS Unveils the ZenWatch at IFA, AnandTech (09-03-2014)	MASAD00250973	MASAD00250976	
PTX-1317	ASUSTek Computer, Inc., - ASUS ZenWatch E-Manual, First Edition (11-2014)	MASAD04143458	MASAD04143515	
PTX-1318	Samsung Electronics, Inc. - SM-G50W, SM-G955W User Manual (2020)	MASAD04143516	MASAD04143782	
PTX-1319	LG Electronics - LG Watch Style LG-W270 User Guide (n/a)	MASAD04143783	MASAD04143849	
PTX-1320	Google, Inc. - Nexus 7 Guidebook For Andriod Mobile Technology Platform 4.1 (2012)	MASAD04143850	MASAD04143955	
PTX-1321	Webpage: Set Up a Screen Lock on Your Galaxy Phone ( <a href="https://www.samsung.com/us/support/answer/ANS10001343/">https://www.samsung.com/us/support/answer/ANS10001343/</a> )			H; F
PTX-1322	S. Ghosh - This Chart Shows iPhone X Adoption Has Overtaken the iPhone 8 and iPhone 8 Plus, Business Insider (12-13-2017)			H; F
PTX-1323	A. Mallick - Why You Shouldn't Be Afraid to Give Up the iPhone' Home Button, iDrop News (07-27-2019)			H; F
PTX-1324	Masimo v. Apple, PTAB Case No. IPR2023-00664, Declaration of Craig S. Rosenberg, Ph.D (03-02-2023)			403
PTX-1325	[REDACTED]	MASAD01445908	MASAD01445909	402; 403; H; F
PTX-1326	[REDACTED]	MASAD02178654	MASAD02178661	

APPLE INC.

87971

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1327	Webpage: 10 Most Groundbreaking Apple Product Innovations ( <a href="https://www.slashgear.com/773534/10-most-groundbreaking-apple-product-innovations/">https://www.slashgear.com/773534/10-most-groundbreaking-apple-product-innovations/</a> )	APL_DELO4012753	APL_DELO4012782	402; 403; H; F
PTX-1328	Webpage: 10 Years Since Pebble - We Remember A Legend of Wearable Tech ( <a href="https://www.wareable.com/smartwatches/pebble-smartwatch-revisited-legacy-7440">https://www.wareable.com/smartwatches/pebble-smartwatch-revisited-legacy-7440</a> )			402; 403; H; F
PTX-1329	INTENTIONALLY OMITTED			
PTX-1330	INTENTIONALLY OMITTED			
PTX-1331	INTENTIONALLY OMITTED			
PTX-1332	Complaint for Patent Infringement (-1377) (10-20-2022)			402; 403; F
PTX-1333	INTENTIONALLY OMITTED			
PTX-1334	INTENTIONALLY OMITTED			
PTX-1335	INTENTIONALLY OMITTED			
PTX-1336	Exhibit 2 to Declaration of Eric Jue in Support of Apple Inc.'s Motion for an Expedited Trial (01-18-2023)			402; 403
PTX-1337	Declaration of Eric Jue in Support of Apple Inc.'s Motion for an Expedited Trial (-1377) (01-18-2023)			402; 403; H; F
PTX-1338	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial (-1377) (01-27-2023)			402; 403; H; E
PTX-1339	Declaration of Joe Kiani in Support of Defendants' Opposition to Plaintiff's Motion to Expedite Trial (-1377) (02-22-2023)			402; 403
PTX-1340	INTENTIONALLY OMITTED			
PTX-1341	INTENTIONALLY OMITTED			
PTX-1342	Disclosures of Counter-Claimants Masimo Corporation and Cercacor Laboratories, Inc. Pursuant to Paragraph 7(A) of the Scheduling Order (05-15-2023)			
PTX-1343	Apple's Final Infringement Contentions for Apple's Asserted Design Patents (08-17-2023)			402; 403; F
PTX-1344	Masimo Corporation and Sound United, LLC's Final Design Patent Invalidity Contentions (08-29-2023)			
PTX-1345	INTENTIONALLY OMITTED			
PTX-1346	Webpage: Masimo WI 510(k) Premarket Notification ( <a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K232512">https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K232512</a> )			
PTX-1347	Clark - A UX Researcher's Review of the Apple Watch, UX Design (08-03-2021)	APL_DELO4012797	APL_DELO4012815	402; 403; H; F
PTX-1348	S&P Global Market Intelligence, Masimo Corporation Nasdaq GS:MASI, Transcript of Analyst/Investor Day, Tuesday, December 13, 2022 (12-13-2022)	APL_DELO00001292	APL_DELO00001331	402; 403; H; F
PTX-1349	E. Lamb - Medial Pioneer Masimo Announces the Full Market Consumer Release of the Masimo W1, the First Watch to Offer Accurate, Continuous Health Data, Masimo Corporation (08-31-2022)	APL_DELO0723901	APL_DELO0723905	

APPLE INC.

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1350	[REDACTED]	APL_DEL01352630	APL_DEL01352630	402; 403; F
PTX-1351	[REDACTED]	APL_DEL01352631	APL_DEL01352631	402; 403; F
PTX-1352	[REDACTED]	APL_DEL01460397	APL_DEL01460397	402; 403; F
PTX-1353	[REDACTED]	APL_DEL03495105	APL_DEL03495105	402; 403; F
PTX-1354	Webpage: Masimo W1 - Advanced Health Tracking Watch (www.masimopersonalhealth.com/products/masimo-w1) (Captured 08-23-2023)	APL_DEL03853308	APL_DEL03853312	
PTX-1355	S. Levy - The Inside Story Behind Pebble's Demise, Wired (12-12-2016)	APL_DEL04013722	APL_DEL04013733	402; 403; H; F
PTX-1356	Webpage: CIQ Pro: Masimo Corporation (NASDAQ:MASI) (https://www.capitaliq.spglobal.com/web/client?auth=inherit#company/profile?id=4812814)	APL_DEL04014530	APL_DEL04014533	402; 403; H; F
PTX-1357	J. Thompson - A Concise History of the Smartwatch, Bloomberg (01-08-2018)	APL-MAS_03063854	APL-MAS_03063855	402; 403; H; F
PTX-1358	[REDACTED]	APL-MAS_01422600	APL-MAS_01422678	402; 403; F; H
PTX-1359	N. Leahy et al. - Apple Watch In-Store Preview and Online Pre-Order Begin Friday, Apple Inc. (04-09-2015)	APL-MAS_02294991	APL-MAS_02294994	402; 403
PTX-1360	[REDACTED]	APL-MAS_02569186	APL-MAS_02569186	402; 403; F; H
PTX-1361	Masimo v. Apple, ITC Case No. 337-TA-1276, Evidentiary Hearing, Volume I (06-06-2022)	APL-MAS_02617587	APL-MAS_02617869	F; H
PTX-1362	N. Kerris et al. - Apple Unveils Apple Watch - Apple's Most Personal Device Ever, Apple Inc. (09-09-2014)	APL-MAS_02640307	APL-MAS_02640310	402; 403
PTX-1363	Webpage: Apple Watch Series 4: Beautifully redesigned with breakthrough communication, fitness and health capabilities   Apple (https://www.apple.com/newsroom/2018/09/redesigned-apple-watch-series-4-revolutionizes-communication-fitness-and-health/)	APL-MAS_03042557	APL-MAS_03042568	402; 403
PTX-1364	Masimo Corporation - Medical Monitoring Pioneer Announces the Limited Market Release of the Masimo W1 Watch for Consumers (05-02-2022)	APL-MAS_03062483	APL-MAS_03062486	
PTX-1365	Masimo Corporation - Medical Monitoring Pioneer Announces the Limited Market Release of the Masimo W1 Watch for Consumers (05-02-2022)	APL-MAS_03062487	APL-MAS_03062491	
PTX-1366	Masimo Corporation Form 10-K Annual Report for Fiscal Year ending January 1, 2022 (01-01-2022)	APL-MAS_03062518	APL-MAS_03062690	402; 403
PTX-1367	R. Johnson - Smartwatch Market Size Will Achieve USD 156.3 Billion by 2030 Growing at 20.1% CAGR - Exclusive Report by Acumen Research and Consulting, Acumen Research and Consulting (08-29-2022)	APL-MAS_03062928	APL-MAS_03062934	402; 403; F; H
PTX-1368	Masimo Corporation Form 10-K Annual Report for Fiscal Year ending January 2, 2021 (01-02-2021)	APL-MAS_03064472	APL-MAS_03064711	402; 403

APPLE INC.

87973

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1369	Masimo Corporation Form 10-K Annual Report for Fiscal Year ending December 28, 2019 (12-28-2019)	APL-MAS_03064712	APL-MAS_03064846	402; 403
PTX-1370	N. Rothberg - Apple Introduces the Advanced New Apple Watch Series 9, Apple Inc. (09-12-2023)	APL_DELO4012401	APL_DELO4012417	402; 403
PTX-1371	T. Mullaney - Apple Product Innovations that Changed the World, CNBC (04-29-2016)			402; 403; H; F
PTX-1372	Webpage: Apple - Apple reveals Apple Watch Series 8 and the new Apple Watch SE (09-07-2022) (www.apple.com/newsroom/2022/09/apple-reveals-apple-watch-series-8-and-the-new-apple-watch-se/)			402; 403
PTX-1373	Webpage: Apple - Apple unveils Apple Watch Series 5 (09-10-2019) (www.apple.com/newsroom/2019/09/apple-unveils-apple-watch-series-5/)			402; 403
PTX-1374	N. Rothberg et al. - Apple Unveils Apple Watch Ultra 2, Apple Inc. (09-12-2023)	APL_DELO4012434	APL_DELO4012447	402; 403
PTX-1375	Webpage: Apple Watch Leads Customer Preferences in the USA - Counterpoint Research (www.counterpointresearch.com/apple-watch-leads-customer-preference-usa/)			402; 403; H; F
PTX-1376	Z. Hall - [Update: ECG App Released] Review: Apple Watch Series 4 - Beautiful Design, Invisible Features (12-07-2018)			402; 403; H; F
PTX-1377	Webpage: Apple Watch Series 6 delivers breakthrough wellness and fitness capabilities (https://www.apple.com/newsroom/2020/09/apple-watch-series-6-delivers-breakthrough-wellness-and-fitness-capabilities/)			402; 403
PTX-1378	Apple Inc. - Apple Watch Series 7 Orders Start Friday, October 8, with Availability Beginning Friday, October 15 (10-04-2021)			402; 403
PTX-1379	K. Kozuch - Apple Watch Series 8 Review, Tom's Guide (07-07-2023)			402; 403; H; F
PTX-1380	Webpage: Are Apple Products Really Worth It? (https://medium.com/geekculture/are-apple-products-really-worth-it-b0631dee8ac2#:~:text=Apple%20products%20are%20worth%20the,many%20of%20Apple's%20loyal%20customers.)			402; 403; H; F
PTX-1381	Boston Consulting Group - Are You Ready for Green Growth? Most Innovative Companies 2022 (09-2022)			402; 403; H; F
PTX-1382	Apple Inc. - Blood Oxygen App On Apple Watch (10-2022)			402; 403; H; F
PTX-1383	Webpage: ECG app and irregular heart rhythm notification available today on Apple Watch (https://www.apple.com/newsroom/2018/12/ecg-app-and-irregular-heart-rhythm-notification-available-today-on-apple-watch/)			
PTX-1384	Webpage: Wirelessly Connect your Speakers with HEOS - Denon US (https://www.denon.com/en-us/category/heos/)			402; 403

APPLE INC.

87974

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1385	Webpage: First Watch Phone of the World ( <a href="https://goldenbookofworldrecords.com/first-watch-phone-of-the-world/">https://goldenbookofworldrecords.com/first-watch-phone-of-the-world/</a> )			402; 403; H; F
PTX-1386	Webpage: From Deep in the Watch Box: The Seiko Data 2000 ( <a href="https://wornandwound.com/from-deep-in-the-watch-box-the-seiko-data-2000/">https://wornandwound.com/from-deep-in-the-watch-box-the-seiko-data-2000/</a> )			402; 403; H; F
PTX-1387	S. Schultz et al. - Garmin Expands ECG App to Additional Smartwatches, Including its Flagship epix Pro and Fēnix 7 Pro Series (10-17-2023)			402; 403; H; F
PTX-1388	Webpage: Venu 3 Silver Stainless Steel Bezel with Whitestone Case and Silicone Band ( <a href="https://www.garmin.com/en-US/p/873008#overview">https://www.garmin.com/en-US/p/873008#overview</a> )			402; 403; H; F
PTX-1389	Webpage: Healthcare - Apple Watch ( <a href="https://www.apple.com/healthcare/apple-watch/">https://www.apple.com/healthcare/apple-watch/</a> )			402; 403
PTX-1390	L. Pappas - Hedge Fund Sues Masimp Corp. In Del. Over Bylaw Changes, Law360 (10-21-2022)			402; 403; H; F
PTX-1391	J. Podolny et al. - How Apple Is Organized for Innovation, Harvard Business Review (11-2020)			402; 403; H; F
PTX-1392	Webpage: How To Use the Blood Oxygen App on Apple Watch ( <a href="https://support.apple.com/en-us/120358">https://support.apple.com/en-us/120358</a> )			402; 403
PTX-1393	A. Mina et al. - Inside Shenzhen's Race to Outdo Silicon Valley, MIT Technology Review, (12-18-2018)	APL_DELO4013327	APL_DELO4013348	402; 403; H; F
PTX-1394	Apple Inc. - Introducing Apple Watch Ultra (09-07-2022)			402; 403
PTX-1395	G. Koroneos - iPhone X Release Date Set for November 3, 2017, Verizon News Archives (10-23-2017)			H; F
PTX-1396	C. Gullo - Jawbone Launches Fitbit-like UP Wristband, MobiHealthNews (11-04-2011)	APL_DELO4012496	APL_DELO4012511	402; 403; H; F
PTX-1397	S. Herbert-Bayliss et al. - Koffey's Politan take 9% stake in Masimo, to Push for Change, Thomas Reuters (08-16-2022)			402; 403; H; F
PTX-1398	R. Ayers - Lessons From Apple on Why Aesthtic Innovation is Important, Innovation Management (07-20-2022)			402; 403; H; F
PTX-1399		MASAD00033226	MASAD00033290	
PTX-1400		MASAD00033610	MASAD00033648	
PTX-1401		MASAD00034102	MASAD00034171	
PTX-1402		MASAD00034617	MASAD00034688	
PTX-1403		MASAD00037431	MASAD00038340	
PTX-1404		MASAD00038662	MASAD00038957	
PTX-1405		MASAD00045882	MASAD00045893	
PTX-1406		MASAD00069492	MASAD00069504	



APPLE INC.

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1407	Masimo Corporation - Masimo W1, Hospital-Grade Continuous Monitoring of SpO2 and Other Parameters in a Consumer Watch Whitepaper (2023)	MASAD00097057	MASAD00097072	
PTX-1408		ASAD00237032	MASAD00237034	
PTX-1409		ASAD00430234	MASAD00430234	402; 403
PTX-1410		ASAD00644864	MASAD00644864	402; 403
PTX-1411		ASAD00646884	MASAD00646885	402; 403
PTX-1412		ASAD00763028	MASAD00763032	
PTX-1413		ASAD00769091	MASAD00769091	402; 403
PTX-1414		ASAD00785705	MASAD00785722	
PTX-1415		ASAD00796620	MASAD00796683	
PTX-1416		ASAD00963214	MASAD00963214	F; 402; 403
PTX-1417		ASAD00963215	MASAD00963256	F; 402; 403
PTX-1418		ASAD01166416	MASAD01166417	F
PTX-1419		ASAD01167070	MASAD01167070	F; 402; 403
PTX-1420		ASAD01167071	MASAD01167105	F; 402; 403
PTX-1421		ASAD01186272	MASAD01186276	F
PTX-1422		ASAD01196337	MASAD01196340	F
PTX-1423		ASAD02035467	MASAD02035467	F
PTX-1424		ASAD02047047	MASAD02047047	F
PTX-1425		ASAD02080043	MASAD02080043	F
PTX-1426		ASAD02080044	MASAD02080044	F
PTX-1427		ASAD02081248	MASAD02081249	F
PTX-1428		ASAD02877383	MASAD02877383	
PTX-1429		ASAD02892109	MASAD02892111	
PTX-1430		ASAD02902188	MASAD02902191	F
PTX-1431		ASAD02903166	MASAD02903168	F; 402; 403

APPLE INC.

87978


## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1432		ASAD02984322	MASAD02984322	F
PTX-1433		ASAD02992166	MASAD02992166	F
PTX-1434		ASAD03010347	MASAD03010348	F
PTX-1435		ASAD03010350	MASAD03010350	F
PTX-1436		ASAD03758121	MASAD03758121	F
PTX-1437		ASAD03847193	MASAD03847193	F
PTX-1438		ASAD03850136	MASAD03850137	F
PTX-1439		ASAD03857229	MASAD03857230	F
PTX-1440		ASAD03876907	MASAD03876907	F
PTX-1441	Webpage: White - MASI Stock: The Masimo-Sound United Deal That Has Investors Scratching Their Heads, Investor Place (02-14-2022)			402; 403; H; F
PTX-1442	Webpage: About   The Masimo Story ( <a href="https://www.masimo.com/en-us/content-pages/about-us.html">https://www.masimo.com/en-us/content-pages/about-us.html</a> )			
PTX-1443	Webpage: Company Evolution ( <a href="https://professional.masimo.com/company/masimo/evolution/">https://professional.masimo.com/company/masimo/evolution/</a> )			
PTX-1444	Webpage: Masimo - Masimo Appoints New Leader for Consumer Division, Masimo Corporation (09-19-2022)			
PTX-1445	Webpage: Masimo - Masimo Closes Acquisition of Sound United, Masimo Corporation (04-12-2022)			
PTX-1446	Webpage: Masimo - Masimo Unveils the Future of Health Tracking and Smart Wearable with the Pre-Sale Launch of the Freedom Smartwatch, Masimo Corporation (03-28-2023)			
PTX-1447	Webpage: Masimo - Masimo W1 Medical Watch Receives FDA 510(k) Clearance for Over-the-Counter and Prescription Use, Masimo Corporation (11-17-2023)			
PTX-1448	Webpage: Masimo - Medical Monitoring Pioneer Announces the Limited Market Release of the Masimo W1 Watch for Consumers, Masimo Corporation (05-02-2022)			
PTX-1449	Webpage: Medical Pioneer Masimo Announces the Full Market Consumer Release of the Masimo W1™, the First Watch to Offer Accurate, Continuous Health Data   Masimo (08-31-2022) ( <a href="https://investor.masimo.com/news/news-details/2022/Medical-Pioneer-Masimo-Announces-the-Full-Market-Consumer-Release-of-the-Masimo-W1-the-First-Watch-to-Offer-Accurate-Continuous-Health-Data/default.aspx">investor.masimo.com/news/news-details/2022/Medical-Pioneer-Masimo-Announces-the-Full-Market-Consumer-Release-of-the-Masimo-W1-the-First-Watch-to-Offer-Accurate-Continuous-Health-Data/default.aspx</a> )			

APPLE INC.

87977

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1450	Webpage: Masimo (MASI) Q2 2022 Earnings Call Transcript (www.fool.com/earnings/call-transcripts/2022/08/10/masimo-masi-q2-2022-earnings-call-transcript/)			402; 403; H; F
PTX-1451	Webpage: Masimo Acquisition of Sound United Spurs Ugly Activist Shareholder Lawsuit (https://www.strata-gee.com/masimo-acquisition-of-sound-united-spurs-ugly-activist-shareholder-lawsuit/)			402; 403; H; F
PTX-1452	Webpage: Gatlin - Is Masimo 'Crazy Like A Fox' For Spending \$1.03 Billion to Buy Sound United, Investor's Business Daily (02-16-2022)			402; 403; H; F
PTX-1453	Webpage: Masimo W1 - Advanced Health Tracking Watch (www.masimopersonalhealth.com/products/masimo-w1)			
PTX-1454	Webpage: Masimo will turn millions of home entertainment systems into health hubs (chrome-extension://mcbpblocmgfnpjppndjkmgaogfceg/fsCaptured.html)			
PTX-1455		ASITC_00454374	MASITC_00454375	F; 402; 403
PTX-1456		ASITC_00454376	MASITC_00454388	F; 402; 403
PTX-1457		ASITC_01078224	MASITC_01078225	106
PTX-1458		ASITC_01129170	MASITC_01129214	
PTX-1459		ASITC_01132275	MASITC_01132277	
PTX-1460		ASITC_01132278	MASITC_01132318	
PTX-1461		ASITC_01132370	MASITC_01132397	F; 106
PTX-1462		ASITC_01137505	MASITC_01137505	
PTX-1463		ASITC_01148653	MASITC_01148654	
PTX-1464		ASITC_01148655	MASITC_01148661	
PTX-1465		ASITC_01148686	MASITC_01148687	
PTX-1466		ASITC_01249678	MASITC_01249682	F
PTX-1467		ASITC_01249878	MASITC_01249879	F
PTX-1468		ASITC_01253790	MASITC_01253790	402; 403

APPLE INC.

87978

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.		Beg Bates	End Bates	Objections
PTX-1469		MASITC_01302948	MASITC_01302952	F
PTX-1470		MASITC_01379392	MASITC_01379392	402; 403; 106
PTX-1471		MASITC_01394449	MASITC_01394450	F; 106
PTX-1472	(https://medium.com/digitalshroud/microsoft-spot-and-the-beginning-of-smartwatches-e29be21f0d33)			402; 403; H; F
PTX-1473	Webpage: Mi Watch Six upgrades for a sportswear style worth emulating (https://www.mi.com/global/product/mi-watch/)			402; 403; H; F
PTX-1474	Webpage: Moto pushes off smartwatches indefinitely - The Verge (www.theverge.com)			402; 403; H; F
PTX-1475	Webpage: No Longer Made: Seiko TV Watch From 1982 (www.ablogtowatch.com)			402; 403; H; F
PTX-1476	Webpage: Oura Integrates With FDA-Cleared Birth Control App, Natural Cycles (https://ouraring.com/blog/oura-partners-with-fda-cleared-birth-control-app-natural-cycles/)			402; 403; H; F
PTX-1477	Webpage: Oura Ring The Most Accurate Smart Ring (https://ouraring.com/most-accurate-ring)			402; 403; H; F
PTX-1478	Webpage: Overlooked: The Caseback (https://www.fratellowatches.com/watch-casebacks/)			402; 403; H; F
PTX-1479		PININFARINA0014061	PININFARINA0014062	H; F
PTX-1480	Webpage: Oura Ring Battery Tips (support.ouraring.com)			402; 403; H; F
PTX-1481	Webpage: Samsung Galaxy Watch Gets FDA Clearance to Monitor for AFib (https://www.pcmag.com/news/samsung-galaxy-watch-gets-fda-clearance-to-monitor-for-afib)			402; 403; H; F
PTX-1482	Webpage: Shop Oura Ring Gen3: Heritage Silver (https://ouraring.com/product/rings/heritage/silver)			402; 403; H; F
PTX-1483	Webpage: Sound United Officially Rebrands as Masimo Consumer (https://www.cepro.com/news/sound-united-rebrands-as-masimo-consumer/)			402; 403; H; F
PTX-1484				402; 403; H; F
PTX-1485	Webpage: The Founding of Apple Computer, Inc. (https://guides.loc.gov/this-month-in-business-history/april/apple-computer-founded)			402; 403; H; F
PTX-1486	Webpage: The new iPad Pro features less bezel, larger screens and USB-C (https://techcrunch.com/2018/10/30/the-new-ipad-pro-features-less-bezel-and-larger-screens/)			402; 403; H; F
PTX-1487	MSI - The Short and Long-term Impacts of Fashion Knockoffs on Original Items (2013)			402; 403; H; F

APPLE INC.

87979

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1488	Webpage: To Wall Street's surprise, Masimo acquires Sound United for \$1B+ (www.bioworld.com)			402; 403; H; F
PTX-1489	Webpage: US judge declares mistrial in Apple-Masimo smartwatch trade secrets fight (https://www.reuters.com/legal/us-judge-declares-mistrial-apple-masimo-smartwatch-trade-secrets-fight-2023-05-01/)			402; 403; H; F
PTX-1490	Webpage: Wearables Are Dead (www.businessinsider.com)			402; 403; H; F
PTX-1491	Webpage: The Journal Record - What do Apple, GM, P&G share? Design. (https://journalrecord.com/2011/03/what-do-apple-gm-pg-share-design-general-news/)			402; 403; H; F
PTX-1492	Webpage: What is an exhibition case back watch and why do we love them so much? (https://www.chronext.com/journal/buyers-guide/what-is-an-exhibition-case-back-watch-and-why-do-we-love-them-so-much)			402; 403; H; F
PTX-1493	Webpage: What the top innovators get right (https://www.strategy-business.com/feature/What-the-Top-Innovators-Get-Right)			402; 403; H; F
PTX-1494	Webpage: Which smartwatch is FDA approved? (chrome-extension://mcbpblocgmgnfpjppndjkmgaogfceg/fsCaptured.html)			402; 403; H; F
PTX-1495	Webpage: Why Apple Is The World's Most Innovative Company (https://www.fastcompany.com/40525409/why-apple-is-the-worlds-most-innovative-company)			402; 403; H; F
PTX-1496	Webpage: Why The Apple Design Is So Successful (https://cleverism.com/why-apple-design-successful/#:~:text=A%20Simple%20Aesthetic&text=More%20than%20being%20flashy%20or,of%20its%20iPhones%20and%20iPads.)			402; 403; H; F
PTX-1497	Webpage: Withings Announces the FDA Clearance of ScanWatch -- Its Most Advanced Hybrid Smartwatch (https://www.prnewswire.com/news-releases/withings-announces-the-fda-clearance-of-scanwatch----its-most-medically-advanced-hybrid-smartwatch-301397927.html)			402; 403; H; F
PTX-1498	Withings - Withings Launches Its Next-Generation Scanwatch With Enhanced Sensors To Monitor Additional Health Metrics 24/7			402; 403; H; F
PTX-1499	Webpage: Xiaomi is the best and the worst thing to happen to Android (https://www.androidauthority.com/xiaomi-11-years-3197446/)			402; 403; H; F
PTX-1500	Webpage: Samsung Newsroom   FDA-Cleared Electrocardiogram Monitor App is Available in the US Starting Today on Galaxy Watch3 and Galaxy Watch Active2 (09-24-2020) (news.samsung.com/global/fda-cleared-electrocardiogram-monitor-app-is-available-in-the-us-starting-today-on-galaxy-watch3-and-galaxy-watch-active2)			402; 403; H; F

APPLE INC.

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1501	Webpage: 20 Best Large Workplaces in Manufacturing and Production ( <a href="https://fortune.com/ranking/best-workplaces-manufacturing-production/2023/search/">https://fortune.com/ranking/best-workplaces-manufacturing-production/2023/search/</a> )			402; 403; H; F
PTX-1502	Masimo v. Apple, ITC Case No. 337-TA-1276, Evidentiary Hearing, Volume IV (06-09-2022)			F; H
PTX-1503	Masimo v. Apple, ITC Case No. 337-TA-1276, Rebuttal Expert Report Of Majid Sarrafzadeh, Ph.D. Regarding Certain Of Plaintiffs' Alleged Technical Trade Secrets (11-04-2022)			402; 403; F; E
PTX-1504	Masimo v. Apple, C.D. Cal. Case No. 8:20-cv-00048-JVS, Minutes - Jury Trial Day 17 (05-01-2023)			402; 403
PTX-1505	Masimo v. Apple, ITC Case No. 337-TA-1276, Letter from H. Calkins to Members of the ITC (06-05-2023)			402; 403; F
PTX-1506	Masimo v. Apple, ITC Case No. 337-TA-1276, Letter from R. Passman to U.S. International Trade Commission re Public Interest Comments (06-05-2023)			402; 403; F
PTX-1507	Defendants Masimo Corporation and Sound United, LLC's Second Supplemental Response to Apple Inc.'s First Set of Interrogatories (No. 2) (-1378) (08-10-2023)			H; F
PTX-1508	Webpage: Mosaid - About ( <a href="https://mosaid.com/">https://mosaid.com/</a> )			402; 403; H; F
PTX-1509	Webpage: About Schiller ( <a href="https://www.schillerus.com/home/about">https://www.schillerus.com/home/about</a> )			402; 403; H; F
PTX-1510	Webpage: About Us: Corporate Information and Culture - Mindray Global ( <a href="https://www.mindray.com/en/about-us#mr--about_us--purpose">https://www.mindray.com/en/about-us#mr--about_us--purpose</a> )			402; 403; H; F
PTX-1511	Webpage: All of the ways the Apple Watch can make you healthier ( <a href="https://www.cnet.com/health/all-of-the-ways-the-apple-watch-can-make-you-healthier/">https://www.cnet.com/health/all-of-the-ways-the-apple-watch-can-make-you-healthier/</a> )			402; 403; H; F
PTX-1512	Webpage: Apple Watch Series 9 [GPS 41mm] Smartwatch with Silver Aluminum Case with Storm Blue Sport Band S/M. Fitness Tracker, Blood Oxygen & ECG Apps, Always-On Retina Display ( <a href="https://www.amazon.com/Apple-Smartwatch-Aluminum-Fitness-Tracker/dp/B0CHX92WB8/ref=sr_1_2?keywords=apple+watch&amp;qid=1703785512&amp;sr=8-2&amp;th=1">https://www.amazon.com/Apple-Smartwatch-Aluminum-Fitness-Tracker/dp/B0CHX92WB8/ref=sr_1_2?keywords=apple+watch&amp;qid=1703785512&amp;sr=8-2&amp;th=1</a> )			H; F; 402; 403
PTX-1513	Webpage: Masimo W1® Sport Advanced Health Tracking Wearable Now Including FDA-Cleared Module ( <a href="https://www.amazon.com/Masimo-Advanced-Fitness-Activity-Trackers/dp/B0C5JY26W2">https://www.amazon.com/Masimo-Advanced-Fitness-Activity-Trackers/dp/B0C5JY26W2</a> )			
PTX-1514	Webpage: Masimo W1 - Advanced Health Tracking Watch ( <a href="https://www.masimopersonalhealth.com/products/masimo-w1">https://www.masimopersonalhealth.com/products/masimo-w1</a> )	APL_DEL00723999	APL_DEL00724013	H; F; UK; ID
PTX-1515	[REDACTED]	APL_DEL03841986	APL_DEL03842004	402; 403
PTX-1516	Webpage: Masimo W1 - Advanced Health Tracking Watch ( <a href="https://www.masimopersonalhealth.com/products/masimo-w1">www.masimopersonalhealth.com/products/masimo-w1</a> ) (Captured 11-29-2023)	APL_DEL04012341	APL_DEL04012355	

APPLE INC.

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1517		APL-MAS 00058020	APL-MAS 00058038	402; 403
PTX-1518		APL-MAS 00060602	APL-MAS 00060606	402; 403
PTX-1519	Apple 10k Form 2023			
PTX-1520	Webpage: Apple to halt Apple Watch Series 9 and Apple Watch Ultra 2 sales in the US this week ( <a href="https://9to5mac.com/2023/12/18/apple-halting-apple-watch-series-9-and-apple-watch-ultra-2-sales/">https://9to5mac.com/2023/12/18/apple-halting-apple-watch-series-9-and-apple-watch-ultra-2-sales/</a> )			402; 403; H; F
PTX-1521	Webpage: Apple resuming watch sales in U.S. after court pauses ban ( <a href="https://www.axios.com/2023/12/27/apple-watch-ban-tic-appeals-court-pause">https://www.axios.com/2023/12/27/apple-watch-ban-tic-appeals-court-pause</a> )			402; 403; H; F
PTX-1522	Webpage: Apple unveils its first carbon neutral products ( <a href="https://www.apple.com/newsroom/2023/09/apple-unveils-its-first-carbon-neutral-products/">https://www.apple.com/newsroom/2023/09/apple-unveils-its-first-carbon-neutral-products/</a> )			402; 403
PTX-1523	Webpage: Smarwatch comparison - Apple Watch Series 4 vs Samsung Galaxy Watch ( <a href="https://versus.com/en/apple-watch-series-4-vs-samsung-galaxy-watch">https://versus.com/en/apple-watch-series-4-vs-samsung-galaxy-watch</a> )			402; 403; H; F
PTX-1524	Webpage: Apple wins UN Climate Action award for environmental work ( <a href="https://appleinsider.com/articles/19/09/26/apple-wins-un-climate-action-award-for-environmental-work">https://appleinsider.com/articles/19/09/26/apple-wins-un-climate-action-award-for-environmental-work</a> )			402; 403; H; F
PTX-1525	Webpage: Apple's Search Engine Negotiations With Google Took Months of Near-Daily Meetings ( <a href="https://www.macrumors.com/2019/06/10/apple-lawyer-bruce-sewell-google-negotiations/">https://www.macrumors.com/2019/06/10/apple-lawyer-bruce-sewell-google-negotiations/</a> )			402; 403; H; F
PTX-1526	Webpage: ASE Group - Wikipedia ( <a href="https://en.wikipedia.org/wiki/ASE_Group">https://en.wikipedia.org/wiki/ASE_Group</a> )			402; 403; H; F
PTX-1527	Webpage: Business Areas and Products ( <a href="https://www.nihonkohden.com/information/company/business.html">https://www.nihonkohden.com/information/company/business.html</a> )			402; 403; H; F
PTX-1528	Webpage: CARESCAPE B650 Monitor ( <a href="https://www.gehealthcare.com/products/patient-monitoring/patient-monitors/carescape-monitor-b650">https://www.gehealthcare.com/products/patient-monitoring/patient-monitors/carescape-monitor-b650</a> )			402; 403; H; F
PTX-1529	Webpage: Company Overview ( <a href="https://www.zoll.com/about-zoll/company-overview">https://www.zoll.com/about-zoll/company-overview</a> )			402; 403; H; F
PTX-1530	Webpage: Company ompare Apple Watch Series 4 vs. Samsung Galaxy Watch ( <a href="https://www.gsmarena.com/compare.php3?idPhone1=9321&amp;idPhone2=9289">https://www.gsmarena.com/compare.php3?idPhone1=9321&amp;idPhone2=9289</a> )			402; 403; H; F
PTX-1531	Webpage: ECG app and irregular heart rhythm notification available today on Apple Watch ( <a href="https://www.apple.com/newsroom/2018/12/ecg-app-and-irregular-heart-rhythm-notification-available-today-on-apple-watch/">https://www.apple.com/newsroom/2018/12/ecg-app-and-irregular-heart-rhythm-notification-available-today-on-apple-watch/</a> )			

APPLE INC.  
# 67982  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1532	Webpage: Certain Light Based Physiological Measurement Devices and Components Thereof; Notice of Commission's Final Determination Finding a Violation of Section 337; Issuance of a Limited Exclusion Order and a Cease and Desist Order; Termination of the Investigation			
PTX-1533	Webpage: MightySat Medical ( <a href="https://www.masimo.com/en-us/product/health-monitoring/137737.html">https://www.masimo.com/en-us/product/health-monitoring/137737.html</a> )			
PTX-1534	Webpage: My Apple Watch saved my life: 5 people share their stories ( <a href="https://www.cnet.com/tech/mobile/galaxy-s24-ultra-one-day-with-samsungs-new-phone/">https://www.cnet.com/tech/mobile/galaxy-s24-ultra-one-day-with-samsungs-new-phone/</a> )			402; 403; H; F
PTX-1535	Masimo v. Apple, C.D. Cal. Case No. 8:20-cv-00048-JVS, Deposition of Jackie Harlow (08-05-2022)			402; 403; H; F
PTX-1536	Webpage: Health on Apple Watch Apple Watch. Empowering your patients to live a healthier day. ( <a href="https://www.apple.com/healthcare/apple-watch/">https://www.apple.com/healthcare/apple-watch/</a> )			402; 403
PTX-1537	Webpage: How to use the Blood Oxygen app on Apple Watch ( <a href="https://support.apple.com/en-us/HT211027">https://support.apple.com/en-us/HT211027</a> )			402; 403
PTX-1538	Webpage: Is Masimo 'Crazy Like A Fox' For Spending \$1.03 Billion To Buy Sound United? ( <a href="https://www.investors.com/news/technology/masimo-stock-is-its-sound-united-buyout-crazy/">https://www.investors.com/news/technology/masimo-stock-is-its-sound-united-buyout-crazy/</a> )			402; 403; H; F
PTX-1539	Webpage: iSpO2 Pulse Oximeter ( <a href="https://www.masimopersonhealth.com/pages/ispo2-o2-monitor-android-ios">https://www.masimopersonhealth.com/pages/ispo2-o2-monitor-android-ios</a> )			
PTX-1540	K201456 - Debreuil Xavier (10-05-2021)			402; 403; H; F
PTX-1541	K232512 - Sindura Penubarthi (11-17-2023)			
PTX-1542	[REDACTED]			
PTX-1543	Webpage: Local 12: Apple Watch saves local women's life from deadly blood clot ( <a href="https://www.uc.edu/news/articles/2023/06/local-12--apple-watch-saves-local-womans-life-from-deadly-blood-clot.html">https://www.uc.edu/news/articles/2023/06/local-12--apple-watch-saves-local-womans-life-from-deadly-blood-clot.html</a> )			402; 403; H; F
PTX-1544	Masimo W1™ Hospital-Grade Continuous Monitoring of SpO2 and Other Parameters in a Consumer Watch			
PTX-1545	[REDACTED]	MASAD00439092	MASAD00439093	F; 402; 403
PTX-1546	Masimo 510(k) Summary K232512	MASAD04143270	MASAD04143280	
PTX-1547	Webpage: Masimo Named a Great Place to Work for 2020-21 ( <a href="https://www.masimo.com/company/masimo/awards/#award-0db2eedf-85d*-4633-ae6a-f5d80968d122">https://www.masimo.com/company/masimo/awards/#award-0db2eedf-85d*-4633-ae6a-f5d80968d122</a> )			
PTX-1548	Webpage: Masimo - GE Healthcare ( <a href="https://www.masimo.com/oem/partners/ge-healthcare/">https://www.masimo.com/oem/partners/ge-healthcare/</a> )			



APPLE INC  
# 67983  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1549	Webpage: Masimo Introduces the MX-7 rainbow SET Technology Board for Original Equipment Manufacturing Partners ( <a href="https://investor.masimo.com/news/news-details/2021/Masimo-Introduces-the-MX-7-rainbow-SET-Technology-Board-for-Original-Equipment-Manufacturing-Partners/default.aspx">https://investor.masimo.com/news/news-details/2021/Masimo-Introduces-the-MX-7-rainbow-SET-Technology-Board-for-Original-Equipment-Manufacturing-Partners/default.aspx</a> )			
PTX-1550	Webpage: Radius PPG® Tetherless Pulse Oximetry ( <a href="https://professional.masimo.com/products/sensors/radius-ppg/">https://professional.masimo.com/products/sensors/radius-ppg/</a> )			
PTX-1551	Webpage: Masimo Signal Extraction Technology (SET) ( <a href="https://professional.masimo.com/technology/co-oximetry/set/">https://professional.masimo.com/technology/co-oximetry/set/</a> )			
PTX-1552	Webpage: The Future of Wearables Technology Masimo Freedom Smart Health Watch & Band ( <a href="https://www.masimoconsumer.com">https://www.masimoconsumer.com</a> )			
PTX-1553	Webpage: Masimo Stork - A Revolutionary Baby Monitor ( <a href="https://www.masimostork.com/en-us/">https://www.masimostork.com/en-us/</a> )			
PTX-1554	Webpage: Masimo W1 - Advanced Health Tracking Watch ( <a href="http://www.masimopersonalhealth.com/products/masimo-w1">www.masimopersonalhealth.com/products/masimo-w1</a> ) (Captured 01-24-2024)			
PTX-1555	Masimos W1 invented to do things the Apple Watch cant - CEO Joe Kiani on The Claman Countdown.mp4			
PTX-1556		MASITC_01254226	MASITC_01254227	402; 403; H; F
PTX-1557		MASITC_01259368	MASITC_01259370	402; 403
PTX-1558				
PTX-1559	Webpage: Our Mission: Society for Technology in Anesthesia ( <a href="https://www.stahq.org/about/our-mission">https://www.stahq.org/about/our-mission</a> )			402; 403; H; F
PTX-1560	Webpage: ScanWatch 2 - Frequently asked questions ( <a href="https://support.withings.com/hc/en-us/articles/17089241113617-ScanWatch-2-Frequently-asked-questions">https://support.withings.com/hc/en-us/articles/17089241113617-ScanWatch-2-Frequently-asked-questions</a> )			402; 403; H; F
PTX-1561	Webpage: Sound United Officially Previous Next Rebrands as Masimo Consumer ( <a href="https://www.cepro.com/news/sound-united-rebrands-as-masimo-consumer/">https://www.cepro.com/news/sound-united-rebrands-as-masimo-consumer/</a> )			402; 403; H; F
PTX-1562	Webpage: Start Your Wellness Journey: 15 Ways to Get Healthy With Your Apple Watch ( <a href="https://www.pcmag.com/how-to/get-healthy-with-your-apple-watch">https://www.pcmag.com/how-to/get-healthy-with-your-apple-watch</a> )			402; 403; H; F
PTX-1563	Webpage: Stork Baby Monitors, Cameras, and Hubs   Masimo Stork ( <a href="https://www.masimostork.com/en-us/shop-stork.html">https://www.masimostork.com/en-us/shop-stork.html</a> )			
PTX-1564	Stork Hub User's Manual (Masimo 301169/11835A-0623)			
PTX-1565	Stork Vitals Smart Home Baby Monitor User's Manual			

APPLE INC.  
# 67984  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1566	Webpage: Survey: 83 percent of Apple Watch owners said device contributes to their overall health ( <a href="https://www.mobihealthnews.com/47482/survey-83-percent-of-apple-watch-owners-said-device-contributes-to-their-overall-health">https://www.mobihealthnews.com/47482/survey-83-percent-of-apple-watch-owners-said-device-contributes-to-their-overall-health</a> )			402; 403; F; H
PTX-1567	Webpage: Tank Louis Cartier watch ( <a href="https://www.cartier.com/en-us/watches/collections/tank/tank-louis-cartier-watch--CRWGTA0067.html">https://www.cartier.com/en-us/watches/collections/tank/tank-louis-cartier-watch--CRWGTA0067.html</a> )			402; 403; F; H
PTX-1568	INTENTIONALLY OMITTED			
PTX-1569	INTENTIONALLY OMITTED			
PTX-1570	Webpage: To Wall Street's surprise, Masimo acquires Sound United for \$1B+ ( <a href="https://www.bioworld.com/articles/516146-to-wall-streets-surprise-masimo-acquires-sound-united-for-1b?v=preview">https://www.bioworld.com/articles/516146-to-wall-streets-surprise-masimo-acquires-sound-united-for-1b?v=preview</a> )			402; 403; F; H
PTX-1571	Webpage: Track daily activity with Apple Watch ( <a href="https://support.apple.com/en-mz/guide/watch/apd3bf6d85a6/watchos">https://support.apple.com/en-mz/guide/watch/apd3bf6d85a6/watchos</a> )			402; 403
PTX-1572	Webpage: Watch - Corporate Wellness - Apple ( <a href="https://www.apple.com/watch/corporate-wellness/">https://www.apple.com/watch/corporate-wellness/</a> )			402; 403
PTX-1573	Apple Inc.'s Fourth Supplemental Response to Defendants' First Set of Interrogatories (No. 3) (-1377) (11-09-2023)			F; H
PTX-1574	Opening Expert Report of Alan D. Ball (11-22-2023)			E
PTX-1575	Opening Expert Report of Joel Delman Regarding the Invalidity of U.S. Patent Nos. D883,279, D947,842, D962,936, and D735,131 (11-22-2023)			
PTX-1576	Opening Expert Report of Vijay K. Madiseti, Ph.D. (11-22-2023)			
PTX-1577	Opening Expert Report of James E. Malackowski (11-22-2023)			E
PTX-1578	Expert Report of Robert L. Stoll (11-22-2023)			
PTX-1579	INTENTIONALLY OMITTED			
PTX-1580	Webpage: [Update: ECG app released] Review: Apple Watch Series 4 - beautiful design, invisible features   9to5Mac (12-07-2018) ( <a href="https://9to5mac.com/2018/12/07/apple-watch-series-4-review-2/">9to5mac.com/2018/12/07/apple-watch-series-4-review-2/</a> )	APL_DEL04012924	APL_DEL04012942	402; 403; F; H
PTX-1581	Webpage: AWINNER Charger Compatible for Huawei Watch GT Classic Sport, GT2, GT 2e, Honor Watch Magic Magic 2, Honor Watch Dream - USB Charging Cable 100cm   Amazon ( <a href="https://www.amazon.com/AWINNER-Charger-Compatible-Huawei-Class/dp/B08HNFTVT2?th=1">www.amazon.com/AWINNER-Charger-Compatible-Huawei-Class/dp/B08HNFTVT2?th=1</a> )	APL_DEL00038403	APL_DEL00038407	402; 403; F; H
PTX-1582	Webpage: Emilydeals Charger for Fitbit Versa/Versa Lite, Replacement USB Charging Dock with 3.3ft Cable Cord for Fitbit Versa Lite, Versa Smartwatch (Black)   Amazon ( <a href="https://www.amazon.com/Emilydeals-Compatible-Replacement-Charging-Smartwatch/dp/B09LD87WB8/">www.amazon.com/Emilydeals-Compatible-Replacement-Charging-Smartwatch/dp/B09LD87WB8/</a> )	APL_DEL00038408	APL_DEL00038412	402; 403; F; H

APPLE INC  
# 67985  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1583	Webpage: Charger Stand Compatible with Huawei Band 6, Huawei Watch Fit, Huawei4X, Honor Band 6, Honor Watch ES, Replacement USB Charger Cable Fit for Honor Smartwatch   Amazon (www.amazon.com/Charger-Compatible-Huawei4X-Replacement-Smartwatch/dp/B09NS8YD67/)	APL_DEL00038413	APL_DEL00038417	402; 403; F; H
PTX-1584	Webpage: Digipower Wireless Charger - 3 in 1 Magnetic Charging Station - Fast Wireless Charger Stand for iPhone 14/13/12/Pro/Max, for Apple Watch 7/6/5/4/3/2/SE, AirPods 3/2/Pro   Amazon (www.amazon.com/Magnetic-Wireless-Charger-Charging-Station/dp/B09PPF15NX/)	APL_DEL00038421	APL_DEL00038425	402; 403; F; H
PTX-1585	Webpage: Fintie Watch Charger Compatible with Fitbit Versa 4 / Versa 3 / Sense 2 / Sense, Portable Magnetic USB Wireless Charger Fast Charging, Travel Cordless Car Charger, White   Amazon (www.amazon.com/Compatible-Portable-Magnetic-Wireless-Smartwatch/dp/B0989PF2WW/)	APL_DEL00038426	APL_DEL00038430	402; 403; F; H
PTX-1586	Webpage: Google Pixel Watch USB-C Magnetic Charging Cable   Google Store (store.google.com/us/product/watch_charger?hl=en-US)	APL_DEL00038443	APL_DEL00038445	402; 403; F; H
PTX-1587	Webpage: HATALKIN Upgraded Wireless Charger for Google Pixel Watch, 3 in 1 Wireless Charging Station for Google Pixel 7/7A/7 Pro/6/6 Pro/5/4/3/XL, Pixel Fold, Pixel Buds Pro, iPhone 14/Samsung S23, Air-pods   Amazon (www.amazon.com/HATALKIN-Upgraded-Wireless-Charging-Air-pods/dp/B0BRNC61DP/?th=1)	APL_DEL00038446	APL_DEL00038453	402; 403; F; H
PTX-1588	Webpage: New Product Launch - GO 2 Fast Charger   hellomaco (www.hellomaco.com/products/go-charger?variant=31710914052139)	APL_DEL00038454	APL_DEL00038473	402; 403; F; H
PTX-1589	Webpage: NEWDERY Charger for Apple Watch Portable iWatch USB Wireless Charger, Travel Cordless Charger with Light Weight Magnetic Quick Charge for Apple Watch Ultra Series 8 7 SE 6 5 4 3 2 1, White   Amazon (www.amazon.com/NEWDERY-Cordless-Portable-Wireless-Magnetic/dp/B07ZFVYNRQ/?th=1)	APL_DEL00038542	APL_DEL00038549	402; 403; F; H
PTX-1590	Webpage: [2-Pack] Portable Charger for Google Pixel Watch, USB-C/Micro USB 2 in 1 Mini Black Google Pixel Watch Charging Stand Magnetic Travel Charger Adapter, with 1.6ft/0.5m 2 in 1 Charging Cable   Amazon (www.amazon.com/Charger-Portable-Charging-Adapter-Included/dp/B0BXH321P5/?th=1)	APL_DEL00038553	APL_DEL00038559	402; 403; F; H
PTX-1591	Webpage: Portable Watch Charger Stand - Wireless Magnetic Charging Station with Charging Cable, Compatible with iWatch Series SE 8 7 6 5 4 3 2 (38/40/42/44mm) - Black   Amazon (www.amazon.com/Portable-Watch-Charger-Stand-Wireless/dp/B09JW8M5L7/?th=1)	APL_DEL00038560	APL_DEL00038565	402; 403; F; H

APPLE INC  
# 67986  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1592	Webpage: Samsung Galaxy Watch Wireless Charging Dock / Charger (EP-YO805) 2015 through 2020 models - Couch Black   Amazon (www.amazon.com/Original-Samsung-Wireless-Charging-EP-YO805/dp/B07HJSKN91)	APL_DEL00038572	APL_DEL00038577	402; 403; F; H
PTX-1593	Webpage: Smart Watch Charger for Amazfit GTS2 Mini/Pop Pro USB Charging Cable Line   Walmart (www.walmart.com/ip/Smart-Watch-Charger-for-Amazfit-GTS2-Mini-Pop-Pro-USB-Charging-Cable-Line/3549126858)	APL_DEL00038578	APL_DEL00038580	402; 403; F; H
PTX-1594	Webpage: Fitbit Smartwatch Charging Cable   Fitbit (www.fitbit.com/global/us/products/accessories/versa3-sense-charging-cable)	APL_DEL00038581	APL_DEL00038583	402; 403; F; H
PTX-1595		APL_DEL00125922	APL_DEL00126458	
PTX-1596		APL_DEL00196918	APL_DEL00197004	
PTX-1597		APL_DEL00229706	APL_DEL00229784	403
PTX-1598				MD; 402; 403
PTX-1599				MD; 402; 403
PTX-1600				MD; 402; 403
PTX-1601				MD; 402; 403
PTX-1602				MD; 402; 403
PTX-1603				MD; 402; 403
PTX-1604				MD; 402; 403
PTX-1605				MD; 402; 403

APPLE INC.  
# 67987  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1606				MD; 402; 403
PTX-1607		APL_DEL01009346	APL_DEL01009424	403
PTX-1608	Webpage: Aries Watches Watch AW80 - Unisex   Allegro (allegro.pl/oferta/smartwatch-zegarek-ekg-pulsoksymetrtermometr-pl-9927412179)	APL_DEL01352329	APL_DEL01352336	F; H; 402; 403
PTX-1609	Webpage: 0.96 Inch Health Monitoring Smart Watch P11 Plus ECG+PPG Bracelet Heart Rate Bluetooth Waterproof Wearable Devices Smart Bands   Alibaba (www.alibaba.com/productdetail/0-96-Inch-Health-MonitoringSmart_1600315358892.html?spm=a2700.7724857.0.0.7fac6ca930d1xN)	APL_DEL01352337	APL_DEL01352352	F; H; 402; 403
PTX-1610	Webpage: ECG PPG P11 Plus Smart Band Watch Body Temperature Heart Rate Blood Pressure Oxygen Bracelet IP67   AliExpress (www.aliexpress.us/item/3256801861931242.html?gatewayAdapt=glo2usa4itemAdapt)	APL_DEL01352381	APL_DEL01352384	F; H; 402; 403
PTX-1611	Webpage: Fitbit Charge 5 + Premium: Redefine Your Routine   YouTube (02-21-2023) (www.youtube.com/watch?v=DFIMoZS8BDI&t=74s)	APL_DEL01352461	APL_DEL01352461	F; H; 402; 403
PTX-1612	Webpage: How to Charge AirPods Pro 2 - 3 Ways   YouTube (09-23-2022) (www.youtube.com/watch?v=ktQHyeJQDb8)	APL_DEL01352541	APL_DEL01352541	F; H; 402; 403
PTX-1613		APL_DEL01544573	APL_DEL01544574	
PTX-1614		APL-MAS 00462145	APL-MAS 00462162	
PTX-1615	Webpage: Damskie   Allegro Achiwum (archiwum.allegro.pl/oferta/zegarek-smartwatch-ekg-cisnieniomierz-polskie-menu-i13944657432.html)			F; H; 402; 403
PTX-1616	Masimo v. Apple, C.D. Cal. Case No. 8:20-cv-00048-JVS, Deposition of Ueyn Block (07-21-2022)			F; H; 402; 403
PTX-1617	Masimo v. Apple, ITC Case No. 337-TA-1276, Deposition of Mathieu Charbonneau-Lefort (02-16-2022)			F; H; 402; 403
PTX-1618	CN Patent Publication Appl. No. 106527106A			
PTX-1619	Declaration of R. James Duckworth, Ph.D. in Support of Masimo's Answering Claim Construction Brief (08-10-2023)			F
PTX-1620	Declaration of Steven Warren, Ph.D. Regarding Plaintiff Apple Inc.'s Reply Claim Construction Brief (08-17-2023)			F, E
PTX-1621	Masimo v. Apple, PTAB Case No. IPR2023-00774, Declaration of R. James Duckworth, Ph.D. (03-24-2023)			403; F
PTX-1622	Masimo v. Apple, PTAB Case No. IPR2023-00728, Declaration of R. James Duckworth, Ph.D. (03-14-2023)			403; F

APPLE INC  
# 67988  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1623	Masimo v. Apple, PTAB Case No. IPR2023-00702, Declaration of R. James Duckworth, Ph.D. (03-08-2023)			403; F
PTX-1624	Masimo v. Apple, PTAB Case No. IPR2023-00831, Declaration of R. James Duckworth, Ph.D. (04-10-2023)			403; F
PTX-1625	Webpage: Fitbit User Manuals   Fitbit Help Center (support.google.com/fitbit/answer/14253977#samd)			F; H; 402; 403
PTX-1626	Webpage: Garmin Vivoactive 3 - In-Depth Review   DC Rainmaker (www.dcrainmaker.com/2017/10/garmin-vivoactive-3-in-depth-review.html)	GARMIN0000067	GARMIN0000105	F; H; 402; 403
PTX-1627	INTENTIONALLY OMITTED			
PTX-1628	Webpage: Google Pixel Watch 2   Google Store (store.google.com/product/google_pixel_watch?hl=en-US)			F; H; 402; 403
PTX-1629	Webpage: What is the Fitbit ECG app?   Fitbit Help Center (support.google.com/fitbit/answer/14236718)			F; H; 402; 403
PTX-1630				F; H; 402; 403
PTX-1631		MASA00159519	MASA00159525	
PTX-1632				
PTX-1633		MASAD00013801	MASAD00013831	
PTX-1634	CN Design Regulation No. 303285726	MASAD00019150	MASAD00019153	
PTX-1635	CN Design Regulation No. 304027493	MASAD00019157	MASAD00019159	
PTX-1636	CN Design Regulation No. 304385323	MASAD00019160	MASAD00019162	
PTX-1637	CN Design Regulation No. 302687306	MASAD00020249	MASAD00020251	
PTX-1638	JP Design Regulation No. 1436448	MASAD00020276	MASAD00020280	
PTX-1639	Webpage: Chinese Designs, 201330531838.X (www3.wipo.int/designdb/en/)	MASAD00020386	MASAD00020387	
PTX-1640	Mendelson et al. - Measurement Site and Photodetector Size Considerations in Optimizing Power Consumption of a Wearable Reflectance Pulse Oximeter, Proceedings of the 25th IEEE Conference (2003)	MASA10320472	MASA10320475	
PTX-1641	Masimo v. Apple, ITC Case No. 337-TA-1276, Deposition of Stephen Scruggs (02-18-2022)			402; 403
PTX-1642	Webpage: Charge AirPods (all generations) or AirPods Pro (all generations)   Apple Support (support.apple.com/guide/airpods/charge-airpods-or-airpods-pro-devde25a4bbe/web)			402; 403
PTX-1643	Webpage: Design number 4032616 (www.registered-design-service.gov.uk/find/4032616)	MASAD00020289	MASAD00020296	
PTX-1644	U.S. Patent No. 10,610,157 (Pandya)	MASAD00019689	MASAD00019760	
PTX-1645	U.S. Patent No. 10,912,502 (Poeze)	MASAD00000264	MASAD00000373	

APPLE INC  
# 67989  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1646	U.S. Patent Application Publication No. 2014/0117926 (Hwu)			
PTX-1647	U.S. Patent Application Publication No. 2017/0086743 (Bushnell)			
PTX-1648	U.S. Patent Application Publication No. 2019/0324593 (Chung)			
PTX-1649	U.S. Patent No. D645,818 (Guccione)			
PTX-1650	U.S. Patent No. D694,182 (Lee)			
PTX-1651	U.S. Patent No. D697,027 (Ho)			
PTX-1652	U.S. Patent No. D704,634 (Eidelman)			
PTX-1653	U.S. Patent No. D718,233 (Aumiller)			
PTX-1654	U.S. Patent No. D753,510 (Puttorngul)			
PTX-1655	U.S. Patent No. 11,806,119 (LeFrancois)			
PTX-1656	U.S. Patent Application Publication No. 2012/0104999 (Teggatz)			
PTX-1657	U.S. Patent Application Publication No. 2016/0100758 (Jeong)			
PTX-1658	U.S. Patent Application Publication No. 2023/0147750 (Barker)			
PTX-1659	U.S. Patent No. 9,460,846 (Graham)	MASAD00020312	MASAD00020325	
PTX-1660	Webpage: ScanWatch   Withings ( <a href="http://www.withings.com/us/en/scanwatch">www.withings.com/us/en/scanwatch</a> )			F; H; 402; 403
PTX-1661	U.S. Patent No. D718,234 (Rautiainen)			
PTX-1662	Garmin - Venu 2 Plus Owner's Manual (09-2023)			F; H; 402; 403
PTX-1663	W.O. Patent Publication Appl. No. 2017/165532 (Paulke)			
PTX-1664	Webpage: AirPods Pro (2nd generation)   Apple ( <a href="http://www.apple.com/airpods-pro/specs/">www.apple.com/airpods-pro/specs/</a> )			F; H; 402; 403
PTX-1665	Webpage: charge 5   Google Fitbit ( <a href="http://www.fitbit.com/global/us/products/trackers/charge5">www.fitbit.com/global/us/products/trackers/charge5</a> )			F; H; 402; 403
PTX-1666	Webpage: Garmin Technology - Garmin ECG App ( <a href="http://www.garmin.com/en-US/garmin-technology/health-science/ecg/">www.garmin.com/en-US/garmin-technology/health-science/ecg/</a> )			F; H; 402; 403
PTX-1667	Webpage: Sports & Fitness / Fitness Tracking   Garmin ( <a href="http://www.garmin.com/en-US/p/730659">www.garmin.com/en-US/p/730659</a> )			F; H; 402; 403
PTX-1668	Webpage: UGUMO P11 Plus Smart Bracelet Body Temperature Monitoring Smart Wristband ECG PPG Smart Watch Heart Rate Blood Pressure Bracelet   AliExpress ( <a href="http://www.aliexpress.com/i/3256801541431573.html?gatewayAdapt=4itemAdapt">www.aliexpress.com/i/3256801541431573.html?gatewayAdapt=4itemAdapt</a> )			F; H; 402; 403
PTX-1669	Webpage: Manual of Patent Examining Procedure (MPEP) - US Patent and Trademark Office, 1505 Term of Design Patent [R-08.2017], 35 USC 173, Term of design patent ( <a href="https://www.uspto.gov/web/offices/pac/mpep/1505.html">https://www.uspto.gov/web/offices/pac/mpep/1505.html</a> )			402; 403
PTX-1670	Webpage: BCG - 16 Years of the Most Innovating Companies ( <a href="https://web.archive.org/web/20230129121343/https://www.bcg.com/publications/most-innovative-companies-historical-rankings">https://web.archive.org/web/20230129121343/https://www.bcg.com/publications/most-innovative-companies-historical-rankings</a> )			F; H; 402; 403

APPLE INC.  
# 67990  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1671	Webpage: Manual of Patent Examining Procedure (MPEP) - US Patent and Trademark Office, 2701 Patent Term [R-07.2022], 35 USC 154, Contents and term of patent; provisional rights ( <a href="https://www.uspto.gov/web/offices/pac/mpep/s2701.html">https://www.uspto.gov/web/offices/pac/mpep/s2701.html</a> )			402; 403
PTX-1672	Webpage: Fitbit - Sense 2 ( <a href="https://www.fitbit.com/global/us/products/smartwatches/sense2?sku=521BKGB">https://www.fitbit.com/global/us/products/smartwatches/sense2?sku=521BKGB</a> )	APL_DELO4012816	APL_DELO4012821	F; H; 402; 403
PTX-1673	Webpage: Galaxy Watch6   Samsung ( <a href="http://www.samsung.com/us/watches/galaxy-watch6/#health">www.samsung.com/us/watches/galaxy-watch6/#health</a> )	APL_DELO4013129	APL_DELO4013135	F; H; 402; 403
PTX-1674	Webpage: Fitbit - Check for atrial fibrillation with Fitbit ( <a href="https://www.fitbit.com/global/us/technology/irregular-rhythm">https://www.fitbit.com/global/us/technology/irregular-rhythm</a> )	APL_DELO4013161	APL_DELO4013167	F; H; 402; 403
PTX-1675	Webpage: Google Store - Pixel Watch 2 ( <a href="https://store.google.com/us/product/pixel_watch_2?hl=en-US">https://store.google.com/us/product/pixel_watch_2?hl=en-US</a> )	APL_DELO4013204	APL_DELO4013218	F; H; 402; 403
PTX-1676	Webpage: Masimo - Masimo Appoints New Leader for Consumer Division (09-19-2022) ( <a href="https://investor.masimo.com/news/news-details/2022/Masimo-Appoints-New-Leader-for-Consumer-Division/default.aspx">https://investor.masimo.com/news/news-details/2022/Masimo-Appoints-New-Leader-for-Consumer-Division/default.aspx</a> )	APL_DELO4013444	APL_DELO4013448	
PTX-1677	Webpage: Withings - Heart health hybrid smartwatch, Health guardian on duty 24/7 ( <a href="https://www.withings.com/us/scanwatch-2">https://www.withings.com/us/scanwatch-2</a> )	APL_DELO4013746	APL_DELO4013778	F; H; 402; 403
PTX-1678	Apple Inc. Form 10-K Annual Report for Fiscal Year ending September 30, 2017 (09-30-2017)			
PTX-1679	Apple Inc. Form 10-K Annual Report for Fiscal Year ending September 29, 2018 (09-29-2018)			
PTX-1680	Apple Inc. Form 10-K Annual Report for Fiscal Year ending September 28, 2019 (09-28-2019)			
PTX-1681	Apple Inc. Form 10-K Annual Report for Fiscal Year Ending September 26, 2020 (09-26-2020)			
PTX-1682	Apple Inc. Form 10-K Annual Report for Fiscal Year ending September 25, 2021 (09-25-2021)			
PTX-1683	Apple Inc. Form 10-K Annual Report for Fiscal Year ending September 24, 2022 (09-24-2022)			
PTX-1684	E-mail from M. Tartakovsky to C.Cruz et al. re Apple v. Masimo (C.A. Nos. 1377/1378) - Narrowed Asserted Claims (11-09-2023)			F; H; 402; 403
PTX-1685		ASA11239035	MASA11239035	402; 403
PTX-1686		ASAD00430236	MASAD00430236	402; 403
PTX-1687	Webpage: Seeking Alpha - Masimo Corporation (MASI) Q1 2023 Earnings Call Transcript (05-09-2023) ( <a href="https://seekingalpha.com/article/4602257-masimo-corporation-masi-q1-2023-earnings-call-transcript">https://seekingalpha.com/article/4602257-masimo-corporation-masi-q1-2023-earnings-call-transcript</a> )			402; 403
PTX-1688	Masimo Corporation Form 10-K Annual Report for Fiscal Year ending December 30, 2017 (12-30-2017)			402; 403



APPLE INC.  
# 67991  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1689	Masimo Corporation Form 10-K Annual Report for Fiscal Year ending December 29, 2018 (12-29-2018)			402; 403
PTX-1690	Webpage: Masimo W1 - Advanced Health Tracking Watch (www.masimopersonalhealth.com/products/masimo-w1) (Captured 12-06-2023)			
PTX-1691	Webpage: Google Store - Firness goals deserve a fitness watch, The Google Pixel Watch 2 delivers data to help you live better (https://store.google.com/intl/en/ideas/articles/pixel-watch-2/)			F; H; 402; 403
PTX-1692	Webpage: OceanTomo, Shirley Webster, CBE Curriculum Vitae (https://oceantomo.com/zh-hant/team/shirley-webster)			F; H; 402; 403
PTX-1693	Webpage: Business Insider - How Apple charges a premium for its high-end products (transcript) (09-16-2020) (https://www.businessinsider.com/why-apple-products-are-so-expensive-iphone-macbook-2019-11)			F; H; 402; 403
PTX-1694	Masimo v. Apple, ITC Case No. 337-TA-1276, Respondent Apple Inc.'s Response to the Commissions's Notice to Review in Part a Final Initial Determination and Request for Written Submissions (06-05-2023)			F; H; 402; 403
PTX-1695	Webpage: LinkedIn - Boris Teksler, Experience (https://www.linkedin.com/in/boris-teksler-69571a3/details/experience)			F; H; 402; 403
PTX-1696	Webpage: Apple - Apple Watch Series 8, A healthy leap ahead (https://web.archive.org/web/20230826085703/https://www.apple.com/apple-watch-series-8)			402; 403
PTX-1697	Webpage: Masimo - Masimo W1, Advanced Health Tracking Watch (https://web.archive.org/web/20230224021527/https://www.masimopersonalhealth.com/products/masimo-w1)			
PTX-1698	INTENTIONALLY OMITTED			
PTX-1699	Photograph: LG Watch Style produced by Masimo bearing tag MASAD_P_019-B (APL_DELO4028315 - APL_DELO4028320) (6 native documents)			ID; MD; UK
PTX-1700	Photograph: Samsung Galaxy S8 produced by Masimo bearing tag MASAD_P_023-B (APL_DELO4028431)			
PTX-1701	Photograph: Asus ZenWatch produced by Masimo bearing tag MASAD_P_025 (APL_DELO4028458 - APL_DELO4028474) (17 native documents)			
PTX-1702	Photograph: Asus Google Nexus 7 produced by Masimo bearing tag MASAD_P_034 (APL_DELO4028540 - APL_DELO4028546) (7 native documents)			
PTX-1703		MASAD SC 0007	MASAD SC 0007	
PTX-1704		MASAD SC 0008	MASAD SC 0008	
PTX-1705		MASAD SC 0009	MASAD SC 0009	
PTX-1706		MASAD SC 0010	MASAD SC 0010	

APPLE INC.  
# 67992  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1707		ASAD SC 0011	MASAD SC 0011	
PTX-1708		ASAD SC 0012	MASAD SC 0012	
PTX-1709	1377) (12-12-2022)			F; H
PTX-1710	Webpage: Allegro - Smartwatch Zegarek EKG PULSOKSYMETR Termometr PL 9927412179 ( <a href="https://allegro.pi.oferta/smartwatch-zegarek-ekg-pulsoksymetr-termometr-pl-9927412179">https://allegro.pi.oferta/smartwatch-zegarek-ekg-pulsoksymetr-termometr-pl-9927412179</a> )			F; H; 402; 403
PTX-1711	Webpage: Apple Support - Apple Watch Series 1, Technical Specifications ( <a href="https://support.apple.com/en-us/111985">https://support.apple.com/en-us/111985</a> )			402; 403
PTX-1712	Webpage: Apple Support - Apple Watch Series 4, Technical Specifications ( <a href="https://support.apple.com/en-us/111984">https://support.apple.com/en-us/111984</a> )			
PTX-1713	Webpage: Apple Support - Apple Watch Series 5, Technical Specifications ( <a href="https://support.apple.com/en-us/118453">https://support.apple.com/en-us/118453</a> )			402; 403
PTX-1714	Webpage: Apple Support - Apple Watch Series 8, Technical Specifications ( <a href="https://support.apple.com/en-us/111848">https://support.apple.com/en-us/111848</a> )			402; 403
PTX-1715	Webpage: Apple Support - Apple Watch Ultra, Technical Specifications ( <a href="https://support.apple.com/en-us/111852">https://support.apple.com/en-us/111852</a> )			402; 403
PTX-1716	Webpage: Google Patents - List of Apple Inc. Patent Assignments ( <a href="https://patents.google.com/?assignee=apple+inc">https://patents.google.com/?assignee=apple+inc</a> )			F; H; 402; 403
PTX-1717	High Quality Image of Fig. 1, U.S. Patent No. D883,279			
PTX-1718	High Quality Image of Fig. 9, U.S. Patent No. D883,279			
PTX-1719	High Quality Image of Fig. 1, U.S. Patent No. D883,279			
PTX-1720	High Quality Image of Fig. 1, U.S. Patent No. D947,842			
PTX-1721	High Quality Image of Fig. 1, U.S. Patent No. D947,842			
PTX-1722	High Quality Image of Fig. 1, U.S. Patent No. D962,936			
PTX-1723	High Quality Image of Fig. 1, U.S. Patent No. D962,936			
PTX-1724	Webpage: Patel - Apple Watch Review, The Definitive Review, A Day in the Life ( <a href="http://www.theverge.com">www.theverge.com</a> )			F; H; 402; 403
PTX-1725	Webpage: Alibaba - New Arrival 0.96inch Smart Bracelet P11 Plus ECG+PPG Body Temperature Blood Pressure Heart Rate Monitor Pedometer Smart Watches ( <a href="https://www.alibaba.com/product-detail/New-Arrival-0-96inch-Smart-Bracelet_1600443704752.html">https://www.alibaba.com/product-detail/New-Arrival-0-96inch-Smart-Bracelet_1600443704752.html</a> )			F; H; 402; 403
PTX-1726	Webpage: Alibaba - New P11 Plus Smart Bracelet ECG + PPG Smartwatch for Men Heart Rate Blood Pressure Body Temperature Monitoring Smart Wristband ( <a href="https://www.aliexpress.us/item/3256805404541443.html?gatewayAdapt=gl_o2usa4itemAdapt">https://www.aliexpress.us/item/3256805404541443.html?gatewayAdapt=gl_o2usa4itemAdapt</a> )			F; H; 402; 403
PTX-1727	Webpage: Fowler - Apple Watch Review: The Smartwatch Finally Makes Sense, Wall Street Journal (04-08-2015) ( <a href="https://www.wsj.com/articles/apple-watch-review-the-smartwatch-finally-makes-sense-1428494495">https://www.wsj.com/articles/apple-watch-review-the-smartwatch-finally-makes-sense-1428494495</a> )			F; H; 402; 403

APPLE INC.  
#: 67993

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1728	Webpage: Garmin - Connect IQ Store, Free Watch Faces and Apps ( <a href="https://apps.garmin.com/en-US/apps/230667a0-e5a6-49bo-aefd-856806870d7a">https://apps.garmin.com/en-US/apps/230667a0-e5a6-49bo-aefd-856806870d7a</a> )			F; H; 402; 403
PTX-1729	Crilly et al. - Seeing things: consumer response to the visual domain in product design, Pre-press draft, Design Studies, 25(6), 547-477			F; H; 402; 403
PTX-1730	Dawes - The Robus Beauty of Improper Linear Models in Decision Making, America Psychologist, Vol. 34, No. 7, pp. 571-582, July 1979 (1979)			F; H; 402; 403
PTX-1731	Webpage: Rowe - Watches You Can Afford - Dual Time and GMT Watches You Will Surely Love - 20 Picks! ( <a href="https://watchesyoucanafford.com/dual-time-and-gmt-watches/#.~:text=For the frequent traveler or...">https://watchesyoucanafford.com/dual-time-and-gmt-watches/#.~:text=For the frequent traveler or...</a> )			F; H; 402; 403
PTX-1732	Webpage: Apple Watch			402; 403
PTX-1733	Webpage: Garmin - Garmin Forerunner 955, Premium Running Watch ( <a href="https://www.garmin.com/en-US/p/777655#specs">https://www.garmin.com/en-US/p/777655#specs</a> )			F; H; 402; 403
PTX-1734	Webpage: Masimo W1 Sport Health Watch, Advanced health tracking wearable with FDA-cleared module ( <a href="https://www.masimo.com/en-us/product/shop-health-wearables/137726.html">https://www.masimo.com/en-us/product/shop-health-wearables/137726.html</a> )			
PTX-1735	Simonson et al. - Experimental Evidence on the Negative Effect of Product Features and Sales Promotions on Brand Choice, Marketing Science, Vol. 13, No. 1, Winter 1994 (1994)			402; 403
PTX-1736	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 1A: Design Impact Survey - Masimo Watch, Overall Respondent Breakdown (01-27-2023)			106; E; 402; 403
PTX-1737	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 1B: Design Impact Survey - Masimo Watch, QS50 (01-27-2023)			106; E; 402; 403
PTX-1738	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 1C: Design Impact Survey - Masimo Watch, QS60 (01-27-2023)			106; E; 402; 403
PTX-1739	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 1D: Design Impact Survey - Masimo Watch, QS70 (01-27-2023)			106; E; 402; 403
PTX-1740	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 1E: Design Impact Survey - Masimo Watch, QS80 (01-27-2023)			106; E; 402; 403
PTX-1741	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 1F: Design Impact Survey - Masimo Watch, QS100 (01-27-2023)			106; E; 402; 403
PTX-1742	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 1G: Design Impact Survey - Masimo Watch, Q1 (01-27-2023)			106; E; 402; 403

APPLE INC.  
# 67994  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1743	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 1H: Design Impact Survey - Masimo Watch, Q2 (01-27-2023)			106; E; 402; 403
PTX-1744	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 1I: Design Impact Survey - Masimo Watch, Q3 (01-27-2023)			106; E; 402; 403
PTX-1745	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 2A: Design Impact Survey - Apple Watch Series 5, Overall Respondent Breakdown (01-27-2023)			106; E; 402; 403
PTX-1746	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 2B: Design Impact Survey - Apple Watch Series, QS50 (01-27-2023)			106; E; 402; 403
PTX-1747	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 2C: Design Impact Survey - Apple Watch Series, QS60 (01-27-2023)			106; E; 402; 403
PTX-1748	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 2D: Design Impact Survey - Apple Watch Series, QS70 (01-27-2023)			106; E; 402; 403
PTX-1749	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 2E: Design Impact Survey - Apple Watch Series, QS80 (01-27-2023)			106; E; 402; 403
PTX-1750	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 2F: Design Impact Survey - Apple Watch Series, QS100 (01-27-2023)			106; E; 402; 403
PTX-1751	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 2G: Design Impact Survey - Apple Watch Series, Q1 (01-27-2023)			106; E; 402; 403
PTX-1752	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 2H: Design Impact Survey - Apple Watch Series, Q2 (01-27-2023)			106; E; 402; 403
PTX-1753	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 2I: Design Impact Survey - Apple Watch Series, Q3 (01-27-2023)			106; E; 402; 403
PTX-1754	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 3A: Design Impact Survey - Apple Watch Series 8, Overall Respondent Breakdown (01-27-2023)			106; E; 402; 403
PTX-1755	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 3B: Design Impact Survey - Apple Watch Series 8, QS50 (01-27-2023)			106; E; 402; 403
PTX-1756	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 3C: Design Impact Survey - Apple Watch Series 8, QS60 (01-27-2023)			106; E; 402; 403

APPLE INC.  
# 67995  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1757	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 3D: Design Impact Survey - Apple Watch Series 8, QS70 (01-27-2023)			106; E; 402; 403
PTX-1758	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 3E: Design Impact Survey - Apple Watch Series 8, QS80 (01-27-2023)			106; E; 402; 403
PTX-1759	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 3F: Design Impact Survey - Apple Watch Series 8, QS100 (01-27-2023)			106; E; 402; 403
PTX-1760	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 3G: Design Impact Survey - Apple Watch Series 8, Q1 (01-27-2023)			106; E; 402; 403
PTX-1761	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 3H: Design Impact Survey - Apple Watch Series 8, Q2 (01-27-2023)			106; E; 402; 403
PTX-1762	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 3I: Design Impact Survey - Apple Watch Series 8, Q3 (01-27-2023)			106; E; 402; 403
PTX-1763	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 4A: Association Survey - Apple Watch Series 5, Overall Respondent Breakdown (01-27-2023)			106; E; 402; 403
PTX-1764	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 4B: Association Survey - Apple Watch Series 5, QS50 (01-27-2023)			106; E; 402; 403
PTX-1765	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 4C: Association Survey - Apple Watch Series 5, QS60 (01-27-2023)			106; E; 402; 403
PTX-1766	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 4D: Association Survey - Apple Watch Series 5, QS70 (01-27-2023)			106; E; 402; 403
PTX-1767	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 4E: Association Survey - Apple Watch Series 5, QS80 (01-27-2023)			106; E; 402; 403
PTX-1768	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 4F: Association Survey - Apple Watch Series 5, QS100 (01-27-2023)			106; E; 402; 403
PTX-1769	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 4G: Association Survey - Apple Watch Series 5, QS110 (01-27-2023)			106; E; 402; 403
PTX-1770	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 4H: Association Survey - Apple Watch Series 5, Q1 (01-27-2023)			106; E; 402; 403

APPLE INC.  
# 67996  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1771	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 5A: Association Survey - Apple Watch Series 8, Overall Respondent Breakdown (01-27-2023)			106; E; 402; 403
PTX-1772	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 5B: Association Survey - Apple Watch Series 8, QS50 (01-27-2023)			106; E; 402; 403
PTX-1773	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 5C: Association Survey - Apple Watch Series 8, QS60 (01-27-2023)			106; E; 402; 403
PTX-1774	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 5D: Association Survey - Apple Watch Series 8, QS70 (01-27-2023)			106; E; 402; 403
PTX-1775	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 5E: Association Survey - Apple Watch Series 8, QS80 (01-27-2023)			106; E; 402; 403
PTX-1776	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 5F: Association Survey - Apple Watch Series 8, QS100 (01-27-2023)			106; E; 402; 403
PTX-1777	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 5G: Association Survey - Apple Watch Series 8, QS110 (01-27-2023)			106; E; 402; 403
PTX-1778	Declaration of Dr. Itamar Simonson in Support of Apple Inc.'s Motion for an Expedited Trial, Exhibit 5H: Association Survey - Apple Watch Series 8, Q1 (01-27-2023)			106; E; 402; 403
PTX-1779	Supplemental Expert Report of Dr. Itamar Simonson, Exhibit 1A: Design Impact Survey - Masimo W1, Overall Respondent Breakdown (11-22-2023)			106; E; 402; 403
PTX-1780	Supplemental Expert Report of Dr. Itamar Simonson, Exhibit 1B: QS50 (11-22-2023)			106; E; 402; 403
PTX-1781	Supplemental Expert Report of Dr. Itamar Simonson, Exhibit 1C: Design Impact Survey - Masimo W1, QS60 (11-22-2023)			106; E; 402; 403
PTX-1782	Supplemental Expert Report of Dr. Itamar Simonson, Exhibit 1D: Design Impact Survey - Masimo W1, QS70 (11-22-2023)			106; E; 402; 403
PTX-1783	Supplemental Expert Report of Dr. Itamar Simonson, Exhibit 1E: Design Impact Survey - Masimo W1, QS80 (11-22-2023)			106; E; 402; 403
PTX-1784	Supplemental Expert Report of Dr. Itamar Simonson, Exhibit 1F: Design Impact Survey - Masimo W1, QS100 (11-22-2023)			106; E; 402; 403
PTX-1785	Supplemental Expert Report of Dr. Itamar Simonson, Exhibit 1G: Design Impact Survey - Masimo W1, Q1 (11-22-2023)			106; E; 402; 403
PTX-1786	Supplemental Expert Report of Dr. Itamar Simonson, Exhibit 1H: Design Impact Survey - Masimo W1, Q2 (11-22-2023)			106; E; 402; 403

APPLE INC.  
#: 67997

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1787	Supplemental Expert Report of Dr. Itamar Simonson, Exhibit 1I: Design Impact Survey - Masimo W1, Q3 (11-22-2023)			106; E; 402; 403
PTX-1788	Supplemental Expert Report of Dr. Itamar Simonson, Exhibit 2A: Design Impact Survey - Masimo Freedom, Overall Respondent Breakdown (11-22-2023)			106; E; 402; 403
PTX-1789	Supplemental Expert Report of Dr. Itamar Simonson, Exhibit 2B: Design Impact Survey - Masimo Freedom, QS50 (11-22-2023)			106; E; 402; 403
PTX-1790	Supplemental Expert Report of Dr. Itamar Simonson, Exhibit 2C: Design Impact Survey - Masimo Freedom, QS60 (11-22-2023)			106; E; 402; 403
PTX-1791	Supplemental Expert Report of Dr. Itamar Simonson, Exhibit 2D: Design Impact Survey - Masimo Freedom, QS70 (11-22-2023)			106; E; 402; 403
PTX-1792	Supplemental Expert Report of Dr. Itamar Simonson, Exhibit 2E: Design Impact Survey - Masimo Freedom, QS80 (11-22-2023)			106; E; 402; 403
PTX-1793	Supplemental Expert Report of Dr. Itamar Simonson, Exhibit 2F: Design Impact Survey - Masimo Freedom, QS100 (11-22-2023)			106; E; 402; 403
PTX-1794	Supplemental Expert Report of Dr. Itamar Simonson, Exhibit 2G: Design Impact Survey - Masimo Freedom, Q1 (11-22-2023)			106; E; 402; 403
PTX-1795	Supplemental Expert Report of Dr. Itamar Simonson, Exhibit 2H: Design Impact Survey - Masimo Freedom, Q2 (11-22-2023)			106; E; 402; 403
PTX-1796	Supplemental Expert Report of Dr. Itamar Simonson, Exhibit 2I: Design Impact Survey - Masimo Freedom, Q3 (11-22-2023)			106; E; 402; 403
PTX-1797	Declaration of Alan D. Ball in Support of Apple Inc.'s Motion for an Expedited Trial (-1377) (01-29-2023)			E; 402; 403
PTX-1798				MD; 402; 403

APPLE INC.  
# 67998  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1799				MD
PTX-1800				F; H
PTX-1801				F; H
PTX-1802		APL_DEL00205161	APL_DEL00205161	F; H
PTX-1803		APL_DEL00205162	APL_DEL00205162	F; H
PTX-1804				F; H
PTX-1805				F; H
PTX-1806				F; H
PTX-1807				F; H
PTX-1808				F; H
PTX-1809				F; H
PTX-1810				F; H
PTX-1811				F; H
PTX-1812				F; H
PTX-1813				F; H
PTX-1814				F; H
PTX-1815				E; 402; 403
PTX-1816		APL_DEL00722615	APL_DEL00722773	402; 403
PTX-1817		APL_DEL00722774	APL_DEL00723027	402; 404
PTX-1818		APL_DEL00723028	APL_DEL00723247	402; 405



APPLE INC  
#: 67999

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1819		PL_DEL00723248	APL_DEL00723443	402; 406
PTX-1820	Arslan et al. - Accuracy of the Apple Watch in measuring oxygen saturation: comparison with pulse oximetry and ABG, Irish Journal of Medical Science (07-13-2023)	APL_DEL00723830	APL_DEL00723836	F; H; 402; 403
PTX-1821	Shapiro et al. - Pulse Oximetry Values from 33,080 Participants in the Apple Heart & Movement Study (07-15-2022)	APL_DEL00723939	APL_DEL00723973	F; H; 402; 403
PTX-1822	Webpage: Warrior Watch Study   Mount Sinai - New York (www.mountsinai.org/about/covid19/warrior-watch-study)	APL_DEL00724014	APL_DEL00724016	F; H; 402; 403
PTX-1823	Webpage: UnitedHealthcare Motion   UnitedHealthcare (www.unitedhealthcaremotion.com)	APL_DEL00724044	APL_DEL00724045	F; H; 402; 403
PTX-1824		PL_DEL00899321	APL_DEL00899355	
PTX-1825		PL_DEL01248762	APL_DEL01248832	
PTX-1826		PL_DEL01250923	APL_DEL01250964	402; 403
PTX-1827		PL_DEL01510011	APL_DEL01510018	402; 403
PTX-1828		PL_DEL01510420	APL_DEL01510432	
PTX-1829		PL_DEL01510481	APL_DEL01510490	
PTX-1830		PL_DEL02008225	APL_DEL02008370	402; 403
PTX-1831		PL_DEL02008371	APL_DEL02008644	402; 403
PTX-1832		PL_DEL03106324	APL_DEL03106609	402; 403
PTX-1833		PL-MAS_02638279	APL-MAS_02638478	402; 403
PTX-1834		PL-MAS_00153518	APL-MAS_00153521	402; 403
PTX-1835		PL-MAS_00154316	APL-MAS_00154496	402; 403
PTX-1836		PL-MAS_00154497	APL-MAS_00154648	402; 403

APPLE INC  
#: 68000

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1837		PL-MAS_00155245	APL-MAS_00155373	402; 403
PTX-1838		PL-MAS_00155804	APL-MAS_00156029	402; 403
PTX-1839		PL-MAS_00156208	APL-MAS_00156471	402; 403
PTX-1840		PL-MAS_00156472	APL-MAS_00156732	402; 403
PTX-1841		PL-MAS_00156733	APL-MAS_00157034	402; 403
PTX-1842		PL-MAS_00157432	APL-MAS_00157537	402; 403
PTX-1843		PL-MAS_00157528	APL-MAS_00157640	402; 403
PTX-1844		PL-MAS_00157641	APL-MAS_00157905	402; 403
PTX-1845		PL-MAS_00157906	APL-MAS_00158000	402; 403
PTX-1846		PL-MAS_00158001	APL-MAS_00158264	402; 403
PTX-1847		PL-MAS_00158265	APL-MAS_00158503	402; 403
PTX-1848		PL-MAS_00158639	APL-MAS_00158802	402; 403
PTX-1849		PL-MAS_00350839	APL-MAS_00350853	402; 403
PTX-1850		PL-MAS_00674768	APL-MAS_00674789	F; H; 402; 403
PTX-1851		PL-MAS_01544029	APL-MAS_01544192	402; 403
PTX-1852		PL-MAS_02367373	APL-MAS_02367385	402; 403
PTX-1853		PL-MAS_02414552	APL-MAS_02414564	402; 403
PTX-1854		PL-MAS_02557026	APL-MAS_02557045	F; H; 402; 403

APPLE INC.  
#: 68001  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1855		APL-MAS_02637515	APL-MAS_02637615	402; 403
PTX-1856		APL-MAS_02637616	APL-MAS_02637862	402; 403
PTX-1857		APL-MAS_02637863	APL-MAS_02638070	402; 403
PTX-1858		APL-MAS_02638071	APL-MAS_02638278	402; 403
PTX-1859	Spaccarotella et al. - Assessment of Non-Invasive Measurements of Oxygen Saturation and Heart Rate with an Apple Smartwatch: Comparison with a Standard Pulse Oximeter, Journal of Clinical Medicine, Vol. 11 (03-08-2022)	APL-MAS_02640300	APL-MAS_02640306	F; H; 402; 403
PTX-1860	Webpage: Use fall detection with Apple Watch   Apple Support (03-31-2022) (support.apple.com/en-us/HT208944)	APL-MAS_02924596	APL-MAS_02924599	402; 403
PTX-1861	Webpage: How to use the Blood Oxygen app on Apple Watch Series 6 or Series 7   Apple Support (support.apple.com/en-us/HT211027)	APL-MAS_02924688	APL-MAS_02924692	402; 403
PTX-1862	Apple - Using Apple Watch for Arrhythmia Detection (12-2020)	APL-MAS_03048839	APL-MAS_03048885	402; 403
PTX-1863	Webpage: Medical Pioneer Masimo Announces the Full Market Consumer Release of the Masimo W1™, the First Watch to Offer Accurate, Continuous Health Data   Masimo (08-31-2022) (investor.masimo.com/news/news-details/2022/Medical-Pioneer-Masimo-Announces-the-Full-Market-Consumer-Release-of-the-Masimo-W1-the-First-Watch-to-Offer-Accurate-Continuous-Health-Data/default.aspx)	APL-MAS_03058627	APL-MAS_03058633	
PTX-1864				
PTX-1865		MASAD00769088	MASAD00769090	F
PTX-1866		MASAD00797557	MASAD00797564	
PTX-1867		MASAD02004680	MASAD02004680	F; 106
PTX-1868		MASAD03726716	MASAD03726719	F
PTX-1869	Masimo v. Apple, C.D. Cal. Case No. 8:20-cv-00048-JVS, Defendant Apple Inc.'s Supplemental Objections and Responses to Plaintiffs Masimo Corporation and Cercacor Laboratories, Inc.'s First Set of Interrogatories to Defendant Apple Inc. (Nos. 1-5) (09-06-2022)			F; H; 402
PTX-1870	Masimo v. Apple, C.D. Cal. Case No. 8:20-cv-00048-JVS, Defendant Apple Inc.'s Supplemental Objections and Responses to Plaintiffs Masimo Corporation and Cercacor Laboratories, Inc.'s Second Set of Interrogatories to Defendant Apple Inc. (Nos. 6-10) (09-06-2022)			F; H; 402

APPLE INC.

# 68002

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1871	Masimo v. Apple, C.D. Cal. Case No. 8:20-cv-00048-JVS, Defendant Apple Inc.'s Supplemental Objections and Responses to Plaintiffs Masimo Corporation and Cercacor Laboratories, Inc.'s Fifth Set of Interrogatories to Defendant Apple Inc. (Nos. 17-22) (09-12-2022)			F; H; 402
PTX-1872	Masimo v. Apple, C.D. Cal. Case No. 8:20-cv-00048-JVS, Defendant Apple Inc.'s Supplemental Objections and Responses to Plaintiffs Masimo Corporation and Cercacor Laboratories, Inc.'s Third Set of Interrogatories to Defendant Apple Inc. (Nos. 11-13) (10-07-2022)			F; H; 402
PTX-1873	Masimo v. Apple, C.D. Cal. Case No. 8:20-cv-00048-JVS, Defendant Apple Inc.'s Supplemental Objections and Responses to Plaintiffs Masimo Corporation and Cercacor Laboratories, Inc.'s Fourth Set of Interrogatories to Defendant Apple Inc. (Nos. 14-16) (10-07-2022)			F; H; 402
PTX-1874	Defendant Masimo Corporation's Answer to Complaint and Counterclaims (-1378) (12-12-2022)			
PTX-1875	Masimo v. Apple, C.D. Cal. Case. No. 8:20-cv-00048-JVS, Apple's Memorandum in Support of Its Motion for Partial Summary Judgment on Plaintiffs' Trade Secret Claim and Plaintiffs' Lost Profits Damages Theory (Sealed) (12-20-2022)			F; H; 402
PTX-1876	Masimo v. Apple, C.D. Cal. Case. No. 8:20-cv-00048-JVS, Apple's Corrected Memorandum in Support of Its Motion for Partial Summary Judgment on Plaintiffs' Trade Secret Claim and Plaintiffs' Lost Profits Damages Theory (Sealed) (12-23-2022)			F; H; 402
PTX-1877	Masimo v. Apple, C.D. Cal. Case No. 8:20-cv-00048-JVS, Plaintiff's Response to Defendant's Memorandum of Evidentiary Objections (01-30-2023)			F; H; 402
PTX-1878	Defendants' Answering Brief in Opposition to Plaintiff's Motion to Stay Discovery Pending Resolution of Motion to Dismiss (-1378) (03-29-2023)			F; H; 402
PTX-1879	Masimo v. Apple, C.D. Cal. Case. No. 8:20-cv-00048-JVS, Apple's Memorandum in Support of Its Oral Motion for Judgment as a Matter of Law under Rule 50(a) (Sealed) (04-22-2023)			F; H; 402
PTX-1880	Masimo v. Apple, C.D. Cal. Case. No. 8:20-cv-00048-JVS, Apple's Memorandum in Support of Its Renewed Motion for Judgment as a Matter of Law under Rule 50(b) (Sealed) (06-01-2023)			F; H; 402
PTX-1881	Masimo v. Apple, ITC Case No. 337-TA-1276, Complainants' Submission in Response to the Commission's May 15, 2023 Notice of Commission Determination to Review in Part (06-05-2023)			F; H; 402
PTX-1882	Minute Entry re Hearing for Motions to Dismiss (Design and Utility) (06-15-2023)			F; H; 402
PTX-1883	Transcript of Motion Hearing (06-15-2023)			F; H; 402
PTX-1884	Apple Inc.'s Initial Response to Design Patent Invalidity Contentions (06-22-2023)			F; H; 403

APPLE INC.  
# 68003  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1885	Apple Inc.'s Initial Response to Utility Patent Invalidity Contentions (06-22-2023)			F; H; 403
PTX-1886	Declaration of Justin J. Gillett (09-22-2023)			F; H; 402; 403
PTX-1887	Webpage: Ember User Guide   Cercacor (www.cercacor.com/pages/ember-user-guide)	APL_DEL00723870	APL_DEL00723888	
PTX-1888	Webpage: Getting Started, Masimo SafetyNet   Masimo (www.mymasimo.com/products/masimo-safetynet/)	APL_DEL00723889	APL_DEL00723900	
PTX-1889		APL_DEL00956847	APL_DEL00956848	106; 402; 403
PTX-1890		APL_DEL03550796	APL_DEL03550796	402; 403
PTX-1891	Webpage: Masimo Corporation (MASI) Q1 2023 Earnings Call Transcript   Seeking Alpha (05-09-2023) (www.seekingalpha.com/article/4602257-masimo-corporation-masi-q1-2023-earnings-call-transcript)	APL_DEL03853538	APL_DEL03853558	402; 403
PTX-1892				402; 403; F
PTX-1893	Masimo v. Apple, C.D. Cal. Case No. 8:20-cv-00048-JVS, Deposition of Kristen Budreau (08-16-2022)			F; H; 402; 403
PTX-1894	Webpage: Masimo CEO on how its watch compares to the Apple Watch   CNBC (01-11-2023) (www.cnbc.com/video/2023/01/11/masimo-ceo-on-how-its-watch-compares-to-the-apple-watch.html)			106; 403
PTX-1895	Masimo v. Apple, C.D. Cal. Case No. 8:20-cv-00048-JVS, Plaintiffs' Notice of Motion and Contingent Motion to Strike and Request for Evidentiary Sanctions (01-09-2023)			F; H; 402
PTX-1896	Mallinckrodt v. Masimo, C.D. Cal. Case No. 2:00-cv-06506-MRP, Final Judgment (08-04-2004)			
PTX-1897	Masimo v. Apple, C.D. Cal. Case. No. 8:20-cv-00048-JVS, Apple's Memorandum in Support of Its Motion for Partial Summary Judgment on Plaintiffs' Trade Secret Claim and Plaintiffs' Lost Profits Damages Theory (Redacted) (12-19-2022)			F; H; 402; 403
PTX-1898	Masimo v. Apple, ITC Case No. 337-TA-1276, Declaration of Bilal Muhsin (06-05-2023)			
PTX-1899	INTENTIONALLY OMITTED			
PTX-1900	Masimo v. Apple, C.D. Cal. Case No. 8:20-cv-00048-JVS, Deposition of Joseph Kiani (08-05-2022)			F; H; 402; 403
PTX-1901		MASA02957554	MASA02957573	
PTX-1902		MASA03582963	MASA03582966	F; 106
PTX-1903		MASAD00033011	MASAD00033018	

APPLE INC.  
# 68004  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1904		ASAD00033019	MASAD00033047	
PTX-1905		ASAD00033357	MASAD00033374	
PTX-1906		ASAD00033525	MASAD00033531	402; 403
PTX-1907		ASAD00033603	MASAD00033609	
PTX-1908		ASAD00033917	MASAD00033943	
PTX-1909		ASAD00034339	MASAD00034381	402; 403
PTX-1910		ASAD00034382	MASAD00034454	402; 403
PTX-1911		ASAD00035340	MASAD00035369	402; 403
PTX-1912		ASAD00036232	MASAD00036435	402; 403
PTX-1913		ASAD00044310	MASAD00044341	402; 403
PTX-1914		ASAD00044696	MASAD00044727	402; 403
PTX-1915		ASAD00044850	MASAD00044914	402; 403
PTX-1916		ASAD00237027	MASAD00237030	
PTX-1917		ASAD00438992	MASAD00438993	F
PTX-1918		ASAD00641026	MASAD00641070	402; 403
PTX-1919		ASAD00644862	MASAD00644863	F; 402; 403
PTX-1920		ASAD00646886	MASAD00646886	402; 403
PTX-1921		ASAD00677758	MASAD00677759	
PTX-1922		ASAD00727091	MASAD00727467	F; H; 402; 403
PTX-1923		ASAD00727468	MASAD00727469	F; 402; 403
PTX-1924		ASAD00727470	MASAD00727825	F; H; 402; 403
PTX-1925		ASAD00727829	MASAD00727842	
PTX-1926		ASAD00743196	MASAD00743198	F

APPLE INC  
#: 68005

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1927		ASAD00763096	MASAD00763099	F; 402; 403
PTX-1928		ASAD00792302	MASAD00792302	
PTX-1929		ASAD00982014	MASAD00982018	F; 402; 403
PTX-1930		ASAD00982019	MASAD00982034	F; 402; 403
PTX-1931		ASAD01020986	MASAD01020989	
PTX-1932		ASAD01170244	MASAD01170245	F
PTX-1933		ASAD01425450	MASAD01425453	F; 402; 403
PTX-1934		ASAD02043760	MASAD02043766	F
PTX-1935		ASAD03398485	MASAD03398485	F
PTX-1936		ASAD03407356	MASAD03407356	F; 106
PTX-1937		ASAD03434925	MASAD03434946	F; H
PTX-1938		ASAD03758907	MASAD03758908	402; 403
PTX-1939		ASAD03849399	MASAD03849409	
PTX-1940		ASITC 01270075	MASITC 01270126	
PTX-1941				F; 402; 403
PTX-1942				
PTX-1943		ASAD00006600	MASAD00006600	402; 403
PTX-1944		PL_DEL00208553	APL_DEL00208577	
PTX-1945		PL_DEL00275285	APL_DEL00275365	
PTX-1946		PL_DEL00278058	APL_DEL00278311	402; 403
PTX-1947		PL_DEL00286984	APL_DEL00287002	402; 403
PTX-1948		PL_DEL00312235	APL_DEL00312262	402; 403
PTX-1949		PL_DEL00723707	APL_DEL00723767	402; 403

APPLE INC  
# 68096  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1950		PL_DEL00955174	APL_DEL00955228	402; 403
PTX-1951		PL_DEL00955231	APL_DEL00955285	402; 403
PTX-1952		PL_DEL00956849	APL_DEL00956878	402; 403
PTX-1953		PL_DEL00956881	APL_DEL00956910	402; 403
PTX-1954		PL_DEL00956919	APL_DEL00956984	402; 403
PTX-1955		PL_DEL00960474	APL_DEL00960747	402; 403
PTX-1956		PL_DEL01088901	APL_DEL01088905	402; 403
PTX-1957		PL_DEL01165890	APL_DEL01165944	402; 403
PTX-1958		PL_DEL01166674	APL_DEL01166728	402; 403
PTX-1959		PL_DEL01173410	APL_DEL01173439	402; 403
PTX-1960		PL_DEL01355760	APL_DEL01355788	402; 403
PTX-1961		PL-MAS_00157297	APL-MAS_00157341	402; 403
PTX-1962		PL-MAS_00157389	APL-MAS_00157431	402; 403
PTX-1963		PL-MAS_00561030	APL-MAS_00561043	402; 403
PTX-1964		PL-MAS_00614176	APL-MAS_00614220	402; 403
PTX-1965		PL-MAS_00723365	APL-MAS_00723419	402; 403
PTX-1966		PL-MAS_00922514	APL-MAS_00922524	402; 403
PTX-1967		PL-MAS_01045411	APL-MAS_01045466	402; 403
PTX-1968		PL-MAS_01045472	APL-MAS_01045527	402; 403
PTX-1969		PL-MAS_01672276	APL-MAS_01672284	402; 403
PTX-1970		PL-MAS_01682507	APL-MAS_01682563	402; 403



APPLE INC.  
# 68007  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1971		PL-MAS_02490956	APL-MAS_02490957	402; 403
PTX-1972		PL_MAS_ITC_00413485	APL_MAS_ITC_00413506	402; 403
PTX-1973	Stephen C. Jensen in Support of Plaintiffs' Motion for Protective Order (06-26-2020)			F; H; 402; 403
PTX-1974	Masimo v. Apple, ITC Case No. 337-TA-1276, Declaration of Stephen C. Jensen in Support of Complainants' Opposition to Respondent's Motion to Exclude Stephen Jensen from Access to Apple's Confidential Business Information under the Protective Order (Order No. 1) (09-13-2021)			F; H; 402; 403
PTX-1975	Masimo v. Apple, ITC Case No. 337-TA-1276, Declaration of Joe Kiani in Support of Complainants' Opposition to Respondent's Motion to Exclude Stephen Jensen from Access to Apple's Confidential Business Information under the Protective Order (Order No. 1) (09-12-2021)			402; 403
PTX-1976	Defendants Masimo Corporation and Sound United, LLC's Opposition to Plaintiff Apple Inc.'s Motion for Expedited Discovery (Sealed) (-1377) (11-17-2022)			F; H; 402; 403
PTX-1977	Transcript of Hearing on Apple Inc.'s Motion for Expedited Discovery (-1377) (12-21-2022)			F; H; 402; 403
PTX-1978	Letter to the Honorable Jennifer L. Hall from David E. Moore (-1377) (06-29-2023)			F; H; 402; 403
PTX-1979	Transcript of Hearing on Discovery Disputes (07-07-2023)			F; H; 402; 403
PTX-1980	Masimo v. Apple, ITC Case No. 337-TA-1276, Order No. 7 Granting Respondent's Motion to Preclude Stephen Jensen from Access to Confidential Business Information under the Protective Order while Serving on Complainant's Board of Directors (11-18-2021)			F; H; 402; 403
PTX-1981	Apple v. Masimo, PTAB Case No. IPR2022-01291, Decision Granting-in-Part Patent Owner's Motion for Additional Discovery (03-17-2023)			F; H; 402; 403
PTX-1982	Masimo v. Apple, ITC Case No. 337-TA-1276, Deposition of Scott Cromar (12-21-2021)			F; H; 402; 403; ID
PTX-1983	Webpage: Litigation Department of the Year, Intellectual Property: Knobbe Martens Olson & Bear   Law.com (04-24-2015) ( <a href="http://www.law.com/therecorder/almID/1202724129923/">www.law.com/therecorder/almID/1202724129923/</a> )			F; H; 402; 403
PTX-1984	Webpage: Fiscal Year 2020 10-K Annual Report   Masimo (investor.masimo.com/financials/sec-filings/sec-filings-details/default.aspx?FilingId=14736544)			402; 403
PTX-1985	Webpage: Top CEO's 4 'Guiding Principles' Turn Startup into \$10 Billion Success   Investor's Business Daily (04-09-2020) ( <a href="http://www.investors.com/news/management/leaders-and-success/masimo-ceo-four-guiding-principles-turn-startup-success/">www.investors.com/news/management/leaders-and-success/masimo-ceo-four-guiding-principles-turn-startup-success/</a> )			F; H; 402; 403

APPLE INC  
# 68008  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1986	Webpage: Fiscal Year 2018 Form 10-K, Annual Report   Masimo (investor.masimo.com/financials/sec-filings/sec-filings-details/default.aspx?FilingId=13255271)			402; 403
PTX-1987	Webpage: Masimo's W1 invented to do things the Apple Watch can't: CEO Joe Kiani   Fox Business (12-21-2022) (www.foxbusiness.com/video/6317609549112)			
PTX-1988	Webpage: New Directors are Needed at Masimo   Business Insider (05-2023) (mms.businesswire.com/media/20230529005187/en/1806142/1/Politan_Investor_Presentation_May_2023_1.pdf)			F; H; 402; 403
PTX-1989	Webpage: Steve Jensen   Knobbe Martens (05-30-2023) (web.archive.org/web/20230530102319/https://www.knobbe.com/attorneys/steve-jensen)			F; H; 402; 403
PTX-1990	Webpage: Steven Jensen   Knobbe Martens (11-28-2022) (web.archive.org/web/20221128005244/https://www.knobbe.com/attorneys/steve-jensen)			F; H; 402; 403
PTX-1991	Webpage: Steve Jensen   Knobbe Martens (12-08-2021) (web.archive.org/web/20211208213026/https://www.knobbe.com/attorneys/steve-jensen)			F; H; 402; 403
PTX-1992	Webpage: Steve Jensen   Knobbe Martens (06-29-2022) (web.archive.org/web/20220629030452/https://www.knobbe.com/attorneys/steve-jensen)			F; H; 402; 403
PTX-1993	Webpage: How activist Politan Capital may find an opportunity to trim costs, build value at Masimo   CNBC (08-20-2022) (www.cnbc.com/2022/08/20/how-activist-politan-capital-may-find-an-opportunity-to-trim-costs-build-value-at-masimo.html)			F; H; 402; 403
PTX-1994	Webpage: Company Evolution   Masimo (www.masimo.com/company/masimo/evolution/)			
PTX-1995	Webpage: Joe Kiani, Letter from the Chief Executive Officer   Masimo (www.masimo.com/letter-from-founder/)			
PTX-1996	Webpage: Court Upholds \$134.5 Million Verdict Against Nellcor for Infringement of Masimo's Patents   Masimo (07-16-2004) (www.masimo.com/company/news/news-media/2004/#news-2f5e00c6-d7af-4d79-92bb-a3345ea49465)			
PTX-1997	Webpage: Masimo and Dolphin Announce Settlement of Patent Dispute   Masimo (04-27-2006) (www.masimo.com/company/news/news-media/2006#news-ce7f5903-c045-4afa-8c904e81ca557fb5)			
PTX-1998	Webpage: Masimo and Nellcor Announce Settlement of Patent Litigation   Masimo (01-23-2006) (www.masimo.com/company/news/news-media/2006#news-76f2c84e-7857-4cff-a3648a7af3b2221e)			

APPLE INC  
#: 68009

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-1999	Webpage: Masimo and Respiroics Announce an Expanded Relationship, the Adoption of Masimo Rainbow SET Pulse CO-Oximetry, and Settlement of Patent Dispute   Masimo (08-01-2006) (www.masimo.com/company/news/news-media/2006#news-0cac0538250f-4c11-b412-217e20006e5e)			
PTX-2000	Webpage: Court Upholds Award of \$467 Million to Masimo for Philips' Patent Infringement   Masimo (05-19-2015) (www.masimo.com/company/news/news-media/2015/#news-3497b147-8519-44ce-8b05c7c14db3d95d)			
PTX-2001	Webpage: Philips and Masimo Sign Multi-Year Business Partnership Agreement in Patient Monitoring and Select Therapy Solutions (11-07-2016) (www.masimo.com/company/news/news-media/2016/#news-3c555bf2-2e14-4eaa-abc0-5b723675c1e9)			
PTX-2002	Webpage: Masimo Announces Amendment to Nellcor Royalty Agreement   Masimo (09-02-2016) (www.masimo.com/company/news/news-media/2016/#news-0f61fb9f0af5-4245-b4e2-a329ad0562a6)			
PTX-2003	Webpage: Board of Directors   Masimo Foundation (www.masimofoundation.com/about/board-of-directors.htm)			
PTX-2004	Webpage: Masimo Acquires SEDLine and Enters the Brain Function Monitoring Market   PR Newswire (07-13-2010) (www.prnewswire.com/newsreleases/masimo-acquires-sedline-and-enters-the-brain-function-monitoring-market-98308829.html)			F; H; 402; 403
PTX-2005	Webpage: Masimo shareholders elect Politan's two director nominees to board   Reuters (07-26-2023) (www.reuters.com/business/masimo-shareholders-poised-elect-politans-two-director-nominees-board-sources-2023-06-26/)			F; H; 402; 403
PTX-2006	Webpage: Fifth Amended and Restated Registration Rights Agreement, Masimo Corporation   SEC (www.sec.gov/Archives/edgar/data/937556/000119312507082880/dex42.htm)			402; 403
PTX-2007	Webpage: Cercacor Laboratories, Inc.'s Notice of Exempt Offering of Securities (Form D)   SEC (06-03-2016) (www.sec.gov/Archives/edgar/data/1061031/000114036116073170/xslFormDX01/primary_doc.xml)			402; 403
PTX-2008	Webpage: Cercacor Laboratories, Inc.'s Notice of Exempt Offering of Securities (Form D)   SEC (11-29-2017) (www.sec.gov/Archives/edgar/data/1061031/000114036117044552/xslFormDX01/primary_doc.xml)			402; 403

APPLE INC  
# 68010  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-2009	Webpage: Big Changes Hit Sound United as Terminated President Duffy Exits Today   Strata-Gee (08-05-2022) (www.strata-gee.com/big-changes-hit-sound-united-as-terminated-president-duffy-exits-today/)			F; H; 402; 403
PTX-2010	E-mail from J. Bunker to B. Luehrs et al. re W1 commercial production (07-31-2023)			F; H; 402; 403
PTX-2011	E-mail from J. Bunker to B. Luehrs et al. re W1 commercial production (08-29-2023)			F; H; 402; 403
PTX-2012	Webpage: Apple stole our technology, employees: Masimo CEO Joe Kiani   Fox Business (www.foxbusiness.com/video/6330943150112)	APL_DEL03853462	APL_DEL03853462	
PTX-2013		MASAD00237978	MASAD00237998	
PTX-2014		MASAD00438085	MASAD00438086	402; 403
PTX-2015		MASAD00438087	MASAD00438088	402; 403
PTX-2016		MASITC_01226947	MASITC_01226949	F
PTX-2017	areas/patents)			F; H; 402; 403
PTX-2018	Apple Inc.'s Response to Masimo Corporation and Sound United, LLC's Final Design Patent Invalidity Contentions (09-07-2023)			F; H; 402; 403
PTX-2019		APL_DEL00956617	APL_DEL00956651	402; 403
PTX-2020	Webpage: Best FDA Approved ECG Smartwatches 2023   Apple, Fitbit, Samsung ECG Watches (01-16-2023) (www.smartwatchcrunch.com/fda-approved-ecg-smart-watches/)	APL_DEL01460398	APL_DEL01460417	F; H; 402; 403
PTX-2021	Webpage: Apple announces revolutionary iPhone X with Face ID and no home button (09-12-2017) (www.digitalspy.com/tech/apple/a837895/iphone-x-features-detail-price-wireless-charging-release-date/)	APL_DEL01460451	APL_DEL01460456	F; H; 402; 403
PTX-2022	Webpage: Apple launched a brand-new, high-end iPhone - and it doesn't have a home button   Insider (09-12-2017) (www.insider.com/apple-iphone-x-no-home-button-2017-9)	APL_DEL01460457	APL_DEL01460458	F; H; 402; 403
PTX-2023	Webpage: Apple's now defunct home button is a reminder that even the best buttons can fail   The Verge (02-28-2019) (www.theverge.com/circuitbreaker/2019/2/28/18244645/apple-home-button-user-interface-iphone-7-fake)	APL_DEL01460459	APL_DEL01460461	F; H; 402; 403
PTX-2024	Webpage: Wearable Tech Awards 2018: All the big winners revealed (12-12-2018) (www.wearable.com/wearable-tech/wearable-tech-awards-2018-winners-revealed-6815)	APL_DEL01460478	APL_DEL01460483	F; H; 402; 403

APPLE INC.  
# 68011  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-2025	Webpage: iPhone X review: Apple finally knocks it out of the park   The Guardian (11-10-2017) (www.theguardian.com/technology/2017/nov/10/iphone-x-review-apple-face-id-all-screen-design-home-button)	APL_DELO1460491	APL_DELO1460496	F; H; 402; 403
PTX-2026	Baumgart, D. - Smartphones in Clinical Practice, Medical Education, and Research - Arch Intern Med, Vol. 171, Issue 14 (07-25-2011)	APL_DELO3850998	APL_DELO3851000	F; H; 402; 403
PTX-2027	Webpage: Apple Receives Patent for Integrated Heart Rate Monitor (02-24-2014) (www.mpo-mag.com/contents/view_breaking-news/2014-02-24/apple-receives-patent-for-integrated-heart-rate-monitor/)	APL_DELO3851001	APL_DELO3851001	F; H; 402; 403
PTX-2028	Webpage: Apple is granted hover and heart-rate monitoring patents (12-26-2013) (www.phys.org/news/2013-12-apple-granted-heart-rate-patents.html)	APL_DELO3851003	APL_DELO3851005	F; H; 402; 403
PTX-2029	Webpage: Apple Patents Integrated Heart Rate Monitor for Smartphones, Hover Touch Sensors (12-24-2013) (www.techcrunch.com/2013/12/24/apple-patents-integrated-heart-rate-monitor-for-smartphones-hover-touch-sensors/)	APL_DELO3851010	APL_DELO3851010	F; H; 402; 403
PTX-2030		APL-MAS 00198977	APL-MAS 00199012	402; 403
PTX-2031		APL_MAS_ITC_00311662	APL_MAS_ITC_00311720	402; 403
PTX-2032		APL_MAS_ITC_00317600	APL_MAS_ITC_00317638	F; 402; 403
PTX-2033		APL MAS ITC 00332768	APL MAS ITC 00332842	F; 402; 403
PTX-2034	(www.apple.com/watch/compare/)	MASA11397769	MASA11397780	402; 403
PTX-2035	Webpage: I bought a \$50 Apple Watch Ultra clone, and it blew me away (01-24-2023) (www.digitaltrends.com/mobile/apple-watch-ultra-clone-hands-on-blew-me-away/)	MASAD00031831	MASAD00031866	F; H; 402; 403
PTX-2036	Webpage: Patent   Masimo (www.masimo.com/company/masimo/patents/)			
PTX-2037	Webpage: Which Apple Watch is right for you?   Apple (www.apple.com/watch/compare/)	MASITC_00918335	MASITC_00918342	402; 403
PTX-2038	Webpage: Why Apple Watch - It's the ultimate device for a healthy life.   Apple (www.apple.com/apple-watch-series-7/why-apple-watch/)	MASITC_00976303	MASITC_00976323	402; 403
PTX-2039	File history for U.S. Patent No. 10,335,068			
PTX-2040	File history for U.S. Patent No. 10,448,871 (Al-Ali)			
PTX-2041	File history for U.S. Patent No. 11,234,602			
PTX-2042	U.S. Patent Application Publication No. 2016/0378069 (Rothkopf)			
PTX-2043	U.S. Patent Application Publication No. 2016/0378071			
PTX-2044	File history for U.S. Patent No. 11,234,602			
PTX-2045	U.S. Patent Application Publication No. 2016/0378071			

APPLE INC.  
#: 68012

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-2046	Defendants Masimo Corporation and Sound United, LLC's Responses and Objections to Apple's Interrogatory No. 1 (-1377) (01-11-2023)			F; H
PTX-2047	Defendants Masimo Corporation and Sound United, LLC's Responses and Objections to Apple's Second Set of Interrogatories (Nos. 2-4) (-1377) (03-17-2023)			F; H
PTX-2048	Defendants Masimo Corporation and Sound United, LLC's Responses to Apple Inc.'s First Set of Requests for Admission (Nos. 1-8) (-1378) (03-27-2023)			F; H
PTX-2049	Defendants Masimo Corporation and Sound United, LLC's Responses and Objections to Apple Inc.'s First Set of Interrogatories (Nos. 1-3) (-1378) (03-27-2023)			F; H
PTX-2050	Defendants Masimo Corporation and Sound United, LLC's First Supplemental Response to Apple's First Set of Interrogatories (No. 1) (-1377) (06-19-2023)			F; H
PTX-2051	Defendants Masimo Corporation and Sound United, LLC's First Supplemental Response to Apple Inc.'s First Set of Interrogatories (Nos. 1-2) (-1378) (06-19-2023)			F; H
PTX-2052	Defendants Masimo Corporation and Sound United, LLC's First Supplemental Response to Apple's Second Set of Interrogatories (Nos. 2-4) (-1377) (06-19-2023)			F; H
PTX-2053	Defendant Masimo Corporation's Responses and Objections to Apple Inc.'s Second Set of Interrogatories (Nos. 4-14) (-1378) (06-26-2023)			F; H
PTX-2054	Defendants Masimo Corporation and Sound United, LLC's First Amended Responses to Apple Inc.'s First Set of Requests for Admission (Nos. 1-4, 6) (-1378) (07-14-2023)			F; H
PTX-2055	Defendants Masimo Corporation and Sound United, LLC's Responses to Apple Inc.'s Second Set of Requests for Admission (Nos. 9-22) (07-14-2023)			F; H
PTX-2056	Defendant Masimo Corporation's First Supplemental Response to Apple Inc.'s Second Set of Interrogatories (No. 6) (-1378) (08-02-2023)			F; H
PTX-2057	Defendants Masimo Corporation and Sound United, LLC's Second Supplemental Response to Appel Inc.'s First Set of Interrogatories (No. 2) (-1378) (08-10-2023)			F; H
PTX-2058	Defendant Masimo Corporation's Second Supplemental Responses to Apple Inc.'s Second Set of Interrogatories (Nos. 11-12) (-1378) (08-19-2023)			F; H
PTX-2059	Defendants Masimo Corporation and Sound United, LLC, and Cercacor Laboratories' Responses and Objections to Apple Inc.'s Third Set of Interrogatories (Nos. 15-34) (08-21-2023)			F; H
PTX-2060	Defendants Masimo Corporation and Sound United, LLC, and Cercacor Laboratories' First Supplemental Responses and Objections to Apple Inc.'s Third Set of Interrogatories (No. 15) (08-30-2023)			F; H

APPLE INC.  
#: 68013

## FOURTH AMENDED TRIAL EXHIBIT LIST


PTX No.	Description	Beg Bates	End Bates	Objections
PTX-2061	Defendants Masimo Corporation and Sound United, LLC, and Cercacor Laboratories' Second Supplemental Responses and Objections to Apple Inc.'s Third Set of Interrogatories (No. 30) (09-08-2023)			F; H
PTX-2062	Defendant Masimo Corporation's Responses and Objections to Apple Inc.'s Fourth Set of Interrogatories (Nos. 35-43) (09-11-2023)			F; H
PTX-2063	Masimo Corporation, Sound United, LLC, and Cercacor Laboratories, Inc.'s Responses to Apple Inc.'s Third Set of Requests for Admission (Nos. 23-88) (09-18-2023)			F; H
PTX-2064	Masimo Corporation, Sound United, LLC, and Cercacor Laboratories' Responses and Objections to Apple Inc.'s Fifth Set of Interrogatories (No. 44) (09-18-2023)			F; H
PTX-2065	Masimo Corporation, Sound United, LLC, and Cercacor Laboratories, Inc.'s Responses to Apple Inc.'s Fourth Set of Requests for Admission (Nos. 89-114) (09-25-2023)			F; H
PTX-2066	Masimo Corporation, Sound United, LLC, and Cercacor Laboratories, Inc.'s Responses and Objections to Apple Inc.'s Sixth Set of Interrogatories (Nos. 45-46) (09-25-2023)			F; H
PTX-2067	Masimo Corporation, Sound United, LLC, and Cercacor Laboratories' Fourth Supplemental Responses and Objections to Apple Inc.'s Third Set of Interrogatories (Nos. 26-27) (09-26-2023)			F; H
PTX-2068	Masimo Corporation, Sound United, LLC, and Cercacor Laboratories' Second Supplemental Responses and Objections to Apple Inc.'s Third Set of Interrogatories (No. 15) (10-17-2023)			F; H
PTX-2069	Masimo and Cercacor's Supplemental Responses and Objections to Apple Inc.'s Interrogatories 36 and 37 (11-01-2023)			F; H
PTX-2070	Masimo Corporation, Sound United, LLC, and Cercacor Laboratories' Sixth Supplemental Responses and Objections to Apple Inc.'s Third Set of Interrogatories (No. 26) (11-07-2023)			F; H
PTX-2071	Masimo Corporation, Sound United, LLC, and Cercacor Laboratories' Seventh Supplemental Response to Apple Inc.'s Third Set of Interrogatories (No. 33) (11-08-2023)			F; H
PTX-2072	Masimo and Cercacor's Second Supplemental Responses and Objections to Apple Inc.'s Fourth Set of Interrogatories (No. 36) (11-09-2023)			F; H
PTX-2073	Defendant Masimo Corporation's Third Supplemental Response to Apple Inc.'s Second Set of Interrogatories (Nos. 11-12) (-1378) (11-09-2023)			F; H
PTX-2074	Masimo Corporation, Sound United, LLC, and Cercacor Laboratories' Supplemental Responses and Objections to Apple Inc.'s Interrogatory No. 34 (11-09-2023)			F; H

APPLE INC.  
# 68014  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-2075	Defendant Masimo Corporation's Supplemental Responses and Objections to Apple Inc.'s Second Set of Interrogatories (No. 4, 6-10) (-1378) (11-09-2023)			F; H
PTX-2076	Masimo v. Apple, PTAB Case No. IPR2023-00807, Decision Denying Institution of Inter Partes Review (11-21-2023)			
PTX-2077	Masimo v. Apple, PTAB Case No. IPR2024-00071, Decision Denying Inter Partes Review (04-25-2024)			
PTX-2078	Webpage: The Motley Fool   Masimo (MASI) Q2 2022 Earnings Call Transcript (08-10-2022) (www.fool.com/earnings/call-transcripts/2022/08/10/masimo-masi-q2-2022-earnings-call-transcript/)	APL_DEL00001217	APL_DEL00001247	402; 403
PTX-2079	Webpage: Youtube   September Event 2018 - Apple (09-13-2018) (www.youtube.com/watch?v=wFTmQ27S7OQ)	APL_DEL00001336	APL_DEL00001336	402; 403
PTX-2079.1	Still from: Webpage: Youtube   September Event 2018 - Apple (09-13-2018) (www.youtube.com/watch?v=wFTmQ27S7OQ) at 11 minutes, 28 seconds	APL_DEL00001336	APL_DEL00001336	402; 403
PTX-2079.2	Still from: Webpage: Youtube   September Event 2018 - Apple (09-13-2018) (www.youtube.com/watch?v=wFTmQ27S7OQ) at 12 minutes, 5 seconds	APL_DEL00001336	APL_DEL00001336	402; 403
PTX-2079.3	Still from: Webpage: Youtube   September Event 2018 - Apple (09-13-2018) (www.youtube.com/watch?v=wFTmQ27S7OQ) at 16 minutes, 23 seconds	APL_DEL00001336	APL_DEL00001336	402; 403
PTX-2079.4	Still from: Webpage: Youtube   September Event 2018 - Apple (09-13-2018) (www.youtube.com/watch?v=wFTmQ27S7OQ) at 20 minutes, 45 seconds	APL_DEL00001336	APL_DEL00001336	402; 403
PTX-2079.5	Still from: Webpage: Youtube   September Event 2018 - Apple (09-13-2018) (www.youtube.com/watch?v=wFTmQ27S7OQ) at 21 minutes, 19 seconds	APL_DEL00001336	APL_DEL00001336	402; 403
PTX-2079.6	Still from: Webpage: Youtube   September Event 2018 - Apple (09-13-2018) (www.youtube.com/watch?v=wFTmQ27S7OQ) at 22 minutes, 49 seconds	APL_DEL00001336	APL_DEL00001336	402; 403
PTX-2079.7	Still from: Webpage: Youtube   September Event 2018 - Apple (09-13-2018) (www.youtube.com/watch?v=wFTmQ27S7OQ) at 23 minutes, 1 second	APL_DEL00001336	APL_DEL00001336	402; 403
PTX-2080		PL_DEL00195393	APL_DEL00195427	
PTX-2081		PL_DEL00196190	APL_DEL00196291	
PTX-2082		PL_DEL01266442	APL_DEL01266443	402; 403
PTX-2083		APL_DEL03854223	APL_DEL03854231	
	Band (www.masimoconsumer.com)			



APPLE INC  
# 68015  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-2084	Webpage: D&AD   D&AD Awards 2019 Pencil Winner - Apple Watch Series 4 (www.dandad.org/awards/professional/2019/product-design/231063/apple-watch-series-4/)	APL_DELO4012203	APL_DELO4012204	F; H; 402; 403
PTX-2085	Webpage: Forbes   A Look Inside Shenzhen's High-Tech Empire (07-14-2016) (www.forbes.com/sites/wadeshepard/2016/07/14/a-look-inside-shenzhens-high-tech-empire/?sh=4b5cb1734f36)	APL_DELO4012783	APL_DELO4012796	F; H; 402; 403
PTX-2086	Webpage: Nasdaq   Apple Leads the Pack in Survey of Brands Consumers Love Most (10-07-2020) (www.nasdaq.com/articles/apple-leads-the-pack-in-survey-of-brands-customers-love-most-2020-10-07)	APL_DELO4012908	APL_DELO4012916	F; H; 402; 403
PTX-2087	Webpage: Samsung Newsroom   FDA-Cleared Electrocardiogram Monitor App is Available in the US Starting Today on Galaxy Watch3 and Galaxy Watch Active2 (09-24-2020) (news.samsung.com/global/fda-cleared-electrocardiogram-monitor-app-is-available-in-the-us-starting-today-on-galaxy-watch3-and-galaxy-watch-active2)	APL_DELO4013144	APL_DELO4013147	F; H; 402; 403
PTX-2088	Webpage: Apple   Healthcare - Apple Watch (www.apple.com/healthcare/apple-watch/)	APL_DELO4013219	APL_DELO4013227	402; 403
PTX-2089	Webpage: PCMag   Samsung Galaxy Watch Gets FDA Clearance to Monitor for Afib (05-09-2023) (www.pcmag.com/news/samsung-galaxy-watch-gets-fda-clearance-to-monitor-for-afib)	APL_DELO4013679	APL_DELO4013684	F; H; 402; 403
PTX-2090	Webpage: Retently   The Reasons Behind Apple's Customer Loyalty and High NPS (04-01-2022) (www.retently.com/blog/apple-nps/)	APL_DELO4013734	APL_DELO4013745	F; H; 402; 403
PTX-2091	Webpage: Amazon   Masimo W1 Advanced Fitness Tracker Smartwatch, Continuous Activity and Fitness Trackers - Heart Rate, Oxygen Level (SpO2), Step Count, Hydration Index, Sleep and More, Android/iOS Fitness Watch (www.amazon.com/Masimo-Advanced-Fitness-Activity-Trackers/dp/B0C5JY26W2)	APL_DELO4014432	APL_DELO4014440	
PTX-2092	Webpage: reddit   Red Dot Design Award: Apple Watch Series 4 (www.reddit.org/project/apple-watch-series-4-37071)	APL_DELO4014663	APL_DELO4014665	F; H; 402; 403
PTX-2093		APL MAS-03104758	APL-MAS 03104816	
PTX-2094		MASA03114316	MASA03114322	
PTX-2095		MASA10914881	MASA10914901	402; 403
PTX-2096		MASA11128304	MASA11128304	F
PTX-2097		MASAD00231003	MASAD00231134	
PTX-2098		MASAD00232145	MASAD00232175	
PTX-2099		MASAD00232194	MASAD00232211	

APPLE INC  
#: 68016

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-2100		MASAD00718002	MASAD00718002	
PTX-2101		MASAD00718003	MASAD00718069	
PTX-2102		MASAD02997395	MASAD02997395	F
PTX-2103		MASAD02997396	MASAD02997411	F
PTX-2104	(06-07-2022)			F; H
PTX-2105	Masimo v. Apple, ITC Case No. 337-TA-1276, Evidentiary Hearing, Volume III (06-08-2022)			F; H
PTX-2106	Masimo v. Apple, C.D. Cal. Case No. 8:20-cv-00048-JVS, Certified copy of Reporter's Transcript of Proceedings, Jury Trial, Day 2, Volume I (04-05-2023)			F; H
PTX-2107	Masimo v. Apple, C.D. Cal. Case No. 8:20-cv-00048-JVS, Certified copy of Reporter's Transcript of Proceedings, Jury Trial, Day 2, Volume II (04-05-2023)			F; H
PTX-2108	Masimo v. Apple, C.D. Cal. Case No. 8:20-cv-00048-JVS, Certified copy of Reporter's Transcript of Proceedings, Jury Trial, Day 3, Volume I (04-06-2023)			F; H
PTX-2109	Masimo v. Apple, C.D. Cal. Case No. 8:20-cv-00048-JVS, Certified copy of Reporter's Transcript of Proceedings, Jury Trial, Day 3, Volume II (04-06-2023)			F; H
PTX-2110	Masimo v. Apple, C.D. Cal. Case No. 8:20-cv-00048-JVS, Certified copy of Reporter's Transcript of Proceedings, Jury Trial, Day 4 (04-07-2023)			F; H
PTX-2111	Masimo v. Apple, C.D. Cal. Case No. 8:20-cv-00048-JVS, Certified copy of Reporter's Transcript of Proceedings, Jury Trial, Day 5 (04-10-2023)			F; H
PTX-2112	Masimo v. Apple, C.D. Cal. Case No. 8:20-cv-00048-JVS, Certified copy of Reporter's Transcript of Proceedings, Jury Trial, Day 6, Volume I (04-11-2023)			F; H
PTX-2113	Masimo v. Apple, C.D. Cal. Case No. 8:20-cv-00048-JVS, Certified copy of Reporter's Transcript of Proceedings, Jury Trial, Day 6, Volume II (04-11-2023)			F; H
PTX-2114	Masimo v. Apple, C.D. Cal. Case No. 8:20-cv-00048-JVS, Certified copy of Reporter's Transcript of Proceedings, Jury Trial, Day 7, Volume I (04-12-2023)			F; H
PTX-2115	Masimo v. Apple, C.D. Cal. Case No. 8:20-cv-00048-JVS, Certified copy of Reporter's Transcript of Proceedings, Jury Trial, Day 7, Volume II (04-12-2023)			F; H

APPLE INC.  
# 68017  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-2116	Masimo v. Apple, C.D. Cal. Case No. 8:20-cv-00048-JVS, Certified copy of Reporter's Transcript of Proceedings, Jury Trial, Day 8, Volume I (04-13-2023)			F; H
PTX-2117	Masimo v. Apple, C.D. Cal. Case No. 8:20-cv-00048-JVS, Certified copy of Reporter's Transcript of Proceedings, Jury Trial, Day 11, Volume II (04-19-2023)			F; H
PTX-2118	Masimo v. Apple, C.D. Cal. Case No. 8:20-cv-00048-JVS, Certified copy of Reporter's Transcript of Proceedings, Jury Trial, Day 12, Volume II (04-20-2023)			F; H
PTX-2119	Masimo v. Apple, C.D. Cal. Case No. 8:20-cv-00048-JVS, Certified copy of Reporter's Transcript of Proceedings, Jury Trial, Day 13 (04-25-2023)			F; H
PTX-2120	U.S. Patent No. D890,708 (Forrest)	APL-MAS 02068749	APL-MAS 02068763	402; 403
PTX-2121		APL_DEL00066518	APL_DEL00066546	402; 403
PTX-2122		MASAD04143282	MASAD04143283	
PTX-2123	Webpage: Masimo W1 Medical Smartwatch Specifications   Masimo (www.masimoconsumer.com)	MASAD01322796	MASAD01322796	
PTX-2124	Webpage: Masimo W1 Advanced Health Tracking Watch Specifications   Masimo (www.masimoconsumer.com)	MASAD03149220	MASAD03149220	
PTX-2125	Presentation: Masimo - 2022 Investor Day (12-13-2022)	APL-MAS 03104758	APL-MAS 03104816	
PTX-2126	A. Kharpal - Apple Watch Design: 'Damn Good' or 'Bulky'?, CNBC (09-11-2014)	APL_DEL00038387	APL_DEL00038389	F; H; 402; 403
PTX-2127	K. Kozuch - Apple Watch Series 8 Review, Tom's Guide (03-24-2023)	APL_DEL00038394	APL_DEL00038402	F; H; 402; 403
PTX-2128	B. Desarnauts - First Large Apple Watch Customer Satisfaction Study, Medium (07-19-2015)	APL_DEL00038431	APL_DEL00038442	F; H; 402; 403
PTX-2129	B. Clymer - In-Depth A Watch Guy's Thought On The Apple Watch After Seeing It In The Metal (Tons of Live Photos), Hodinkee (09-10-2014)	APL_DEL00038516	APL_DEL00038536	F; H; 402; 403
PTX-2130	C. Booth - The Apple Watch Design is Already a Classic - Will It Ever Change? (10-26-2020)	APL_DEL00038584	APL_DEL00038589	F; H; 402; 403
PTX-2131		APL_DEL01377090	APL_DEL01377126	402; 403
PTX-2132	Z. Hall - [Update: ECG App Released] Review: Apple Watch Series 4 - Beautiful Design, Invisible Features (12-07-2018)	APL_DEL04012924	APL_DEL04012942	F; H; 402; 403
PTX-2133	D. Phelan - Apple Watch Series 8 Review: A Spectacular, Everyday Smartwatch, Forbes (10-18-2022)	APL_DEL04012957	APL_DEL04012970	F; H; 402; 403
PTX-2134	J. Maring et al. - Apple Watch Series 8 Review: The Best Apple Watch Gets Better, Digital Trends (03-26-2023)	APL_DEL04012996	APL_DEL04013024	F; H; 402; 403
PTX-2135		MASA00384942	MASA00384943	F; 402; 403
PTX-2136		MASAD00006501	MASAD00006501	
PTX-2137		MASAD00006642	MASAD00006642	
PTX-2138		MASAD00006643	MASAD00006643	

APPLE INC  
# 68018  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-2139		MASAD00006703	MASAD00006703	
PTX-2140		MASAD00006770	MASAD00006770	
PTX-2141		MASAD00007356	MASAD00007356	
PTX-2142		MASAD00007430	MASAD00007430	
PTX-2143		MASAD00012163	MASAD00012163	
PTX-2144		MASAD00012305	MASAD00012305	
PTX-2145		MASAD00012346	MASAD00012346	
PTX-2146		MASAD00013455	MASAD00013455	
PTX-2147		MASAD00016598	MASAD000166629	
PTX-2148		MASITC 01077008	MASITC 01077008	ID
PTX-2149		MASITC 01082749	MASITC 01082749	
PTX-2150				UK; 402; 403
PTX-2151				UK; 402; 403
PTX-2152				UK; 402; 403
PTX-2153				UK; 402; 403
PTX-2154				UK; 402; 403
PTX-2155				UK; F; H; 402; 403
PTX-2156				UK; F; H; 402; 403
PTX-2157				UK; F; H; 402; 403
PTX-2158				UK; F; H; 402; 403
PTX-2159				UK; F; H; 402; 403
PTX-2160				UK; F; H; 402; 403
PTX-2161				UK; F; H; 402; 403
PTX-2162				UK; F; H; 402; 403
PTX-2163				UK; F; H; 402; 403
PTX-2164				UK; F; H; 402; 403
PTX-2165				UK; F; H; 402; 403
PTX-2166				UK; 402; 403
PTX-2167				UK; 402; 403
PTX-2168				UK; 402; 403

APPLE INC  
# 68019  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-2169				UK; 402; 403
PTX-2170				UK; 402; 403
PTX-2171				UK; 402; 403
PTX-2172				UK; 402; 403
PTX-2173				UK; 402; 403
PTX-2174				UK; 402; 403
PTX-2175	Physical: Apple Watch Series 5			
PTX-2176	Physical: Apple Watch Series 7			
PTX-2177	Physical: Apple Watch Series 8			
PTX-2178	Physical: Apple Watch Ultra			
PTX-2179	Physical: Apple Watch charger			
PTX-2180	Physical: Google Pixel Watch			UK; 402; 403
PTX-2181	Physical: Google Pixel Watch charger			UK; 402; 403
PTX-2182	Physical: Fitbit Versa 2 Watch			UK; 402; 403
PTX-2183	Physical: Fitbit Versa 2 Watch charger			UK; 402; 403
PTX-2184	Physical: Masimo Redesigned W1 Watch			
PTX-2185	Physical: Apple Watch First Generation with charger			
PTX-2186	Physical: Apple Watch Series 4 with charger			
PTX-2187	Physical: Apple Watch Series 0 produced by Apple			
PTX-2188	Physical: Apple Watch Series 0 produced by Apple			
PTX-2189	Physical: Withings ScanWatch			UK; 402; 403
PTX-2190	Physical: Apple Watch Series 9			
PTX-2191	Physical: Apple Watch Ultra 2			
PTX-2192		APL DEL00300780	APL DEL00300780	
PTX-2193	Photograph: Withings Scanwatch, front	APL DEL00300796	APL DEL00300796	402; 403
PTX-2194	Photograph: Withings Scanwatch, back	APL DEL00300798	APL DEL00300798	402; 403
PTX-2195	Photograph: Withings Scanwatch, back, and charger	APL DEL00300825	APL DEL00300825	402; 403
PTX-2196	Photograph: Withings Scanwatch, back, and charger, zoomed in	APL DEL00300826	APL DEL00300826	402; 403
PTX-2197		APL_DEL00300833	APL_DEL00300833	
PTX-2198		APL DEL00300868	APL DEL00300868	
PTX-2199		APL DEL00300875	APL DEL00300875	
PTX-2200		APL DEL00300876	APL DEL00300876	
PTX-2201		APL DEL00300887	APL DEL00300887	
PTX-2202		APL DEL00300889	APL DEL00300889	
PTX-2203		APL DEL00300903	APL DEL00300903	

APPLE INC  
# 68020  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-2204	Photograph: Fitbit Versa 2 watch, back, and charger	APL DEL00300925	APL DEL00300925	402; 403
PTX-2205	Photograph: Fitbit Versa 2 watch, back, and charger, zoomed in	APL DEL00300926	APL DEL00300926	402; 403
PTX-2206	Photograph: 11 Apple Watches	APL DEL00300940	APL DEL00300940	
PTX-2207				UK; 402; 403
PTX-2208				UK; 402; 403
PTX-2209				UK; 402; 403
PTX-2210				UK; 402; 403
PTX-2211				UK; 402; 403
PTX-2212				UK; 402; 403
PTX-2213				UK; 402; 403
PTX-2214				UK; 402; 403
PTX-2215				UK; 402; 403
PTX-2216				UK; 402; 403
PTX-2217				UK; 402; 403
PTX-2218				UK; 402; 403
PTX-2219				UK; 402; 403
PTX-2220				UK; 402; 403
PTX-2221				UK; 402; 403
PTX-2222				UK; 402; 403
PTX-2223				UK; 402; 403
PTX-2224				UK; 402; 403
PTX-2225				UK; 402; 403
PTX-2226				UK; 402; 403
PTX-2227				UK; 402; 403
PTX-2228				UK; 402; 403
PTX-2229				UK; 402; 403
PTX-2230				UK; 402; 403
PTX-2231				UK; 402; 403
PTX-2232				UK; 402; 403
PTX-2233				UK; 402; 403
PTX-2234				UK; 402; 403
PTX-2235				UK; 402; 403
PTX-2236				UK; 402; 403
PTX-2237				UK; 402; 403
PTX-2238				UK; 402; 403
PTX-2239				UK; 402; 403
PTX-2240				UK; 402; 403
PTX-2241				UK; 402; 403
PTX-2242				UK; 402; 403
PTX-2243				UK; 402; 403
PTX-2244				UK; 402; 403
PTX-2245				UK; 402; 403

APPLE INC.  
# 68021  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-2246				UK; 402; 403
PTX-2247				UK; 402; 403
PTX-2248				UK; 402; 403
PTX-2249				UK; 402; 403
PTX-2250				UK; 402; 403
PTX-2251				UK; 402; 403
PTX-2252				UK; 402; 403
PTX-2253				UK; 402; 403
PTX-2254				UK; 402; 403
PTX-2255				UK; 402; 403
PTX-2256				UK; 402; 403
PTX-2257				UK; 402; 403
PTX-2258				UK; 402; 403
PTX-2259				UK; 402; 403
PTX-2260				UK; 402; 403
PTX-2261				UK; 402; 403
PTX-2262				UK; 402; 403
PTX-2263				UK; 402; 403
PTX-2264				UK; 402; 403
PTX-2265				UK; 402; 403
PTX-2266				UK; 402; 403
PTX-2267				UK; 402; 403
PTX-2268				UK; 402; 403
PTX-2269				UK; 402; 403
PTX-2270				UK; 402; 403
PTX-2271				UK; 402; 403
PTX-2272				UK; 402; 403
PTX-2273				UK; 402; 403
PTX-2274				UK; 402; 403
PTX-2275				UK; 402; 403
PTX-2276				UK; 402; 403
PTX-2277				UK; 402; 403
PTX-2278				UK; 402; 403
PTX-2279				UK; 402; 403
PTX-2280				UK; 402; 403
PTX-2281				UK; 402; 403
PTX-2282				UK; 402; 403
PTX-2283				UK; 402; 403
PTX-2284				UK; 402; 403
PTX-2285				UK; 402; 403
PTX-2286				UK; 402; 403
PTX-2287				UK; 402; 403

APPLE INC

# 68022

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-2288				UK; 402; 403
PTX-2289				UK; 402; 403
PTX-2290				UK; 402; 403
PTX-2291				
PTX-2292				402; 403
PTX-2293				
PTX-2294				
PTX-2295				
PTX-2296				
PTX-2297				
PTX-2298				
PTX-2299				
PTX-2300	Physical: Fitbit Versa 2 watch and charger produced by Masimo bearing tag MASA_P_102 as shown in APL_DEL00300924 - APL_DEL00300927			402; 403
PTX-2301	Physical: Apple Watch produced by Masimo bearing tag MASA P 086			
PTX-2302	Physical: Apple Watch produced by Masimo bearing tag JTX-P-119 as shown in APL_DEL00300939			
PTX-2303	Physical: Apple Watch produced by Masimo bearing tag JTX-P-120 as shown in APL_DEL00300939			
PTX-2304	Physical: Apple Watch produced by Masimo bearing tag JTX-P-121 as shown in APL_DEL00300939			
PTX-2305	Physical: Apple Watch produced by Masimo bearing tag JTX-P-122 as shown in APL_DEL00300939			
PTX-2306	Physical: Apple Watch produced by Masimo bearing tag JTX-P-123 as shown in APL_DEL00300939			
PTX-2307	Physical: Apple Watch produced by Masimo bearing tag JTX-P-124 as shown in APL_DEL00300939			
PTX-2308	Physical: Apple Watch produced by Masimo bearing tag JTX-P-125 as shown in APL_DEL00300939			



APPLE INC.  
#: 68023

## FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-2309	Physical: Apple Watch produced by Masimo bearing tag JTX-P-126 as shown in APL DEL00300939			
PTX-2310	Physical: Apple Watch produced by Masimo bearing tag JTX-P-128 as shown in APL DEL00300939			
PTX-2311	Physical: Apple Watch produced by Masimo bearing tag JTX-P-129 as shown in APL DEL00300939			
PTX-2312	Physicals made available for inspection by Masimo as shown in photographs at APL DEL00204564-00205106			MD; UK
PTX-2313	Physicals made available for inspection by Masimo as shown in photographs at APL DEL00300780-00300940			MD; UK
PTX-2314				
PTX-2315				
PTX-2316				
PTX-2317				
PTX-2318				
PTX-2319				
PTX-2320				
PTX-2321				
PTX-2322				
PTX-2323	Physical: Withings Scanwatch produced by Masimo bearing tag CPX-0165 as shown in APL DEL00300915 - APL DEL00300917			402; 403
PTX-2324	Physical: Freedom produced by Masimo bearing tag MASA_P_100 as shown in APL DEL00300918 - APL DEL00300920			
PTX-2325	Physical: Fitbit Sense produced by Masimo bearing tag MASA_P_101 as shown in APL DEL00300921 - APL DEL003002923			402; 403
PTX-2326	Physical: Masimo W1 (Redesign) produced by Masimo bearing tag MASAD_P_050			
PTX-2327	Physical: Masimo W1 (Redesign) produced by Masimo bearing tag MASAD P 042			
PTX-2328	Webpage: SPS, 신개념 스마트폰 충전 기술 개발 - 전자신문 (www.etnews.com/201211220496)			F; H; 402; 403

APPLE INC.  
# 68024  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-2329	Physical: Asus Google Nexus 7 produced by Masimo bearing tag MASAD P 034 as shown in APL DEL04028540 - APL DEL04028546			
PTX-2330	Physical: Asus ZenWatch produced by Masimo bearing tag MASAD_P_025 as shown in APL_DEL04028458 - APL_DEL04028474			
PTX-2331	Physical: Contec CMS50K Wearable SpO2/ECG Monitor produced by Masimo bearing tag MASAD_P_038 as shown in APL_DEL04028547 - APL_DEL04028572 and APL_DEL04028268-APL_DEL04028284			
PTX-2332	Physical: Epson Pulsense PS-100 produced by Masimo bearing tag MASAD P 027 as shown in APL DEL04028488 - APL DEL04028501			
PTX-2333	Physical: Epson Pulsense PS-100 produced by Masimo bearing tag MASAD P 028 as shown in APL DEL04028502 - APL DEL04028523			
PTX-2334	Physical: Epson Pulsense PS-100 produced by Masimo bearing tag MASAD P 029 as shown in APL DEL04028524 - APL DEL04028539			
PTX-2335	Physical: Fossil Abacus AU4002 with packaging and charger produced by Masimo bearing tags MASAD_P_022A through MASAD_P_022C as shown in APL DEL04028408 - APL DEL04028427			
PTX-2336	Physical: Fossil Abacus AU4005 produced by Masimo bearing tag MASAD_P_053 as shown in APL_DEL04028657 - APL_DEL04028691			
PTX-2337	Physical: LG Watch Style produced by Masimo bearing tag MASAD_P_019-B as shown in APL DEL04028315 - APL DEL04028320			
PTX-2338	Physical: Masimo W1 watch sensor produced by Masimo bearing tag MASAD P 001 as shown in MASAD00109989 - MASAD00109991			
PTX-2339	Physical: Mio Fuse smartwatch with packaging produced by Masimo bearing tags MASAD_P_021-A through MASAD_P_021-B as shown in APL_DEL04028367 - APL_DEL04028407			
PTX-2340	Physical: Mio Shape smartwatch produced by Masimo bearing tag MASAD P 040 as shown in APL DEL04028573 - APL DEL04028595			
PTX-2341	Physical: Polar Pacer Heart Monitor with Chest Band, User's Guide and packaging produced by Masimo bearing tags MASAD_P_020-A through MASAD_P_20-C as shown in APL_DEL04028334 - APL_DEL04028366; MASAD04145202 - MASAD04145235			
PTX-2342	Physical: Polar Pacer Heart Rate Monitor produced by Masimo bearing tag MASAD P 041 as shown in APL DEL04028429 - APL DEL04028611			
PTX-2343	Physical: Qualcomm Toq smartwatch and charger produced by Masimo bearing tag MASAD_P_024 as shown in APL_DEL04028445 - APL_DEL04028457			
PTX-2344	Physical: Qualcomm Toq smartwatch and charger produced by Masimo bearing tag MASAD_P_052 as shown in APL_DEL04028612 - APL_DEL04028656			
PTX-2345	Physical: Samsung Galaxy S8 produced by Masimo bearing tag MASAD_P_023-B as shown by APL DEL04028431			

APPLE INC  
# 68025  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-2346	Opening Expert Report of Pedro P. Irazoqui, Ph.D. Concerning Masimo Corporation and Sound United, LLC's Infringement of U.S. Patent Nos. 10,076,257; 10,627,783; 10,942,491; 11,474,483; and 10,987,054 (11-22-2023), Appendix F			E; 402; 403
PTX-2347	Physical: Apple Watch Series 0 as shown in APL_DEL04028285-APL_DEL04028293			UK; ID
PTX-2348	Rebuttal Expert Report of Pedro P. Irazoqui, Ph.D. Concerning Validity of U.S. Patent Nos. 10,076,257; 10,627,783; 10,942,491; 11,474,483; and 10,987,054 (12-15-2023) and Appendices			E; 402; 403
PTX-2349		APL_DEL01352806	APL_DEL01352835	402; 403
PTX-2350	Photograph of W1 Teardown			F
PTX-2351	Photograph of W1 Teardown			F
PTX-2352	Photograph of W1 Teardown			F
PTX-2353	Photograph of W1 Teardown			F
PTX-2354	Photograph of W1 Teardown			F
PTX-2355	Photograph of W1 Teardown			F
PTX-2356	Photograph of W1 Teardown			F
PTX-2357	Photograph of W1 Teardown			F
PTX-2358	Photograph of W1 Teardown			F
PTX-2359	Photograph of W1 Teardown			F
PTX-2360	Photograph of W1 Teardown			F
PTX-2361	Photograph of W1 Teardown			F
PTX-2362	Photograph of W1 Teardown			F
PTX-2363	Photograph of W1 Teardown			F
PTX-2364	Photograph of W1 Teardown			F
PTX-2365	Photograph of W1 Teardown			F
PTX-2366	Photograph of W1 Teardown			F
PTX-2367	Photograph of W1 Teardown			F
PTX-2368	Photograph of W1 Teardown			F
PTX-2369	Photograph of W1 Teardown			F
PTX-2370	Photograph of W1 Teardown			F
PTX-2371	Photograph of W1 Teardown			F
PTX-2372	Photograph of W1 Teardown			F
PTX-2373	Photograph of W1 Teardown			F
PTX-2374	Photograph of W1 Teardown			F
PTX-2375	Photograph of W1 Teardown			F
PTX-2376	Photograph of W1 Teardown			F
PTX-2377	Photograph of W1 Teardown			F
PTX-2378	Photograph of W1 Teardown			F
PTX-2379	Photograph of W1 Teardown			F
PTX-2380	Photograph of W1 Teardown			F
PTX-2381	Photograph of W1 Teardown			F

APPLE INC  
# 68026  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-2382	Photograph of W1 Teardown			F
PTX-2383	Photograph of W1 Teardown			F
PTX-2384	Photograph of W1 Teardown			F
PTX-2385	Photograph of W1 Teardown			F
PTX-2386	Photograph of W1 Teardown			F
PTX-2387	Photograph of W1 Teardown			F
PTX-2388	Photograph of W1 After 24 Hours of Charging			F; 402; 403
PTX-2389	Photograph of Ambient Temperature Reading			F; 402; 403
PTX-2390	Photograph of Temperature Reading on Back of Apple Watch			F; 402; 403
PTX-2391	Photograph of Temperature Reading on Front of Apple Watch			F; 402; 403
PTX-2392	Photograph of W1 Charger			F; 402; 403
PTX-2393	Photograph of ECG Side Contact			F; 402; 403
PTX-2394	Photograph of W1 Heart Rate Measurement			F; 402; 403
PTX-2395	Photograph of W1 Vitals Screen			F; 402; 403
PTX-2396	Photograph of W1 at Start of ECG			F; 402; 403
PTX-2397	Photograph of W1 Time Display			F; 402; 403
PTX-2398	Photograph of W1 Vitals Screen			F; 402; 403
PTX-2399	Photograph of W1 Vitals Screen			F; 402; 403
PTX-2400	Photograph of W1 LEDs			F; 402; 403
PTX-2401	Photograph of W1 Temperature Reading on Back of Watch			F; 402; 403
PTX-2402	Photograph of W1 Temperature Reading on Front of Watch			F; 402; 403
PTX-2403	Photograph of W1 and Charger			F
PTX-2404		PL_DELO1544572	APL_DELO1544574	
PTX-2405		MASITC_01254118	MASITC_01254118	402; 403
PTX-2406				F; H
PTX-2407		MASITC_01206199	MASITC_01206199	402; 403
PTX-2408		MASITC_01207936	MASITC_01207938	402; 403; F; H
PTX-2409		MASITC_01201500	MASITC_01201500	402; 403; F; H
PTX-2410	CapEdge (02-24-2021) ( <a href="https://capedge.com/transcript/937556/2020Q4/MASI">https://capedge.com/transcript/937556/2020Q4/MASI</a> )			402; 403
PTX-2411	Webpage: Masimo Corporation (MASI) Q1 2021 Earnings Call Transcript, CapEdge (04-27-2021) ( <a href="https://capedge.com/transcript/937556/2021Q1/MASI">https://capedge.com/transcript/937556/2021Q1/MASI</a> )			402; 403

APPLE INC.  
# 68027  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-2412	Webpage: Masimo Corporation (MASI) Q2 2021 Earnings Call Transcript, CapEdge (07-28-2021) (https://capedge.com/transcript/937556/2021Q2/MASI)			402; 403
PTX-2413	Webpage: Masimo Corporation (MASI) Q3 2021 Earnings Call Transcript, CapEdge (10-21-2021) (https://capedge.com/transcript/937556/2021Q3/MASI)			402; 403
PTX-2414	Webpage: Masimo Corporation (MASI) Q1 2022 Earnings Call Transcript, CapEdge (05-03-2022) (https://capedge.com/transcript/937556/2022Q1/MASI)			402; 403
PTX-2415	Webpage: Masimo Corporation (MASI) Q3 2022 Earnings Call Transcript, CapEdge (11-09-2022) (https://capedge.com/transcript/937556/2022Q3/MASI)			402; 403
PTX-2416	Webpage: Masimo Corporation (MASI) Q4 2022 Earnings Call Transcript, CapEdge (02-28-2023) (https://capedge.com/transcript/937556/2022Q4/MASI)			402; 403
PTX-2417	Webpage: Masimo Corporation (MASI) Q2 2023 Earnings Call Transcript, CapEdge (08-08-2023) (https://capedge.com/transcript/937556/2023Q2/MASI)			402; 403
PTX-2418	Webpage: Masimo Corporation (MASI) Q3 2023 Earnings Call Transcript, CapEdge (11-23-2023) (https://capedge.com/transcript/937556/2023Q3/MASI)			402; 403
PTX-2419	CN Patent No. 205041396 (Hu)	MASAD00251218	MASAD00251232	
PTX-2420	Photograph of Nymi Band	APL DEL04028252	APL DEL04028252	F
PTX-2421	Photograph of Nymi Band	APL DEL04028253	APL DEL04028253	F
PTX-2422	Photograph of Nymi Band	APL DEL04028254	APL DEL04028254	F
PTX-2423	Photograph of Nymi Band	APL DEL04028255	APL DEL04028255	F
PTX-2424	Photograph of Nymi Band	APL DEL04028256	APL DEL04028256	F
PTX-2425	Photograph of Nymi Band	APL DEL04028257	APL DEL04028257	F
PTX-2426	Photograph of Nymi Band	APL DEL04028258	APL DEL04028258	F
PTX-2427	Photograph of Nymi Band	APL DEL04028259	APL DEL04028259	F
PTX-2428	Photograph of Nymi Band	APL DEL04028260	APL DEL04028260	F
PTX-2429	Photograph of Nymi Band	APL DEL04028261	APL DEL04028261	F
PTX-2430	Photograph of Nymi Band	APL DEL04028262	APL DEL04028262	F
PTX-2431	Photograph of Nymi Band	APL DEL04028263	APL DEL04028263	F
PTX-2432	Photograph of Nymi Band	APL DEL04028264	APL DEL04028264	F
PTX-2433	Photograph of Nymi Band	APL DEL04028265	APL DEL04028265	F
PTX-2434	Photograph of Nymi Band	APL DEL04028266	APL DEL04028266	F
PTX-2435	Photograph of Nymi Band	APL DEL04028267	APL DEL04028267	F
PTX-2436	Photograph of testing of Oranger Watch	APL DEL04028268	APL DEL04028268	F
PTX-2437	Photograph of testing of Oranger Watch	APL DEL04028269	APL DEL04028269	F
PTX-2438	Photograph of testing of Oranger Watch	APL DEL04028270	APL DEL04028270	F
PTX-2439	Photograph of testing of Oranger Watch	APL DEL04028271	APL DEL04028271	F

APPLE INC  
# 68028  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-2440	Photograph of testing of Oranger Watch	APL DEL04028272	APL DEL04028272	F
PTX-2441	Photograph of testing of Oranger Watch	APL DEL04028273	APL DEL04028273	F
PTX-2442	Photograph of testing of Oranger Watch	APL DEL04028274	APL DEL04028274	F
PTX-2443	Photograph of testing of Oranger Watch	APL DEL04028275	APL DEL04028275	F
PTX-2444	Photograph of testing of Oranger Watch	APL DEL04028276	APL DEL04028276	F
PTX-2445	Photograph of testing of Oranger Watch	APL DEL04028277	APL DEL04028277	F
PTX-2446	Photograph of Oranger Watch and Epson Pulsense	APL DEL04028278	APL DEL04028278	F
PTX-2447	Photograph of Oranger Watch and Epson Pulsense	APL DEL04028279	APL DEL04028279	F
PTX-2448	Photograph of Oranger Watch and Epson Pulsense	APL DEL04028280	APL DEL04028280	F
PTX-2449	Photograph of testing of Oranger Watch	APL DEL04028281	APL DEL04028281	F
PTX-2450	Photograph of testing of Oranger Watch	APL DEL04028282	APL DEL04028282	F
PTX-2451	Photograph of testing of Oranger Watch	APL DEL04028283	APL DEL04028283	F
PTX-2452	Photograph of testing of Oranger Watch	APL DEL04028284	APL DEL04028284	F
PTX-2453	Photograph of Apple Watch Series 0	APL DEL04028285	APL DEL04028285	402; 403; F
PTX-2454	Photograph of Apple Watch Series 0	APL DEL04028286	APL DEL04028286	402; 403; F
PTX-2455	Photograph of Apple Watch Series 0	APL DEL04028287	APL DEL04028287	402; 403; F
PTX-2456	Photograph of Apple Watch Series 0	APL DEL04028288	APL DEL04028288	402; 403; F
PTX-2457	Photograph of Apple Watch Series 0	APL DEL04028289	APL DEL04028289	402; 403; F
PTX-2458	Photograph of Apple Watch Series 0	APL DEL04028290	APL DEL04028290	402; 403; F
PTX-2459	Photograph of Apple Watch Series 0	APL DEL04028291	APL DEL04028291	402; 403; F
PTX-2460	Photograph of Apple Watch Series 0	APL DEL04028292	APL DEL04028292	402; 403; F
PTX-2461	Photograph of Apple Watch Series 0	APL DEL04028293	APL DEL04028293	402; 403; F
PTX-2462	Photograph of Masimo W1			402; 403; F; UK
PTX-2463	Photograph of Masimo W1			402; 403; F; UK
PTX-2464	Photograph of Masimo W1			402; 403; F; UK
PTX-2465	Photograph of Masimo W1			402; 403; F; UK
PTX-2466	Photograph of Masimo W1			402; 403; F; UK
PTX-2467	Photograph of Masimo W1			402; 403; F; UK
PTX-2468	Photograph of Masimo W1			402; 403; F; UK
PTX-2469	Photograph of Masimo W1			402; 403; F; UK
PTX-2470	Photograph of Masimo W1			402; 403; F; UK
PTX-2471	Photograph of Masimo W1			402; 403; F; UK
PTX-2472	Photograph of Masimo W1			402; 403; F; UK
PTX-2473	Photograph of Masimo W1			402; 403; F; UK
PTX-2474	Photograph of Masimo W1			402; 403; F; UK
PTX-2475	Photograph of Masimo W1			402; 403; F; UK
PTX-2476	Photograph of Masimo W1			402; 403; F; UK
PTX-2477	Photograph of Masimo W1			402; 403; F; UK
PTX-2478	Photograph of Masimo W1			402; 403; F; UK
PTX-2479	Photograph of Masimo W1			402; 403; F; UK
PTX-2480	Photograph of Masimo W1			402; 403; F; UK
PTX-2481	Photograph of Masimo W1			402; 403; F; UK

APPLE INC  
# 68029  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-2482	Photograph of Masimo W1			402; 403; F; UK
PTX-2483	Photograph of Masimo W1			402; 403; F; UK
PTX-2484	Photograph of Masimo W1			402; 403; F; UK
PTX-2485	Photograph of Masimo W1			402; 403; F; UK
PTX-2486	Photograph of Masimo W1			402; 403; F; UK
PTX-2487	Photograph of Masimo W1			402; 403; F; UK
PTX-2488	Photograph of Masimo W1			402; 403; F; UK
PTX-2489	Photograph of Masimo W1			402; 403; F; UK
PTX-2490	Photograph of Masimo W1			402; 403; F; UK
PTX-2491	Photograph of Masimo W1			402; 403; F; UK
PTX-2492	Photograph of Masimo W1			402; 403; F; UK
PTX-2493	Photograph of Masimo W1			402; 403; F; UK
PTX-2494	Photograph of Masimo W1			402; 403; F; UK
PTX-2495	Photograph of Masimo W1			402; 403; F; UK
PTX-2496	Photograph of Masimo W1			402; 403; F; UK
PTX-2497	Photograph of Masimo W1			402; 403; F; UK
PTX-2498	Photograph of Masimo W1			402; 403; F; UK
PTX-2499	Photograph of Masimo W1			402; 403; F; UK
PTX-2500	Photograph of Masimo W1			402; 403; F; UK
PTX-2501	Photograph of Masimo W1			402; 403; F; UK
PTX-2502	Photograph of Masimo W1			402; 403; F; UK
PTX-2503	Photograph of Masimo W1			402; 403; F; UK
PTX-2504	Photograph of Masimo W1			402; 403; F; UK
PTX-2505	Photograph of Masimo W1			402; 403; F; UK
PTX-2506	Photograph of Masimo W1			402; 403; F; UK
PTX-2507	Photograph of Masimo W1			402; 403; F; UK
PTX-2508	Photograph of Masimo W1			402; 403; F; UK
PTX-2509	Photograph of Masimo W1			402; 403; F; UK
PTX-2510	Photograph of Masimo W1			402; 403; F; UK
PTX-2511	Photograph of Masimo W1			402; 403; F; UK
PTX-2512	Photograph of Masimo W1			402; 403; F; UK
PTX-2513	Photograph of Masimo W1			402; 403; F; UK
PTX-2514	Photograph of Masimo W1			402; 403; F; UK
PTX-2515	Photograph of Masimo W1			402; 403; F; UK
PTX-2516	Photograph of Masimo W1			402; 403; F; UK
PTX-2517	Photograph of Masimo W1			402; 403; F; UK
PTX-2518	Photograph of Masimo W1			402; 403; F; UK
PTX-2519	Photograph of Masimo W1			402; 403; F; UK
PTX-2520	Photograph of Masimo W1			402; 403; F; UK
PTX-2521	Photograph of Masimo W1			402; 403; F; UK
PTX-2522	Photograph of Masimo W1			402; 403; F; UK
PTX-2523	Photograph of Masimo W1			402; 403; F; UK

APPLE INC  
# 68030  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-2524	Photograph of Masimo W1			402; 403; F; UK
PTX-2525	Photograph of Masimo W1			402; 403; F; UK
PTX-2526	Photograph of Masimo W1			402; 403; F; UK
PTX-2527	Photograph of Masimo W1			402; 403; F; UK
PTX-2528	Photograph of Masimo W1			402; 403; F; UK
PTX-2529	Photograph of Masimo W1			402; 403; F; UK
PTX-2530	Photograph of Masimo W1			402; 403; F; UK
PTX-2531	Photograph of Masimo W1			402; 403; F; UK
PTX-2532	Photograph of Masimo W1			402; 403; F; UK
PTX-2533	Photograph of Masimo W1			402; 403; F; UK
PTX-2534	Photograph of Masimo W1			402; 403; F; UK
PTX-2535	Photograph of Masimo W1			402; 403; F; UK
PTX-2536	Photograph of Masimo W1			402; 403; F; UK
PTX-2537	Photograph of Masimo W1			402; 403; F; UK
PTX-2538	Photograph of Masimo W1			402; 403; F; UK
PTX-2539	Photograph of Masimo W1			402; 403; F; UK
PTX-2540	Photograph of Masimo W1			402; 403; F; UK
PTX-2541	Photograph of Masimo W1			402; 403; F; UK
PTX-2542	Photograph of Masimo W1			402; 403; F; UK
PTX-2543	Photograph of Masimo W1			402; 403; F; UK
PTX-2544	Photograph of Masimo W1			402; 403; F; UK
PTX-2545	Photograph of Masimo W1			402; 403; F; UK
PTX-2546	Photograph of Masimo W1			402; 403; F; UK
PTX-2547	Photograph of Masimo W1			402; 403; F; UK
PTX-2548	Photograph of Masimo W1			402; 403; F; UK
PTX-2549	Photograph of Masimo W1			402; 403; F; UK
PTX-2550	Photograph of Masimo W1			402; 403; F; UK
PTX-2551	Photograph of Masimo W1			402; 403; F; UK
PTX-2552	Photograph of Masimo W1			402; 403; F; UK
PTX-2553	Photograph of Masimo W1			402; 403; F; UK
PTX-2554	Photograph of Masimo W1			402; 403; F; UK
PTX-2555	Photograph of Masimo W1			402; 403; F; UK
PTX-2556	Photograph of Masimo W1			402; 403; F; UK
PTX-2557	Photograph of Masimo W1			402; 403; F; UK
PTX-2558	Photograph of Masimo W1			402; 403; F; UK
PTX-2559	Photographs of Masimo Freedom	APL DEL00905048	APL DEL00905056	402; 403; F; UK
PTX-2560	Reply Expert Report of Alan L. Oslan On Invalidity Of U.S. Patent NO. 10,076,257 And U.S. Patent NO. 10,987,054 (01-03-2024), Exhibit 2			E; 402; 403
PTX-2561	Reply Expert Report of Alan L. Oslan On Invalidity Of U.S. Patent NO. 10,076,257 And U.S. Patent NO. 10,987,054 (01-03-2024), Exhibit 3			E; 402; 403
PTX-2562	Reply Expert Report of Alan L. Oslan On Invalidity Of U.S. Patent NO. 10,076,257 And U.S. Patent NO. 10,987,054 (01-03-2024), Exhibit 4			E; 402; 403



APPLE INC.  
# 68031  
FOURTH AMENDED TRIAL EXHIBIT LIST

PTX No.	Description	Beg Bates	End Bates	Objections
PTX-2563	Reply Expert Report of Alan L. Oslan On Invalidity Of U.S. Patent NO. 10,076,257 And U.S. Patent NO. 10,987,054 (01-03-2024), Exhibit 5			E; 402; 403
PTX-2564	Reply Expert Report of Alan L. Oslan On Invalidity Of U.S. Patent NO. 10,076,257 And U.S. Patent NO. 10,987,054 (01-03-2024), Exhibit 6			E; 402; 403
PTX-2565	Reply Expert Report of Alan L. Oslan On Invalidity Of U.S. Patent NO. 10,076,257 And U.S. Patent NO. 10,987,054 (01-03-2024), Exhibit 7			E; 402; 403
PTX-2566	Reply Expert Report of Alan L. Oslan On Invalidity Of U.S. Patent NO. 10,076,257 And U.S. Patent NO. 10,987,054 (01-03-2024), Exhibit 8			E; 402; 403
PTX-2567	Reply Expert Report of Alan L. Oslan On Invalidity Of U.S. Patent NO. 10,076,257 And U.S. Patent NO. 10,987,054 (01-03-2024), Exhibit 9			E; 402; 403
PTX-2568	Reply Expert Report of Alan L. Oslan On Invalidity Of U.S. Patent NO. 10,076,257 And U.S. Patent NO. 10,987,054 (01-03-2024), Exhibit 10			E; 402; 403
PTX-2569	Reply Expert Report of Alan L. Oslan On Invalidity Of U.S. Patent NO. 10,076,257 And U.S. Patent NO. 10,987,054 (01-03-2024), Exhibit 11			E; 402; 403
PTX-2570	Reply Expert Report of Alan L. Oslan On Invalidity Of U.S. Patent NO. 10,076,257 And U.S. Patent NO. 10,987,054 (01-03-2024), Exhibit 12			E; 402; 403
PTX-2571	Reply Expert Report of Alan L. Oslan On Invalidity Of U.S. Patent NO. 10,076,257 And U.S. Patent NO. 10,987,054 (01-03-2024), Exhibit 13			E; 402; 403
PTX-2572	Reply Expert Report of Alan L. Oslan On Invalidity Of U.S. Patent NO. 10,076,257 And U.S. Patent NO. 10,987,054 (01-03-2024), Exhibit 14			E; 402; 403
PTX-2573	Reply Expert Report of Alan L. Oslan On Invalidity Of U.S. Patent NO. 10,076,257 And U.S. Patent NO. 10,987,054 (01-03-2024), Exhibit 15			E; 402; 403
PTX-2574	Reply Expert Report of Alan L. Oslan On Invalidity Of U.S. Patent NO. 10,076,257 And U.S. Patent NO. 10,987,054 (01-03-2024), Exhibit 16			E; 402; 403
PTX-2575	Reply Expert Report of Alan L. Oslan On Invalidity Of U.S. Patent NO. 10,076,257 And U.S. Patent NO. 10,987,054 (01-03-2024), Exhibit 17			E; 402; 403
PTX-2576	Reply Expert Report of Alan L. Oslan On Invalidity Of U.S. Patent NO. 10,076,257 And U.S. Patent NO. 10,987,054 (01-03-2024), Exhibit 18			E; 402; 403
PTX-2577	Opening Expert Report of Pedro P. Irazoqui, Ph.D. Concerning Masimo Corporation and Sound United, LLC's Infringement of U.S. Patent Nos. 10,076,257; 10,627,783; 10,942,491; 11,474,483; and 10,987,054 (11-22-2023), Exhibit 1			E; 402; 403


# **EXHIBIT 7**

**FILED UNDER SEAL**

## Masimo's Trial Exhibit 68030 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
1			LinkedIn Profile of Adam Clavelle	403; NREL; LFND; HRS; ATH
2				403; NREL; LFND
3	APL_DEL00087032	APL_DEL00087046		403; NREL; LFND; ILLEG; HRS
4	APL_DEL00085201	APL_DEL00085220		403; NREL; LFND; HRS
5	APL_DEL00085654	APL_DEL00085683		403; NREL; LFND; HRS
6	APL_MAS_ITC_00520849	APL_MAS_ITC_00520851		403; NREL; LFND; HRS
7	APL_MAS_ITC_00764929	APL_MAS_ITC_00764929		403; NREL; LFND; HRS
8	APL_MAS_ITC_00401730	APL_MAS_ITC_00401733		403; NREL; LFND; HRS
9	APL_MAS_ITC_00565294	APL_MAS_ITC_00565301		403; NREL; LFND; HRS
10	APL_MAS_ITC_00565213	APL_MAS_ITC_00565216		403; NREL; LFND; HRS
11	APL_MAS_ITC_00584708	APL_MAS_ITC_00584712		403; NREL; LFND; HRS
12	APL-MAS_00415341	APL-MAS_00415342		403; NREL; LFND; MIL; HRS
13			Printout of Amazon product page - Apple Watch Series 5 (GPS + Cellular, 44 MM) - Space Gray Aluminum Case with Black Sport Band (Renewed)	403; NREL; LFND; HRS; ATH
14	APL-MAS_01890890	APL-MAS_01890891		403; NREL; LFND; MIL; HRS
15	APL_DEL01479812	APL_DEL01479813		403; NREL; LFND; HRS
16			Printout of Amazon product page - Apple Watch Series 8 (enlarged thumbnail images)	403; NREL; LFND; HRS
17	APL_DEL00125922	APL_DEL00126458		403; NREL; LFND; DUP; HRS
18			Printout of Amazon product page - Masimo W1® (enlarged thumbnail images)	403; NREL; LFND; ATH; HRS
19			Printout of Best Buy webpage - Search results for Apple Watch Series 5	403; NREL; LFND; ATH; HRS
20			Printout of Best Buy product page - Geek Squad Certified Refurbished Apple Watch Series 5 Space Gray	403; NREL; LFND; ATH; HRS
21			Printout of Best Buy product page - Geek Squad Certified Refurbished Apple Watch Series 5 Pink	403; NREL; LFND; ATH; HRS
22			Printout of Best Buy product page - Geek Squad Certified	403; NREL; LFND; ATH; HRS
23	APL-MAS_00067169	APL-MAS_00067172		03; NREL; LFND; MIL; HRS


## Masimo's Trial Exhibit 68034 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
24			Printout of Best Buy product page - Apple Watch Series 8 Midnight	403; NREL; LFND; ATH; HRS
25			U.S. Patent No. 9,632,537 B2 (Memering et al.)	403; NREL; LFND
26			Printout of Best Buy product page - Apple Watch Series 8 Starlight	403; NREL; LFND; ATH; HRS
27			Printout of Best Buy product page - Product and Customer Images of Apple Watch Series 8 Starlight	403; NREL; LFND; ATH; HRS
28			Printout of Best Buy product page - Fitbit Sense 2	403; NREL; LFND; ATH; HRS
29			Printout of Best Buy product page - Product and Customer Images of Fitbit Sense 2	403; NREL; LFND; ATH; HRS
30			Printout of Best Buy webpage - Search results for Amazfit	403; NREL; LFND; ATH; HRS
31	APL-MAS_00433571	APL-MAS_00433577		403; NREL; LFND
32				403; NREL; LFND; ATH; HRS
33	APL_DEL00125922	APL_DEL00126458		DUP; 403; NREL; LFND; HRS
34				403; NREL; LFND; ATH; HRS
35	APL-MAS_00069683	APL-MAS_00069825		403; NREL; LFND; HRS
36				403; NREL; LFND; ATH; HRS
37				403; NREL; LFND; NE
38	APL-MAS_00196613	APL-MAS_00196642		403; NREL; LFND; HRS
39	APL-MAS_00819220	APL-MAS_00819222		403; NREL; LFND; MIL; HRS
40	APL-MAS_02995056	APL-MAS_02995058		403; NREL; LFND; HRS
41	APL_DEL01249088	APL_DEL01249110		403; NREL; LFND; HRS
42				403; NREL; LFND; MIL; MIS
43	APL_DEL01409991	APL_DEL010409992		403; NREL; LFND; MIL; HRS
45	APL-MAS_00197001	APL-MAS_00197003		403; NREL; LFND; HRS
46	APL-MAS_00197004	APL-MAS_00197018		403; NREL; LFND; HRS
47	APL-MAS_00188998	APL-MAS_00188998		403; NREL; LFND; HRS
48	APL-MAS_00163706	APL-MAS_00163709		403; NREL; LFND
49	APL-MAS_00095312	APL-MAS_00095394		403; NREL; LFND; HRS


## Masimo's Trial Exhibit 68035 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
58	APL-MAS_00399124	APL-MAS_00399125		03; NREL; LFND; MIL; HRS
59	APL-MAS_02506931	APL-MAS_02506933		03; NREL; LFND; MIL; HRS
62	APL_DEL00899321	APL_DEL00899355		03; NREL; LFND; HRS
63	APL_MAS_ITC_00310919	APL_MAS_ITC_00310952		03; NREL; LFND; HRS
64	APL-MAS_01972650	APL-MAS_01972658		03; NREL; LFND; HRS
65	APL_MAS_ITC_01470838	APL_MAS_ITC_01470871		03; NREL; LFND; DUP; HRS
66	APL_DEL01345372	APL_DEL01345396		03; NREL; LFND; HRS
67	APL_DEL01345036	APL_DEL01345091		03; NREL; LFND; HRS
68			U.S. Patent No. 10,076,257 B2 (Lin et al.)	403; NREL; LFND
69	APL_DEL00005158	APL_DEL00005221	U.S. Patent No. 10,627,783 ('783 patent)	403; NREL; LFND; DUP
70	APL_DEL00006854	APL_DEL00006917	U.S. Patent No. 10,942,491 ('491 patent)	403; NREL; LFND; DUP
71			U.S. Patent No. 11,106,352 B2 (Tyler)	403; NREL; LFND
72	APL_DEL00010259	APL_DEL00010324	U.S. Patent No. 11,474,483 ('483 patent)	403; NREL; LFND; DUP
73	APL_DEL00229706	APL_DEL00229784		403; NREL; LFND; HRS
81	APL_DEL03152523	APL_DEL03152633		403; NREL; LFND; HRS
82	APL_DEL03152370	APL_DEL03152461		403; NREL; LFND; HRS
83	APL_DEL01918691	APL_DEL01918783		403; NREL; LFND; HRS
84	APL_DEL03152183	APL_DEL03152369		403; NREL; LFND; HRS
85	APL_MAS_ITC_00562437	APL_MAS_ITC_00562530		403; NREL; LFND; HRS
86	APL_MAS_ITC_00306447	APL_MAS_ITC_00306617		403; NREL; LFND; HRS
87	APL_MAS_ITC_00657130	APL_MAS_ITC_00657199		403; NREL; LFND; HRS
88	APL_MAS_ITC_00306773	APL_MAS_ITC_00306828		403; NREL; LFND; HRS
89	APL-MAS_00095716	APL-MAS_00095741		403; NREL; LFND; HRS
90	APL_MAS_ITC_00331988	APL_MAS_ITC_00332044		403; NREL; LFND; HRS
91	APL_MAS_ITC_00313305	APL_MAS_ITC_00313346		403; NREL; LFND
92	APL_MAS_ITC_01187128	APL_MAS_ITC_01187204		403; NREL; LFND
96				403; NREL; LFND; HRS; ATH
97	APL_DEL00194268	APL_DEL00194306		403; NREL; LFND
98				403; NREL; LFND; NE
99	APL_DEL00197448	APL_DEL00197732		403; NREL; LFND
100				403; NREL; LFND; NE

## Masimo's Trial Exhibit 68036 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
101	APL_DEL00193833	APL_DEL00193847		403; NREL; LFND
102				403; NREL; LFND; NE
103	APL_DEL00194740	APL_DEL00194772		403; NREL; LFND
104				403; NREL; LFND; NE
105	APL_DEL00196397	APL_DEL00196522		403; NREL; LFND
106				403; NREL; LFND; NE
107	APL_DEL00196708	APL_DEL00196750		403; NREL; LFND
108				403; NREL; LFND; NE
109	APL_DEL00193781	APL_DEL00193796		403; NREL; LFND
110				403; NREL; LFND; NE
111	APL_DEL02740323	APL_DEL02740336		403; NREL; LFND
112				403; NREL; LFND; NE
113	APL_DEL00193699	APL_DEL00193702		403; NREL; LFND
114				403; NREL; LFND; NE
115	APL_DEL02739894	APL_DEL02739898		403; NREL; LFND; HRS
116	APL_DEL01376573	APL_DEL01376574		403; NREL; LFND; HRS
117	APL-MAS_01138975	APL-MAS_01139001		403; NREL; LFND; MD; CMP; HRS
118	APL_DEL01728569	APL_DEL01728581		403; NREL; LFND
119	APL-MAS_01728873	APL-MAS_01728895		403; NREL; LFND
120	MASAD00722003	MASAD00722015		403; NREL; LFND; HRS
121	MASAD00236924	MASAD00236937		403; NREL; LFND; HRS
122	MASAD00236947	MASAD00236959		403; NREL; LFND; HRS
123	MASAD00236938	MASAD00236946		403; NREL; LFND; HRS
124	MASAD00721554	MASAD00721570		403; NREL; LFND
125	MASAD00236899	MASAD00236923		403; NREL; LFND
126	MASAD00236885	MASAD00236898		403; NREL; LFND
127	MASAD00236854	MASAD00236858		403; NREL; LFND
128	MASAD00236859	MASAD00236863		403; NREL; LFND
129	MASAD00236849	MASAD00236853		403; NREL; LFND
130	APL_DEL01249078	APL_DEL01249087		403; NREL; LFND
131	APL-MAS_00288462	APL-MAS_00288496		403; NREL; LFND; HRS
135				403; NREL; LFND
136			U.S. Design Patent D883,279 S (Akana et al.)	403; NREL; LFND; DUP
137			U.S. Design Patent D947,842 S (Akana et al.)	403; NREL; LFND; DUP

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
138			U.S. Design Patent D962 936 S (Akana et al.)	403; NREL; LFND; DUP
139	APL-DEL01466431	APL-DEL01466433		403; NREL; LFND; HRS
140	APL-DEL01470432	APL-DEL01470441		403; NREL; LFND; HRS
141	APL-MAS_00976389	APL-MAS_00976397		403; NREL; LFND; DUP; HRS
142	APL-MAS_00671609	APL-MAS_00671611		403; NREL; LFND; HRS
143	APL-MAS_00230888	APL-MAS_00230910		403; NREL; LFND; DUP; HRS
144	APL-MAS_00273328	APL-MAS_00273345		403; NREL; LFND; HRS
145	APL_DEL01468322	APL_DEL01468326		403; NREL; LFND; HRS
146	APL_MAS_ITC_01191634	APL_MAS_ITC_01191636		403; NREL; LFND; HRS
147	APL_DEL01470664	APL_DEL01470670		403; NREL; LFND; HRS
149				403; NREL; LFND; NE
150				403; NREL; LFND; NE
153	APL-MAS_00239842	APL-MAS_00239845		403; NREL; LFND; MIL; HRS
154	APL-MAS_00240663	APL-MAS_00240674		403; NREL; LFND; MIL; HRS
155	APL-MAS_00404966	APL-MAS_00404967		403; NREL; LFND; HRS
156	MASA00104967	MASA00104970		403; NREL; LFND; HRS
157	MASA03352645	MASA03352702		403; NREL; LFND; HRS
158				403; NREL; LFND; NE
159	MASA00203148	MASA00203149		403; NREL; LFND; MIL; HRS
160	APL-MAS_01891934	APL-MAS_01891935		403; NREL; LFND; MIL; HRS

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
161	APL-MAS_00676290	APL-MAS_00676290		03; NREL; LFND; HRS; MIL
162	APL-MAS_00676497	APL-MAS_00676498		03; NREL; LFND; MIL; HRS
163	APL-MAS_00674742	APL-MAS_00674745		03; NREL; LFND; IDSCR; HRS
164	APL-MAS_00517664	APL-MAS_00517666		03; NREL; LFND; HRS
165	APL-MAS_01368506	APL-MAS_01368527		03; NREL; LFND; DUP; HRS
166	APL_DEL01569131	APL_DEL01569135		03; NREL; LFND; HRS; MIL
167				03; NREL; LFND; NE
168	APL-MAS_02557093	APL-MAS_02557119		03; NREL; LFND
169				03; NREL; LFND; NE
170	CONTEC00004	CONTEC00004		03; NREL; LFND; ATH; HRS
171	CONTEC00005	CONTEC00005		03; NREL; LFND; ATH; HRS
172	CONTEC00006	CONTEC00043		03; NREL; LFND; ATH; HRS
173	CONTEC00001	CONTEC00003		03; NREL; LFND; ATH; HRS
174				03; NREL; LFND; HRS; ATH
175	APL_DEL00025983	APL_DEL00026073		03; NREL; LFND; DUP; HRS
176	APL_DEL03826657	APL_DEL03826715		03; NREL; LFND; HRS
177	APL_DEL02660787	APL_DEL02660795		03; NREL; LFND; HRS
178	APL_DEL02660778	APL_DEL02660782		03; NREL; LFND; HRS
179	APL_DEL01452617	APL_DEL01452618		03; NREL; LFND; HRS
180	APL_DEL01009346	APL_DEL01009424		03; NREL; LFND; DUP; HRS
181	APL-MAS_01808114	APL-MAS_01808119		03; NREL; LFND; DUP; HRS
182	APL-MAS_01807986	APL-MAS_01807992		03; NREL; LFND; HRS
183	APL-MAS_00648368	APL-MAS_00648370		03; NREL; LFND; DUP; HRS



## Masimo's Trial Exhibit 68039 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
184	APL-MAS_00473322	APL-MAS_00473323		03; NREL; LFND; DUP; HRS
185	APL-MAS_00462145	APL-MAS_00462162		03; NREL; LFND; DUP; HRS
186	APL-MAS_00690298	APL-MAS_00690300		03; NREL; LFND; HRS
187	APL-MAS_00230888	APL-MAS_00230910		UP; 403; NREL; LFND; HRS
188				03; NREL; LFND; HRS; ATH
189	APL-MAS_00937816	APL-MAS_00937825		03; NREL; LFND; HRS
190	APL-MAS_00230843	APL-MAS_00230852		03; NREL; LFND; DUP; HRS
191	APL-MAS_00499741	APL-MAS_00499742		03; NREL; LFND; DUP; HRS
192	APL-MAS_00230888	APL-MAS_00230909		UP; INC; 403; NREL; LFND; HRS
193	APL-MAS_00473322	APL-MAS_00473323		UP; 403; NREL; LFND; HRS
194	APL-MAS_00648368	APL-MAS_00648370		UP; 403; NREL; LFND; HRS
195	APL_DEL01544572	APL_DEL01544574		03; NREL; LFND; HRS
196	APL-MAS_00188581	APL-MAS_00188595		03; NREL; LFND; HRS
197	APL_DEL01425205	APL_DEL01425215		03; NREL; LFND; HRS
198				03; NREL; LFND; NE
199	APL_DEL000005158	APL_DEL000005221		UP; 403; NREL; LFND
200	APL_DEL00003012	APL_DEL000005157		03; NREL; LFND
201	APL_DEL00006854	APL_DEL00006917		UP; 403; NREL; LFND
202	APL_DEL00005222	APL_DEL00006853		03; NREL; LFND
203	APL_DEL00010259	APL_DEL00010324		UP; 403; NREL; LFND
204	APL_DEL00009209	APL_DEL00010258		03; NREL; LFND
205				03; NREL; LFND; NE; ATH; HRS
206	APL_DEL03056765	APL_DEL03056775		03; NREL; LFND; HRS
207			9/8/2023 Apple's Third Supplemental Response to Defendants' First Set of Interrogatories (No. 3)	403; NREL; LFND; NE
208	MASAD00032245	MASAD00032317	U.S. Patent No. 11,432,766 B2 (Pandya et al.)	403; NREL; LFND; DUP
209			U.S. Patent No. 10,987,054 B2 (Pandya et al.)	403; NREL; LFND

## Masimo's Trial Exhibit 68040 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
210	STERNE00000001	STERNE00000001	Docket Report	403; NREL; LFND
211	APL_DEL00008353	APL_DEL00008426	U.S. Patent No. 10,987,054 B2 (Pandya et al.)	403; NREL; LFND
212			U.S. Patent No. 10,610,157 B2 (Pandya et al.)	403; NREL; LFND
213			U.S. Patent No. 11,432,766 B2 (Pandya et al.)	403; NREL; LFND
214	MASAD00020312	MASAD00020325	U.S. Patent No. 9,460,846 B2 (Graham et al.)	403; NREL; LFND; DUP
215			10/16/2017 Masimo - San Diego Bankruptcy Court Rules Sotera Employees Misappropriated Masimo Trade Secrets	403; NREL; LFND; HRS; MIL
225			9/1/2023 Masimo, Sound United, LLC, and Cercacor Labs., Inc.'s Notice of Deposition of Apple Inc. Pursuant to FRCP 30(b)(6)	403; NREL; LFND; NE
226	APL_MAS_00214780	APL_MAS_00214798		403; NREL; LFND; MD; CMP; HRS
227	APL_MAS_00211210	APL_MAS_00211241		403; NREL; LFND; MD; CMP; HRS
228	APL_MAS_00211200	APL_MAS_00211205		403; NREL; LFND; MD; CMP; HRS
229	APL_DEL01510819	APL_DEL01510824		403; NREL; LFND; HRS
230	APL_DEL00956847	APL_DEL00956878		403; NREL; LFND; MD; CMP; HRS
231	APL_DEL01173404	APL_DEL01173439		403; NREL; LFND; MD; CMP; IDSCR; HRS
232	APL_DEL01170539	APL_DEL01170578		403; NREL; LFND; MD; CMP; HRS
233	APL-MAS_01875995	APL-MAS_01876151		403; NREL; LFND; HRS; MIL
234	APL_DEL00206553	APL_DEL00206686		403; NREL; LFND; HRS
235	APL_DEL00273938	APL_DEL00274053		403; NREL; LFND; HRS
236	APL_DEL00951639	APL_DEL00951646		403; NREL; LFND; MD; CMP; HRS
237	APL_DEL01163945	APL_DEL01163947		403; NREL; LFND; HRS
238	APL-MAS_00498535	APL-MAS_00498536		403; NREL; LFND; HRS; MIL
239	APL_DEL02530598	APL_DEL02530763		403; NREL; LFND; MD; CMP; HRS
240	APL_DEL01103706	APL_DEL01103756		403; NREL; LFND; MD; CMP; HRS
241	APL_DEL02519225	APL_DEL02519323		403; NREL; LFND; MD; CMP; DUP; HRS

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
242	APL-MAS_00171697	APL-MAS_00171722		03; NREL; LFND; MD; CMP; HRS
243	APL_DEL00001341	APL_DEL00001349		03; NREL; LFND; HRS
244	APL_DEL00722570	APL_DEL00722614		03; NREL; LFND; HRS
245	APL_DEL03699676	APL_DEL03699676		03; NREL; LFND; ATH; HRS
246	APL_DEL03699672	APL_DEL03699672		03; NREL; LFND; MIL; ATH; HRS
247	MASA10914881; MASITC_00918307	MASA10914901; MASITC_10914901		03; NREL; LFND
248	APL_DEL00945918	APL_DEL00945962		03; NREL; LFND; MD; CMP; HRS
249	APL_DEL01159757	APL_DEL01159759		03; NREL; LFND; HRS
250	APL_DEL01103998	APL_DEL01104001		03; NREL; LFND; HRS
251	APL_DEL01105131	APL_DEL01105131		03; NREL; LFND; HRS
252	APL_MAS01289920	APL_MAS01289920		03; NREL; LFND; HRS
254	APL_DEL000008906	APL_DEL000009208		03; NREL; LFND
256	APL-MAS_02468578	APL-MAS_02468581		03; NREL; LFND; HRS
257	APL-MAS_02364457	APL-MAS_02364461		03; NREL; LFND; HRS
259	APL-MAS_00403772	APL-MAS_00403784		03; NREL; LFND; MD; CMP; MIL; HRS
261				03; NREL; LFND; NE
262	APL_DEL01117836	APL_DEL01117867		03; NREL; LFND; DUP; HRS
263	APL_DEL01545464	APL_DEL01545472		03; NREL; LFND; HRS
264	APL_MAS_ITC_00312179	APL_MAS_ITC_00312186		03; NREL; LFND; HRS
265	APL_DEL01509802	APL_DEL01509809		03; NREL; LFND; HRS
266	APL_DEL02517765	APL_DEL02517797		03; NREL; LFND; HRS

## Masimo's Trial Exhibit 68042 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
267	APL_DEL01135433	APL_DEL01135434		403; NREL; LFND; HRS
268	APL_MAS_ITC_00309307	APL_MAS_ITC_00309350		403; NREL; LFND; HRS
269	APL_MAS_ITC_00309369	APL_MAS_ITC_00309417		403; NREL; LFND; HRS
270	APL_MAS_ITC_00552697	APL_MAS_ITC_00552712		403; NREL; LFND; HRS
271	APL_MAS_ITC_02213472	APL_MAS_ITC_02213544		403; NREL; LFND; HRS
272	APL_MAS_ITC_00309231	APL_MAS_ITC_00309302		403; NREL; LFND; DUP; HRS
273	APL_DEL02517693	APL_DEL02517764		403; NREL; LFND; DUP; HRS
274	APL_MAS_ITC_00347547	APL_MAS_ITC_00347574		403; NREL; LFND; HRS
275	APL_MAS_ITC_00310490	APL_MAS_ITC_00310918		403; NREL; LFND; HRS
276	APL_MAS_ITC_01187731	APL_MAS_ITC_01187731		403; NREL; LFND
277	APL_MAS_ITC_00565270	APL_MAS_ITC_00565284		403; NREL; LFND; HRS
278	APL_DEL01009346	APL_DEL01009424		DUP; 403; NREL; LFND; HRS
279	APL-MAS_00462145	APL-MAS_00462162		DUP; 403; NREL; LFND; HRS
280	APL_DEL01383095	APL_DEL01383100		403; NREL; LFND; HRS
281	APL_MAS_ITC_00449521	APL_MAS_ITC_00449593		403; NREL; LFND; HRS
282	APL_MAS_ITC_00309231	APL_MAS_ITC_00309302		403; NREL; LFND; DUP; HRS
283	APL_DEL02517693	APL_DEL02517764		403; NREL; LFND; DUP; HRS
284	APL_DEL02517870	APL_DEL02517894		403; NREL; LFND; HRS
285	APL_DEL01117836	APL_DEL01117867		403; NREL; LFND; DUP; HRS
286	MASITC_01402291; MASITC_01402294	MASITC_01402291; MASITC_01402294		403; NREL; LFND
287	APL-MAS_00731464	APL-MAS_00731466		403; NREL; LFND; HRS
288	APL-MAS_00478488	APL-MAS_00478525		403; NREL; LFND; HRS
289	APL-MAS_01146683	APL-MAS_01146685		403; NREL; LFND; HRS
290	APL_DEL00993065	APL_DEL00993069		403; NREL; LFND; HRS
291	APL-MAS_01945235	APL-MAS_01945339		403; NREL; LFND; HRS
292	APL-MAS_01943702	APL-MAS_01943792		403; NREL; LFND; HRS

## Masimo's Trial Exhibit 68043 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
293	APL_DEL02512462	APL_DEL02512596		03; NREL; LFND; HRS
294	APL_DEL02512597	APL_DEL02512727		03; NREL; LFND; HRS
295	APL_DEL00265000	APL_DEL00265097		03; NREL; LFND; HRS
296	APL_DEL00263207	APL_DEL00263314		03; NREL; LFND; HRS
297	APL_DEL00025983	APL_DEL00026073		UP; 403; NREL; LFND; HRS
298	APL_DEL03819475	APL_DEL03819535		03; NREL; LFND; HRS
299				03; NREL; LFND; NE
300	APL_DEL02519225	APL_DEL02519323		03; NREL; LFND; DUP; HRS
301	APL-MAS_01853231	APL-MAS01853406		03; NREL; LFND; HRS
302	APL_DEL01146166	APL_DEL01146169		03; NREL; LFND; HRS
303	APL-MAS_02497270	APL-MAS_02497272		03; NREL; LFND; HRS
304	APL_DEL01171338	APL_DEL01171339		03; NREL; LFND; HRS
305	APL-MAS_00214780	APL-MAS_00214798		03; NREL; LFND; HRS
306	APL-MAS_00170033	APL-MAS_00170051		03; NREL; LFND; HRS
307	APL_DEL01178264	APL_DEL01178265		03; NREL; LFND; HRS
308	APL_DEL01706530	APL_DEL01706539		03; NREL; LFND; DUP; HRS
309	APL_DEL03346963	APL_DEL03346993		03; NREL; LFND; DUP; HRS
310	APL_DEL03356969	APL_DEL03356999		03; NREL; LFND; DUP; HRS
311	APL_DEL00955663	APL_DEL00955876		03; NREL; LFND; HRS
312	APL_DEL00960471	APL_DEL00960747		03; NREL; LFND; HRS
316	APL-MAS_00433706	APL-MAS_00433710		03; NREL; LFND; MIL; HRS
320	APL-MAS_01896101	APL-MAS_01896103		03; NREL; LFND; MIL; HRS
330	APL-MAS_00671287	APL-MAS_00671291		03; NREL; LFND; HRS

## Masimo's Trial Exhibit 68044 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
331	APL-MAS_02997659	APL-MAS_02997661		03; NREL; LFND; DUP; HRS
332	APL-MAS_02997659	APL-MAS_02997661		03; NREL; LFND; DUP; HRS
333	APL-MAS_00316530	APL-MAS_00316539		UP; 403; NREL; LFND; HRS
334	MASAD00438018	MASAD00438019		03; NREL; LFND; HRS; MIL
335	MASAD00437988	MASAD00437988		03; NREL; LFND; HRS; MIL
336	MASAD00246202	MASAD00246203		03; NREL; LFND; HRS; MIL
337	APL_DELO3487301	APL_DELO3487357		03; NREL; LFND; HRS
338	APL_DELO2661429	APL_DELO2661431		03; NREL; LFND; HRS
339	APL_DELO3003597	APL_DELO3003607		03; NREL; LFND; HRS
340	APL-MAS_00182672	APL-MAS_00182674		03; NREL; LFND; HRS
341	APL_DELO3004821	APL_DELO3004849		03; NREL; LFND; HRS
342	APL_DELO0946005	APL_DELO0946006		03; NREL; LFND; HRS
343				03; NREL; LFND; ATH; HRS
344				03; NREL; LFND; ATH; HRS
345	APL_DELO1515870	APL_DELO1515872		03; NREL; LFND; HRS
346				03; NREL; LFND; ATH; HRS; MIL
347				03; NREL; LFND; ATH; HRS
348	APL-MAS_02291898	APL-MAS_02291968		03; NREL; LFND; HRS
349	APL_DELO1341303	APL_DELO1341313		03; NREL; LFND; HRS
350	APL_MAS_ITC_01470838	APL_MAS_ITC_01470871		UP; 403; NREL; LFND; HRS
351	APL_DELO0029096	APL_DELO0029458		03; NREL; LFND; HRS
352	APL_DELO0028791	APL_DELO0029082		03; NREL; LFND; HRS

## Masimo's Trial Exhibit 68045 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
353	APL_DEL00028388	APL_DEL00028790		03; NREL; LFND; HRS
354	APL_DEL00029459	APL_DEL00029918		03; NREL; LFND; HRS
355	MASAD04059862	MASAD0406052		03; NREL; LFND; HRS
356	MASAD00020646	MASAD00020648		03; NREL; LFND; HRS
357	APL_DEL00027756	APL_DEL00027759		03; NREL; LFND; HRS
358	MASAD04060267	MASAD04060269		03; NREL; LFND; HRS
359	APL_DEL00237724	APL_DEL00237761		03; NREL; LFND; HRS
360	APL_DEL00238905	APL_DEL00238906		03; NREL; LFND; HRS
361	APL-MAS_02971307	APL-MAS_02971312		03; NREL; LFND; HRS
362	APL_DEL02171004	APL_DEL02171035		03; NREL; LFND; HRS
363	APL_DEL02140858	APL_DEL02140944		03; NREL; LFND; HRS
364	APL_DEL00904770	APL_DEL00904784		03; NREL; LFND; HRS
365	APL_DEL01686810	APL_DEL01686815		03; NREL; LFND; HRS
366	APL-MAS_01541287	APL-MAS_01541301		03; NREL; LFND; HRS
367	APL-MAS_01199554	APL-MAS_01199581		03; NREL; LFND; HRS
368	APL_DEL01217064	APL_DEL01217102		03; NREL; LFND; HRS
369	APL_DEL00247573	APL_DEL00247620		03; NREL; LFND; HRS
370	APL-MAS_00554285	APL-MAS_00554288		03; NREL; LFND; HRS
371	APL_DEL01697798	APL_DEL01697833		03; NREL; LFND; HRS
377				03; NREL; LFND; HRS; MIL
378				03; NREL; LFND; HRS
392				03; NREL; LFND; MIL; HRS
393				03; NREL; LFND; MIL; HRS
394				03; NREL; LFND; MIL; HRS

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
395				03; NREL; LFND; MIL; HRS
400				03; NREL; LFND; HRS; ATH
401	APL-MAS_00208323	APL-MAS_00208334		03; NREL; LFND; HRS
402	APL-MAS_00262398	APL-MAS_00262400		03; NREL; LFND; HRS
403	APL-MAS_03085494	APL-MAS_03085502		03; NREL; LFND; HRS
404	APL-MAS_00152416	APL-MAS_00152519		03; NREL; LFND; HRS
405	APL-MAS_00182789	APL-MAS_00182826		03; NREL; LFND; HRS
406	APL-MAS_00167962	APL-MAS_00168029		03; NREL; LFND; HRS
407	APL-MAS_00208496	APL-MAS_00208498		03; NREL; LFND; HRS
408	APL-MAS_01368506	APL-MAS_01368527		UP; 403; NREL; LFND; HRS
411				03; NREL; LFND; HRS; MIL
412				03; NREL; LFND; HRS; MIL
415				03; NREL; LFND; HRS; MIL
416				03; NREL; LFND; HRS; MIL
422				03; NREL; LFND; HRS
423				03; NREL; LFND; HRS
425	APL-MAS_02364484	APL-MAS_02364488		03; NREL; LFND; HRS; MIL
426	APL_DEL01428981	APL_DEL01428982		03; NREL; LFND; HRS; MIL




DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
427	APL_DEL02710481	APL_DEL02710483		03; NREL; LFND; HRS; MIL
428	APL_DEL03095980	APL_DEL03096017		03; NREL; LFND; HRS; MIL
429	APL_DEL03675127	APL_DEL03675139		03; NREL; LFND; HRS; MIL
430	APL-MAS_00660230	APL-MAS_00660244		03; NREL; LFND; HRS; MIL
431	APL-MAS_00631182	APL-MAS_00631183		03; NREL; LFND; MIL; HRS
432	APL-MAS_00723491	APL-MAS_00723497		03; NREL; LFND; HRS; MIL
433	APL_DEL00951868	APL_DEL00951891		03; NREL; LFND; HRS; MIL
434	APL-MAS_00316530	APL-MAS_00316539		UP; 403; NREL; LFND; HRS; MIL
435	APL_DEL02805523	APL_DEL02805545		03; NREL; LFND; HRS; MIL
436	APL_DEL01858311	APL_DEL01858343		03; NREL; LFND; MIL
437	APL-MAS_02364342	APL-MAS_02364349		03; NREL; LFND; HRS; MIL
438	APL_DEL02691839	APL_DEL02691846		03; NREL; LFND; HRS; MIL
439				03; NREL; LFND; HRS
440	APL_DEL01143441	APL_DEL01143444		03; NREL; LFND; HRS
441	APL_DEL02720065	APL_DEL02720068		03; NREL; LFND; HRS; MIL
442	APL-MAS_01291114	APL-MAS_01291118		03; NREL; LFND; MIL
443	APL_DEL03677883	APL_DEL03677910		03; NREL; LFND; HRS; MIL
444	APL-MAS_01590692	APL-MAS_01590698		03; NREL; LFND; HRS; MIL
445	APL-MAS_00171691	APL-MAS_00171696		03; NREL; LFND; HRS; MIL
446				03; NREL; NE; OBJ; LA; MIL
447	APL_DEL02646321	APL_DEL02646400		03; NREL; LFND; IEXP; CLC; ATH; MIL
448	MASAO3019103	MASAO3019182		03; NREL; LFND; IEXP; CLC; ATH; MIL
449				03; NREL; LFND; IEXP; CLC; ATH; MIL

## Masimo's Trial Exhibit 68048 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
450	MASA03028081	MASA03028103		03; NREL; LFND; IEXP; CLC; MIL; CM
451	APL_DEL01937094	APL_DEL01937115		03; NREL; LFND; IEXP; CLC; MIL; CM
452	APL_DEL02646275	APL_DEL02646298		03; NREL; LFND; IEXP; CLC; MIL; CM
453	APL_DEL03549605	APL_DEL03549631		03; NREL; LFND; IEXP; CLC; MIL; CM
454	APL_DEL03070920	APL_DEL03070947		03; NREL; LFND; IEXP; CLC; MIL; CM
455	APL_DEL01191547	APL_DEL01191576		03; NREL; LFND; IEXP; CLC; MIL; CM
456	APL_DEL03855237	APL_DEL03855238		03; NREL; LFND; MIL
457	APL_DEL03855615	APL_DEL03855619?		03; NREL; LFND; MIL; HRS
458	APL_DEL01191888	APL_DEL01191892		03; NREL; LFND; MIL; HRS
459	APL_DEL03819782			03; NREL; LFND; HRS; MIL; MIS
460	APL_DEL01189019	APL_DEL01189025		03; NREL; LFND; MIL; HRS
461	APL_DEL01368829	APL_DEL01368830		03; NREL; LFND; MIL; HRS
462	APL_DEL01191027	APL_DEL01191030		03; NREL; LFND; MIL; HRS
463	APL_DEL01191869	APL_DEL01191871		03; NREL; LFND; MIL; HRS
464	APL_DEL01246610	APL_DEL01246613		03; NREL; LFND; MIL; HRS
465	APL_DEL03827666	APL_DEL03827688		03; NREL; LFND; MIL; HRS
466	APL_DEL03551662	APL_DEL03551666		03; NREL; LFND; MIL; HRS
467	APL_DEL01938620			
468	APL_DEL03125484	APL_DEL03125495		03; NREL; LFND; MIL; HRS
469	APL_DEL01189965	APL_DEL01189969		03; NREL; LFND; MIL; HRS
470	APL_DEL03827647	APL_DEL03827665		03; NREL; LFND; MIL; HRS
471	APL_DEL01369591	APL_DEL01369592		03; NREL; LFND; MIL; HRS
472	APL_DEL01369226	APL_DEL01369230		03; NREL; LFND; MIL; HRS
473	APL_DEL03827784	APL_DEL03827794		03; NREL; LFND; MIL; HRS
475	APL-MAS_00083085	APL-MAS_00083104		03; NREL; LFND; ILLEG; MIL
476	APL-MAS_00083087	APL-MAS_00083087		03; NREL; LFND; MIL

## Masimo's Trial Exhibit 68049 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
477	APL-MAS_00083940	APL-MAS_00083940		UP; 403; NREL; LFND; ILLEG; MIL
478	APL-MAS_00083940	APL-MAS_00083940		UP; 403; NREL; LFND; ILLEG; MIL
479	APL_DEL00125922	APL_DEL00126458		UP; 403; NREL; LFND
480	APL-MAS_03077337	APL-MAS_03077341		03; NREL; LFND; HRS; MIL
481	APL-MAS_00909102	APL-MAS_00909134		03; NREL; LFND; HRS; MIL
482	APL-TW_00000010	APL-TW_00000013		03; NREL; LFND; HRS; MIL
483	APL-MAS_01853759	APL-MAS_01853795		03; NREL; LFND; MIL
484	APL-MAS_00359941	APL-MAS_00359941		03; NREL; LFND; HRS; MIL
485	APL-MAS_00359928	APL-MAS_00359929		03; NREL; LFND; HRS; MIL
486	APL-TW_00000720	APL-TW_00000721		03; NREL; LFND; HRS; MIL
487	APL-MAS_00359988	APL-MAS_00359990		03; NREL; LFND; HRS; MIL
488	APL-TW_00000439	APL-TW_00000439		03; NREL; LFND; HRS; MIL
489	APL-MAS_00237567	APL-MAS_00237571		03; NREL; LFND; HRS; MIL
490	APL-MAS_00233250	APL-MAS_00233251		03; NREL; LFND; HRS; MIL
491	APL-MAS_00241566	APL-MAS_00241568		03; NREL; LFND; HRS; MIL
492	APL-MAS_00241716	APL-MAS_00241727		03; NREL; LFND; HRS; MIL
493	APL-MAS_00417705	APL-MAS_00417719		03; NREL; LFND; HRS; MIL
494	APL-MAS_00429627	APL-MAS_00429629		03; NREL; LFND; HRS; MIL
495	APL-MAS_00233541	APL-MAS_00233542		03; NREL; LFND; HRS; MIL
496	APL-MAS_00574476	APL-MAS_00574526		03; NREL; LFND; HRS; MIL
497				03; NREL; HRS; LFND; ATH; NE; MIL
498	APL-MAS_00180353	APL-MAS_00180355		03; NREL; LFND; HRS
499	APL-MAS_00230191	APL-MAS_00230195		03; NREL; LFND; HRS
500	APL-MAS_00249195	APL-MAS_00249195		03; NREL; LFND; HRS


DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
501	APL-MAS_00230843	APL-MAS_00230851		UP; 403; NREL; LFND; INC; HRS
502	APL-MAS_01808114	APL-MAS_01808115		UP; 403; NREL; LFND; INC; HRS
503	APL-MAS_00230888	APL-MAS_00230892		UP; 403; NREL; LFND; INC
504	APL-MAS_00230910	APL-MAS_00230910		03; NREL; LFND
505	APL-MAS_00473322	APL-MAS_00473323		UP; 403; NREL; LFND; HRS
507				03; NREL; LFND; HRS; MIL
510				03; NREL; LFND; ATH; HRS
511	APL_DEL03893132	APL_DEL03893134		03; NREL; LFND; HRS; CM; MIL
512	APL_DEL03978336	APL_DEL03978344		03; NREL; LFND; HRS; CM; MIL
513	APL_DEL03967232	APL_DEL03967235		03; NREL; LFND; HRS; CM; MIL
514	APL_DEL03910942	APL_DEL03910955		03; NREL; LFND; HRS; CM; MIL
515	APL_DEL03907424	APL_DEL03907426		03; NREL; LFND; HRS; CM; MIL
516	APL_DEL03902970	APL_DEL03902972		03; NREL; LFND; HRS; CM; MIL
517	APL_DEL03930994	APL_DEL03931036		03; NREL; LFND; HRS; CM; MIL
518	APL_DEL03980368	APL_DEL03980479		03; NREL; LFND; HRS; CM; MIL
519	APL_DEL03939857	APL_DEL03939862		03; NREL; LFND; HRS; CM; MIL
520	APL_DEL03963872	APL_DEL03963903		03; NREL; LFND; HRS; CM; MIL
521	APL_DEL03875661	APL_DEL03875675		03; NREL; LFND; HRS; CM; MIL

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
522	APL_DEL03971431	APL_DEL03971445		03; NREL; LFND; HRS; CM; MIL
523	APL_DEL03910469	APL_DEL03910473		03; NREL; LFND; HRS; CM; MIL
524	APL_DEL03918242	APL_DEL03918243		03; NREL; LFND; HRS; CM; MIL
525	APL_DEL03947212	APL_DEL03947218		03; NREL; LFND; HRS; CM; MIL
526	APL_DEL03857014	APL_DEL03857017		03; NREL; LFND; HRS; CM; MIL
527	APL_DEL03875826	APL_DEL03875842		03; NREL; LFND; HRS; CM; MIL
528				03; NREL; LFND; CM; HRS; MIL
529				03; NREL; LFND; CM; HRS; MIL
531	APL-MAS_00187821	APL-MAS_00187826		03; NREL; LFND; HRS
533	APL-MAS_00980152	APL-MAS_00980180		03; NREL; LFND; HRS
534				03; NREL; LFND; NE
535	FOSSIL_AU4002			03; NREL; LFND; ATH; HRS; INC
536	FOSSIL_AU4005			03; NREL; LFND; ATH; HRS; INC
537	MASAD00251160	MASAD00251177		03; NREL; LFND; ATH; HRS; INC
541				03; NREL; LFND; MIL
548	APL_MAS_ITC_00407892	APL_MAS_ITC_00407916		03; NREL; LFND; HRS
549	APL-MAS_01346977	APL-MAS_01346979		03; NREL; LFND; HRS
550	APL_MAS_ITC_00387987	APL_MAS_ITC_00388013		03; NREL; LFND; HRS
551	MASITC_01401070	MASITC_01401088		03; NREL; LFND
552	APL_MAS_ITC_00054864	APL_MAS_ITC_00054890		03; NREL; LFND; HRS
553	APL-MAS_00666110	APL-MAS_00666141		03; NREL; LFND; HRS
554	APL-MAS_00388198	APL-MAS_00388211		03; NREL; LFND; HRS

## Masimo's Trial Exhibit 68052 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
555	APL_DELO1372020	APL_DELO1372030		03; NREL; LFND; HRS
556	APL-MAS_00938440	APL-MAS_00938443		03; NREL; LFND; HRS
557	APL-MAS_00666663	APL-MAS_00666664		03; NREL; LFND; HRS
558	MASAD00237745	MASAD00237760		DUP; 403; NREL; HRS; LFND; ATH
559	MASA03217800			03; NREL; LFND; MIL; HRS
585				03; NREL; LFND; NE
586				03; NREL; LFND; NE
587	MASAD00253657	MASAD00253684		03; NREL; LFND; HRS; ATH
588	INNOMINDS_000001	INNOMINDS_000009		03; NREL; LFND; HRS; ATH
589	INNOMINDS_000028	INNOMINDS_000039		03; NREL; LFND; HRS; ATH
590	INNOMINDS_000010	INNOMINDS_000017		03; NREL; LFND; HRS; ATH
591	INNOMINDS_000018	INNOMINDS_000027		03; NREL; LFND; HRS; ATH
592			Nears Release of Developer Units"	403; NREL; LFND; HRS; INC; ATH
593			Video: Bionym's Nymi Nears Release of Developer Units	403; NREL; LFND; HRS; ATH; MIS
594			Screenshot of YouTube video dated 2/13/2014, "CES 2014: Authenticate Your Identity with the Nymi"	403; NREL; LFND; HRS; INC; ATH
595			Video: CES 2014 Authenticate Your Identity with the Nymi	403; NREL; LFND; HRS; ATH; MIS
596			11/7/2023 Masimo's Subpoena for Deposition to Epson America, Inc.	403; NREL; LFND; NE
597			7/25/2023 Masimo's Subpoena to Produce Documents to Epson America, Inc.	403; NREL; LFND; NE
598	EPSON0001	EPSON0041		03; NREL; LFND; HRS; ATH
599	EPSON0047	EPSON0050		03; NREL; LFND; HRS; ATH
600	EPSON0051	EPSON0097		03; NREL; LFND; HRS; ATH
601	EPSON0043	EPSON0046		03; NREL; LFND; HRS; ATH
602	MASAD00251180	MASAD00251217		03; NREL; LFND; HRS; INC; ATH
603	MASAD00251100	MASAD00251102		03; NREL; LFND; HRS; INC; ATH
604	MASAD00251146	MASAD00251156		03; NREL; LFND; HRS; INC; ATH
605	EPSON0042	EPSON0042		03; NREL; LFND; HRS; ATH

## Masimo's Trial Exhibit 68050 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
607			LinkedIn Profile of Liz Dickinson	403; LFND; HRS; NREL; ATH; NP
608	MASAD00253643	MASAD00253656	12/14/2002 Strieteimeier, J., "Mio SHAPE Heart Rate Watch Review"	403; HRS; NREL; LFND; ATH
609	MASAD00251552	MASAD00251556	7/31/2014 Mio Introduces Its Next Breakthrough Product: The Most Accurate Wrist-Based Heart Rate Monitoring without a Chest Strap Now Paired with Daily Activity Tracking - "Your Day. In Action!"	403; NREL; HRS; LFND; ATH
610				403; NREL; HRS; NP; LFND; ATH; MIL
614				403; NREL; HRS; NP; LFND; ATH; MIL
615				403; NREL; HRS; LFND; ATH; NE
616	APL_DEL03495104			403; NREL; LFND; MIS
617	APL_DEL03495106			403; NREL; LFND; MIS
618	APL-MAS_03104817			403; NREL; LFND; MIS
619	APL-MAS_02962191			403; NREL; LFND; MIS
620	APL-DEL_03495105			403; NREL; LFND; MIS
621	APL-MAS_02470099	APL-MAS_02470099		403; NREL; HRS; LFND; MIL
623	APL_DEL03356969	APL_DEL03356999		UP; 403; NREL; LFND; HRS
624	APL_DEL03346963	APL_DEL03346993		UP; INC; 403; NREL; LFND; HRS
625	APL_DEL03823612			403; NREL; HRS; LFND; MIL; MIS
626	MASAD00721753	MASAD00721760		403; NREL; HRS; LFND; ATH; MIL
627	MASAD00721802	MASAD00721811		403; NREL; HRS; LFND; ATH; MIL
628	MASAD00721877	MASAD00721884		403; NREL; HRS; LFND; ATH; MIL
629	APL_DEL03986394			403; NREL; LFND; MIS
630	APL_DEL03986574			403; NREL; HRS; LFND; MIL; MIS
631	APL_DEL03986575			403; NREL; HRS; LFND; MIL; MIS

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
632	APL_DEL03986576			03; NREL; HRS; LFND; MIL; MIS
633	APL_DEL03986577			03; NREL; HRS; LFND; MIL; MIS
634	APL_DEL03986578			03; NREL; HRS; LFND; MIL; MIS
635	APL_DEL03994175			03; NREL; HRS; LFND; MIL; MIS
636	APL_DEL03994176			03; NREL; HRS; LFND; MIL; MIS
637	APL_DEL03994177			03; NREL; HRS; LFND; MIL; MIS
638	APL_DEL03994178			03; NREL; HRS; LFND; MIL; MIS
639	APL_DEL03994179			03; NREL; HRS; LFND; MIL; MIS
640	APL_DEL03994180			03; NREL; HRS; LFND; MIL; MIS
641	APL_DEL03994181			03; NREL; HRS; LFND; MIL; MIS
642	APL_DEL01706530	APL_DEL01706539		UP; 403; NREL; HRS; LFND; MIL
643	APL_DEL03766446	APL_DEL03766468		03; NREL; HRS; LFND; MIL
644				03; NREL; HRS; LFND; ATH; NE
645				03; NREL; HRS; LFND; ATH; MIL; NE
646				03; NREL; HRS; LFND; ATH; MIL; NE
647				03; NREL; LFND; ATH
648	APL_DEL01378954	APL_DEL01378956		03; NREL; HRS; LFND
649	APL-MAS_00634347	APL-MAS_00634348		03; NREL; HRS; LFND
650	APL-MAS_00625926	APL-MAS_00625927		03; NREL; HRS; LFND
651	APL_DEL01428916	APL_DEL01428917		03; NREL; HRS; LFND
652	APL-MAS_00647879	APL-MAS_00647881		03; NREL; HRS; LFND
653	APL-MAS_00637532	APL-MAS_00637541		03; NREL; HRS; LFND



## Masimo's Trial Exhibit 68055 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
654	APL-MAS_01135120	APL-MAS_01135122		03; NREL; HRS; LFND
655	APL-MAS_00653965	APL-MAS_00653972		03; NREL; HRS; LFND
656	APL_DEL01534228	APL_DEL01534231		03; NREL; HRS; LFND
657	APL_DEL01367285	APL_DEL01367286		03; NREL; HRS; LFND
658	APL-MAS_01808114	APL-MAS_01808119		UP; 403; NREL; HRS; LFND
659	APL-MAS_00499741	APL-MAS_00499742		UP; 403; NREL; HRS; LFND
660	APL_DEL01424966	APL_DEL01424975		03; NREL; HRS; LFND
661	APL-MAS_00652165	APL-MAS_00652171		03; NREL; HRS; LFND
662	APL_DEL01525964	APL_DEL01525967		03; NREL; HRS; LFND
663	APL_DEL01521475	APL_DEL01521494		03; NREL; HRS; LFND
664	APL_DEL01902110	APL_DEL01902125		03; NREL; HRS; LFND
665	APL_DEL01535192	APL_DEL01535203		03; NREL; HRS; LFND
666	APL_DEL01423109	APL_DEL01423115		03; NREL; HRS; LFND
667	APL_DEL02419009	APL_DEL02419020		03; NREL; HRS; LFND
668	APL_DEL01472712	APL_DEL01472713		03; NREL; HRS; LFND
669	APL_DEL00002564	APL_DEL00002575		03; NREL; LFND; DUP
670	APL_DEL00002576	APL_DEL00002586		03; NREL; LFND; DUP
671	APL_DEL00002587	APL_DEL00002597		03; NREL; LFND; DUP
672				03; NREL; HRS; LFND; NE
673	APL-MAS_00976389	APL-MAS_00976397		UP; 403; NREL; HRS; LFND
674	APL-MAS_00230888	APL-MAS_00230909		UP; INC; 403; NREL; LFND; HRS
675	APL-MAS_00980152	APL-MAS_00980180		UP; 403; NREL; LFND; HRS
676				03; NREL; LFND; ATH

## Masimo's Trial Exhibit 68056 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
677			D279 Fig. 4 (Modified) (pg. 5)	403; NREL; LFND; ATH
678			D279 Fig. 4 (Modified) (pg. 8)	403; NREL; LFND; ATH
679			D279 Fig. 4 (Modified) (pg. 34)	403; NREL; LFND; ATH
680			Printout from Brownstein's website - Intellectual Property Litigation	403; NREL; HRS; LFND; ATH; NP
681			Printout from Brownstein's website - S. Craig Hemenway Bio	403; NREL; HRS; LFND; ATH; NP
682	APL_MAS_ITC_00366722	APL_MAS_ITC_00366754	PCT Publication WO 2005/092182 A1 (Kotangi) [foreign language]	403; NREL; HRS; LFND
683			Translation of PCT Publication WO 2005/092182 A2 (Kotangi)	403; NREL; HRS; LFND; NP; ATH
684	KMMASD_00104696	KMMASD_00104731	Japanese Unexamined Patent Application Publication JP 2005-270543 (Otanagi)	403; NREL; HRS; LFND; NP; ATH
685	MASAD00018067	MASAD00018098	PCT Publication WO 2012/140559 A1 (Shmueli)	403; NREL; HRS; LFND; ATH
686	MASITC_01379393	MASITC_01379465	U.S. Patent Application Publication No. 2019/0072912 A1 (Pandya)	403; NREL; HRS; LFND; ATH
687	MASAD00032245	MASAD00032317	U.S. Patent No. 11,432,766 B2 (Pandya et al.)	DUP; 403; NREL; HRS; LFND; ATH
688	APL_DEL00008354	APL_DEL00008426	U.S. Patent No. 10,987,054 B2 (Pandya et al.)	403; NREL; LFND
689	APL-MAS_02626296	APL-MAS_02626367	U.S. Patent No. 10,610,157 B2 (Pandya et al.)	403; NREL; LFND
690	MASAD00020312	MASAD00020325	U.S. Patent No. 9,460,846 B2 (Graham et al.)	DUP; 403; NREL; HRS; LFND; ATH
691	BROWNSTEIN000001	BROWNSTEIN000001	Listing of three issued patents prepared by Brownstein	403; NREL; HRS; LFND; ATH
692			7/15/2022 Petition for Inter Partes Review of U.S. Patent No. 10,912,501 (Apple v. Masimo, IPR2022-01271)	403; NREL; HRS; LFND; ATH; MIL; NE
693			7/15/2022 Petition for Inter Partes Review of U.S. Patent No. 10,912,501 (Apple v. Masimo, IPR2022-01272)	403; NREL; HRS; LFND; ATH; MIL; NE
694			7/15/2022 Petition for Inter Partes Review of U.S. Patent No. 10,912,502 (Apple v. Masimo, IPR2022-01273)	403; NREL; HRS; LFND; ATH; MIL; NE
695			7/15/2022 Petition for Inter Partes Review of U.S. Patent No. 10,912,502 (Apple v. Masimo, IPR2022-01274)	403; NREL; HRS; LFND; ATH; MIL; NE
696			7/15/2022 Petition for Inter Partes Review of U.S. Patent No. 10,945,648 (Apple v. Masimo, IPR2022-01275)	403; NREL; HRS; LFND; ATH; MIL; NE
697			7/15/2022 Petition for Inter Partes Review of U.S. Patent No. 10,945,648 (Apple v. Masimo, IPR2022-01276)	403; NREL; HRS; LFND; ATH; MIL; NE
698			Screenshot of Fish & Richardson's website - Main Page	403; NREL; HRS; LFND; ATH; NP; MIL
699			Screenshot of Fish & Richardson's website - Patent Prosecution	403; NREL; HRS; LFND; ATH; NP; MIL
700			9/30/2020 Petition for Inter Partes Review of U.S. Patent No. 10,624,564 (Apple v. Masimo, IPR2020-01713)	403; NREL; HRS; LFND; ATH; MIL; NE
701			9/30/2020 Petition for Inter Partes Review of U.S. Patent No. 10,631,765 (Apple v. Masimo, IPR2020-01714)	403; NREL; HRS; LFND; ATH; MIL; NE
702			9/30/2020 Petition for Inter Partes Review of U.S. Patent No. 10,631,765 (Apple v. Masimo, IPR2020-01715)	403; NREL; HRS; LFND; ATH; MIL; NE
703			6/9/2021 Petition for Inter Partes Review of U.S. Patent No. 9,572,499 (Apple v. AliveCor, IPR2021-00970)	403; NREL; HRS; LFND; ATH; MIL; NE
704			6/9/2021 Petition for Inter Partes Review of U.S. Patent No. 10,595,731 (Apple v. AliveCor, IPR2021-00971)	403; NREL; HRS; LFND; ATH; MIL; NE
705			6/9/2021 Petition for Inter Partes Review of U.S. Patent No. 10,638,941 (Apple v. AliveCor, IPR2021-00972)	403; NREL; HRS; LFND; ATH; MIL; NE

## Masimo's Trial Exhibit 68057 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
706			9/26/2022 Petition for Inter Partes Review of U.S. Patent No. 9,420,956 (Apple v. AliveCor, IPR2022-01560)	403; NREL; HRS; LFND; ATH; MIL; NE
707			9/26/2022 Petition for Inter Partes Review of U.S. Patent No. 10,159,415 (Apple v. AliveCor, IPR2022-01562)	403; NREL; HRS; LFND; ATH; MIL; NE
708			8/9/2021 Petitioner Apple's Power of Attorney in Post Grant Proceedings Before the Patent Trial and Appeal Board re USP 10,912,501	403; NREL; HRS; LFND; ATH; MIL; NE
709			8/9/2021 Petitioner Apple's Power of Attorney in Post Grant Proceedings Before the Patent Trial and Appeal Board re USP 10,912,501	403; NREL; HRS; LFND; ATH; MIL; NE
710			8/9/2021 Petitioner Apple's Power of Attorney in Post Grant Proceedings Before the Patent Trial and Appeal Board re USP 10,912,502	403; NREL; HRS; LFND; ATH; MIL; NE
711			8/9/2021 Petitioner Apple's Power of Attorney in Post Grant Proceedings Before the Patent Trial and Appeal Board re USP 10,912,502	403; NREL; HRS; LFND; ATH; MIL; NE
712			8/9/2021 Petitioner Apple's Power of Attorney in Post Grant Proceedings Before the Patent Trial and Appeal Board re USP 10,945,648	403; NREL; HRS; LFND; ATH; MIL; NE
713			8/9/2021 Petitioner Apple's Power of Attorney in Post Grant Proceedings Before the Patent Trial and Appeal Board re USP 10,945,648	403; NREL; HRS; LFND; ATH; MIL; NE
714			5/6/2021 Petitioner Apple's Power of Attorney in Inter Partes Review Proceedings Before the Patent Trial and Appeal Board re USP 9,572,499	403; NREL; HRS; LFND; ATH; MIL; NE
715			5/6/2021 Petitioner Apple's Power of Attorney in Inter Partes Review Proceedings Before the Patent Trial and Appeal Board re USP 10,595,731	403; NREL; HRS; LFND; ATH; MIL; NE
716			5/6/2021 Petitioner Apple's Power of Attorney in Inter Partes Review Proceedings Before the Patent Trial and Appeal Board re USP 10,638,941	403; NREL; HRS; LFND; ATH; MIL; NE
717			8/12/2022 Petitioner Apple's Power of Attorney in Post Grant Proceedings Before the Patent Trial and Appeal Board re USP 9,420,956	403; NREL; HRS; LFND; ATH; MIL; NE
718			8/12/2022 Petitioner Apple's Power of Attorney in Post Grant Proceedings Before the Patent Trial and Appeal Board re USP 10,159,415	403; NREL; HRS; LFND; ATH; MIL; NE
721	MASAD00985191	MASAD00985290		03; NREL; HRS; LFND; ATH
724	APL-MAS_00506515	APL-MAS_00506546		03; NREL; HRS; LFND
725	APL_DEL00723837	APL_DEL00723851		03; NREL; HRS; LFND

## Masimo's Trial Exhibit 68058 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
726	APL_DEL00723939	APL_DEL00723973	Shapiro, I., et al., "Pulse Oximetry Values from 33,080 Participants in the Apple Heart & Movement Study," Research Square (2022)	403; NREL; HRS; LFND
727			Rafl, J., et al., "Commercial smartwatch with pulse oximeter detects short-time hypoxemia as well as standard medical-grade device: Validation study," Digital Health, 8:1-9 (2022)	403; NREL; HRS; LFND; ATH; NP
728	APL-MAS02640300	APL-MAS_02640306	Spaccarotella, C., et al., "Assessment of Non-Invasive Measurements of Oxygen Saturation and Heart Rate with an Apple Smartwatch: Comparison with a Standard Pulse Oximeter," J. Clin. Med., 11:1467 (2022)	403; NREL; HRS; LFND
729	APL-MAS_01875507	APL-MAS_01875513	Pipek, L., et al., "Comparison of SpO <sub>2</sub> and heart rate values on Apple Watch and conventional commercial oximeters devices in patients with lung disease," Scientific Reports, 11:18901 (2021)	403; NREL; HRS; LFND
730	APL_DEL00723830	APL_DEL00723836	Arslan, B., et al., "Accuracy of the Apple Watch in measuring oxygen saturation: comparison with pulse oximetry and ABG," Irish Journal of Medical Science (2023)	403; NREL; HRS; LFND
731	MASAD00237745	MASAD00237760	2023 Masimo Whitepaper, "Masimo W1™ Hospital-Grade Continuous Monitoring of SpO <sub>2</sub> and Other Parameters in a Consumer Watch"	DUP; 403; NREL; HRS; LFND; ATH
736				03; NREL; HRS; LFND; IDSCR; MIL
762				03; NREL; HRS; LFND; IDSCR; MIL
769				03; NREL; HRS; LFND; IDSCR; ATH; MIL
773	MASAD00035121	MASAD00035171		403; NREL; HRS; LFND; ATH
774	MASAD00033357	MASAD00033374		403; NREL; HRS; LFND; ATH
775	MASITC_00454376	MASITC_00454388		403; NREL; HRS; LFND; ATH
776	APL-MAS_02600136	APL-MAS_02600165		03; NREL; HRS; LFND
777				03; NREL; HRS; LFND; IDSCR; ATH; MIL
780				03; NREL; HRS; LFND; IDSCR; ATH; MIL
781				03; NREL; HRS; LFND; IDSCR; ATH
782				03; NREL; LFND; IDSCR; ATH
784				03; NREL; HRS; LFND; IDSCR; ATH; MIL
786				03; NREL; HRS; LFND; IDSCR; ATH; MIL
798				03; NREL; HRS; LFND; IDSCR; ATH

## Masimo's Trial Exhibit 68059 and Apple's Objections


DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
800	APL_MAS_ITC_00372141	APL_MAS_ITC_00372351	Love, J., et al., "Personal Status Monitor," Sandia Report (1997)	403; NREL; HRS; LFND
804	APL_DEL00037708	APL_DEL00037739	U.S. Patent No. 6,608,562 B1 (Kimura et al.)	403; NREL; HRS; LFND
805	APL_DEL00031229	APL_DEL00031239	U.S. Patent Application Publication Number 2002/0015034 A1 (Malmborg)	403; NREL; HRS; LFND
808				03; NREL; HRS; LFND; IDSCR; ATH; MIL
810				03; NREL; HRS; LFND; IDSCR; ATH; MIL
811				03; NREL; HRS; LFND; IDSCR; ATH; MIL
827				03; NREL; HRS; LFND; IDSCR; ATH; MIL
828				03; NREL; HRS; LFND; IDSCR; ATH; MIL
831				03; NREL; HRS; LFND; IDSCR; ATH; MIL
832				03; NREL; HRS; LFND; IDSCR; ATH; MIL
851				03; NREL; HRS; LFND; IDSCR; MIL
859				03; NREL; HRS; LFND; IDSCR; MIL
880				03; NREL; HRS; LFND; IDSCR; MIL
881				03; NREL; HRS; LFND; IDSCR; ATH; MIL
920	MASAD00110729	MASAD00110729		03; NREL; HRS; LFND; ATH
921				03; NREL; LFND; IDSCR
922				03; NREL; LFND; IDSCR
923				03; NREL; LFND; IDSCR
924				03; NREL; LFND; IDSCR
925				03; NREL; LFND; IDSCR
926				03; NREL; LFND
927				03; NREL; HRS; LFND; ATH
928				03; NREL; LFND; IDSCR; ATH
930				03; NREL; HRS; LFND; ATH; NP; NE
932				03; NREL; HRS; LFND; NP; ATH
933				03; NREL; HRS; LFND; NP; ATH
934				03; NREL; HRS; LFND; NP; ATH
935				03; NREL; HRS; LFND; IDSCR; ATH; MIL

## Masimo's Trial Exhibit 68060 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
936				03; NREL; HRS; LFND; IDSCR; ATH; MIL
937				03; NREL; HRS; LFND; IDSCR; ATH; MIL
940				03; NREL; HRS; LFND; NP; ATH
941				03; NREL; HRS; LFND; NP; ATH
942				03; NREL; HRS; LFND; NP; ATH
943				03; NREL; HRS; LFND; NP; ATH; INC
1000	MASAD_P_1000		Physical: Masimo W1	403; NREL; LFND; ATH; INC
1001	MASAD_P_1001		Physical: Apple Watch Series 4	403; NREL; LFND; ATH; INC
1002	MASAD_P_1002		Physical: Masimo W1 Charger	403; NREL; LFND; ATH; INC
1003	APL-MAS_00304771	APL-MAS_00304778		03; NREL; LFND; HRS; MIL
1004	APL-MAS_00443343	APL-MAS_00443345		03; NREL; LFND; HRS
1005	APL-MAS_00028917	APL-MAS_00029072		03; NREL; LFND; HRS; MIL
1006	APL-MAS_00067173	APL-MAS_00067175		03; NREL; LFND; HRS; MIL
1007	APL-MAS_00068732	APL-MAS_00068819		03; NREL; LFND; HRS; MIL
1008	APL-MAS_00089399	APL-MAS_00089569		03; NREL; LFND; HRS; MIL
1009	APL-MAS_00107160	APL-MAS_00107211		03; NREL; LFND; HRS; MIL
1010	APL-MAS_00169370	APL-MAS_00169371		03; NREL; LFND; HRS; MIL
1011	APL-MAS_00180415	APL-MAS_00180447		03; NREL; LFND; HRS; MIL
1012	APL-MAS_00180664	APL-MAS_00180679		03; NREL; LFND; HRS; MIL
1013	APL-MAS_00183242	APL-MAS_00183248		03; NREL; LFND; HRS
1014	APL-MAS_00197637	APL-MAS_00197657		03; NREL; LFND; HRS; MIL
1015	APL-MAS_00239728	APL-MAS_00239733		03; NREL; LFND; HRS; MIL

## Masimo's Trial Exhibit 680 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
1016	APL-MAS_00241367	APL-MAS_00241369		03; NREL; LFND; HRS; MIL
1017	APL-MAS_00290959	APL-MAS_00290962		03; NREL; LFND; HRS; MIL
1018	APL-MAS_00310721	APL-MAS_00310722		03; NREL; LFND; HRS; MIL
1019	APL-MAS_00360367	APL-MAS_00360368		03; NREL; LFND; HRS; MIL
1020	APL-MAS_00399304	APL-MAS_00399304		03; NREL; LFND; HRS; MIL
1021	APL-MAS_00413821	APL-MAS_00413837		03; NREL; LFND; HRS; MIL
1022	APL-MAS_00414570	APL-MAS_00414570		03; NREL; LFND; HRS; MIL
1023	APL-MAS_00414788	APL-MAS_00414793		03; NREL; LFND; HRS; MIL
1024	APL-MAS_00414846	APL-MAS_00414846		03; NREL; LFND; HRS; MIL
1025	APL-MAS_00414954	APL-MAS_00414955		03; NREL; LFND; HRS; MIL
1026	APL-MAS_00415008	APL-MAS_00415009		03; NREL; LFND; HRS; MIL
1027	APL-MAS_00415200	APL-MAS_00415201		03; NREL; LFND; HRS; MIL
1028	APL-MAS_00420607	APL-MAS_00420611		03; NREL; LFND; HRS; MIL
1029	APL-MAS_00433535	APL-MAS_00433538		03; NREL; LFND; HRS; MIL
1030	APL-MAS_00610772	APL-MAS_00610780		03; NREL; LFND; HRS
1031	APL-MAS_00826994	APL-MAS_00826997		03; NREL; LFND; HRS; MIL
1032	APL-MAS_01403427	APL-MAS_01403431		03; NREL; LFND; HRS; MIL
1033	APL-MAS_01847518	APL-MAS_01847528		03; NREL; LFND; HRS
1034	APL-MAS_01860875	APL-MAS_01860888		03; NREL; LFND; HRS; MIL
1035	APL-MAS_02292370	APL-MAS_02292456		03; NREL; LFND; HRS
1036	APL-MAS_02470121	APL-MAS_02470121		03; NREL; LFND; HRS

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
1037	APL-MAS_02489864	APL-MAS_02489865		03; NREL; LFND; HRS
1038	MASA00296750	MASA00296750		03; NREL; LFND; HRS; ATH; MIL
1039	MASA00533431	MASA00533431		03; NREL; LFND; HRS; ATH; INC
1040	MASA01812946	MASA01812948		03; NREL; LFND; HRS; ATH
1041	MASA03051352	MASA03051352		03; NREL; LFND; ATH; MIL
1042	APL-MAS_00804746	APL-MAS_00804800		03; NREL; LFND; HRS
1043	APL-MAS_00690233	APL-MAS_00690235		03; NREL; HRS; LFND; IDSCR
1044	APL-MAS_02503577	APL-MAS_02503581		03; NREL; HRS; LFND; IDSCR; MIL
1045	APL-MAS_00226719	APL-MAS_00226786		03; NREL; HRS; LFND; IDSCR
1046	APL-MAS_00242928	APL-MAS_00242930		03; NREL; HRS; LFND; IDSCR; MIL
1047	APL-MAS_01129091	APL-MAS_01129092		03; NREL; HRS; LFND; IDSCR
1048	APL-MAS_01873721	APL-MAS_01873728		03; NREL; HRS; LFND; IDSCR; MIL
1049				03; NREL; HRS; LFND; IDSCR
1050	APL-MAS_00185921	APL-MAS_00185948		03; NREL; HRS; LFND; IDSCR
1051	APL-MAS_01350536	APL-MAS_01350561		03; NREL; HRS; LFND; IDSCR
1052	APL-MAS_00350839	APL-MAS_00350853		03; NREL; HRS; LFND; IDSCR
1053	APL-MAS_00160964	APL-MAS_00161023		03; NREL; HRS; LFND; IDSCR




## Masimo's Trial Exhibit 68000 and Apple's Objections


DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
1054	APL-MAS_02370379	APL-MAS_02370391		3; NREL; HRS; LFND; IDSCR
1055	APL-MAS_00819226	APL-MAS_00819233		3; NREL; HRS; LFND; IDSCR
1056	MASA03600374	MASA03600453		3; NREL; HRS; LFND; IDSCR; ATH; MIL
1057	MASA03600696	MASA03600885		3; NREL; HRS; LFND; IDSCR; ATH; MIL
1058	MASA03600454	MASA03600695		3; NREL; HRS; LFND; IDSCR; ATH; MIL
1059	MOR_MAS_00004576	MOR_MAS_00004696		3; NREL; HRS; LFND; IDSCR; ATH; MIL
1060	MOR_APL_MAS_00000238	MOR_APL_MAS_00000358		3; NREL; HRS; LFND; IDSCR; MIL
1061	MOR_APL_MAS_00000663	MOR_APL_MAS_00000800		3; NREL; HRS; LFND; IDSCR; MIL
1062	MOR_APL_MAS_00000570	MOR_APL_MAS_00000640		3; NREL; HRS; LFND; IDSCR; MIL
1063	MOR_APL_MAS_00000641	MOR_APL_MAS_00000662		3; NREL; HRS; LFND; IDSCR; MIL
1064	MOR_APL_MAS_00000359	MOR_APL_MAS_00000431		3; NREL; HRS; LFND; IDSCR; MIL
1065	MOR_APL_MAS_00000174	MOR_APL_MAS_00000237		3; NREL; HRS; LFND; IDSCR; MIL
1066	MOR_APL_MAS_00000475	MOR_APL_MAS_00000569		3; NREL; HRS; LFND; IDSCR; MIL
1067	MOR_APL_MAS_00000001	MOR_APL_MAS_00000115		3; NREL; HRS; LFND; IDSCR; MIL
1068	MOR_APL_MAS_00000116	MOR_APL_MAS_00000173		3; NREL; HRS; LFND; IDSCR; MIL
1069	APL-MAS_00514479	APL-MAS_00514482		3; NREL; HRS; LFND; IDSCR; MIL
1070	APL-MAS_00534643	APL-MAS_00534645		3; NREL; HRS; LFND; IDSCR; MIL
1071	APL-MAS_02927989	APL-MAS_02927996		3; NREL; HRS; LFND; IDSCR; MIL
1072	APL-MAS_02927779	APL-MAS_02928095		3; NREL; HRS; LFND; IDSCR; MIL
1073	APL-MAS_00434182	APL-MAS_00434199		3; NREL; HRS; LFND; IDSCR; MIL
1074	APL-MAS_01831295	APL-MAS_01831295		3; NREL; HRS; LFND; IDSCR

## Masimo's Trial Exhibit 680 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
1075	APL-TW_00000010	APL-TW_00000013		03; NREL; HRS; LFND; IDSCR; ATH; NP; MIL
1076	APL-TW_00000439	APL-TW_00000440		03; NREL; HRS; LFND; IDSCR; ATH; NP; MIL
1077	APL-TW_00000535	APL-TW_00000538		03; NREL; HRS; LFND; IDSCR; ATH; NP; MIL
1078	APL-TW_00000956	APL-TW_00000957		03; NREL; HRS; LFND; IDSCR; ATH; NP; MIL
1079	APL-TW_00000414	APL-TW_00000414		03; NREL; HRS; LFND; IDSCR; ATH; NP; MIL
1080	APL-TW_00000325	APL-TW_00000326		03; NREL; HRS; LFND; IDSCR; ATH; NP; MIL
1081	APL-TW_00000164	APL-TW_00000166		03; NREL; HRS; LFND; IDSCR; ATH; NP; MIL
1082				03; NREL; HRS; LFND; NP; ATH
1083				03; NREL; HRS; LFND; NP; ATH
1084	MASA00086120	MASA00086339		03; NREL; HRS; LFND; IDSCR; ATH; MIL
1085				03; NREL; HRS; LFND; IDSCR; ATH; MIL
1086	MASA03578124	MASA03578129		03; NREL; HRS; LFND; IDSCR; ATH
1087	MASA03051351	MASA03051351		03; NREL; LFND; IDSCR; ATH; MIL
1088	MASA03051347	MASA03051347		03; NREL; LFND; IDSCR; ATH; MIL
1089	MASA00296733	MASA00296733		03; NREL; HRS; LFND; IDSCR; ATH
1090	MASA00369484	MASA00369484		03; NREL; HRS; LFND; IDSCR; ATH; MIL
1091	MASA03016371	MASA03016371		03; NREL; LFND; IDSCR; ATH
1092	MASA03602706	MASA03602708		03; NREL; HRS; LFND; IDSCR; ATH; MIL
1093	APL-MAS_01211705	APL-MAS_01211725		03; NREL; HRS; LFND; IDSCR
1094	APL-MAS_00431845	APL-MAS_00431860		03; NREL; HRS; LFND; IDSCR; MIL

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
1095	APL-MAS_00431849	APL-MAS_00431860		403; NREL; HRS; LFND; IDSCR
1096	APL-MAS_00115785	APL-MAS_00115828		403; NREL; HRS; LFND; IDSCR
1097	APL-MAS_01417628	APL-MAS_01417669		403; NREL; HRS; LFND; IDSCR
1098	APL-MAS_00082628	APL-MAS_00082671		403; NREL; HRS; LFND; IDSCR; MIL
1099	MASA03602777	MASA03602777		403; NREL; HRS; LFND; IDSCR; ATH; MIL
1100	MASA03602778	MASA03602790		403; NREL; HRS; LFND; IDSCR; ATH; MIL
1101	MASA03603300	MASA03603312		403; NREL; HRS; LFND; IDSCR; ATH; MIL
1102	MASA02171862	MASA02171914		403; NREL; HRS; LFND; IDSCR; ATH
1103	APL-MAS_00430063	APL-MAS_00430068		403; NREL; HRS; LFND; IDSCR; MIL
1104	APL-MAS_00796522	APL-MAS_00796601		403; NREL; HRS; LFND; IDSCR
1105	MASA03054594	MASA03054653		403; NREL; HRS; LFND; IDSCR; ATH; MIL
1106	MASA00026937	MASA00027024		403; NREL; HRS; LFND; IDSCR; ATH; MIL
1107	MASA02985549	MASA02985641		403; NREL; HRS; LFND; IDSCR; ATH
1108	APL-MAS_00058140	APL-MAS_00058157		403; NREL; HRS; LFND; IDSCR; MIL
1109	APL-MAS_00057677	APL-MAS_00057695		403; NREL; HRS; LFND; IDSCR; MIL
1110	APL-MAS_00058158	APL-MAS_00058174		403; NREL; HRS; LFND; IDSCR; MIL
1111	MASA00043812	MASA00043885		403; NREL; HRS; LFND; IDSCR; ATH; MIL
1112	APL-MAS_00058258	APL-MAS_00058274		403; NREL; HRS; LFND; IDSCR; MIL
1113	APL-MAS_01892427	APL-MAS_01892443		403; NREL; HRS; LFND; IDSCR; MIL
1114	MASA00021301	MASA00021380		403; NREL; HRS; LFND; IDSCR; ATH
1115	MASA00330784	MASA00330790		403; NREL; HRS; LFND; IDSCR; ATH

## Masimo's Trial Exhibit 68060 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
1116	MASA00081231	MASA00081272		03; NREL; HRS; LFND; IDSCR; ATH
1117	MASA11398453	MASA11398453		03; NREL; LFND; IDSCR; ATH; HRS
1118	MASA00264856	MASA00264874		03; NREL; HRS; LFND; IDSCR; ATH
1119				03; NREL; HRS; LFND; IDSCR; ATH
1120	MASA03581366	MASA03581462		03; NREL; HRS; LFND; IDSCR; ATH
1121				03; NREL; HRS; LFND; IDSCR; ATH
1122	MASA11076684	MASA11076691		03; NREL; HRS; LFND; IDSCR; ATH
1123				03; NREL; LFND
1124	APL-MAS_00158001	APL-MAS_00158264		03; NREL; HRS; LFND
1125	APL-MAS_01039202	APL-MAS_01039503		03; NREL; HRS; LFND
1126	APL-MAS_00156472	APL-MAS_00156732		03; NREL; HRS; LFND
1127	APL-MAS_00156208	APL-MAS_00156471		03; NREL; HRS; LFND
1128	APL-MAS_00157641	APL-MAS_00157905		03; NREL; HRS; LFND
1129	APL-MAS_00158265	APL-MAS_00158503		03; NREL; HRS; LFND
1130	APL-MAS_00158504	APL-MAS_00158638		03; NREL; HRS; LFND
1131	APL-MAS_00157906	APL-MAS_00158000		03; NREL; HRS; LFND
1132	APL-MAS_02491436	APL-MAS_02491438		03; NREL; HRS; LFND; IDSCR; MIL
1133	APL-MAS_00292884	APL-MAS_00292885		03; NREL; HRS; LFND; IDSCR; MIL
1134	APL-MAS_02589774	APL-MAS_02589789		03; NREL; HRS; LFND; IDSCR; MIL
1135	APL-MAS_00204513	APL-MAS_00204518		03; NREL; HRS; LFND; IDSCR

## Masimo's Trial Exhibit 680 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
1136	MASA10914881	MASA10914901	Apple Watch Series 6 Website from 12/28/2020 (S6211599-apple-watch-series-6-overview.PDF), MASA10914881-MASA10914901	403; NREL; HRS; LFND; IDSCR; ATH
1137	APL-MAS_01361869	APL-MAS_01361898		03; NREL; HRS; LFND; IDSCR
1138	APL-MAS_00520808	APL-MAS_00520811		03; NREL; HRS; LFND; IDSCR; MIL
1139	MASA03578444	MASA03578449		03; NREL; HRS; LFND; IDSCR; ATH
1140	MASA002745550	MASA002745585		03; NREL; HRS; LFND; IDSCR; ATH
1141	MASA00128581	MASA00128677		03; NREL; HRS; LFND; IDSCR; ATH; MIL
1142	MASA03256824	MASA03256827		03; NREL; HRS; LFND; IDSCR; ATH
1143	MLAMEGO0000061	MLAMEGO0000063		03; NREL; HRS; LFND; IDSCR; ATH; MIL
1144	APL-MAS_03042557	APL-MAS_03042568		03; NREL; HRS; LFND; IDSCR
1145	MASA03578462	MASA03578471		03; NREL; HRS; LFND; IDSCR; ATH
1146	MASA03578457	MASA03578461		03; NREL; HRS; LFND; IDSCR; ATH
1147	APL_MAS_ITC_00019129	APL_MAS_ITC_00019136		03; NREL; HRS; LFND; IDSCR
1148	APL_MAS_ITC_00310490	APL_MAS_ITC_00310918		03; NREL; HRS; LFND; IDSCR
1149	MASA00020042	MASA00020144		03; NREL; HRS; LFND; IDSCR; ATH
1150	APL-MAS_00058456	APL-MAS_00058724		03; NREL; HRS; LFND; IDSCR
1151	APL-MAS_00060227	APL-MAS_00060546		03; NREL; HRS; LFND; IDSCR
1152	APL-MAS_01892124	APL-MAS_01892426		03; NREL; HRS; LFND; IDSCR
1153	MASA03363837	MASA03363837		03; NREL; LFND; IDSCR; ATH
1154	MASA03373933	MASA03373933		03; NREL; LFND; IDSCR; ATH; MIL
1155	MASA03373934	MASA03373934		03; NREL; LFND; IDSCR; ATH; MIL
1156	MASA11373589	MASA11373602		03; NREL; HRS; LFND; IDSCR; ATH; INC

## Masimo's Trial Exhibit 68068 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
1157	APL-MAS_00359988	APL-MAS_00359990		03; NREL; HRS; LFND; IDSCR; ATH; MIL
1158	MASA00123202	MASA00123202		03; NREL; HRS; LFND; IDSCR; ATH; MIL
1159	MASA00131518	MASA00131565		03; NREL; HRS; LFND; IDSCR; ATH; MIL
1160	MASA00203107	MASA00203110		03; NREL; HRS; LFND; IDSCR; ATH; MIL
1161	MASA00204532	MASA00204544		03; NREL; HRS; LFND; IDSCR; ATH; MIL
1162	MASA01176896	MASA01176900		03; NREL; HRS; LFND; IDSCR; ATH; MIL
1163	MASA03374156	MASA03374157		03; NREL; HRS; LFND; IDSCR; ATH; MIL
1164	MASA11252687	MASA11252822		03; NREL; HRS; LFND; IDSCR; ATH
1165	MASA11199201	MASA11199203		03; NREL; HRS; LFND; IDSCR; ATH
1166	MASA02285105	MASA02285107		03; NREL; HRS; LFND; IDSCR; ATH
1167	APL_MAS_ITC_00295847	APL_MAS_ITC_00295875		03; NREL; HRS; LFND; IDSCR
1168	APL-MAS_00058093	APL-MAS_00058098		03; NREL; HRS; LFND; IDSCR; MIL
1169	MASA10915342	MASA10915346		03; NREL; HRS; LFND; IDSCR; ATH
1170	MASA03363011	MASA03363012		03; NREL; HRS; LFND; IDSCR; ATH; MIL
1171	MASA03352215	MASA03352215		03; NREL; HRS; LFND; IDSCR; ATH; DUP; CUM; MIL
1172	APL-MAS_02044086	APL-MAS_02044147		03; NREL; HRS; LFND; IDSCR; MIL
1173	APL-MAS_00060602	APL-MAS_00060606		03; NREL; HRS; LFND; IDSCR; MIL
1174	APL-MAS_00332212	APL-MAS_00332220		03; NREL; HRS; LFND; IDSCR; MIL
1175	APL-MAS_03042557	APL-MAS_03042568	Communication, Fitness and Health Capabilities, Apple Newsroom, 2010, APL-MAS_03042557-APL-MAS_03042568	403; NREL; HRS; LFND; IDSCR

## Masimo's Trial Exhibit 68069 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
1176	APL-MAS_02640367	APL-MAS_02640367	Apple reveals Apple Watch Series 7, featuring a larger, more advanced display, Sept. 14, 2021, APL-MAS_02640367-APL-MAS_02640379	403; NREL; HRS; LFND; IDSCR
1177	APL-MAS_026403	APL-MAS_02640357	Apple Watch Series 6 delivers breakthrough wellness and fitness capabilities, Sept. 15, 2020, APL-MAS_02640346-APL-MAS_02640357	403; NREL; HRS; LFND; IDSCR
1178	APL-MAS_03042106	APL-MAS_03042115	Healthcare - Apple Watch, Apple, APL-MAS_03042106-APL-MAS_03042115	403; NREL; HRS; LFND; IDSCR
1179	APL-MAS_00062423	APL-MAS_00062423	What you need to know about Apple Watch and the Blood Oxygen app , APL-MAS_00062423-APL-MAS_00062425	403; NREL; HRS; LFND; IDSCR
1180	APL-MAS_00062372	APL-MAS_00062372	What you need to know about Apple Watch, the ECG app, and health features , APL-MAS_00062372-APL-MAS_00062375	403; NREL; HRS; LFND; IDSCR
1181	APL-MAS_03059558	APL-MAS_03059558	Google search for broader precision diagnosis dataset, returning no results, APL-MAS_03059558-APL-MAS_03059558	403; NREL; HRS; LFND; IDSCR
1182	APL-MAS_0305955	APL-MAS_03059559	Google search for broader precision diagnosis, returning no results, APL-MAS_03059559-APL-MAS_03059559	403; NREL; HRS; LFND; IDSCR
1183	APL-MAS_02015530	APL-MAS_02015556	U.S. Patent Application Publication No. 2011/0237911 ("Lamego 2011"), APL-MAS_02015530-APL-MAS_02015556	403; NREL; HRS; LFND; IDSCR
1184	APL-MAS_01876137	APL-MAS_01876151		03; NREL; HRS; LFND; IDSCR; MIL
1185	APL-MAS_03053148	APL-MAS_03053149		03; NREL; HRS; LFND; IDSCR
1186	APL-MAS_03053260	APL-MAS_03053611		03; NREL; HRS; LFND; IDSCR
1187	APL-MAS_02055921	APL-MAS_02056012		03; NREL; HRS; LFND; IDSCR; MIL
1188	APL-MAS_00060557	APL-MAS_00060579		03; NREL; HRS; LFND; IDSCR; MIL
1189	APL-MAS_01831752	APL-MAS_01831753		03; NREL; HRS; LFND; IDSCR; MIL
1190	MASA002456175	MASA002456344		03; NREL; HRS; LFND; IDSCR; ATH; MIL
1191	APL-MAS_00060581	APL-MAS_00060586		03; NREL; HRS; LFND; IDSCR; MIL
1192	APL-MAS_02637515	APL-MAS_02637615		03; NREL; HRS; LFND
1193	APL-MAS_02638279	APL-MAS_02638478		03; NREL; HRS; LFND
1194	APL-MAS_02637863	APL-MAS_02638070		03; NREL; HRS; LFND

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
1195	APL-MAS_02909702	APL-MAS_02909949		03; NREL; HRS; LFND
1196	APL-MAS_02638071	APL-MAS_02638278		03; NREL; HRS; LFND
1197	APL-MAS_01842193	APL-MAS_01842195		03; NREL; HRS; LFND; IDSCR; MIL
1198	APL-MAS_03057674	APL-MAS_03057684		03; NREL; HRS; LFND; IDSCR; MIL
1199	APL-MAS_03056474	APL-MAS_03056537		03; NREL; HRS; LFND; IDSCR; MIL
1200	APL-MAS_03056172	APL-MAS_03056180		03; NREL; HRS; LFND; IDSCR
1201	APL-MAS_01366539	APL-MAS_01366555		03; NREL; HRS; LFND; IDSCR; MIL
1202	APL-MAS_01005947	APL-MAS_01005950		03; NREL; HRS; LFND; IDSCR; MIL
1203	APL-MAS_02600436	APL-MAS_02600465		03; NREL; HRS; LFND; IDSCR
1204	APL-MAS_01361068	APL-MAS_01361071		03; NREL; HRS; LFND; IDSCR; MIL
1205	APL-MAS_01440884	APL-MAS_01440894		03; NREL; HRS; LFND; IDSCR; MIL
1206	APL-MAS_00360015	APL-MAS_00360017		03; NREL; HRS; LFND; IDSCR; MIL
1207	APL-MAS_00233250	APL-MAS_00233251		03; NREL; HRS; LFND; IDSCR; MIL
1208	APL-MAS_01842235	APL-MAS_01842236		03; NREL; HRS; LFND; IDSCR; MIL
1209	APL-MAS_01011868	APL-MAS_01011911		03; NREL; HRS; LFND; IDSCR
1210				03; NREL; HRS; LFND; ATH; NP
1211				03; NREL; HRS; LFND; ATH; NP
1212	APL-MAS_03077337	APL-MAS_03077341		03; NREL; HRS; LFND; IDSCR; MIL
1213	MASA03581467	MASA03581467		03; NREL; HRS; LFND; IDSCR; ATH; MIL
1214	APL-MAS_03004638	APL-MAS_03004669		03; NREL; HRS; LFND; IDSCR; MIL
1215	APL-MAS_00700552	APL-MAS_00700561		03; NREL; HRS; LFND; IDSCR; MIL



## Masimo's Trial Exhibit 680 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
1216	APL-MAS_00158639	APL-MAS_00158802		403; NREL; HRS; LFND; IDSCR
1217	MASA00020042	MASA00020144		403; NREL; HRS; LFND; IDSCR; ATH
1218	MASA00020287	MASA00020297		403; NREL; HRS; LFND; IDSCR; ATH
1219	MASA00021301	MASA00021380		403; NREL; HRS; LFND; IDSCR; ATH
1220	MASA00021562			403; NREL; HRS; LFND; IDSCR; ATH
1221	MASA00203107	MASA00203110		403; NREL; HRS; LFND; ATH; MIL
1222	MASA002456175	MASA002456344		403; NREL; HRS; LFND; IDSCR; ATH; MIL
1223	MASA03352215	MASA03352215		403; NREL; HRS; LFND; IDSCR; ATH; DUP; CUM; MIL
1224	MASA03363837			403; NREL; LFND; IDSCR; ATH
1225	MASA03581366	MASA03581454		403; NREL; HRS; LFND; IDSCR; ATH; INC
1226	MASA11076684	MASA11076691		403; NREL; HRS; LFND; IDSCR; ATH
1227	MASA11108572	MASA11108637		403; NREL; HRS; LFND; IDSCR; ATH
1228	MASA11199201	MASA11199203		403; NREL; HRS; LFND; IDSCR; ATH
1229	MASA11252687	MASA11252822		403; NREL; HRS; LFND; IDSCR; ATH; DUP
1230			Delman	403; NREL; HRS; LFND; ATH; NE
1231			Appendix 2 to Delman Expert Report - Materials Considered	403; NREL; HRS; LFND; ATH; NE
1232	MASAD00020289	MASAD00020296	Application for United Kingdom Design Re. No. 4032616	403; NREL; HRS; LFND; ATH; NP
1233	MASAD00028874	MASAD00028881	Certified English Translation of Chinese Design Re. No. 302864470 ("CN-470")	403; NREL; HRS; LFND; ATH; NP
1234	MASAD00019072	MASAD00019135	Certified English Translation of Korean Pat. Appl. No. 102018-0038206 ("Chung-KR-Application")	403; NREL; HRS; LFND; ATH; NP
1235	MASAD00020245	MASAD00020248	Certified English Translation of Korean Registered Design No. 30-0645410 (Korean Reg. Design No. 30-0645410)	403; NREL; HRS; LFND; ATH; NP
1236	MASAD00020386	MASAD00020387	Chinese Design Reg. No. 302864470	403; NREL; HRS; LFND; IDSCR; ATH
1237			WITHDRAWN	
1238	MASAD00019150	MASAD00019153	Chinese Design Reg. No. 303285726	403; NREL; HRS; LFND; NP; ATH
1239	MASAD00019163	MASAD00019165	CN Design Reg. No. 304481666 ("CN-666")	403; NREL; HRS; LFND; NP; ATH
1240	APL_DEL00000001	APL_DEL000000161	Certified File History of the D735131 Patent	403; NREL; LFND
1241	APL_DEL000000162	APL_DEL000000454	Certified File History of the D883279 Patent	403; NREL; LFND
1242	APL_DEL000000455	APL_DEL000000835	Certified File History of the D947842 Patent	403; NREL; LFND
1243	APL_DEL000000836	APL_DEL000001216	Certified File History of the D962936 Patent	403; NREL; LFND
1244	MASAD00020259	MASAD00020270	GOV.UK Designs Journal Entry for Lee-616, <a href="https://www.registereddesign.service.gov.uk/view/2013/11/215">https://www.registereddesign.service.gov.uk/view/2013/11/215</a> (last visited Mar. 28, 2023)	403; NREL; HRS; LFND; ATH; IDSCR
1245	MASAD00019177	MASAD00019238	Korean Pat. Appl. No. 10-2018-0038206	403; NREL; HRS; LFND; ATH; IDSCR
1246	MASAD00020285	MASAD00020287	Korean Registered Design No. 30-0645410	403; NREL; HRS; LFND; ATH; IDSCR
1247	MASAD00018640	MASAD00018740	PCT Appl. Pub. No. WO 2017/165532 ("Paulke")	403; NREL; HRS; LFND; ATH; IDSCR
1248	APL_DEL00011033	APL_DEL0001166	provisional application 62/554,196 (the "'196 Application")	403; NREL; HRS; LFND; ATH; IDSCR
1249	APL_DEL00011127	APL_DEL00011233	provisional application 62/644,886 (the "'886 Application")	403; NREL; HRS; LFND; ATH; IDSCR

## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
1250	MASITC_01379393	MASITC_01379465	U.S. Pat. App. Pub. No. US2019/0072912 (the "'912 Publication")	403; NREL; HRS; LFND; ATH; IDSCR
1251	MASAD00020297	MASAD00020304	U.S. Pat. Appl. Pub. No. 2014/0104999 ("999 Pat. Appl. Pub.")	403; NREL; HRS; LFND; ATH; IDSCR
1252	MASAD00020305	MASAD00020311	U.S. Pat. Appl. Pub. No. 2014/0117926 ("926 Pat. Appl. Pub.")	403; NREL; HRS; LFND; ATH; IDSCR
1253	MASAD00020305	MASAD00020311	U.S. Pat. Appl. Pub. No. 2014/0117926 ("926 Pat. Appl. Pub.")	403; NREL; HRS; LFND; ATH
1254	MASAD00019386	MASAD00019403	U.S. Pat. Appl. Pub. No. 2017/0086743 ("Bushnell")	403; NREL; HRS; LFND; ATH; IDSCR
1255	MASAD00035606	MASAD00035632	U.S. Pat. Appl. Pub. No. 2017/0325744 ("744 Pat. Appl. Pub.")	403; NREL; HRS; LFND; ATH; IDSCR
1256	MASAD00019433	MASAD00019451	U.S. Pat. Appl. Pub. No. 2019/0196411 ("Yuen")	403; NREL; HRS; LFND; ATH; IDSCR
1257	MASAD00019452	MASAD00019479	U.S. Pat. Appl. Pub. No. 2019/0324593 ("Chung")	403; NREL; HRS; LFND; ATH; NP
1258			U.S. Pat. Appl. Pub. No. 2019/0101870	403; NREL; HRS; LFND; ATH; IDSCR
1259			U.S. Pat. Appl. Pub. No. 2020/0229761	403; NREL; HRS; LFND; ATH; IDSCR
1260	MASAD00019689	MASAD00019760	U.S. Pat. No. 10,610,157 ("157 Patent")	403; NREL; HRS; LFND; ATH; IDSCR
1261	MASAD00019303	MASAD00019364	U.S. Pat. No. 10,627,783 ("783 Patent")	403; NREL; HRS; LFND; ATH; IDSCR
1262			Certified U.S. Pat. No. 10,912,501 ("501 Patent")	403; NREL; HRS; LFND; ATH; IDSCR; MIL
1263	MASITC_0162520	MASITC_0162629	U.S. Pat. No. 10,912,502	403; NREL; HRS; LFND; ATH; IDSCR; MIL
1264	MASAD00028261	MASAD00028371	Certified U.S. Pat. No. 10,945,648	403; NREL; HRS; LFND; ATH; IDSCR; MIL
1265	APL_DEL00008353	APL_DEL00008426	Certified U.S. Pat. No. 10,987,054 (the "'054 Patent")	403; NREL; HRS; LFND; ATH; IDSCR
1266	APL_DEL00003613	APL_DEL00003685	U.S. Pat. No. 11,432,766 ("766 Patent")	403; NREL; HRS; LFND; ATH; IDSCR
1267	MASAD00018216	MASAD00018241	U.S. Pat. No. 6,265,789 ("Honda")	403; NREL; HRS; LFND; ATH; IDSCR
1268	MASAD00019480	MASAD00019495	U.S. Pat. No. 6,801,799 ("Mendelson")	403; NREL; HRS; LFND; ATH; IDSCR
1269	MASAD00020312	MASAD00020325	U.S. Pat. No. 9,460,846 ("846 Patent")	403; NREL; HRS; LFND; ATH; IDSCR
1270	MASAD00020326	MASAD00020332	U.S. Pat. No. D620,884 ("D'884 Patent")	403; NREL; HRS; LFND; ATH; IDSCR
1271	MASAD00020333	MASAD00020343	U.S. Pat. No. D645,818 ("D'818 Patent")	403; NREL; HRS; LFND; ATH; IDSCR
1272	MASAD00020344	MASAD00020348	U.S. Pat. No. D694,182 ("D'182 Patent")	403; NREL; HRS; LFND; ATH; IDSCR
1273	MASAD00020349	MASAD00020354	U.S. Pat. No. D697,027 ("D'027 Patent")	403; NREL; HRS; LFND; ATH; IDSCR
1274	MASAD00020355	MASAD00020362	U.S. Pat. No. D704,634 ("D'634 Patent")	403; NREL; HRS; LFND; ATH; IDSCR
1275	MASAD00020363	MASAD00020369	U.S. Pat. No. D718,233 ("D'233 Patent")	403; NREL; HRS; LFND; ATH; IDSCR
1276	MASAD00020376	MASAD00020379	U.S. Pat. No. D718,236 ("Murray")	403; NREL; HRS; LFND; ATH; IDSCR
1277	MASAD00020370	MASAD00020375	U.S. Pat. No. D718,324 ("D'324 Patent")	403; NREL; HRS; LFND; ATH; IDSCR
1278	MASAD00020380	MASAD00020385	U.S. Pat. No. D720,289 ("Chiang")	403; NREL; HRS; LFND; ATH; IDSCR
1279	APL_DEL00002505	APL_DEL00002513	Certified U.S. Pat. No. D735,131 ("the '131 patent")	403; NREL; HRS; LFND
1280	MASAD00019496	MASAD00019504	U.S. Pat. No. D753,510 ("510 Patent")	403; NREL; HRS; LFND; ATH; IDSCR
1281	MASAD00019505	MASAD00019514	U.S. Pat. No. D782,537	403; NREL; HRS; LFND; ATH; IDSCR
1282	MASAD00019515	MASAD00019523	U.S. Pat. No. D816,524 ("Akana-524")	403; NREL; HRS; LFND; ATH; IDSCR
1283	MASAD00019524	MASAD00019527	U.S. Pat. No. D827,831 ("Fong")	403; NREL; HRS; LFND; ATH; IDSCR
1284	APL_DEL00002564	APL_DEL00002575	Certified U.S. Pat. No. D883,279 ("D'279 Patent")	DUP; 403; NREL; HRS; LFND
1285	APL_DEL00002576	APL_DEL00002586	Certified U.S. Pat. No. D947,842 ("D'842 Patent")	DUP; 403; NREL; HRS; LFND
1286	APL_DEL00002587	APL_DEL00002597	Certified U.S. Pat. No. D962,936 ("D'936 Patent")	DUP; 403; NREL; HRS; LFND
1287			U.S. Pat. Appl. No. 16/118,282 (the "'282 Application")	403; NREL; HRS; LFND; ATH; IDSCR
1288			U.S. Pat. Appl. No. 16/193,836 (the "'836 Application")	403; NREL; HRS; LFND; ATH; IDSCR
1289			U.S. Pat. Appl. No. 16/841,543	403; NREL; HRS; LFND; ATH; IDSCR
1290			U.S. Pat. Appl. No. 29/684,822 (the "'822 Application")	403; NREL; HRS; LFND; ATH; IDSCR

## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
1291	MASAD00020240	MASAD00020244	United Kingdom Design Reg. No. 4032616, <a href="https://www.registereddesign.service.gov.uk/find/4032616">https://www.registereddesign.service.gov.uk/find/4032616</a> (last visited Mar. 28, 2023) ("Lee-616")	403; NREL; HRS; LFND; ATH; IDSCR
1292	MASAD00020386	MASAD00020387	WIPO Global Design Database Entry for Chinese Design Reg. No. 302864470	403; NREL; HRS; LFND; ATH; IDSCR
1293	MASAD00019166	MASAD00019176	Konig et al., Reflectance Pulse Oximetry – Principles and Obstetric Application in the Zurich System, 1998 ("Konig")	403; NREL; HRS; LFND; ATH; IDSCR
1294	MASAD00019787	MASAD00019809	N. Meziane et al., Dry Electrodes for Electrocardiography, Physiological Measurement 34 (2013)	403; NREL; HRS; LFND; ATH; IDSCR
1295	MASAD00019299	MASAD00019302	Y. Mendelson et al., "Measurement Site and Photodetector Size Considerations in Optimizing Power Consumption of a Wearable Reflectance Pulse Oximeter," Proceedings of the 25th IEEE Conference (2003)	403; NREL; HRS; LFND; ATH; IDSCR
1296	MASAD00019267	MASAD00019298	Yitzhak Mendelson, Invasive and Noninvasive Blood Gas Monitoring, 1991 ("Mendelson-1991")	403; NREL; HRS; LFND; ATH; IDSCR
1297	MASAD00019819	MASAD00019822	"Apple Unveils Apple Watch—Apple's Most Personal Device Ever," <a href="https://www.apple.com/newsroom/2014/09/09Apple-Unveils-Apple-Watch-Apples-Most-Personal-Device-Ever/">https://www.apple.com/newsroom/2014/09/09Apple-Unveils-Apple-Watch-Apples-Most-Personal-Device-Ever/</a> (last visited Mar. 31, 2023) ("Apple Unveils Apple Watch")	403; NREL; HRS; LFND; ATH; IDSCR
1298	MASAD00639191	MASAD00639200	"Apple Watch – Technology," archived on September 11, 2014 by the Internet Organization's "Wayback Machine" at <a href="https://web.archive.org/web/20140911003437/http://www.apple.com/watch/technology/">https://web.archive.org/web/20140911003437/http://www.apple.com/watch/technology/</a>	403; NREL; HRS; LFND; ATH; IDSCR
1299			"Apple Watch Magnetic Charging Cable (1 m)," <a href="https://www.apple.com/shop/product/MX2E2AM/A/apple-watch-magnetic-charging-cable-1m">https://www.apple.com/shop/product/MX2E2AM/A/apple-watch-magnetic-charging-cable-1m</a> (last visited Mar. 6, 2023) ("Apple Watch Magnetic Charging Cable (1 m)")	403; NREL; HRS; LFND; ATH; IDSCR
1300	MASAD00639201	MASAD00639212	"Apple Watch Series 4 – Health," archived on September 20, 2018 by the Internet Organization's "Wayback Machine" at <a href="https://web.archive.org/web/20180920103403/https://www.apple.com/apple-watch-series-4/health/">https://web.archive.org/web/20180920103403/https://www.apple.com/apple-watch-series-4/health/</a> ("Apple Watch Series 4 – Health")	403; NREL; HRS; LFND; ATH; IDSCR
1301	MASAD00019668	MASAD00019681	"Apple Watch Series 4 Teardown," <a href="https://www.ifixit.com/Teardown/Apple+Watch+Series+4+Teardown/113044">https://www.ifixit.com/Teardown/Apple+Watch+Series+4+Teardown/113044</a> (last visited Mar. 6, 2023) ("Apple Watch Series 4 Teardown")	403; NREL; HRS; LFND; ATH; IDSCR
1302	MASAD00639213	MASAD00639223	"Apple Watch Series 4: Beautifully redesigned with breakthrough communication, fitness and health capabilities," archived on September 12, 2018 by the Internet Organization's "Wayback Machine" at <a href="https://web.archive.org/web/20180912191250/https://www.apple.com/newsroom/2018/09/redesigned-apple-watch-series-4-revolutionizes-communication-fitness-andhealth/">https://web.archive.org/web/20180912191250/https://www.apple.com/newsroom/2018/09/redesigned-apple-watch-series-4-revolutionizes-communication-fitness-andhealth/</a> ("Apple Watch Series 4: Beautifully redesigned")	403; NREL; HRS; LFND; ATH; IDSCR

## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
1303	MASAD00032207	MASAD00032226	"Apple Watch Teardown – iFixit," <a href="https://www.ifixit.com/Teardown/Apple+Watch+Teardown/40655">https://www.ifixit.com/Teardown/Apple+Watch+Teardown/40655</a> (last visited Apr. 3, 2023)	403; NREL; HRS; LFND; ATH; IDSCR
1304	APL_MAS_00000081	APL_MAS_00000084	"Charge Apple Watch," <a href="https://support.apple.com/guide/watch/charge-apple-watchapd2b717523a/watchos">https://support.apple.com/guide/watch/charge-apple-watchapd2b717523a/watchos</a> (last visited Mar. 6, 2023) ("Charge Apple Watch")	403; NREL; HRS; LFND; ATH; IDSCR
1305	MASAD00639270	MASAD00639273	"Your heart rate. What it means, and where on Apple Watch you'll find it," archived on January 23, 2019 by the Internet Organization's "Wayback Machine" at <a href="https://web.archive.org/web/20190123031906/https://support.apple.com/en-us/HT204666">https://web.archive.org/web/20190123031906/https://support.apple.com/en-us/HT204666</a> ("Your heart rate. What it means")	403; NREL; HRS; LFND; ATH; IDSCR
1306			Copy of YouTube Video titled "GMYLE(R) Qi Wireless Charger Review (Nexus 5)," <a href="https://www.youtube.com/watch?v=EvJ4Jkvj_R8">https://www.youtube.com/watch?v=EvJ4Jkvj_R8</a> (last visited Mar. 28, 2023) ("GMYLE Charger YouTube")	403; NREL; HRS; LFND; ATH; IDSCR; MIS
1307	MASAD00019629	MASAD00019651	<a href="https://web.archive.org/web/20161008160451/https://www.ifixit.com/Teardown/Apple+Watch+Series+2+Teardown/67385">https://web.archive.org/web/20161008160451/https://www.ifixit.com/Teardown/Apple+Watch+Series+2+Teardown/67385</a>	403; NREL; HRS; LFND; ATH; IDSCR
1308	MASAD00019652	MASAD00019667	<a href="https://web.archive.org/web/20230418082322/https://www.ifixit.com/Teardown/Apple+Watch+Series+3+Teardown/97521">https://web.archive.org/web/20230418082322/https://www.ifixit.com/Teardown/Apple+Watch+Series+3+Teardown/97521</a>	403; NREL; HRS; LFND; ATH; IDSCR
1309	MASAD00019810	MASAD00019818	<a href="https://www.apple.com/newsroom/2016/09/apple-introduces-apple-watch-series-2/">https://www.apple.com/newsroom/2016/09/apple-introduces-apple-watch-series-2/</a>	403; NREL; HRS; LFND; ATH; IDSCR
1310	MASAD00019823	MASAD00019833	<a href="https://www.apple.com/newsroom/2017/09/apple-watch-series-3-features-built-incellular-and-more/">https://www.apple.com/newsroom/2017/09/apple-watch-series-3-features-built-incellular-and-more/</a>	403; NREL; HRS; LFND; ATH; IDSCR
1311			K192415 510(k) Summary for Verily Study Watch, <a href="https://www.accessdata.fda.gov/cdrh_docs/pdf19/K192415.pdf">https://www.accessdata.fda.gov/cdrh_docs/pdf19/K192415.pdf</a> (last visited Mar. 6, 2023)	403; NREL; HRS; LFND; ATH; NP
1312	MASAD00020414	MASAD00020415	etnews SPS Develops new Concept Smartphaone Charging technology 2012-112-22	403; NREL; HRS; LFND; ATH; IDSCR
1313			WITHDRAWN	
1314	MASAD00019065	MASAD00019071	Scott Jung, "Medgadget Joins the Verily Baseline Project Study, Part 2: The Tech," archived on October 27, 2017 by the Internet Organization's "Wayback Machine" at <a href="https://web.archive.org/web/20171027221742/https://www.medgadget.com/2017/10/medgadget-joins-verily-baseline-project-study-part-2-tech.html">https://web.archive.org/web/20171027221742/https://www.medgadget.com/2017/10/medgadget-joins-verily-baseline-project-study-part-2-tech.html</a> ("Medgadget Joins the Verily Baseline Project Study")	403; NREL; HRS; LFND; ATH; IDSCR
1315			Screenshot of <a href="https://www.youtube.com/watch?v=EvJ4Jkvj_R8">https://www.youtube.com/watch?v=EvJ4Jkvj_R8</a> (last visited Mar. 28, 2013)	403; NREL; HRS; LFND; ATH; NP
1316	MASAD00020072	MASAD00020077	Introducing Verily Study Watch 04/14/2017	403; NREL; HRS; LFND; ATH; IDSCR
1317			Appendix 3 to Delman Rebuttal Report - images of the Original Electrode Design and Wave Electrode Design	403; NREL; HRS; LFND; ATH
1318	APL_DEL00967760	APL_DEL00967838	[REDACTED]	403; NREL; HRS; LFND

## Masimo's Trial Exhibit 680-75 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
1319	MASA00159626	MASA00159626	WITHDRAWN	
1320	MASAD92496985	MASAD92496985		403; NREL; HRS; LFND; ATH; MIS
1321			WITHDRAWN	
1322			WITHDRAWN	
1323			WITHDRAWN	
1324			WITHDRAWN	
1325			WITHDRAWN	
1326			WITHDRAWN	
1327			WITHDRAWN	
1328			WITHDRAWN	
1329			WITHDRAWN	
1330			WITHDRAWN	
1331			WITHDRAWN	
1332	MASAD00033755	MASAD00033818		403; NREL; HRS; LFND; ATH
1333	MASAD00050104	MASAD00050105		403; NREL; HRS; LFND; ATH
1334	MASAD00104824	MASAD00104833		403; NREL; HRS; LFND; ATH
1335	MASAD00105249	MASAD00105261		403; NREL; HRS; LFND; ATH
1336	MASAD00178816	MASAD00178830		403; NREL; HRS; LFND; ATH
1337	MASAD00234625	MASAD00234629		403; NREL; HRS; LFND; ATH
1338	MASAD00237401	MASAD00237401		403; NREL; HRS; LFND; IDSCR; ATH
1339			U.S. Patent Application 14/310,694	403; NREL; HRS; LFND; ATH; IDSCR
1340			U.S. Patent Publication No. 2015/0371768	403; NREL; HRS; LFND; ATH; IDSCR
1341			U.S. Patent Application 29/654,754	403; NREL; HRS; LFND; ATH; IDSCR
1342			U.S. Patent App. No. 29/816,024	403; NREL; HRS; LFND; ATH; IDSCR
1343			U.S. Patent App. No. 29/816,025	403; NREL; HRS; LFND; ATH; IDSCR
1344			U.S. Patent App. No. 29/498,998	403; NREL; HRS; LFND; ATH; IDSCR
1345			D131 Drawings (High Resolution)	403; NREL; HRS; LFND; ATH; IDSCR
1346			D279 Drawings (High Resolution)	403; NREL; HRS; LFND; ATH; IDSCR
1347			D842 Drawings (High Resolution)	403; NREL; HRS; LFND; ATH; IDSCR
1348			D936 Drawings (High Resolution)	403; NREL; HRS; LFND; ATH; IDSCR
1349			Original Apple Design Patent Figures (High Resolution)	403; NREL; HRS; LFND; ATH; IDSCR
1350			U.S. Patent D883,279 (High Resolution)	403; NREL; HRS; LFND; ATH; IDSCR
1351			U.S. Patent D947,842 (High Resolution)	403; NREL; HRS; LFND; ATH; IDSCR
1352			U.S. Patent D962,936 (High Resolution)	403; NREL; HRS; LFND; ATH; IDSCR
1353			Photograph of Series 6 Back Crystal	403; NREL; LFND; ATH; NP
1354			Photograph of Ultra Back Crystal	403; NREL; LFND; ATH; NP
1355			Photograph of Ultra 2 Back Crystal	403; NREL; LFND; ATH; NP
1356			Masimo Corp. v. Apple Inc. , IPR2023-00702, Patent Owner's Preliminary Response for '842 Patent (PTAB June 29, 2023)	403; NREL; HRS; LFND; ATH; NE
1357			Masimo Corp. v. Apple Inc. , IPR2023-00728, Patent Owner's Preliminary Response for '936 Patent (PTAB June 21, 2023)	403; NREL; HRS; LFND; ATH; NE

## Masimo's Trial Exhibit 680-70 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
1358			<i>Masimo Corp. v. Apple Inc.</i> , IPR2023-00774, Patent Owner's Preliminary Response for '279 Patent (PTAB July 12, 2023)	403; NREL; HRS; LFND; ATH; NE
1359			<i>Masimo Corp. v. Apple Inc.</i> , IPR2023-00774, Decision Denying Institution of <i>Inter Partes</i> Review for '279 Patent (PTAB Sept. 27, 2023)	403; NREL; HRS; LFND; ATH; NE
1360			<i>Masimo Corp. v. Apple Inc.</i> , IPR2023-00702, Decision Denying Institution of <i>Inter Partes</i> Review for '842 Patent (PTAB Sept. 27, 2023)	403; NREL; HRS; LFND; ATH; NE
1361			<i>Masimo Corp. v. Apple Inc.</i> , IPR2023-00728, Decision Denying Institution of <i>Inter Partes</i> Review for '936 Patent (PTAB Sept. 18, 2023)	403; NREL; HRS; LFND; ATH; NE
1362			<i>Masimo Corp. v. Apple Inc.</i> , IPR2023-00831, Patent Owner's Preliminary Response for '131 Patent (PTAB Aug. 24, 2023)	403; NREL; HRS; LFND; ATH; NE
1363			<i>Masimo Corp. v. Apple Inc.</i> , IPR2023-00831, Decision Denying Institution of <i>Inter Partes</i> Review for '131 Patent (PTAB Nov. 21, 2023)	403; NREL; HRS; LFND; ATH; NE
1364	APL_DELO24109009	APL_DELO24109020		403; NREL; LFND
1365	APL-MAS_00180807	APL-MAS_00180814		403; NREL; LFND
1366	APL-MAS_00180882	APL-MAS_00180891		403; NREL; LFND
1367	APL-MAS_00181712	APL-MAS_00181721		403; NREL; LFND
1368	APL-MAS_00438410	APL-MAS_00438413		403; NREL; LFND
1369	APL-MAS_00593043	APL-MAS_00593046		403; NREL; LFND
1370	APL-MAS_00593427	APL-MAS_00593430		403; NREL; LFND
1371	APL-MAS_01152970	APL-MAS_01152975		403; NREL; LFND
1372	APL-MAS_01161518	APL-MAS_01161521		403; NREL; LFND
1373	APL-MAS_01326592	APL-MAS_01326595		403; NREL; LFND
1374				403; ID; ATH; NP; LFND; MIS; ILLEG
1375			Photograph of the Apple Watch Series 5 with a band	403; ID; ATH; NP; LFND; MIS; ILLEG
1376			Photograph of the Masimo watch with the original electrode design gold electrodes	403; ID; ATH; NP; LFND; MIS; ILLEG
1377			Photograph of the Masimo watch with the wave electrode design silver electrodes	403; ID; ATH; NP; LFND; MIS; ILLEG
1378			Photograph of the Masimo watch with the original electrode design silver electrodes	403; ID; ATH; NP; LFND; MIS; ILLEG

**Masimo's Trial Exhibit List and Apple's Objections**

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
1379			Printout of USPTO website re Design Patent Application Guide on Jan. 31, 2024	403; ATH; HRS; ID; LFND; NE; NP; NREL; MM
1380			US Provisional Patent Application No. 62/644886	403; ATH; LFND; NREL; MM
1381			Excerpts of December 1, 2021 Expert Report of Alan Ball in Think Green Limited d/b/a/ Haakaa v. Medela AG, No. 1:21-cv-05445 (N.D. Ill.)	403; ATH; HRS; INC; LFND; LA; MIS; NE; NP; NREL; MM
1382			December 1, 2021 Expert Report of Alan Ball in Think Green Limited d/b/a/ Haakaa v. Medela AG, No. 1:21-cv-05445 (N.D. Ill.)	403; ATH; HRS; INC; LFND; LA; MIS; NE; NP; NREL; MM
1383			Jan. 22, 2016 Rebuttal Decl. of Alan Ball in Dyson v. SharkNinja	403; ATH; HRS; INC; LFND; LA; MIS; NE; NP; NREL; MM
1384			Ball Depo. Tr. Think Green Limited dba Haakaa v. Medela AG, No. 21-cv-05445 (N.D. Ill.)	403; ATH; HRS; INC; LFND; LA; MIS; NE; NP; NREL; MM
1385			Expert Rebuttal Report of Shirley Webster dated November 17, 2022, No. 8:20-cv-00048 (C.D. Cal.)	403; ATH; HRS; INC; LFND; LA; MIS; NE; NP; NREL; MM; MIL
1386			Expert Rebuttal Report of Majid Sarrafzadeh dated November 4, 2022, No. 8:20-cv-00048 (C.D. Cal.)	403; ATH; HRS; INC; LFND; LA; MIS; NE; NP; NREL; MM; MIL
1387	MASAD04145299	MASAD04145299	Photograph of Masimo charger, produced as MASAD04145299	403; ATH; IDSCR; ID; LFND; NREL; NP
1388	MASAD04145300	MASAD04145300	Photograph of Masimo charger, produced as MASAD04145300	403; ATH; IDSCR; ID; LFND; NREL; NP
1389	MASAD04145301	MASAD04145301	Photograph of Masimo charger, produced as MASAD04145301	403; ATH; IDSCR; ID; LFND; NREL; NP
1390	MASAD04145302	MASAD04145302	Photograph of Masimo charger, produced as MASAD04145302	403; ATH; IDSCR; ID; LFND; NREL; NP
1391	MASAD04145303	MASAD04145303	Photograph of Masimo charger, produced as MASAD04145303	403; ATH; IDSCR; ID; LFND; NREL; NP
1392	MASAD04145304	MASAD04145304	Photograph of Masimo charger, produced as MASAD04145304	403; ATH; IDSCR; ID; LFND; NREL; NP
1393	MASAD04145305	MASAD04145305	Photograph of Masimo Freedom with the Original Electrode Design, produced as MASAD04145305	403; ATH; IDSCR; ID; LFND; NREL; NP
1394	MASAD04145306	MASAD04145306	Photograph of Masimo Freedom with the Original Electrode Design, produced as MASAD04145306	403; ATH; IDSCR; ID; LFND; NREL; NP
1395	MASAD04145307	MASAD04145307	Photograph of Masimo Freedom with the Original Electrode Design, produced as MASAD04145307	403; ATH; IDSCR; ID; LFND; NREL; NP
1396	MASAD04145308	MASAD04145308	Photograph of Masimo Freedom with the Original Electrode Design, produced as MASAD04145308	403; ATH; IDSCR; ID; LFND; NREL; NP
1397	MASAD04145309	MASAD04145309	Photograph of Masimo Freedom with the Original Electrode Design, produced as MASAD04145309	403; ATH; IDSCR; ID; LFND; NREL; NP
1398	MASAD04145310	MASAD04145310	Photograph of Masimo Freedom with the Original Electrode Design, produced as MASAD04145310	403; ATH; IDSCR; ID; LFND; NREL; NP
1399	MASAD04145311	MASAD04145311	Photograph of Masimo Freedom with the Original Electrode Design, produced as MASAD04145311	403; ATH; IDSCR; ID; LFND; NREL; NP
1400	MASAD04145312	MASAD04145312	Photograph of Masimo Freedom with the Original Electrode Design, produced as MASAD04145312	403; ATH; IDSCR; ID; LFND; NREL; NP
1401	MASAD04145313	MASAD04145313	Photograph of Masimo Health Module with the Original Electrode Design, produced as MASAD04145313	403; ATH; IDSCR; ID; LFND; NREL; NP

## Masimo's Trial Exhibit 680-78 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
1402	MASAD04145314	MASAD04145314	Photograph of Masimo Health Module with the Original Electrode Design, produced as MASAD04145314	403; ATH; IDSCR; ID; LFND; NREL; NP
1403	MASAD04145315	MASAD04145315	Photograph of Masimo W1 with the Original Electrode Design, produced as MASAD04145315	403; ATH; IDSCR; ID; LFND; NREL; NP
1404	MASAD04145316	MASAD04145316	Photograph of Masimo W1 with the Original Electrode Design, produced as MASAD04145316	403; ATH; IDSCR; ID; LFND; NREL; NP
1405	MASAD04145317	MASAD04145317	Photograph of Masimo W1 with the Original Electrode Design, produced as MASAD04145317	403; ATH; IDSCR; ID; LFND; NREL; NP
1406	MASAD04145318	MASAD04145318	Photograph of Masimo W1 with the Original Electrode Design, produced as MASAD04145318	403; ATH; IDSCR; ID; LFND; NREL; NP
1407	MASAD04145319	MASAD04145319	Photograph of Masimo W1 with the Original Electrode Design, produced as MASAD04145319	403; ATH; IDSCR; ID; LFND; NREL; NP
1408	MASAD04145320	MASAD04145320	Photograph of Masimo W1 with the Original Electrode Design, produced as MASAD04145320	403; ATH; IDSCR; ID; LFND; NREL; NP
1409	MASAD04145321	MASAD04145321	Photograph of Masimo W1 with the Original Electrode Design, produced as MASAD04145321	403; ATH; IDSCR; ID; LFND; NREL; NP
1410	MASAD04145322	MASAD04145322	Photograph of Masimo W1 with the Original Electrode Design, produced as MASAD04145322	403; ATH; IDSCR; ID; LFND; NREL; NP
1411	MASAD04145323	MASAD04145323	Photograph of Masimo W1 with the Original Electrode Design, produced as MASAD04145323	403; ATH; IDSCR; ID; LFND; NREL; NP
1412			Photograph of Apple Watch Series 5 on Ex. A-2, p.3 of Apple's Final Infringement Contentions in C.A. No. 22-1377, dated August 17, 2023	403; ATH; IEXP; IDSCR; ID; INC; LFND; MIS; MD; CMP; NE; NREL; NOID
1413	APL_MAS_ITC_00019137	APL_MAS_ITC_00019144		03; IDSCR; LFND; NREL
1414	MASAD00081555	MASAD00081560		03; ATH; HRS; LFND
1415	MASAD03459535	MASAD03459536		03; ATH; HRS; LFND; NREL
1416	MASA00159626	MASA00159626		03; NREL; ATH; HRS; LFND; INC; WTH
1417	MASA00159627	MASA00159627		03; HRS; INC;
1418	MASA03082690	MASA03082693		03; ATH; HRS; LFND; NREL
1419	MASA03090946	MASA03090947		03; ATH; HRS; LFND; NREL
1420	MASA03091047	MASA03091050		03; ATH; HRS; LFND; NREL
1421	MASA03103446	MASA03103447		03; ATH; HRS; LFND; NREL
1422	MASA03109102	MASA03109102		RS



## Masimo's Trial Exhibit 680 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
1423	MASA03114314	MASA03114315		HRS; INC
1424	MASA03114330	MASA03114331		HRS
1425	MASAD00457179	MASAD00457181		HRS
1426	MASITC_00919646	MASITC_00919646		03; ATH; HRS; LFND
1427	MASITC_01378120	MASITC_01378120		03; ATH; HRS; IEXP; 1006; IDSCR; ID; INC; LFND; MD; CMP; NREL
1428	MASITC_01379391	MASITC_01379391		HRS
1429				
1430			U.S. Patent No. D882,563	403; LFND; NP; NREL
1431			U.S. Patent No. D882,566	403; LFND; NP; NREL
1432			U.S. Patent No. D949,145	403; LFND; NP; NREL
1433			U.S. Patent No. D949,146	403; LFND; NP; NREL
1434			U.S. Patent No. D962,933	403; LFND; NP; NREL
1435			U.S. Patent No. D962,937	403; LFND; NP; NREL
1436			U.S. Patent No. D947,841	DUP; 403; LFND; NP; NREL
1437			U.S. Patent No. D962,934	403; LFND; NP; NREL
1438			U.S. Patent No. D949,144	403; LFND; NP; NREL
1439			U.S. Patent No. D882,565	403; LFND; NP; NREL
1440			U.S. Patent No. D917,470	403; LFND; NP; NREL
1441	MASAD00043943	MASAD00044204	U.S. Patent No. D962,935	403; LFND; NP; NREL
1442	MASITC_00343919	MASITC_00343922		S
1443	MASITC_00344655	MASITC_00344658		3; ATH; HRS; LFND; NREL
1444	MASITC_00344660	MASITC_00344661		3; ATH; HRS; LFND; NREL
1445	MASITC_00344706	MASITC_00344711		3; ATH; HRS; LFND; NREL
1446	MASITC_00344727	MASITC_00344727		3; ATH; HRS; LFND; MD; NREL
1447	MASITC_00345388	MASITC_00345389		3; ATH; HRS; LFND; MD; NREL
1448	MASITC_00345553	MASITC_00345556		3; ATH; HRS; LFND; MD; NREL
1449	MASITC_00345596	MASITC_00345607		3; ATH; HRS; LFND; MD; NREL
1450	MASITC_00345625	MASITC_00345643		S
1451	MASITC_00414063	MASITC_00414070		3; ATH; HRS; LFND; NREL
1452	MASITC_00414105	MASITC_00414109		3; ATH; HRS; LFND; NREL
1453	MASITC_00414188	MASITC_00414191		3; ATH; HRS; LFND; NREL

## Masimo's Trial Exhibit 68030 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
1454	MASITC_00414599	MASITC_00414599		3; ATH; HRS; LFND; NREL
1455	MASITC_00428337	MASITC_00428340		3; ATH; HRS; LFND; NREL
1456	MASITC_00428438	MASITC_00428440		3; ATH; HRS; LFND; NREL
1457	MASITC_00431730	MASITC_00431731		3; ATH; HRS; LFND; NREL
1458	MASITC_00438335	MASITC_00438336		3; ATH; HRS; LFND; NREL
1459	MASITC_00464308	MASITC_00464326		3; HRS; LFND; NREL; MIL
1460	MASITC_00464940	MASITC_00464949		3; ATH; HRS; LFND; NREL; MIL
1461	MASITC_00525973	MASITC_00525998		3; ATH; HRS; LFND; NREL; MIL
1462	MASITC_00526699	MASITC_00526702		3; ATH; HRS; LFND; NREL; MIL
1463	MASITC_00526703	MASITC_00526704		3; ATH; HRS; LFND; NREL; MIL
1464	MASITC_00528649	MASITC_00528673		3; ATH; HRS; LFND; NREL; MIL
1465	MASITC_00528757	MASITC_00528758		3; ATH; HRS; LFND; NREL; MIL
1466	MASITC_00528759	MASITC_00528760		3; ATH; HRS; LFND; NREL; MIL
1467	MASITC_00529139	MASITC_00529150		3; ATH; HRS; LFND; NREL; MIL
1468	MASITC_00529163	MASITC_00529173		3; ATH; HRS; LFND; NREL; MIL
1469	MASITC_00538180	MASITC_00538192		3; ATH; HRS; LFND; NREL; MIL
1470	MASITC_00584694	MASITC_00584697		3; ATH; HRS; LFND; NREL; MIL
1471	MASITC_00584698	MASITC_00584701		3; ATH; HRS; LFND; NREL; MIL
1472	MASITC_00584715	MASITC_00584718		3; ATH; HRS; LFND; NREL; MIL
1473	MASITC_00584774	MASITC_00584778		3; ATH; HRS; LFND; NREL; MIL
1474	MASITC_00584976	MASITC_00584976		NREL; 403; LFND; ATH
1475	MASITC_00617720	MASITC_00617720		NREL; 403; LFND; ATH
1476	MASITC_00618013	MASITC_00618013		NREL; 403; LFND; ATH
1477	MASITC_00919146	MASITC_00919150		3; ATH; HRS; LFND; NREL; MIL
1478	MASITC_00958182	MASITC_00958185		3; ATH; HRS; LFND; NREL; MIL
1479	MASITC_00958194	MASITC_00958197		3; ATH; HRS; LFND; NREL; MIL
1480	MASITC_00958794	MASITC_00958796		3; ATH; HRS; LFND; NREL; MIL
1481	MASITC_00958913	MASITC_00958914		3; ATH; HRS; LFND; NREL; MIL
1482	MASITC_00958942	MASITC_00958943		3; ATH; HRS; LFND; NREL; MIL
1483	MASITC_00959028	MASITC_00959029		3; ATH; HRS; LFND; NREL; MIL
1484	MASITC_00959039	MASITC_00959041		3; ATH; HRS; LFND; NREL; MIL

## Masimo's Trial Exhibit 680 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
1485	MASITC_00959149	MASITC_00959149	Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
1486	MASITC_00959254	MASITC_00959259		403; ATH; HRS; LFND; NREL; MIL
1487	MASITC_00959267	MASITC_00959272		403; ATH; HRS; LFND; NREL; MIL
1488	MASITC_00959290	MASITC_00959293		403; ATH; HRS; LFND; NREL; MIL
1489	MASITC_00959294	MASITC_00959298		403; ATH; HRS; LFND; NREL; MIL
1490	MASITC_00959303	MASITC_00959306		403; ATH; HRS; LFND; NREL; MIL
1491	MASITC_00959307	MASITC_00959307		403; ATH; HRS; LFND; NREL; MIL
1492	MASITC_00959308	MASITC_00959313		403; ATH; HRS; LFND; NREL; MIL
1493	MASITC_00959314	MASITC_00959319		403; ATH; HRS; LFND; NREL; MIL
1494	MASITC_00959320	MASITC_00959325		403; ATH; HRS; LFND; NREL; MIL
1495	MASITC_00959407	MASITC_00959417		403; ATH; HRS; LFND; NREL; MIL
1496	MASITC_00959418	MASITC_00959428		403; ATH; HRS; LFND; NREL; MIL
1497	MASITC_00959478	MASITC_00959503		403; ATH; HRS; LFND; NREL; MIL
1498	MASITC_00959504	MASITC_00959533		403; ATH; HRS; LFND; NREL; MIL
1499	MASITC_00959652	MASITC_00959658		403; ATH; HRS; LFND; NREL; MIL
1500	MASITC_00959659	MASITC_00959665		403; ATH; HRS; LFND; NREL; MIL
1501	MASITC_00959666	MASITC_00959672		403; ATH; HRS; LFND; NREL; MIL
1502	MASITC_00959673	MASITC_00959678		403; ATH; HRS; LFND; NREL; MIL
1503	MASITC_00959679	MASITC_00959684		403; ATH; HRS; LFND; NREL; MIL
1504	MASITC_00959685	MASITC_00959690		403; ATH; HRS; LFND; NREL; MIL
1505	MASITC_00959691	MASITC_00959700		403; ATH; HRS; LFND; NREL; MIL
1506	MASITC_00959701	MASITC_00959711		403; ATH; HRS; LFND; NREL; MIL
1507	MASITC_00959725	MASITC_00959732		403; ATH; HRS; LFND; NREL; MIL
1508	MASITC_00959733	MASITC_00959737		403; ATH; HRS; LFND; NREL; MIL
1509	MASITC_00959738	MASITC_00959747		403; ATH; HRS; LFND; NREL; MIL
1510	MASITC_00959748	MASITC_00959757		403; ATH; HRS; LFND; NREL; MIL
1511	MASITC_00959758	MASITC_00959768		403; ATH; HRS; LFND; NREL; MIL
1512	MASITC_00959769	MASITC_00959795		403; ATH; HRS; LFND; NREL; MIL
1513	MASITC_00959898	MASITC_00959914		403; ATH; HRS; LFND; NREL; MIL
1514	MASITC_00966470	MASITC_00966470		403; ATH; HRS; LFND; NREL; MIL
1515	MASITC_00966471	MASITC_00966472		403; ATH; HRS; LFND; NREL; MIL
1516	MASITC_00966488	MASITC_00966488		403; ATH; HRS; LFND; NREL; MIL
1517	MASITC_00966489	MASITC_00966489		403; ATH; HRS; LFND; NREL; MIL
1518	MASITC_00966509	MASITC_00966509		403; ATH; HRS; LFND; NREL; MIL
1519	MASITC_00966510	MASITC_00966510		403; ATH; HRS; LFND; NREL; MIL
1520	MASITC_00966535	MASITC_00966538		403; ATH; HRS; LFND; NREL; MIL
1521	MASITC_00966539	MASITC_00966544		403; ATH; HRS; LFND; NREL; MIL
1522	MASITC_00966914	MASITC_00966917		403; ATH; HRS; LFND; NREL; MIL
1523	MASITC_00966918	MASITC_00966924		403; ATH; HRS; LFND; NREL; MIL
1524	MASITC_00966926	MASITC_00966928		403; ATH; HRS; LFND; NREL; MIL
1525	MASITC_00966930	MASITC_00966933		403; ATH; HRS; LFND; NREL; MIL
1526	MASITC_00966934	MASITC_00966940		403; ATH; HRS; LFND; NREL; MIL
1527	MASITC_00966942	MASITC_00966942		403; ATH; HRS; LFND; NREL; MIL
1528	MASITC_00966944	MASITC_00966947		403; ATH; HRS; LFND; NREL; MIL
1529	MASITC_00966948	MASITC_00966953		403; ATH; HRS; LFND; NREL; MIL

## Masimo's Trial Exhibit 68030 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
1530	MASITC_00966955	MASITC_00966956		403; ATH; HRS; LFND; NREL; MIL
1531	MASITC_00966958	MASITC_00966961		403; ATH; HRS; LFND; NREL; MIL
1532	MASITC_00966962	MASITC_00966966		403; ATH; HRS; LFND; NREL; MIL
1533	MASITC_00966969	MASITC_00966973		403; ATH; HRS; LFND; NREL; MIL
1534	MASITC_00967420	MASITC_00967421		403; ATH; HRS; LFND; NREL; MIL
1535	MASITC_00968497	MASITC_00968497		NREL; 403; LFND; ATH
1536	MASITC_00971267	MASITC_00971267		NREL; 403; LFND; ATH
1537	MASITC_00971518	MASITC_00971518		NREL; 403; LFND; ATH
1538	MASITC_00971578	MASITC_00971578		NREL; 403; LFND; ATH
1539	MASITC_00971974	MASITC_00971974		NREL; 403; LFND; ATH
1540	MASITC_00972482	MASITC_00972484		403; ATH; HRS; LFND; NREL; MIL
1541	MASITC_00972485	MASITC_00972492		403; ATH; HRS; LFND; NREL; MIL
1542	MASITC_00972493	MASITC_00972496		403; ATH; HRS; LFND; NREL; MIL
1543	MASITC_00972505	MASITC_00972511		403; ATH; HRS; LFND; NREL; MIL
1544	MASITC_00972512	MASITC_00972521		403; ATH; HRS; LFND; NREL; MIL
1545	MASITC_00972538	MASITC_00972572		403; ATH; HRS; LFND; NREL; MIL
1546	MASITC_00972677	MASITC_00972685		403; ATH; HRS; LFND; NREL; MIL
1547	MASITC_00972686	MASITC_00972690		403; ATH; HRS; LFND; NREL; MIL
1548	MASITC_00972696	MASITC_00972702		403; ATH; HRS; LFND; NREL; MIL
1549	MASITC_00972703	MASITC_00972707		403; ATH; HRS; LFND; NREL; MIL
1550	MASITC_00972720	MASITC_00972725		403; ATH; HRS; LFND; NREL; MIL
1551	MASITC_00972726	MASITC_00972729		403; ATH; HRS; LFND; NREL; MIL
1552	MASITC_00972730	MASITC_00972733		403; ATH; HRS; LFND; NREL; MIL
1553	MASITC_00972749	MASITC_00972749		403; ATH; HRS; LFND; NREL; MIL
1554	MASITC_00972754	MASITC_00972756		403; ATH; HRS; LFND; NREL; MIL
1555	MASITC_00972768	MASITC_00972770		403; ATH; HRS; LFND; NREL; MIL
1556	MASITC_00972772	MASITC_00972772		403; ATH; HRS; LFND; NREL; MIL
1557	MASITC_00972782	MASITC_00972785		403; ATH; HRS; LFND; NREL; MIL
1558	MASITC_00972862	MASITC_00972864		403; ATH; HRS; LFND; NREL; MIL
1559	MASITC_00972870	MASITC_00972900		403; ATH; HRS; LFND; NREL; MIL
1560	MASITC_00974183	MASITC_00974186		403; ATH; HRS; LFND; NREL; MIL
1561	MASITC_00974205	MASITC_00974211		403; ATH; HRS; LFND; NREL; MIL
1562	MASITC_00974212	MASITC_00974215		403; ATH; HRS; LFND; NREL; MIL
1563	MASITC_00974216	MASITC_00974219		403; ATH; HRS; LFND; NREL; MIL
1564	MASITC_00974230	MASITC_00974242		403; ATH; HRS; LFND; NREL; MIL
1565	MASITC_00974247	MASITC_00974251		403; ATH; HRS; LFND; NREL; MIL
1566	MASITC_00974272	MASITC_00974276		403; ATH; HRS; LFND; NREL; MIL
1567	MASITC_00974282	MASITC_00974282		403; ATH; HRS; LFND; NREL; MIL
1568	MASITC_00974301	MASITC_00974304		403; ATH; HRS; LFND; NREL; MIL
1569	MASITC_00974305	MASITC_00974306		403; ATH; HRS; LFND; NREL; MIL
1570	MASITC_00974471	MASITC_00974471		403; ATH; HRS; LFND; NREL; MIL
1571	MASITC_00975775	MASITC_00975775		403; ATH; HRS; LFND; NREL; MIL
1572	MASITC_00976047	MASITC_00976047		NREL; 403; LFND; ATH
1573	MASITC_00976130	MASITC_00976130		NREL; 403; LFND; ATH
1574	MASITC_00976172	MASITC_00976172		403; ATH; HRS; LFND; NREL; MIL

## Masimo's Trial Exhibit 68030 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
1575	MASITC_01060787	MASITC_01060787		REL; 403; LFND; ATH
1576	MASITC_01060788	MASITC_01060788		REL; 403; LFND; ATH
1577	MASITC_01060793	MASITC_01060793		REL; 403; LFND; ATH
1578	MASITC_01060803	MASITC_01060803		REL; 403; LFND; ATH
1579	MASITC_01060805	MASITC_01060805		REL; 403; LFND; ATH
1580	MASITC_01060817	MASITC_01060817		REL; 403; LFND; ATH
1581	MASITC_01060825	MASITC_01060825		REL; 403; LFND; ATH
1582	MASITC_01060827	MASITC_01060827		REL; 403; LFND; ATH
1583	MASITC_01060838	MASITC_01060838		REL; 403; LFND; ATH
1584	MASITC_01060845	MASITC_01060845		REL; 403; LFND; ATH
1585	MASITC_01060847	MASITC_01060847		REL; 403; LFND; ATH
1586	MASITC_01060859	MASITC_01060859		REL; 403; LFND; ATH
1587	MASITC_01076820	MASITC_01076898		03; ATH; HRS; LFND; NREL; MIL
1588	MASITC_01076938	MASITC_01076938		03; ATH; LFND; NREL; MIL
1589	MASITC_01076939	MASITC_01076939		03; ATH; LFND; NREL; MIL
1590	MASITC_01076944	MASITC_01076944		03; ATH; LFND; NREL; MIL
1591	MASITC_01076945	MASITC_01076945		03; ATH; LFND; NREL; MIL
1592	MASITC_01076946	MASITC_01076946		03; ATH; LFND; MIL
1593	MASITC_01076947	MASITC_01076947		03; ATH; LFND; MIL
1594	MASITC_01076949	MASITC_01076949		03; ATH; LFND; NREL; MIL
1595	MASITC_01076964	MASITC_01076964		03; ATH; LFND; NREL; MIL
1596	MASITC_01076965	MASITC_01076965		03; ATH; LFND; NREL; MIL
1597	MASITC_01077008	MASITC_01077008		03; ATH; LFND; MIL
1598	MASITC_01077010	MASITC_01077010		03; ATH; LFND; MIL
1599	MASITC_01077011	MASITC_01077011		03; ATH; LFND; MIL
1600	MASITC_01077012	MASITC_01077012		03; ATH; LFND; MIL
1601	MASITC_01077013	MASITC_01077013		03; ATH; LFND; MIL
1602	MASITC_01077022	MASITC_01077022		03; ATH; LFND; MIL
1603	MASITC_01077023	MASITC_01077023		03; ATH; LFND; MIL
1604	MASITC_01077024	MASITC_01077024		03; ATH; LFND; MIL
1605	MASITC_01077025	MASITC_01077025		03; ATH; LFND; MIL
1606	MASITC_01077026	MASITC_01077026		03; ATH; LFND; MIL
1607	MASITC_01077027	MASITC_01077027		03; ATH; LFND; MIL
1608	MASITC_01077028	MASITC_01077028		03; ATH; LFND; MIL
1609	MASITC_01077029	MASITC_01077029		03; ATH; LFND; MIL
1610	MASITC_01077034	MASITC_01077034		03; ATH; LFND; MIL
1611	MASITC_01077035	MASITC_01077035		03; ATH; LFND; MIL
1612	MASITC_01077036	MASITC_01077036		03; ATH; LFND; MIL
1613	MASITC_01077037	MASITC_01077037		03; ATH; LFND; MIL
1614	MASITC_01077638	MASITC_01077849		03; ATH; HRS; LFND; NREL
1615	MASITC_01080093	MASITC_01080093		REL; 403; LFND; ATH
1616	MASITC_01080108	MASITC_01080109		03; ATH; FOR; HRS; LFND; MIL
1617	MASITC_01080765 MASITC_00966470	MASITC_01080765 MASITC_00966470		03; ATH; HRS; LFND; NREL; MIL
1618	MASITC_01080766 MASITC_00958769	MASITC_01080766 MASITC_00958769		03; ATH; HRS; LFND; NREL; MIL

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
1619	MASITC_01080768 MASITC_00966507	MASITC_01080768 MASITC_00966507		03; ATH; HRS; LFND; NREL; MIL
1620	MASITC_01080770 MASITC_00966509	MASITC_01080770 MASITC_00966509		03; ATH; HRS; LFND; NREL; MIL
1621	MASITC_01080771 MASITC_00958675	MASITC_01080771 MASITC_00958675		03; ATH; HRS; LFND; NREL; MIL
1622	MASITC_01080773 MASITC_00526571	MASITC_01080773 MASITC_00526576		03; ATH; HRS; LFND; NREL; MIL
1623	MASITC_01080774 MASITC_00392125	MASITC_01080776 MASITC_00392127		03; ATH; HRS; LFND; NREL; MIL
1624	MASITC_01080784 MASITC_00958662	MASITC_01080784 MASITC_00958662		03; ATH; HRS; LFND; NREL; MIL
1625	MASITC_01080785 MASITC_00966488	MASITC_01080785 MASITC_00966488		03; ATH; HRS; LFND; NREL; MIL
1626	MASITC_01080791 MASITC_00584761	MASITC_01080791 MASITC_00584767		03; ATH; HRS; LFND; NREL; MIL
1627	MASITC_01080815 MASITC_00966491	MASITC_01080818 MASITC_00966494		03; ATH; HRS; LFND; NREL; MIL
1628	MASITC_01080819 MASITC_00966498	MASITC_01080819 MASITC_00966501		03; ATH; HRS; LFND; NREL; MIL
1629	MASITC_01080828 MASITC_00584691	MASITC_01080828 MASITC_00584693		03; ATH; HRS; LFND; NREL; MIL
1630	MASITC_01080829 MASITC_00974668	MASITC_01080829 MASITC_00974668		03; ATH; HRS; LFND; NREL; MIL
1631	MASITC_01080838 MASITC_00584754	MASITC_01080838 MASITC_00584760		03; ATH; HRS; LFND; NREL; MIL
1632	MASITC_01080941	MASITC_01080944		03; ATH; HRS; LFND; NREL; MIL
1633	MASITC_01080949	MASITC_01080950		03; ATH; HRS; LFND; NREL; MIL
1634	MASITC_01080951	MASITC_01080951		03; ATH; HRS; LFND; NREL; MIL
1635	MASITC_01081028	MASITC_01081028		03; ATH; HRS; LFND; NREL; MIL
1636	MASITC_01081029	MASITC_01081029		03; ATH; HRS; LFND; NREL; MIL
1637	MASITC_01081031	MASITC_01081031		03; ATH; HRS; LFND; NREL; MIL
1638	MASITC_01081033	MASITC_01081033		03; ATH; HRS; LFND; NREL; MIL
1639	MASITC_01081071	MASITC_01081071		03; ATH; HRS; LFND; NREL; MIL
1640	MASITC_01081072	MASITC_01081072		03; ATH; HRS; LFND; NREL; MIL
1641	MASITC_01081076	MASITC_01081076		03; ATH; HRS; LFND; NREL; MIL
1642	MASITC_01081109	MASITC_01081109		03; ATH; HRS; LFND; NREL; MIL
1643	MASITC_01081135	MASITC_01081135		03; ATH; HRS; LFND; NREL; MIL
1644	MASITC_01081136	MASITC_01081136		03; ATH; HRS; LFND; NREL; MIL
1645	MASITC_01081137	MASITC_01081137		03; ATH; HRS; LFND; NREL; MIL
1646	MASITC_01081218	MASITC_01081218		03; ATH; HRS; LFND; NREL; MIL
1647	MASITC_01081223	MASITC_01081223		03; ATH; HRS; LFND; NREL; MIL
1648	MASITC_01081233	MASITC_01081233		03; ATH; HRS; LFND; NREL; MIL
1649	MASITC_01081236	MASITC_01081236		03; ATH; HRS; LFND; NREL; MIL
1650	MASITC_01081267	MASITC_01081267		03; ATH; HRS; LFND; NREL; MIL
1651	MASITC_01081278	MASITC_01081278		03; ATH; HRS; LFND; NREL; MIL

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
1652	MASITC_01081279	MASITC_01081279		03; ATH; HRS; LFND; NREL; MIL
1653	MASITC_01081283	MASITC_01081283		03; ATH; HRS; LFND; NREL; MIL
1654	MASITC_01081285	MASITC_01081285		03; ATH; HRS; LFND; NREL; MIL
1655	MASITC_01081319	MASITC_01081319		03; ATH; HRS; LFND; NREL; MIL
1656	MASITC_01081320	MASITC_01081320		03; ATH; HRS; LFND; NREL; MIL
1657	MASITC_01081331	MASITC_01081331		03; ATH; HRS; LFND; NREL; MIL
1658	MASITC_01081332	MASITC_01081332		03; ATH; HRS; LFND; NREL; MIL
1659	MASITC_01081339	MASITC_01081339		03; ATH; HRS; LFND; NREL; MIL
1660	MASITC_01081343	MASITC_01081343		03; ATH; HRS; LFND; NREL; MIL
1661	MASITC_01081344	MASITC_01081344		03; ATH; HRS; LFND; NREL; MIL
1662	MASITC_01081345	MASITC_01081345		03; ATH; HRS; LFND; NREL; MIL
1663	MASITC_01081359	MASITC_01081359		03; ATH; HRS; LFND; NREL; MIL
1664	MASITC_01081360	MASITC_01081360		03; ATH; HRS; LFND; NREL; MIL
1665	MASITC_01081363	MASITC_01081363		03; ATH; HRS; LFND; NREL; MIL
1666	MASITC_01081416	MASITC_01081421		03; ATH; HRS; LFND; NREL; MIL
1667	MASITC_01081432	MASITC_01081432		REL; 403; LFND; ATH
1668	MASITC_01081434	MASITC_01081434		REL; 403; LFND; ATH
1669	MASITC_01081507 MASITC_00976172	MASITC_01081507 MASITC_00976172		03; ATH; HRS; LFND; NREL; MIL
1670	MASITC_01081508 MASITC_00976172	MASITC_01081508 MASITC_00976172		03; ATH; HRS; LFND; NREL; MIL
1671	MASITC_01081509	MASITC_01081509		03; ATH; HRS; LFND; NREL; MIL
1672	MASITC_01081523	MASITC_01081545		03; ATH; HRS; LFND; NREL; MIL
1673	MASITC_01081546	MASITC_01081568		03; ATH; HRS; LFND; NREL; MIL
1674	MASITC_01081585	MASITC_01081597		03; ATH; HRS; LFND; NREL; MIL
1675	MASITC_01081721 MASITC_00976219	MASITC_01081721 MASITC_00976219		03; ATH; HRS; LFND; NREL; MIL
1676	MASITC_01081723	MASITC_01081730		03; ATH; HRS; LFND; NREL; MIL
1677	MASITC_01081742 MASITC_00975855	MASITC_01081742 MASITC_00975855		03; ATH; HRS; LFND; NREL; MIL
1678	MASITC_01081743 MASITC_00584715	MASITC_01081743 MASITC_00584718		03; ATH; HRS; LFND; NREL; MIL
1679	MASITC_01081744	MASITC_01081744		03; ATH; HRS; LFND; NREL; MIL
1680	MASITC_01081766	MASITC_01081766		03; ATH; HRS; LFND; NREL; MIL
1681	MASITC_01081776	MASITC_01081776		03; ATH; HRS; LFND; NREL; MIL
1682	MASITC_01081778 MASITC_00975929	MASITC_01081778 MASITC_00975929		03; ATH; HRS; LFND; NREL; MIL
1683	MASITC_01081781 MASITC_00976093	MASITC_01081781 MASITC_00976093		03; ATH; HRS; LFND; NREL; MIL
1684	MASITC_01081801	MASITC_01081801		03; ATH; HRS; LFND; NREL; MIL
1685	MASITC_01081803	MASITC_01081803		03; ATH; HRS; LFND; NREL; MIL
1686	MASITC_01081807	MASITC_01081807		03; ATH; HRS; LFND; NREL; MIL
1687	MASITC_01081820	MASITC_01081820		03; ATH; HRS; LFND; NREL; MIL
1688	MASITC_01081821	MASITC_01081821		03; ATH; HRS; LFND; NREL; MIL
1689	MASITC_01081825	MASITC_01081825		03; ATH; HRS; LFND; NREL; MIL
1690	MASITC_01081891	MASITC_01081891		03; ATH; HRS; LFND; NREL; MIL

## Masimo's Trial Exhibit 68030 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
1691	MASITC_01082050	MASITC_01082050		03; ATH; HRS; LFND; NREL; MIL
1692	MASITC_01082897	MASITC_01082897		03; ATH; HRS; LFND; NREL; MIL
1693	MASITC_01083137	MASITC_01083137		03; ATH; HRS; LFND; NREL; MIL
1694	MASITC_01083164	MASITC_01083164		03; ATH; HRS; LFND; NREL; MIL
1695	MASITC_01083165	MASITC_01083165		03; ATH; HRS; LFND; NREL; MIL
1696	MASITC_01145724	MASITC_01145751		03; ATH; HRS; LFND; NREL; MIL
1697	MASITC_01170029	MASITC_01170029		03; ATH; HRS; LFND; NREL; MIL
1698	MASITC_01256448	MASITC_01256460		03; ATH; LFND; NREL; MIL
1699	MASITC_01256461	MASITC_01256461		03; ATH; HRS; LFND; NREL; MIL
1700	MASITC_01256462	MASITC_01256462		03; ATH; HRS; LFND; NREL; MIL
1701	MASITC_01256463	MASITC_01256463		03; ATH; HRS; LFND; NREL; MIL
1702	MASITC_01256464	MASITC_01256464		03; ATH; HRS; LFND; NREL; MIL
1703	MASITC_01256478	MASITC_01256478		03; ATH; LFND; NREL; MIL
1704	MASITC_01256557	MASITC_01256575		03; ATH; HRS; LFND; NREL; MIL
1705	MASITC_01260915	MASITC_01260916		03; ATH; HRS; LFND; NREL; MIL
1706	MASITC_01260919	MASITC_01260920		03; ATH; HRS; LFND; NREL; MIL
1707	MASITC_01270075	MASITC_01270126		03; ATH; HRS; LFND; NREL; MIL
1708	MASITC_01270127	MASITC_01270226		03; ATH; HRS; LFND; NREL; MIL
1709	MASITC_01270227	MASITC_01270338		03; ATH; HRS; LFND; NREL; MIL
1710	MASITC_01270339	MASITC_01270339		03; ATH; HRS; LFND; NREL; MIL
1711	MASITC_01270340	MASITC_01270340		03; ATH; HRS; LFND; NREL; MIL
1712	MASITC_01270341	MASITC_01271345		03; ATH; HRS; LFND; NREL; MIL
1713	MASITC_01271346	MASITC_01271346		03; ATH; HRS; LFND; NREL; MIL
1714	MASITC_01271347 MASITC_00584715 MASITC_00975855	MASITC_00584715 MASITC_00584718 MASITC_00975855		03; ATH; HRS; LFND; NREL; MIL
1715	MASITC_01271348	MASITC_01271348		03; ATH; HRS; LFND; NREL; MIL
1716	MASITC_01271349	MASITC_01271349		03; ATH; HRS; LFND; NREL; MIL
1717	MASITC_01271350	MASITC_01271350		03; ATH; HRS; LFND; NREL; MIL
1718	MASITC_01271362	MASITC_01271362		03; ATH; HRS; LFND; NREL; MIL
1719	MASITC_01271375	MASITC_01271375		03; ATH; HRS; LFND; NREL; MIL
1720	MASITC_01281160	MASITC_01281160		03; ATH; HRS; LFND; NREL; MIL
1721	MASITC_01281342	MASITC_01281342		03; ATH; LFND; NREL; MIL
1722	MASITC_01281345	MASITC_01281345		03; ATH; LFND; NREL; MIL
1723	MASITC_01281347	MASITC_01281347		03; ATH; LFND; NREL; MIL
1724	MASITC_01281348	MASITC_01281348		03; ATH; LFND; NREL; MIL
1725	MASITC_01398421	MASITC_01398583		03; ATH; LFND; NREL; MIL
1726	MASITC_01398645	MASITC_01398663		03; ATH; LFND; NREL; MIL
1727				03; ATH; HRS; LFND; NREL; NE; MIL
1728	MASITC_01388409	MASITC_01388410		03; ATH; HRS; LFND; NREL; MIL
1729	MASITC_01388411	MASITC_01388412		03; ATH; HRS; LFND; NREL; MIL
1730	MASITC_01388413	MASITC_01388414		03; ATH; HRS; LFND; NREL; MIL
1731	MASITC_01388415	MASITC_01388416		03; ATH; HRS; LFND; NREL; MIL
1732	MASITC_01388417	MASITC_01388418		03; ATH; HRS; LFND; NREL; MIL



DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
1733	MASITC_01388419	MASITC_01388420		403; ATH; HRS; LFND; NREL; MIL
1734	MASITC_01388421	MASITC_01388422		403; ATH; HRS; LFND; NREL; MIL
1735	MASITC_01388423	MASITC_01388424		403; ATH; HRS; LFND; NREL; MIL
1736	MASITC_01388425	MASITC_01388426		403; ATH; HRS; LFND; NREL; MIL
1737	MASITC_01388427	MASITC_01388428		403; ATH; HRS; LFND; NREL; MIL
1738	MASITC_01388429	MASITC_01388430		403; ATH; HRS; LFND; NREL; MIL
1739	MASITC_01388431	MASITC_01388431		403; ATH; HRS; LFND; NREL; MIL
1740	MASITC_01388432	MASITC_01388432		403; ATH; HRS; LFND; NREL; MIL
1741	MASITC_01388433	MASITC_01388433		403; ATH; HRS; LFND; NREL; MIL
1742	MASITC_01388434	MASITC_01388434		403; ATH; HRS; LFND; NREL; MIL
1743	MASITC_01388435	MASITC_01388435		403; ATH; HRS; LFND; NREL; MIL
1744	MASITC_01388436	MASITC_01388436		403; ATH; HRS; LFND; NREL; MIL
1745	MASITC_01388437	MASITC_01388437		403; ATH; HRS; LFND; NREL; MIL
1746	MASITC_01388438	MASITC_01388438		403; ATH; HRS; LFND; NREL; MIL
1747	MASITC_01388439	MASITC_01388439		403; ATH; HRS; LFND; NREL; MIL
1748	MASITC_01388440	MASITC_01388440		403; ATH; HRS; LFND; NREL; MIL
1749	MASITC_01388441	MASITC_01388441		403; ATH; HRS; LFND; NREL; MIL
1750	MASITC_01388442	MASITC_01388442		403; ATH; HRS; LFND; NREL; MIL
1751	MASITC_01388443	MASITC_01388443		403; ATH; HRS; LFND; NREL; MIL
1752	MASITC_01388444	MASITC_01388444		403; ATH; HRS; LFND; NREL; MIL
1753	MASITC_01388445	MASITC_01388445		403; ATH; HRS; LFND; NREL; MIL
1754	MASITC_01388446	MASITC_01388446		403; ATH; HRS; LFND; NREL; MIL
1755	MASITC_01388447	MASITC_01388447		403; ATH; HRS; LFND; NREL; MIL
1756	MASITC_01388448	MASITC_01388448		403; ATH; HRS; LFND; NREL; MIL
1757	MASITC_01388449	MASITC_01388449		403; ATH; HRS; LFND; NREL; MIL
1758	MASITC_01388450	MASITC_01388450		403; ATH; HRS; LFND; NREL; MIL
1759	MASITC_01388451	MASITC_01388451		403; ATH; HRS; LFND; NREL; MIL
1760	MASITC_01388452	MASITC_01388452		403; ATH; HRS; LFND; NREL; MIL
1761	MASITC_01388453	MASITC_01388453		403; ATH; HRS; LFND; NREL; MIL
1762	MASITC_01388454	MASITC_01388454		403; ATH; HRS; LFND; NREL; MIL
1763	MASITC_01388455	MASITC_01388455		403; ATH; HRS; LFND; NREL; MIL
1764	MASITC_01388456	MASITC_01388456		403; ATH; HRS; LFND; NREL; MIL
1765	MASITC_01388457	MASITC_01388457		403; ATH; HRS; LFND; NREL; MIL
1766	MASITC_01388458	MASITC_01388458		403; ATH; HRS; LFND; NREL; MIL
1767	MASITC_01388459	MASITC_01388459		403; ATH; HRS; LFND; NREL; MIL
1768	MASITC_01388460	MASITC_01388460		403; ATH; HRS; LFND; NREL; MIL
1769	MASITC_01388461	MASITC_01388461		403; ATH; HRS; LFND; NREL; MIL
1770	MASITC_01388462	MASITC_01388462		403; ATH; HRS; LFND; NREL; MIL
1771	MASITC_01388463	MASITC_01388463		403; ATH; HRS; LFND; NREL; MIL
1772	MASITC_01388464	MASITC_01388464		403; ATH; HRS; LFND; NREL; MIL
1773	MASITC_01388465	MASITC_01388465		403; ATH; HRS; LFND; NREL; MIL
1774	MASITC_01388466	MASITC_01388466		403; ATH; HRS; LFND; NREL; MIL
1775	MASITC_01388467	MASITC_01388467		403; ATH; HRS; LFND; NREL; MIL
1776	MASITC_01388468	MASITC_01388468		403; ATH; HRS; LFND; NREL; MIL
1777	MASITC_01388469	MASITC_01388469		403; ATH; HRS; LFND; NREL; MIL
1778	MASITC_01388470	MASITC_01388470		403; ATH; HRS; LFND; NREL; MIL

## Masimo's Trial Exhibit 68028 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
1779	MASITC_01388471	MASITC_01388471		03; ATH; HRS; LFND; NREL; MIL
1780	MASITC_01388472	MASITC_01388472		03; ATH; HRS; LFND; NREL; MIL
1781	MASITC_01388473	MASITC_01388473		03; ATH; HRS; LFND; NREL; MIL
1782	MASITC_01388474	MASITC_01388474		03; ATH; HRS; LFND; NREL; MIL
1783	MASITC_01388475	MASITC_01388475		03; ATH; HRS; LFND; NREL; MIL
1784	MASITC_01388476	MASITC_01388476		03; ATH; HRS; LFND; NREL; MIL
1785	MASITC_01388477	MASITC_01388477		03; ATH; HRS; LFND; NREL; MIL
1786	MASITC_01388478	MASITC_01388478		03; ATH; HRS; LFND; NREL; MIL
1787	MASITC_01388479	MASITC_01388479		03; ATH; HRS; LFND; NREL; MIL
1788	MASITC_01388480	MASITC_01388480		03; ATH; HRS; LFND; NREL; MIL
1789	MASITC_01388481	MASITC_01388481		03; ATH; HRS; LFND; NREL; MIL
1790	MASITC_01388482	MASITC_01388482		03; ATH; HRS; LFND; NREL; MIL
1791	MASITC_01388483	MASITC_01388483		03; ATH; HRS; LFND; NREL; MIL
1792	MASITC_01388484	MASITC_01388484		03; ATH; HRS; LFND; NREL; MIL
1793	MASITC_01388485	MASITC_01388485		03; ATH; HRS; LFND; NREL; MIL
1794	MASITC_01388486	MASITC_01388486		03; ATH; HRS; LFND; NREL; MIL
1795	MASITC_01388487	MASITC_01388487		03; ATH; HRS; LFND; NREL; MIL
1796	MASITC_01388488	MASITC_01388488		03; ATH; HRS; LFND; NREL; MIL
1797	MASITC_01388489	MASITC_01388489		03; ATH; HRS; LFND; NREL; MIL
1798	MASITC_01388490	MASITC_01388490		03; ATH; HRS; LFND; NREL; MIL
1799	MASITC_01388491	MASITC_01388491		03; ATH; HRS; LFND; NREL; MIL
1800	MASITC_01388492	MASITC_01388492		03; ATH; HRS; LFND; NREL; MIL
1801	MASITC_01388493	MASITC_01388493		03; ATH; HRS; LFND; NREL; MIL
1802	MASITC_01388494	MASITC_01388494		03; ATH; HRS; LFND; NREL; MIL
1803	MASITC_01388495	MASITC_01388495		03; ATH; HRS; LFND; NREL; MIL
1804	MASITC_01388497	MASITC_01388497		03; ATH; HRS; LFND; NREL; MIL
1805	MASITC_01388499	MASITC_01388499		03; ATH; HRS; LFND; NREL; MIL
1806	MASITC_01388501	MASITC_01388501		03; ATH; HRS; LFND; NREL; MIL
1807	MASITC_01388503	MASITC_01388503		03; ATH; HRS; LFND; NREL; MIL
1808	MASITC_01388505	MASITC_01388505		03; ATH; HRS; LFND; NREL; MIL
1809	MASITC_01388507	MASITC_01388507		03; ATH; HRS; LFND; NREL; MIL
1810	MASITC_01388508	MASITC_01388508		03; ATH; HRS; LFND; NREL; MIL
1811	MASITC_01388509	MASITC_01388509		03; ATH; HRS; LFND; NREL; MIL
1812	MASITC_01388510	MASITC_01388510		03; ATH; HRS; LFND; NREL; MIL
1813	MASITC_01388511	MASITC_01388511		03; ATH; HRS; LFND; NREL; MIL
1814	MASITC_01388512	MASITC_01388512		03; ATH; HRS; LFND; NREL; MIL
1815	MASITC_01388513	MASITC_01388513		03; ATH; HRS; LFND; NREL; MIL
1816	MASITC_01388514	MASITC_01388514		03; ATH; HRS; LFND; NREL; MIL
1817	MASITC_01388515	MASITC_01388515		03; ATH; HRS; LFND; NREL; MIL
1818	MASITC_01388516	MASITC_01388516		03; ATH; HRS; LFND; NREL; MIL
1819	MASITC_01388517	MASITC_01388517		03; ATH; HRS; LFND; NREL; MIL
1820	MASITC_01388518	MASITC_01388518		03; ATH; HRS; LFND; NREL; MIL
1821	MASITC_01388519	MASITC_01388519		03; ATH; HRS; LFND; NREL; MIL
1822	MASITC_01388520	MASITC_01388520		03; ATH; HRS; LFND; NREL; MIL
1823	MASITC_01388521	MASITC_01388521		03; ATH; HRS; LFND; NREL; MIL

## Masimo's Trial Exhibit 68039 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
1824	MASITC_01388522	MASITC_01388522		403; ATH; HRS; LFND; NREL; MIL
1825	MASITC_01388523	MASITC_01388523		403; ATH; HRS; LFND; NREL; MIL
1826	MASITC_01388524	MASITC_01388524		403; ATH; HRS; LFND; NREL; MIL
1827	MASITC_01388525	MASITC_01388525		403; ATH; HRS; LFND; NREL; MIL
1828	MASITC_01388526	MASITC_01388526		403; ATH; HRS; LFND; NREL; MIL
1829	MASITC_01388527	MASITC_01388527		403; ATH; HRS; LFND; NREL; MIL
1830	MASITC_01388528	MASITC_01388528		403; ATH; HRS; LFND; NREL; MIL
1831	MASITC_01388529	MASITC_01388529		403; ATH; HRS; LFND; NREL; MIL
1832	MASITC_01388530	MASITC_01388530		403; ATH; HRS; LFND; NREL; MIL
1833	MASITC_01388531	MASITC_01388531		403; ATH; HRS; LFND; NREL; MIL
1834	MASITC_01388532	MASITC_01388532		403; ATH; HRS; LFND; NREL; MIL
1835	MASITC_01388533	MASITC_01388533		403; ATH; HRS; LFND; NREL; MIL
1836	MASITC_01388534	MASITC_01388534		403; ATH; HRS; LFND; NREL; MIL
1837	MASITC_01388535	MASITC_01388535		403; ATH; HRS; LFND; NREL; MIL
1838	MASITC_01388536	MASITC_01388536		403; ATH; HRS; LFND; NREL; MIL
1839	MASITC_01388537	MASITC_01388537		403; ATH; HRS; LFND; NREL; MIL
1840	MASITC_01388538	MASITC_01388538		403; ATH; HRS; LFND; NREL; MIL
1841	MASITC_01388539	MASITC_01388539		403; ATH; HRS; LFND; NREL; MIL
1842	MASITC_01388540	MASITC_01388540		403; ATH; HRS; LFND; NREL; MIL
1843	MASITC_01388541	MASITC_01388541		403; ATH; HRS; LFND; NREL; MIL
1844	MASITC_01388542	MASITC_01388542		403; ATH; HRS; LFND; NREL; MIL
1845	MASITC_01388543	MASITC_01388543		403; ATH; HRS; LFND; NREL; MIL
1846	MASITC_01388544	MASITC_01388544		403; ATH; HRS; LFND; NREL; MIL
1847	MASITC_01388545	MASITC_01388545		403; ATH; HRS; LFND; NREL; MIL
1848	MASITC_01388546	MASITC_01388546		403; ATH; HRS; LFND; NREL; MIL
1849	MASITC_01388547	MASITC_01388547		403; ATH; HRS; LFND; NREL; MIL
1850	MASITC_01388548	MASITC_01388548		403; ATH; HRS; LFND; NREL; MIL
1851	MASITC_01388549	MASITC_01388549		403; ATH; HRS; LFND; NREL; MIL
1852	MASITC_01388550	MASITC_01388550		403; ATH; HRS; LFND; NREL; MIL
1853	MASITC_01388551	MASITC_01388551		403; ATH; HRS; LFND; NREL; MIL
1854	MASITC_01388552	MASITC_01388552		403; ATH; HRS; LFND; NREL; MIL
1855	MASITC_01388553	MASITC_01388553		403; ATH; HRS; LFND; NREL; MIL
1856	MASITC_01388554	MASITC_01388554		403; ATH; HRS; LFND; NREL; MIL
1857	MASITC_01388555	MASITC_01388555		403; ATH; HRS; LFND; NREL; MIL
1858	MASITC_01388556	MASITC_01388556		403; ATH; HRS; LFND; NREL; MIL
1859	MASITC_01388557	MASITC_01388557		403; ATH; HRS; LFND; NREL; MIL
1860	MASITC_01388558	MASITC_01388558		403; ATH; HRS; LFND; NREL; MIL
1861	MASITC_01388559	MASITC_01388559		403; ATH; HRS; LFND; NREL; MIL
1862	MASITC_01388560	MASITC_01388560		403; ATH; HRS; LFND; NREL; MIL
1863	MASITC_01388561	MASITC_01388562		403; ATH; HRS; LFND; NREL; MIL
1864	MASITC_01394980	MASITC_01394981		403; ATH; HRS; LFND; NREL; MIL
1865	MASITC_01394982	MASITC_01394983		403; ATH; HRS; LFND; NREL; MIL
1866	MASITC_01394984	MASITC_01394985		403; ATH; HRS; LFND; NREL; MIL
1867	MASITC_01394986	MASITC_01394986		403; ATH; HRS; LFND; NREL; MIL
1868	MASITC_01394987	MASITC_01394988		403; ATH; HRS; LFND; NREL; MIL
1869	MASITC_01394989	MASITC_01394990		403; ATH; HRS; LFND; NREL; MIL

## Masimo's Trial Exhibit 68090 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
1870	MASITC_01394991	MASITC_01394992		403; ATH; HRS; LFND; NREL; MIL
1871	MASITC_01394993	MASITC_01394994		403; ATH; HRS; LFND; NREL; MIL
1872	MASITC_01394995	MASITC_01394996		403; ATH; HRS; LFND; NREL; MIL
1873	MASITC_01394997	MASITC_01394998		403; ATH; HRS; LFND; NREL; MIL
1874	MASITC_01394999	MASITC_01395000		403; ATH; HRS; LFND; NREL; MIL
1875	MASITC_01395001	MASITC_01395002		403; ATH; HRS; LFND; NREL; MIL
1876	MASITC_01395003	MASITC_01395004		403; ATH; HRS; LFND; NREL; MIL
1877	MASITC_01395005	MASITC_01395006		403; ATH; HRS; LFND; NREL; MIL
1878	MASITC_01395007	MASITC_01395008		403; ATH; HRS; LFND; NREL; MIL
1879	MASITC_01395009	MASITC_01395010		403; ATH; HRS; LFND; NREL; MIL
1880	MASITC_01395011	MASITC_01395012		403; ATH; HRS; LFND; NREL; MIL
1881	MASITC_01395013	MASITC_01395014		403; ATH; HRS; LFND; NREL; MIL
1882	MASITC_01395015	MASITC_01395015		403; ATH; HRS; LFND; NREL; MIL
1883	MASITC_01395016	MASITC_01395016		403; ATH; HRS; LFND; NREL; MIL
1884	MASITC_01395017	MASITC_01395017		403; ATH; HRS; LFND; NREL; MIL
1885	MASITC_01395018	MASITC_01395018		403; ATH; HRS; LFND; NREL; MIL
1886	MASITC_01395019	MASITC_01395019		403; ATH; HRS; LFND; NREL; MIL
1887	MASITC_01395020	MASITC_01395020		403; ATH; HRS; LFND; NREL; MIL
1888	MASITC_01395021	MASITC_01395021		403; ATH; HRS; LFND; NREL; MIL
1889	MASITC_01395022	MASITC_01395022		403; ATH; HRS; LFND; NREL; MIL
1890	MASITC_01395023	MASITC_01395023		403; ATH; HRS; LFND; NREL; MIL
1891	MASITC_01395024	MASITC_01395024		403; ATH; HRS; LFND; NREL; MIL
1892	MASITC_01395025	MASITC_01395025		403; ATH; HRS; LFND; NREL; MIL
1893	MASITC_01395026	MASITC_01395026		403; ATH; HRS; LFND; NREL; MIL
1894	MASITC_01395027	MASITC_01395027		403; ATH; HRS; LFND; NREL; MIL
1895	MASITC_01395028	MASITC_01395028		403; ATH; HRS; LFND; NREL; MIL
1896	MASITC_01395029	MASITC_01395029		403; ATH; HRS; LFND; NREL; MIL
1897	APL_MAS_ITC_00347163	APL_MAS_ITC_00347170	Physicals, Oct. 20, 2021	403; ID; ATH; LFND; CMP; MIL
1898	APL_MAS_ITC_00347171	APL_MAS_ITC_00347171	Video of Apple's Inspection of Masimo Physicals, Oct. 20, 2021	403; ATH; HRS; LFND; NREL; MIL
1899	APL_MAS_ITC_00347172	APL_MAS_ITC_00347176	Collection of Images from Apple's Inspection of Masimo Physicals, Oct. 20, 2021	403; ATH; HRS; LFND; NREL; CMP; MIL
1900	APL_MAS_ITC_00347177	APL_MAS_ITC_00347177	Video of Apple's Inspection of Masimo Physicals, Oct. 20, 2021	403; ATH; HRS; LFND; NREL; MIL
1901	APL_MAS_ITC_00347178	APL_MAS_ITC_00347220	Collection of Images from Apple's Inspection of Masimo Physicals, Oct. 20, 2021	403; ATH; HRS; LFND; NREL; CMP; MIL
1902	APL_MAS_ITC_00347221	APL_MAS_ITC_00347221	Video of Apple's Inspection of Masimo Physicals, Oct. 20, 2021	403; ATH; HRS; LFND; NREL; MIL
1903	APL_MAS_ITC_00347222	APL_MAS_ITC_00347222	Video of Apple's Inspection of Masimo Physicals, Oct. 20, 2021	403; ATH; HRS; LFND; NREL; MIL
1904	APL_MAS_ITC_00347223	APL_MAS_ITC_00347228	Collection of Images from Apple's Inspection of Masimo Physicals, Oct. 20, 2021	403; ATH; HRS; LFND; NREL; CMP; MIL
1905	APL_MAS_ITC_00347229	APL_MAS_ITC_00347229	Video of Apple's Inspection of Masimo Physicals, Oct. 20, 2021	403; ATH; HRS; LFND; NREL; MIL

## Masimo's Trial Exhibit 68091 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
1906	APL_MAS_ITC_00347230	APL_MAS_ITC_00347230	Video of Apple's Inspection of Masimo Physicals, Oct. 20, 2021	403; ATH; HRS; LFND; NREL; MIL
1907	APL_MAS_ITC_00347242	APL_MAS_ITC_00347242	Video of Apple's Inspection of Masimo Physicals, Oct. 20, 2021	403; ATH; HRS; LFND; NREL; MIL
1908	APL_MAS_ITC_00347243	APL_MAS_ITC_00347264	Collection of Images from Apple's Inspection of Masimo Physicals, Oct. 20, 2021	403; ATH; HRS; LFND; NREL; CMP; MIL
1909	APL_MAS_ITC_00347265	APL_MAS_ITC_00347265	Video of Apple's Inspection of Masimo Physicals, Oct. 20, 2021	403; ATH; HRS; LFND; NREL; MIL
1910	APL_MAS_ITC_00347266	APL_MAS_ITC_00347271	Collection of Images from Apple's Inspection of Masimo Physicals, Oct. 20, 2021	403; ATH; HRS; LFND; NREL; CMP; MIL
1911	APL_MAS_ITC_00347272	APL_MAS_ITC_00347272	Video of Apple's Inspection of Masimo Physicals, Oct. 20, 2021	403; ATH; HRS; LFND; NREL; MIL
1912	APL_MAS_ITC_00347273	APL_MAS_ITC_00347273	Video of Apple's Inspection of Masimo Physicals, Oct. 20, 2021	403; ATH; HRS; LFND; NREL; MIL
1913	APL_MAS_ITC_00347274	APL_MAS_ITC_00347280	Collection of Images from Apple's Inspection of Masimo Physicals, Oct. 20, 2021	403; ATH; HRS; LFND; NREL; CMP; MIL
1914	APL_MAS_ITC_00347281	APL_MAS_ITC_00347281	Video of Apple's Inspection of Masimo Physicals, Oct. 20, 2021	403; ATH; HRS; LFND; NREL; MIL
1915	APL_MAS_ITC_00347282	APL_MAS_ITC_00347290	Collection of Images from Apple's Inspection of Masimo Physicals, Oct. 20, 2021	403; ATH; HRS; LFND; NREL; CMP; MIL
1916	APL_MAS_ITC_00347291	APL_MAS_ITC_00347291	Video of Apple's Inspection of Masimo Physicals, Oct. 20, 2021	403; ATH; HRS; LFND; NREL; MIL
1917	APL_MAS_ITC_00347292	APL_MAS_ITC_00347292	Video of Apple's Inspection of Masimo Physicals, Oct. 20, 2021	403; ATH; HRS; LFND; NREL; MIL
1918	APL_MAS_ITC_00347293	APL_MAS_ITC_00347293	Video of Apple's Inspection of Masimo Physicals, Oct. 20, 2021	403; ATH; HRS; LFND; NREL; MIL
1919	APL_MAS_ITC_00347294	APL_MAS_ITC_00347294	Video of Apple's Inspection of Masimo Physicals, Oct. 20, 2021	403; ATH; HRS; LFND; NREL; MIL
1920	APL_MAS_ITC_00347295	APL_MAS_ITC_00347295	Video of Apple's Inspection of Masimo Physicals, Oct. 20, 2021	403; ATH; HRS; LFND; NREL; MIL
1921	APL_MAS_ITC_00347296	APL_MAS_ITC_00347296	Video of Apple's Inspection of Masimo Physicals, Oct. 20, 2021	403; ATH; HRS; LFND; NREL; MIL
1922	APL_MAS_ITC_00347297	APL_MAS_ITC_00347297	Video of Apple's Inspection of Masimo Physicals, Oct. 20, 2021	403; ATH; HRS; LFND; NREL; MIL
1923	APL_MAS_ITC_00347298	APL_MAS_ITC_00347298	Video of Apple's Inspection of Masimo Physicals, Oct. 20, 2021	403; ATH; HRS; LFND; NREL; MIL
1924	APL_MAS_ITC_00347299	APL_MAS_ITC_00347299	Video of Apple's Inspection of Masimo Physicals, Oct. 20, 2021	403; ATH; HRS; LFND; NREL; MIL
1925	APL_MAS_ITC_00347300	APL_MAS_ITC_00347301	Collection of Images from Apple's Inspection of Masimo Physicals, October 20, 2021	403; ATH; HRS; LFND; NREL; CMP; MIL
1926	APL_MAS_ITC_00348741	APL_MAS_ITC_00348741	Video of Apple's Inspection of Masimo Physicals, Nov. 10, 2021	403; ATH; HRS; LFND; NREL; MIL
1927	APL_MAS_ITC_00348742	APL_MAS_ITC_00348767	Collection of Images from Apple's Inspection of Masimo Physicals, Nov. 10, 2021	403; ATH; HRS; LFND; NREL; CMP; MIL
1928	APL_MAS_ITC_00348768	APL_MAS_ITC_00348768	Video of Apple's Inspection of Masimo Physicals, Nov. 10, 2021	403; ATH; HRS; LFND; NREL; MIL

## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
1929	APL_MAS_ITC_00348895	APL_MAS_ITC_00348895	Video of Apple's Inspection of Masimo Physicals, Nov. 10, 2021	403; ATH; HRS; LFND; NREL; MIL
1930	APL_MAS_ITC_00348896	APL_MAS_ITC_00348968	Collection of Images from Apple's Inspection of Masimo Physicals, Nov. 10, 2021	403; ATH; HRS; LFND; NREL; CMP; MIL
1931	APL_MAS_ITC_00348969	APL_MAS_ITC_00348969	Video of Apple's Inspection of Masimo Physicals, Nov. 10, 2021	403; ATH; HRS; LFND; NREL; MIL
1932	APL_MAS_ITC_00348970	APL_MAS_ITC_00348970	Video of Apple's Inspection of Masimo Physicals, Nov. 10, 2021	403; ATH; HRS; LFND; NREL; MIL
1933	APL_MAS_ITC_00348971	APL_MAS_ITC_00348971	Video of Apple's Inspection of Masimo Physicals, Nov. 10, 2021	403; ATH; HRS; LFND; NREL; MIL
1934	APL_MAS_ITC_00348974	APL_MAS_ITC_00348974	Video of Apple's Inspection of Masimo Physicals, Nov. 10, 2021	403; ATH; HRS; LFND; NREL; MIL
1935	APL_MAS_ITC_00348975	APL_MAS_ITC_00348975	Video of Apple's Inspection of Masimo Physicals, Nov. 10, 2021	403; ATH; HRS; LFND; NREL; MIL
1936	APL_MAS_ITC_00348977	APL_MAS_ITC_00348977	Video of Apple's Inspection of Masimo Physicals, Nov. 10, 2021	403; ATH; HRS; LFND; NREL; MIL
1937	APL_MAS_ITC_00348979	APL_MAS_ITC_00348979	Video of Apple's Inspection of Masimo Physicals, Nov. 10, 2021	403; ATH; HRS; LFND; NREL; MIL
1938	APL_MAS_ITC_00348980	APL_MAS_ITC_00348987	Collection of Images from Apple's Inspection of Masimo Physicals, Nov. 10, 2021	403; ATH; HRS; LFND; NREL; CMP; MIL
1939	APL_MAS_ITC_00348988	APL_MAS_ITC_00348988	Video of Apple's Inspection of Masimo Physicals, Nov. 10, 2021	403; ATH; HRS; LFND; NREL; MIL
1940	APL_MAS_ITC_00348989	APL_MAS_ITC_00348991	Collection of Images from Apple's Inspection of Masimo Physicals, Nov. 10, 2021	403; ATH; HRS; LFND; NREL; CMP; MIL
1941	APL_MAS_ITC_00378976	APL_MAS_ITC_00378978	Collection of Images from Apple's Inspection of Masimo Physical MASITC_P_127	403; ATH; HRS; LFND; NREL; CMP; MIL
1942	MASITC_00966431	MASITC_00966431	Photograph of CPX-20 (back)	403; ATH; LFND; NREL; MIL
1943	MASITC_00966434	MASITC_00966434	Photograph of CPX-19 (back)	403; ATH; LFND; NREL; MIL
1944			Screenshots from MASITC_00584976	403; ATH; LFND; NREL; NP; MIL
1945			Screenshots from MASITC_00617720	403; ATH; LFND; NREL; NP; MIL
1946			Screenshots from MASITC_00618013	403; ATH; LFND; NREL; NP; MIL
1947			Screenshots from MASITC_00968497	403; ATH; LFND; NREL; NP; MIL
1948			Screenshots from MASITC_00971267	403; ATH; LFND; NREL; NP; MIL
1949			Screenshots from MASITC_00971518	403; ATH; LFND; NREL; NP; MIL
1950			Screenshots from MASITC_00971578	403; ATH; LFND; NREL; NP; MIL
1951			Screenshots from MASITC_00971974	403; ATH; LFND; NREL; NP; MIL
1952			Screenshots from MASITC_00976047	403; ATH; LFND; NREL; NP; MIL
1953			Screenshots from MASITC_00976130	403; ATH; LFND; NREL; NP; MIL
1954			Screenshots from MASITC_01060787	403; ATH; LFND; NREL; NP; MIL
1955			Screenshots from MASITC_01060788	403; ATH; LFND; NREL; NP; MIL
1956			Screenshots from MASITC_01060793	403; ATH; LFND; NREL; NP; MIL
1957			Screenshots from MASITC_01060803	403; ATH; LFND; NREL; NP; MIL
1958			Screenshots from MASITC_01060805	403; ATH; LFND; NREL; NP; MIL
1959			Screenshots from MASITC_01060817	403; ATH; LFND; NREL; NP; MIL
1960			Screenshots from MASITC_01060825	403; ATH; LFND; NREL; NP; MIL
1961			Screenshots from MASITC_01060827	403; ATH; LFND; NREL; NP; MIL

## Masimo's Trial Exhibit List and Apple's Objections


DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
1962			Screenshots from MASITC_01060838	403; ATH; LFND; NREL; NP; MIL
1963			Screenshots from MASITC_01060845	403; ATH; LFND; NREL; NP; MIL
1964			Screenshots from MASITC_01060847	403; ATH; LFND; NREL; NP; MIL
1965			Screenshots from MASITC_01060859	403; ATH; LFND; NREL; NP; MIL
1966			Screenshots from MASITC_01080093	403; ATH; LFND; NREL; NP; MIL
1967			Screenshots from MASITC_01081432	403; ATH; LFND; NREL; NP; MIL
1968			Screenshots from MASITC_01081434	403; ATH; LFND; NREL; NP; MIL
1969	MASITC_01281350	MASITC_01281350		REL; 403; LFND; ATH; HRS
1970	MASITC_01281346	MASITC_01281346		REL; 403; LFND; ATH; HRS
1971	MASITC_01365105	MASITC_01365248		REL; 403; LFND; ATH; HRS
1972				REL; 403; LFND; ATH; HRS; NP; NE
1973	MASITC_00972526	MASITC_00972537		REL; 403; LFND; ATH; HRS
1974	MASITC_00425793	MASITC_00425795		REL; 403; LFND; ATH; HRS
1975	MASITC_00959402	MASITC_00959406		REL; 403; LFND; ATH; HRS
1976	MASITC_01076948	MASITC_01076948		NREL; 403; LFND; ATH
1977			Appendix 1 to Madisetti Opening Expert Report - Curriculum Vitae of Dr. Vijay K. Madisetti	NREL; 403; LFND; ATH; HRS; NP; NE; IDSCR
1978			Appendix 2 to Madisetti Opening Expert Report - Materials Considered	NREL; 403; LFND; ATH; HRS; NP; NE; IDSCR
1979			U.S. Patent Appl. Pub. No. 2017/0325744	NREL; 403; LFND; ATH
1980			WITHDRAWN	
1981			WITHDRAWN	
1982			U.S. Patent No. D718,234	NREL; 403; LFND; ATH
1983			WITHDRAWN	
1984			WITHDRAWN	
1985			WITHDRAWN	
1986			Masimo Corp. et al. v. Apple Inc., Excerpts of Public Final Initial Determination on Violation of Section 337, ITC Inv. No 337-TA-1276	NREL; 403; LFND; ATH; HRS; NP; NE; MIL
1987			WITHDRAWN	
1988			WITHDRAWN	
1989			WITHDRAWN	
1990			WITHDRAWN	
1991			WITHDRAWN	
1992			WITHDRAWN	
1993			WITHDRAWN	
1994			WITHDRAWN	
1995			Masimo Corp. et al. v. Apple Inc., Apple's September 14, 2022 Public Second Corrected Post-Hearing Brief, ITC Inv. No 337-TA-1276	NREL; 403; LFND; ATH; HRS; NP; NE; MIL
1996			WITHDRAWN	
1997			WITHDRAWN	
1998			WITHDRAWN	
1999			WITHDRAWN	
2000			WITHDRAWN	

## Masimo's Trial Exhibit 68094 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
2001			WITHDRAWN	
2002			WITHDRAWN	
2003			WITHDRAWN	
2004			WITHDRAWN	
2005			WITHDRAWN	
2006			WITHDRAWN	
2007			WITHDRAWN	
2008			WITHDRAWN	
2009			WITHDRAWN	
2010			WITHDRAWN	
2011			WITHDRAWN	
2012			Appendix 1 to Madisetti Rebuttal Report - Materials Considered	NREL; 403; LFND; ATH; HRS; NP; NE; IDSCR
2013	MASITC_00584694			REL; 403; LFND; ATH
2014	MASITC_00958194			REL; 403; LFND; ATH
2015	MASITC_00958794			REL; 403; LFND; ATH
2016	MASITC_01060793			REL; 403; LFND; ATH
2017	MASITC_01060827			REL; 403; LFND; ATH
2018	APL_MAS_ITC_02562849		Video from the Inspection by Apple Experts of Masimo Physicals, Mar. 14, 2024	NREL; 403; LFND; HRS; ILLEG
2019	APL_MAS_ITC_02562851		Video from the Inspection by Apple Experts of Masimo Physicals, Mar. 14, 2026	NREL; 403; LFND; HRS; ILLEG
2020	APL_MAS_ITC_02562855		Video from the Inspection by Apple Experts of Masimo Physicals, Mar. 14, 2030	NREL; 403; LFND; HRS; ILLEG
2021	APL_MAS_ITC_02562856		Video from the Inspection by Apple Experts of Masimo Physicals, Mar. 14, 2031	NREL; 403; LFND; HRS; ILLEG
2022	MASA03584132	MASA03584135		NREL; 403; LFND; ATH; IDSCR
2023	MASA03584136	MASA03584137		NREL; 403; LFND; ATH; IDSCR
2024	MASA03584142	MASA03584146		NREL; 403; LFND; ATH; IDSCR
2025	MASA03584160	MASA03584161		NREL; 403; LFND; ATH; IDSCR
2026	MASA03584164	MASA03584165		NREL; 403; LFND; ATH; IDSCR
2027	MASA03584168	MASA03584169		NREL; 403; LFND; ATH; IDSCR
2028	MASA03584170	MASA03584171		NREL; 403; LFND; ATH; IDSCR
2029	MASA03584184	MASA03584185		NREL; 403; LFND; ATH; IDSCR
2030	MASA03584232	MASA03584233		NREL; 403; LFND; ATH; IDSCR
2031	MASA03584238	MASA03584239		NREL; 403; LFND; ATH; IDSCR
2032	MASA03584242	MASA03584243		NREL; 403; LFND; ATH; IDSCR
2033	MASA03584246	MASA03584247		NREL; 403; LFND; ATH; IDSCR
2034	MASA03584260	MASA03584261		NREL; 403; LFND; ATH; IDSCR
2035	MASA03584397	MASA03584398		NREL; 403; LFND; ATH; IDSCR
2036	MASA03584399	MASA03584400		NREL; 403; LFND; ATH; IDSCR
2037	MASA03584401	MASA03584402		NREL; 403; LFND; ATH; IDSCR
2038	MASA03584421	MASA03584424		NREL; 403; LFND; ATH; IDSCR
2039	MASA03584434	MASA03584435		NREL; 403; LFND; ATH; IDSCR
2040	MASA03584546	MASA03584563		NREL; 403; LFND; ATH; HRS; IDSCR
2041	MASITC_00344647			NREL; 403; LFND; ATH; HRS



## Masimo's Trial Exhibit 68095 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
2042	MASITC_00344662			NREL; 403; LFND; ATH; HRS
2043	MASITC_00344685			NREL; 403; LFND; ATH; HRS
2044	MASITC_00344692			NREL; 403; LFND; ATH; HRS
2045	MASITC_00345680			NREL; 403; LFND; ATH; HRS
2046	MASITC_00427882			NREL; 403; LFND; ATH; HRS
2047	MASITC_00452255			NREL; 403; LFND; ATH; HRS
2048	MASITC_00516398			NREL; 403; LFND; ATH; HRS
2049	MASITC_00959546			NREL; 403; LFND; ATH; HRS
2050	MASITC_01076790			NREL; 403; LFND; ATH; HRS
2051	MASITC_01080111			NREL; 403; LFND; ATH; HRS
2052	MASITC_01080119			NREL; 403; LFND; ATH; HRS
2053	MASITC_01080317			NREL; 403; LFND; ATH; HRS
2054	MASITC_01080773			NREL; 403; LFND; ATH; NP; IDSCR
2055	MASITC_01080785			NREL; 403; LFND; ATH; NP; IDSCR
2056	MASITC_01080791			NREL; 403; LFND; ATH; NP; IDSCR
2057	MASITC_01080829			NREL; 403; LFND; ATH; NP; IDSCR
2058	MASITC_01080838			NREL; 403; LFND; ATH; NP; IDSCR
2059	MASITC_01083125			NREL; 403; LFND; ATH
2060	MASITC_01213086			NREL; 403; LFND; ATH; HRS
2061				NREL; 403; LFND; ATH; HRS; NP; LA
2062	MASITC_01271347			NREL; 403; LFND; ATH; HRS; NP; IDSCR
2063			Appendix 1 to Madisetti Reply Report - Materials Considered	NREL; 403; LFND; ATH; HRS; NP; NE; IDSCR
2064			Masimo's Requests for Rehearing in IPR2023-00774 (D'279 Patent)	NREL; 403; LFND; ATH; HRS; NP; NE
2065			Masimo's Requests for Rehearing in IPR2023-00702 (D'842 Patent)	NREL; 403; LFND; ATH; HRS; NP; NE
2066			Masimo's Requests for Rehearing in IPR2023-00728 (D'936 Patent)	NREL; 403; LFND; ATH; HRS; NP; NE
2067			Masimo's Requests for Rehearing in IPR2023-00831 (D'131 Patent)	NREL; 403; LFND; ATH; HRS; NP; NE
2068			WITHDRAWN	
2069			WITHDRAWN	
2070			D'279 IPR Petition	NREL; 403; LFND; ATH; HRS; NP; NE
2071			Duckworth D'279 IPR Declaration	NREL; 403; LFND; ATH; HRS; NP; NE
2072			Delman D'279 IPR Declaration	NREL; 403; LFND; ATH; HRS; NP; NE
2073			WITHDRAWN	
2074			WITHDRAWN	
2075			WITHDRAWN	
2076			WITHDRAWN	
2077			WITHDRAWN	

## Masimo's Trial Exhibit 68096 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
2078			U.S. Patent No. 10,942,491 File History	NREL; 403; LFND; ATH; HRS
2079			U.S. Patent No. 11,474,483 File History	NREL; 403; LFND; ATH; HRS
2080			WITHDRAWN	
2081			WITHDRAWN	
2082			WITHDRAWN	
2083			WITHDRAWN	
2084			WITHDRAWN	
2085			WITHDRAWN	
2086	APL_DEL03013810	APL_DEL03013814		REL; 403; LFND; HRS
2087	APL_DEL1009346	APL_DEL1009424		REL; 403; LFND; HRS
2088			U.S. Patent No. 10,984,911 and file history	NREL; 403; LFND; ATH; HRS; NP
2089			U.S. Patent No. 7,930,197	NREL; 403; LFND; ATH; HRS; NP
2090			U.S. Patent No. 5,732,333	NREL; 403; LFND; ATH; HRS; NP
2091			U.S. Patent No. 5,179,702	NREL; 403; LFND; ATH; HRS; NP
2092			U.S. Patent No. 6,195,676	NREL; 403; LFND; ATH; HRS; NP
2093			U.S. Patent No. 6,914,128	NREL; 403; LFND; ATH; HRS; NP
2094			U.S. Patent No. 7,980,443	NREL; 403; LFND; ATH; HRS; NP
2095			U.S. Patent No. 8,875,972	NREL; 403; LFND; ATH; HRS; NP
2096			U.S. Patent No. 9,913,647	NREL; 403; LFND; ATH; HRS; NP
2097			U.S. Patent No. 7,013,469	NREL; 403; LFND; ATH; HRS; NP
2098			U.S. Patent No. 7,017,162	NREL; 403; LFND; ATH; HRS; NP
2099			U.S. Patent No. 11,381,445	NREL; 403; LFND; ATH; HRS; NP
2100			U.S. Patent No. 9,131,882	NREL; 403; LFND; ATH; HRS; NP
2101			U.S. Patent No. 9,167,995	NREL; 403; LFND; ATH; HRS; NP
2102			U.S. Patent No. 9,241,662	NREL; 403; LFND; ATH; HRS; NP
2103			U.S. Patent No. 9,351,675	NREL; 403; LFND; ATH; HRS; NP
2104			U.S. Patent No. 9,549,696	NREL; 403; LFND; ATH; HRS; NP
2105			U.S. Patent No. 10,123,726	NREL; 403; LFND; ATH; HRS; NP
2106			U.S. Patent No. 10,251,585	NREL; 403; LFND; ATH; HRS; NP
2107			U.S. Patent No. 7,764,982	NREL; 403; LFND; ATH; HRS; NP
2108			U.S. Patent No. 10,367,677 and File History	NREL; 403; LFND; ATH; HRS; NP
2109			U.S. Application No. 17/028,655 and File History	NREL; 403; LFND; ATH; HRS; NP; MIL
2110			U.S. Application No. 11/367,013 and File History	NREL; 403; LFND; ATH; HRS; NP
2111			U.S. Application No. 12/422,915 and File History	NREL; 403; LFND; ATH; HRS; NP
2112			U.S. Application No. 13/776,065 and File History	NREL; 403; LFND; ATH; HRS; NP
2113			U.S. Application No. 14/472,760 and File History	NREL; 403; LFND; ATH; HRS; NP
2114			U.S. Application No. 15/694,541 and File History	NREL; 403; LFND; ATH; HRS; NP
2115			U.S. Application No. 16/437,611 and File History	NREL; 403; LFND; ATH; HRS; NP
2116			U.S. Application No. 11/367,013 and File History	NREL; 403; LFND; ATH; HRS; NP
2117			U.S. Application No. 11/366,995 and File History	NREL; 403; LFND; ATH; HRS; NP
2118			U.S. Application No. 11/366,209 and File History	NREL; 403; LFND; ATH; HRS; NP; MIL
2119			U.S. Application No. 11/366,210 and File History	NREL; 403; LFND; ATH; HRS; NP
2120			U.S. Application No. 11/366,833 and File History	NREL; 403; LFND; ATH; HRS; NP
2121			U.S. Application No. 11/366,997 and File History	NREL; 403; LFND; ATH; HRS; NP
2122			U.S. Application No. 11/367,034 and File History	NREL; 403; LFND; ATH; HRS; NP
2123			U.S. Application No. 11/367,036 and File History	NREL; 403; LFND; ATH; HRS; NP
2124			U.S. Application No. 11/367,033 and File History	NREL; 403; LFND; ATH; HRS; NP; MIL

## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
2125			U.S. Application No. 11/367,014 and File History	NREL; 403; LFND; ATH; HRS; NP
2126			U.S. Application No. 11/366,208 and File History	NREL; 403; LFND; ATH; HRS; NP
2127			U.S. Application No. 12/839,326 and File History	NREL; 403; LFND; ATH; HRS; NP
2128			U.S. Application No. 13/477,975 and File History	NREL; 403; LFND; ATH; HRS; NP
2129			<a href="https://patentlyo.com/patent/2021/03/continued-growth-inventors.html">https://patentlyo.com/patent/2021/03/continued-growth-inventors.html</a>	NREL; 403; LFND; ATH; HRS; NP
2130	APL-MAS_00980152			NREL; 403; LFND; HRS; DUP; INC
2131	APL-MAS_00980159	APL-MAS_00980169		NREL; 403; LFND; HRS
2132	APL-MAS_00587611	APL-MAS_00587614		NREL; 403; LFND; HRS
2133			Appendix A to Stoll Reply Report - Materials Considered	NREL; 403; LFND; ATH; HRS; NP; NE; IDSCR
2134			Appendix B-1 - USPTO Patent Center Records, D883,279	NREL; 403; LFND; ATH; HRS; NP; NE; IDSCR
2135			Appendix B-2 - USPTO Patent Center Records, D947,842	NREL; 403; LFND; ATH; HRS; NP; NE; IDSCR
2136			Appendix B-3 - USPTO Patent Center Records, D962,936	NREL; 403; LFND; ATH; HRS; NP; NE; IDSCR
2137			Appendix B-4 - USPTO Patent Center Records, D735,131	NREL; 403; LFND; ATH; HRS; NP; NE; IDSCR
2138			Appendix B-5 - USPTO Patent Center Records, 10,627,783	NREL; 403; LFND; ATH; HRS; NP; NE; IDSCR
2139			Appendix B-6 - USPTO Patent Center Records, 10,942,491	NREL; 403; LFND; ATH; HRS; NP; NE; IDSCR
2140			Appendix B-7 - USPTO Patent Center Records, 11,474,483	NREL; 403; LFND; ATH; HRS; NP; NE; IDSCR
2141			Appendix A to Expert Report of Robert Stoll - Curriculum Vitae of Robert L. Stoll	NREL; 403; LFND; ATH; HRS; NP; NE; IDSCR
2142			Appendix B to Expert Report of Robert Stoll - Materials Considered	NREL; 403; LFND; ATH; HRS; NP; NE; IDSCR
2143	MASAD04144973	MASAD04144983	U.S. Pat. No. 6,775,566 ("Nissila")	NREL; 403; LFND; ATH; HRS; DUP
2144	MASAD00007358	MASAD00007358		NREL; 403; LFND
2145	MASAD00014301	MASAD00014301		NREL; 403; LFND
2146	MASAD00116642	MASAD00116642		NREL; 403; LFND
2147	MASAD04144463	MASAD04144465	OXFORD ADVANCED LEARNER'S DICTIONARY (defining "wearable" as "a small computing device that you can wear, for example on your wrist")	NREL; 403; LFND; ATH; HRS; MM
2148	PEI_SUBPOENA_000028	PEI_SUBPOENA_000028		NREL; 403; LFND; ATH; HRS
2149	PEI_SUBPOENA_000029	PEI_SUBPOENA_000029		NREL; 403; LFND; ATH; HRS
2150			Alan Oslan CV	NREL; 403; LFND; ATH; HRS; NP; NE; IDSCR
2151			U.S. Pat. No. 10,687,745 (Al-Ali)	NREL; 403; LFND; ATH; HRS; NP; IDSCR; MIL
2152			Gilles (U.S. Pat. No. 4,635,646)	NREL; 403; LFND; ATH; HRS; NP; IDSCR
2153			Weiss (U.S. Pat. No. 5,623,926)	NREL; 403; LFND; ATH; HRS; NP; IDSCR
2154	MASAD00018913	MASAD00018946	Kegasawa (U.S. Pat. Pub. No. 2016/0338598)	NREL; 403; LFND; ATH; HRS
2155			Polar Electro Inc. (Sander Werring) Decl. (authenticating the PEI documents)	NREL; 403; LFND; ATH; HRS; NP; IDSCR
2156			Polar Electro Inc. (Peggy Ang) Decl. (authenticating the PEI documents)	NREL; 403; LFND; ATH; HRS; NP; IDSCR
2157	MASAD00019047	MASAD00019055	CN104181809A (Contec's patent)	NREL; 403; LFND; ATH; HRS; FOR
2158			WITHDRAWN	
2159			WITHDRAWN	
2160			IPR2023-00635 File History	NREL; 403; LFND; ATH; HRS; NP; NE; IDSCR; MIL
2161			WITHDRAWN	

## Masimo's Trial Exhibit 68198 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
2162			Certificate for the translation in MASAD00251323 (Ushiyama)	NREL; 403; LFND; ATH; HRS; NP; IDSCR
2163			WITHDRAWN	
2164			WITHDRAWN	
2165			WITHDRAWN	
2166			WITHDRAWN	
2167	APL_DEL00723772	APL_DEL00723791	Masimo W1 User Guide	NREL; 403; LFND; HRS
2168	MASAD00006999	MASAD00007002	Operator's Manual for the W1	NREL; 403; LFND; HRS; ILLEG
2169			"detect," WILEY ELECTRICAL AND ELECTRONICS ENGINEERING DICTIONARY (2004)	NREL; 403; LFND; ATH; HRS; MM; NP; IDSCR
2170	MASAD00073612	MASAD00073612		NREL; 403; LFND
2171	MASAD00059684	MASAD00059689		NREL; 403; LFND; ATH; HRS
2172			Merriam Webster Dictionary (defining "mount" as "to attach to a support")	NREL; 403; LFND; ATH; HRS; MM; NP; IDSCR
2173	MASAD00053444	MASAD00053444		NREL; 403; LFND
2174	MASAD00237001	MASAD00237001		NREL; 403; LFND; ATH; HRS
2175	MASAD00236994	MASAD00236995		NREL; 403; LFND; ATH; HRS
2176	MASAD00236996	MASAD00236997		NREL; 403; LFND; ATH; HRS
2177	MASAD00237002	MASAD00237006		NREL; 403; LFND; ATH; HRS
2178	MASAD00071298	MASAD00071298		NREL; 403; LFND
2179	MASAD00071221	MASAD00071275		NREL; 403; LFND; HRS; ILLEG
2180	MASAD00033524	MASAD00033524		NREL; 403; LFND; HRS
2181	MASAD00033533	MASAD00033541		NREL; 403; LFND; HRS
2182	MASAD00012158	MASAD00012162		NREL; 403; LFND
2183	MASA03206438	MASA03206451		NREL; 403; LFND; ATH; HRS
2184	MASAD00237022	MASAD00237026		NREL; 403; LFND; ATH; HRS
2185			McGraw-Hill Dictionary of Scientific and Technical Terms (6th Ed. 2003)	NREL; 403; LFND; ATH; HRS; MM; NP; IDSCR
2186	MASAD00237465	MASAD00237510	Masimo W1 marketing slide deck	NREL; 403; LFND; ATH; HRS
2187			R.H. French et al., Optical Properties of Materials for Concentrator Photovoltaic Systems, IEEE Photovoltaics Specialist Conference (2009)	NREL; 403; LFND; ATH; HRS; NP; IDSCR
2188	MASA03073980	MASA03073982	Lexan Helathcare Resin HP2 specification	NREL; 403; LFND; HRS; ILLEG
2189			Cambridge Dctionary, "appreciable"	NREL; 403; LFND; ATH; HRS; MM; NP; IDSCR
2190			"refractive index", COMPREHENSIVE DICTIONARY OF ELECTRICAL ENGINEERING 540 (1999)	NREL; 403; LFND; ATH; HRS; MM; NP; IDSCR
2191			WITHDRAWN	
2192	MASAD00237020	MASAD00237021		NREL; 403; LFND; ATH
2193	MASAD00237007	MASAD00237017		NREL; 403; LFND; ATH
2194	MASAD00237018	MASAD00237019		NREL; 403; LFND; ATH

## Masimo's Trial Exhibit 68099 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
2195	MASAD00236999	MASAD00236999		REL; 403; LFND; ATH; HRS
2196	MASAD00254494	MASAD00254495		REL; 403; LFND; ATH; HRS
2197	MASAD00006403	MASAD00006403		REL; 403; LFND
2198	MASAD00007367	MASAD00007367		REL; 403; LFND
2199	MASAD00006616	MASAD00006622		REL; 403; LFND; HRS
2200	MASAD00184338	MASAD00184343		REL; 403; LFND; HRS
2201	MASITC_01299351	MASITC_01299355		REL; 403; LFND; HRS
2202	MASAD00008614	MASAD00008615		REL; 403; LFND; HRS
2203	MASAD00071280	MASAD00071280		REL; 403; LFND
2204	MASAD00124013	MASAD00124013		REL; 403; LFND; HRS
2205			SABIC brochure "Bold + Bright – Advanced Materials for LED Design", bro_pol_sabic pla 6826 led_en_260418 ( <a href="https://www.sabic.com/en/Images/POLAdvanced-Materials-for-LED-EN_tcm1010-5330.pdf">https://www.sabic.com/en/Images/POLAdvanced-Materials-for-LED-EN_tcm1010-5330.pdf</a> )	NREL; 403; LFND; ATH; HRS; NP; IDSCR
2206			Bicycling magazine, "Beep Beep ... Beep Beep Beep—A Buyer's Guide to Heart Rate Monitors" (May 1991)	NREL; 403; LFND; ATH; HRS; NP; IDSCR
2207			Men's Fitness, Volume 9 Number 10, magazine article is entitled "With every beat of your heart" (October 1993)	NREL; 403; LFND; ATH; HRS; NP; IDSCR
2208			The Los Angeles Times newspaper article in the GEAR AND GADGETS section entitled "Keeping Fitness Programs on Track When You're On the Road" (September 5, 1993)	NREL; 403; LFND; ATH; HRS; NP; IDSCR
2209			USA TODAY newspaper advertisement "Treadmills lead the way" (September 21, 1989)	NREL; 403; LFND; ATH; HRS; NP; IDSCR
2210			Fitness shopping spree tips offered, The Palladium-Times, Aug. 16, 1991	NREL; 403; LFND; ATH; HRS; NP; IDSCR
2211			SPORTY GIFTS FOR, Plain Dealer (Cleveland, OH), Nov. 24, 1991	NREL; 403; LFND; ATH; HRS; NP; IDSCR
2212			Portable Fitness Aids, Chicago Sun-Times (IL), Sept. 26, 1993	NREL; 403; LFND; ATH; HRS; NP; IDSCR
2213			Moul, The effects of 16-week walking and 16-week weight-training programs on the performance of men and women ages 65-77 on the Ross Information Processing Assessment, 1993	NREL; 403; LFND; ATH; HRS; NP; IDSCR
2214			WITHDRAWN	
2215			Amended Certification of Sander Werring Certifying Records Pursuant to Federal Rule of Evidence 902 (12)	NREL; 403; LFND; ATH; HRS; NP; IDSCR; NE
2216	MASAD04145237	MASAD04145272	certified English translation of PEI_SUBPOENA_000001-PEI_SUBPOENA_000019	NREL; 403; LFND; ATH; HRS
2217			<b>Photos of MASAD_P_054 (A-E)</b>	NREL; 403; LFND; ATH; NP; IDSCR
2218	APL_DEL04028846	APL_DEL04028848	Enclosure, THE NEW OXFORD AMERICAN ENGLISH (2001)	NREL; 403; LFND; HRS; MM

**Masimo's Trial Exhibit List and Apple's Objections**

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
2219			Marvell's 88W8360 chip set, <a href="https://www.edn.com/vendor-introduces-ewc-based-wlan-chip-set/">https://www.edn.com/vendor-introduces-ewc-based-wlan-chip-set/</a> . Published Oct. 17, 2005 (last accessed on Jan. 3, 2024)	NREL; 403; LFND; HRS
2220	APL_DEL03851011	APL_DEL03851011	Michael Rougeu, Apple's latest patents cover heart rate monitors and hover touch displays, TECHRADAR (Dec. 24, 2013)	NREL; 403; LFND; HRS
2221	APL_DEL03851002	APL_DEL03851002	Brian Dolan, Apple patents "seamless" heart rate sensor for authentication, personalization, MOBIHEALTHNEWS (Jan. 02, 2014)	NREL; 403; LFND; HRS
2222	APL_DEL03850995	APL_DEL03850995	Michelle Meyers, Apple awarded stocking full of patents, including heart monitor, CNET (Dec. 24, 2013)	NREL; 403; LFND; HRS
2223	APL_DEL03850996	APL_DEL03850996	Tim Stevens, Apple's Seamlessly Embedded Heart Rate Monitor could turn the iPhone into a new-age mood ring, ENGADGET (Jul. 19, 2019)	NREL; 403; LFND; HRS
2224	APL_DEL03851012	APL_DEL03851021	Nico Bruining, et. al, Acquisition and analysis of cardiovascular signals on smartphones: potential, pitfalls and perspectives, 2014 Vol. 21 Preventive Cardiology (Sept. 3, 2014)	NREL; 403; LFND; HRS
2225	APL_DEL03850998	APL_DEL03851000	Smartphones in Clinical Practice, Medical Education, and Research, ARCH INTERN MED, Vol. 171 (No. 14), July 25, 2011	NREL; 403; LFND; HRS
2226	APL_DEL03850997	APL_DEL03850997	Rob Williams, Apple Patents 'Touch and Hover' Sensing, Embedded Heart Rate Monitor, HOT HARDWARE (Dec. 24, 2013)	NREL; 403; LFND; HRS
2227			the Wayback Machine page of the DC RAINMAKER article archived on August 14, 2014	NREL; 403; LFND; ATH; HRS; NP; IDSCR
2228			the Wayback Machine page of the medGadget article archived on January 16, 2014	NREL; 403; LFND; ATH; HRS; NP; IDSCR
2229			Translation certificate for Oranger Watch 2.0/CMS50K document	NREL; 403; LFND; ATH; HRS; NP; IDSCR, NE
2230			Translation certificate for Oranger Watch 2.0/CMS50K document	NREL; 403; LFND; ATH; HRS; NP; IDSCR, NE
2231			Translation certificate for Oranger Watch 2.0/CMS50K document	NREL; 403; LFND; ATH; HRS; NP; IDSCR, NE
2232			Translation certificate for Oranger Watch 2.0/CMS50K document	NREL; 403; LFND; ATH; HRS; NP; IDSCR, NE
2233			Translation certificate for CN 104181809 A	NREL; 403; LFND; ATH; HRS; NP; IDSCR, NE
2234			Drew et. al, Practice Standards for Electrocardiographic Monitoring in Hospital Settings, AHA Scientific Statement, 2721-46 (2004)	NREL; 403; LFND; ATH; HRS; NP; IDSCR
2235			Hamamatsu Si PIN photodiodes datasheet, available at <a href="https://www.hamamatsu.com/us/en/product/optical-sensors/photodiodes/si-photodiodes/S5821-03.html">https://www.hamamatsu.com/us/en/product/optical-sensors/photodiodes/si-photodiodes/S5821-03.html</a> (last visited Nov. 29, 2023).	NREL; 403; LFND; ATH; HRS; NP; IDSCR
2236			certificate for the translation in MASAD00251218 for Hu [2-24-2016]	NREL; 403; LFND; ATH; HRS; NP; IDSCR, NE
2237	MASA02215050	MASA02215056	Advertisement email from Withings showing the Withings Move	NREL; 403; LFND; ATH; HRS

## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
2238			Surround, MERRIAM- WEBSTER DICTIONARY ONLINE, <a href="https://www.merriam-webster.com/dictionary/surround">https://www.merriam-webster.com/dictionary/surround</a>	NREL; 403; LFND; ATH; HRS; NP; IDSCR; MM
2239	APL_DEL01460441	APL_DEL01460443	Paul Lamkin, Apple Watch Series 4 Named Wearable Of The Year, Forbes (Dec. 13, 2018)	NREL; 403; LFND; HRS
2240	APL_DEL01460418	APL_DEL01460429	John Rayes, 8 Best ECG Smartwatches & Devices Of 2022, JustWearable (Jan. 12, 2022)	NREL; 403; LFND; HRS
2241	APL_DEL01460444	APL_DEL01460450	Catlin McGarry, Apple Watch Series 4 review, Tom's Guide (Sept. 17, 2021)	NREL; 403; LFND; HRS
2242			Oslan photo 1 (Polar Pacer physical device)	NREL; 403; LFND; ATH; NP; IDSCR
2243			Oslan photo 2 (Polar Pacer physical device)	NREL; 403; LFND; ATH; NP; IDSCR
2244			Oslan photo 3 (Polar Pacer physical device)	NREL; 403; LFND; ATH; NP; IDSCR
2245			Oslan photo 4 (Polar Pacer physical device)	NREL; 403; LFND; ATH; NP; IDSCR
2246			Oslan photo 5 (Polar Pacer physical device)	NREL; 403; LFND; ATH; NP; IDSCR
2247			Oslan photo 6 (Polar Pacer physical device)	NREL; 403; LFND; ATH; NP; IDSCR
2248			Oslan photo 7 (Polar Pacer physical device)	NREL; 403; LFND; ATH; NP; IDSCR
2249			Oslan photo 8 (Polar Pacer physical device)	NREL; 403; LFND; ATH; NP; IDSCR
2250			Oslan photo 9 (Polar Pacer physical device function testing)	NREL; 403; LFND; ATH; NP; IDSCR
2251			Oslan photo 10 (Polar Pacer physical device)	NREL; 403; LFND; ATH; NP; IDSCR
2252			Oslan photo 11 (Polar Pacer physical device)	NREL; 403; LFND; ATH; NP; IDSCR
2253			Oslan photo 12 (Polar Pacer physical device)	NREL; 403; LFND; ATH; NP; IDSCR
2254			Oslan photo 13 (Polar Pacer physical device)	NREL; 403; LFND; ATH; NP; IDSCR
2255			Oslan photo 14 (Polar Pacer physical device)	NREL; 403; LFND; ATH; NP; IDSCR
2256			Oslan photo 15 (Polar Pacer physical device)	NREL; 403; LFND; ATH; NP; IDSCR
2257			Oslan photo 16 (Polar Pacer physical device)	NREL; 403; LFND; ATH; NP; IDSCR
2258			Oslan photo 17 (Polar Pacer physical device circuitry testing)	NREL; 403; LFND; ATH; NP; IDSCR
2259			Oslan photo 18 (Polar Pacer physical device circuitry testing)	NREL; 403; LFND; ATH; NP; IDSCR
2260			Oslan photo 19 (Polar Pacer physical device)	NREL; 403; LFND; ATH; NP; IDSCR
2261			Oslan photo 20 (Polar Pacer physical device circuitry testing oscilloscope waveform)	NREL; 403; LFND; ATH; NP; IDSCR
2262			Oslan photo 21 (Polar Pacer physical device circuitry testing oscilloscope waveform)	NREL; 403; LFND; ATH; NP; IDSCR
2263			Oslan photo 22 (Polar Pacer physical device circuitry testing oscilloscope waveform)	NREL; 403; LFND; ATH; NP; IDSCR
2264			Oslan photo 23 (Polar Pacer physical device)	NREL; 403; LFND; ATH; NP; IDSCR
2265			Oslan photo 24 (Polar Pacer physical device)	NREL; 403; LFND; ATH; NP; IDSCR
2266			Oslan photo 25 (Polar Pacer physical device circuitry testing)	NREL; 403; LFND; ATH; NP; IDSCR
2267			Oslan photo 26 (Polar Pacer physical device circuitry testing oscilloscope waveform)	NREL; 403; LFND; ATH; NP; IDSCR
2268			Oslan photo 27 (Polar Pacer physical device circuitry testing oscilloscope waveform)	NREL; 403; LFND; ATH; NP; IDSCR
2269			Oslan photo 28 (Polar Pacer physical device circuitry testing oscilloscope waveform)	NREL; 403; LFND; ATH; NP; IDSCR
2270			Oslan photo 29 (Polar Pacer physical device circuitry testing)	NREL; 403; LFND; ATH; NP; IDSCR

## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
2271			Oslan photo 30 (Polar Pacer physical device circuitry testing oscilloscope waveform)	NREL; 403; LFND; ATH; NP; IDSCR
2272			Oslan photo 31 (Polar Pacer physical device)	NREL; 403; LFND; ATH; NP; IDSCR
2273			Oslan photo 32 (Polar Pacer physical device)	NREL; 403; LFND; ATH; NP; IDSCR
2274			Oslan photo 33 (Polar Pacer physical device)	NREL; 403; LFND; ATH; NP; IDSCR
2275			Oslan photo 34 (Polar Pacer physical device)	NREL; 403; LFND; ATH; NP; IDSCR
2276			Oslan photo 35 (Polar Pacer physical device)	NREL; 403; LFND; ATH; NP; IDSCR
2277			Oslan photo 36 (Polar Pacer physical device)	NREL; 403; LFND; ATH; NP; IDSCR
2278			Oslan photo 37 (Polar Pacer physical device function testing)	NREL; 403; LFND; ATH; NP; IDSCR
2279			Oslan photo 38 (Polar Pacer physical device)	NREL; 403; LFND; ATH; NP; IDSCR
2280			Oslan photo 39 (Polar Pacer physical device)	NREL; 403; LFND; ATH; NP; IDSCR
2281			Oslan photo 40 (Polar Pacer physical device)	NREL; 403; LFND; ATH; NP; IDSCR
2282			Oslan photo 41 (Polar Pacer physical device)	NREL; 403; LFND; ATH; NP; IDSCR
2283			Oslan photo 42 (Polar Pacer physical device)	NREL; 403; LFND; ATH; NP; IDSCR
2284			Oslan photo 43 (Polar Pacer physical device)	NREL; 403; LFND; ATH; NP; IDSCR
2285			Oslan photo 44 (Contec CMS50K physical device)	NREL; 403; LFND; ATH; NP; IDSCR
2286			Oslan photo 45 (Contec CMS50K physical device)	NREL; 403; LFND; ATH; NP; IDSCR
2287			Oslan photo 46 (Contec CMS50K physical device)	NREL; 403; LFND; ATH; NP; IDSCR
2288			Oslan photo 47 (Contec CMS50K physical device)	NREL; 403; LFND; ATH; NP; IDSCR
2289			Oslan photo 48 (Contec CMS50K physical device function testing)	NREL; 403; LFND; ATH; NP; IDSCR
2290			Oslan photo 49 (Contec CMS50K physical device function testing)	NREL; 403; LFND; ATH; NP; IDSCR
2291			Oslan photo 50 (Contec CMS50K physical device function testing)	NREL; 403; LFND; ATH; NP; IDSCR
2292			Oslan photo 51 (Epson Pulsense PS-100 physical device)	NREL; 403; LFND; ATH; NP; IDSCR
2293			Oslan photo 52 (Epson Pulsense PS-100 physical device)	NREL; 403; LFND; ATH; NP; IDSCR
2294			Oslan photo 53 (Epson Pulsense PS-100 physical device)	NREL; 403; LFND; ATH; NP; IDSCR
2295			Oslan photo 54 (Epson Pulsense PS-100 physical device)	NREL; 403; LFND; ATH; NP; IDSCR
2296			Oslan photo 55 (Epson Pulsense PS-100 physical device)	NREL; 403; LFND; ATH; NP; IDSCR
2297			Oslan photo 56 (Epson Pulsense PS-100 physical device)	NREL; 403; LFND; ATH; NP; IDSCR
2298			Oslan photo 57 (Epson Pulsense PS-100 physical device)	NREL; 403; LFND; ATH; NP; IDSCR
2299			Oslan photo 58 (W1 Original Electrode Design)	NREL; 403; LFND; ATH; NP; IDSCR
2300			Oslan photo 59 (W1 Wave Electrode Design)	NREL; 403; LFND; ATH; NP; IDSCR
2301			Oslan photo 60 (W1 Original Electrode Design)	NREL; 403; LFND; ATH; NP; IDSCR
2302			Oslan photo 61 (Freedom Original Electrode Design)	NREL; 403; LFND; ATH; NP; IDSCR
2303			Oslan photo 62 (Masimo Health Module Original Electrode Design)	NREL; 403; LFND; ATH; NP; IDSCR
2304			Oslan photo 63 (W1 Original Electrode Design)	NREL; 403; LFND; ATH; NP; IDSCR
2305			Oslan photo 64 (W1 Original Electrode Design)	NREL; 403; LFND; ATH; NP; IDSCR
2306			Oslan photo 65 (W1 Original Electrode Design)	NREL; 403; LFND; ATH; NP; IDSCR
2307			Oslan photo 66 (W1 Original Electrode Design)	NREL; 403; LFND; ATH; NP; IDSCR
2308			Oslan photo 67 (W1 Original Electrode Design)	NREL; 403; LFND; ATH; NP; IDSCR
2309			Oslan photo 68 (W1 ECG function testing)	NREL; 403; LFND; ATH; NP; IDSCR
2310			Oslan photo 69 (Masimo Health Module Original Design conductivity testing)	NREL; 403; LFND; ATH; NP; IDSCR



## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
2311			Oslan photo 70 (Masimo Health Module Original Design conductivity testing)	NREL; 403; LFND; ATH; NP; IDSCR
2312			Oslan photo 71 ("Transparency" Testing)	NREL; 403; LFND; ATH; NP; IDSCR
2313			Oslan photo 72 ("Transparency" Testing)	NREL; 403; LFND; ATH; NP; IDSCR
2314			Oslan photo 73 ("Transparency" Testing)	NREL; 403; LFND; ATH; NP; IDSCR
2315			Oslan photo 74 ("Transparency" Testing)	NREL; 403; LFND; ATH; NP; IDSCR
2316			Oslan photo 75 (W1 Original Electrode Design)	NREL; 403; LFND; ATH; NP; IDSCR
2317			Oslan photo 76 (Masimo Health Module optic board)	NREL; 403; LFND; ATH; NP; IDSCR
2318			Oslan photo 77 (W1 Original Electrode Design)	NREL; 403; LFND; ATH; NP; IDSCR
2319			Oslan photo 78 (W1 Original Electrode Design)	NREL; 403; LFND; ATH; NP; IDSCR
2320			Oslan photo 79 ("Transparency" Testing)	NREL; 403; LFND; ATH; NP; IDSCR
2321			Oslan photo 80 ("Transparency" Testing)	NREL; 403; LFND; ATH; NP; IDSCR
2322			Oslan photo 81 ("Transparency" Testing)	NREL; 403; LFND; ATH; NP; IDSCR
2323			Oslan photo 82 ("Transparency" Testing)	NREL; 403; LFND; ATH; NP; IDSCR
2324			Oslan photo 83 (W1 Original Electrode Design)	NREL; 403; LFND; ATH; NP; IDSCR
2325			Oslan photo 84 (Masimo Health Module lens exterior)	NREL; 403; LFND; ATH; NP; IDSCR
2326			Oslan photo 85 (Masimo Health Module lens interior)	NREL; 403; LFND; ATH; NP; IDSCR
2327			Oslan photo 86 (Masimo Health Module lens exterior)	NREL; 403; LFND; ATH; NP; IDSCR
2328			Oslan CAD file image 1 of MASAD00007358	NREL; 403; LFND; ATH; NP; IDSCR
2329			Oslan CAD file image 2 of MASAD00007358	NREL; 403; LFND; ATH; NP; IDSCR; MIS
2330			Oslan CAD file image 1 of MASAD00007367	NREL; 403; LFND; ATH; NP; IDSCR
2331			Oslan CAD file image 1 of MASAD00116642	NREL; 403; LFND; ATH; NP; IDSCR
2332			Oslan CAD file image 1 of MASAD00014301	NREL; 403; LFND; ATH; NP; IDSCR
2333			Oslan CAD file image 2 of MASAD00014301	NREL; 403; LFND; ATH; NP; IDSCR
2334			Oslan CAD file image 3 of MASAD00014301	NREL; 403; LFND; ATH; NP; IDSCR
2335			Oslan CAD file image 4 of MASAD00014301	NREL; 403; LFND; ATH; NP; IDSCR
2336			Oslan CAD file image 5 of MASAD00014301	NREL; 403; LFND; ATH; NP; IDSCR
2337			Oslan CAD file image 6 of MASAD00014301	NREL; 403; LFND; ATH; NP; IDSCR
2338			Oslan CAD file image 1 of MASAD00006405	NREL; 403; LFND; ATH; NP; IDSCR
2339			Oslan CAD file image 2 of MASAD00006405	NREL; 403; LFND; ATH; NP; IDSCR
2340			Oslan CAD file image 3 of MASAD00006405	NREL; 403; LFND; ATH; NP; IDSCR
2341			Oslan CAD file image 1 of MASAD00073612	NREL; 403; LFND; ATH; NP; IDSCR
2342			Oslan CAD file image 1 of MASAD00006403	NREL; 403; LFND; ATH; NP; IDSCR
2343			Oslan CAD file image 1 of MASAD00053444	NREL; 403; LFND; ATH; NP; IDSCR
2344			Oslan CAD file image 1 of MASAD00071298	NREL; 403; LFND; ATH; NP; IDSCR
2345			Oslan CAD file image 1 of MASD000071280	NREL; 403; LFND; ATH; NP; IDSCR
2346			Oslan CAD file image 2 of MASD000071280	NREL; 403; LFND; ATH; NP; IDSCR
2347			Oslan CAD file image 3 of MASAD00071280	NREL; 403; LFND; ATH; NP; IDSCR
2348			Oslan CAD file image 4 of MASAD00071280	NREL; 403; LFND; ATH; NP; IDSCR
2349			Oslan CAD file image 5 of MASAD00071280	NREL; 403; LFND; ATH; NP; IDSCR
2350			Oslan CAD file image 6 of MASAD00071280	NREL; 403; LFND; ATH; NP; IDSCR
2351	APL_DEL00002610	APL-DEL00002994	U.S. Patent No. 10,076,257 Prosecution History	NREL; 403; LFND; HRS
2352	APL_DEL00006918	APL_DEL00008352	U.S. Patent No. 10,987,054 Prosecution History	NREL; 403; LFND; HRS
2353	MASAD00018881	MASAD00018884	Francis Johnson, "ECG monitoring leads and special leads", INDIAN PACING AND ELECTROPHYSIOL. J., 2016	NREL; 403; LFND; ATH; HRS
2354	MASAD00018242	MASAD00018259	U.S. Pat. No. 5,351,695 ("Mills")	NREL; 403; LFND; ATH; HRS
2355	MASAD04144973	MASAD04144983	U.S. Pat. No. 6,775,566 ("Nissila")	NREL; 403; LFND; ATH; HRS; DUP
2356	MASAD04144836	MASAD04144842	Wet and Dry Electrodes for EEG	NREL; 403; LFND; ATH; HRS


## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
2357	MASAD04144848	MASAD04144860	A Searle & L Kirkup, A direct comparison of wet, dry and insulating bioelectric recording electrodes, 21 PHYSIOL. MEAS. 271, 271 (2000)	NREL; 403; LFND; ATH; HRS
2358	MASAD04144958	MASAD04144966	Measurement of the electrical properties of ungelled ECG electrodes (2008)	NREL; 403; LFND; ATH; HRS
2359	MASAD04144967	MASAD04144972	Technical Note, Dobrev, D. Two Electrode Low Voltage ECG Amplifier (2004)	NREL; 403; LFND; ATH; HRS; IDSCR
2360	APL_DEL02369494	APL_DEL02369517	Meziane, N., et al., "Dry electrodes for electrocardiography" Physiol. Meas. 34:R47-R69 (2013)	NREL; 403; LFND; HRS
2361	MASAD04144984	MASAD04145010	U.S. Pat. No. 10,687,745	NREL; 403; LFND; ATH; HRS; MIL
2362	MASAD00018285	MASAD00018326	U.S. Patent Publication No. 2007/0021677 ("Markel")	NREL; 403; LFND; ATH; HRS
2363	PEI_SUBPOENA_000001	PEI_SUBPOENA_0000019	Polar Pacer User Manual	NREL; 403; LFND; ATH; HRS
2364	PEI_SUBPOENA_000020	PEI_SUBPOENA_000027	Polar Sport Tester User Manual	NREL; 403; LFND; ATH; HRS
2365	MASAD00018327	MASAD00018329	Japanese Laid-Open Publication No. 57-37438 ("Ushiyama")	NREL; 403; LFND; ATH; HRS; FOR
2366	MASAD00251323	MASAD00251326	English Translation of Japanese Laid-Open Publication No. 57-37438 ("Ushiyama")	NREL; 403; LFND; ATH; HRS
2367	MASAD00018277	MASAD00018284	U.S. Patent No. 6,982,930 ("Hung")	NREL; 403; LFND; ATH; HRS
2368	MASAD04060866	MASAD04060872	Oranger's official website, Oranger Watch 2.0	NREL; 403; LFND; ATH; HRS
2369	MASAD00029258	MASAD00029267	Chinese publication related to the Oranger Watch 2.0	NREL; 403; LFND; ATH; HRS; FOR
2370	MASAD00253905	MASAD00253919	Snoring can be treated (certified English translation of MASAD00029258-MASAD00029267)	NREL; 403; LFND; ATH; HRS
2371	MASAD00253888	MASAD025904	Oranger Dr Watch 2.0: A Doctor's Care for Her Snoring Mother	NREL; 403; LFND; ATH; HRS
2372	MASAD00253864	MASAD00253868	ORANGER WATCH 2.0/CMS50K Releases Overall Solution for Sleep and Breathing	NREL; 403; LFND; ATH; HRS
2373	MASAD00253869	MASAD00253877	English translation for CN104181809A (Contec's patent)	NREL; 403; LFND; ATH; HRS
2374	MASAD00018767	MASAD00018825	U.S. Appl. Patent Publication No. 2016/0058375 (Rothkopf)	NREL; 403; LFND; ATH; HRS
2375	MASAD00251105	MASAD00251145	Epson Pulsense PS-100 User's Guide	NREL; 403; LFND; ATH; HRS
2376	MASAD00018594	MASAD00018605	Chinese Utility Patent No. 205041396 ("Hu [2-24-2016]")	NREL; 403; LFND; ATH; HRS; FOR
2377	MASAD00251218	MASAD00251232	English Translation of Chinese Utility Patent No. 205041396 ("Hu [2-24-2016]")	NREL; 403; LFND; ATH; HRS
2378	MASAD00018826	MASAD00018854	U.S. Patent Appl. No. 2016/0073914 ("Lapetina," Mar. 17, 2016)	NREL; 403; LFND; ATH; HRS
2379	MASAD04144843	MASAD04144845	STEVEN M. KAPLAN, WILEY ELECTRICAL AND ELECTRONICS ENGINEERING DICTIONARY 605 (2004)	NREL; 403; LFND; ATH; HRS; MM
2380	MASAD04144807	MASAD04144830	Texas Instruments, Miniaturized Pulse Oximeter Reference Design, TIDA-00301 (2014) (Design Note for AFE4403)	NREL; 403; LFND; ATH; HRS
2381	MASAD04144861	MASAD04144957	Texas Instruments, AFE4403 Ultra-Small, Integrated Analog Front-End for Heart Rate Monitors and Low-Cost Pulse Oximeters, SBAS650B (2014)	NREL; 403; LFND; ATH; HRS
2382	MASAD00014131	MASAD00014134	[REDACTED]	NREL; 403; LFND; HRS
2383				NREL; 403; LFND; ATH; HRS; MM; NP; IDSCR
2384			R.H. French et al., Optical Properties of Materials for Concentrator Photovoltaic Systems, IEEE Photovoltaics Specialist Conference (2009)	NREL; 403; LFND; ATH; HRS; NP; IDSCR
2385			WITHDRAWN	

## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
2386	MASAD04145236		Translation certificate	NREL; 403; LFND; ATH; HRS; NE
2387	PEI_SUBPOENA_000041	PEI_SUBPOENA_000046		NREL; 403; LFND; ATH; HRS
2388	PEI_SUBPOENA_000047			NREL; 403; LFND; ATH; HRS
2389	MASAD_P_054		The Polar Pacer	NREL; 403; LFND; ATH; IDSCR
2390			WITHDRAWN	
2391	MASAD04144449	MASAD04144462	CAMBRIDGE DICTIONARY ("Wearable technology consists of things that can be worn, such as clothing or glasses, that contain computer technology or can connect to the internet.")	NREL; 403; LFND; ATH; HRS; MM
2392	MASAD04144228	MASAD04144240	Alexandros Pantelopoulos & Nikolaos G. Bourbakis, A Survey on Wearable Sensor-Based Systems for Health Monitoring and Prognosis, 40 IEEE TRANSACTIONS ON SYSTEMS, MAN, AND CYBERNETICS 1 (2010)	NREL; 403; LFND; ATH; HRS; MM
2393	MASAD04144831	MASAD04144835	SCIENTIFIC ENCYCLOPEDIA 1109 (Douglas M. Considine 8th ed., 1995) (defining "electrocardiography")	NREL; 403; LFND; ATH; HRS; MM
2394	MASAD04144846	MASAD04144847	Barold S. Serge, Willem Einthoven and the birth of clinical electrocardiography a hundred year ago, CARD. ELECTROPHYSIOL. REV., Jan. 2003	NREL; 403; LFND; ATH; HRS
2395	MASAD04144542	MASAD04144798	EUAN A. ASHLEY & JOSEF NIEBAUER, CARDIOLOGY (2004)	NREL; 403; LFND; ATH; HRS
2396	MASAD00017903	MASAD00017928	U.S. Patent Appl. Publication No. 2015/0135310 ("Lee [5-14-2015]")	NREL; 403; LFND; ATH; HRS
2397	MASITC_01029103	MASITC_01029364	J. G. WEBSTER, DESIGN OF PULSE OXIMETERS 143 (1997)	NREL; 403; LFND; ATH; HRS; MM
2398			Comprehensive Dictionary of Electrical Engineering - definition of refractive index	NREL; 403; LFND; ATH; HRS; MM; NP; IDSCR
2399			Excerpts of Bicycling magazine (May 1991)	NREL; 403; LFND; ATH; HRS; NP; IDSCR
2400			Excerpts of Men's Fitness magazine (October 1993)	NREL; 403; LFND; ATH; HRS; NP; IDSCR
2401			9/5/1993 Dash, J., "Keeping Fitness Programs on Track When You're On the Road," Gear and Gadgets, Los Angeles Times	NREL; 403; LFND; ATH; HRS; NP; IDSCR; DUP
2402			9/21/1989 USA Today article, "Treadmills lead the way,"	NREL; 403; LFND; ATH; HRS; NP; IDSCR; DUP
2403			8/16/1991 Scarton, D., "Fitness shopping spree tips," The Palladium-Times	NREL; 403; LFND; ATH; HRS; NP; IDSCR; DUP
2404			11/24/1991 French, J., "Sporty Gifts For," The Plain Dealer	NREL; 403; LFND; ATH; HRS; NP; IDSCR; DUP
2405			9/26/1993 Dash, J., "Portable Fitness Aids," Chicago Sun-Times	NREL; 403; LFND; ATH; HRS; NP; IDSCR; DUP
2406			2/17/1993 Moul, J., "The effects of 16-week walking and 16-week weight-training programs on the performance of men and women ages 65-77 on the Ross Information Processing Assessment" Dissertation submitted to the University of North Carolina at Greensboro	NREL; 403; LFND; ATH; HRS; NP; IDSCR; DUP
2407			12/8/2023 Certificate of Translation of Hu-CN 205041396 U	NREL; 403; LFND; ATH; HRS; NE; NP; IDSCR; DUP
2408			12/11/2023 Certificate of Translation	NREL; 403; LFND; ATH; HRS; NE; NP; IDSCR; DUP
2409			12/11/2023 Certificate of Translation	NREL; 403; LFND; ATH; HRS; NE; NP; IDSCR; DUP
2410			12/11/2023 Certificate of Translation	NREL; 403; LFND; ATH; HRS; NE; NP; IDSCR; DUP
2411			12/11/2023 Certificate of Translation	NREL; 403; LFND; ATH; HRS; NE; NP; IDSCR; DUP
2412			12/8/2023 Certificate of Translation of Japanese Laid-Open Publication No. 57-37438	NREL; 403; LFND; ATH; HRS; NE; NP; IDSCR; DUP
2413			1/3/2024 Certificate of Translation of CN104181809A	NREL; 403; LFND; ATH; HRS; NE; NP; IDSCR; DUP

## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
2414	MASAD04144803	MASAD04144806	DORLAND'S ILLUSTRATED MEDICAL DICTIONARY	NREL; 403; LFND; ATH; HRS; MM
2415	MASAD04144799	MASAD04144802	Dorland's Illustrated Medical Dictionary	NREL; 403; LFND; ATH; HRS; MM
2416			Curriculum Vitae of Craig S. Rosenberg	NREL; 403; LFND; ATH; HRS; NE
2418	MASAD04145013		Video: Nexus 7 Tablet	NREL; 403; LFND; ATH; HRS
2419	MASAD04145011		Video: ASUS ZenWatch	NREL; 403; LFND; ATH; HRS
2420	MASAD04145014		Video: Samsung Galaxy S8	NREL; 403; LFND; ATH; HRS
2421	MASAD04145012		Video: LG Watch Style	NREL; 403; LFND; ATH; HRS
2422	MASAD04143850	MASAD04143955	2012 Nexus 7 Guidebook	NREL; 403; LFND; ATH; HRS
2423	MASAD04143458	MASAD04143515	11/2014 ASUS ZenWatch E-Manual	NREL; 403; LFND; ATH; HRS
2424	MASAD04143783	MASAD04143849	LG Watch Style LG-W270 User Guide	NREL; 403; LFND; ATH; HRS
2425	MASAD04143447	MASAD04143457	10/29/2020 Difference between Samsung Android 8.0 Oreo device and 7.0 Nougat device - Samsung Support	NREL; 403; LFND; ATH; HRS
2426	MASAD00017374	MASAD00017414	U.S. Patent Application Publication No. 2012/0129495 A1 (Chae et al.)	NREL; 403; LFND; ATH; HRS
2427	MASAD04143516	MASAD04143782	Samsung User Manual for SM-G950W and SM-G955W	NREL; 403; LFND; ATH; HRS
2428			Change your watch's home screen - Wear OS by Google Help	NREL; 403; LFND; ATH; HRS; NP; IDSCR
2429			Organize the Home Screen and App Library on your iPhone - Apple Support	NREL; 403; LFND; ATH; HRS; NP; IDSCR
2430	APL_DEL00008906		U.S. Patent No. 11,106,352	NREL; 403; LFND; HRS
2431	MASAD00017444	MASAD00017467	U.S. Patent Application Publication No. 2013/0305351 A1 (Narendra et al.)	NREL; 403; LFND; ATH; HRS
2432	MASAD00252533		U.S. Patent No. 8,311,514 ("Bandyopadhyay")	NREL; 403; LFND; ATH; HRS
2433	APL-MAS_00172416	APL-MAS_00172424		NREL; 403; LFND; HRS
2434	APL-MAS_00209687	APL-MAS_00209697		NREL; 403; LFND; HRS
2435	APL_DEL00971820	APL_DEL00971829		NREL; 403; LFND; HRS
2436	APL_DEL01425149	APL_DEL01425156		NREL; 403; LFND; HRS
2437	ASUS_00000001			NREL; 403; ATH; LFND; HRS; NOID; MIS
2438	SAMSUNG_00000003		Samsung Galaxy S8 and S8+ FAQs and Comparisons	NREL; 403; LFND; ATH; HRS; IDSCR
2439	SAMSUNG_00000006		4/11/2017 Slides entitled Galaxy S8 Launch Kits	NREL; 403; LFND; ATH; HRS; IDSCR
2440	MASAD00017739		작고, 얇고, 가벼운 LG워치 스타일 개봉기&간단사용기!(LG Watch Style Unboxing & Review) (MP4 copy of March 24, 2017 YouTube video)	NREL; 403; LFND; ATH; HRS; FOR
2441	MASAD00017740		갤럭시s8 리뷰, 홈버튼 느낌은 어떨까? [4K] (Galaxy S8 review, how does the home button feel? [4K]) (MP4 copy of April 5, 2017 YouTube video)	NREL; 403; LFND; ATH; HRS; FOR
2442	MASAD00250973	MASAD00250976	9/3/2014 Article entitled ASUS Unveils the ZenWatch at IFA	NREL; 403; ATH; LFND; HRS
2443			Phone Arena Webpage, "How to enable Theater mode on any Android Wear Smartwatch," <a href="https://www.phonearena.com/news/How-to-enable-Theater-mode-on-any-Android-Wear-smartwatch_id70167">https://www.phonearena.com/news/How-to-enable-Theater-mode-on-any-Android-Wear-smartwatch_id70167</a>	NREL; 403; ATH; LFND; HRS; NP; IDSCR
2444			Ebeling, F. A., Johnson, R. L., & Goldhor, R. S. (1973), University of Illinois US3775560.	NREL; 403; ATH; LFND; HRS; NP; IDSCR

## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
2445	APL_DEL00008427	APL_DEL00008905	File History for U.S. Patent No. 11,106,352	NREL; 403; LFND; HRS
2446	MASAD00007252	MASAD00007253		NREL; 403; ATH; LFND; HRS
2447	MASAD00010737	MASAD00010756		NREL; 403; LFND; HRS
2448	MASAD_SC_0001-0061			NREL; 403; ATH; LFND; HRS
2449	MASAD01311466	MASAD01311473	Masimo W1 Customer Support Documents - "PLM-14487A, Webpage, Customer Support - Daily Monitoring, Masimo W1 Telehealth, OUS"	NREL; 403; ATH; LFND; HRS
2450	APL-MAS_02640519	APL-MAS_02640546	Masimo W1 Operator's Manual	NREL; 403; LFND; HRS
2451			Organize the Home Screen and App Library on your iPhone, accessed from <a href="https://support.apple.com/en-us/HT211345">https://support.apple.com/en-us/HT211345</a>	NREL; 403; LFND; ATH; HRS; NP; IDSCR
2452			October 31, 2023 FRE 902(11) Certification of Sharon Wou, Senior Manager of Finance for Asus Computer International	NREL; 403; LFND; ATH; HRS; NP; IDSCR; NE
2453			Darrin J. Young's Curriculum Vitae	NREL; 403; LFND; ATH; HRS; NP; IDSCR; NE
2454	MASAD_P_021		Physical Mio Fuse and Charger	NREL; 403; ATH; LFND
2455			Photo (Young 14) - Mio Fuse	NREL; 403; LFND; ATH; NP; IDSCR
2456			Photo (Young 15) - Mio Fuse	NREL; 403; LFND; ATH; NP; IDSCR
2457			Photo (Young 16) - Mio Fuse	NREL; 403; LFND; ATH; NP; IDSCR
2458			Photo (Young 17) - Mio Fuse	NREL; 403; LFND; ATH; NP; IDSCR
2459			Photo (Young 18) - Mio Fuse	NREL; 403; LFND; ATH; NP; IDSCR
2460			Photo (Young 19) - Mio Fuse	NREL; 403; LFND; ATH; NP; IDSCR
2461			Photo (Young 20) - Mio Fuse	NREL; 403; LFND; ATH; NP; IDSCR
2462			Photo (Young 21) - Mio Fuse	NREL; 403; LFND; ATH; NP; IDSCR
2463			Photo (Young 22) - Mio Fuse	NREL; 403; LFND; ATH; NP; IDSCR
2464			Photo (Young 23) - Mio Fuse	NREL; 403; LFND; ATH; NP; IDSCR
2465			Photo (Young 24) - Fossil Abacus	NREL; 403; LFND; ATH; NP; IDSCR
2466			Photo (Young 25) - Fossil Abacus	NREL; 403; LFND; ATH; NP; IDSCR
2467			Photo (Young 26) - Fossil Abacus	NREL; 403; LFND; ATH; NP; IDSCR
2468			Photo (Young 27) - Fossil Abacus	NREL; 403; LFND; ATH; NP; IDSCR
2469			Photo (Young 28) - Fossil Abacus	NREL; 403; LFND; ATH; NP; IDSCR
2470			Photo (Young 29) - Fossil Abacus	NREL; 403; LFND; ATH; NP; IDSCR
2471			Photo (Young 30) - Fossil Abacus	NREL; 403; LFND; ATH; NP; IDSCR
2472			Photo (Young 31) - Fossil Abacus	NREL; 403; LFND; ATH; NP; IDSCR
2473			Photo (Young 32) - Fossil Abacus	NREL; 403; LFND; ATH; NP; IDSCR
2474			Photo (Young 33) - Fossil Abacus	NREL; 403; LFND; ATH; NP; IDSCR
2475			Photo (Young 34) - Fossil Abacus	NREL; 403; LFND; ATH; NP; IDSCR
2476			Photo (Young 35) - Fossil Abacus	NREL; 403; LFND; ATH; NP; IDSCR
2477			Photo (Young 36) - Fossil Abacus	NREL; 403; LFND; ATH; NP; IDSCR
2478			Photo (Young 37) - Fossil Abacus	NREL; 403; LFND; ATH; NP; IDSCR
2479			Photo (Young 38) - Fossil Abacus	NREL; 403; LFND; ATH; NP; IDSCR
2480			Photo (Young 39) - Nymi Band	NREL; 403; LFND; ATH; NP; IDSCR
2481			Photo (Young 40) - Nymi Band	NREL; 403; LFND; ATH; NP; IDSCR
2482			Photo (Young 41) - Nymi Band	NREL; 403; LFND; ATH; NP; IDSCR
2483			Photo (Young 42) - Epson Pulsense PS-100	NREL; 403; LFND; ATH; NP; IDSCR
2484			Photo (Young 43) - Epson Pulsense PS-100	NREL; 403; LFND; ATH; NP; IDSCR
2485			Photo (Young 44) - Epson Pulsense PS-100	NREL; 403; LFND; ATH; NP; IDSCR
2486			Photo (Young 45) - Epson Pulsense PS-100	NREL; 403; LFND; ATH; NP; IDSCR
2487			Photo (Young 46) - Epson Pulsense PS-100	NREL; 403; LFND; ATH; NP; IDSCR

## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
2488			Photo (Young 47) - Epson Pulsense PS-100	NREL; 403; LFND; ATH; NP; IDSCR
2489			Photo (Young 48) - Epson Pulsense PS-100	NREL; 403; LFND; ATH; NP; IDSCR
2490			Photo (Young 49) - Epson Pulsense PS-100	NREL; 403; LFND; ATH; NP; IDSCR
2491			Photo (Young 50) - Epson Pulsense PS-100	NREL; 403; LFND; ATH; NP; IDSCR
2492			Photo (Young 51) - Epson Pulsense PS-100	NREL; 403; LFND; ATH; NP; IDSCR
2493			Photo (Young 52) - Epson Pulsense PS-100	NREL; 403; LFND; ATH; NP; IDSCR
2494			Photo (Young 53) - Epson Pulsense PS-100	NREL; 403; LFND; ATH; NP; IDSCR
2495			Photo (Young 54) - Epson Pulsense PS-100	NREL; 403; LFND; ATH; NP; IDSCR
2496			Photo (Young 55) - Qualcomm Toq	NREL; 403; LFND; ATH; NP; IDSCR
2497			Photo (Young 56) - Qualcomm Toq	NREL; 403; LFND; ATH; NP; IDSCR
2498			Photo (Young 57) - Qualcomm Toq	NREL; 403; LFND; ATH; NP; IDSCR
2499			Photo (Young 58) - Qualcomm Toq	NREL; 403; LFND; ATH; NP; IDSCR
2500			Photo (Young 59) - Qualcomm Toq	NREL; 403; LFND; ATH; NP; IDSCR
2501			Photo (Young 60) - Qualcomm Toq	NREL; 403; LFND; ATH; NP; IDSCR
2502			Photo (Young 61) - Qualcomm Toq	NREL; 403; LFND; ATH; NP; IDSCR
2503			Photo (Young 62) - Qualcomm Toq	NREL; 403; LFND; ATH; NP; IDSCR
2504			Photo (Young 63) - Qualcomm Toq	NREL; 403; LFND; ATH; NP; IDSCR
2505			Photo (Young 64) - Qualcomm Toq	NREL; 403; LFND; ATH; NP; IDSCR
2506			Photo (Young 65) - Qualcomm Toq	NREL; 403; LFND; ATH; NP; IDSCR
2507			U.S. Provisional No. Provisional No. 61/886,930	NP; LFND; LA; NREL; 403
2508	MASAD00018410	MASAD00018440	PCT Publication No. WO 2015/150199 ("Coppola")	LFND; LA; NREL; 403
2509			WITHDRAWN	
2510			WITHDRAWN	
2511	MASA03197483	MASA03197484	[REDACTED]	NREL; 403; LFND; ATH; HRS
2512			WITHDRAWN	
2513			Article, R.H. French et al., Optical Properties of Materials for Concentrator Photovoltaic Systems, IEEE Photovoltaics Specialist Conference (2009)	NREL; 403; NP; ATH; LFND; HRS
2514			Article, Wen H. Ko et al., "Design of radio-frequency powered coils for implant instruments," 15 Med. & Biol. Eng. & Comput. 634, 635 (1977)	NREL; 403; NP; ATH; LFND; HRS; DUP
2515			Article, Rafael Mendes Duarte and Gordana Klaric Felic, "Analysis of the Coupling Coefficient in Inductive Energy Transfer Systems," Active and Passive Electronic Components at 5 (January 8, 2014)	NREL; 403; NP; ATH; LFND; HRS; DUP
2516			[REDACTED]	NREL; 403; IDSCR; ATH; LFND
2517			[REDACTED]	NREL; 403; IDSCR; ATH; LFND
2518			[REDACTED]	NREL; 403; IDSCR; ATH; LFND
2519			[REDACTED]	NREL; 403; IDSCR; ATH; LFND
2520			[REDACTED]	NREL; 403; IDSCR; ATH; LFND
2521			[REDACTED]	NREL; 403; IDSCR; ATH; LFND
2522			[REDACTED]	NREL; 403; IDSCR; ATH; LFND
2523			[REDACTED]	NREL; 403; IDSCR; ATH; LFND
2524			[REDACTED]	NREL; 403; IDSCR; ATH; LFND
2525			[REDACTED]	NREL; 403; IDSCR; ATH; LFND
2526			[REDACTED]	NREL; 403; IDSCR; ATH; LFND
2527			[REDACTED]	NREL; 403; IDSCR; ATH; LFND

## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
2528				NREL; 403; IDSCR; ATH; LFND
2529				NREL; 403; IDSCR; ATH; LFND
2530			Article, R.H. French et al., Optical Properties of Materials for Concentrator Photovoltaic Systems, IEEE Photovoltaics Specialist Conference (2009)	NREL; 403; NP; LFND; HRS; NP; IDSCR; NOID
2531			Article, Wen H. Ko et al., Design of radio-frequency powered coils for implant instruments, 15 MED. & BIOL. ENG. & COMPUT. 634, 635 (1977)	NREL; 403; NP; ATH; LFND; HRS; DUP
2532			Article, Rafael Mendes Duarte and Gordana Klaric Felic, Analysis of the Coupling Coefficient in Inductive Energy Transfer Systems, ACTIVE AND PASSIVE ELECTRONIC COMPONENTS at 5 (January 8, 2014)	NREL; 403; NP; ATH; LFND; HRS; DUP
2533			U.S. Patent No. 5,738,104 (Lo)	NREL; 403; NP; LFND
2534			Photo (Young 1) - W1 Original Electrode Design	NREL; 403; NP; IDSCR; LFND; ATH
2535			Photo (Young 2) - Freedom Original Electrode Design	NREL; 403; NP; IDSCR; LFND; ATH
2536			Photo (Young 3) - Masimo Health Module Original Electrode Design	NREL; 403; NP; IDSCR; LFND; ATH
2537			Photo (Young 4) - W1 Wave Electrode Design	NREL; 403; NP; IDSCR; LFND; ATH
2538			Photo (Young 5) - Freedom Side View	NREL; 403; NP; IDSCR; LFND; ATH
2539			Photo (Young 6) - Conductivity Testing	NREL; 403; NP; IDSCR; LFND; ATH
2540			Photo (Young 7) - Transparency Testing	NREL; 403; NP; IDSCR; LFND; ATH
2541			Photo (Young 8) - Transparency Testing	NREL; 403; NP; IDSCR; LFND; ATH
2542			Photo (Young 9) - Transparency Testing	NREL; 403; NP; IDSCR; LFND; ATH
2543			Photo (Young 10) - Transparency Testing	NREL; 403; NP; IDSCR; LFND; ATH
2544			Photo (Young 11) - Transparency Testing	NREL; 403; NP; IDSCR; LFND; ATH
2545			Photo (Young 12) - W1 Sensor Lens from Masimo's Website	NREL; 403; NP; IDSCR; LFND; ATH
2546			Photo (Young 13) - W1 Sensor Lens Textured Finish	NREL; 403; NP; IDSCR; LFND; ATH
2547			WITHDRAWN	
2548			U.S. Patent No. 9,583,256 ("Lapetina")	NREL; 403; NP; LFND
2549			WITHDRAWN	
2550			PCT Publication No. WO 2015/150199 ("Coppola")	NREL; 403; NP; LFND
2551			8/11/2014 Post, DC Rainmaker, "Hands-on with Epson's new Pulsense optical heart rate activity trackers," available at Wayback Machine, <a href="https://web.archive.org/web/20140814002213/https://www.dcrainmaker.com/2014/08/pulsesense-activity-trackers.html">https://web.archive.org/web/20140814002213/https://www.dcrainmaker.com/2014/08/pulsesense-activity-trackers.html</a>	NREL; 403; NP; ATH; LFND; HRS; DUP
2552			8/8/2021 Post, DC Rainmaker, "Mio shows off new Mio Velo and Mio Fuse optical heart rate units," <a href="https://www.dcrainmaker.com/2014/08/optical-heartunits.html/comment-page-7?amp=1">https://www.dcrainmaker.com/2014/08/optical-heartunits.html/comment-page-7?amp=1</a>	NREL; 403; NP; ATH; LFND; HRS; DUP
2553			<i>Follow Your Heart</i> , 31 Shape Magazine (Sept. 2014)	NREL; 403; NP; ATH; LFND; HRS; INC; DUP
2554			<i>The Wearable Runway</i> , Canadian Technology Review (June 27, 2014)	NREL; 403; NP; ATH; LFND; HRS; DUP
2555			12/28/2022 Press, Screen Rant, "This \$36 Apple Watch Ultra Ripoff Looks Just Like The Real Thing," <a href="https://screenrant.com/pebble-cosmos-engage-apple-watch-ultra-budgetclone/">https://screenrant.com/pebble-cosmos-engage-apple-watch-ultra-budgetclone/</a>	NREL; 403; NP; ATH; LFND; HRS; DUP



## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
2556			1/2005 PC Magazine article, "MSN Smart Watches"	NREL; 403; NP; ATH; LFND; HRS; INC
2557			1/17/2014 Comstock, J., "In-depth: the MobiHealthNews CES 2014 Wrap-Up," MobiHealthNews (The Wayback Machine)	NREL; 403; NP; ATH; LFND; HRS
2558			8/11/2014 Article, DC Rainmaker, "Hands-on with Epson's new Pulesense optical heart rate activity trackers," (The Wayback Machine)	NREL; 403; NP; ATH; LFND; HRS; DUP
2559			8/15/2014 PRNewswire, "CTIA Announces Emerging Technology, Hot for the Holidays and MobITs Award Finalists"	NREL; 403; NP; ATH; LFND; HRS; NOID; IDSCR
2560			8/8/2014 DC Rainmaker, "Mio shows off new Mio Velo and Mio Fuse optical heart reate units"	NREL; 403; NP; ATH; LFND; HRS; DUP
2561			9/2014 Shape Magazine article, " Follow Your Heart"	NREL; 403; NP; ATH; LFND; HRS; INC; DUP
2562			6/27/2014 Young, R., et al., "The Wearable Runway" Canadian Technology Review, Canaccord Genuity	NREL; 403; NP; ATH; LFND; HRS
2563			12/28/2022 Onawole, H., "This \$36 Apple Watch Ultra Ripoff Looks Just Like The Real Thing" Screen Rant	NREL; 403; NP; ATH; LFND; HRS
2564			3/27/2015 Article, Gibbs, S., "Asus ZenWatch review: a sophisticated-looking Android smartwatch"	NREL; 403; NP; ATH; LFND; HRS; INC
2565	MASAD00006949	MASAD00006972		NREL; 403; IMP; HRS; ATH; LFND
2566	MASAD00014300			NREL; 403; LFND
2567	MASAD00114809	MASAD00114811		NREL; 403; LFND; ATH
2568	MASAD00254495			NREL; 403; NP; NOID; NE; HRS; ATH; LFND; IDSCR
2569			IPR2023-00634 File History	NREL; 403; NP; NOID; NE; HRS; ATH; LFND; IDSCR; MIL
2570			IPR2023-00734 File History	NREL; 403; NP; NOID; NE; HRS; ATH; LFND; IDSCR; MIL
2571			IPR2023-00664 File History	NREL; 403; NP; NOID; NE; HRS; ATH; LFND; IDSCR; MIL
2572			U.S. Patent No. D883,279	NOID; DUP; LFND; IDSCR
2573			U.S. Patent No. D947,842	NOID; DUP; LFND; IDSCR
2574			U.S. Patent No. D962,936	NOID; LFND; IDSCR
2575			U.S. Patent No. D735,131	NOID; LFND; IDSCR
2576			Photograph of Series 9 Back Crystal	NREL; 403; NP; NOID; ATH; LFND
2577	APL_DEL00003012	APL_DEL00005157	File History for U.S. Patent No. 10,627,783	NREL; 403; LFND
2578	APL_DEL00005222	APL_DEL00006853	File History for U.S. Patent No. 10,942,491	NREL; 403; LFND
2579	APL_DEL00009209	APL_DEL00010258	File History for U.S. Patent No. 11,474,483	NREL; 403; LFND
2580	MASAD00017839	MASAD00017862	WITHDRAWN	
2581	MASAD00017965	MASAD00017996	WITHDRAWN	
2582	MASAD00018441	MASAD00018471	WITHDRAWN	
2583	MASAD00251684	MASAD00251685	Qualcomm Toq Smartwatch Manual	NREL; 403; ATH; HRS; LFND
2584	MASAD00251588	MASAD00251591	11/17/2013 Press, Qualcomm, Qualcomm Announces Availability of Qualcomm Toq Smartwatch	NREL; 403; ATH; LFND; HRS
2585	MASAD00251594	MASAD00251601	9/10/2013 Blog, Qualcomm, Hands On: The Qualcomm Toq Smartwatch	NREL; 403; ATH; LFND; HRS
2586	MASAD00251602	MASAD00251620	12/11/2013 Lee Hutchinson, Review: Qualcomm's Toq smartwatch lasts an extra, extra, extra long time	NREL; 403; ATH; LFND; HRS
2587	MASAD04144241	MASAD04144275	4/3/2011 Review, Ashraf Darwish, Sensors, Wearable and implantable wireless sensor network solutions for healthcare monitoring	NREL; 403; ATH; LFND; HRS; IMP



## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
2588	MASAD04144276	MASAD04144289	S. Geetha, EMI Shielding: Methods and Materials—A Review, J. Applied Polymer Sci. (2009)	NREL; 403; ATH; LFND; HRS
2589	MASAD04144290	MASAD04144304	Nuno Borges Carvalho et al., Wireless Power Transmission: R&D Activities Within Europe, 62 IEEE TRANSACTIONS ON MICROWAVE THEORY AND TECHNIQUES 1031 (Apr. 4, 2014)	NREL; 403; ATH; LFND; HRS
2590	MASAD04144305	MASAD04144324	Article, V. Komarov et al., ResearchGate, Permittivity and Measurements (2005)	NREL; 403; ATH; LFND; HRS
2591	MASAD04144325	MASAD04144410	Qi v1.0.1, Wireless Power Consortium (October 2010)	NREL; 403; ATH; LFND; HRS; NOID
2592	MASAD04144411	MASAD04144423	S.Y. Hui, Planar Wireless Charging Technology for Portable Electronic Products and Qi, 101 PROCEEDINGS OF THE IEEE 1290 (2013)	NREL; 403; ATH; LFND; HRS
2593	MASAD04144424	MASAD04144440	Article, Scott Stein, Smartwatches to watch at CES 2014 (pictures), CNET, <a href="https://www.cnet.com/pictures/smartwatches-to-watch-at-ces-2014-pictures/">https://www.cnet.com/pictures/smartwatches-to-watch-at-ces-2014-pictures/</a> .	NREL; 403; ATH; LFND; HRS; INC
2594	MASAD04144441	MASAD04144448	Neha Chawla, State of the Art in Inductive Charging for Electronic Appliances and its Future in Transportation (May 10–11, 2012)	NREL; 403; ATH; LFND; HRS
2595			Appendix A to Expert Report of Alan L. Oslan - Curriculum Vitae of Alan L. Oslan	NREL; 403; NP; HRS; NE; IDSCR; NE
2596			Appendix A to Expert Report of Darrin Young - Curriculum Vitae of Darrin J. Young	NREL; 403; NP; HRS; NE; IDSCR; NE
2597	MASITC_00620761	MASITC_00620762		NREL; 403; ATH; LFND
2598	MASAD00237000	MASAD00237000		NREL; 403; LFND; HRS
2599	MASAD00016237	MASAD00016241		NREL; 403; ATH; LFND; DUP
2600	MASAD00012385	MASAD00012391		NREL; 403; LFND
2601	MASAD00051056	MASAD00051059		NREL; 403; LFND; HRS
2602	MASAD00053277	MASAD00053280		NREL; 403; LFND
2603	MASAD00112870	MASAD00112870		NREL; 403; LFND; HRS; DUP
2604	MASAD00079667	MASAD00079688		NREL; 403; LFND; HRS
2605	MASAD00006405	MASAD00006405		NREL; 403; LFND
2606	MASD000071280	MASD000071280		NREL; 403; ATH; LFND; DUP
2607	MASA03109106	MASA03109109		NREL; 403; LFND; HRS
2608				NREL; 403; NP; NOID; LFND; IDSCR; HRS; ATH
2609	MASITC_00975691	MASITC_00975691		NREL; 403; ATH; LFND
2610	MASAD00006744	MASAD00006750		NREL; 403; ATH; LFND
2611	MASAD00012159	MASAD00012162		NREL; 403; LFND
2612	MASITC_00584719	MASITC_00584719		NREL; 403; ATH; LFND

## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
2613	MASA00176554	MASA00176554		NREL; 403; LFND; HRS
2614	MASAD00013476	MASAD00013490		NREL; 403; LFND; HRS
2615	MASAD00071331	MASAD00071331		NREL; 403; LFND
2616	MASITC_01290584	MASITC_01290587		NREL; 403; LFND; HRS; ATH
2617	MASAD00237172	MASAD00237228		NREL; 403; LFND; HRS
2618	MASAD00033048	MASAD00033069		NREL; 403; LFND; HRS
2619	MASAD00033139	MASAD00033179		NREL; 403; LFND; HRS
2620	MASAD00089486	MASAD00089486		NREL; 403; LFND; HRS; ATH
2621	MASAD00089482	MASAD00089482		NREL; 403; LFND; HRS; ATH
2622	MASAD00089484	MASAD00089484		NREL; 403; LFND; HRS; ATH
2623	MASAD00089487	MASAD00089487		NREL; 403; LFND; HRS; ATH
2624	MASAD00089489	MASAD00089489		NREL; 403; LFND; HRS; ATH
2625	MASAD00089490	MASAD00089490		NREL; 403; LFND; HRS; ATH
2626	MASAD00089491	MASAD00089491		NREL; 403; LFND; HRS; ATH
2627			Curriculum Vitae of Dr. Bruce Isaacson (December 2023) and Testimony Experience	NREL; 403; NP; HRS; NE; IDSCR; NE
2628			Cross Tabulation Tables from the Isaacson Association Survey	NREL; 403; NP; HRS; NE; IDSCR; LFND; NE
2629			All Responses from All Respondents to the Isaacson Design Impact Survey - Survey Data File and Survey Data Map	NREL; 403; NP; HRS; NE; IDSCR; LFND; NE
2630			All Responses from All Respondents to the Isaacson Supplemental Design Impact Survey - Survey Data File and Survey Data Map	NREL; 403; NP; HRS; NE; IDSCR; LFND; NE
2631			All Responses from All Respondents to the Isaacson Association Survey - Survey Data File and Survey Data Map	NREL; 403; NP; HRS; NE; IDSCR; LFND; NE
2632			Images from the Isaacson Rebuttal Surveys	NREL; 403; NP; HRS; NE; IDSCR; LFND
2633			The Masimo W1 on Masimo's Website and the Apple Watch Series 8 on Apple's Website	NREL; 403; NP; HRS; NE; IDSCR; LFND
2634			Qualifying Questions, Main Questionnaires, and Screenshots for the Isaacson Rebuttal Surveys	NREL; 403; NP; HRS; NE; IDSCR; LFND
2635			Recruiting Methods and Panel Description for the Isaacson Rebuttal Surveys	NREL; 403; NP; HRS; NE; IDSCR; LFND
2636			Quality Control Measures for the Isaacson Rebuttal Surveys	NREL; 403; NP; HRS; NE; IDSCR; LFND
2637			Termination and Removal Summary for the Isaacson Rebuttal Surveys	NREL; 403; NP; HRS; NE; IDSCR; LFND
2638			Cross Tabulation Tables from the Isaacson Design Impact Survey	NREL; 403; NP; HRS; NE; IDSCR; LFND
2639			Cross Tabulation Tables from the Isaacson Supplemental Design Impact Survey	NREL; 403; NP; HRS; NE; IDSCR; LFND

## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
2640			Article, Diamond, Shari Seidman. "Reference Guide on Survey Research." Reference Manual on Scientific Evidence, 3rd ed., National Academies Press, 2011	NREL; 403; NP; HRS; LFND; ATH; INC; DUP
2641			Article, Simonson, Itamar and Ran Kivetz. "Demand Effects in Likelihood of Confusion Surveys: The Importance of Marketplace Conditions." Trademark and Deceptive Advertising Surveys: Law, Science, and Design, edited by Shari Seidman Diamond and Jerre B. Swann, ABA Publishing, 2012	NREL; 403; NP; HRS; LFND; ATH; INC; DUP
2642			Article, Simonson, Itamar, Ziv Carmon, and Suzanne O'Curry. "Experimental Evidence on the Negative Effect of Product Features and Sales Promotions on Brand Choice." Marketing Science, 13, no.1, 1994	NREL; 403; NP; HRS; LFND; ATH; INC
2643			Article, Barber, William G and Giulio E. Yaquinto. Trademark and Deceptive Advertising Surveys: Law, Science, and Design, edited by Shari Seidman Diamond and Jerre B. Swann, 2nd ed., ABA Publishing "The Universe."	NREL; 403; NP; HRS; LFND; ATH; INC
2644			Website, "The t-Test." JMP Statistical Discovery, <a href="https://www.jmp.com/en_us/statistics-knowledge-portal/t-test.html">https://www.jmp.com/en_us/statistics-knowledge-portal/t-test.html</a>	NREL; 403; NP; HRS; LFND; ATH
2645			Article, Qualtrics Survey Analysis Methods, "An introduction to t-test theory for surveys" <a href="https://www.qualtrics.com/experience-management/research/t-test-analysis">https://www.qualtrics.com/experience-management/research/t-test-analysis</a>	NREL; 403; NP; HRS; LFND; ATH
2646			Jay, E. Deborah. "Ten Truths of False Advertising Surveys." <i>The Trademark Reporter</i> , vol. 103, no. 5, 2013	NREL; 403; NP; HRS; LFND; ATH; INC
2647			Article, Orne, Martin T. "On the Social Psychology of the Psychological Experiment: With Particular Reference to Demand Characteristics and Their Implications." <i>American Psychologist</i> , vol. 17, no. 11, 1962	NREL; 403; NP; HRS; LFND; ATH
2648			"A Healthy Leap Ahead." Apple, February 13, 2023, <a href="https://web.archive.org/web/20230213175921/https://www.apple.com/apple-watch-series-8/">https://web.archive.org/web/20230213175921/https://www.apple.com/apple-watch-series-8/</a> .	NREL; 403; NP; HRS; LFND; ATH; ILLEG
2649			Masimo W1, <a href="https://web.archive.org/web/20230821061725/https://www.masimopersonalhealth.com/products/masimo-w1">https://web.archive.org/web/20230821061725/https://www.masimopersonalhealth.com/products/masimo-w1</a> .	NREL; 403; NP; HRS; LFND; ATH; ILLEG
2650			Palladino, Vincent. "Secondary Meaning Surveys." <i>Trademark and Deceptive Advertising Surveys: Law, Science, and Design</i> , edited by Shari Seidman Diamond and Jerre B. Swann, ABA Publishing, 2012	NREL; 403; NP; HRS; LFND; ATH; INC
2651			Materials and Finishes." Apple, <a href="https://web.archive.org/web/20230213175854/https://www.apple.com/watch/compare/">https://web.archive.org/web/20230213175854/https://www.apple.com/watch/compare/</a> .	NREL; 403; NP; HRS; LFND; ATH; ILLEG
2652			"Jewelry & Watches." Macy's, <a href="https://www.macys.com/shop/jewelrywatches/apple?id=101043">https://www.macys.com/shop/jewelrywatches/apple?id=101043</a> .	NREL; 403; NP; HRS; LFND; ATH; ILLEG

**Masimo's Trial Exhibit List and Apple's Objections**

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
2653			"Apple Watch Bands." <i>Target</i> , <a href="https://www.target.com/s/apple+watch+bands?ignoreBrandExac tness=true&amp;moveTo=product-list-grid">https://www.target.com/s/apple+watch+bands?ignoreBrandExac tness=true&amp;moveTo=product-list-grid</a> .	NREL; 403; NP; HRS; LFND; ATH; INC
2654			WITHDRAWN	
2655			"Masimo W1 Sport." <i>Masimo</i> , <a href="https://www.masimopersonalhealth.com/products/masimo-w1">https://www.masimopersonalhealth.com/products/masimo-w1</a> .	NREL; 403; NP; HRS; LFND; ATH
2656			"Apple Watch Series 5 [GPS + Cellular] 40mm Stainless Steel Case with Black Sport Band – Space Black Stainless Steel." Best Buy, <a href="https://www.bestbuy.com/site/apple-watch-series-5-gps-cellular-40mm-stainless-steel-case-with-blacksport- band-space-black-stainless-steel/6215979.p?skuld=6215979">https://www.bestbuy.com/site/apple-watch-series-5-gps-cellular-40mm-stainless-steel-case-with-blacksport- band-space-black-stainless-steel/6215979.p?skuld=6215979</a> .	NREL; 403; NP; HRS; LFND; ATH
2657			Watch Series 8 [GPS + Cellular] 45mm Aluminum Case with Midnight Sport Band – S/M – Midnight." <i>Best Buy</i> , <a href="https://www.bestbuy.com/site/apple-watch-series-8-gps-cellular-45mm-aluminum-case-with-midnight-sport-band-s-m-midnight/6495330.p?skuld=6495">https://www.bestbuy.com/site/apple-watch-series-8-gps-cellular-45mm-aluminum-case-with-midnight-sport-band-s-m-midnight/6495330.p?skuld=6495</a>	NREL; 403; NP; HRS; LFND; ATH
2658			"Masimo W1 Sport Advanced Health Tracking Wearable." <i>Masimo</i> , <a href="https://www.masimopersonalhealth.com/products/masimo-w1">https://www.masimopersonalhealth.com/products/masimo-w1</a> .	NREL; 403; NP; HRS; LFND; ATH; ILLEG
2659			"Masimo W1 Medical Wearable." <i>Masimo</i> , <a href="https://www.masimopersonalhealth.com/products/masimow1%C2%AE-medical-wearable">https://www.masimopersonalhealth.com/products/masimow1%C2%AE-medical-wearable</a>	NREL; 403; NP; HRS; LFND; ATH
2660			Article, Dhar, Ravi, Stephen M. Nowlis, and Steven J. Sherman. "Trying Hard or Hardly Trying: An Analysis of Context Effects in Choice." <i>Journal of Consumer Psychology</i> , vol. 9, no. 4, 2000	NREL; 403; NP; HRS; LFND; ATH; INC
2661			Article, Trueblood, Jennifer S. et al. "Not Just for Consumers: Context Effects Are Fundamental to Decision Making." <i>Psychological Science</i> , vol. 24, no. 6, 2013	NREL; 403; NP; HRS; LFND; ATH; INC
2662			Article, Evangelidis, Ioannis, Jonathan Levav, and Itamar Simonson. Abstract to "The Upscaling Effect: How the Decision Context Influences Tradeoffs between Desirability and Feasibility." <i>Journal of Consumer Research</i> , vol. 50, no. 3, 2023, <a href="https://academic.oup.com/jcr/article-abstract/50/3/492/6935792">https://academic.oup.com/jcr/article-abstract/50/3/492/6935792</a>	NREL; 403; NP; HRS; LFND; ATH; INC
2663			Evangelidis, Ioannis, Jonathan Levav, and Itamar Simonson. "The Asymmetric Impact of Context on Advantaged Versus Disadvantaged Options." <i>Journal of Market Research</i> , vol. 55, no. 2, 2018	NREL; 403; NP; HRS; LFND; ATH

## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
2664			Diamond, Shari Seidman. "Control Foundations: Rationales and Approaches." Trademark and Deceptive Advertising Surveys: Law, Science, and Design, edited by Shari Seidman Diamond and Jerre B. Ericksen, Eugene P. and Melissa A. Pittaoulis. "Control Groups in Lanham Act Surveys." The Trademark Reporter, vol. 104, no. 3, 2014 Swann, 2nd ed., ABA Publishing, 2022 Diamond, Shari Seidman. "Reference Guide on Survey Research." Reference Manual on Scientific Evidence, 3rd ed., National Academies Press, 2011	NREL; 403; NP; HRS; LFND; ATH; INC
2665			Masimo Consumer Website - "Masimo Freedom Smart Health Watch & Band" www.masimoconsumer.com/.	NREL; 403; NP; HRS; LFND; ATH
2666			Swann, Jerre B. "Likelihood-of-Confusion Surveys." Trademark and Deceptive Advertising Surveys: Law, Science, and Design, edited by Shari Seidman Diamond and Jerre B. Swann, ABA Publishing, 2022,	NREL; 403; NP; HRS; LFND; ATH; INC
2667			Simonson, Itamar, and Ran Kivetz. "Demand Effects in Likelihood of Confusion Surveys: The Importance of Marketplace Conditions." Trademark and Deceptive Advertising Surveys: Law, Science, and Design, edited by Shari Seidman Diamond and Jerre B. Swann, ABA Publishing, 2012	NREL; 403; NP; HRS; LFND; ATH; INC
2668			Article, Diamond, Shari Seidman. "Control Foundations: Rationales and Approaches." Trademark and Deceptive Advertising Surveys: Law, Science, and Design, edited by Shari Seidman Diamond and Jerre B. Swann, 2nd ed., ABA Publishing, 2022	NREL; 403; NP; HRS; LFND; ATH; INC
2669			Article, Diamond, Shari Seidman. "Reference Guide on Survey Research." Reference Manual on Scientific Evidence, 3rd ed., National Academies Press, 2011	NREL; 403; NP; HRS; LFND; ATH; INC; DUP
2670			Garmin Website - Forerunner® 955 https://www.garmin.com/en-US/p/777655	NREL; 403; NP; HRS; LFND; ATH; ILLEG
2671			WITHDRAWN	
2672			WITHDRAWN	
2673			WITHDRAWN	
2674			WITHDRAWN	
2675			Best Buy Website - Samsung -Galaxy Watch 5 Aluminum Smartwatch 40mm LTE - Graphite, https://www.bestbuy.com/site/samsung-galaxy-watch5-aluminum-smartwatch-40mm-ite-graphite/6510883.p?skuld=6510883	NREL; 403; NP; HRS; LFND; ATH

## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
2676			Amazon Website - Samsung -Galaxy Watch 5 (40mm, WIFI + 4G LTE) 1.2" Super AMOLED Smartwatch GPS Bluetooth Fully Unlocked w/ Sleep Coach, 3-in-1 Bioactive Sensor, Water Resistant R905U (w/Fast Charging Cable, Graphite), <a href="https://www.amazon.com/SAMSUNG-Smartwatch-Bluetooth-Bioactive-Resistant/dp/B0BMTBY7H2/ref=asc_df_B0BMTBY7H2/?tag=hypr od-20&amp;linkCode=df0&amp;hvadid=673692501349&amp;hvpos=&amp;hvnetw=g&amp;h vrand=9609693166196465408&amp;hvpone=&amp;hvptwo=&amp;hvmqmt=&amp;hv dev=c&amp;hvdvcmdl=&amp;hvlocint=&amp;hvlocphy=9030946&amp;hvtargid=pla-2202057727580&amp;mcid=c1e1460ef0443b4cb92d4fe5bc28ac2d&amp;th =1">https://www.amazon.com/SAMSUNG-Smartwatch-Bluetooth-Bioactive-Resistant/dp/B0BMTBY7H2/ref=asc_df_B0BMTBY7H2/?tag=hypr od-20&amp;linkCode=df0&amp;hvadid=673692501349&amp;hvpos=&amp;hvnetw=g&amp;h vrand=9609693166196465408&amp;hvpone=&amp;hvptwo=&amp;hvmqmt=&amp;hv dev=c&amp;hvdvcmdl=&amp;hvlocint=&amp;hvlocphy=9030946&amp;hvtargid=pla-2202057727580&amp;mcid=c1e1460ef0443b4cb92d4fe5bc28ac2d&amp;th =1</a>	NREL; 403; NP; HRS; LFND; ATH
2677			Best Buy Website - Garmin - Forerunner 955 GPS Smartwatch 47 mm Fiber-reinforced polymer - Black, <a href="https://www.bestbuy.com/site/garminforerunner-955-gps-smartwatch-48-mm-fiber-reinforced-polymer-black/6513344.p?skuld=6513344">https://www.bestbuy.com/site/garminforerunner-955-gps-smartwatch-48-mm-fiber-reinforced-polymer-black/6513344.p?skuld=6513344</a>	NREL; 403; NP; HRS; LFND; ATH
2678			Best Buy Website - Fitbit - Sense 2 Advanced Health Smartwatch - Graphite, <a href="https://www.bestbuy.com/site/fitbit-sense-2-advanced-health-smartwatch-graphite/6514034.p?skuld=6514034#anchor=productVariations">https://www.bestbuy.com/site/fitbit-sense-2-advanced-health-smartwatch-graphite/6514034.p?skuld=6514034#anchor=productVariations</a>	NREL; 403; NP; HRS; LFND; ATH
2679			Best Buy Website - Amazfit GTR 4 Smartwatch - Black <a href="https://www.bestbuy.com/site/amazfit-gtr-4-smartwatch-black/6535645.p?skuld=6535645#anchor=productVariations">https://www.bestbuy.com/site/amazfit-gtr-4-smartwatch-black/6535645.p?skuld=6535645#anchor=productVariations</a>	NREL; 403; NP; HRS; LFND; ATH
2680			WITHDRAWN	
2681			WITHDRAWN	
2682			WITHDRAWN	
2683			WITHDRAWN	
2684			WITHDRAWN	
2685			WITHDRAWN	
2686			WITHDRAWN	
2687			WITHDRAWN	
2688			WITHDRAWN	
2689			WITHDRAWN	
2690			WITHDRAWN	
2691			WITHDRAWN	
2692	MASAD00018050	MASAD00018066	Aldinger, Advanced Ceramics and Future Materials (2010)	NREL; 403; HRS; LFND; ATH; INC; ILLEG
2693	MASAD00018135	MASAD00018157	Kingery, Introduction to Ceramics (1960)	NREL; 403; HRS; LFND; ATH; INC
2694	MASAD00018158	MASAD00018170	Loehman, Characterization of Ceramics (1993)	NREL; 403; HRS; LFND; ATH; INC
2695	MASAD00018171	MASAD00018203	Shackelford, Ceramic and Glass Materials (2008)	NREL; 403; HRS; LFND; ATH; INC
2696	MASAD00018204	MASAD00018209	Shi, Ceramic Materials - Progress In Modern Ceramics (2012)	NREL; 403; HRS; LFND; ATH; INC

## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
2697			In the Matter of Certain Light-Based Physiological Measurement Devices and Components Thereof, "Final Initial Determination of Violation of Section 337," U.S. International Trade Commission, Inv. No. 337-TA-1276, issued January 10, 2023.	NREL; 403; NP; HRS; LFND; NE; MIL
2698			In the Matter of Certain Light-Based Physiological Measurement Devices and Components Thereof, "Cease and Desist Order," U.S. International Trade Commission, Inv. No. 337-TA-1276, issued October 26, 2023.	NREL; 403; NP; HRS; LFND; NE; MIL
2699			In the Matter of Certain Light-Based Physiological Measurement Devices and Components Thereof, "Notice of the Commission's Final Determination Finding a Violation of Section 337; Issuance of a Limited Exclusion Order and a Cease and Desist Order; Termination of the Investigation," U.S. International Trade Commission, Inv. No. 337-TA-1276, October 26, 2023.	NREL; 403; NP; HRS; LFND; NE; MIL
2700			In the Matter of Certain Light-Based Physiological Measurement Devices and Components Thereof, "Commission Opinion," U.S. International Trade Commission, Inv. No. 337-TA-1276, issued November 14, 2023.	NREL; 403; NP; HRS; LFND; NE; MIL
2701			Apple Inc., Form 10-K for the fiscal year ended September 24, 2022.	NREL; 403; NP; HRS; LFND; ATH; MIL
2702			Apple Inc., Form 10-K for the fiscal year ended September 30, 2023.	NREL; 403; NP; HRS; LFND; ATH; MIL
2703			Masimo Corporation, Annual Report, 2012.	NREL; 403; NP; HRS; LFND; ATH
2704			Masimo Corporation, International and Investor Edition, Annual Report, 2014.	NREL; 403; NP; HRS; LFND; ATH
2705			Masimo Corporation, Form 10-K for the fiscal year ended December 29, 2018.	NREL; 403; NP; HRS; LFND; ATH
2706			Masimo Corporation, Form 10-K for the fiscal year ended December 28, 2019.	NREL; 403; NP; HRS; LFND; ATH
2707			Masimo Corporation, Form 10-K for the fiscal year ended January 2, 2021.	NREL; 403; NP; HRS; LFND; ATH
2708			Masimo Corporation, Form 10-K for the fiscal year ended January 1, 2022.	NREL; 403; NP; HRS; LFND; ATH
2709			Masimo Corporation, Form 10-K for the fiscal year ended December 31, 2022.	NREL; 403; NP; HRS; LFND; ATH
2710			WITHDRAWN	
2711			WITHDRAWN	
2712			WITHDRAWN	
2713			WITHDRAWN	
2714			WITHDRAWN	
2715			WITHDRAWN	
2716			WITHDRAWN	
2717			WITHDRAWN	
2718			WITHDRAWN	
2719			WITHDRAWN	

## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
2720			WITHDRAWN	
2721			WITHDRAWN	
2722			WITHDRAWN	
2723			WITHDRAWN	
2724			WITHDRAWN	
2725			WITHDRAWN	
2726			WITHDRAWN	
2727			WITHDRAWN	
2728			WITHDRAWN	
2729			WITHDRAWN	
2730			WITHDRAWN	
2731			"2022 Investor Day," Masimo, December 13, 2022, <a href="https://s24.q4cdn.com/336820108/files/doc_presentations/Masimo-2022-Investor-Day-121322.pdf">https://s24.q4cdn.com/336820108/files/doc_presentations/Masimo-2022-Investor-Day-121322.pdf</a> .	NREL; 403; NP; HRS; LFND; ATH
2732			"Masimo Corporation (MASI) Q1 2023 Earnings Call Transcript," Seeking Alpha, May 9, 2023, <a href="https://seekingalpha.com/article/4602257-masimo-corporation-masi-q1-2023-earnings-calltranscript">https://seekingalpha.com/article/4602257-masimo-corporation-masi-q1-2023-earnings-calltranscript</a> .	NREL; 403; NP; HRS; LFND; ATH
2733			"Masimo (MASI) Q2 2022 Earnings Call Transcript," The Motley Fool, August 10, 2022, <a href="https://www.fool.com/earnings/call-transcripts/2022/08/10/masimo-masi-q2-2022-earnings-call-transcript/">https://www.fool.com/earnings/call-transcripts/2022/08/10/masimo-masi-q2-2022-earnings-call-transcript/</a> .	NREL; 403; NP; HRS; LFND; ATH
2734			WITHDRAWN	
2735			WITHDRAWN	
2736			WITHDRAWN	
2737			WITHDRAWN	
2738			WITHDRAWN	
2739			WITHDRAWN	
2740			WITHDRAWN	
2741			WITHDRAWN	
2742			WITHDRAWN	
2743			WITHDRAWN	
2744			WITHDRAWN	
2745			WITHDRAWN	
2746			WITHDRAWN	
2747			WITHDRAWN	
2748			WITHDRAWN	
2749			WITHDRAWN	
2750			WITHDRAWN	
2751			WITHDRAWN	
2752			<a href="https://www.masimo.com/company/news/news-media/2007/#news-5a4f7a11-c359-4736-993c-372ed3633172">https://www.masimo.com/company/news/news-media/2007/#news-5a4f7a11-c359-4736-993c-372ed3633172</a> .	NREL; 403; NP; HRS; LFND; ATH
2753			<a href="https://www.masimo.com/company/news/news-media/2007/#news-e926feca-ff9b-4628-9afd-191ac5baebd1">https://www.masimo.com/company/news/news-media/2007/#news-e926feca-ff9b-4628-9afd-191ac5baebd1</a> .	NREL; 403; NP; HRS; LFND; ATH



## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
2754			<a href="https://www.masimo.com/company/news/news-media/2006/#news-ed6d3f46-99f9-4b6a-a9fd-f03c7a5c2cd9">https://www.masimo.com/company/news/news-media/2006/#news-ed6d3f46-99f9-4b6a-a9fd-f03c7a5c2cd9</a> .	NREL; 403; NP; HRS; LFND; ATH
2755			<a href="https://www.biospace.com/article/releases/nellcor-and-masimo-corporation-announce-settlement-of-patent-litigation-/">https://www.biospace.com/article/releases/nellcor-and-masimo-corporation-announce-settlement-of-patent-litigation-/</a> .	NREL; 403; NP; HRS; LFND; ATH; 408; DUP; MIL
2756			<a href="https://www.sec.gov/Archives/edgar/data/937556/000119312507082880/dex1030.htm">https://www.sec.gov/Archives/edgar/data/937556/000119312507082880/dex1030.htm</a> .	NREL; 403; NP; HRS; LFND; ATH; 408; DUP; MIL
2757			WITHDRAWN	
2758			WITHDRAWN	
2759			WITHDRAWN	
2760			"Medical Monitoring Pioneer Announces the Limited Market Release of the Masimo W1 Watch for Consumers," Masimo, May 2, 2022, <a href="https://investor.masimo.com/news/news-details/2022/Medical-Monitoring-Pioneer-Announcethe-Limited-Market-Release-of-the-Masimo-W1-Watch-for-Consumers/default.aspx">https://investor.masimo.com/news/news-details/2022/Medical-Monitoring-Pioneer-Announcethe-Limited-Market-Release-of-the-Masimo-W1-Watch-for-Consumers/default.aspx</a> ; APL-MAS_03062483-486 at 483.	NREL; 403; NP; HRS; LFND; ATH; ILLEG
2761			"Medical Pioneer Masimo Announces the Full Market Consumer Release of the Masimo W1, the First Watch to Offer Accurate, Continuous Health Data," Masimo, August 31, 2022, <a href="https://investor.masimo.com/news/newsdetails/2022/Medical-Pioneer-Masimo-Announces-the-Full-Market-Consumer-Release-of-the-Masimo-W1-the-First-Watch-to-Offer-Accurate-Continuous-Health-Data/default.aspx">https://investor.masimo.com/news/newsdetails/2022/Medical-Pioneer-Masimo-Announces-the-Full-Market-Consumer-Release-of-the-Masimo-W1-the-First-Watch-to-Offer-Accurate-Continuous-Health-Data/default.aspx</a> ; APL-MAS_03058627-633 at 627-630.	NREL; 403; NP; HRS; LFND; ATH; INC
2762			"Masimo W1," Masimo, <a href="https://www.masimopersonalhealth.com/products/masimo-w1">https://www.masimopersonalhealth.com/products/masimo-w1</a> .	NREL; 403; NP; HRS; LFND; ATH
2763			WITHDRAWN	
2764			WITHDRAWN	
2765			WITHDRAWN	
2766			WITHDRAWN	
2767			WITHDRAWN	
2768			WITHDRAWN	
2769			WITHDRAWN	
2770			WITHDRAWN	
2771			WITHDRAWN	
2772			WITHDRAWN	
2773			WITHDRAWN	
2774			WITHDRAWN	
2775			WITHDRAWN	
2776			WITHDRAWN	
2777			WITHDRAWN	
2778			WITHDRAWN	
2779			WITHDRAWN	
2780			WITHDRAWN	

## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
2781			WITHDRAWN	
2782			WITHDRAWN	
2783			WITHDRAWN	
2784			WITHDRAWN	
2785			WITHDRAWN	
2786			WITHDRAWN	
2787			WITHDRAWN	
2788			WITHDRAWN	
2789			WITHDRAWN	
2790			WITHDRAWN	
2791			WITHDRAWN	
2792			WITHDRAWN	
2793			"Advanced Health Tracking Watch," Masimo, <a href="http://www.masimopersonalhealth.com">www.masimopersonalhealth.com</a> .	NREL; 403; NP; HRS; LFND; ATH
2794			"Advanced Health Tracking Watch," Masimo, <a href="https://www.masimopersonalhealth.com/products/masimo-w1">https://www.masimopersonalhealth.com/products/masimo-w1</a> .	NREL; 403; NP; HRS; LFND; ATH
2795			"Masimo W1 Medical Watch Receives FDA 510(k) Clearance for Over-The-Counter and Prescription Use," Masimo, November 17, 2023, <a href="https://investor.masimo.com/news/news-details/2023/Masimo-W1-Medical-Watch-Receives-FDA-510k-Clearance-for-Over-the-Counter-and-Prescription-Use/default.aspx">https://investor.masimo.com/news/news-details/2023/Masimo-W1-Medical-Watch-Receives-FDA-510k-Clearance-for-Over-the-Counter-and-Prescription-Use/default.aspx</a>	NREL; 403; NP; HRS; LFND; ATH
2796			"501(k) Premarket Notification," U.S. Food and Drug Administration, November 17, 2023, <a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K232512">https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K232512</a> .	NREL; 403; NP; HRS; LFND; ATH; INC
2797			WITHDRAWN	
2798			"The Future of Wearable Technology – Masimo Freedom Smart Health Watch & Band," Masimo Consumer, <a href="https://www.masimoconsumer.com/">https://www.masimoconsumer.com/</a> .	NREL; 403; NP; HRS; LFND; ATH
2799			"Masimo Freedom Smartwatch," Masimo Consumer, <a href="https://www.masimoconsumer.com/">https://www.masimoconsumer.com/</a> .	NREL; 403; NP; HRS; LFND; ATH
2800			"How to Use the Blood Oxygen App on Apple Watch," Apple, <a href="https://support.apple.com/en-us/HT211027">https://support.apple.com/en-us/HT211027</a> .	NREL; 403; NP; HRS; LFND; ATH
2801			"Health," Apple, <a href="https://www.apple.com/healthcare/apple-watch/">https://www.apple.com/healthcare/apple-watch/</a> .	NREL; 403; NP; HRS; LFND; ATH
2802			"Blood Oxygen App on Apple Watch," Apple, <a href="https://www.apple.com/healthcare/docs/site/Blood_Oxygen_app_on_Apple_Watch_October_2022.pdf">https://www.apple.com/healthcare/docs/site/Blood_Oxygen_app_on_Apple_Watch_October_2022.pdf</a> .	NREL; 403; NP; HRS; LFND; ATH
2803			WITHDRAWN	
2804			WITHDRAWN	
2805			WITHDRAWN	
2806			WITHDRAWN	
2807			WITHDRAWN	
2808			WITHDRAWN	
2809			WITHDRAWN	

## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
2810			WITHDRAWN	
2811			WITHDRAWN	
2812			WITHDRAWN	
2813			WITHDRAWN	
2814			WITHDRAWN	
2815			WITHDRAWN	
2816			WITHDRAWN	
2817			WITHDRAWN	
2818			WITHDRAWN	
2819			WITHDRAWN	
2820			WITHDRAWN	
2821			WITHDRAWN	
2822			WITHDRAWN	
2823			WITHDRAWN	
2824			WITHDRAWN	
2825			WITHDRAWN	
2826			WITHDRAWN	
2827			"US trade tribunal issues potential Apple Watch import ban in Masimo Patent Fight," Reuters, October 27, 2023, <a href="https://www.reuters.com/technology/us-trade-tribunal-issues-potential-apple-watch-import-ban-masimo-patent-fight-2023-10-26/">https://www.reuters.com/technology/us-trade-tribunal-issues-potential-apple-watch-import-ban-masimo-patent-fight-2023-10-26/</a>	NREL; 403; NP; HRS; LFND; ATH; MIL
2828			"Masimo's W1 invented to do things the Apple Watch can't: CEO Joe Kiani on 'The Claman Countdown,'" YouTube, February 9, 2023, <a href="https://www.youtube.com/watch?v=_rsy0BqCB8I">https://www.youtube.com/watch?v=_rsy0BqCB8I</a> .	NREL; 403; NP; HRS; LFND; ATH; MIL; MIS
2829			WITHDRAWN	
2830			"Masimo W1 Hospital-Grad Continuous Monitoring of SpO2 and Other Parameters in a Consumer Watch," Masimo, December 13, 2022, <a href="https://cdn.shopify.com/s/files/1/0097/9809/0814/files/PLM-14384A_Whitepaper_Masimo_W1_US_fc3c3edf-b889-4234-894a-c192c5cba3fa.pdf?v=1698882071">https://cdn.shopify.com/s/files/1/0097/9809/0814/files/PLM-14384A_Whitepaper_Masimo_W1_US_fc3c3edf-b889-4234-894a-c192c5cba3fa.pdf?v=1698882071</a> .	NREL; 403; NP; HRS; LFND; ATH
2831			WITHDRAWN	
2832			WITHDRAWN	
2833			WITHDRAWN	
2834			WITHDRAWN	
2835			WITHDRAWN	
2836			WITHDRAWN	
2837			WITHDRAWN	
2838			WITHDRAWN	
2839			WITHDRAWN	
2840			WITHDRAWN	
2841			WITHDRAWN	
2842			WITHDRAWN	
2843			WITHDRAWN	
2844			WITHDRAWN	
2845			WITHDRAWN	

## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
2846			WITHDRAWN	
2847			WITHDRAWN	
2848			WITHDRAWN	
2849			WITHDRAWN	
2850			WITHDRAWN	
2851			WITHDRAWN	
2852			WITHDRAWN	
2853			WITHDRAWN	
2854			WITHDRAWN	
2855			WITHDRAWN	
2856			WITHDRAWN	
2857			WITHDRAWN	
2858			WITHDRAWN	
2859			WITHDRAWN	
2860			<a href="https://www.masimo.com/company/news/news-media/2006/#news-5406c602-a3f1-477a-a44b-8f2517a42931">https://www.masimo.com/company/news/news-media/2006/#news-5406c602-a3f1-477a-a44b-8f2517a42931</a> .	NREL; 403; NP; HRS; LFND; ATH
2861			WITHDRAWN	
2862			WITHDRAWN	
2863			WITHDRAWN	
2864			Murphy, Rachel, "I Tried the Newest Competitor to the Apple Watch and Learned I'm Dehydrated," verywellhealth.com, February 24, 2023, <a href="https://www.verywellhealth.com/health-tracking-watches-masimo-vs-apple-7111935">https://www.verywellhealth.com/health-tracking-watches-masimo-vs-apple-7111935</a> .	NREL; 403; NP; HRS; LFND; ATH; ILLEG; INC
2865			Brown, Mark, "Apple Bans Phone Story Game That Exposes Seedy Side of Smartphone Creation," Wired.com, September 14, 2011, <a href="https://www.wired.com/2011/09/phone-story/">https://www.wired.com/2011/09/phone-story/</a> .	NREL; 403; NP; HRS; LFND; ATH; MIL
2866			Federal Register Notice 46275 / Vol. 86, No. 157, August 18, 2021.	NREL; 403; NP; LFND; ATH; HRS; NE; MIL
2867			"Masimo Corp-MASI: W1 Receives FDA Clearance; We View Approval as an Incremental Positive," AlphaSense, Inc., November 20, 2023.	NREL; 403; NP; NOID; ATH; LFND; IDSCR; HRS
2868			"Masimo Corp-MASI: W1 Doctor Feedback Largely Positive; Five Things that We Learned," AlphaSense, Inc., November 27, 2023.	NREL; 403; NP; NOID; ATH; LFND; IDSCR; HRS
2869			WITHDRAWN	
2870			WITHDRAWN	
2871			WITHDRAWN	
2872			WITHDRAWN	
2873			"These are all the ideas Apple stole from other companies, or people, and sold for billions," Ashraf, October 28, 2012.	NREL; 403; NP; HRS; LFND; ATH; MIL
2874			Blood Oxygen app on Apple Watch, October 2022.	NREL; 403; NP; NOID; ATH; LFND; IDSCR; HRS
2875			Clover, Juli, "Apple's Search Engine Negotiations with Google Took Months of Near-Daily Meetings," MacRumors, June 10, 2019.	NREL; 403; NP; HRS; LFND; ATH; MIL

## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
2876			"Galaxy Watch4 and Galaxy Watch4 Classic: Reshaping the Smartwatch Experience," Samsung Global Newsroom, August 11, 2021, <a href="https://news.samsung.com/global/galaxy-watch4-and-galaxy-watch4-classic-reshaping-the-smartwatch-experience">https://news.samsung.com/global/galaxy-watch4-and-galaxy-watch4-classic-reshaping-the-smartwatch-experience</a> .	NREL; 403; NP; HRS; LFND; ATH
2877			WITHDRAWN	
2878			"Smart Watch Men Fitness Tracker," Amazon, available at <a href="https://www.amazon.com/dp/B0C7QXKGVQ/">https://www.amazon.com/dp/B0C7QXKGVQ/</a> .	NREL; 403; NP; HRS; LFND; ATH
2879			WITHDRAWN	
2880			"Smart Watch, Infrared True Blood," Amazon, available at <a href="https://www.amazon.com/dp/B0CDPR42PR/">https://www.amazon.com/dp/B0CDPR42PR/</a> .	NREL; 403; NP; HRS; LFND; ATH
2881			"Smart Watch(Answer/Make Call) watch for men women," Amazon, available at <a href="https://www.amazon.com/dp/B0CLG5RSHW">https://www.amazon.com/dp/B0CLG5RSHW</a> .	NREL; 403; NP; HRS; LFND; ATH
2882			WITHDRAWN	
2883			WITHDRAWN	
2884			WITHDRAWN	
2885			WITHDRAWN	
2886			"SKG R8 Military Smart Watches for Men," Amazon, available at <a href="https://a.co/d/aMrG3D">https://a.co/d/aMrG3D</a> .	NREL; 403; NP; HRS; LFND; ATH
2887			WITHDRAWN	
2888			"Smart Watch for Men Women (Call Receive/Dial)," Amazon, available at <a href="https://a.co/d/dQO6OW3">https://a.co/d/dQO6OW3</a> .	NREL; 403; NP; HRS; LFND; ATH
2889			"Gydom Smart Watches for Women," Amazon, available at <a href="https://a.co/d/i2E3t3R">https://a.co/d/i2E3t3R</a> .	NREL; 403; NP; HRS; LFND; ATH
2890			"TOOBUR Smart Watch for Women," Amazon, available at <a href="https://a.co/d/7NMJWmV">https://a.co/d/7NMJWmV</a> .	NREL; 403; NP; HRS; LFND; ATH
2891			"Fitpolo Smart Watch for Women," Amazon, available at <a href="https://a.co/d/j5C0VyM">https://a.co/d/j5C0VyM</a> .	NREL; 403; NP; HRS; LFND; ATH
2892			"Smart Watch, Infrared True Blood Oxygen Monitor, 1.91" HD Smartwatch for Women," Amazon, available at <a href="https://a.co/d/52uuzex">https://a.co/d/52uuzex</a> .	NREL; 403; NP; HRS; LFND; ATH
2893			"Smart Watch with Bluetooth Cal Answer/Dial for Men Women," Amazon, available at <a href="https://a.co/d/4GkMiky">https://a.co/d/4GkMiky</a> .	NREL; 403; NP; HRS; LFND; ATH
2894			"Smart Watch for Men Women," Amazon, available at <a href="https://a.co/d/4B0sisl">https://a.co/d/4B0sisl</a> .	NREL; 403; NP; HRS; LFND; ATH
2895			"Smart Watch for Women Men, 30-Day Long Standby," Amazon, available at <a href="https://a.co/d/gbtgUOv">https://a.co/d/gbtgUOv</a> .	NREL; 403; NP; HRS; LFND; ATH; INC
2896			"Smart Watch for Men Women, 1.69 Inch Fitness Watch Sport," Amazon, available at DT.	NREL; 403; NP; HRS; LFND; ATH; INC
2897			WITHDRAWN	
2898			WITHDRAWN	
2899			WITHDRAWN	
2900			WITHDRAWN	
2901			WITHDRAWN	
2902			WITHDRAWN	
2903			WITHDRAWN	

## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
2904			Bohn, Dieter, "Apple Watch Series 6 review: minute improvements," The Verge, October 1, 2020, available at <a href="https://www.theverge.com/21496141/apple-watch-series-6-review-blood-oxygen-monitor-watchos-7">https://www.theverge.com/21496141/apple-watch-series-6-review-blood-oxygen-monitor-watchos-7</a> .	NREL; 403; NP; HRS; LFND; ATH; INC
2905			Kazilbash, Sana, "Can the Apple Watch Series 6 Keep the Doctor Away," engineering.com, October 7, 2020, available at <a href="https://www.engineering.com/story/can-the-apple-watch-series-6-keep-the-doctor-away">https://www.engineering.com/story/can-the-apple-watch-series-6-keep-the-doctor-away</a> .	NREL; 403; NP; HRS; LFND; ATH
2906			WITHDRAWN	
2907			WITHDRAWN	
2908			WITHDRAWN	
2909			Sarwar, N., "I bought a \$50 Apple Watch Ultra clone, and it blew me away," Digital Trends, January 24, 2023, available at <a href="https://www.digitaltrends.com/mobile/apple-watch-ultra-clone-hands-on-blew-me-away/">https://www.digitaltrends.com/mobile/apple-watch-ultra-clone-hands-on-blew-me-away/</a> .	NREL; 403; NP; HRS; LFND; ATH
2910			"iSpO2 Pulse Oximeter," Masimo, available at <a href="https://www.masimopersonalhealth.com/pages/ispo2-o2-monitor-android-ios">https://www.masimopersonalhealth.com/pages/ispo2-o2-monitor-android-ios</a> .	NREL; 403; NP; HRS; LFND; ATH
2911			"Recognition for Excellence," Masimo, available at <a href="https://www.masimo.com/company/masimo/awards/">https://www.masimo.com/company/masimo/awards/</a> .	NREL; 403; NP; HRS; LFND; ATH; INC
2912			Masimo W1 Medical Watch, Masimo, available at <a href="https://web.archive.org/web/20231227165136/https://www.masimo.com/products/monitors/masimo-w1-medical-watch/">https://web.archive.org/web/20231227165136/https://www.masimo.com/products/monitors/masimo-w1-medical-watch/</a> .	NREL; 403; NP; HRS; LFND; ATH; INC
2913			"Masimo W1 Medical Watch Receives FDA 510(k) Clearance for Over-the-Counter and Prescription Use," Masimo, available at <a href="https://investor.masimo.com/news/news-details/2023/Masimo-W1-Medical-Watch-Receives-FDA-510k-Clearance-for-Over-the-Counter-and-Prescription-Use/default.aspx">https://investor.masimo.com/news/news-details/2023/Masimo-W1-Medical-Watch-Receives-FDA-510k-Clearance-for-Over-the-Counter-and-Prescription-Use/default.aspx</a> .	NREL; 403; NP; HRS; LFND; ATH
2914			Masimo Sustainability Report, 2021 ("Our main manufacturing facility is located in North America, our largest market.")	NREL; 403; NP; HRS; LFND; ATH
2915			Memorandum Opinion, Masimo Corporation v. Philips N. Am. Corp., 1:09-cv-00080-LPS, D.I. 997, (D. Del. May 18, 2015).	NREL; 403; NP; HRS; LFND; ATH; NE; MIL
2916			WITHDRAWN	
2917			"Masimo Signs Three-Year, Dual-Source Agreement with Novation for Pulse Oximetry, and New Masimo Rainbow SET Technology," Masimo, February 2, 2006, available at <a href="https://www.masimo.com/company/news/news-media/2006/#news-ed6d3f46-99f9-4b6a-a9fd-f03c7a5c2cd9">https://www.masimo.com/company/news/news-media/2006/#news-ed6d3f46-99f9-4b6a-a9fd-f03c7a5c2cd9</a> .	NREL; 403; NP; HRS; LFND; ATH
2918			WITHDRAWN	
2919			WITHDRAWN	
2920			WITHDRAWN	
2921			Chris McCarthy Public Interest Statement, EDIS Doc. ID 789080, February 1, 2023	NREL; 403; NP; HRS; LFND; ATH; NE; MIL

## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
2922			Medical Device Manufacturers Association Public Interest Statement., EDIS Doc. ID 791167, February 27, 2023, (citing <a href="https://www.verywellhealth.com/health-tracking-watches-masimo-vs-apple-7111935">https://www.verywellhealth.com/health-tracking-watches-masimo-vs-apple-7111935</a> ).	NREL; 403; NP; HRS; LFND; ATH; NE; MIL
2923			"MightySat", Masimo, available at <a href="https://www.masimopersonalhealth.com/pages/mightysat">https://www.masimopersonalhealth.com/pages/mightysat</a> .	NREL; 403; NP; HRS; LFND; ATH; INC
2924			"Nationwide Respiratory Signs Preferred Pulse Oximetry Agreement with Masimo," Masimo, December 13, 2007, available at <a href="https://www.masimo.com/company/news/news-media/2007/#news-5a4f7a11-c359-4736-993c-372ed3633172">https://www.masimo.com/company/news/news-media/2007/#news-5a4f7a11-c359-4736-993c-372ed3633172</a> .	NREL; 403; NP; HRS; LFND; ATH
2925			"Nellcor And Masimo Corporation Announce Settlement of Patent Litigation," BioSpace, January 24, 2006, available at <a href="https://www.biospace.com/article/releases/nellcor-and-masimo-corporation-announce-settlement-of-patent-litigation-/">https://www.biospace.com/article/releases/nellcor-and-masimo-corporation-announce-settlement-of-patent-litigation-/</a> .	NREL; 403; NP; HRS; LFND; ATH; 408, DUP; MIL
2926			"OEM Solutions," Masimo, available at <a href="https://www.masimo.com/oem/solutions/#MX-7">https://www.masimo.com/oem/solutions/#MX-7</a> .	NREL; 403; NP; HRS; LFND; ATH
2927			Osenga, Kristen Jakobsen, "'Efficient' Infringement and Other Lies," Seton Hall Law Review, 2022, 52(4): 1085–1110	DUP; NREL; 403; NP; HRS; LFND; ATH; IEXP; MIL
2928			WITHDRAWN	
2929			Peter Pronovost Public Interest Statement, EDIS Doc. ID 791162, February 26, 2023, (citing <a href="https://academic.oup.com/jamia/article/27/9/1359/5911974?log_in=false">https://academic.oup.com/jamia/article/27/9/1359/5911974?log_in=false</a> ).	NREL; 403; NP; HRS; LFND; ATH; NE; MIL
2930			Patient Safety Movement Foundation Public Interest Statement, EDIS Doc. ID 791175, February 27, 2023.	NREL; 403; NP; HRS; LFND; ATH; NE; MIL
2931			"Settlement Agreement and Release of Claims," SEC, January 17, 2006, available at <a href="https://www.sec.gov/Archives/edgar/data/937556/000119312507082880/dex1030.htm">https://www.sec.gov/Archives/edgar/data/937556/000119312507082880/dex1030.htm</a> .	NREL; 403; NP; HRS; LFND; ATH; NE; 408; DUP; MIL
2932			WITHDRAWN	
2933			Denning, Steve, "The Lost Interview: Steve Jobs Tells Us What Really Matters," Forbes , November 17, 2011, available at <a href="https://www.forbes.com/sites/stevedenning/2011/11/17/the-lost-interview-steve-jobs-tells-us-what-really-matters/?sh=78be55fd6c3a">https://www.forbes.com/sites/stevedenning/2011/11/17/the-lost-interview-steve-jobs-tells-us-what-really-matters/?sh=78be55fd6c3a</a>	NREL; 403; NP; HRS; LFND; ATH; INC; MIL
2934			"The Trouble With Patent-Troll Hunting," The Economist , December 14, 2019, <a href="https://www.economist.com/business/2019/12/14/the-trouble-with-patent-troll-hunting">https://www.economist.com/business/2019/12/14/the-trouble-with-patent-troll-hunting</a>	NREL; 403; NP; HRS; LFND; ATH; INC; IEXP; MIL

## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
2935			"University of Wisconsin Hospitals and Clinics Complete System-Wide Conversion to Masimo SET Pulse Oximetry Technology," Masimo, September 6, 2007, available at <a href="https://www.masimo.com/company/news/news-media/2007/#news-e926feca-ff9b-4628-9afd-191ac5baebd1">https://www.masimo.com/company/news/news-media/2007/#news-e926feca-ff9b-4628-9afd-191ac5baebd1</a>	NREL; 403; NP; HRS; LFND; ATH
2936			WITHDRAWN	
2937			Wyatt, Kirk D., Poole, Lisa R., et al., "Clinical evaluation and diagnostic yield following evaluation of abnormal pulse detected using Apple Watch," Journal of the American Medical Informatics Association, 27(9), 2020, 1359-1363.	NREL; 403; NP; HRS; LFND; ATH
2938			Mickle, Tripp, "After Steve - How Apple Became a Trillion-Dollar Company and Lost Its Soul," HarperCollins Publishers, May 3, 2022.	NREL; 403; NP; HRS; LFND; ATH; MIL
2939			Albergotti, Reed, "How Apple uses its App Store to copy the best ideas," The Washington Post, September 5, 2019.	NREL; 403; NP; HRS; LFND; ATH; MIL
2940			Chan, Jenny, Selden, Mark and Pun Ngai, "Dying for an iPhone: Apple, Foxconn, and The Lives of China's Workers," Haymarket Books, 2020.	NREL; 403; NP; HRS; LFND; ATH; MIL
2941			Fowler, Geoffrey A., "The new Apple Watch says my lungs may be sick. Or perfect. It can't decide," The Washington Post, September 23, 2020.	NREL; 403; NP; HRS; LFND; ATH
2942			Shirky, Clay, "Apple Inc., 'After Steve'," The New York Times, May 1, 2022, available at <a href="https://www.nytimes.com/2022/05/01/books/review/after-steve-tripp-mickle.html">https://www.nytimes.com/2022/05/01/books/review/after-steve-tripp-mickle.html</a> .	NREL; 403; NP; HRS; LFND; ATH; INC; MIL
2943			Pakes, Ariel, and Mark Schankerman, An Exploration into the Determinants of Research Intensity, pp. 209-232 in Griliches, Zvi, R&D, Patents, and Productivity, University of Chicago Press, 1984.	NREL; 403; NP; HRS; LFND; ATH
2944			Data, Anusua, "Divestiture and its Implications for Innovation and Productivity Growth in U.S. Telecommunications," Southern Economic Journal, January 2003, 69(3): 644-658.	NREL; 403; NP; HRS; LFND; ATH
2945			Adams, William James, "Firm Size and Research Activity: France and the United States," The Quarterly Journal of Economics, August 1970, 84(3): 386-409.	NREL; 403; NP; HRS; LFND; ATH
2946			Moncada-Paterno-Castello, Pietro and Nicola Grassano, "The EU vs US Corporate R&D Intensity Gap: Investigating Key Sectors and Firms," Industrial and Corporate Change, 2022, 31: 19-38.	NREL; 403; NP; HRS; LFND; ATH
2947			Solarin, Sakiru Adebola, Gema Lopez, and Luis A. Gil-Alana (2002), "Persistence Analysis of Research Intensity in OECD Countries Since 1870," Australian Economic Papers, 61: 738-750.	NREL; 403; NP; HRS; LFND; ATH



## Masimo's Trial Exhibit 68127 and Apple's Objections


DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
2948			Romero, Joao P., Ana Bottega, and Arthur B. Cordeiro (2023), "The Impact of Demand on Innovation and Research Intensity," International Review of Applied Economics, 37(2): 217-235.	NREL; 403; NP; HRS; LFND; ATH
2949			Romero, Joao P. and Gustavo Britto (2017), "Increasing Returns to Scale, Technological Catch-up and Research Intensity: Endogenising the Verdoorn Coefficient," Cambridge Journal of Economics 41: 391-412.	NREL; 403; NP; HRS; LFND; ATH
2950	APL_DEL00001292	APL_DEL00001331		NREL; 403; HRS; LFND
2951	APL_DEL00208553	APL_DEL00208577		NREL; 403; HRS; LFND
2952	APL_DEL00275285	APL_DEL00275365		NREL; 403; HRS; LFND
2953	APL_DEL00278058	APL_DEL00278311		NREL; 403; HRS; LFND
2954	APL_DEL00286984	APL_DEL00287002		NREL; 403; HRS; LFND
2955	APL_DEL00723707	APL_DEL00723767		NREL; 403; HRS; LFND
2956	APL_DEL00723901	APL_DEL00723905		NREL; 403; HRS; LFND
2957	APL_DEL00955231	APL_DEL00955285		NREL; 403; HRS; LFND
2958	APL_DEL00956919	APL_DEL00956984		NREL; 403; HRS; LFND
2959	APL_DEL00960474	APL_DEL00960747		NREL; 403; HRS; LFND
2960	APL_DEL01352630			NREL; 403; HRS; LFND
2961	APL_DEL01352631			NREL; 403; HRS; LFND
2962	APL_DEL01355760	APL_DEL01355788		NREL; 403; HRS; LFND
2963	APL_DEL01460397			NREL; 403; HRS; LFND
2964	APL_DEL03495105			NREL; 403; HRS; LFND
2965	APL_DEL03853308	APL_DEL03853312		NREL; 403; HRS; LFND
2966	APL_DEL03862805	APL_DEL03862809		NREL; 403; HRS; LFND
2967	APL_DEL03867619	APL_DEL03867622		NREL; 403; HRS; LFND
2968	APL_DEL03867833	APL_DEL03867836		NREL; 403; HRS; LFND
2969	APL_DEL03869063	APL_DEL03869065		NREL; 403; HRS; LFND
2970	APL_DEL03889352	APL_DEL03889355		NREL; 403; HRS; LFND
2971	APL_DEL03894614	APL_DEL03894615		NREL; 403; HRS; LFND

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
2972	APL_DELO3908271	APL_DELO3908276		REL; 403; HRS; LFND
2973	APL_DELO3925534	APL_DELO3925538		REL; 403; HRS; LFND
2974	APL_DELO3927088	APL_DELO3927090		REL; 403; HRS; LFND
2975	APL_DELO3934226	APL_DELO3934232		REL; 403; HRS; LFND
2976	APL_DELO3934965	APL_DELO3934966		REL; 403; HRS; LFND
2977	APL_DELO3950177	APL_DELO3950181		REL; 403; HRS; LFND
2978	APL_DELO3950891	APL_DELO3950897		REL; 403; HRS; LFND
2979	APL_DELO3952968	APL_DELO3952986		REL; 403; HRS; LFND
2980	APL_DELO3960509	APL_DELO3960510		REL; 403; HRS; LFND
2981	APL_DELO3962099	APL_DELO3962103		REL; 403; HRS; LFND
2982	APL_MAS_ITC_00413485	APL_MAS_ITC_00413506		REL; 403; HRS; LFND
2983	APL-MAS_00157297	APL-MAS_00157341		REL; 403; HRS; LFND
2984	APL-MAS_00157389	APL-MAS_00157431		REL; 403; HRS; LFND
2985	APL-MAS_00433808	APL-MAS_00433810		REL; 403; HRS; LFND; MIL
2986	APL-MAS_00614176	APL-MAS_006141220		REL; 403; HRS; LFND
2987	APL-MAS_00723842	APL-MAS_00723846		REL; 403; HRS; LFND; ATH
2988	APL-MAS_00922514	APL-MAS_00922524		REL; 403; NP; NOID; LFND; IDSCR; HRS
2989	APL-MAS_01422600	APL-MAS_01422678		REL; 403; HRS; LFND; ATH
2990	APL-MAS_02294991	APL-MAS_02294994		REL; 403; HRS; LFND
2991	APL-MAS_02490956	APL-MAS_02490956		REL; 403; HRS; LFND
2992	APL-MAS_02569186	APL-MAS_02569186		REL; 403; HRS; LFND

## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
2993	APL-MAS_02617587	APL-MAS_02617869	06/06/2022 ITC Investigation No. 337-TA-1276 - Transcript Volume I of Evidentiary Hearing in Certain Light-based Physiological Measurement Devices and Components Thereof (Full)	NREL; 403; HRS; LFND; NE; MIL
2994	APL-MAS_02623951	APL-MAS_02623997	02/18/2022 ITC Investigation No. 337-TA-1276 Transcript of Deposition of Stephen Waudu, PH.D.; 03/22/2022 Errata Sheet	NREL; 403; HRS; LFND; NE; MIL
2995	APL-MAS_02640307	APL-MAS_02640310	09/09/2014 Apple Unveils Apple Watch-Apple's Most Personal Device Ever	NREL; 403; HRS; LFND
2996	APL-MAS_03042557	APL-MAS_03042568	09/12/2018 Apple Watch Series 4: Beautifully Redesigned with Breakthrough Communication, Fitness and Health Capabilities	NREL; 403; HRS; LFND
2997	APL-MAS_03058627	APL-MAS_03058633	08/31/2022 Medical Pioneer Masimo Announces the Full Market Consumer Release of the Masimo W1, the First Watch to Offer Accurate, Continuous Health Data	NREL; 403; HRS; LFND; ATH
2998	APL-MAS_03062483	APL-MAS_03062486	05/02/2022 Medical Monitoring Pioneer Announces the Limited Market Release of the Masimo W1 Watch for Consumers	NREL; 403; HRS; LFND; ATH
2999	APL-MAS_03062487	APL-MAS_03062491	05/02/2022 Medical Monitoring Pioneer Announces the Limited Market Release of the Masimo W1 Watch for Consumers	NREL; 403; HRS; LFND; ATH
3000	APL-MAS_03062518	APL-MAS_03062690	01/01/2022 U.S. Securities and Exchange Commission Form 10-K	NREL; 403; HRS; LFND; ATH
3001	APL-MAS_03062928	APL-MAS_03062934	08/29/2022 Smartwatch Market Size Will Achieve USD 156.3 Billion by 2030 Rowing at 20.1% CAGR - Exclusive Report by Acumen Research and Consulting	NREL; 403; HRS; LFND; ATH
3002	APL-MAS_03064472	APL-MAS_03064711	Masimo Corporation Form 10-K for the fiscal year ended January 2, 2021	NREL; 403; HRS; LFND; ATH
3003	APL-MAS_03064712	APL-MAS_03064846	Masimo Corporation Form 10-K for the fiscal year ended	NREL; 403; HRS; LFND; ATH
3004	APL-MAS_00239694	APL-MAS_00239698		NREL; 403; HRS; LFND; MIL
3005	APL-MAS_00403772	APL-MAS_00403784		NREL; 403; HRS; LFND; MIL
3006	APL-MAS_00432923	APL-MAS_00432924		NREL; 403; HRS; LFND; MIL
3007	APL-MAS_00778320	APL-MAS_00778323		NREL; 403; HRS; LFND
3008	APL-MAS_00778324	APL-MAS_00778353		NREL; 403; HRS; LFND
3009	APL-MAS_00700552	APL-MAS_00700561		NREL; 403; HRS; LFND
3010	APL-MAS_00676516	APL-MAS_00676517		NREL; 403; HRS; LFND; MIL
3011	APL-MAS_02503577	APL-MAS_02503581		NREL; 403; HRS; LFND

## Masimo's Trial Exhibit 68130 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
3012	APL-MAS_00226067	APL-MAS_00226071		NREL; 403; HRS; LFND; MIL
3013	APL-MAS_00226719	APL-MAS_00226786		NREL; 403; HRS; LFND
3014	APL-MAS_01873721	APL-MAS_01873728		NREL; 403; HRS; LFND
3015	APL-MAS_00434182	APL-MAS_00434199		NREL; 403; HRS; LFND
3016	APL-MAS_01831295	APL-MAS_01831295		NREL; 403; HRS; LFND; MIL
3017				NREL; 403; HRS; LFND; ATH; NP; IDSCR; MIL
3018				NREL; 403; NP; HRS; LFND; ATH
3019				NREL; 403; NP; HRS; LFND; ATH
3020	MASA00081231	MASA00081272		NREL; 403; LFND; ATH; HRS
3021	MASA03352621	MASA03352624		NREL; 403; LFND; ATH; HRS; ILLEG
3022	MASA11398210	MASA11398225		NREL; 403; LFND; ATH; HRS
3023	MASA11398280	MASA11398296		NREL; 403; LFND; ATH; HRS
3024	MASAD00031831	MASAD00031866		NREL; 403; LFND; ATH; HRS
3025	MASAD00032163	MASAD00032188		DUP; NREL; 403; LFND; ATH; HRS; IEXP; MIL
3026	MASAD00033019	MASAD00033047		NREL; 403; LFND; ATH; HRS
3027	MASAD00033226	MASAD00033290		NREL; 403; LFND; ATH; HRS
3028	MASAD00033610	MASAD00033648		NREL; 403; LFND; ATH; HRS
3029	MASAD00034102	MASAD00034171		NREL; 403; LFND; ATH; HRS
3030	MASAD00034339	MASAD00034381		NREL; 403; LFND; ATH; HRS
3031	MASAD00034617	MASAD00034617		NREL; 403; LFND; ATH; HRS
3032	MASAD00037431	MASAD00038340		NREL; 403; LFND; ATH; HRS
3033	MASAD00038662	MASAD00038957		NREL; 403; LFND; ATH; HRS; ILLEG
3034	MASAD00043026			NREL; 403; LFND; ATH; HRS
3035	MASAD00045882	MASAD00045893		NREL; 403; LFND; ATH; HRS
3036	MASAD00059492			NREL; 403; LFND; ATH
3037	MASAD00059493		Photo of back of Masimo Watch	NREL; 403; LFND; ATH
3038	MASAD00059494		Photo of front of Masimo Watch	NREL; 403; LFND; ATH
3039	MASAD00059495		Photo of front of Masimo Watch	NREL; 403; LFND; ATH

## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
3040	MASAD00059496		Photo of front of Masimo Watch	NREL; 403; LFND; ATH
3041	MASAD00059497			NREL; 403; LFND; ATH
3042	MASAD00059498			NREL; 403; LFND; ATH
3043	MASAD00059499			NREL; 403; LFND; ATH
3044	MASAD00059500			NREL; 403; LFND; ATH
3045	MASAD00059501			NREL; 403; LFND; ATH
3046	MASAD00059502			NREL; 403; LFND; ATH
3047	MASAD00059503			NREL; 403; LFND; ATH
3048	MASAD00059504			NREL; 403; LFND; ATH
3049	MASAD00069492			NREL; 403; LFND; ATH; HRS
3050	MASAD00097057	MASAD00097072		NREL; 403; LFND; ATH; HRS
3051	MASAD00237032	MASAD00237034		NREL; 403; LFND; ATH; HRS
3052	MASAD00238635	MASAD00238637		NREL; 403; LFND; ATH; HRS; IEXP; MIL
3053	MASAD00430234			NREL; 403; LFND; ATH; HRS
3054	MASAD00430236			NREL; 403; LFND; ATH; HRS
3055	MASAD00430237			NREL; 403; LFND; ATH; HRS
3056	MASAD00439092	MASAD00439093		NREL; 403; LFND; ATH; HRS
3057	MASAD00644864			NREL; 403; LFND; ATH; HRS
3058	MASAD00646884	MASAD00646885		NREL; 403; LFND; ATH; HRS
3059	MASAD00763028	MASAD00763032		NREL; 403; LFND; ATH; HRS
3060	MASAD00769091			NREL; 403; LFND; ATH; HRS
3061	MASAD00785705			NREL; 403; LFND; ATH; HRS
3062	MASAD00796620	MASAD00796683		NREL; 403; LFND; ATH; HRS
3063	MASAD00899339	MASAD00899341		NREL; 403; LFND; ATH; HRS
3064	MASAD00963214			NREL; 403; LFND; ATH; HRS
3065	MASAD00963215	MASAD00963256		NREL; 403; LFND; ATH; HRS
3066	MASAD01166416	MASAD01166417		NREL; 403; LFND; ATH; HRS
3067	MASAD01167070			NREL; 403; LFND; ATH; HRS
3068	MASAD01167071	MASAD01167105		NREL; 403; LFND; ATH; HRS
3069	MASAD01170244	MASAD01170245		NREL; 403; LFND; ATH; HRS
3070	MASAD01186272	MASAD01186276		NREL; 403; LFND; ATH; HRS

## Masimo's Trial Exhibit 68130 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
3071	MASAD01196337	MASAD01196340		REL; 403; LFND; ATH; HRS
3072	MASAD01425450	MASAD01425453		REL; 403; LFND; ATH; HRS
3073	MASAD02035467			REL; 403; LFND; ATH; HRS; IDSCR
3074	MASAD02047047			REL; 403; LFND; ATH; HRS; IDSCR
3075	MASAD02080043			REL; 403; LFND; ATH; HRS; IDSCR
3076	MASAD02080044			REL; 403; LFND; ATH; IDSCR
3077	MASAD02081248	MASAD02081249		REL; 403; NP; NOID; ATH; HRS; LFND
3078	MASAD02877383			REL; 403; LFND; ATH; HRS; IDSCR
3079	MASAD02892109	MASAD02892111		REL; 403; LFND; ATH; HRS
3080	MASAD02902188	MASAD02902191		REL; 403; LFND; ATH; HRS
3081	MASAD02903166	MASAD02903168		REL; 403; LFND; ATH; HRS
3082	MASAD02984322			REL; 403; LFND; ATH; HRS; IDSCR
3083	MASAD02992166			REL; 403; LFND; ATH; HRS; IDSCR
3084	MASAD03010347	MASAD03010348		REL; 403; LFND; ATH; HRS
3085	MASAD03010350			REL; 403; LFND; ATH; IDSCR
3086	MASAD03758121			REL; 403; LFND; ATH; HRS; IDSCR
3087	MASAD03847193			REL; 403; LFND; ATH; HRS; IDSCR
3088	MASAD03850136	MASAD03850137		REL; 403; LFND; ATH; HRS
3089	MASAD03857229	MASAD03857230		REL; 403; LFND; ATH; HRS
3090	MASAD03876907			REL; 403; LFND; ATH; HRS; IDSCR
3091	MASAD04143270	MASAD04143280		REL; 403; LFND; ATH; HRS
3092	MASAD04143281	MASAD04143281		REL; 403; LFND; ATH; HRS
3093	MASAD04143282	MASAD04143283		REL; 403; LFND; ATH; HRS
3094	MASAD04143390	MASAD04143394		REL; 403; LFND; ATH; HRS
3095	MASITC_00454374			REL; 403; LFND; ATH; HRS; IDSCR
3096	MASITC_01078224			REL; 403; LFND; ATH; HRS; IDSCR
3097	MASITC_01129170			REL; 403; LFND; ATH; HRS; IDSCR

## Masimo's Trial Exhibit 68130 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
3098	MASITC_01132275	MASITC_01132277		NREL; 403; LFND; ATH; HRS
3099	MASITC_01132278	MASITC_01132318		NREL; 403; LFND; HRS
3100	MASITC_01132370			NREL; 403; LFND; ATH; HRS; IDSCR
3101	MASITC_01137505	MASITC_01137505		NREL; 403; LFND; ATH; HRS
3102	MASITC_01148528			NREL; 403; LFND; ATH; HRS; IDSCR
3103	MASITC_01148653	MASITC_01148654		NREL; 403; LFND; ATH; HRS
3104	MASITC_01148655	MASITC_01148661		NREL; 403; LFND; ATH; HRS
3105	MASITC_01148686			NREL; 403; LFND; ATH; HRS; IDSCR
3106	MASITC_01249678			NREL; 403; LFND; ATH; HRS; IDSCR
3107	MASITC_01249878			NREL; 403; LFND; ATH; HRS; IDSCR
3108	MASITC_01253789			NREL; 403; LFND; ATH; HRS; IDSCR
3109	MASITC_01253790			NREL; 403; LFND; ATH; HRS; IDSCR
3110	MASITC_01254226	MASITC_01254227		NREL; 403; LFND; ATH; HRS
3111	MASITC_01259368			NREL; 403; LFND; ATH; HRS; IDSCR
3112	MASITC_01302948	MASITC_01302952		NREL; 403; LFND; ATH; HRS
3113	MASITC_01379392	MASITC_01379392		NREL; 403; LFND; HRS
3114	MASITC_01394449			NREL; 403; LFND; ATH; HRS; IDSCR
3115	SAMSUNG_00000005			NREL; 403; LFND; ATH; HRS; NP
3116	MASAD00034382	MASAD00034454		NREL; 403; LFND; ATH; HRS
3117			Apple Design Awards"	NREL; 403; LFND; ATH; HRS; NP; IDSCR
3118			10/30/2023 Apple Press Release, "Apple unveils M3, M3 Pro, and M3 Max, the most advanced chips for a personal computer"	NREL; 403; LFND; ATH; HRS; NP; IDSCR
3119			6/5/2023 Apple Press Release, "Introducing Apple Vision Pro: Apple's first spatial computer"	NREL; 403; LFND; ATH; HRS; NP; IDSCR
3120			Printout of Apple's product page - Apple Watch Series 8	NREL; 403; LFND; ATH; HRS; NP; IDSCR
3121			9/10/2019 Apple Press Release, "Apple unveils Apple Watch Series 5"	NREL; 403; LFND; ATH; HRS; NP; IDSCR
3122			Compilation of images of Apple's Press Release re Apple Watch Series 5	NREL; 403; LFND; ATH; HRS; NP; IDSCR
3123			9/7/2022 Apple Press Release, "Apple reveals Apple Watch Series 8 and the new Apple Watch SE"	NREL; 403; LFND; ATH; HRS; NP; IDSCR

## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
3124			Compilation of images of Apple's Press Release re Apple Watch 8	NREL; 403; LFND; ATH; HRS; NP; IDSCR
3125			Printout of Amazon product page - Apple Watch Series 5 (GPS + Cellular, 44 MM) - Space Gray Aluminum Case with Black Sport Band (Renewed) (enlarged thumbnail images)	NREL; 403; LFND; ATH; HRS; NP; IDSCR
3126			Printout of Amazon product page - Apple Watch Series 8	NREL; 403; LFND; ATH; HRS; NP; IDSCR
3127			Printout of Amazon product page - Masimo W1®	NREL; 403; LFND; ATH; HRS; NP; IDSCR
3128			Printout of Best Buy webpage - Search results for Apple Watch Series 8	NREL; 403; LFND; ATH; HRS; NP; IDSCR
3129			Printout of Best Buy product page - Product and Customer Images of Apple Watch Series 8 Midnight	NREL; 403; LFND; ATH; HRS; NP; IDSCR
3130			Attachment A to Expert Report of Cleve Tyler - Curriculum Vitae of Cleve Tyler	NREL; 403; LFND; ATH; HRS; NP; IDSCR; NE
3131			Attachment B to Expert Report of Cleve Tyler - Materials Considered	NREL; 403; LFND; ATH; HRS; NP; IDSCR; NE
3132	MASA03651464			REL; 403; LFND; ATH; HRS; NP; IDSCR
3133	MASA03651465	MASA03651479		REL; 403; LFND; ATH; HRS; NP
3134	MASA03651531			REL; 403; LFND; ATH; HRS; NP; IDSCR
3135	MASA03651532	MASA03651533		REL; 403; LFND; ATH; HRS; NP
3136	MASA03655893			REL; 403; LFND; ATH; HRS; NP; IDSCR; FOR
3137	MASA03655894	MASA03655897		REL; 403; LFND; ATH; HRS; NP
3138	MASA03655957			REL; 403; LFND; ATH; HRS; NP; IDSCR; FOR
3139	MASA03655958	MASA03655964		REL; 403; LFND; ATH; HRS; NP
3140	MASA00124159	MASA00124159		REL; 403; LFND; ATH; HRS; NP; IDSCR
3141	MASA00124160	MASA00124160		REL; 403; LFND; ATH; HRS; NP; IDSCR
3142	MASA00124161	MASA00124162		REL; 403; LFND; ATH; HRS; NP; IDSCR
3143	MASA00124163	MASA00124163		REL; 403; LFND; ATH; HRS
3144	MASA00124164	MASA00124164		REL; 403; LFND; ATH; HRS
3145	MASA00124165	MASA00124165		REL; 403; LFND; ATH; HRS
3146	MASA00124166	MASA00124166		REL; 403; LFND; ATH; HRS
3147	MASA00124167	MASA00124167		REL; 403; LFND; ATH; HRS
3148	MASA00124168	MASA00124175		REL; 403; LFND; ATH; HRS
3149	MASA00124176	MASA00124177		REL; 403; LFND; ATH; HRS
3150	MASA00124178	MASA00124183		REL; 403; LFND; ATH; HRS
3151	MASA00124184	MASA00124185		REL; 403; LFND; ATH; HRS
3152	MASA00124186	MASA00124187		REL; 403; LFND; ATH; HRS
3153	MASA00124188	MASA00124281		REL; 403; LFND; ATH; HRS
3154	MASA00124282	MASA00124292		REL; 403; LFND; ATH; HRS



## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
3155	MASA00124293	MASA00124296	0705 Masimo CEO Joe Kiani Named Ernst & Young Entrepreneur of the Year.pdf	NREL; 403; LFND; ATH; HRS
3156	MASA00124297	MASA00124299	Masimo Corporation - Recipient of the 2000 Market Engineering Competitive Strategy Award from Frost & Sullivan	NREL; 403; LFND; ATH; HRS
3157	MASA00124300	MASA00124301	Masimo Receives 2001 Medical Design Excellence Award for Radical™ Signal Extraction Pulse Oximeter	NREL; 403; LFND; ATH; HRS
3158	MASA00124302	MASA00124303	Frost & Sullivan Market Engineering Awards for the Blood Gas Monitoring Equipment Market	NREL; 403; LFND; ATH; HRS
3159	MASA00124304	MASA00124305	The Society for Critical Care Medicine Honors Masimo Corporation with the SCCM Technology Excellence Award	NREL; 403; LFND; ATH; HRS
3160	MASA00124306	MASA00124308	Audie Lewis Consulting Releases Independent Quality/Benefits Audit on Masimo SET Pulse Oximetry	NREL; 403; LFND; ATH; HRS
3161	MASA00124309	MASA00124314	Audie Lewis Consulting Releases Independent Quality/Benefits Report of the Masimo Corporation and Signal Extraction Technology (SET)	NREL; 403; LFND; ATH; HRS
3162	MASA00124315	MASA00124315	Masimo Receives Frost & Sullivan's Product Quality Leadership Award	NREL; 403; LFND; ATH; HRS
3163	MASA00124316	MASA00124325	Frost & Sullivan Honors Masimo for Setting Patient Monitoring Standard of Care	NREL; 403; LFND; ATH; HRS
3164	MASA00124326	MASA00124362	Masimo Corporation Recognitions for Excellence	NREL; 403; LFND; ATH; HRS
3165	MASA002445845	MASA002445885	2012 Annual Report	NREL; 403; LFND; ATH; HRS; ILLEG
3166	MASA002709160	MASA002709187	2009 Annual Report	NREL; 403; LFND; ATH; HRS; ILLEG
3167	MASA10961896	MASA10961915	2008 Annual Report	NREL; 403; LFND; ATH; HRS
3168	MASA10962770	MASA10962793	2007 Annual Report	NREL; 403; LFND; ATH; HRS
3169	MASA11167784	MASA11167810	2011 Annual Report	NREL; 403; LFND; ATH; HRS
3170	MASA10960156	MASA10960196	2012 Annual Report	NREL; 403; LFND; ATH; HRS
3171	MASA11252687	MASA11252822	[REDACTED]	NREL; 403; NP; NOID; DUP; ATH; LFND; ILLEG
3172	MASA11395665	MASA11395676	Barker, "Motion-Resistant" Pulse Oximetry: A Comparison of New and Old Models, Anesthesia & Analgesia, Oct. 2002	NREL; 403; LFND; ATH; HRS
3173	MASA11395677	MASA11395680	FDA 510(k) Premarket Approval for Masimo MS-1 Pulse Oximeter and LNOP Series of Sensors and Cables	NREL; 403; LFND; ATH; HRS; ILLEG
3174	MASA11395681	MASA11395683	FDA 510(k) Premarket Approval for Masimo MS-1P Pulse Oximeter and LNOP Series of Sensors and Cables	NREL; 403; LFND; ATH; HRS; ILLEG
3175	MASA11395587	MASA11395640	[REDACTED]	NREL; 403; LFND; ATH; HRS
3176	MASA11395572	MASA11395579	Barker, The Effects of Motion on the Performance of Pulse Oximeters in Volunteers, Anesthesiology, Jan. 1997	NREL; 403; LFND; ATH; HRS
3177	MASA11395580	MASA11395580	Excerpt of Respiratory Care Vol. 42, No. 11, November 1997	NREL; 403; LFND; ATH; HRS; ILLEG
3178	MASA11156127	MASA11156127	[REDACTED]	NREL; 403; LFND; ATH; HRS
3179	MASA11267979	MASA11267985	[REDACTED]	NREL; 403; LFND; ATH; HRS
3180	MASA11397116	MASA11397126	Masimo Corp. v. Philips Elec. North America Corp., No. 09-80-LPS, 2015 WL 2406061 (D. Del. May 18, 2015)	NREL; 403; LFND; ATH; HRS; NE; MIL

**Masimo's Trial Exhibit List and Apple's Objections**

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
3181	MASA11397127	MASA11397145	Masimo Corp. v. Philips Elec. North America Corp., No. 09-80-LPS, 2015 WL 2379485 (D. Del. May 18, 2015)	NREL; 403; LFND; ATH; HRS; NE; MIL
3182	MASA11395581	MASA11395586		NREL; 403; LFND; ATH; HRS
3183	APL-MAS_00197134	APL-MAS_00197135		NREL; 403; LFND; HRS; MIL
3184	MASA10960449	MASA10960692	2009 Masimo 10-K	NREL; 403; LFND; HRS
3185	MASA10960693	MASA10960932	2021 Masimo 10-K	NREL; 403; LFND; HRS
3186	MASA10960933	MASA10961146	2008 Masimo 10-K	NREL; 403; LFND; HRS
3187	MASA10961147	MASA10961298	2014 Masimo 10-K	NREL; 403; LFND; HRS
3188	MASA10961299	MASA10961433	2020 Masimo 10-K	NREL; 403; LFND; HRS
3189	MASA10961434	MASA10961546	2010 Masimo 10-K	NREL; 403; LFND; HRS
3190	MASA10961547	MASA10961895	2016 Masimo 10-K	NREL; 403; LFND; HRS
3191	MASA10961916	MASA10962053	2018 Masimo 10-K	NREL; 403; LFND; HRS
3192	MASA10962054	MASA10962099	2013 Masimo 10-K Amended	NREL; 403; LFND; HRS
3193	MASA10962100	MASA10962232	2017 Masimo 10-K	NREL; 403; LFND; HRS
3194	MASA10962233	MASA10962489	2019 Masimo 10-K	NREL; 403; LFND; HRS
3195	MASA10962490	MASA10962662	2015 Masimo 10-K	NREL; 403; LFND; HRS
3196	MASA10962879	MASA10963004	2012 Masimo 10-K	NREL; 403; LFND; HRS
3197	MASA10960225	MASA10960331	2011 Masimo 10-K	NREL; 403; LFND; HRS
3198			1/31/2023 [789029] Public Interest Statement of Dr. Adam Waddell, MD in Support of Masimo	403; NREL; HRS; LFND; ATH; MIL
3199			2/1/2023 [789080] Public Interest Statement of Chris McCarthy in Support of Masimo	403; NREL; HRS; LFND; ATH; MIL
3200			2/3/2023 [789338] Public Interest Statement of Cynthia Persaud in Support of Masimo	403; NREL; HRS; LFND; ATH; MIL
3201			2/22/2023 [790787] Letter from Josh Malone ISO ITC Enforcing Recommended Remedial Orders against Apple	403; NREL; HRS; LFND; ATH; MIL
3202			2/22/2023 [790883] Public Interest Statement of Dr. David E. Albert, M.D. in Support of Masimo	403; NREL; HRS; LFND; ATH; MIL
3203			2/22/2023 [790884] Public Interest Statement of Dr. Kevin Ward, M.D. in Support of Masimo	403; NREL; HRS; LFND; ATH; MIL
3204			2/23/2023 [790943] Public Interest Statement of Medical Device Manufacturers Association (MDMA) in Support of Masimo	403; NREL; HRS; LFND; ATH; MIL
3205			2/23/2023 [790962] Public Interest Statement of Bill Carpou of Octane in Support of Masimo	403; NREL; HRS; LFND; ATH; MIL
3206			2/23/2023 [790980] Public Interest Statement of Dr. Michael Ramsay, M.D. of Patient Safety Movement Foundation (PSMF) in Support of Masimo	403; NREL; HRS; LFND; ATH; MIL
3207			2/23/2023 [790986] Public Interest Statement of Dr. Mitchell Goldstein, M.D. in Support of Masimo	403; NREL; HRS; LFND; ATH; MIL
3208			2/23/2023 [790991] Public Interest Statement of Ryan Drant of Questa Capital in Support of Masimo	403; NREL; HRS; LFND; ATH; MIL
3209			2/23/2023 [791000] Public Interest Statement of Bobby Yazdani of Cota Capital in Support of Masimo	403; NREL; HRS; LFND; ATH; MIL
3210			2/23/2023 [791006] Public Interest Statement of Mark Cooper of Consumer Federation of America	403; NREL; HRS; LFND; ATH; MIL


**Masimo's Trial Exhibit List and Apple's Objections**

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
3211			2/23/2023 [791012] Public Interest Statement of Mike Guerra of California Life Sciences (CLS) ISO Imposing Limited Exclusion Order	403; NREL; HRS; LFND; ATH; MIL
3212			2/23/2023 [791041] Public Interest Statement of Randy Landreneau of US Inventor in Support Remedial Orders	403; NREL; HRS; LFND; ATH; MIL
3213			2/23/2023 [791047] Public Interest Statement of Congressman Ken Buck (along with Congressman Hank Johnson and Congresswoman Kate Porter) in Support of Masimo	403; NREL; HRS; LFND; ATH; MIL
3214			2/23/2023 [791048] Public Interest Statement of Brian Pomper of Innovation Alliance in Support of Masimo	403; NREL; HRS; LFND; ATH; MIL
3215			2/23/2023 [791050] Complainants' Statement on the Public Interest	403; NREL; HRS; LFND; ATH; MIL
3216			2/23/2023 [791069] Public Interest Statement of Third Party Law Professors Adam Mossoff and Kristen Osenga	403; NREL; HRS; LFND; ATH; MIL
3217			2/27/2023 [791162] Public Interest Statement of Non-Party Dr. Peter Pronovost, M.D. in Support of Masimo	403; NREL; HRS; LFND; ATH; MIL
3218			2/27/2023 [791163] Public Interest Statement of Mark Cooper of Consumer Federation of America (CFA) of Masimo	403; NREL; HRS; LFND; ATH; MIL
3219			2/27/2023 [791167] Public Interest Statement of Mark Leahey of Non-Party Medical Device Manufacturers Association (MDMA)	403; NREL; HRS; LFND; ATH; MIL
3220			2/27/2023 [791175] Public Interest Statement of Dr. Michael Ramsay, M.D. of Non-Party Patient Safety Movement Foundation (PSMF)	403; NREL; HRS; LFND; ATH; MIL
3221			2/27/2023 [791177] Public Interest Statement of Bobby Yazdani of Cota Capital in Support of Masimo	403; NREL; HRS; LFND; ATH; MIL
3223			2/27/2023 [791179] Public Interest Statement of Dr. Mitchell Goldstein, M.D. from LLU School of Medicine in Support of Masimo	403; NREL; HRS; LFND; ATH; MIL
3224			3/2/2023 [791567] Public Interest Statement of Frank Cullen of Council for Innovation Promotion (C4IP) ISO Exclusion Order	403; NREL; HRS; LFND; ATH; MIL
3225			3/3/2023 [791674] Public Interest Statement of Robert P. Taylor of the Alliance for U.S. Startups and Inventors for Jobs (USIJ) in Support of Masimo	403; NREL; HRS; LFND; ATH; MIL
3226			3/3/2023 [791686] Public Interest Statement of David Dinielli and Michael Enseki-Frank	403; NREL; HRS; LFND; ATH; MIL
3227			6/5/2023 [797854] Public Interest Statements of Frank Cullen of Council for Innovation Promotion (C4IP) in Support of Masimo	403; NREL; HRS; LFND; ATH; MIL
3228			6/12/2023 [798257] Public Interest Statements of Professors Francisco J. Valero-Cuevas, PhD and Najmedin Meshkati, PhD, CPE of USC in Support of Masimo	403; NREL; HRS; LFND; ATH; MIL
3229	MASAD00097057		Masimo W1 White Paper: Hospital-Grade Continuous Monitoring of SpO2 and Other Parameters in a Consumer Watch	403; NREL; HRS; LFND; ATH; MIL

## Masimo's Trial Exhibit 68138 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
3230			Article - MedPage Today, Anthony Pearson, Should You Trust the New Apple Watch on Blood Oxygen Readings	403; NREL; HRS; LFND; ATH; ILLEG; MIL
3231			Washington Post, Geoffrey Fowler, The new Apple Watch says my lungs may be sick. Or perfect. It can't decide	403; NREL; HRS; LFND; ATH; MIL
3232			Wall Street Journal, Joanna Stern, Watch Out for the Upsell	403; NREL; HRS; LFND; ATH; MIL
3233			Verge, Dieter Bohn, Apple Watch Series 6 review Minute improvements	403; NREL; HRS; LFND; ATH; MIL
3234			CNet - Fitbit and Apple know their Smartwatches Arent Medical Devices	403; NREL; HRS; LFND; ATH; MIL
3235			Engineering - Can the Apple Watch Series 6 Keep the Doctor Away	403; NREL; HRS; LFND; ATH; INC; MIL
3236			Inc - The New Apple Watch 6 May have a Problem	403; NREL; HRS; LFND; ATH; MIL
3237			Input - The Apple Watch_s blood oxygen sensor is less accurate than you think	403; NREL; HRS; LFND; ATH; MIL
3238			Verge - Apple Watch Blood Oxygen For Wellness Not Medicine	403; NREL; HRS; LFND; ATH; MIL
3252				403; NREL; HRS; LFND; INC; MIL
3258	MASA03660075	MASA03660088		403; NREL; HRS; LFND; ATH; NP
3260	MASA00124157	MASA00124157		403; NREL; HRS; LFND; ATH; INC; CUM
3263	MASA00124158	MASA00124158		403; NREL; HRS; LFND; ATH; INC; CUM
3265				403; NREL; LFND; ID; MIL
3270	MASAD00034786	MASAD00034918		403; HRS; LFND; ATH
3272	APL-MAS_00233252	APL-MAS_00233253		403; NREL; LFND; HRS; MIL
3293				403; NREL; LFND; HRS; MIL
3317				403; NREL; LFND; MIL
3335				403; NREL; LFND; CUM; HRS; MIL
3421	APL-MAS_00432316	APL-MAS_00432317		403; NREL; LFND; HRS; MIL
3426				403; LFND
3429	APL-MAS_00414174	APL-MAS_00414175		403; NREL; LFND; HRS; CUM; MIL
3510				403; NREL; LFND; HRS; MIL
3512				403; NREL; LFND; HRS; MIL
3513				403; NREL; LFND; NE; HRS; MIL
3514	APL-MAS_00227728	APL-MAS_00227772		403; NREL; LFND; HRS; MIL
3515	APL-MAS_00229732	APL-MAS_00229735		403; NREL; LFND; HRS; MIL
3516	APL-MAS_02469202	APL-MAS_02469203		403; NREL; LFND; HRS; MIL

## Masimo's Trial Exhibit 68139 and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
3517	APL-MAS_00335253	APL-MAS_00335255		03; NREL; LFND; HRS; MIL
3518	APL-MAS_00926335	APL-MAS_00926338		03; NREL; LFND; HRS; MIL
3519	APL-MAS_00432016	APL-MAS_00432017		03; NREL; LFND; HRS; MIL
3520	APL-MAS_00314770	APL-MAS_00314770		03; NREL; LFND; HRS; MIL
3521	APL-MAS_01595027	APL-MAS_01595031		03; NREL; LFND; HRS; MIL
3522	APL-MAS_00242089	APL-MAS_00242089		03; NREL; LFND; HRS; MIL
3523	APL-MAS_00285363	APL-MAS_00285363		03; NREL; LFND; HRS; MIL
3524	APL-MAS_00300536	APL-MAS_00300537		03; NREL; LFND; HRS; MIL
3525	APL-MAS_02601444	APL-MAS_02601474		03; NREL; LFND; HRS; INC
3526	APL-MAS_00157432	APL-MAS_00157527		03; LFND
3527	APL-MAS_00744479	APL-MAS_00744481		03; LFND; HRS
3528	APL-MAS_01039879	APL-MAS_01039888		03; LFND; HRS; INC
3529	APL-MAS_00362536	APL-MAS_00362544		03; NREL; LFND; HRS; INC; MIL
3530	APL-MAS_00362441	APL-MAS_00362441		03; NREL; LFND; HRS; MIL
3531	APL-MAS_00362134	APL-MAS_00362139		03; NREL; LFND; HRS; INC; MIL
3532	APL-MAS_00203385	APL-MAS_00203387		03; NREL; LFND; HRS; MIL
3533	APL-MAS_00745532	APL-MAS_00745535		03; NREL; HRS; LFND
3534	APL_MAS_ITC_00019374	APL_MAS_ITC_00019374		03; NREL; LFND
3535	APL_MAS_ITC_00019375	APL_MAS_ITC_00019375	Apple Watch Series 6 (GPS + Cellular) First Look	403; NREL; LFND
3536	APL_MAS_ITC_00310976	APL_MAS_ITC_00310989	Apple Press Release, "Apple Watch Series 6 delivers breakthrough wellness and fitness capabilities," 9/15/2020	403; LFND
3537			Screen capture from Apple website, "Skills: Personalizing Your Apple Watch" (CX-243)	403; LFND
3538	APL_MAS_ITC_00309029	APL_MAS_ITC_00309036	Screen capture from apple.com/newsroom, "New Apple Watch and iPad features enable wellness, fitness, and creativity"	403; LFND

## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
3539	APL_MAS_ITC_01097560	APL_MAS_ITC_01097562	[REDACTED]	403; NREL; LFND; HRS; MIL
3540	APL_MAS_ITC_00379631	APL_MAS_ITC_00379634	[REDACTED]	403; NREL; LFND; HRS; MIL
3541	APL_MAS_ITC_00449343	APL_MAS_ITC_00449346	[REDACTED]	403; NREL; LFND; HRS; MIL
3542	APL_MAS_ITC_00449506	APL_MAS_ITC_00449510	[REDACTED]	403; NREL; LFND; HRS; MIL
3543	MASITC_01399431	MASITC_01399432	Article, Pronovost, P., "Remote Patient Monitoring During COVID-19 - An Unexpected Patient Safety Benefit", JAMA, 327(12):1125-1126 (2022)	403; NREL; LFND; HRS; ATH; MIL
3544	MASITC_01399433	MASITC_01399435	Article, Lee, K., et al., "Pulse Oximetry for Monitoring Patients with Covid-19 at Home - A Pragmatic, Randomized Trial", The New England Journal of Medicine, pp. 1-3 (2022)	403; NREL; LFND; HRS; ATH; MIL
3545	MASITC_00918307	MASITC_00918327	Apple Watch Series 6 - Apple Webpage	403; LFND
3546	APL_MAS_ITC_01472770	APL_MAS_ITC_01472863	[REDACTED]	403; NREL; LFND; HRS
3547	MASITC_01399130	MASITC_01399134	Wyatt, K., et al., "Clinical evaluation and diagnostic yield following evaluation of abnormal pulse detected using Apple Watch", Journal of the American Medical Informatics Association, 27(9):1359-1363 (2020)	403; NREL; LFND; HRS; ATH; MIL
3548			9/15/2023 Apple's Objections and Responses to Masimo and Sound United's First Set of Requests for Admission (1-6) [1377/1378]	403; NREL; LFND; ATH; NE; MIL
3549			9/25/2023 [HC-AEO] Apple's Objections and Responses to Masimo and Sound United's Second Set of Requests for Admission (7-89) [1377/1378]	403; NREL; LFND; ATH; NE; MIL
3550			11/9/2023 Apple's First Supplemental Objections and Responses to Masimo's First Set of Requests for Admissions (No. 6) [1377/1378]	403; NREL; LFND; ATH; NE; MIL
3551			4/17/2023 Apple's Objections and Responses to Masimo's First Set of Interrogatories (Nos. 1-5) [1377]	403; NREL; LFND; ATH; NE
3552			4/17/2023 Apple's Objections and Responses to Masimo's First Set of Interrogatories (Nos. 1-5) [1378]	403; NREL; LFND; ATH; NE
3553			6/29/2023 [Confidential-AEO] Apple's Objections and Responses to Masimo and Sound United's Second Set of Interrogatories (Nos. 6-18) [1377/1378]	403; NREL; LFND; ATH; NE; MIL
3554			7/5/2023 [Confidential-AEO] Apple's Objections and Responses to Masimo and Sound United's Third Set of Interrogatories (Nos. 19-23) [1377/1378]	403; NREL; LFND; ATH; NE; MIL
3555			7/14/2023 Apple First Supplemental Objections and Responses to Masimo and Sound United's Interrogatory No. 4 [1378]	403; NREL; LFND; ATH; NE
3556			7/17/2023 [Confidential-AEO] Apple's Response to Masimo and Sound United's Fourth Set of Interrogatories to Apple (Nos. 24-28) [1377/1378]	403; NREL; LFND; ATH; NE
3557			7/31/2023 [HC-AEO] Apple First Supplemental Response to Masimo and Sound United's First of Interrogatories (Nos. 1 and 3) [1377]	403; NREL; LFND; ATH; NE

**Masimo's Trial Exhibit List and Apple's Objections**

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
3558			7/31/2023 [HC-AEO] Apple First Supplemental Response to Masimo and Sound United's First Set of Interrogatories (No. 3) [1378]	403; NREL; LFND; ATH; NE
3559			8/2/2023 [Confidential-AEO] Apple First Supplemental Response to Masimo and Sound United's Third Set of Interrogatories (No. 19) [1377/1378]	403; NREL; LFND; ATH; NE; MIL
3560			8/2/2023 Apple First Supplemental Objections and Responses to Masimo and Sound United's Third Set of Interrogatories (No. 23) [1377/1378]	403; NREL; LFND; ATH; NE; MIL
3561			8/7/2023 Apple's Response to Masimo and Sound United's Fifth Set of Interrogatories (Nos. 29-30) [1377/1378]	403; NREL; LFND; ATH; NE; MIL
3562			8/11/2023 [Confidential-AEO] Apple's First Supplemental Response to Masimo and Sound United's Second Set of Interrogatories (Nos. 11-15) [1377/1378]	403; NREL; LFND; ATH; NE; MIL
3563			8/17/2023 [Confidential-AEO] Apple's Second Supplemental Objections and Responses to Masimo and Sound United's Second Set of Interrogatories (Nos. 7, 10) [1377/1378]	403; NREL; LFND; ATH; NE; MIL
3564			8/22/2023 [HC-AEO] Apple's Second Supplemental Response to Masimo and Sound United's First Set of Interrogatories (No. 3) [1377]	403; NREL; LFND; ATH; NE
3565			8/23/2023 [Confidential-AEO] Apple's First Supplemental Objections and Responses to Masimo and Sound United's Fourth Set of Interrogatories (No. 25) [1377/1378]	403; NREL; LFND; ATH; NE; MIL
3566			8/30/2023 [HC-AEO] Apple's Objections and Responses to Masimo and Sound United's Sixth Set of Interrogatories (Nos. 31-36) [1377/1378]	403; NREL; LFND; ATH; NE; MIL
3567			9/5/2023 [HC-AEO] Apple's Objections and Responses to Masimo and Sound United's Seventh Set of Interrogatories (Nos. 37-38) [1377/1378]	403; NREL; LFND; ATH; NE
3568			9/8/2023 [HC-AEO] Apple's Third Supplemental Response to Defendants' First Set of Interrogatories (No. 3) [1377]	403; NREL; LFND; ATH; NE
3569			9/11/2023 [Confidential-AEO] CORRECTED Apple's Second Supplemental Objections and Responses to Masimo and Sound United's Fourth Set of Interrogatories [1377/1378] (corrected from 9/8/23)	403; NREL; LFND; ATH; NE
3570			9/13/2023 [Confidential-AEO] Apple's First Supplemental Response to Masimo and Sound United's Fourth Set of Interrogatories (No. 27) [1377/1378]	403; NREL; LFND; ATH; NE
3571			9/25/2023 [HC-AEO] Apple's Objections and Responses to Masimo's and Sound United's Eighth Set of Interrogatories (Nos. 39-49) [1377/1378]	403; NREL; LFND; ATH; NE; MIL
3572			9/29/2023 [Confidential-AEO] Apple's First Supplemental Response to Masimo and Sound United's Fifth Set of Interrogatories (Nos. 29-30) [1377/1378]	403; NREL; LFND; ATH; NE; MIL

**Masimo's Trial Exhibit List and Apple's Objections**

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
3573			9/29/2023 [Confidential-AEO] Apple's Second Supplemental Objections and Responses to Masimo and Sound United's Third Set of Interrogatories (No. 23) [1377/1378]	403; NREL; LFND; ATH; NE
3574			9/29/2023 [Confidential-AEO] Apple's Second Supplemental Response to Masimo and Sound United's Second Set of Interrogatories (Nos. 11, 13-15, 18) [1377/1378]	403; NREL; LFND; ATH; NE; MIL
3575			10/2/2023 [Confidential-AEO] Apple's First Supplemental Objections and Responses to Masimo and Sound United's Fourth Set of Interrogatories (No. 28) [1377/1378]	403; NREL; LFND; ATH; NE
3576			10/2/2023 [Confidential-AEO] Apple's Second Supplemental Objections and Responses to Masimo and Sound United's Fourth Set of Interrogatories (Nos. 24-25) [1377/1378]	403; NREL; LFND; ATH; NE
3577			10/2/2023 [Confidential-AEO] Apple's Third Supplemental Objections and Responses to Masimo and Sound United's Fourth Set of Interrogatories (No. 25) [1377/1378]	403; NREL; LFND; ATH; NE
3578			10/18/2023 [Confidential-AEO] Apple's Third Supplemental Objections and Responses to Masimo and Sound United's Second Set of Interrogatories (No. 10) [1377/1378]	403; NREL; LFND; ATH; NE; MIL
3579			10/30/2023 [Confidential-AEO] Apple's First Supplemental Objections and Responses to Masimo's Sixth Set of Interrogatories (No. 33) [1377/1378]	403; NREL; LFND; ATH; NE; MIL
3580			11/9/2023 [Confidential-AEO] Apple's Fourth Supplemental Responses to Second Set of Interrogatories (Nos. 6-9, 11-15) [1377/1378]	403; NREL; LFND; ATH; NE; MIL
3581			11/9/2023 [Confidential-AEO] Apple's Objections and Responses to Masimo and Sound United's Ninth Set of Interrogatories (No. 50) [1377/1378]	403; NREL; LFND; ATH; NE; MIL
3582			11/9/2023 [Confidential-AEO] Apple's Second Supplemental Objections and Responses to Masimo's Eighth Set of Interrogatories (Nos. 41, 49) [1377/1378]	403; NREL; LFND; ATH; NE; MIL
3583			11/9/2023 [Confidential-AEO] Apple's Second Supplemental Objections and Responses to Masimo's First Set of Interrogatories (Nos. 1, 3, 4) [1378]	403; NREL; LFND; ATH; NE
3584			11/9/2023 [Confidential-AEO] Apple's Second Supplemental Objections and Responses to Masimo's Sixth Set of Interrogatories (No. 33) [1377/1378]	403; NREL; LFND; ATH; NE; MIL
3585			11/9/2023 [Confidential-AEO] Apple's Second Supplemental Response to Masimo and Sound United's Fifth Set of Interrogatories (Nos. 29-30) [1377/1378]	403; NREL; LFND; ATH; NE; MIL
3586			11/9/2023 [Confidential-AEO] Apple's Second Supplemental Response to Masimo's Third Set of Interrogatories (Nos. 19-21) [1377/1378]	403; NREL; LFND; ATH; NE; MIL
3587			11/9/2023 [Confidential-AEO] Apple's Supplemental Objections and Responses to Masimo's Second Set of Interrogatories (No. 17) [1377/1378]	403; NREL; LFND; ATH; NE; MIL



## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
3588			11/9/2023 [Confidential-AEO] Apple's Third Supplemental Objections and Responses to Masimo's Third Set of Interrogatories (No. 23) [1377/1378]	403; NREL; LFND; ATH; NE; MIL
3589			11/9/2023 [Confidential-AEO] Apple's First Supplemental Objections and Responses to Masimo's Eighth Set of Interrogatories (Nos. 44-47) [1377/1378]	403; NREL; LFND; ATH; NE; MIL
3590			11/9/2023 [Confidential-AEO] Apple's First Supplemental Objections and Responses to Masimo's Seventh Set of Interrogatories (No. 37) [1377/1378]	403; NREL; LFND; ATH; NE
3591			11/9/2023 [Confidential-AEO] Apple's First Supplemental Objections and Responses to Masimo's Sixth Set of Interrogatories (No. 35) [1377/1378]	403; NREL; LFND; ATH; NE
3592			11/9/2023 [Confidential-AEO] Apple's Supplemental Responses to Masimo's Fourth Set of Interrogatories (Nos. 24-28) [1377/1378]	403; NREL; LFND; ATH; NE
3593			11/9/2023 [HC-AEO] Apple's Fourth Supplemental Response to Masimo's First Set of Interrogatories (No. 3) [1377]	403; NREL; LFND; ATH; NE
3594	APL_MAS_ITC_000191137	APL_MAS_ITC_000191144	[REDACTED]	403; NREL; LFND; HRS
3595			Apple Says Masimo Secretly Copied Watch Tech to Make a Rival	403; NREL; LFND; ATH; NP; HRS; MIL
3596			Apple lawsuits say health monitoring company Masimo copied Apple Watch _ Reuters	403; NREL; LFND; ATH; NP; HRS; MIL
3597			IPR2023-00745 File History	403; NREL; HRS; LFND; ATH; NE
3598			IPR2023-00807 File History	403; NREL; HRS; LFND; ATH; NE
3599	MASAD00017699	MASAD00017699	Native File: Video - Android Lock Screen Widgets	403; NREL; LFND; ATH; HRS; MIS
3600	MASITC_01010975	MASITC_01010975	Article, Cohen, E., et al., A plan to save coronavirus patients from dying at home, <a href="https://www.cnn.com/2020/04/11/health/monitoring-covid19-at-home/index.html">https://www.cnn.com/2020/04/11/health/monitoring-covid19-at-home/index.html</a>	403; NREL; LFND; ATH; HRS
3601	MASAD00030776	MASAD00030933	Masimo Corporation, News & Media - 2020	403; NREL; LFND; ATH; HRS
3602	MASITC_01351676		Masimo Corporation 2020 Annual Report	403; NREL; LFND; ATH; HRS
3603	APL_DEL00229778	APL_DEL00229778	[REDACTED]	403; NREL; LFND; HRS; INC
3604	MASAD00081556	MASAD00081556	[REDACTED]	403; NREL; LFND; ATH; HRS; INC
3605	MASAD00029585	MASAD00029723	Masimo Corporation Form 10-K, 2022	403; NREL; LFND; ATH; HRS
3606	MASAD00029724	MASAD00029784	Masimo Corporation Form 10-K/A (Amendment No. 1), 2022	403; NREL; LFND; ATH; HRS
3607	MASITC_01139373	MASITC_01139373	[REDACTED]	403; NREL; LFND; ATH; HRS
3608	MASA11079675	MASA11079678	[REDACTED]	403; NREL; LFND; ATH; HRS
3609	MASA11079679	MASA11079682	Article, FDA Innovation Challenge: Devices to Prevent and Treat Opioid Use Disorder	403; NREL; LFND; ATH; HRS

## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
3610			Apple Presentation titled "Direct Examination of Professor Steven Warren, Ph.D." dated June 10, 2022, from ITC Inv. No. 337-TA-1276	403; NREL; LFND; ATH; NP; NE; HRS; MIL
3611			Apple Presentation titled "Apple's Opening Presentation" dated June 6, 2022, from ITC Inv. No. 337-TA-1276	403; NREL; LFND; ATH; NP; NE; HRS; MIL
3612			Apple Inc.'s Second Corrected Post-Hearing Brief, dated September 2, 2022, from ITC Inv. No. 337-TA-1276	403; NREL; LFND; ATH; NP; NE; HRS; MIL
3613			Excerpt of Expert Report of Steve Warren, Ph.D. Regarding Certain of Plaintiffs' Alleged Technical Trade Secrets, dated September 23, 2022, from Masimo Corp, et al. v. Apple Inc., No. 8:20-cv-00048 (C.D. Cal.)	403; NREL; LFND; ATH; NP; NE; HRS; INC; MIL
3614	MASAD00029387	MASAD00029405	U.S. Patent No. 6,522,915 (Ceballos)	403; NREL; LFND; ATH; HRS
P-0012	MASITC_P_012	MASITC_P_012	CPX-0012C - Laptop	403; ATH; LFND; NREL; MIL
P-0012a			CPX-0012aC - Photograph of laptop	403; ATH; LFND; NREL; MIL
P-0013	MASITC_P_013	MASITC_P_013	CPX-0013C - nRF52840 dongle	403; ATH; LFND; NREL; MIL
P-0013a			CPX-0013aC - Photograph of nRF52840 dongle	403; ATH; LFND; NREL; MIL
P-0014	MASITC_P_014	MASITC_P_014	CPX-0014 - Masimo Rad-97	403; ATH; LFND; NREL; MIL
P-0014a			CPX-0014a - Photograph of Masimo Rad-97	403; ATH; LFND; NREL; MIL
P-0015	MASITC_P_015	MASITC_P_015	CPX-0015 - Masimo RD rainbow SET M20 -12	403; ATH; LFND; NREL; MIL
P-0015a			CPX-0015a - Photograph of Masimo RD rainbow SET M20 -12	403; ATH; LFND; NREL; MIL
P-0016	MASITC_P_016	MASITC_P_016	CPX-0016C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0016a			CPX-0016aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0017	MASITC_P_017	MASITC_P_017	CPX-0017C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0017a			CPX-0017aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0018	MASITC_P_018	MASITC_P_018	CPX-0018C - Masimo Watch back module prototype	403; ATH; LFND; NREL; MIL
P-0018a			CPX-0018aC - Photograph of Masimo Watch back module prototype	403; ATH; LFND; NREL; MIL
P-0019	MASITC_P_019	MASITC_P_019	CPX-0019C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0019a			CPX-0019aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0020	MASITC_P_020	MASITC_P_020	CPX-0020C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0020a			CPX-0020aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0021	MASITC_P_021	MASITC_P_021	CPX-0021C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0021a			CPX-0021aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0022	MASITC_P_022	MASITC_P_022	CPX-0022C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0022a			CPX-0022aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0023	MASITC_P_023	MASITC_P_023	CPX-0023C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0023a			CPX-0023aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0024	MASITC_P_024	MASITC_P_024	CPX-0024C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0024a			CPX-0024aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0025	MASITC_P_025	MASITC_P_025	CPX-0025C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0025a			CPX-0025aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0026	MASITC_P_026	MASITC_P_026	CPX-0026C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0026a			CPX-0026aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0027	MASITC_P_027	MASITC_P_027	CPX-0027C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0027a			CPX-0027aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0028	MASITC_P_028	MASITC_P_028	CPX-0028C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0028a			CPX-0028aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0029	MASITC_P_029	MASITC_P_029	CPX-0029C - Masimo Watch Article	403; ATH; LFND; NREL; MIL

## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
P-0029a			CPX-0029aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0030	MASITC_P_030	MASITC_P_030	CPX-0030C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0030a			CPX-0030aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0031	MASITC_P_031	MASITC_P_031	CPX-0031C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0031a			CPX-0031aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0032	MASITC_P_032	MASITC_P_032	CPX-0032C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0032a			CPX-0032aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0033	MASITC_P_033	MASITC_P_033	CPX-0033C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0033a			CPX-0033aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0034	MASITC_P_034	MASITC_P_034	CPX-0034C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0034a			CPX-0034aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0035	MASITC_P_035	MASITC_P_035	CPX-0035C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0035a			CPX-0035aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0036	MASITC_P_036	MASITC_P_036	CPX-0036C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0036a			CPX-0036aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0037	MASITC_P_037	MASITC_P_037	CPX-0037C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0037a			CPX-0037aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0038	MASITC_P_038	MASITC_P_038	CPX-0038C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0038a			CPX-0038aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0039	MASITC_P_039	MASITC_P_039	CPX-0039C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0039a			CPX-0039aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0040	MASITC_P_040	MASITC_P_040	CPX-0040C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0040a			CPX-0040aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0041	MASITC_P_041	MASITC_P_041	CPX-0041C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0041a			CPX-0041aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0042	MASITC_P_042	MASITC_P_042	CPX-0042C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0042a			CPX-0042aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0043	MASITC_P_043	MASITC_P_043	CPX-0043C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0043a			CPX-0043aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0044	MASITC_P_044	MASITC_P_044	CPX-0044C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0044a			CPX-0044aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0045	MASITC_P_045	MASITC_P_045	CPX-0045C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0045a			CPX-0045aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0046	MASITC_P_046	MASITC_P_046	CPX-0046C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0046a			CPX-0046aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0047	MASITC_P_047	MASITC_P_047	CPX-0047C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0047a			CPX-0047aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0048	MASITC_P_048	MASITC_P_048	CPX-0048C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0048a			CPX-0048aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0049	MASITC_P_049	MASITC_P_049	CPX-0049C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0049a			CPX-0049aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0050	MASITC_P_050	MASITC_P_050	CPX-0050C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0050a			CPX-0050aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0051	MASITC_P_051	MASITC_P_051	CPX-0051C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0051a			CPX-0051aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0052	MASITC_P_052	MASITC_P_052	CPX-0052C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0052a			CPX-0052aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0053	MASITC_P_053	MASITC_P_053	CPX-0053C - Masimo Watch Article	403; ATH; LFND; NREL; MIL

## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
P-0053a			CPX-0053aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0054	MASITC_P_054	MASITC_P_054	CPX-0054C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0054a			CPX-0054aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0055	MASITC_P_055	MASITC_P_055	CPX-0055C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0055a			CPX-0055aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0056	MASITC_P_056	MASITC_P_056	CPX-0056C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0056a			CPX-0056aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0057	MASITC_P_057	MASITC_P_057	CPX-0057C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0057a			CPX-0057aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0058	MASITC_P_058	MASITC_P_058	CPX-0058C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0058a			CPX-0058aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0059	MASITC_P_059	MASITC_P_059	CPX-0059C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0059a			CPX-0059aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0060	MASITC_P_060	MASITC_P_060	CPX-0060C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0060a			CPX-0060aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0061	MASITC_P_061	MASITC_P_061	CPX-0061C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0061a			CPX-0061aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0062	MASITC_P_062	MASITC_P_062	CPX-0062C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0062a			CPX-0062aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0063	MASITC_P_063	MASITC_P_063	CPX-0063C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0063a			CPX-0063aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0064	MASITC_P_064	MASITC_P_064	CPX-0064C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0064a			CPX-0064aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0065	MASITC_P_065	MASITC_P_065	CPX-0065C - Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0065a			CPX-0065aC - Photograph of Masimo Watch Article	403; ATH; LFND; NREL; MIL
P-0066	MASITC_P_066	MASITC_P_066	CPX-0066C - Masimo Air Carrier	403; ATH; LFND; NREL; MIL
P-0066a			CPX-0066aC - Photograph of Masimo Air Carrier	403; ATH; LFND; NREL; MIL
P-0067	MASITC_P_067	MASITC_P_067	CPX-0067C - Masimo Watch back module prototype	403; ATH; LFND; NREL; MIL
P-0067a			CPX-0067aC - Photograph of Masimo Watch back module prototype	403; ATH; LFND; NREL; MIL
P-0068	MASITC_P_068	MASITC_P_068	CPX-0068C - Masimo Watch back module prototype	403; ATH; LFND; NREL; MIL
P-0068a			CPX-0068aC - Photograph of Masimo Watch back module prototype	403; ATH; LFND; NREL; MIL
P-0069	MASITC_P_069	MASITC_P_069	CPX-0069C - Masimo Watch back module prototype	403; ATH; LFND; NREL; MIL
P-0069a			CPX-0069aC - Photograph of Masimo Watch back module prototype	403; ATH; LFND; NREL; MIL
P-0070	MASITC_P_070	MASITC_P_070	CPX-0070C - Masimo Watch back module prototype	403; ATH; LFND; NREL; MIL
P-0070a			CPX-0070aC - Photograph of Masimo Watch back module prototype	403; ATH; LFND; NREL; MIL
P-0071	MASITC_P_071	MASITC_P_071	CPX-0071C - Masimo Watch back module prototype	403; ATH; LFND; NREL; MIL
P-0071a			CPX-0071aC - Photograph of Masimo Watch back module prototype	403; ATH; LFND; NREL; MIL
P-0072	MASITC_P_072	MASITC_P_072	CPX-0072C - Masimo Radius PPG Reusable Chip	403; ATH; LFND; NREL; MIL
P-0072a			CPX-0072aC - Photograph of Masimo Radius PPG Reusable Chip	403; ATH; LFND; NREL; MIL
P-0073	MASITC_P_073	MASITC_P_073	CPX-0073 - Masimo Radius PPG Sensor Lot E19GWA	403; ATH; LFND; NREL; MIL
P-0073a			CPX-0073a - Photograph of Masimo Radius PPG Sensor Lot E19GWA	403; ATH; LFND; NREL; MIL

## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
P-0110	MASA_P_110		Physical - Masimo W1, MASA_P_110	403; ATH; LFND; NREL; MIL
P-0114	MASA_P_114		Physical - Masimo W1 (silver electrodes)	403; ATH; LFND; NREL; MIL; MIS
P-0127	MASITC_P_127	MASITC_P_127	CPX-0127C - Masimo Watch	403; ATH; LFND; NREL; MIL
P-0127a			CPX-0127aC - Photograph of Masimo Watch	403; ATH; LFND; NREL; MIL
P-0128	MASITC_P_128	MASITC_P_128	CPX-0128C - Masimo Watch Article back module	403; ATH; LFND; NREL; MIL
P-0128a			CPX-0128aC - Photograph of Masimo Watch Article back module	403; ATH; LFND; NREL; MIL
P-0129	MASITC_P_129	MASITC_P_129	CPX-0129C - Masimo Watch Article back module	403; ATH; LFND; NREL; MIL
P-0129a			CPX-0129aC - Photograph of Masimo Watch Article back module	403; ATH; LFND; NREL; MIL
P-0130	MASITC_P_130	MASITC_P_130	CPX-0130C - Masimo Watch Article back module	403; ATH; LFND; NREL; MIL
P-0130a			CPX-0130aC - Photograph of Masimo Watch Article back module	403; ATH; LFND; NREL; MIL
P-0131	MASITC_P_131	MASITC_P_131	CPX-0131C - Masimo Watch Article sensor board	403; ATH; LFND; NREL; MIL
P-0131a			CPX-0131aC - Photograph of Masimo Watch Article sensor board	403; ATH; LFND; NREL; MIL
P-0132	MASITC_P_132	MASITC_P_132	CPX-0132C - Set of 8 Masimo sensor boards	403; ATH; LFND; NREL; MIL
P-0132a			CPX-0132aC - Photograph of set of 8 Masimo sensor boards	403; ATH; LFND; NREL; MIL
P-0133	MASITC_P_133	MASITC_P_133	CPX-0133 - Masimo Radius-7 battery/screen	403; ATH; LFND; NREL; MIL
P-0133a			CPX-0133a - Photograph of Masimo Radius-7 battery/screen	403; ATH; LFND; NREL; MIL
P-0134	MASITC_P_134	MASITC_P_134	CPX-0134 - Masimo Radius-7	403; ATH; LFND; NREL; MIL
P-0134a			CPX-0134a - Photograph of Masimo Radius-7	403; ATH; LFND; NREL; MIL
P-0135	MASITC_P_135	MASITC_P_135	CPX-0135 - Masimo Radius-7 cuff	403; ATH; LFND; NREL; MIL
P-0135a			CPX-0135a - Photograph of Masimo Radius-7 cuff	403; ATH; LFND; NREL; MIL
P-0136	MASITC_P_136	MASITC_P_136	CPX-0136 - Masimo Radius-7 cuff (sealed)	403; ATH; LFND; NREL; MIL
P-0136a			CPX-0136a - Photograph of Masimo Radius-7 cuff (sealed)	403; ATH; LFND; NREL; MIL
P-0137	MASITC_P_137	MASITC_P_137	CPX-0137C - Cercacor prototype	403; ATH; LFND; NREL; MIL
P-0137a			CPX-0137aC - Photograph of Cercacor prototype	403; ATH; LFND; NREL; MIL
P-0138	MASITC_P_138	MASITC_P_138	CPX-0138 - Masimo Pronto 7	403; ATH; LFND; NREL; MIL
P-0138a			CPX-0138a - Photograph of Masimo Pronto 7	403; ATH; LFND; NREL; MIL
P-0139	MASITC_P_139	MASITC_P_139	CPX-0139C - 2016 Cercacor prototype	403; ATH; LFND; NREL; MIL
P-0139a			CPX-0139aC - Photograph of 2016 Cercacor prototype	403; ATH; LFND; NREL; MIL
P-0140	MASITC_P_140	MASITC_P_140	CPX-0140C - 2017 Cercacor prototype	403; ATH; LFND; NREL; MIL
P-0140a			CPX-0140aC - Photograph of 2017 Cercacor prototype	403; ATH; LFND; NREL; MIL
P-0141	MASITC_P_141		CPX-0141C - Samsung phone with App	403; ATH; LFND; NREL; MIL
P-0141a			CPX-0141aC - Photograph of Samsung phone with App	403; ATH; LFND; NREL; MIL
P-0142	MASITC_P_142		CPX-0142C - Masimo Watch (W1) box	403; ATH; LFND; NREL; MIL
P-0142a	MASITC_01083120	MASITC_01083122	CPX-0142aC - Photograph of Masimo Watch (W1) box	403; ATH; LFND; NREL; MIL
P-0143	MASITC_P_143		CPX-0143C - Masimo Watch (W1) insert	403; ATH; LFND; NREL; MIL
P-0143a	MASITC_01083148	MASITC_01083148	CPX-0143aC - Photograph of Masimo Watch (W1) insert	403; ATH; LFND; NREL; MIL
P-0144	MASITC_P_144		CPX-0144C - Masimo Watch (W1) instructions	403; ATH; LFND; NREL; MIL
P-0144a	MASITC_01083133	MASITC_01083133	CPX-0144aC - Photograph of Masimo Watch (W1) instructions	403; ATH; LFND; NREL; MIL
P-0145	MASITC_P_145		CPX-0145C - Masimo Watch (W1) charger	403; ATH; LFND; NREL; MIL
P-0145a	MASITC_01083158	MASITC_01083159	CPX-0145aC - Photograph of Masimo Watch (W1) charger	403; ATH; LFND; NREL; MIL
P-0146	MASITC_P_146	MASITC_P_146	CPX-0146C - Masimo Watch (W1)	403; ATH; LFND; NREL; MIL
P-0146a	MASITC_01083136	MASITC_01083137	CPX-0146aC - Photograph of Masimo Watch (W1)	403; ATH; LFND; NREL; MIL

## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
P-0147	MASITC_P_147	MASITC_P_147	CPX-0147 - Masimo Pronto 7 sensor	403; ATH; LFND; NREL; MIL
P-0147a			CPX-0147a - Photograph of Masimo Pronto 7 sensor	403; ATH; LFND; NREL; MIL
P-0148	MASITC_P_148	MASITC_P_148	CPX-0148 - Withings Scanwatch	403; ATH; LFND; NREL; MIL
P-0148a			CPX-0148a - Photograph of Withings Scanwatch	403; ATH; LFND; NREL; MIL
P-0149	MASITC_P_149	MASITC_P_149	CPX-0149 - Amazfit GTR 2e Smartwatch	403; ATH; LFND; NREL; MIL
P-0149a			CPX-0149a - Photograph of Amazfit GTR 2e Smartwatch	403; ATH; LFND; NREL; MIL
P-0155	CPX-0155C		CPX-0155C - Masimo Watch (W1)	403; ATH; LFND; NREL; MIL
P-0155a	CPX-0155aC		CPX-0155aC - Photograph of Masimo Watch (W1)	403; ATH; LFND; NREL; MIL
P-0182			CPX-0182 - Movie, Personal Gold: An Underdog Story	403; ATH; LFND; NREL; MIL
P-0182a			CPX-0182a - Photograph of Movie, Personal Gold: An Underdog Story	403; ATH; LFND; NREL; MIL
P-0183			CPX-0183 - Movie, Steve Job: The Lost Interview	403; ATH; LFND; NREL; MIL
P-0183a			CPX-0183a - Photograph of Movie, Steve Job: The Lost Interview	403; ATH; LFND; NREL; MIL
P-0188			CPX-0188 - Oxiclick Sensor	403; ATH; LFND; NREL; MIL
P-0188a			CPX-0188a - Photograph of Oxiclick Sensor	403; ATH; LFND; NREL; MIL
P-0189			CPX-0189 - Oxisensor II Sensor	403; ATH; LFND; NREL; MIL
P-0189a			CPX-0189a - Photograph of Oxisensor II Sensor	403; ATH; LFND; NREL; MIL
P-0190			CPX-0190 - Masimo LNOP Sensor	403; ATH; LFND; NREL; MIL
P-0190a			CPX-0190a - Photograph of Masimo LNOP Sensor	403; ATH; LFND; NREL; MIL
P-0201	MASAD_P_001		Masimo Freedom Physical Specimen	403; ATH; LFND; NREL; MIL
P-0201a	MASAD_P_001	MASAD_P_001	Photo of Freedom's back	403; LFND; NREL
P-0202	MASAD_P_002		Masimo Freedom Physical Specimen	403; ATH; LFND; NREL
P-0203	MASAD_P_003		Physical - ECG leads	403; ATH; LFND; NREL; MIS
P-0204	MASAD_P_004		Physical - ECG leads	403; ATH; LFND; NREL; MIS
P-0205	MASAD_P_005		Physical - Wave electrode component	403; ATH; LFND; NREL; MIS
P-0206	MASAD_P_006		Physical - Wave electrode component	403; ATH; LFND; NREL; MIS
P-0207	MASAD_P_007		Physical - Wave electrode component	403; ATH; LFND; NREL; MIS
P-0208	MASAD_P_008		Physical - Arc electrode component	403; ATH; LFND; NREL; MIS
P-0209	MASAD_P_009		Physical - Wave electrode component	403; ATH; LFND; NREL; MIS
P-0210	MASAD_P_010		Physical - W1 Wave electrode	403; ATH; LFND; NREL; MIS
P-0211	MASAD_P_011		Physical - Freedom Band	403; ATH; LFND; NREL
P-0212	MASAD_P_012		Physical - Wave electrode component	403; ATH; LFND; NREL; MIS
P-0213	MASAD_P_013		Physical - Arc electrode component	403; ATH; LFND; NREL; MIS
P-0214	MASAD_P_014		Physical - Arc electrode component	403; ATH; LFND; NREL; MIS
P-0215	MASAD_P_015		Physical - Arc electrode component	403; ATH; LFND; NREL; MIS
P-0216	MASAD_P_016		Physical - Arc electrode component	403; ATH; LFND; NREL; MIS
P-0217	MASAD_P_017		Physical - pill charger	403; ATH; LFND; NREL; MIS
P-0218	MASAD_P_018		Physical - pill charger	403; ATH; LFND; NREL; MIS
P-0219	MASAD_P_019		LG Watch Style Physical Specimen	403; ATH; LFND; NREL; MIS
P-0220-A	MASAD_P_020-A	MASAD_P_020-A	Polar Pacer (1991) physical device, user manual	403; ATH; LFND; NREL
P-0220-B	MASAD_P_020-B	MASAD_P_020-B	Polar Pacer (1991) physical device, watch	403; ATH; LFND; NREL
P-0220-C	MASAD_P_020-C	MASAD_P_020-C	Polar Pacer (1991) physical device, chest band	403; ATH; LFND; NREL
P-0221	MASAD_P_021		Mio Fuse and Charger	403; ATH; LFND; NREL
P-0222	MASAD_P_022		Physical Fossil Abacus AU4002 and Charger	403; ATH; LFND; NREL
P-0223	MASAD_P_023		Samsung Galaxy S8 Physical Specimen	403; ATH; LFND; NREL
P-0224	MASAD_P_024		Physical Qualcomm Toq and Charger	403; ATH; LFND; NREL
P-0225	MASAD_P_025		Asus ZenWatch Physical Specimen	403; ATH; LFND; NREL



## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
P-0227	MASAD_P_027		Physical Epson Pulsense PS-100	403; ATH; LFND; NREL
P-0228	MASAD_P_028		Physical Epson Pulsense PS-100	403; ATH; LFND; NREL
P-0229	MASAD_P_029		Physical Epson Pulsense PS-100	403; ATH; LFND; NREL
P-0234	MASAD_P_034		Asus Google Nexus 7 Physical Specimen	403; ATH; LFND; NREL
P-0235	MASAD_P_035		Physical - W1 Watch	403; ATH; LFND; NREL
P-0236	MASAD_P_036		Physical - W1 Watch Wave Electrode	403; ATH; LFND; NREL; MIS
P-0237	MASAD_P_037		Physical - Freedom	403; ATH; LFND; NREL
P-0238	MASAD_P_038	MASAD_P_038	the Oranger Watch 2.0/CMS50K physical device	403; ATH; LFND; NREL; MIS
P-0239	MASAD_P_039		Physical - Masimo W1	403; ATH; LFND; NREL
P-0240	MASAD_P_040		Mio Shape	403; ATH; LFND; NREL
P-0241	MASAD_P_041	MASAD_P_041	Polar Pacer (1991) physical device; Oslan destructive teardown performed	403; ATH; LFND; NREL; MIS
P-0244	MASAD_P_044	MASAD_P_044	W1 physical device inspected by Oslan (destructive teardown performed)	403; ATH; LFND; NREL; MIS
P-0245	MASAD_P_045	MASAD_P_045	W1 physical device	403; ATH; LFND; NREL; MIS
P-0248	MASAD_P_048		Masimo W1 Physical Specimen	403; ATH; LFND; NREL; MIS
P-0252	MASAD_P_052		Physical Qualcomm Toq and Charger	403; ATH; LFND; NREL; MIS
P-0253	MASAD_P_053		Physical Fossil Abacus AU4005 and Charger	403; ATH; LFND; NREL; MIS
P-0254	MASAD_P_054	MASAD_P_054	Polar Pacer (1997)	403; ATH; LFND; NREL; MIS
P-0254-A	MASAD_P_054-A	MASAD_P_054-A	Chest band of MASAD_P_054	403; ATH; LFND; NREL; MIS
P-0254-B	MASAD_P_054-B	MASAD_P_054-B	Wrist monitor of MASAD_P_054	403; ATH; LFND; NREL; MIS
P-0254-C	MASAD_P_054-C	MASAD_P_054-C	Elastic band of MASAD_P_054	403; ATH; LFND; NREL; MIS
P-0254-D	MASAD_P_054-D	MASAD_P_054-D	User guide of MASAD_P_054	403; ATH; LFND; NREL; MIS
P-0254-E	MASAD_P_054-E	MASAD_P_054-E	Customer registration card of MASAD_P_054	403; ATH; LFND; NREL; MIS
P-0255			Physical - Masimo pill charger	403; ATH; LFND; NREL; NP; MIS
P-0256			Physical - Masimo W1 Wave Design	403; ATH; LFND; NREL; NP
P-0257			Physical - Masimo Freedom Wave Design	403; ATH; LFND; NREL; NP
P-0258			Physical - Samsung Galaxy Watch 4	403; ATH; LFND; NREL; NP
P-0259			Physical - Basis Watch	403; ATH; LFND; NREL; NP
P-0260			Physical - Apple Watch Series 0	403; ATH; LFND; NREL; NP
P-0261			Physical - Apple Watch Series 1	403; ATH; LFND; NREL; NP
P-0262			Physical - Apple Watch Series 2	403; ATH; LFND; NREL; NP
P-0263			Physical - Apple Watch Series 3	403; ATH; LFND; NREL; NP
P-0264			Physical - Apple Watch Series 4	403; ATH; LFND; NREL; NP
P-0265			Physical - Apple Watch Series 5	403; ATH; LFND; NREL; NP
P-0266			Physical - Apple Watch Series 6	403; ATH; LFND; NREL; NP
P-0267			Physical - Apple Watch Series 7	403; ATH; LFND; NREL; NP
P-0268			Physical - Apple Watch Series 8	403; ATH; LFND; NREL; NP
P-0269			Physical - Apple Watch Series 9	403; ATH; LFND; NREL; NP
P-0270			Physical - Apple Watch Series Ultra	403; ATH; LFND; NREL; NP
P-0271			Physical - Apple Watch Series Ultra 2	403; ATH; LFND; NREL; NP
P-0272			Physical - Apple Watch Series SE	403; ATH; LFND; NREL; NP
P-0273			Physical - Apple Watch Series SE (2nd Gen)	403; ATH; LFND; NREL; NP
P-0301	MASA_P_001		Physical - Radius PPG Neo sensor, MASA_P_001	403; ATH; LFND; NREL; MIS
P-0302	MASA_P_002		Physical - Radius PPG reusable chip, MASA_P_002	403; ATH; LFND; NREL; MIS
P-0305	MASA_P_005		Physical - TF-I (Ref. No. 4055) (Current), MASA_P_005	403; ATH; LFND; NREL; MIL; MIS
P-0316	MASA_P_016		TI eZ430-Chronos	403; ATH; LFND; NREL; MIS
P-0318	MASA_P_018		Physical - iSpO2, iOS (30 pin), MASA_P_018	403; ATH; LFND; NREL

## Masimo's Trial Exhibit List and Apple's Objections

DTX Trial Ex. No.	Prod Beg	Prod End	Description	Objections
P-0320	MASA_P_020		iSpO2 with 30 pin connector	403; ATH; LFND; NREL; MIS
P-0322	MASA_P_022		MightySat	403; ATH; LFND; NREL
P-0323	MASA_P_023		Physical - MightySat Rx (2019), MASA_P_023	403; ATH; LFND; NREL
P-0395	MASA_P_095		Physical - Masimo W1, charger	403; ATH; LFND; NREL
P-0396	MASA_P_096		Physical - Masimo Health Module (Current), MASA_P_096	403; ATH; LFND; NREL; MIS
P-0398	MASA_P_098		Physical - Masimo Health Module Board (Current), MASA_P_098	403; ATH; LFND; NREL; MIS
P-0399	MASA_P_099		Physical - Masimo Health Module Boards, Group of 2 (Current), MASA_P_099	403; ATH; LFND; NREL; MIS
P-0400			Apple Watch Charger	403; ATH; LFND; NREL; NP
P-0401			Pautios Smart Watch	403; ATH; LFND; NREL; NP
P-0401a			Photo of Pautios Smart Watch	403; ATH; LFND; NREL; NP
P-0402			Magconn Charger (physical)	403; NREL; LFND; ATH; NP
P-0403			Verily Study Watch (physical)	403; NREL; LFND; ATH; NP
P-1000	MASAD_P_1000		Physical - Masimo Watch	403; ATH; LFND; NREL
P-1001	MASAD_P_1001		Apple Watch Series 4	403; ATH; LFND; NREL



# EXHIBIT 8

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

APPLE INC.,

Plaintiff,

v.

MASIMO CORPORATION AND SOUND  
UNITED, LLC,

Defendants.

---

MASIMO CORPORATION AND CERCACOR  
LABORATORIES, INC.,

Counterclaim-Plaintiffs,

v.

APPLE INC.,

Counterclaim-Defendant.

---

C.A. No. 1:22-cv-1377-JLH

C.A. No. 1:22-cv-1378-JLH

**CONFIDENTIAL**

**APPLE INC.'S AMENDED TRIAL WITNESS LIST**

Plaintiff Apple Inc. identifies the following persons as witnesses likely to be called at trial. Apple reserves the right to supplement and/or amend this list to account for future developments, including but not limited to any decisions issued in response to the parties' pending summary judgment and *Daubert* motions. Apple further reserves the right to call any witness identified on Masimo's<sup>1</sup> witness list. Apple further reserves the right to amend or supplement its trial witness list as part of the meet and confer process leading up to trial, in response to Masimo's pretrial disclosures and objections, in response to any pretrial rulings or orders from the Court, and in the event that any of the individuals listed below become unable to attend the trial or otherwise unable

---

<sup>1</sup> "Masimo" refers to Defendants and Counterclaim-Plaintiffs collectively.

to provide testimony. Apple further reserves the right to call any other witnesses necessary for impeachment and/or rebuttal and reserves the right to call additional witnesses as may be required for document authentication if Masimo challenges the authenticity of any documents, articles, or things presented by Apple at trial. Inclusion on this list does not imply or establish that Masimo may compel the live testimony of that witness and does not waive any objections that Apple may have should Masimo seek to introduce testimony of that witness.

**Live Witnesses (Will Call):**

- Anderson, Molly
- Ball, Alan
- Caldbeck, Deidre
- Irazoqui, Pedro
- Matal, Joe
- Rothkopf, Fletcher
- Simonson, Itamar
- Terveen, Loren
- Warren, Steve

**Live Witnesses (May Call):**

- Block, Ueyn
- Charbonneau-Lefort, Mathieu
- Clavelle, Adam
- Hoellwarth, Quin
- Klaassen, Erno
- Land, Brian
- Malackowski, Jim
- Mehra, Saahil
- Venugopal, Vivek

**Live or By Designation Witness (May Call):**

- Perica, Adrian

**Witnesses By Designation (May Call):**

- Abdul-Hafiz, Yassir
- Ahmed, Omar
- Al-Ali, Ammar
- Anacone, Matt
- Barker, Nicholas
- Budreau, Kristen
- Cardinali, Steven

- Coleman, Jon
- Da Soller, Claudio
- Dalke, David
- De Jong, Erik
- DeJong, Chad
- Diab, Mohamed
- Durkin, Tracy-Gene
- Hankey, Evans
- Harrison-Noonan, Tobias
- Hemenway, Craig
- Hotelling, Steve
- Kesler, Jarom
- Kiani, Joseph
- Kinast, Eric
- Kokawa, Naoki
- Koo, Peter
- Kotcherha, Kyla
- Lodato, Franco
- McClenahan, Tom
- Menawat, Devesh
- Muhsin, Bilal
- Nakajima, Taido
- Park, Linus
- Priddell, Richard
- Russell-Clarke, Peter
- Scruggs, Stephen
- Smith, Dan
- Smith, Robert A.
- Stephens, Nicholas
- Tripodi, Blair
- Wei, Crystal
- Wilson, William
- Yorke, Jacqueline
- Young, Micah
- Zorkendorfer, Rico

# **EXHIBIT 9**

**IN THE U.S. DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

APPLE INC.,  <i>Plaintiff,</i>  v.  MASIMO CORPORATION and SOUND UNITED, LLC,  <i>Defendants.</i>	C.A. No. 22-1377-JLH  <b>JURY TRIAL DEMANDED</b>
MASIMO CORPORATION,  <i>Counter-Claimant,</i>  v.  APPLE INC.  <i>Counter-Defendant.</i>	
APPLE INC.,  <i>Plaintiff,</i>  v.  MASIMO CORPORATION and SOUND UNITED, LLC,  <i>Defendants.</i>	C.A. No. 22-1378-JLH  <b>JURY TRIAL DEMANDED</b>
MASIMO CORPORATION and CERCACOR LABORATORIES, INC.,  <i>Counter-Claimants,</i>  v.  APPLE INC.  <i>Counter-Defendant.</i>	

**MASIMO'S PRELIMINARY WITNESS LIST**

Pursuant to Local Rule 16.3(c)(7) and the Stipulation and Order Regarding Pretrial Schedule (D.I. 1377-659; D.I. 1378-675), Defendant and Counter-Claimant Masimo Corporation, Defendant Sound United, LLC, and Counter-Claimant Cercacor Laboratories, Inc. (collectively “Masimo”) submit the following preliminary witness list.

Masimo reserves the right to amend its list of witnesses as the parties continue pretrial preparation and in view of events at trial or other developments, including evidentiary or other rulings by the Court and narrowing of issues to be presented at trial. Masimo also reserves the right not to call any witness (live, by deposition, or otherwise) set forth in the list below, or to present by deposition a witness listed as live below. If any witness listed as a person Masimo intends to call to testify in person is unavailable, Masimo reserves the right to offer deposition testimony from such witness. For witnesses identified as testifying by deposition or trial testimony, Masimo reserves the right to call such witness to testify live if such witness is made available to do so. With respect to Apple’s witnesses, Masimo reserves the right to introduce testimony through deposition or live examination, as appropriate. Masimo also reserves the right to call any witnesses called by Apple or anyone appearing on Apple’s witness list. The identification of a witness on this list is not an admission that the witness’s testimony is admissible if called by Apple. Masimo also reserves its right to object to any witness or testimony that is objectionable or inadmissible. Masimo further reserves the right to call additional witnesses to establish the authenticity or admissibility of any trial exhibit to which Apple objects to authenticity or admissibility. Masimo also reserves the right to call any witness for impeachment purposes. Masimo further reserves the right to call additional witnesses not listed below in rebuttal to witnesses called by Apple.

Masimo identifies the following Masimo witnesses and Masimo experts.

**Will Call Live**

1. Joel Delman
2. Joe Kiani
3. Vijay Madiseti
4. Alan Oslan
5. Craig Rosenberg
6. Stephen Scruggs
7. Robert Stoll
8. Darrin Young

**May Call Live**

9. Omar Ahmed
10. Bruce Isaacson
11. Richard Priddell
12. Cleve Tyler

Masimo identifies the following witnesses that Masimo may call by deposition or by prior trial testimony, pending the parties' pretrial discussions and Apple's final witness list. As explained above, Masimo reserves the right to call live any witness Apple calls to testify live.

**Witnesses to be Called By Deposition / Prior Trial Testimony**

13. Molly Anderson
14. Ueyn Block
15. Deidre Caldbeck
16. Steven Cardinali



17. Mathieu Charbonneau-Lefort
18. Adam Clavelle
19. Erik G. de Jong
20. Jarvis DeMeulenaere (Fossil Group, Inc.)
21. Elisabeth Dickinson (Mio)
22. Chinsan Han
23. Evans Hankey
24. Tobias Harrison-Noonan
25. Quin Hoellwarth
26. Steven Hotelling
27. Richard Howarth
28. Eric Jue
29. Eugene Kim
30. Eric Kinast
31. Erno Klaassen
32. Marcelo Lamego
33. Brian Land
34. Paul Mannheimer
35. Bob Mansfield
36. Saahil Mehra
37. Kathy Mester (Epson America, Inc.)
38. Taido Nakajima
39. Michael O'Reilly

40. Sameer Pandya
41. Adrian Perica
42. Cameron Pilling
43. Steven “Colin” Roach
44. Fletcher Rothkopf
45. Peter Russell-Clarke
46. Denby Sellers
47. Benjamin Shaffer
48. Gregor Simeonov (Innominds Software, Inc.)
49. David Tom
50. Meng Tong (Contec Medical Systems USA, Inc.)
51. William “Mac” Tyler
52. Vivek Venugopal
53. Steven Waydo
54. Jeff Williams
55. Michael Wittenberg
56. Jacqueline Yorke (Transperfect)
57. Zhipeng Zhang
58. Rico Zorkendorfer
59. Amended Certification Of Sander Werring Certifying Records Pursuant To Federal

Rule Of Evidence 902(12) (Polar Electro Oy)

60. FRE 902(11) Certification of Sharon Wou (Asus Computer International)

August 7, 2024

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

By: /s/ Kendall M. Loebbaka

Joseph R. Re  
Stephen C. Jensen  
Stephen W. Larson  
Benjamin A. Katzenellenbogen  
Edward M. Cannon  
Brian C. Claassen  
Jared C. Bunker  
Mark Lezama  
Kendall M. Loebbaka  
Douglas B. Wentzel  
Knobbe, Martens, Olson & Bear, LLP  
2040 Main Street, 14th Floor  
Irvine, CA 92614  
(949) 760-0404 Telephone  
(949) 760-9502 Facsimile  
joe.re@knobbe.com  
steve.jensen@knobbe.com  
stephen.larson@knobbe.com  
ben.katzenellenbogen@knobbe.com  
ted.cannon@knobbe.com  
brian.claassen@knobbe.com  
jared.bunker@knobbe.com  
mark.lezama@knobbe.com  
kendall.loebbaka@knobbe.com  
douglas.wentzel@knobbe.com

Brian Horne  
Knobbe, Martens, Olson & Bear, LLP  
1925 Century Park East, Suite 600  
Los Angeles, CA 90067  
(310) 551-3450 Telephone  
(310) 551-3458 Facsimile  
brian.horne@knobbe.com  
Adam Powell  
Daniel P. Hughes  
Knobbe, Martens, Olson & Bear, LLP  
3579 Valley Centre Drive, Suite 300  
San Diego, CA 92130  
(858) 707-4000 Telephone  
(858) 707-4001 Facsimile

adam.powell@knobbe.com  
Daniel.hughes@knobbe.com

Carol M. Pitzel Cruz  
Knobbe, Martens, Olson & Bear, LLP  
925 4th Ave., #2500  
Seattle, WA 98104  
206-405-2000 Telephone  
206-405-2001 Facsimile  
carol.pitzelcruz@knobbe.com

PHILLIPS MCLAUGHLIN & HALL, P.A.  
John C. Phillips, Jr. (No. 110)  
Megan C. Haney (No. 5016)  
1200 North Broom Street  
Wilmington, DE 19806  
(302) 655-4200 Telephone  
(302) 655-4210 Fax  
jcp@pmhdelaw.com  
mch@pmhdelaw.com

*Counsel for Defendant and Counter-Claimant  
Masimo Corporation; Defendant Sound United,  
LLC; and Counter-Claimant Cercacor  
Laboratories, Inc.*

### CERTIFICATE OF SERVICE

I hereby certify that on August 7, 2024, a true and correct copy of the foregoing document was served on the following counsel of record at the addresses and in the manner indicated:

***VIA ELECTRONIC MAIL:***

David E. Moore Bindu A. Palapura Andrew L. Brown Hercules Plaza, 6th Floor 1313 N. Market Street Wilmington, DE 19801 dmoore@potteranderson.com bpalapura@potteranderson.com abrown@potteranderson.com	John M. Desmarais Kerri-Ann Limbeek Cosmin Maier Jordan N. Malz Benjamin N. Luehrs Joze Welsh Jamie L. Kringstein Jennifer M. Przybylski Carson Olsheski Jeffrey Scott Seddon, II Amy I. Wann Raymond N. Habbaz Lee Matalon Taeg Sang Cho Eli Balsam Patrick Reilly Marie Weisfeiler Ryan G. Thorne Paul A. Bondor Desmarais LLP 230 Park Avenue, 26th Floor New York, NY 10169 jdesmarais@desmaraisllp.com klimbeek@desmaraisllp.com cmaier@desmaraisllp.com jmalz@desmaraisllp.com bluehrs@desmaraisllp.com jwelsh@desmaraisllp.com jkringstein@desmaraisllp.com jprzybylski@desmaraisllp.com colsheski@desmaraisllp.com jseddon@desmaraisllp.com awann@desmaraisllp.com rhabbaz@desmaraisllp.com lmatalon@desmaraisllp.com tcho@desmaraisllp.com ebalsam@desmaraisllp.com preilly@desmaraisllp.com
--	--

	mweisfeiler@desmaraisllp.com rthorne@desmaraisllp.com pbondor@desmaraisllp.com
Peter C. Magic Kyle Curry Maria Tartakovsky DESMARAIS LLP 101 California Street San Francisco, CA 94111 pmagic@desmaraisllp.com kcurry@desmaraisllp.com mtartakovsky@desmaraisllp.com	Jennifer Milici Dominic Vote Leon B. Greenfield Heath Brooks John O'Toole Wilmer Cutler Pickering Hale and Dorr LLP 2100 Pennsylvania Avenue NW Washington, DC 20037 jennifer.milici@wilmerhale.com dominic.vote@wilmerhale.com leon.greenfield@wilmerhale.com heath.brooks@wilmerhale.com john.otoole@wilmerhale.com
Mark A. Ford Vinita Ferrera Wilmer Cutler Pickering Hale and Dorr LLP 60 State Street Boston, MA 02109 mark.ford@wilmerhale.com vinita.ferrera@wilmerhale.com	David J. Cho David J. Shaw Desmarais LLP 1899 Pennsylvania Avenue NW, Suite 400 Washington, DC 20006 dcho@desmaraisllp.com dshaw@desmaraisllp.com
Lydia Turnage Wilmer Cutler Pickering Hale and Dorr LLP 7 World Trade Center 250 Greenwich Street New York, NY 10007 lydia.turnage@wilmerhale.com	Bethany Stevens Hannah Cannom Walker Stevens Cannom LLP 500 Molino Street, Suite 118 Los Angeles, CA 90013 bstevens@wscllp.com hcannom@wscllp.com
Lauren Ige Cristina Salcedo Wilmer Cutler Pickering Hale and Dorr LLP 250 South Grand Avenue, Suite 2400 Los Angeles, CA 90071 lauren.ige@wilmerhale.com cristina.salcedo@wilmerhale.com	IPservice@potteranderson.com
AppleMasimoService@desmaraisllp.com	whmasimoantitrustservice@wilmerhale.com

August 7, 2024

/s/ Kendall M. Loebbaka  
Kendall M. Loebbaka

# **EXHIBIT 10**

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
02/18/22	Abdul-Hafiz, Yassir (ITC)	5:5-12					
02/18/22	Abdul-Hafiz, Yassir (ITC)	5:25-6:18		6:23-7:22; 8:3-11; 10:21-11:2; 14:16-15:20	[6:23-7:22] AMB; NREL; 403[8:3-11] AMB; NREL; 403[14:16-15:20] HRS; LFND; NREL; 403; MIL; AMB	15:21-16:2; 16:7-14	402; 403; H; F; SP
02/18/22	Abdul-Hafiz, Yassir (ITC)	17:8-18:22	402; 403; H; F; SP	17:5-7; 19:8-11	[17:5-7] AMB; NREL; 403[19:8-11] NREL; 403		
02/18/22	Abdul-Hafiz, Yassir (ITC)	109:5-115:2	402; 403; H; F; SP	102:21-103:19; 108:21-109:4	[102:21-103:19] SPC; HRS; NREL; 403[108:21-109:4] NREL; 403	106:25-107:2	402; 403; F; SP
11/02/23	Ahmed, Omar	8:18-21					
11/02/23	Ahmed, Omar	9:25-10:3		18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3	
11/02/23	Ahmed, Omar	11:4-8		18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3	
11/02/23	Ahmed, Omar	12:11-13:24 [withdrawn]	402; F; SP	18:5-11	[18:5-11] NREL; OBJ; 403	18:20-19:3	
11/02/23	Ahmed, Omar	20:20-21:4 [withdrawn]					
11/02/23	Ahmed, Omar	38:21-39:7					
11/02/23	Ahmed, Omar	39:15-18					
11/02/23	Ahmed, Omar	40:16-19					
11/02/23	Ahmed, Omar	42:11-12		42:13-18			
11/02/23	Ahmed, Omar	43:12-21	402; 403; F; SP; LC; EX; V; M	18:5-11; 43:4-11	[18:5-11] NREL; OBJ; 403	18:20-19:3	
11/02/23	Ahmed, Omar	44:8-10	402; 403; F; SP; LC; EX; V; M	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3	
11/02/23	Ahmed, Omar	44:19-23	402; 403; F; SP; LC; EX; V; M	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3	
11/02/23	Ahmed, Omar	45:8-12	402; 403; F; SP; LC; EX; V; M	18:5-11; 45:4-7	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3	
11/02/23	Ahmed, Omar	46:13-15	402; 403; F; SP; LC; EX; V; M	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3	
11/02/23	Ahmed, Omar	54:3-6	402; 403; F; SP; LC; EX; V; M	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3	
11/02/23	Ahmed, Omar	60:10-12	402; 403; F; SP; LC; EX; V; M	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3	
11/02/23	Ahmed, Omar	61:8-14	402; 403; F; SP; LC; EX; V; M	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3	
11/02/23	Ahmed, Omar	63:2-15	402; 403; F; SP; LC; EX; V; M	18:5-11; 63:23-24; 64:3-6; 64:8-15	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3	
11/02/23	Ahmed, Omar	78:7-11	F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3	
11/02/23	Ahmed, Omar	88:3-4	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3	
11/02/23	Ahmed, Omar	89:19-22	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3	
11/02/23	Ahmed, Omar	90:9-13	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3	
11/02/23	Ahmed, Omar	94:14-16	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3	
11/02/23	Ahmed, Omar	95:7-12	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3	
11/02/23	Ahmed, Omar	95:20-25	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3	
11/02/23	Ahmed, Omar	98:8-13	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3	



DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER- COUNTERS
11/02/23	Ahmed, Omar	102:5-6	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	104:16-17	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	104:20-20	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	104:22-23	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	104:25-25	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	106:9-10	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	106:14-15	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	106:17-17	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	106:22-22	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	106:24-25	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	107:2-2	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	107:4-6	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	107:8-8	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	107:18-20	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	107:22-22	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	107:24-25	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	108:1-3	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	108:5-5	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	111:12-112:6	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	112:21-113:16	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	113:19-21	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	115:6-9	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER- COUNTERS
11/02/23	Ahmed, Omar	115:18-19	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	116:4-7	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	116:21-24	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	117:3-6	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	117:10-13	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	118:10-14	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	119:15-17	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	120:2-17	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	120:24-121:3	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	121:6-10	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	122:4-7	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	122:13-14	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	123:5-8	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	123:11-14	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	123:19-22	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	131:21-25	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	132:1-1	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	132:14-18	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	133:9-13	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	133:15-15	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	133:25-134:3	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	134:9-25	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
11/02/23	Ahmed, Omar	135:9-12	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	135:22-25	402; 403; F; SP; LC; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	139:7-11	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	139:16-18	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	139:21-22	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	140:17-19	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	140:21-24	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	141:15-25	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	142:1-9	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	143:4-7	402; 403; F; SP; LC; EX; V; AF	18:5-11; 143:8-10	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	143:11-13	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	144:15-17	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	147:12-13	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	147:15-16	402; 403; F; SP; LC; EX; V; AF	18:5-11; 147:18-18; 147:21-148:1	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	148:23-149:11	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	149:15-150:2	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	150:5-5	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	152:16-18	402; 403; F; SP; LC; EX; V; AF	18:5-11; 152:19-153:5	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	154:12-17	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	154:20-21	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	155:14-19	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	156:3-6	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
11/02/23	Ahmed, Omar	158:10-10	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	158:15-17	402; 403; F; SP; LC; EX; V; AF	18:5-11; 158:12-14	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	159:12-25	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	160:1-1	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	160:15-162:11	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	162:15-17	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	162:19-20	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	162:22-25	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	163:2-4	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	163:7-10	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	163:12-14	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	163:16-17	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	163:19-20	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	163:24-25	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	166:3-5	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	166:8-9	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	166:11-14	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	166:16-17	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	167:19-22	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	167:24-25	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	170:3-6	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	170:10-11	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
11/02/23	Ahmed, Omar	171:23-25	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	172:2-3	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	172:8-12	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	172:17-21	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	172:25-173:1	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	177:11-12	402; 403; F; SP; LC; EX; V; AF	18:5-11; 176:24-25; 177:2-10	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	177:14-15	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	177:17-18	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	177:20-21	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	182:23-23	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	183:3-8	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	184:2-6	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	184:13-14	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	184:16-22	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	184:24-185:1	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	185:3-7	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	185:9-11	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	186:4-11	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	186:20-22	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	186:25-187:1	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	187:3-9	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	193:4-15	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER- COUNTERS
11/02/23	Ahmed, Omar	193:24-194:2	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	194:11-13	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	194:15-16	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	194:21-21	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	195:5-11	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	195:18-19	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	195:22-23	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	195:25-196:6	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	196:10-17	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	196:21-197:1	402; 403; F; SP; LC; EX; V; AF	18:5-11; 197:2-7	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	197:13-199:6	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	199:22-200:8	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	201:8-202:3	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	204:13-16	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	205:4-9	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	207:13-17	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	207:20-22	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	209:16-227:24	402; 403; F; SP; LC; EX; V; AF; AC	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	211:19-21	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	212:2-4	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	215:12-13	402; 403; F; SP; LC; EX; V; AF; AC	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	215:21-23	402; 403; F; SP; LC; EX; V; AF; AC	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
11/02/23	Ahmed, Omar	218:7-8	402; 403; F; SP; LC; EX; V; AF; AC	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	218:16-17	402; 403; F; SP; LC; EX; V; AF; AC	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	219:12-18	402; 403; F; SP; LC; EX; V; AF; AC	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	219:21-23	402; 403; F; SP; LC; EX; V; AF; AC	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	220:23-221:5	402; 403; F; SP; LC; EX; V; AF; AC	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	221:8-9	402; 403; F; SP; LC; EX; V; AF; AC	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	221:11-15	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	221:18-19	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	225:14-16	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	298:14-15	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	298:17-19	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	300:5-7	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	300:9-14	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	302:24-303:9	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	304:22-24	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	305:10-13	402; 403; F; SP; LC; EX; V; AF	18:5-11; 305:25-306:2	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	306:25-307:3	402; 403; F; SP; LC; EX; V; AF	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	319:12-14	402; 403; F; SP; LC; EX; V; AF; AC	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	319:22-320:2	402; 403; F; SP; LC; EX; V; AF; AC	18:5-11	[18:5-11] NREL; OBJ; 403	[18:5-11] 18:20-19:3 [43:4-4] 42:24-43:3	
11/02/23	Ahmed, Omar	323:17-324:16					
11/01/23	Al-Ali, Ammar	9:12-13					
11/01/23	Al-Ali, Ammar	9:16-18					
11/01/23	Al-Ali, Ammar	9:25-10:11	AC, WP				
11/01/23	Al-Ali, Ammar	10:15-11:3	AC, WP				
11/01/23	Al-Ali, Ammar	12:1-10	AC, WP				
11/01/23	Al-Ali, Ammar	12:23-24	AC, WP				
11/01/23	Al-Ali, Ammar	13:16-19	AC, WP				
11/01/23	Al-Ali, Ammar	15:25-16:9	402, 403, AC, WP				
11/01/23	Al-Ali, Ammar	16:15-21	402, 403, AC, WP				
11/01/23	Al-Ali, Ammar	17:4-10	402, 403, AC, WP				

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER- COUNTERS
11/01/23	Al-Ali, Ammar	17:19-25	402, 403, AC, WP				
11/01/23	Al-Ali, Ammar	19:6-8	402, 403, AC, WP				
11/01/23	Al-Ali, Ammar	19:25-20:3	402, 403, AC, WP				
11/01/23	Al-Ali, Ammar	20:21-23	402, 403, AC, WP				
11/01/23	Al-Ali, Ammar	21:9-22:15	402, 403, AC, WP, AG, F, H, M, SP, V				
11/01/23	Al-Ali, Ammar	22:20-23:5	402, 403, AC, WP, AG, F, H, M, SP, V				
11/01/23	Al-Ali, Ammar	24:5-10	402, 403, AC, WP, AG, F, H, M, SP, V				
11/01/23	Al-Ali, Ammar	24:16-19	402, 403, AC, WP, AG, F, H, M, SP, V				
11/01/23	Al-Ali, Ammar	25:2-18	402, 403, AC, WP, AG, F, H, M, SP, V				
11/01/23	Al-Ali, Ammar	29:5-24	402, 403, AC, WP, AG, F, H, M, SP, V				
11/01/23	Al-Ali, Ammar	30:14-17	402, 403, AC, WP, AG, F, H, M, SP, V				
11/01/23	Al-Ali, Ammar	31:25-32:6	402, 403, AC, WP, AG, F, H, M, SP, V				
11/01/23	Al-Ali, Ammar	32:15-33:2	402, 403, AC, WP, AG, F, H, M, SP, V				
11/01/23	Al-Ali, Ammar	35:3-8	402, 403, AC, WP, AG, F, H, M, SP, V				
11/01/23	Al-Ali, Ammar	35:12-25	402, 403, AC, WP, AG, F, H, M, SP, V				
11/01/23	Al-Ali, Ammar	36:3-5	402, 403, AC, WP, AG, F, H, M, SP, V				
11/01/23	Al-Ali, Ammar	36:7-8	402, 403, AC, WP, AG, F, H, M, SP, V				
11/01/23	Al-Ali, Ammar	37:3-7	402, 403, AC, WP, AG, F, H, M, SP, V				
11/01/23	Al-Ali, Ammar	37:12-17	402, 403, AC, WP, AG, F, H, M, SP, V				
11/01/23	Al-Ali, Ammar	39:17-20	402, 403, AC, WP, AG, F, H, M, SP, V				
11/01/23	Al-Ali, Ammar	40:7-25	402, 403				
11/01/23	Al-Ali, Ammar	41:7-8	402, 403				
11/01/23	Al-Ali, Ammar	41:12-21	402, 403				
11/01/23	Al-Ali, Ammar	42:8-16	402, 403				
11/01/23	Al-Ali, Ammar	43:7-20	402, 403				
11/01/23	Al-Ali, Ammar	43:24-44:15	402, 403				
11/01/23	Al-Ali, Ammar	44:23-45:4	402, 403, M				
11/01/23	Al-Ali, Ammar	46:22-25	402, 403, M				
11/01/23	Al-Ali, Ammar	49:13-16	402, 403, M				
11/01/23	Al-Ali, Ammar	49:23-25	402, 403, AA, M				
11/01/23	Al-Ali, Ammar	50:1-7	402, 403, AA, M				
11/01/23	Al-Ali, Ammar	51:22-25	402, 403, AA, M				
11/01/23	Al-Ali, Ammar	52:1-14	402, 403, AA, M				
11/01/23	Al-Ali, Ammar	53:2-5	402, 403, AA, M				
11/01/23	Al-Ali, Ammar	53:8-9	402, 403, AA, M				
11/01/23	Al-Ali, Ammar	53:13-22	402, 403, AA, AS, M, V				
11/01/23	Al-Ali, Ammar	54:4-10	402, 403, AS, M, V				
11/01/23	Al-Ali, Ammar	54:16-25	402, 403, AS, M, V				
11/01/23	Al-Ali, Ammar	55:7-9	402, 403, AS, M, V				
11/01/23	Al-Ali, Ammar	55:14-24	402, 403, AS, M, V				
11/01/23	Al-Ali, Ammar	56:13-25	402, 403				
11/01/23	Al-Ali, Ammar	57:1-12	402, 403				
11/01/23	Al-Ali, Ammar	57:17-25	402, 403				
11/01/23	Al-Ali, Ammar	58:1-1	402, 403				
11/01/23	Al-Ali, Ammar	58:16-25	402, 403, F, LW, SP	320:25-321:24			
11/01/23	Al-Ali, Ammar	60:1-9	402, 403, F, LW, SP	320:25-321:24			
11/01/23	Al-Ali, Ammar	60:22-25	402, 403, F, LW, SP	320:25-321:24			
11/01/23	Al-Ali, Ammar	61:1-1	402, 403, F, LW, SP	320:25-321:24			
11/01/23	Al-Ali, Ammar	61:9-20	402, 403, F, LW, SP	320:25-321:24			
11/01/23	Al-Ali, Ammar	62:24-25	402, 403, F, LW, SP	320:25-321:24			
11/01/23	Al-Ali, Ammar	63:3-3	402, 403, F, LW, SP	320:25-321:24			
11/01/23	Al-Ali, Ammar	63:5-25	402, 403, F, LW, SP	320:25-321:24			
11/01/23	Al-Ali, Ammar	64:1-4	402, 403, F, LW, SP	320:25-321:24			
11/01/23	Al-Ali, Ammar	64:25-25	402, 403, F, LW, SP	320:25-321:24			
11/01/23	Al-Ali, Ammar	65:1-3	402, 403, F, LW, SP	320:25-321:24			
11/01/23	Al-Ali, Ammar	65:5-7	402, 403, F, LW, SP	320:25-321:24			
11/01/23	Al-Ali, Ammar	65:21-25	402, 403, AA, AS, AF, F, M, V	320:25-321:24			
11/01/23	Al-Ali, Ammar	66:1-11	402, 403, AA, AS, AF, F, M, V	320:25-321:24			
11/01/23	Al-Ali, Ammar	66:16-16	402, 403, AA, AS, AF, F, M, V	320:25-321:24			
11/01/23	Al-Ali, Ammar	66:18-24	402, 403, AA, AS, AF, F, M, V	320:25-321:24			
11/01/23	Al-Ali, Ammar	67:20-25	402, 403, AA, AS, AF, F, M, V	320:25-321:24			
11/01/23	Al-Ali, Ammar	68:1-1	402, 403, AA, AS, AF, F, M, V	320:25-321:24			
11/01/23	Al-Ali, Ammar	70:15-19	402, 403, AA, AS, AF, F, M, V	320:25-321:24			
11/01/23	Al-Ali, Ammar	71:10-25	402, 403				
11/01/23	Al-Ali, Ammar	72:1-11	402, 403				
11/01/23	Al-Ali, Ammar	72:18-25	402, 403				



DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
11/01/23	Al-Ali, Ammar	73:1-24	402, 403				
11/01/23	Al-Ali, Ammar	75:7-14	402, 403, M				
11/01/23	Al-Ali, Ammar	76:5-9	402, 403, M				
11/01/23	Al-Ali, Ammar	79:5-25					
11/01/23	Al-Ali, Ammar	80:1-6					
11/01/23	Al-Ali, Ammar	80:10-17					
11/01/23	Al-Ali, Ammar	80:25-25	402, 403, M				
11/01/23	Al-Ali, Ammar	81:1-25	402, 403, M				
11/01/23	Al-Ali, Ammar	82:1-1	402, 403, M				
11/01/23	Al-Ali, Ammar	82:2-25	402, 403, M				
11/01/23	Al-Ali, Ammar	83:1-7	402, 403, M				
11/01/23	Al-Ali, Ammar	83:18-25	402, 403, M				
11/01/23	Al-Ali, Ammar	84:1-7	402, 403, M				
11/01/23	Al-Ali, Ammar	84:24-25	402, 403, M				
11/01/23	Al-Ali, Ammar	85:1-12	402, 403, M				
11/01/23	Al-Ali, Ammar	87:7-11	402, 403, M				
11/01/23	Al-Ali, Ammar	90:20-25	402, 403, AF, F, M, O, V				
11/01/23	Al-Ali, Ammar	91:1-19	402, 403, AF, F, M, O, V				
11/01/23	Al-Ali, Ammar	94:22-25	402, 403, AF, F, M, O, V				
11/01/23	Al-Ali, Ammar	95:1-2	402, 403, AF, F, M, O, V				
11/01/23	Al-Ali, Ammar	95:6-9	402, 403, AF, F, M, O, V				
11/01/23	Al-Ali, Ammar	96:1-11	402, 403, AF, F, M, O, V				
11/01/23	Al-Ali, Ammar	96:21-25	402, 403, AF, F, M, O, V				
11/01/23	Al-Ali, Ammar	97:1-4	402, 403, AF, F, M, O, V				
11/01/23	Al-Ali, Ammar	98:14-25	402, 403, AF, F, M, O, V				
11/01/23	Al-Ali, Ammar	99:1-4	402, 403, AF, F, M, O, V				
11/01/23	Al-Ali, Ammar	99:7-16	402, 403, AF, F, M, O, V				
11/01/23	Al-Ali, Ammar	100:10-15	402, 403, AF, F, M, O, V				
11/01/23	Al-Ali, Ammar	101:10-25	402, 403, AF, F, M, O, V				
11/01/23	Al-Ali, Ammar	102:1-3	402, 403, AF, F, M, O, V				
11/01/23	Al-Ali, Ammar	103:21-25	402, 403, AS, F, M, O, SP, V, AC, WP				
11/01/23	Al-Ali, Ammar	104:1-13	402, 403, AS, F, M, O, SP, V, AC, WP				
11/01/23	Al-Ali, Ammar	105:4-7	402, 403, AS, F, M, O, SP, V, AC, WP				
11/01/23	Al-Ali, Ammar	105:13-16	402, 403, AS, F, M, O, SP, V, AC, WP				
11/01/23	Al-Ali, Ammar	106:16-24	402, 403, AS, F, M, O, SP, V, AC, WP				
11/01/23	Al-Ali, Ammar	111:13-17	402, 403, AS, F, M, O, SP, V, AC, WP				
11/01/23	Al-Ali, Ammar	112:23-24	402, 403, AS, F, M, O, SP, V, AC, WP				
11/01/23	Al-Ali, Ammar	113:11-13	402, 403, AS, F, M, O, SP, V, AC, WP				
11/01/23	Al-Ali, Ammar	114:14-25	402, 403, AF, AS, F, M, O, SP, V, AC, WP				
11/01/23	Al-Ali, Ammar	115:1-1	402, 403, AF, AS, F, M, O, SP, V, AC, WP				
11/01/23	Al-Ali, Ammar	115:24-24	402, 403, AF, AS, F, M, O, SP, V, AC, WP				
11/01/23	Al-Ali, Ammar	116:1-25	402, 403, AF, AS, F, M, O, SP, V, AC, WP				
11/01/23	Al-Ali, Ammar	117:1-8	402, 403, AF, AS, F, M, O, SP, V, AC, WP				
11/01/23	Al-Ali, Ammar	120:6-9	402, 403, AF, AS, F, M, O, SP, V, AC, WP				
11/01/23	Al-Ali, Ammar	123:25-25	402, 403, AF, AS, F, M, O, SP, V, AC, WP				
11/01/23	Al-Ali, Ammar	124:1-7	402, 403, AF, AS, F, M, O, SP, V, AC, WP				
11/01/23	Al-Ali, Ammar	124:11-14	402, 403, AF, AS, F, M, O, SP, V, AC, WP				
11/01/23	Al-Ali, Ammar	125:15-25	402, 403, AF, F, M				
11/01/23	Al-Ali, Ammar	126:1-11	402, 403, AF, F, M				
11/01/23	Al-Ali, Ammar	127:12-19	402, 403, AF, F, M				
11/01/23	Al-Ali, Ammar	127:21-25	402, 403, AF, F, M				
11/01/23	Al-Ali, Ammar	128:1-1	402, 403, AF, F, M				
11/01/23	Al-Ali, Ammar	130:13-22	402, 403, F, M				
11/01/23	Al-Ali, Ammar	131:7-25	402, 403, F, M				
11/01/23	Al-Ali, Ammar	132:1-3	402, 403, F, M				
11/01/23	Al-Ali, Ammar	132:9-25	402, 403, F, M				
11/01/23	Al-Ali, Ammar	133:1-2	402, 403, F, M				
11/01/23	Al-Ali, Ammar	135:2-5	402, 403, F, M				
11/01/23	Al-Ali, Ammar	135:17-19	402, 403, F, M				
11/01/23	Al-Ali, Ammar	136:17-25	402, 403, F				
11/01/23	Al-Ali, Ammar	137:1-16	402, 403, F				
11/01/23	Al-Ali, Ammar	138:9-20	402, 403				
11/01/23	Al-Ali, Ammar	139:2-12	402, 403				
11/01/23	Al-Ali, Ammar	140:7-25	402, 403, AS, AF, F, M, V				
11/01/23	Al-Ali, Ammar	141:1-7	402, 403, AS, AF, F, M, V				
11/01/23	Al-Ali, Ammar	141:20-25	402, 403, AS, AF, F, M, V				
11/01/23	Al-Ali, Ammar	142:2-11	402, 403, AS, AF, F, M, V				
11/01/23	Al-Ali, Ammar	143:3-5	402, 403, AS, AF, F, M, V				

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
11/01/23	Al-Ali, Ammar	143:13-25	402, 403, AS, AF, F, M, V				
11/01/23	Al-Ali, Ammar	144:1-19	402, 403, AS, AF, F, M, V				
11/01/23	Al-Ali, Ammar	144:23-25	402, 403, AS, AF, F, M, V				
11/01/23	Al-Ali, Ammar	145:1-1	402, 403, AS, AF, F, M, V				
11/01/23	Al-Ali, Ammar	145:11-15	402, 403, AS, AF, F, M, V				
11/01/23	Al-Ali, Ammar	146:2-25	402, 403, AS, AF, F, M, V				
11/01/23	Al-Ali, Ammar	147:1-2	402, 403, AS, AF, F, M, V				
11/01/23	Al-Ali, Ammar	147:7-18	402, 403, AS, AF, F, M, V				
11/01/23	Al-Ali, Ammar	147:25-25	402, 403, AS, AF, F, M, V				
11/01/23	Al-Ali, Ammar	148:1-13	402, 403, AS, AF, F, M, V				
11/01/23	Al-Ali, Ammar	150:14-20	402, 403, AS, AF, F, M, V				
11/01/23	Al-Ali, Ammar	150:24-25	402, 403, AS, AF, F, M, V				
11/01/23	Al-Ali, Ammar	151:1-25	402, 403, AS, AF, F, M, V				
11/01/23	Al-Ali, Ammar	152:1-23	402, 403, AS, AF, F, M, V				
11/01/23	Al-Ali, Ammar	153:15-19	402, 403, AS, AF, F, M, V				
11/01/23	Al-Ali, Ammar	154:1-6	402, 403, AS, AF, F, M, V				
11/01/23	Al-Ali, Ammar	154:10-13	402, 403, AS, AF, F, M, V				
11/01/23	Al-Ali, Ammar	154:18-25	402, 403, AS, AF, F, M, V				
11/01/23	Al-Ali, Ammar	155:1-1	402, 403, AS, AF, F, M, V				
11/01/23	Al-Ali, Ammar	155:9-14	402, 403, AS, AF, F, M, V				
11/01/23	Al-Ali, Ammar	155:20-25	402, 403, AF, M	155:17-19, 159:25-160:2			
11/01/23	Al-Ali, Ammar	156:1-8	402, 403, AF, M	155:17-19, 159:25-160:2			
11/01/23	Al-Ali, Ammar	156:13-16	402, 403, AF, M	155:17-19, 159:25-160:2			
11/01/23	Al-Ali, Ammar	157:11-14	402, 403, AF, M	155:17-19, 159:25-160:2			
11/01/23	Al-Ali, Ammar	157:18-22	402, 403, AF, M	155:17-19, 159:25-160:2			
11/01/23	Al-Ali, Ammar	159:20-24	402, 403, AF, M	155:17-19, 159:25-160:2			
11/01/23	Al-Ali, Ammar	168:4-11	402, 403, AS, M, V				
11/01/23	Al-Ali, Ammar	168:23-25	402, 403, AS, M, V				
11/01/23	Al-Ali, Ammar	169:1-3	402, 403, AS, M, V				
11/01/23	Al-Ali, Ammar	169:18-25	402, 403, AS, M, V				
11/01/23	Al-Ali, Ammar	170:1-2	402, 403, AS, M, V				
11/01/23	Al-Ali, Ammar	170:1-3	402, 403, AS, M, V				
11/01/23	Al-Ali, Ammar	170:10-16	402, 403, V				
11/01/23	Al-Ali, Ammar	172:2-9	402, 403, V				
11/01/23	Al-Ali, Ammar	172:12-14	402, 403, V				
11/01/23	Al-Ali, Ammar	172:17-22	402, 403, V				
11/01/23	Al-Ali, Ammar	173:18-24	402, 403, V				
11/01/23	Al-Ali, Ammar	174:1-25	402, 403, V				
11/01/23	Al-Ali, Ammar	175:1-6	402, 403, V				
11/01/23	Al-Ali, Ammar	175:17-176:7	402, 403, V				
11/01/23	Al-Ali, Ammar	179:8-12	A, BE, F, M				
11/01/23	Al-Ali, Ammar	179:15-19	F				
11/01/23	Al-Ali, Ammar	180:4-8	F				
11/01/23	Al-Ali, Ammar	205:2-210:15 [withdrawn]	402, 403, AF				
11/01/23	Al-Ali, Ammar	210:20-25	402, 403, AC, WP, AF, AS, F, O				
11/01/23	Al-Ali, Ammar	211:3-3	402, 403, AC, WP, AF, AS, F, O				
11/01/23	Al-Ali, Ammar	211:5-15	402, 403, AC, WP, AF, AS, F, O				
11/01/23	Al-Ali, Ammar	212:4-10	402, 403, AC, WP, AF, AS, F, O				
11/01/23	Al-Ali, Ammar	264:13-25	402, 403, F				
11/01/23	Al-Ali, Ammar	265:5-15	402, 403, F				
11/01/23	Al-Ali, Ammar	265:22-25	402, 403, F				
11/01/23	Al-Ali, Ammar	266:1-3	402, 403, F				
11/01/23	Al-Ali, Ammar	269:6-13	402, 403, F, O				
11/01/23	Al-Ali, Ammar	271:2-11	402, 403, AF, F, M				
11/01/23	Al-Ali, Ammar	273:17-25	402, 403, AA, AF, AS, F, IH, LW, M				
11/01/23	Al-Ali, Ammar	274:5-12	402, 403, AA, AF, AS, F, IH, LW, M				
11/01/23	Al-Ali, Ammar	274:17-25	402, 403, AA, AF, AS, F, IH, LW, M				
11/01/23	Al-Ali, Ammar	277:1-11	402, 403, AA, AF, AS, F, IH, LW, M				
11/01/23	Al-Ali, Ammar	289:2-9	402, 403, F, O				
11/01/23	Al-Ali, Ammar	289:23-25	402, 403, F, O				
11/01/23	Al-Ali, Ammar	290:1-4	402, 403, F, O				
11/01/23	Al-Ali, Ammar	290:10-12	402, 403, F, O				
11/01/23	Al-Ali, Ammar	291:4-10	402, 403, F, O				
11/01/23	Al-Ali, Ammar	291:18-25	402, 403, F, O				
11/01/23	Al-Ali, Ammar	292:1-2	402, 403, F, O				
11/01/23	Al-Ali, Ammar	293:24-25	402, 403, F, O				
11/01/23	Al-Ali, Ammar	294:1-9	402, 403, F, O				
11/01/23	Al-Ali, Ammar	294:17-25	402, 403, F, O				

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
11/01/23	Al-Ali, Ammar	295:1-5	402, 403, F, O				
11/01/23	Al-Ali, Ammar	295:19-22	402, 403, F, O				
11/01/23	Al-Ali, Ammar	299:15-18	402, 403, F, O				
11/01/23	Al-Ali, Ammar	300:7-16	402, 403, F, O				
11/01/23	Al-Ali, Ammar	300:22-24	402, 403, F, O				
11/01/23	Al-Ali, Ammar	322:5-10	402, 403	320:25-321:24	[320:25-321:24] SPC; CPD; LDG; NREL; 403		
08/17/22	Al-Ali, Ammar (CDCA)	9:16-17					
08/17/22	Al-Ali, Ammar (CDCA)	12:22-14:10 [withdrawn]	402, 403				
08/17/22	Al-Ali, Ammar (CDCA)	21:18-19					
08/17/22	Al-Ali, Ammar (CDCA)	21:20-22:8					
08/17/22	Al-Ali, Ammar (CDCA)	24:20-25:2	402, 403	300:11-302:7	[300:11-302:7] SPC; LDG; NREL; 403		
08/17/22	Al-Ali, Ammar (CDCA)	29:9-21	402, 403	300:11-302:7	[300:11-302:7] SPC; LDG; NREL; 403		
08/17/22	Al-Ali, Ammar (CDCA)	30:12-25	402, 403	300:11-302:7; 302:8-20	[300:11-302:7] SPC; LDG; NREL; 403[302:8-20] SPC; LDG; NREL; 403		
08/17/22	Al-Ali, Ammar (CDCA)	32:4-20	402, 403				
08/17/22	Al-Ali, Ammar (CDCA)	231:7-234:17 [withdrawn]	402, 403, AS, EX, F, I, LC, LW, O, V				
08/17/22	Al-Ali, Ammar (CDCA)	236:1-11	402, 403, AC, F, LW, M, O, SP, V, WP				
08/17/22	Al-Ali, Ammar (CDCA)	237:15-25	402, 403, AC, F, LW, M, O, SP, V, WP				
08/17/22	Al-Ali, Ammar (CDCA)	242:6-15	402, 403, AC, F, LW, M, O, SP, V, WP				
08/17/22	Al-Ali, Ammar (CDCA)	243:23-244:4	402, 403, AC, F, LW, M, O, SP, V, WP				
08/17/22	Al-Ali, Ammar (CDCA)	249:24-250:3	402, 403, AC, F, LW, M, O, SP, V, WP				
08/17/22	Al-Ali, Ammar (CDCA)	250:14-19	402, 403, AC, F, LW, M, O, SP, V, WP				
08/17/22	Al-Ali, Ammar (CDCA)	255:19-256:8	402, 403, O				
08/17/22	Al-Ali, Ammar (CDCA)	258:19-259:8	402, 403, O				
08/17/22	Al-Ali, Ammar (CDCA)	259:1-8	402, 403, O				
08/17/22	Al-Ali, Ammar (CDCA)	260:1-21	402, 403, O				
08/17/22	Al-Ali, Ammar (CDCA)	264:1-266:4	402, 403, O				
08/17/22	Al-Ali, Ammar (CDCA)	266:14-23	402, 403, O				
08/17/22	Al-Ali, Ammar (CDCA)	268:20-269:11	402, 403, O				
08/17/22	Al-Ali, Ammar (CDCA)	269:20-270:2	402, 403, O				
08/17/22	Al-Ali, Ammar (CDCA)	281:9-18	402, 403, AS, F, O, SP, V				
08/17/22	Al-Ali, Ammar (CDCA)	281:25-282:3	402, 403, AS, F, O, SP, V				
08/17/22	Al-Ali, Ammar (CDCA)	291:3-292:9	402, 403, F, O, SP, V				
02/16/22	Al-Ali, Ammar (ITC)	8:12-15					
02/16/22	Al-Ali, Ammar (ITC)	8:19-20					
02/16/22	Al-Ali, Ammar (ITC)	9:25-10:7					
02/16/22	Al-Ali, Ammar (ITC)	106:14-16		106:3-13; 106:17-23			
02/16/22	Al-Ali, Ammar (ITC)	124:14-23	402, 403, AF, AS, F, H, M, O, SP, V	92:3-94:13; 119:6-25; 120:10-15; 121:2-13; 122:5-123:16; 188:18-190:7; 266:2-10; 267:14-19	[92:3-94:13] NREL; 403[119:6-25] SPC; HRS; NREL; 403[120:10-15] HRS; NREL; 403[121:2-13] SPC; NREL; 403[122:5-123:16] SPC; HRS; NREL; 403[188:18-190:7] SPC; NREL; 403[266:2-10] NREL; 403	94:14-24	
02/16/22	Al-Ali, Ammar (ITC)	125:7-8	402, 403, AF, AS, F, H, M, O, SP, V	92:3-94:13; 119:6-25; 120:10-15; 121:2-13; 122:5-123:16; 188:18-190:7; 266:2-10; 267:14-19	[92:3-94:13] NREL; 403[119:6-25] SPC; HRS; NREL; 403[120:10-15] HRS; NREL; 403[121:2-13] SPC; NREL; 403[122:5-123:16] SPC; HRS; NREL; 403[188:18-190:7] SPC; NREL; 403[266:2-10] NREL; 403	94:14-24	
02/16/22	Al-Ali, Ammar (ITC)	128:2-4	402, 403, AF, AS, F, H, M, O, SP, V	92:3-94:13; 119:6-25; 120:10-15; 121:2-13; 122:5-123:16; 188:18-190:7; 266:2-10; 267:14-19	[92:3-94:13] NREL; 403 [119:6-25] SPC; HRS; NREL; 403 [120:10-15] HRS; NREL; 403 [121:2-13] SPC; NREL; 403 [122:5-123:16] SPC; HRS; NREL; 403 [188:18-190:7] SPC; NREL; 403 [266:2-10] NREL; 403	94:14-24	
02/16/22	Al-Ali, Ammar (ITC)	128:13-18	402, 403, AF, AS, F, H, M, O, SP, V	92:3-94:13; 119:6-25; 120:10-15; 121:2-13; 122:5-123:16; 188:18-190:7; 266:2-10; 267:14-19	[92:3-94:13] NREL; 403 [119:6-25] SPC; HRS; NREL; 403 [120:10-15] HRS; NREL; 403 [121:2-13] SPC; NREL; 403 [122:5-123:16] SPC; HRS; NREL; 403 [188:18-190:7] SPC; NREL; 403 [266:2-10] NREL; 403	94:14-24	

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
02/16/22	Al-Ali, Ammar (ITC)	134:7-9		92:3-94:13; 119:6-25; 120:10-15; 121:2-13; 122:5-123:16; 188:18-190:7; 266:2-10; 267:14-19	[92:3-94:13] NREL; 403 [119:6-25] SPC; HRS; NREL; 403 [120:10-15] HRS; NREL; 403 [121:2-13] SPC; NREL; 403 [122:5-123:16] SPC; HRS; NREL; 403 [188:18-190:7] SPC; NREL; 403 [266:2-10] NREL; 403	94:14-24	
02/16/22	Al-Ali, Ammar (ITC)	134:21-22	402, 403, AF, AS, F, H, M, O, SP, V	92:3-94:13; 119:6-25; 120:10-15; 121:2-13; 122:5-123:16; 188:18-190:7; 266:2-10; 267:14-19	[92:3-94:13] NREL; 403 [119:6-25] SPC; HRS; NREL; 403 [120:10-15] HRS; NREL; 403 [121:2-13] SPC; NREL; 403 [122:5-123:16] SPC; HRS; NREL; 403 [188:18-190:7] SPC; NREL; 403 [266:2-10] NREL; 403	94:14-24	
02/16/22	Al-Ali, Ammar (ITC)	139:17-20		92:3-94:13; 119:6-25; 120:10-15; 121:2-13; 122:5-123:16; 188:18-190:7; 266:2-10; 267:14-19	[92:3-94:13] NREL; 403 [119:6-25] SPC; HRS; NREL; 403 [120:10-15] HRS; NREL; 403 [121:2-13] SPC; NREL; 403 [122:5-123:16] SPC; HRS; NREL; 403 [188:18-190:7] SPC; NREL; 403 [266:2-10] NREL; 403	94:14-24	
02/16/22	Al-Ali, Ammar (ITC)	146:6-11	402, 403, AF, AS, F, H, M, O, SP, V	92:3-94:13; 119:6-25; 120:10-15; 121:2-13; 122:5-123:16; 188:18-190:7; 266:2-10; 267:14-19	[92:3-94:13] NREL; 403 [119:6-25] SPC; HRS; NREL; 403 [120:10-15] HRS; NREL; 403 [121:2-13] SPC; NREL; 403 [122:5-123:16] SPC; HRS; NREL; 403 [188:18-190:7] SPC; NREL; 403 [266:2-10] NREL; 403	94:14-24	
02/16/22	Al-Ali, Ammar (ITC)	155:11-15	402, 403, AF, AS, F, H, M, O, SP, V	92:3-94:13; 119:6-25; 120:10-15; 121:2-13; 122:5-123:16; 188:18-190:7; 266:2-10; 267:14-19	[92:3-94:13] NREL; 403 [119:6-25] SPC; HRS; NREL; 403 [120:10-15] HRS; NREL; 403 [121:2-13] SPC; NREL; 403 [122:5-123:16] SPC; HRS; NREL; 403 [188:18-190:7] SPC; NREL; 403 [266:2-10] NREL; 403	94:14-24	
02/16/22	Al-Ali, Ammar (ITC)	183:15-18	402, 403, O				
02/16/22	Al-Ali, Ammar (ITC)	255:12-14	402, 403, A, AA, AC, AF, F, H, LC, LW, SP, V, O, WP				
02/16/22	Al-Ali, Ammar (ITC)	255:18-24	402, 403, A, AA, AC, AF, F, H, LC, LW, SP, V, O, WP				
02/16/22	Al-Ali, Ammar (ITC)	260:16-18	402, 403, A, AA, AC, AF, F, H, LC, LW, SP, V, O, WP				
02/16/22	Al-Ali, Ammar (ITC)	261:13-14	402, 403, A, AA, AC, AF, F, H, LC, LW, SP, V, O, WP				
10/18/23	Anacone, Matt	7:21-8:16					
10/18/23	Anacone, Matt	8:17-9:2					
10/18/23	Anacone, Matt	12:17-13:10					
10/18/23	Anacone, Matt	13:12-14:2	402, 403, F, SP				
10/18/23	Anacone, Matt	14:7-23	402, 403, AG, F, O, SP, V				
10/18/23	Anacone, Matt	14:25-15:6	402, 403, F, O, SP, V				
10/18/23	Anacone, Matt	15:8-18:25	402, 403, F, SP, V				
10/18/23	Anacone, Matt	19:16-20:23	402, 403, F, SP, V				
10/18/23	Anacone, Matt	20:25-25:13	402, 403, AG, CO, F, M, O, SP, V				
10/18/23	Anacone, Matt	27:10-18	402, 403, CO, F, SP				
10/18/23	Anacone, Matt	27:21-32:9	402, 403, F, M, O, SP, V				
10/18/23	Anacone, Matt	45:1-46:4	402, 403, F, O, SP, V				
10/18/23	Anacone, Matt	52:18-53:2	402, 403, F, O, SP				
10/18/23	Anacone, Matt	53:4-7	402, 403, F, O, SP				
10/18/23	Anacone, Matt	53:9-14	402, 403				
10/18/23	Anacone, Matt	53:16-17	402, 403				
10/18/23	Anacone, Matt	85:20-86:8	402, 403, F, O, SP, V				
10/18/23	Anacone, Matt	86:10-23	402, 403, F, SP, V				
10/18/23	Anacone, Matt	105:19-108:10	402, 403, F, O, SP, V				
10/18/23	Anacone, Matt	108:15-113:12	402, 403, AF, AG, F, H, SP, V				
10/10/23	Barker, Nicholas	8:18-21					
10/10/23	Barker, Nicholas	8:24-9:2					
10/10/23	Barker, Nicholas	9:14-21		225:13-15			
10/10/23	Barker, Nicholas	10:6-14 [withdrawn]					

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
10/10/23	Barker, Nicholas	13:6-8					
10/10/23	Barker, Nicholas	15:7-19 [withdrawn]		14:13-19	[14:13-19] AMB; AG; BSD (OS); SPC; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	16:14-18		14:13-19	[14:13-19] AMB; AG; BSD (OS); SPC; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	18:18-19:5		17:21-23; 17:25-18:16	[17:21-23] AMB; AG; BSD (OS); SPC; LFND; MIS; NREL; 403 [17:25-18:16] AMB; AG; BSD (OS); SPC; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	19:16-19 [withdrawn]					
10/10/23	Barker, Nicholas	26:15-20	402, 403				
10/10/23	Barker, Nicholas	27:6-20 [withdrawn]	402, 403	27:21-23, 28:1	403; AG; AMB; BSD (OS); CLC; SPC; LFND; MIS; NREL	25:14-20; 27:6-17; 28:14-28:25; 29:22-30:8	[25:14-20] 402, 403; [27:6-17; 28:14-28:25; 29:22-30:8] 402, 403, F
10/10/23	Barker, Nicholas	28:14-25 [withdrawn]	402, 403				
10/10/23	Barker, Nicholas	29:11-30:8 [withdrawn]	402, 403, F				
10/10/23	Barker, Nicholas	30:12-23 [withdrawn]					
10/10/23	Barker, Nicholas	32:3-5 [withdrawn]					
10/10/23	Barker, Nicholas	32:14-16					
10/10/23	Barker, Nicholas	33:8-10		33:11-34:13	[33:11-34:13] AMB; AG; BSD (OS); CLC; SPC; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	34:14-17					
10/10/23	Barker, Nicholas	35:5-8					
10/10/23	Barker, Nicholas	37:18-21					
10/10/23	Barker, Nicholas	38:21-39:2	402, 403				
10/10/23	Barker, Nicholas	39:16-25	402, 403, LW, LC, F				
10/10/23	Barker, Nicholas	43:4-21 [withdrawn]		44:9-13	AMB; AG; BSD (OS); CLC; SPC; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	45:22-46:9	402, 403, F, SP	45:15-21	[45:15-21] AMB; AG; BSD (OS); CLC; SPC; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	46:21-47:3	402, 403, F, SP	45:15-21			
10/10/23	Barker, Nicholas	47:23-48:3		48:4-10; 48:23-24	[48:4-10] AMB; AG; BSD (OS); CLC; SPC; LFND; MIS; NREL; 403 [48:23-24] AMB; AG; BSD (OS); CLC; SPC; IMPs; INC; LFND; MIS; NR; NREL; 403	48:11-13	I
10/10/23	Barker, Nicholas	48:11-21 [withdrawn]	I	48:23-24	AMB; AG; BSD (OS); CLC; SPC; IMP; INC; LFND; MIS; NR; NREL; 403		
10/10/23	Barker, Nicholas	48:25-49:6 [withdrawn]					
10/10/23	Barker, Nicholas	49:9-15					
10/10/23	Barker, Nicholas	49:22-50:21					
10/10/23	Barker, Nicholas	51:11-52:1	A, F, AF, SP				
10/10/23	Barker, Nicholas	52:23-53:2	A, F, AF, SP				
10/10/23	Barker, Nicholas	53:13-19	A, F, AF, SP	53:20-23; 53:25-54:2			
10/10/23	Barker, Nicholas	54:4-12 [withdrawn]	A, F, AF, SP	54:13-15, 54:17-55:2	403; AG; AMB; BSD (OS); SPC; LFND; MIS; NREL	55:17-20	A, F, AF, SP
10/10/23	Barker, Nicholas	56:1-22	F, AF, SP				
10/10/23	Barker, Nicholas	57:4-12	F, AF, SP				
10/10/23	Barker, Nicholas	59:5-22					
10/10/23	Barker, Nicholas	60:23-61:11	A, F, AF, SP				
10/10/23	Barker, Nicholas	61:12-21	F, AF, SP	62:4-7; 62:10-14; 63:3-9	[62:4-7] AMB; AG; BSD (OS); SPC; LFND; MIS; NREL; 403 [62:10-14] AMB; AG; BSD (OS); SPC; LFND; MIS; NREL; 403 [63:3-9] AMB; AG; BSD (OS); SPC; LFND; MIS; NREL; 403	[62:10-14] 62:16-63:1; 63:21-64:1; 64:12-20 [62:4-7] 62:16-63:1; 63:21-64:1; 64:12-20 [63:3-9] 62:16-63:1; 63:21-64:1; 64:12-20	[62:16-63:1] A, F, AF, SP, LE; [63:21-64:1] F, AF, SP, LE; [64:12-20] V, A, SP, F, AF, LE
10/10/23	Barker, Nicholas	63:21-64:1 [withdrawn]	F, AF, SP	64:4-11	AMB; AG; BSD (OS); SPC; LFND; MIS; NREL; 403	62:16-63:1; 63:21-64:1; 64:12-20	[62:16-63:1] A, F, AF, SP, LE; [63:21-64:1] F, AF, SP, LE; [64:12-20] V, A, SP, F, AF, LE
10/10/23	Barker, Nicholas	65:2-7					
10/10/23	Barker, Nicholas	66:3-7	F, SP, V	66:8-14	[66:8-14] AMB; AG; BSD (OS); SPC; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	67:11-19 [withdrawn]					
10/10/23	Barker, Nicholas	67:24-68:6	F, SP				
10/10/23	Barker, Nicholas	68:7-23	F, AF, SP, V, LW				

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
10/10/23	Barker, Nicholas	70:10-71:25 [withdrawn]	V, LW	69:1-6, 69:9-11, 69:13-14, 69:16-18, 69:20-23, 70:2-4			
10/10/23	Barker, Nicholas	72:1-11	V, LW				
10/10/23	Barker, Nicholas	73:12-23	V, LW, F, SP	75:11-76:7	[75:11-76:7] AMB; AG; BSD (OS); CLC; SPC; IEXP; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	75:4-9	V, LW, F, SP	75:11-76:7	[75:11-76:7] AMB; AG; BSD (OS); CLC; SPC; IEXP; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	76:24-77:8	V, LW				
10/10/23	Barker, Nicholas	77:13-23					
10/10/23	Barker, Nicholas	78:8-11		91:11-15, 91:24-92:17			
10/10/23	Barker, Nicholas	80:14-81:1		86:1-3; 86:6-8; 89:12-14; 89:16-21; 90:7-14; 90:15-19; 90:21-23; 95:23-96:1, 96:3-8	[86:1-3] AMB; AG; BSD (OS); CLC; SPC; IEXP; LFND; MIS; NREL; 403 [86:6-8] AMB; AG; BSD (OS); CLC; SPC; IEXP; LFND; MIS; NREL; 403 [89:12-14] AMB; AG; BSD (OS); CLC; SPC; IEXP; LFND; MIS; NREL; 403; AA [89:16-21] AMB; AA; AG; BSD (OS); CLC; SPC; IEXP; LFND; MIS; NREL; 403 [90:7-14] AMB; AA; AG; BSD (OS); CLC; SPC; IEXP; LFND; MIS; NREL; 403 [90:15-19] AMB; AA; AG; BSD (OS); CLC; SPC; IEXP; LFND; MIS; NREL; 403 [90:21-23] AMB; AA; AG; BSD (OS); CLC; SPC; IEXP; LFND; MIS; NREL; 403	[86:1-3] 93:6-10; 94:19-95:1; 94:19-95:1 [86:6-8] 93:6-10; 94:19-95:1; 94:19-95:1 [89:12-14] 93:6-10; 94:19-95:1; 94:19-95:1 [89:16-21] 93:6-10; 94:19-95:1; 94:19-95:1 [90:21-23] 93:6-10; 94:19-95:1; 94:19-95:1 [90:15-19] 93:6-10; 94:19-95:1; 94:19-95:1 [90:7-14] 93:6-10; 94:19-95:1; 94:19-95:1	[93:6-10] F, SP, V; [94:19-95:1] F, SP, AA, LW
10/10/23	Barker, Nicholas	81:9-17					
10/10/23	Barker, Nicholas	81:25-82:4 [withdrawn]					
10/10/23	Barker, Nicholas	83:14-84:2					
10/10/23	Barker, Nicholas	85:8-12					
10/10/23	Barker, Nicholas	93:11-20 [withdrawn]	F, SP, V	92:22-25, 93:2-4, 93:22-94:2, 94:4-5, 95:23-96:1, 96:3-8	AMB; AA; AG; BSD (OS); CLC; SPC; IEXP; LFND; MIS; NREL; 403	93:6-10; 94:19-95:1; 94:19-95:1	[93:6-10] F, SP, V; [94:19-95:1] F, SP, AA, LW
10/10/23	Barker, Nicholas	97:13-22	F, SP	97:23-98:4	[97:23-98:4] AMB; AA; AG; BSD (OS); CLC; SPC; IEXP; LFND; MIS; NREL; 403	98:5-9; 98:17-22	[98:5-9] F, SP; [98:17-22] F, SP, I
10/10/23	Barker, Nicholas	98:17-21 [withdrawn]	I	98:23-23	AMB; AA; AG; BSD (OS); CLC; SPC; IEXP; LFND; MIS; NREL; 403; INC; IMP	98:17-22	[98:17-22] F, SP, I
10/10/23	Barker, Nicholas	99:3-6					
10/10/23	Barker, Nicholas	99:25-100:4					
10/10/23	Barker, Nicholas	102:25-103:7	V, LW				
10/10/23	Barker, Nicholas	104:19-105:1	V, LW, AG				
10/10/23	Barker, Nicholas	105:25-106:2					
10/10/23	Barker, Nicholas	106:18-25					
10/10/23	Barker, Nicholas	107:14-25 [withdrawn]					
10/10/23	Barker, Nicholas	108:17-109:1 [withdrawn]		109:2-3, 109:5-10	AMB; AG; BSD (OS); SPC; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	109:12-21 [withdrawn]		109:22-25	AMB; AG; BSD (OS); SPC; LFND; MIS; NREL; 403		

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
10/10/23	Barker, Nicholas	111:17-112:5		111:9-10; 111:13-15; 113:11-12; 113:15-19; 113:21-25; 114:3-5; 114:7-14; 114:16-19; 114:21-25; 115:4-8; 115:23-25; 116:4-7; 116:13-15; 116:19-24; 117:14-19; 117:21-118:1; 119:13-17; 119:25-120:9	[111:9-10] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [111:13-15] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [113:11-12] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [113:15-19] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [113:21-25] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [114:3-5] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [114:7-14] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [114:16-19] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [114:21-25] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [115:4-8] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [115:23-25] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [116:4-7] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [116:13-15] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [116:19-24] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [117:14-19] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	112:20-113:9	V, LW, LC, AG, F	111:9-10; 111:13-15; 113:11-12; 113:15-19; 113:21-25; 114:3-5; 114:7-14; 114:16-19; 114:21-25; 115:4-8; 115:23-25; 116:4-7; 116:13-15; 116:19-24; 117:14-19; 117:21-118:1; 119:13-17; 119:25-120:9	[111:9-10] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [111:13-15] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [113:11-12] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [113:15-19] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [113:21-25] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [114:3-5] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [114:7-14] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [114:16-19] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [114:21-25] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [115:4-8] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [115:23-25] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [116:4-7] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [116:13-15] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [116:19-24] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [117:14-19] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	115:10-22	V, LW, LC, AG, F	113:21-25; 114:3-5; 114:7-14; 114:16-19; 114:21-25; 115:4-8			
10/10/23	Barker, Nicholas	120:18-20		120:21-23; 121:1-4	[120:21-23] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [121:1-4] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	124:4-9 [withdrawn]					

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
10/10/23	Barker, Nicholas	125:8-14	V, LW, LC, AG, F	125:16-17; 125:20-24	[125:16-17] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [125:20-24] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	126:7-15	V	127:1-2; 127:6-8, 128:19-20, 128:22-23, 128:25-129:7	[127:1-2] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [127:6-8] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	127:10-17		127:18-19; 127:21-22; 127:24-24; 128:1-4; 128:6-18; 128:19-20; 128:22-23; 128:25-129:7	[127:18-19] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [127:21-22] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [127:24-24] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [128:1-4] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [128:6-129:7] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [128:19-20] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	130:2-23 [withdrawn]		14:13-19, 130:24-131:2, 131:3-10	AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403	131:11-132:4	
10/10/23	Barker, Nicholas	132:24-133:10 [withdrawn]		132:12-23	AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	133:11-25 [withdrawn]					
10/10/23	Barker, Nicholas	134:1-5 [withdrawn]					
10/10/23	Barker, Nicholas	135:3-18					
10/10/23	Barker, Nicholas	136:4-14 [withdrawn]	402, 403, F, SP, M, V	136:15-19, 149:15-18, 149:20, 150:6-9, 150:12-15	AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403	136:20-137:6; 137:23-138:1	[136:20-137:6] 402, 403, F, SP, M, V; [137:23-138:1] A, 402, 403, V, M
10/10/23	Barker, Nicholas	136:25-137:13 [withdrawn]	402, 403, F, SP, M, V	149:15-18, 149:20, 150:6-9, 150:12-15	AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	138:2-7	402, 403, F, SP, M, V	137:14-18; 149:15-18; 149:20-20; 150:6-9; 150:12-15	[137:14-18] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [149:9-20] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [150:6-15] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403	137:23-138:1	[137:23-138:1] A, 402, 403, V, M
10/10/23	Barker, Nicholas	138:24-139:11	402, 403, F, SP, M, V	139:12-16; 149:15-18; 149:20-20; 150:6-9; 150:12-15	[139:12-16] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [149:9-20] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [150:6-15] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	140:10-15 [withdrawn]	402, 403, F, SP, M, V	140:16-22, 145:8-12, 145:15-17, 146:4-146:8, 146:11-14	AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	141:18-142:3	402, 403, F, SP, M, V	142:4-17; 149:15-18; 149:20-20; 150:6-9; 150:12-15	[142:4-17] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [149:9-20] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [150:6-15] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	142:18-25	402, 403, F, SP, M, V	142:4-17; 149:15-18; 149:20-20; 150:6-9; 150:12-15	[142:4-17] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [149:9-20] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [150:6-15] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	148:25-149:8 [withdrawn]	402, 403, F, SP, M, V	147:25-148:5, 148:7-13, 148:14-19, 148:21-23, 149:9-14	AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	150:21-151:8 [withdrawn]					
10/10/23	Barker, Nicholas	152:10-19 [withdrawn]		153:7-13, 153:15-18, 153:20-23, 153:25-154:4	AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403; CMP		
10/10/23	Barker, Nicholas	154:23-155:1 [withdrawn]		155:2-5, 155:7-9	AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403; CMP		
10/10/23	Barker, Nicholas	155:11-156:15 [withdrawn]					



DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
10/10/23	Barker, Nicholas	156:16-157:9		157:10-11; 157:13-16; 157:18-158:11; 158:12-14; 158:16-25	[157:10-158:11] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [158:12-25] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	159:14-25 [withdrawn]		160:1-4, 160:7-8, 160:18-161:6, 161:11-16	AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL		
10/10/23	Barker, Nicholas	166:9-25 [withdrawn]	F, SP	164:19-20, 164:23-25, 165:2-9, 165:11-14, 167:3-11	MB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403	166:23-167:2	V, SP, F, LE
10/10/23	Barker, Nicholas	167:12-15					
10/10/23	Barker, Nicholas	167:16-168:22	A, F, AF, SP				
10/10/23	Barker, Nicholas	169:2-16		177:11-13	[177:11-13] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403	177:21-178:6	
10/10/23	Barker, Nicholas	169:19-170:1 [withdrawn]					
10/10/23	Barker, Nicholas	170:2-15	F, SP, M, H	173:16-20; 173:21-174:1; 174:4-5; 174:7-12; 174:18-20, 174:22-175:5	[173:16-20] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [173:21-174:1] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [174:4-5] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [174:7-12] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [174:18-20] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	170:2-25	F, SP, M, H	173:16-20; 173:21-174:1; 174:4-5; 174:7-12; 174:18-20, 174:22-175:5	[173:16-20] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [173:21-174:1] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [174:4-5] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [174:7-12] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [174:18-20] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [174:22-175:5] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	171:7-17	F, SP, M, H	173:16-20; 173:21-174:1; 174:4-5; 174:7-12; 174:18-20, 174:22-175:5	[173:16-20] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [173:21-174:1] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [174:4-5] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [174:7-12] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [174:18-20] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [174:22-175:5] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	172:9-173:5	F, SP, M, H	173:16-20; 173:21-174:1; 174:4-5; 174:7-12; 174:18-20, 174:22-175:5	[173:16-20] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [173:21-174:1] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [174:4-5] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [174:7-12] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [174:18-20] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [174:22-175:5] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	175:6-8	F, SP, M				
10/10/23	Barker, Nicholas	176:3-15	F, SP, M				
10/10/23	Barker, Nicholas	176:20-177:10 [withdrawn]	F, SP, M				
10/10/23	Barker, Nicholas	178:8-179:12					
10/10/23	Barker, Nicholas	180:15-22	F, SP, M, H	180:5-14; 181:25-182:4	[180:5-14] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [181:25-182:11] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403		

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
10/10/23	Barker, Nicholas	181:12-24	F, SP, M, H	180:5-14; 181:25-182:4	[180:5-14] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [181:25-182:11] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	182:13-183:5		181:25-182:4; 182:6-143:6-8	[181:25-182:11] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	183:19-24 [withdrawn]	F, SP, M				
10/10/23	Barker, Nicholas	184:24-185:13	F, SP, M	185:14-186:5	[185:14-186:5] AMB; AG; BSD (OS); SPC; HRS; IEXP; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	186:16-22		186:23-23; 186:25-187:4	[186:23-187:4] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	187:5-22 [withdrawn]	F, SP, V	187:23-188:5	AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403	188:6-13	
10/10/23	Barker, Nicholas	188:14-18		188:19-189:3			
10/10/23	Barker, Nicholas	189:10-20					
10/10/23	Barker, Nicholas	190:2-6		190:7-15	[190:7-15] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	190:22-191:6 [withdrawn]					
10/10/23	Barker, Nicholas	191:21-192:16	F, SP, M, H	192:17-20; 192:22-193:5; 193:7-14; 193:19-21	[192:17-193:5] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [193:7-14] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [193:19-21] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	194:11-21	F, SP, M				
10/10/23	Barker, Nicholas	194:22-195:8	F, SP, M	195:13-16; 195:18-20	[195:13-20] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	195:24-196:14	F, SP, V				
10/10/23	Barker, Nicholas	197:16-198:21					
10/10/23	Barker, Nicholas	198:22-25					
10/10/23	Barker, Nicholas	199:15-20	M, I	201:11-17	[201:11-17] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	200:19-24	M, I	201:11-17	[201:11-17] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	203:9-18	I	204:1-4, 204:16-20, 208:8-209:3			
10/10/23	Barker, Nicholas	204:5-9		208:8-209:3	[208:8-209:3] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	204:24-205:2		205:21-206:3; 207:3-5; 207:13-18; 208:8-209:3	[205:21-206:3] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [207:3-18] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [208:8-209:3] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	205:14-20		205:21-206:3; 207:3-5; 207:13-18; 208:8-209:3	[205:21-206:3] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [207:3-18] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [208:8-209:3] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	211:7-16		210:4-211:6			
10/10/23	Barker, Nicholas	212:7-19	I	240:4-244:6; 211:17-21; 211:23-212:6; 212:20-24	[210:4-211:6] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [211:17-212:6] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403 [212:20-24] AMB; AG; BSD (OS); SPC; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	212:25-213:11		213:12-24	[213:12-24] AMB; AG; BSD (OS); SPC; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	213:25-214:5		213:12-24	[213:12-24] AMB; AG; BSD (OS); SPC; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	215:22-216:22		214:15-215:21	[214:15-215:21] AMB; AG; BSD (OS); SPC; IEXP; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	218:5-19		218:20-219:3	[218:20-219:3] AMB; AG; BSD (OS); SPC; LFND; MIS; NREL; 403		
10/10/23	Barker, Nicholas	219:8-220:6		224:16-225:4	[224:16-225:4] AMB; AG; BSD (OS); SPC; LFND; MIS; NREL; 403		

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER- COUNTERS
10/10/23	Barker, Nicholas	221:19-22		221:23-222:2; 224:16-225:4; 225:13-15	[221:23-222:2] AMB; AG; BSD (OS); SPC; LFND; MIS; NREL; 403 [224:16-225:4] AMB; AG; BSD (OS); SPC; LFND; MIS; NREL; 403 [225:13-15] AMB; AG; BSD (OS); SPC; LFND; MIS; NREL; 403		
10/26/23	Budreau, Kristen	7:6-16					
10/26/23	Budreau, Kristen	7:21-25					
10/26/23	Budreau, Kristen	9:15-25	V, I				
10/26/23	Budreau, Kristen	15:17-19					
10/26/23	Budreau, Kristen	16:10-17:18					
10/26/23	Budreau, Kristen	17:19-18:18					
10/26/23	Budreau, Kristen	25:20-24					
10/26/23	Budreau, Kristen	27:17-19					
10/26/23	Budreau, Kristen	27:22-29:6					
10/26/23	Budreau, Kristen	30:1-13					
10/26/23	Budreau, Kristen	41:6-42:19					
10/26/23	Budreau, Kristen	43:4-23					
10/26/23	Budreau, Kristen	48:15-18					
10/26/23	Budreau, Kristen	49:18-50:7					
10/26/23	Budreau, Kristen	57:19-58:24					
10/26/23	Budreau, Kristen	61:11-16					
10/26/23	Budreau, Kristen	61:23-63:15					
10/26/23	Budreau, Kristen	64:8-17					
10/26/23	Budreau, Kristen	65:10-23					
10/26/23	Budreau, Kristen	66:14-20					
10/26/23	Budreau, Kristen	69:12-17					
10/26/23	Budreau, Kristen	72:13-16					
10/26/23	Budreau, Kristen	76:12-77:7					
10/26/23	Budreau, Kristen	78:11-20					
10/26/23	Budreau, Kristen	79:10-24					
10/26/23	Budreau, Kristen	80:6-12					
10/26/23	Budreau, Kristen	81:22-82:3					
10/26/23	Budreau, Kristen	84:22-86:1					
10/26/23	Budreau, Kristen	90:3-20					
10/26/23	Budreau, Kristen	90:25-91:9					
10/26/23	Budreau, Kristen	95:16-96:4	402/403				
10/26/23	Budreau, Kristen	96:25-97:4	402/403				
10/26/23	Budreau, Kristen	102:16-103:15					
10/26/23	Budreau, Kristen	107:14-23					
10/26/23	Budreau, Kristen	108:8-15					
10/26/23	Budreau, Kristen	108:23-109:19					
10/26/23	Budreau, Kristen	110:13-111:6					
10/26/23	Budreau, Kristen	114:16-115:25					
10/26/23	Budreau, Kristen	116:17-22					
10/26/23	Budreau, Kristen	117:2-20					
10/26/23	Budreau, Kristen	118:4-19					
10/26/23	Budreau, Kristen	119:14-120:10					
10/26/23	Budreau, Kristen	120:16-121:17					
10/26/23	Budreau, Kristen	123:16-125:3					
10/26/23	Budreau, Kristen	125:16-22					
10/26/23	Budreau, Kristen	146:20-147:5					
10/26/23	Budreau, Kristen	147:18-149:5					
10/26/23	Budreau, Kristen	150:7-20					
10/26/23	Budreau, Kristen	151:8-152:10	F				
10/26/23	Budreau, Kristen	155:8-25					
10/26/23	Budreau, Kristen	164:25-165:19					
08/16/22	Budreau, Kristen (CDCA)	7:13-16					
08/16/22	Budreau, Kristen (CDCA)	8:22-24					
08/16/22	Budreau, Kristen (CDCA)	16:10-16					
08/16/22	Budreau, Kristen (CDCA)	53:22-54:2					
08/16/22	Budreau, Kristen (CDCA)	76:22-77:6					
08/16/22	Budreau, Kristen (CDCA)	77:7-20					
08/16/22	Budreau, Kristen (CDCA)	79:3-9					
08/16/22	Budreau, Kristen (CDCA)	80:6-82:6					
08/16/22	Budreau, Kristen (CDCA)	86:3-12					
08/16/22	Budreau, Kristen (CDCA)	87:24-88:9					
08/16/22	Budreau, Kristen (CDCA)	90:7-93:16	F				

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
08/16/22	Budreau, Kristen (CDCA)	94:21-95:14					
08/16/22	Budreau, Kristen (CDCA)	95:23-96:11					
08/16/22	Budreau, Kristen (CDCA)	96:24-97:10					
08/16/22	Budreau, Kristen (CDCA)	97:11-21					
08/16/22	Budreau, Kristen (CDCA)	97:22-98:22					
08/16/22	Budreau, Kristen (CDCA)	98:23-99:3					
08/16/22	Budreau, Kristen (CDCA)	100:1-6					
08/16/22	Budreau, Kristen (CDCA)	104:22-105:7					
08/16/22	Budreau, Kristen (CDCA)	107:25-109:11					
08/16/22	Budreau, Kristen (CDCA)	115:16-116:13					
08/16/22	Budreau, Kristen (CDCA)	116:15-120:1					
08/16/22	Budreau, Kristen (CDCA)	121:15-22					
08/16/22	Budreau, Kristen (CDCA)	122:17-24					
08/16/22	Budreau, Kristen (CDCA)	123:8-124:4					
08/16/22	Budreau, Kristen (CDCA)	127:10-128:15					
08/16/22	Budreau, Kristen (CDCA)	130:5-19					
09/21/23	Cardinali, Steven	5:15-16					
09/21/23	Cardinali, Steven	5:22-6:2					
09/21/23	Cardinali, Steven	9:22-11:22		12:22-13:2			
09/21/23	Cardinali, Steven	13:5-15:9		16:13-14; 16:16-17; 19:1-12; 19:15-21; 20:1-7; 20:9-13; 20:16-22; 21:3-9; 27:20-22; 28:3-11	[16:13-14] AMB; NREL; 403 [16:16-17] AMB; NREL; 403 [19:1-12] CLC; SPC; IEXP; NREL; 403 [19:15-21] AMB; CLC; SPC; IEXP; NREL; 403 [20:1-7] AMB; CLC; SPC; IEXP; NREL; 403 [20:9-13] AMB; CLC; SPC; IEXP; NREL; 403; AA [20:16-22] AMB; AA; SPC; IEXP; NREL; 403; CLC [21:3-9] AMB; AA; CLC; SPC; IEXP; NREL; 403 [27:20-22] AMB; LFND; NREL; 403 [28:3-11] AMB; LFND; NREL; 403	[27:20-22] 28:12-16; 29:11-18 [28:3-11] 28:12-16; 29:11-18	
09/21/23	Cardinali, Steven	26:7-10		25:9-15; 26:4-6	[25:9-15] AMB	28:12-16; 29:11-18	
09/21/23	Cardinali, Steven	32:1-34:8					
09/21/23	Cardinali, Steven	43:14-44:6	SP				
09/21/23	Cardinali, Steven	44:20-47:1					
10/19/23	Coleman, Jon	7:13-11:20					
10/19/23	Coleman, Jon	13:19-19:10					
10/19/23	Coleman, Jon	19:19-24:1					
10/19/23	Coleman, Jon	43:2-51:11					
10/19/23	Coleman, Jon	61:16-63:12		63:13-64:3; 64:17-65:8	[63:13-64:3] LFND; NREL; OBJ; 403 [64:17-65:8] LFND; NREL; 403	[63:13-64:3] 64:4-16; 85:7-86:2 [64:17-65:8] 64:4-16; 85:7-86:2	[85:7-86:2] F; OS
09/19/23	Dalke, David	6:18-23					
09/19/23	Dalke, David	9:5-10					
09/19/23	Dalke, David	13:1-9	402, 403				
09/19/23	Dalke, David	19:12-25					
09/19/23	Dalke, David	20:5-11					
09/19/23	Dalke, David	26:6-8					
09/19/23	Dalke, David	28:4-9		129:19-24			
09/19/23	Dalke, David	88:2-13	402, 403, F, V				
09/19/23	Dalke, David	106:8-107:6		104:3-9; 105:5-15; 105:22-23; 106:1-6; 107:7-10; 107:14-16; 112:16-21; 113:21-114:3; 114:4-6; 114:11-11; 114:13-17	[105:5-15] AMB; NREL; 403 [105:22-106:6] AMB; NREL; 403 [107:7-10] AMB; LFND; NREL; 403 [107:14-16] AMB; LFND; NREL; 403 [112:19-21] AMB [114:4-6] AMB; NREL; 403; MIL [114:11-11] AMB; NREL; 403; MIL		
09/19/23	Dalke, David	107:22-108:5		104:3-9; 105:5-15; 105:22-23; 106:1-6; 107:7-10; 107:14-16; 112:16-21; 113:21-114:3; 114:4-6; 114:11-11; 114:13-17	[104:3-9] AMB; NREL; 403 [105:5-15] AMB; NREL; 403 [105:22-106:6] AMB; NREL; 403 [107:7-10] AMB; LFND; NREL; 403 [107:14-16] AMB; LFND; NREL; 403 [112:19-21] AMB [114:4-6] AMB; NREL; 403; MIL [114:11-11] AMB; NREL; 403; MIL		
			402, 403				

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
09/19/23	Dalke, David	108:23-109:12		104:3-9; 105:5-15; 105:22-23; 106:1-6; 107:7-10; 107:14-16; 112:16-21; 113:21-114:3; 114:4-6; 114:11-11; 114:13-17	[104:3-9] AMB; NREL; 403 [105:5-15] AMB; NREL; 403 [105:22-106:6] AMB; NREL; 403 [107:7-10] AMB; LFND; NREL; 403 [107:14-16] AMB; LFND; NREL; 403 [112:19-21] AMB [114:4-6] AMB; NREL; 403; MIL [114:11-11] AMB; NREL; 403; MIL		
09/19/23	Dalke, David	109:18-20	402, 403	104:3-9; 105:5-15; 105:22-23; 106:1-6; 107:7-10; 107:14-16; 112:16-21; 113:21-114:3; 114:4-6; 114:11-11; 114:13-17	[104:3-9] AMB; NREL; 403 [105:5-15] AMB; NREL; 403 [105:22-106:6] AMB; NREL; 403 [107:7-10] AMB; LFND; NREL; 403 [107:14-16] AMB; LFND; NREL; 403 [112:19-21] AMB [114:4-6] AMB; NREL; 403; MIL [114:11-11] AMB; NREL; 403; MIL		
09/19/23	Dalke, David	112:7-9	402, 403	104:3-9; 105:5-15; 105:22-23; 106:1-6; 107:7-10; 107:14-16; 112:16-21; 113:21-114:3; 114:4-6; 114:11-11; 114:13-17	[104:3-9] AMB; NREL; 403 [105:5-15] AMB; NREL; 403 [105:22-106:6] AMB; NREL; 403 [107:7-10] AMB; LFND; NREL; 403 [107:14-16] AMB; LFND; NREL; 403 [112:19-21] AMB [114:4-6] AMB; NREL; 403; MIL [114:11-11] AMB; NREL; 403; MIL		
09/19/23	Dalke, David	113:10-13	402, 403, H	104:3-9; 105:5-15; 105:22-23; 106:1-6; 107:7-10; 107:14-16; 112:16-21; 113:21-114:3; 114:4-6; 114:11-11; 114:13-17	[104:3-9] AMB; NREL; 403 [105:5-15] AMB; NREL; 403 [105:22-106:6] AMB; NREL; 403 [107:7-10] AMB; LFND; NREL; 403 [107:14-16] AMB; LFND; NREL; 403 [112:19-21] AMB [114:4-6] AMB; NREL; 403; MIL [114:11-11] AMB; NREL; 403; MIL		
09/19/23	Dalke, David	113:14-19	402, 403, H, SP	104:3-9; 105:5-15; 105:22-23; 106:1-6; 107:7-10; 107:14-16; 112:16-21; 113:21-114:3; 114:4-6; 114:11-11; 114:13-17	[104:3-9] AMB; NREL; 403 [105:5-15] AMB; NREL; 403 [105:22-106:6] AMB; NREL; 403 [107:7-10] AMB; LFND; NREL; 403 [107:14-16] AMB; LFND; NREL; 403 [112:19-21] AMB [114:4-6] AMB; NREL; 403; MIL [114:11-11] AMB; NREL; 403; MIL		
09/19/23	Dalke, David	114:18-115:18	402, 403, AF, F	104:3-9; 105:5-15; 105:22-23; 106:1-6; 107:7-10; 107:14-16; 112:16-21; 113:21-114:3; 114:4-6; 114:11-11; 114:13-17	[104:3-9] AMB; NREL; 403 [105:5-15] AMB; NREL; 403 [105:22-106:6] AMB; NREL; 403 [107:7-10] AMB; LFND; NREL; 403 [107:14-16] AMB; LFND; NREL; 403 [112:19-21] AMB [114:4-6] AMB; NREL; 403; MIL [114:11-11] AMB; NREL; 403; MIL		
09/19/23	Dalke, David	117:6-10	402, 403	117:11-13			
09/19/23	Dalke, David	119:23-120:22	402, 403, V	120:23-121:24	[120:23-121:24] AMB; NR; NREL; 403		
09/19/23	Dalke, David	123:2-4		123:19-21; 123:23-124:3			
09/19/23	Dalke, David	123:14-18		123:19-21; 123:23-124:3			
09/19/23	Dalke, David	124:4-125:25	402, 403, F, SP, V	123:19-21; 123:23-124:3; 126:8-8; 126:10-11; 126:13-17; 126:18-19; 126:22-127:7; 127:10-10; 127:12-15			
09/19/23	Dalke, David	127:16-128:25	402, 403, F, SP, V	123:19-21; 123:23-124:3; 126:8-8; 126:10-11; 126:13-17; 126:18-19; 126:22-127:7; 127:10-10; 127:12-15; 129:19-24			
06/28/22	Dalke, David (CDCA)	10:22-24					
06/28/22	Dalke, David (CDCA)	11:16-22					
06/28/22	Dalke, David (CDCA)	26:21-27:20	402, 403	28:7-20	[28:7-20] AMB; INC		
06/28/22	Dalke, David (CDCA)	30:3-6					
06/28/22	Dalke, David (CDCA)	98:14-24					
11/17/23	Da Solter, Claudio	6:6-13		61:15-62:7			
11/17/23	Da Solter, Claudio	12:14-16					

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
11/17/23	Da Solter, Claudio	14:15-21		14:8-9; 14:13-13; 49:10-12; 56:1-2; 56:5-5; 61:15-62:7	[14:8-13] AMB; AG; SPC; LFND; MIS; NREL; 403 [49:10-12] AMB; AG; SPC; LFND; MIS; NREL; 403 [56:1-2] AMB; AG; SPC; LFND; MIS; NREL; 403 [56:5-5] AMB; AG; SPC; LFND; MIS; NREL; 403		
11/17/23	Da Solter, Claudio	15:5-7		37:21-25; 49:10-12; 56:1-2; 56:5-5	[56:1-2] AMB; AG; SPC; LFND; MIS; NREL; 403 [56:5-5] AMB; AG; SPC; LFND; MIS; NREL; 403		
11/17/23	Da Solter, Claudio	17:16-25		18:12-15	[18:12-15] AMB; AG; SPC; LFND; MIS; NREL; 403		
11/17/23	Da Solter, Claudio	18:19-19:4		19:6-9; 19:11-14	[19:6-9] AMB; AG; SPC; LFND; MIS; NREL; 403 [19:11-14] AMB; AG; SPC; LFND; MIS; NREL; 403		
11/17/23	Da Solter, Claudio	24:3-25:16		26:7-8; 26:10-16; 26:18-18	[26:7-8] AMB; AG; SPC; LFND; MIS; NREL; 403 [26:10-16] AMB; AG; SPC; LFND; MIS; NREL; 403 [26:18-18] AMB; AG; SPC; LFND; MIS; NREL; 403		
11/17/23	Da Solter, Claudio	27:4-25	F, V				
11/17/23	Da Solter, Claudio	28:22-30:25	402, 403, A, F, H, SP	28:19-21	[28:19-21] AMB; AG; SPC; LFND; MIS; NREL; 403		
11/17/23	Da Solter, Claudio	31:8-32:12	402, 403, F, H, SP	32:14-15; 32:17-17; 34:5-7; 34:10-10; 37:17-19	[32:14-17] AMB; AG; SPC; LFND; MIS; NREL; 403 [34:5-10] AMB; AG; SPC; LFND; MIS; NREL; 403 [37:11-19] AMB; AG; SPC; LFND; MIS; NREL; 403	[32:17-17] 33:1-3 [32:14-15] 33:1-3	
11/17/23	Da Solter, Claudio	35:10-20	F				F
11/17/23	Da Solter, Claudio	36:5-37:9		37:11-13; 37:17-19, 37:21-25	[37:11-19] AMB; AG; SPC; LFND; MIS; NREL; 403 [37:21-25] AMB; AG; SPC; LFND; MIS; NREL; 403		
11/17/23	Da Solter, Claudio	38:3-42:1	402, 403, AA, AF, F, H, V				
11/17/23	Da Solter, Claudio	42:10-17		42:18-19; 42:21-21	[42:18-21] AMB; AG; SPC; LFND; MIS; NREL; 403		
11/17/23	Da Solter, Claudio	44:19-45:2					
11/17/23	Da Solter, Claudio	45:7-23					
11/17/23	Da Solter, Claudio	46:12-47:1					
11/17/23	Da Solter, Claudio	48:9-12		61:15-62:7			
09/19/23	De Jong, Erik G.	6:20-21					
09/19/23	De Jong, Erik G.	7:2-4					
09/19/23	De Jong, Erik G.	9:6-13:1		13:2-16; 23:1-2; 23:4-6; 60:19-61:2; 61:5-8	[23:1-2] AMB; NREL; 403 [23:4-6] AMB; NREL; 403 [60:19-61:2] AA; SPC; CPD; NREL; 403 [61:5-8] AA; SPC; CPD; NREL; 403	[23:4-6] 22:15-22 [23:1-2] 22:15-22	V, 402, 403, AS, OS
09/19/23	De Jong, Erik G.	14:9-18:3	F; SP	18:5-6; 18:8-19:1	[18:5-6] AMB; NREL; 403 [18:8-19:1] AMB; NREL; 403		
09/19/23	De Jong, Erik G.	23:7-24:14		24:15-25:3	[24:15-25:3] CLC; SPC; IEXP; NREL; 403		
09/19/23	De Jong, Erik G.	25:4-27:22		33:4-18; 34:6-35:1; 105:22-106:11	[33:4-18] AMB; MIS; NREL; 403; IMPs [34:6-35:1] AMB; MIS; NREL; 403; IMPs [105:22-106:11] AMB; CLC; SPC; IEXP; NREL; 403	22:15-22	
09/19/23	De Jong, Erik G.	40:13-41:8	402; 403; F; LC; EX				
09/19/23	De Jong, Erik G.	42:9-16	402				
09/19/23	De Jong, Erik G.	50:20-51:6					
09/19/23	De Jong, Erik G.	51:22-54:9	F; SP				

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
09/19/23	De Jong, Erik G.	98:5-103:3		33:4-18; 34:6-35:1; 43:1-7; 45:12-15; 45:18-46:2; 46:8-10; 46:12-47:22; 49:1-5; 49:13-50:9; 103:18-20; 104:1-6; 104:8-8; 104:18-105:4; 105:7-14; 105:22-106:11; 106:14-22; 107:3-11	[33:4-18] AMB; MIS; NREL; 403; IMPs [34:6-35:1] AMB; MIS; NREL; 403; IMPs [43:1-7] NREL; 403 [45:12-15] SPC; LFND; NREL; 403 [45:18-46:2] SPC; LFND; NREL; 403 [46:8-10] SPC; LFND; NREL; 403; IEXP; CLC [46:12-47:22] CLC; SPC; IEXP; LFND; NREL; 403 [49:1-5] CLC; SPC; IEXP; LFND; NREL; 403 [49:13-50:9] CLC; SPC; IEXP; LFND; NREL; 403 [103:18-20] AMB; CLC; SPC; IEXP; NREL; 403 [104:1-6] AMB; CLC; SPC; IEXP; NREL; 403 [104:8-8] AMB; CLC; SPC; IEXP; NREL; 403 [104:18-105:4] AMB; CLC; SPC; IEXP; NREL; 403 [105:7-14] AMB; CLC; SPC; IEXP; NREL; 403 [105:22-106:11] AMB; CLC; SPC; IEXP; NREL; 403 [106:14-22] AMB; CLC; SPC; IEXP; NREL; 403; MIS [107:3-11] AMB; CLC; SPC; IEXP; MIS; NREL; 403	[34:6-35:1] 22:15-22 [45:12-15] 46:4-7; 48:5-17 [45:18-46:2] 46:4-7; 48:5-17 [46:12-47:22] 48:5-17 [46:8-10] 48:5-17 [49:1-5] 48:5-17 [49:13-50:9] 48:5-17	
10/13/23	DeJong, Chad	7:15-20	402; 403; F; LC; EX				
10/13/23	DeJong, Chad	10:20-23					
10/13/23	DeJong, Chad	11:22-12:2	402	13:4-16	[13:4-16] AMB; AG; CLC; LFND; MIS; NREL; 403		
10/13/23	DeJong, Chad	14:12-14	402	13:17-21; 15:8-13; 15:17-19	[13:17-21] AMB; AG; CLC; LFND; MIS; NREL; 403 [15:8-13] AMB; AG; CLC; LFND; MIS; NREL; 403 [15:17-19] AMB; AG; CLC; LFND; MIS; NREL; 403	[13:17-21] 13:22-14:11 [15:8-13] 20:8-13; 21:4-8 [15:17-19] 20:8-13; 21:4-8	[13:22-14:11] V, 402, 403, AS; [20:8-13] F, SP, LW; [21:4-8] F, SP, LW
10/13/23	DeJong, Chad	18:3-5	V	23:19-25; 51:4-8; 51:18-52:22	[23:19-25] AMB; AG; CLC; LFND; MIS; NREL; 403		
10/13/23	DeJong, Chad	18:11-14	V	18:8-10			
10/13/23	DeJong, Chad	19:12-14	V	18:8-10			
10/13/23	DeJong, Chad	19:15-19	402, V				
10/13/23	DeJong, Chad	19:20-20:7	402	20:5-7			
10/13/23	DeJong, Chad	21:24-22:11		23:19-25; 51:4-8; 51:18-52:22	[23:19-25] AMB; AG; CLC; LFND; MIS; NREL; 403 [51:4-8] AMB; AG; CLC; SPC; CPD; LFND; MIS; NREL; 403 [51:18-52:22] AMB; AG; CLC; SPC; CPD; LFND; MIS; NREL; 403		
10/13/23	DeJong, Chad	24:6-26:4	V, SP, 402, 403	23:19-25; 51:4-8; 51:18-52:22	[23:19-25] AMB; AG; CLC; LFND; MIS; NREL; 403 [51:4-8] AMB; AG; CLC; SPC; CPD; LFND; MIS; NREL; 403 [51:18-52:22] AMB; AG; CLC; SPC; CPD; LFND; MIS; NREL; 403		
10/13/23	DeJong, Chad	26:7-28:5	V, M, 402, 403	23:19-25; 51:4-8; 51:18-52:22	[23:19-25] AMB; AG; CLC; LFND; MIS; NREL; 403 [51:4-8] AMB; AG; CLC; SPC; CPD; LFND; MIS; NREL; 403 [51:18-52:22] AMB; AG; CLC; SPC; CPD; LFND; MIS; NREL; 403		

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
10/13/23	DeJong, Chad	32:9-17	V, 402, 403	23:19-25; 51:4-8; 51:18-52:22	[23:19-25] AMB; AG; CLC; LFND; MIS; NREL; 403 [51:4-8] AMB; AG; CLC; SPC; CPD; LFND; MIS; NREL; 403 [51:18-52:22] AMB; AG; CLC; SPC; CPD; LFND; MIS; NREL; 403		
10/13/23	DeJong, Chad	36:1-9	V, 402				
10/13/23	DeJong, Chad	37:17-38:18	F, SP	18:8-10	[18:8-10] AMB; AG; CLC; LFND; MIS; NREL; 403		
10/13/23	DeJong, Chad	42:11-18	402, 403				
10/13/23	DeJong, Chad	48:25-51:2	V, SP	23:19-25; 51:4-8; 51:18-52:22	[23:19-25] AMB; AG; CLC; LFND; MIS; NREL; 403 [51:4-8] AMB; AG; CLC; SPC; CPD; LFND; MIS; NREL; 403 [51:18-52:22] AMB; AG; CLC; SPC; CPD; LFND; MIS; NREL; 403		
10/13/23	DeJong, Chad	56:18-20	SP, F	18:8-10; 23:19-25; 51:4-8; 51:18-52:22; 57:2-9	[23:19-25] AMB; AG; CLC; LFND; MIS; NREL; 403 [51:4-8] AMB; AG; CLC; SPC; CPD; LFND; MIS; NREL; 403 [51:18-52:22] AMB; AG; CLC; SPC; CPD; LFND; MIS; NREL; 403 [57:2-9] AMB; AG; CLC; SPC; CPD; LFND; MIS; NREL; 403		
10/13/23	DeJong, Chad	57:11-15	V	18:8-10; 23:19-25; 51:4-8; 51:18-52:22; 57:2-9	[23:19-25] AMB; AG; CLC; LFND; MIS; NREL; 403 [51:4-8] AMB; AG; CLC; SPC; CPD; LFND; MIS; NREL; 403 [51:18-52:22] AMB; AG; CLC; SPC; CPD; LFND; MIS; NREL; 403 [57:2-9] AMB; AG; CLC; SPC; CPD; LFND; MIS; NREL; 403		
10/13/23	DeJong, Chad	57:23-58:1	V	23:19-25; 51:4-8; 51:18-52:22; 57:2-9	[23:19-25] AMB; AG; CLC; LFND; MIS; NREL; 403 [51:4-8] AMB; AG; CLC; SPC; CPD; LFND; MIS; NREL; 403 [51:18-52:22] AMB; AG; CLC; SPC; CPD; LFND; MIS; NREL; 403 [57:2-9] AMB; AG; CLC; SPC; CPD; LFND; MIS; NREL; 403		
10/13/23	DeJong, Chad	58:6-17	M, V	23:19-25; 51:4-8; 51:18-52:22; 57:2-9	[23:19-25] AMB; AG; CLC; LFND; MIS; NREL; 403 [51:4-8] AMB; AG; CLC; SPC; CPD; LFND; MIS; NREL; 403 [51:18-52:22] AMB; AG; CLC; SPC; CPD; LFND; MIS; NREL; 403 [57:2-9] AMB; AG; CLC; SPC; CPD; LFND; MIS; NREL; 403		
10/13/23	DeJong, Chad	59:16-22	M, V	59:24-60:5	[59:24-60:5] AMB; AG; SPC; LFND; MIS; NREL; 403	60:8-10; 60:15-21	[60:8-10] V; [60:15-21] V, F
10/13/23	DeJong, Chad	60:11-14	V				
10/13/23	DeJong, Chad	66:3-11	F, SP				
10/13/23	DeJong, Chad	79:21-80:3	F, SP				
10/13/23	DeJong, Chad	80:13-17					
10/13/23	DeJong, Chad	82:7-18	402, 403				
10/13/23	DeJong, Chad	83:1-13	402, 403	91:19-92:5; 92:13-25; 96:2-17	[91:19-92:5] AMB; AG; SPC; LFND; MIS; NREL; 403 [92:13-25] AMB; AG; SPC; LFND; MIS; NREL; 403 [96:2-17] AMB; AG; SPC; LFND; MIS; NREL; 403	98:16-21	402, 403, V
10/13/23	DeJong, Chad	84:25-85:5	402, 403, SP	91:19-92:5; 92:13-25; 96:2-17	[91:19-92:5] AMB; AG; SPC; LFND; MIS; NREL; 403 [92:13-25] AMB; AG; SPC; LFND; MIS; NREL; 403 [96:2-17] AMB; AG; SPC; LFND; MIS; NREL; 403	98:16-21	402, 403, V
10/13/23	DeJong, Chad	85:15-23	402, 403, SP				



DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
10/13/23	DeJong, Chad	86:8-88:5	402, 403 F				
10/13/23	DeJong, Chad	88:22-89:21	F, 402, 403, SP, M	88:13-21	[88:13-21] AMB; AG; SPC; LFND; MIS; NREL; 403		
10/13/23	DeJong, Chad	90:6-20		91:19-92:5; 92:13-25; 96:2-17; 115:20-23	[91:19-92:5] AMB; AG; SPC; LFND; MIS; NREL; 403 [92:13-25] AMB; AG; SPC; LFND; MIS; NREL; 403 [96:2-17] AMB; AG; SPC; LFND; MIS; NREL; 403 [115:20-23] AMB; AG; SPC; LFND; MIS; NREL; 403	98:16-21	
			402, 403, F, SP, M, V				402, 403, V
10/13/23	DeJong, Chad	93:14-94:11		91:19-92:5; 92:13-25; 96:2-17; 115:20-23	[91:19-92:5] AMB; AG; SPC; LFND; MIS; NREL; 403 [92:13-25] AMB; AG; SPC; LFND; MIS; NREL; 403 [96:2-17] AMB; AG; SPC; LFND; MIS; NREL; 403 [115:20-23] AMB; AG; SPC; LFND; MIS; NREL; 403	98:16-21	
			402, 403, V				402, 403, V
10/13/23	DeJong, Chad	94:24-95:18		91:19-92:5; 92:13-25; 96:2-17; 115:20-23	[91:19-92:5] AMB; AG; SPC; LFND; MIS; NREL; 403 [92:13-25] AMB; AG; SPC; LFND; MIS; NREL; 403 [96:2-17] AMB; AG; SPC; LFND; MIS; NREL; 403 [115:20-23] AMB; AG; SPC; LFND; MIS; NREL; 403	98:16-21	
			402, 403, V				402, 403, V
10/13/23	DeJong, Chad	99:15-21	402, 403, V				
10/13/23	DeJong, Chad	99:23-101:11	402, 403, V				
10/13/23	DeJong, Chad	103:14-25	402, 403, V				
10/13/23	DeJong, Chad	104:19-21					
10/13/23	DeJong, Chad	104:25-105:3					
10/13/23	DeJong, Chad	105:8-106:7	402, 403, F, SP	23:19-25; 51:4-8	[23:19-25] AMB; AG; CLC; LFND; MIS; NREL; 403 [51:4-8] AMB; AG; CLC; SPC; CPD; LFND; MIS; NREL; 403		
10/13/23	DeJong, Chad	108:17-25	402, 403, F, SP				
10/13/23	DeJong, Chad	109:3-110:7	402				
10/13/23	DeJong, Chad	110:18-112:14	402, 403	112:15-113:9	[112:15-113:9] AMB; AG; SPC; LFND; MIS; NREL; 403		
10/13/23	DeJong, Chad	113:18-114:19	402, 403				
10/13/23	DeJong, Chad	118:9-15		91:19-92:5; 92:13-25; 96:2-17; 115:20-23; 119:15-120:6	[91:19-92:5] AMB; AG; SPC; LFND; MIS; NREL; 403 [92:13-25] AMB; AG; SPC; LFND; MIS; NREL; 403 [96:2-17] AMB; AG; SPC; LFND; MIS; NREL; 403 [115:20-23] AMB; AG; SPC; LFND; MIS; NREL; 403 [119:15-120:6] AMB; AG; SPC; LFND; MIS; NREL; 403	[96:2-17] 98:16-21 [119:15-120:6] 120:21-121:11	
			402, 403				[98:16-21] 402, 403, V; [120:21-121:11] 402, 403, V
10/13/23	DeJong, Chad	118:21-25		91:19-92:5; 92:13-25; 96:2-17; 115:20-23; 119:15-120:6	[91:19-92:5] AMB; AG; SPC; LFND; MIS; NREL; 403 [92:13-25] AMB; AG; SPC; LFND; MIS; NREL; 403 [96:2-17] AMB; AG; SPC; LFND; MIS; NREL; 403 [115:20-23] AMB; AG; SPC; LFND; MIS; NREL; 403 [119:15-120:6] AMB; AG; SPC; LFND; MIS; NREL; 403	[96:2-17] 98:16-21 [119:15-120:6] 120:21-121:11	
			402, 403				[98:16-21] 402, 403, V; [120:21-121:11] 402, 403, V

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
10/13/23	DeJong, Chad	119:1-4		91:19-92:5; 92:13-25; 96:2-17; 115:20-23; 119:15-120:6	[91:19-92:5] AMB; AG; SPC; LFND; MIS; NREL; 403 [92:13-25] AMB; AG; SPC; LFND; MIS; NREL; 403 [96:2-17] AMB; AG; SPC; LFND; MIS; NREL; 403 [115:20-23] AMB; AG; SPC; LFND; MIS; NREL; 403 [119:15-120:6] AMB; AG; SPC; LFND; MIS; NREL; 403	[96:2-17] 98:16-21 [119:15-120:6] 120:21-121:11	[98:16-21] 402, 403, V; [120:21-121:11] 402, 403, V
10/13/23	DeJong, Chad	121:12-14		402, 403			
10/13/23	DeJong, Chad	123:8-124:5		402, 403, SP			
10/13/23	DeJong, Chad	125:4-16		23:19-25; 51:4-8; 91:19-92:5; 92:13-25; 96:2-17; 115:20-23; 119:15-120:6	[23:19-25] AMB; AG; CLC; LFND; MIS; NREL; 403 [91:19-92:5] AMB; AG; SPC; LFND; MIS; NREL; 403 [92:13-25] AMB; AG; SPC; LFND; MIS; NREL; 403 [96:2-17] AMB; AG; SPC; LFND; MIS; NREL; 403 [115:20-23] AMB; AG; SPC; LFND; MIS; NREL; 403 [119:15-120:6] AMB; AG; SPC; LFND; MIS; NREL; 403	[96:2-17] 98:16-21 [119:15-120:6] 120:21-121:11	[98:16-21] 402, 403, V; [120:21-121:11] 402, 403, V
10/13/23	DeJong, Chad	126:6-23		402, 403, SP			
10/13/23	DeJong, Chad	140:7-20		402, 403			
10/13/23	DeJong, Chad	141:9-142:10		402, SP			
10/13/23	DeJong, Chad	142:20-144:10		88:13-21	[88:13-21] AMB; AG; SPC; LFND; MIS; NREL; 403		
11/14/23	Durkin, Tracy-Gene	9:21-10:6		402			
11/14/23	Durkin, Tracy-Gene	12:19-13:17		402, 403, SP			
11/14/23	Durkin, Tracy-Gene	15:13-16:1					
11/14/23	Durkin, Tracy-Gene	16:22-18:6					
11/14/23	Durkin, Tracy-Gene	20:1-5					
11/14/23	Durkin, Tracy-Gene	20:11-19					
11/14/23	Durkin, Tracy-Gene	30:16-31:4					
11/14/23	Durkin, Tracy-Gene	31:5-18		32:8-12; 40:3-7	[32:8-12] AMB; AG; PRV; BSD (OS); SPC; LFND; MIS; NREL; 403[40:3-7] AMB; AA; AG; PRV; BSD (OS); CLC; SPC; LFND; LDG; MIS; NREL; 403; BSD (OS)	38:3-39:15; 49:5-15	402, 403, AS, OS, I, V
11/14/23	Durkin, Tracy-Gene	34:9-14		40:3-7	[40:3-7] AMB; AA; AG; PRV; BSD (OS); CLC; SPC; LFND; LDG; MIS; NREL; 403; BSD (OS)	38:3-39:15; 49:5-15	402, 403, AS, OS, I, V
11/14/23	Durkin, Tracy-Gene	35:1-1		40:3-7	[40:3-7] AMB; AA; AG; PRV; BSD (OS); CLC; SPC; LFND; LDG; MIS; NREL; 403; BSD (OS)	38:3-39:15; 49:5-15	402, 403, AS, OS, I, V
11/14/23	Durkin, Tracy-Gene	35:19-36:2		40:3-7	[40:3-7] AMB; AA; AG; PRV; BSD (OS); CLC; SPC; LFND; LDG; MIS; NREL; 403; BSD (OS)	38:3-39:15; 49:5-15	402, 403, AS, OS, I, V
11/14/23	Durkin, Tracy-Gene	36:8-9		40:3-7	[40:3-7] AMB; AA; AG; PRV; BSD (OS); CLC; SPC; LFND; LDG; MIS; NREL; 403; BSD (OS)	38:3-39:15; 49:5-15	402, 403, AS, OS, I, V
11/14/23	Durkin, Tracy-Gene	45:22-46:2					
11/14/23	Durkin, Tracy-Gene	49:5-21		40:3-7	[40:3-7] AMB; AA; AG; PRV; BSD (OS); CLC; SPC; LFND; LDG; MIS; NREL; 403; BSD (OS)	38:3-39:15; 49:5-15	402, 403, AS, OS, I, V
11/14/23	Durkin, Tracy-Gene	50:7-7		40:3-7	[40:3-7] AMB; AA; AG; PRV; BSD (OS); CLC; SPC; LFND; LDG; MIS; NREL; 403; BSD (OS)	38:3-39:15; 49:5-15	402, 403, AS, OS, I, V
11/14/23	Durkin, Tracy-Gene	57:13-13					
11/14/23	Durkin, Tracy-Gene	57:14-20					
11/14/23	Durkin, Tracy-Gene	66:6-20		90:14-17; 90:21-21	[90:14-17] AMB; AA; AG; PRV; BSD (OS); CLC; CPD; LFND; LDG; MIS; NREL; BSD (OS); 403	[90:21-21] 90:22-91:5; 91:15-19 [90:14-17] 90:22-91:5; 91:15-19	[90:22-91:5] AS
11/14/23	Durkin, Tracy-Gene	67:8-14		90:14-17; 90:21-21	[90:14-17] AMB; AA; AG; PRV; BSD (OS); CLC; CPD; LFND; LDG; MIS; NREL; BSD (OS); 403	[90:21-21] 90:22-91:5; 91:15-19 [90:14-17] 90:22-91:5; 91:15-19	[90:22-91:5] AS

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
11/14/23	Durkin, Tracy-Gene	69:13-18		83:7-10; 83:13-16; 90:21-21	[90:14-17] AMB; AA; AG; PRV; BSD (OS); CLC; CPD; LFND; LDG; MIS; NREL; BSD (OS); 403	[83:7-10] 84:9-15 [83:13-16] 84:9-15 [90:21-21] 90:22-91:5; 91:15-19	[84:9-15] I [90:22-91:5] AS
11/14/23	Durkin, Tracy-Gene	70:1-11		70:22-71:2; 83:13-16; 90:14-17; 90:21-21	[70:22-71:2] AMB; AA; AG; PRV; SPC; LFND; LDG; MIS; NREL; BSD (OS); 403 [90:14-17] AMB; AA; AG; PRV; BSD (OS); CLC; CPD; LFND; LDG; MIS; NREL; BSD (OS); 403	[83:13-16] 84:9-15 [90:21-21] 90:22-91:5; 91:15-19 [90:14-17] 90:22-91:5; 91:15-19	[84:9-15] I [90:22-91:5] AS
11/14/23	Durkin, Tracy-Gene	71:3-5		90:21-21	[90:14-17] AMB; AA; AG; PRV; BSD (OS); CLC; CPD; LFND; LDG; MIS; NREL; BSD (OS); 403	90:22-91:5; 91:15-19	[90:22-91:5] AS
11/14/23	Durkin, Tracy-Gene	72:11-75:6		75:7-10; 83:7-10; 83:13-16; 90:14-17; 90:21-21	[75:7-10] AMB; AA; AG; PRV; SPC; LFND; LDG; MIS; NREL; BSD (OS); 403 [90:14-17] AMB; AA; AG; PRV; BSD (OS); CLC; CPD; LFND; LDG; MIS; NREL; BSD (OS); 403	[83:7-10] 84:9-15 [83:13-16] 84:9-15 [90:21-21] 90:22-91:5; 91:15-19 [90:14-17] 90:22-91:5; 91:15-19	[84:9-15] I [90:22-91:5] AS
11/14/23	Durkin, Tracy-Gene	79:6-81:2		83:7-10; 83:13-16; 90:14-17; 90:21-21	[90:14-17] AMB; AA; AG; PRV; BSD (OS); CLC; CPD; LFND; LDG; MIS; NREL; BSD (OS); 403	[83:7-10] 84:9-15 [83:13-16] 84:9-15 [90:21-21] 90:22-91:5; 91:15-19 [90:14-17] 90:22-91:5; 91:15-19	[84:9-15] I [90:22-91:5] AS
11/14/23	Durkin, Tracy-Gene	84:9-15	I	83:7-10; 83:13-16; 84:7-8; 84:19-21; 85:1-2; 85:6-10; 85:14-18; 86:2-5; 86:7-9; 86:11-87:3; 90:14-17; 90:21-21	[84:7-8] AMB; AG; PRV; IMPs; MIS; NE; NREL; OBJ; BSD (OS); 403 [84:19-85:10] AMB; AA; AG; PRV; IMPs; LFND; LDG; MIS; NREL; BSD (OS); 403 [85:14-87:3] AMB; AA; AG; PRV; IMPs; LFND; LDG; MIS; NREL; BSD (OS); 403 [90:14-17] AMB; AA; AG; PRV; BSD (OS); CLC; CPD; LFND; LDG; MIS; NREL; BSD (OS); 403	[83:7-10] 84:9-15 [83:13-16] 84:9-15 [90:21-21] 90:22-91:5; 91:15-19 [90:14-17] 90:22-91:5; 91:15-19	[84:9-15] I [90:22-91:5] AS
11/14/23	Durkin, Tracy-Gene	89:20-90:13		83:7-10; 83:13-16; 90:14-17; 90:21-21	[90:14-17] AMB; AA; AG; PRV; BSD (OS); CLC; CPD; LFND; LDG; MIS; NREL; BSD (OS); 403	[83:7-10] 84:9-15 [83:13-16] 84:9-15 [90:21-21] 90:22-91:5; 91:15-19 [90:14-17] 90:22-91:5; 91:15-19	[84:9-15] I [90:22-91:5] AS
11/09/23	Hankey, Evans	8:19-10:22	I				

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
11/09/23	Hankey, Evans	16:12-17:7		54:8-13; 54:19-19; 55:2-8; 55:11-11; 57:21-58:5; 58:10-11; 58:13-13; 62:15-20; 63:4-6; 64:6-13; 64:21-65:2; 68:10-15	[54:8-13] AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IEXP; LFND; LDG; MIS; NREL; 403; MM; MIL [54:19-19] AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IEXP; LFND; LDG; MIS; NREL; 403; MM; MIL [55:2-11] AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IEXP; LFND; LDG; MIS; NREL; 403; MM; MIL [57:21-58:5] HYP; AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IEXP; LFND; LDG; MIS; NREL; 403; MM; MIL [58:10-13] AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IEXP; HYP; LFND; LDG; MIS; NREL; 403; MM; MIL [62:15-63:6] AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IEXP; HYP; LFND; LDG; MIS; NREL; 403; MM; MIL [64:6-65:2] AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IMPs; IEXP; HYP; INC; LFND; LDG; MIS; NR; NREL; OBJ; 403; MM; MIL [68:10-15] AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IMPs; IEXP; HYP; INC; LFND; LDG; MIS; NR; NREL; OBJ; 403; MM; MIL	[54:19-19] 54:21-55:1 [54:8-13] 54:21-55:1 [64:6-13] 67:2-68:7 [64:21-65:2] 67:2-68:7	[67:2-68:7] 402,403, V, I, EX, LW
11/09/23	Hankey, Evans	19:11-20:5		20:6-8	[20:6-8] AMB; AG; SPC; MIS; NREL; 403; ARG		
11/09/23	Hankey, Evans	19:11-20:5					
11/09/23	Hankey, Evans	20:9-20		20:21-21:20			
11/09/23	Hankey, Evans	21:21-22:17		20:24-24:20	[20:21-21:20] AMB; ARG; AG; SPC; MIS; NREL; 403		
11/09/23	Hankey, Evans	23:5-14		23:15-24:1; 24:15-22	[23:15-24:1] AMB; ARG; AG; SPC; MIS; NREL; 403 [24:15-22] AMB; ARG; AG; CLC; SPC; MIS; NREL; 403; MIL		
11/09/23	Hankey, Evans	24:5-14		24:15-22			
11/09/23	Hankey, Evans	25:15-27:3		27:4-13; 100:18-101:1; 120:6-10; 121:17-122:13	[27:4-13] AMB; ARG; AG; CLC; SPC; MIS; NREL; 403; AA; LFND [100:18-101:1] AMB; AG; SPC; LFND; LDG; MIS; NREL; 403 [120:6-10] AMB; AG; SPC; LFND; LDG; MIS; NREL; 403 [121:17-122:13] AMB; AG; SPC; CPD; LFND; LDG; MIS; NREL; 403		
11/09/23	Hankey, Evans	28:2-13		28:14-19; 100:18-101:1; 120:6-10; 121:17-122:13	[28:14-19] AMB; AA; AG; CLC; SPC; MIS; NREL; 403; ARG; LFND [100:18-101:1] AMB; AG; SPC; LFND; LDG; MIS; NREL; 403 [120:6-10] AMB; AG; SPC; LFND; LDG; MIS; NREL; 403 [121:17-122:13] AMB; AG; SPC; CPD; LFND; LDG; MIS; NREL; 403	29:9-17	
11/09/23	Hankey, Evans	28:21-29:7		29:18-30:9; 100:18-101:1; 120:6-10; 121:17-122:13	[29:18-30:9] AMB; AA; AG; SPC; MIS; NREL; 403; LFND [100:18-101:1] AMB; AG; SPC; LFND; LDG; MIS; NREL; 403 [120:6-10] AMB; AG; SPC; LFND; LDG; MIS; NREL; 403 [121:17-122:13] AMB; AG; SPC; CPD; LFND; LDG; MIS; NREL; 403		
11/09/23	Hankey, Evans	31:3-17					
11/09/23	Hankey, Evans	35:3-20					

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
11/09/23	Hankey, Evans	36:13-37:20		37:21-38:4; 39:11-21; 41:8-15; 41:16-42:1; 54:8-13; 54:19-19; 55:2-8; 55:11-11; 57:21-58:5; 58:10-11; 58:13-13; 62:15-20; 63:4-6; 64:6-13; 64:21-65:2; 68:10-15	[37:21-38:4] AMB; ARG; AA; AG; CLC; SPC; LDG; MIS; NREL; 403; MIL; LFND [39:11-21] AMB; AG; CLC; SPC; MIS; NREL; 403; MIL; LFND [41:8-15] AMB; AG; CLC; SPC; MIS; NREL; 403; MIL; MM; LFND [41:16-42:1] AMB; AG; CLC; SPC; MIS; NREL; 403; MM; MIL; LFND [54:8-13] AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IEXP; LFND; LDG; MIS; NREL; 403; MM; MIL [54:19-19] AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IEXP; LFND; LDG; MIS; NREL; 403; MM; MIL [55:2-11] AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IEXP; LFND; LDG; MIS; NREL; 403; MM; MIL [57:21-58:5] HYP; AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IEXP; LFND; LDG; MIS; NREL; 403; MM; MIL [58:10-13] AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IEXP; HYP; LFND; LDG; MIS; NREL; 403; MM; MIL [62:15-63:6] AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IEXP; HYP; LFND; LDG; MIS; NREL; 403; MM; MIL [64:6-65:2] AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IMPs; IEXP; HYP; INC; LFND; LDG; MIS; NR; NREL; OBJ; 403; MM; MIL	[54:19-19] 54:21-55:1 [54:8-13] 54:21-55:1 [64:6-13] 67:2-68:7 [64:21-65:2] 67:2-68:7	
11/09/23	Hankey, Evans	42:15-21	SP				
11/09/23	Hankey, Evans	43:1-3					
11/09/23	Hankey, Evans	43:8-44:6		44:7-19; 44:20-45:8; 46:7-47:20; 54:8-13; 54:19-19; 55:2-8; 55:11-11; 57:21-58:5; 58:10-11; 58:13-13; 62:15-20; 63:4-6; 64:6-13; 64:21-65:2	[44:7-19] AMB; AG; CLC; SPC; IEXP; MIS; NREL; 403; MM; MIL; LFND [44:20-45:8] AMB; AA; AG; CLC; SPC; IEXP; LFND; MIS; NREL; 403; MM; MIL [46:7-47:20] AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IEXP; LFND; LDG; MIS; NREL; 403; MM; MIL [54:8-13] AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IEXP; LFND; LDG; MIS; NREL; 403; MM; MIL [54:19-19] AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IEXP; LFND; LDG; MIS; NREL; 403; MM; MIL [55:2-11] AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IEXP; LFND; LDG; MIS; NREL; 403; MM; MIL [57:21-58:5] HYP; AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IEXP; LFND; LDG; MIS; NREL; 403; MM; MIL [58:10-13] AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IEXP; HYP; LFND; LDG; MIS; NREL; 403; MM; MIL [62:15-63:6] AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IEXP; HYP; LFND; LDG; MIS; NREL; 403; MM; MIL [64:6-65:2] AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IMPs; IEXP; HYP; INC; LFND; LDG; MIS; NR; NREL; OBJ; 403; MM; MIL	[54:19-19] 54:21-55:1 [54:8-13] 54:21-55:1 [64:6-13] 67:2-68:7 [64:21-65:2] 67:2-68:7	
							[67:2-68:7] 402,403, V, I, EX, LW

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
11/09/23	Hankey, Evans	59:3-19		54:8-13; 54:19-19; 55:2-8; 55:11-11; 57:21-58:5; 58:10-11; 58:13-13; 62:15-20; 63:4-6; 64:6-13; 64:21-65:2; 68:10-15	[54:8-13] AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IEXP; LFND; LDG; MIS; NREL; 403; MM; MIL [54:19-19] AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IEXP; LFND; LDG; MIS; NREL; 403; MM; MIL [55:2-11] AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IEXP; LFND; LDG; MIS; NREL; 403; MM; MIL [57:21-58:5] HYP; AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IEXP; LFND; LDG; MIS; NREL; 403; MM; MIL [58:10-13] AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IEXP; HYP; LFND; LDG; MIS; NREL; 403; MM; MIL [62:15-63:6] AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IEXP; HYP; LFND; LDG; MIS; NREL; 403; MM; MIL [64:6-65:2] AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IMPs; IEXP; HYP; INC; LFND; LDG; MIS; NR; NREL; OBJ; 403; MM; MIL [68:10-15] AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IMPs; IEXP; HYP; INC; LFND; LDG; MIS; NR; NREL; OBJ; 403; MM; MIL	[54:19-19] 54:21-55:1 [54:8-13] 54:21-55:1 [64:6-13] 67:2-68:7 [64:21-65:2] 67:2-68:7	
11/09/23	Hankey, Evans	60:2-12		54:8-13; 54:19-19; 55:2-8; 55:11-11; 57:21-58:5; 58:10-11; 58:13-13; 62:15-20; 63:4-6; 64:6-13; 64:21-65:2; 68:10-15	[54:8-13] AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IEXP; LFND; LDG; MIS; NREL; 403; MM; MIL [54:19-19] AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IEXP; LFND; LDG; MIS; NREL; 403; MM; MIL [55:2-11] AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IEXP; LFND; LDG; MIS; NREL; 403; MM; MIL [57:21-58:5] HYP; AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IEXP; LFND; LDG; MIS; NREL; 403; MM; MIL [58:10-13] AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IEXP; HYP; LFND; LDG; MIS; NREL; 403; MM; MIL [62:15-63:6] AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IEXP; HYP; LFND; LDG; MIS; NREL; 403; MM; MIL [64:6-65:2] AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IMPs; IEXP; HYP; INC; LFND; LDG; MIS; NR; NREL; OBJ; 403; MM; MIL [68:10-15] AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IMPs; IEXP; HYP; INC; LFND; LDG; MIS; NR; NREL; OBJ; 403; MM; MIL	[54:19-19] 54:21-55:1 [54:8-13] 54:21-55:1 [64:6-13] 67:2-68:7 [64:21-65:2] 67:2-68:7	[67:2-68:7] 402,403, V, I, EX, LW

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
11/09/23	Hankey, Evans	61:8-62:7		54:8-13; 54:19-19; 55:2-8; 55:11-11; 57:21-58:5; 58:10-11; 58:13-13; 62:15-20; 63:4-6; 64:6-13; 64:21-65:2; 68:10-15	[54:8-13] AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IEXP; LFND; LDG; MIS; NREL; 403; MM; MIL [54:19-19] AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IEXP; LFND; LDG; MIS; NREL; 403; MM; MIL [55:2-11] AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IEXP; LFND; LDG; MIS; NREL; 403; MM; MIL [57:21-58:5] HYP; AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IEXP; LFND; LDG; MIS; NREL; 403; MM; MIL [58:10-13] AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IEXP; HYP; LFND; LDG; MIS; NREL; 403; MM; MIL [62:15-63:6] AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IEXP; HYP; LFND; LDG; MIS; NREL; 403; MM; MIL [64:6-65:2] AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IMPs; IEXP; HYP; INC; LFND; LDG; MIS; NR; NREL; OBJ; 403; MM; MIL [68:10-15] AMB; ARG; AA; AG; BSD (OS); CLC; SPC; CPD; IMPs; IEXP; HYP; INC; LFND; LDG; MIS; NR; NREL; OBJ; 403; MM; MIL	[54:19-19] 54:21-55:1 [54:8-13] 54:21-55:1 [64:6-13] 67:2-68:7 [64:21-65:2] 67:2-68:7	[67:2-68:7] 402,403, V, I, EX, LW
11/09/23	Hankey, Evans	68:17-69:1					
11/09/23	Hankey, Evans	77:18-78:16		82:5-19; 86:15-87:3; 87:5-6; 87:12-14; 87:16-88:15; 89:19-90:6	[82:5-19] AMB; AA; AG; PRV; BSD (OS); CLC; SPC; CPD; LFND; MIS; NREL; 403 [86:15-87:3] AMB; AA; AG; PRV; BSD (OS); CLC; SPC; CPD; LFND; MIS; NREL; 403 [87:5-6] AMB; ARG; AA; AG; PRV; SPC; LFND; MIS; NREL; 403 [89:19-90:6] AMB; ARG; AA; AG; PRV; CLC; SPC; CPD; LFND; LDG; MIS; NREL; 403	83:21-84:7	
11/09/23	Hankey, Evans	83:21-84:16		82:5-19; 86:15-87:3; 87:5-6; 87:12-14; 87:16-88:15; 89:19-90:6	[82:5-19] AMB; AA; AG; PRV; BSD (OS); CLC; SPC; CPD; LFND; MIS; NREL; 403 [86:15-87:3] AMB; AA; AG; PRV; BSD (OS); CLC; SPC; CPD; LFND; MIS; NREL; 403 [87:5-6] AMB; ARG; AA; AG; PRV; SPC; LFND; MIS; NREL; 403 [89:19-90:6] AMB; ARG; AA; AG; PRV; CLC; SPC; CPD; LFND; LDG; MIS; NREL; 403	83:21-84:7	
11/09/23	Hankey, Evans	84:17-22		82:5-19; 86:15-87:3; 87:5-6; 87:12-14; 87:16-88:15; 89:19-90:6	[82:5-19] AMB; AA; AG; PRV; BSD (OS); CLC; SPC; CPD; LFND; MIS; NREL; 403 [86:15-87:3] AMB; AA; AG; PRV; BSD (OS); CLC; SPC; CPD; LFND; MIS; NREL; 403 [87:5-6] AMB; ARG; AA; AG; PRV; SPC; LFND; MIS; NREL; 403 [89:19-90:6] AMB; ARG; AA; AG; PRV; CLC; SPC; CPD; LFND; LDG; MIS; NREL; 403	83:21-84:7	
11/09/23	Hankey, Evans	85:4-8		82:5-19; 86:15-87:3; 87:5-6; 87:12-14; 87:16-88:15; 89:19-90:6	[82:5-19] AMB; AA; AG; PRV; BSD (OS); CLC; SPC; CPD; LFND; MIS; NREL; 403 [86:15-87:3] AMB; AA; AG; PRV; BSD (OS); CLC; SPC; CPD; LFND; MIS; NREL; 403 [87:5-6] AMB; ARG; AA; AG; PRV; SPC; LFND; MIS; NREL; 403 [89:19-90:6] AMB; ARG; AA; AG; PRV; CLC; SPC; CPD; LFND; LDG; MIS; NREL; 403	83:21-84:7	

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
11/09/23	Hankey, Evans	86:15-87:3		82:5-19; 86:15-87:3; 87:5-6; 87:12-14; 87:16-88:15; 89:19-90:6	[82:5-19] AMB; AA; AG; PRV; BSD (OS); CLC; SPC; CPD; LFND; MIS; NREL; 403 [86:15-87:3] AMB; AA; AG; PRV; BSD (OS); CLC; SPC; CPD; LFND; MIS; NREL; 403 [87:5-6] AMB; ARG; AA; AG; PRV; SPC; LFND; MIS; NREL; 403 [89:19-90:6] AMB; ARG; AA; AG; PRV; CLC; SPC; CPD; LFND; LDG; MIS; NREL; 403	83:21-84:7	
11/09/23	Hankey, Evans	88:3-8		82:5-19; 86:15-87:3; 87:5-6; 87:12-14; 87:16-88:15; 89:19-90:6	[82:5-19] AMB; AA; AG; PRV; BSD (OS); CLC; SPC; CPD; LFND; MIS; NREL; 403 [86:15-87:3] AMB; AA; AG; PRV; BSD (OS); CLC; SPC; CPD; LFND; MIS; NREL; 403 [87:5-6] AMB; ARG; AA; AG; PRV; SPC; LFND; MIS; NREL; 403 [89:19-90:6] AMB; ARG; AA; AG; PRV; CLC; SPC; CPD; LFND; LDG; MIS; NREL; 403	83:21-84:7	
11/09/23	Hankey, Evans	89:19-90:6		82:5-19; 86:15-87:3; 87:5-6; 87:12-14; 87:16-88:15; 89:19-90:6	[82:5-19] AMB; AA; AG; PRV; BSD (OS); CLC; SPC; CPD; LFND; MIS; NREL; 403 [86:15-87:3] AMB; AA; AG; PRV; BSD (OS); CLC; SPC; CPD; LFND; MIS; NREL; 403 [87:5-6] AMB; ARG; AA; AG; PRV; SPC; LFND; MIS; NREL; 403 [89:19-90:6] AMB; ARG; AA; AG; PRV; CLC; SPC; CPD; LFND; LDG; MIS; NREL; 403	83:21-84:7	
11/09/23	Hankey, Evans	90:13-91:5					
11/09/23	Hankey, Evans	92:13-93:19					
11/09/23	Hankey, Evans	117:18-118:12					
11/09/23	Hankey, Evans	118:20-122:7		100:18-101:1; 120:6-10; 121:17-122:13	[100:18-101:1] AMB; AG; SPC; LFND; LDG; MIS; NREL; 403 [120:6-10] AMB; AG; SPC; LFND; LDG; MIS; NREL; 403 [121:17-122:13] AMB; AG; SPC; CPD; LFND; LDG; MIS; NREL; 403		
11/09/23	Hankey, Evans	122:14-22		100:18-101:1; 120:6-10; 121:17-122:13	[100:18-101:1] AMB; AG; SPC; LFND; LDG; MIS; NREL; 403 [120:6-10] AMB; AG; SPC; LFND; LDG; MIS; NREL; 403 [121:17-122:13] AMB; AG; SPC; CPD; LFND; LDG; MIS; NREL; 403		
11/09/23	Hankey, Evans	149:17-150:5		150:6-18	[150:6-18] AMB; ARG; AG; CLC; SPC; CPD; IEXP; LFND; LDG; MIS; NREL; 403		
11/09/23	Hankey, Evans	162:11-163:4		164:3-11; 168:20-169:6; 169:8-14; 172:4-12	[164:3-11] AMB; ARG; AA; AG; CLC; SPC; LFND; LDG; MIS; NREL; 403 [168:20-169:6] AMB; ARG; AA; AG; CLC; SPC; LFND; LDG; MIS; NREL; 403 [172:4-12] AMB; ARG; AA; AG; CLC; SPC; LFND; LDG; MIS; NREL; 403		
11/09/23	Hankey, Evans	163:6-165:15		164:3-11; 168:20-169:6; 169:8-14; 172:4-12	[164:3-11] AMB; ARG; AA; AG; CLC; SPC; LFND; LDG; MIS; NREL; 403 [168:20-169:6] AMB; ARG; AA; AG; CLC; SPC; LFND; LDG; MIS; NREL; 403 [172:4-12] AMB; ARG; AA; AG; CLC; SPC; LFND; LDG; MIS; NREL; 403		
11/09/23	Hankey, Evans	165:17-166:16	SP	164:3-11; 168:20-169:6; 169:8-14; 172:4-12	[164:3-11] AMB; ARG; AA; AG; CLC; SPC; LFND; LDG; MIS; NREL; 403 [168:20-169:6] AMB; ARG; AA; AG; CLC; SPC; LFND; LDG; MIS; NREL; 403 [172:4-12] AMB; ARG; AA; AG; CLC; SPC; LFND; LDG; MIS; NREL; 403		



DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
11/09/23	Hankey, Evans	166:17-168:19		164:3-11; 168:20-169:6; 169:8-14; 172:4-12	[164:3-11] AMB; ARG; AA; AG; CLC; SPC; LFND; LDG; MIS; NREL; 403 [168:20-169:6] AMB; ARG; AA; AG; CLC; SPC; LFND; LDG; MIS; NREL; 403 [172:4-12] AMB; ARG; AA; AG; CLC; SPC; LFND; LDG; MIS; NREL; 403		
11/09/23	Hankey, Evans	170:1-5	SP				
11/09/23	Hankey, Evans	170:15-172:3	SP				
11/09/23	Hankey, Evans	173:22-174:18					
11/09/23	Hankey, Evans	177:15-178:5					
11/09/23	Hankey, Evans	224:1-18		236:4-10	[236:4-10] AMB; ARG; AG; PRV; BSD (OS); SPC; HRS; IEXP; HYP; LFND; LDG; MIS; NE; NREL; 403; MIL		
11/09/23	Hankey, Evans	225:15-226:11	SP	236:4-10	[236:4-10] AMB; ARG; AG; PRV; BSD (OS); SPC; HRS; IEXP; HYP; LFND; LDG; MIS; NE; NREL; 403; MIL		
11/09/23	Hankey, Evans	229:21-230:15	SP				
11/09/23	Hankey, Evans	231:1-233:11		234:7-11	[234:7-11] AMB; ARG; AA; AG; SPC; LFND; LDG; MIS; NREL; 403	233:16-234:6	402, 403, V
11/09/23	Hankey, Evans	234:12-235:1					
10/06/23	Harrison-Noonan, Tobias	6:17-20					
10/06/23	Harrison-Noonan, Tobias	8:22-10:13	SP; 402				
10/06/23	Harrison-Noonan, Tobias	10:14-22					
10/06/23	Harrison-Noonan, Tobias	11:10-16		11:18-21			
10/06/23	Harrison-Noonan, Tobias	12:5-15:2		32:10-12; 32:14-21; 35:20-22; 36:2-5; 38:2-9	[32:10-12] AMB; NREL; 403 [32:14-21] AMB; NREL; 403 [35:20-22] AMB; NREL; 403 [36:2-5] AMB; NREL; 403 [38:2-9] AMB; NREL; 403	[35:20-22] 36:7-16 [36:2-5] 36:7-16	
10/06/23	Harrison-Noonan, Tobias	25:3-18		23:11-12; 23:17-19; 23:22-24:4; 24:6-8; 24:11-15; 24:17-25:2; 27:13-19	[23:17-19] IEXP; NREL; 403 [23:22-24:4] IEXP; NREL; 403 [24:6-8] IEXP; MIS; NREL; 403 [24:11-15] IEXP; MIS; NREL; 403 [24:17-25:2] IEXP; NREL; 403 [27:13-19] CLC; IEXP; NREL; 403		
10/06/23	Harrison-Noonan, Tobias	26:11-15		26:4-5; 26:8-9; 26:16-17	[26:4-5] CLC; IEXP; NREL; 403 [26:8-9] CLC; IEXP; NREL; 403 [26:16-17] CLC; IEXP; NREL; 403		
10/06/23	Harrison-Noonan, Tobias	45:10-15		44:18-45:9	[44:18-45:9] AMB; NREL; 403		
10/06/23	Harrison-Noonan, Tobias	46:1-47:8		47:9-11; 47:13-48:1	[47:9-11] AMB; NREL; 403 [47:13-48:1] AMB; NREL; 403	[47:9-11] 37:6-22; 48:2-12	
10/06/23	Harrison-Noonan, Tobias	52:16-53:14		49:8-13; 50:7-51:4; 51:7-12; 52:1-10; 53:21-54:5	[49:8-13] CLC; SPC; IEXP; NREL; 403 [50:7-51:4] AA; CLC; IEXP; NREL; 403 [51:7-12] AA; CLC; IEXP; NREL; 403 [52:1-10] CLC; IEXP; MIS; NREL; 403 [53:21-54:5] CLC; IEXP; MIS; NREL; 403	[49:8-13] 37:6-22 [50:7-51:4] 37:6-22 [51:7-12] 37:6-22 [52:1-10] 37:6-22	
11/16/23	Hemenway, Craig	12:3-9					
11/16/23	Hemenway, Craig	12:13-17					
11/16/23	Hemenway, Craig	15:11-13					
11/16/23	Hemenway, Craig	16:4-6					
11/16/23	Hemenway, Craig	17:7-22					
11/16/23	Hemenway, Craig	19:1-13					
11/16/23	Hemenway, Craig	31:13-17					
11/16/23	Hemenway, Craig	32:12-33:11					
11/16/23	Hemenway, Craig	34:16-35:3					
11/16/23	Hemenway, Craig	40:9-18					
11/16/23	Hemenway, Craig	50:4-21					
11/16/23	Hemenway, Craig	52:3-6					
11/16/23	Hemenway, Craig	56:20-57:13					
11/16/23	Hemenway, Craig	60:21-61:11					

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
11/16/23	Hemenway, Craig	61:20-62:4					
11/16/23	Hemenway, Craig	63:19-64:2					
11/16/23	Hemenway, Craig	64:11-16					
11/16/23	Hemenway, Craig	127:5-14					
11/16/23	Hemenway, Craig	129:10-16					
11/16/23	Hemenway, Craig	131:11-14					
11/16/23	Hemenway, Craig	132:18-133:8					
11/16/23	Hemenway, Craig	133:16-18					
11/16/23	Hemenway, Craig	134:9-18					
11/16/23	Hemenway, Craig	134:22-135:2					
11/16/23	Hemenway, Craig	135:17-22					
11/16/23	Hemenway, Craig	140:6-15		153:18-20; 154:4-11; 155:2-5; 155:12-12	[153:18-20] AMB; AA; AG; PRV; BSD (OS); CLC; SPC; IEXP; LFND; MIS; NP; NREL; 403 [154:4-11] AMB; AA; AG; PRV; BSD (OS); CLC; SPC; IEXP; LFND; MIS; NP; NREL; 403 [155:2-5] AMB; AA; AG; PRV; BSD (OS); CLC; SPC; IEXP; LFND; MIS; NP; NREL; 403 [155:12-12] AMB; AA; AG; PRV; BSD (OS); CLC; SPC; IEXP; LFND; MIS; NP; NREL; 403		
11/16/23	Hemenway, Craig	160:13-22	F, SP	161:1-5; 161:8-8	[161:1-5] AMB; ARG; AA; AG; PRV; BSD (OS); CLC; SPC; IEXP; LFND; LDG; MIS; NP; NREL; 403 [161:8-8] AMB; ARG; AA; AG; PRV; BSD (OS); CLC; SPC; IEXP; LFND; LDG; MIS; NP; NREL; 403		
11/16/23	Hemenway, Craig	228:22-229:11	402, 403				
11/16/23	Hemenway, Craig	233:15-234:4	402, 403, F, SP, O, V				
11/16/23	Hemenway, Craig	243:5-12					
11/16/23	Hemenway, Craig	255:9-16	F, SP				
11/16/23	Hemenway, Craig	256:9-257:7	F, SP				
11/16/23	Hemenway, Craig	258:1-8	F, SP				
11/16/23	Hemenway, Craig	259:14-260:9	F, SP				
11/16/23	Hemenway, Craig	261:5-15	AF, F, H, SP				
11/03/23	Hotelling, Steven	31:2-16					
11/03/23	Hotelling, Steven	31:18-21					
11/03/23	Hotelling, Steven	33:2-18		33:19-34:9; 35:4-13; 170:16-172:4	[33:19-34:9] AMB; LFND; LDG; NREL; 403 [35:4-13] AMB; AA; NREL; 403 [170:16-172:4] AMB; HRS; LFND; LDG; MIS; NREL; 403	[33:19-34:9] 36:11-17; 37:5-12 [35:4-13] 36:11-17; 37:5-12 [170:16-172:4] 37:5-12; 44:3-9; 172:5-8	
11/03/23	Hotelling, Steven	34:10-35:3		170:16-172:4	[170:16-172:4] AMB; HRS; LFND; LDG; MIS; NREL; 403	37:5-12; 44:3-9; 172:5-8	
11/03/23	Hotelling, Steven	35:14-20					
11/03/23	Hotelling, Steven	36:11-17					
11/03/23	Hotelling, Steven	37:5-12		36:21-37:4; 37:14-17; 37:20-38:3; 38:5-10; 38:12-14; 39:20-40:4	[36:21-37:4] AMB; CPD [37:14-17] AMB; LFND; NREL; 403 [37:20-38:3] AMB; LFND; NREL; 403 [38:5-10] AMB; LFND; LDG; NREL; 403 [38:12-14] AMB; LFND; LDG; NREL; 403 [39:20-40:4] AMB; LFND; LDG; NREL; 403; BSD (OS)	[36:21-37:4] 37:5-12 [37:20-38:3] 37:5-12 [37:14-17] 37:5-12 [38:12-14] 37:5-12 [38:5-10] 37:5-12 [39:20-40:4] 37:5-12	

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
11/03/23	Hotelling, Steven	41:1-42:17		42:19-22; 43:3-5; 43:7-9; 43:11-14; 44:11-12; 44:15-17; 44:19-21	[42:19-22] AMB; HYP; LFND; LDG; NREL; 403 [43:3-5] AMB; HYP; LFND; LDG; NREL; 403 [43:7-9] AMB; HYP; LFND; LDG; NREL; 403 [43:11-14] AMB; HYP; LFND; LDG; NREL; 403 [44:11-12] AMB; HYP; LFND; NREL; 403 [44:15-17] AMB; HYP; LFND; NREL; 403 [44:19-21] AMB; LFND; NREL; 403	[42:19-22] 44:3-9 [43:11-14] 44:3-9 [43:3-5] 44:3-9 [43:7-9] 44:3-9 [44:11-12] 44:3-9 [44:15-17] 44:3-9 [44:19-21] 44:3-9	
11/03/23	Hotelling, Steven	161:3-162:9					
11/03/23	Hotelling, Steven	163:12-164:15					
11/03/23	Hotelling, Steven	175:15-17		180:16-181:3	[180:16-181:3] AMB; AA; NREL; 403	178:15-180:14	
11/03/23	Hotelling, Steven	176:14-180:3		180:16-181:3	[180:16-181:3] AMB; AA; NREL; 403	178:15-180:14	
11/03/23	Hotelling, Steven	180:5-14					
11/03/23	Hotelling, Steven	183:3-4		189:8-15; 191:1-11	[189:8-15] AMB; BER; LFND; LDG; NREL; 403 [191:1-11] AMB; BER	[189:8-15] 36:11-17; 37:5-12 [191:1-11] 37:5-12	
11/03/23	Hotelling, Steven	184:5-187:9		189:8-15; 191:1-11	[189:8-15] AMB; BER; LFND; LDG; NREL; 403 [191:1-11] AMB; BER	[189:8-15] 36:11-17; 37:5-12 [191:1-11] 37:5-12	
11/03/23	Hotelling, Steven	200:18-203:2		36:21-37:4; 204:18-205:1; 206:3-15; 207:20-208:4; 209:3-5	[36:21-37:4] AMB; CPD [204:18-205:1] AMB; ARG; AG; BER; SPC; HRS; 1006; LFND; LDG; MIS; NREL; OBJ; 403; MIL [206:3-15] MIL; AMB; ARG; AG; BER; CLC; SPC; CPD; HRS; 1006; LFND; LDG; MIS; NREL; OBJ; 403 [207:20-208:4] AMB; ARG; AG; BER; CLC; SPC; HRS; 1006; LFND; LDG; MIS; NREL; OBJ; 403; MIL [209:3-5] AMB; ARG; AG; LDG; NREL; 403; MIL	37:5-12	
11/20/23	Kesler, Jarom	7:10-25	402/403				
11/20/23	Kesler, Jarom	13:3-15	402/403/AC/WP				
11/20/23	Kesler, Jarom	13:17-15:2	402/403/AC/WP				
11/20/23	Kesler, Jarom	19:25-20:4	402/403				
11/20/23	Kesler, Jarom	25:16-26:7	402/403				
11/20/23	Kesler, Jarom	114:21-117:7	402/403				
10/31/23	Kinast, Eric	8:17-20					
10/31/23	Kinast, Eric	9:21-25					
10/31/23	Kinast, Eric	10:23-11:3		11:9-12:2; 22:3-6; 22:20-23:6	[11:9-12:2] AMB; LFND; NREL; 403 [22:3-6] AMB; NREL; 403 [22:20-23:6] SPC; NREL; 403	[22:20-23:6] 25:12-18	F; H; SP
10/31/23	Kinast, Eric	12:7-13:2	F; H; SP	11:9-12:2; 22:3-6; 22:20-23:6	[11:9-12:2] AMB; LFND; NREL; 403 [22:3-6] AMB; NREL; 403 [22:20-23:6] SPC; NREL; 403	[22:20-23:6] 25:12-18	F; H; SP
10/31/23	Kinast, Eric	14:13-18	F; H; M	11:9-12:2; 22:3-6; 22:20-23:6	[11:9-12:2] AMB; LFND; NREL; 403 [22:3-6] AMB; NREL; 403 [22:20-23:6] SPC; NREL; 403	[22:20-23:6] 25:12-18	F; H; SP
10/31/23	Kinast, Eric	14:20-15:10	402; 403; F; LC; EX; SP	11:9-12:2; 22:3-6; 22:20-23:6	[11:9-12:2] AMB; LFND; NREL; 403 [22:3-6] AMB; NREL; 403 [22:20-23:6] SPC; NREL; 403	[22:20-23:6] 25:12-18	F; H; SP
10/31/23	Kinast, Eric	15:16-25	402; 403; F; LC; EX; SP	11:9-12:2; 22:3-6; 22:20-23:6	[11:9-12:2] AMB; LFND; NREL; 403 [22:3-6] AMB; NREL; 403 [22:20-23:6] SPC; NREL; 403	[22:20-23:6] 25:12-18	F; H; SP
10/31/23	Kinast, Eric	16:1-2	402; 403; F; LC; EX; SP	11:9-12:2; 22:3-6; 22:20-23:6	[11:9-12:2] AMB; LFND; NREL; 403 [22:3-6] AMB; NREL; 403 [22:20-23:6] SPC; NREL; 403	[22:20-23:6] 25:12-18	F; H; SP
10/31/23	Kinast, Eric	16:4-11	402; 403; F; LC; EX; SP	11:9-12:2; 22:3-6; 22:20-23:6	[11:9-12:2] AMB; LFND; NREL; 403 [22:3-6] AMB; NREL; 403 [22:20-23:6] SPC; NREL; 403	[22:20-23:6] 25:12-18	F; H; SP

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
10/31/23	Kinast, Eric	16:15-25	402; 403; F; LC; EX; SP	11:9-12:2; 22:3-6; 22:20-23:6	[11:9-12:2] AMB; LFND; NREL; 403 [22:3-6] AMB; NREL; 403 [22:20-23:6] SPC; NREL; 403	[22:20-23:6] 25:12-18 [22:3-6] 25:12-18	F; H; SP
10/31/23	Kinast, Eric	17:1-14	402; 403; F; LC; EX; SP	11:9-12:2; 22:3-6; 22:20-23:6	[11:9-12:2] AMB; LFND; NREL; 403 [22:3-6] AMB; NREL; 403 [22:20-23:6] SPC; NREL; 403	[22:20-23:6] 25:12-18 [22:3-6] 25:12-18	F; H; SP
10/31/23	Kinast, Eric	17:17-25	402; 403; F; LC; EX; SP	11:9-12:2; 22:3-6; 22:20-23:6	[11:9-12:2] AMB; LFND; NREL; 403 [22:3-6] AMB; NREL; 403 [22:20-23:6] SPC; NREL; 403	[22:20-23:6] 25:12-18 [22:3-6] 25:12-18	F; H; SP
10/31/23	Kinast, Eric	18:1-15	402; 403; F; LC; EX; SP	11:9-12:2; 22:3-6; 22:20-23:6	[11:9-12:2] AMB; LFND; NREL; 403 [22:3-6] AMB; NREL; 403 [22:20-23:6] SPC; NREL; 403	[22:20-23:6] 25:12-18 [22:3-6] 25:12-18	F; H; SP
10/31/23	Kinast, Eric	18:18-25	402; 403; F; LC; EX; SP	11:9-12:2; 22:3-6; 22:20-23:6	[11:9-12:2] AMB; LFND; NREL; 403 [22:3-6] AMB; NREL; 403 [22:20-23:6] SPC; NREL; 403	[22:20-23:6] 25:12-18 [22:3-6] 25:12-18	F; H; SP
10/31/23	Kinast, Eric	19:1-15	402; 403; F; LC; EX; SP	11:9-12:2; 22:3-6; 22:20-23:6	[11:9-12:2] AMB; LFND; NREL; 403 [22:3-6] AMB; NREL; 403 [22:20-23:6] SPC; NREL; 403	[22:20-23:6] 25:12-18 [22:3-6] 25:12-18	F; H; SP
10/31/23	Kinast, Eric	19:18-25	402; 403; F; LC; EX; SP	11:9-12:2; 22:3-6; 22:20-23:6	[11:9-12:2] AMB; LFND; NREL; 403 [22:3-6] AMB; NREL; 403 [22:20-23:6] SPC; NREL; 403	[22:20-23:6] 25:12-18 [22:3-6] 25:12-18	F; H; SP
10/31/23	Kinast, Eric	20:1-16	402; 403; F; LC; EX; SP	11:9-12:2; 22:3-6; 22:20-23:6	[11:9-12:2] AMB; LFND; NREL; 403 [22:3-6] AMB; NREL; 403 [22:20-23:6] SPC; NREL; 403	[22:20-23:6] 25:12-18 [22:3-6] 25:12-18	F; H; SP
10/31/23	Kinast, Eric	20:19-25	402; 403; F; LC; EX; SP	11:9-12:2; 22:3-6; 22:20-23:6	[11:9-12:2] AMB; LFND; NREL; 403 [22:3-6] AMB; NREL; 403 [22:20-23:6] SPC; NREL; 403	[22:20-23:6] 25:12-18 [22:3-6] 25:12-18	F; H; SP
10/31/23	Kinast, Eric	21:1-14	402; 403; F; LC; EX; SP	11:9-12:2; 22:3-6; 22:20-23:6	[11:9-12:2] AMB; LFND; NREL; 403 [22:3-6] AMB; NREL; 403 [22:20-23:6] SPC; NREL; 403	[22:20-23:6] 25:12-18 [22:3-6] 25:12-18	F; H; SP
10/31/23	Kinast, Eric	23:7-25:8	F; H; SP	11:9-12:2; 22:3-6; 22:20-23:6	[11:9-12:2] AMB; LFND; NREL; 403 [22:3-6] AMB; NREL; 403 [22:20-23:6] SPC; NREL; 403	[22:20-23:6] 25:12-18 [22:3-6] 25:12-18	F; H; SP
10/31/23	Kinast, Eric	27:15-28:3	H	26:20-27:14; 31:1-8; 32:13-15	[26:20-27:14] SPC; HRS; NREL; 403; AMB [31:1-8] SPC; NREL; 403; AMB [32:13-15] AMB; NREL; 403	31:9-15	F; SP
10/31/23	Kinast, Eric	25:12-18	F; H; SP	25:19-23			
10/31/23	Kinast, Eric	26:8-14 [withdrawn]	F; H; SP				
10/31/23	Kinast, Eric	30:15-19	H	26:20-27:14; 31:1-8; 32:13-15	[26:20-27:14] SPC; HRS; NREL; 403; AMB [31:1-8] SPC; NREL; 403; AMB [32:13-15] AMB; NREL; 403	31:9-15	F; SP
10/31/23	Kinast, Eric	32:16-34:7	F; H; SP				
10/31/23	Kinast, Eric	34:14-36:25	F; H; SP				
10/31/23	Kinast, Eric	37:11-38:2	F; H; SP				
10/31/23	Kinast, Eric	39:2-40:2	F; H; SP				
10/31/23	Kinast, Eric	41:7-44:3	F; H; SP				
10/31/23	Kinast, Eric	44:4-7 [withdrawn]	AF				
10/31/23	Kinast, Eric	45:1-47:15	F; SP				
10/31/23	Kinast, Eric	47:16-49:22	F; SP	50:7-9			
10/31/23	Kinast, Eric	50:10-51:5	402; 403; F; SP; LC; EX; AF	111:4-112:4	[111:4-112:4] HRS; AMB; SPC; LFND; 403		
10/31/23	Kinast, Eric	52:22-53:19	402; 403; F; SP; LC; EX; AF	111:4-112:4	[111:4-112:4] HRS; AMB; SPC; LFND; 403		
10/31/23	Kinast, Eric	54:15-19	402; 403; F; SP; LC; EX; AF	111:4-112:4	[111:4-112:4] HRS; AMB; SPC; LFND; 403		
10/31/23	Kinast, Eric	55:10-56:8	402; 403; F; SP; LC; EX; AF	111:4-112:4	[111:4-112:4] HRS; AMB; SPC; LFND; 403		
10/31/23	Kinast, Eric	57:3-59:3	402; 403; F; SP; LC; EX; AF	111:4-112:4	[111:4-112:4] HRS; AMB; SPC; LFND; 403		
10/31/23	Kinast, Eric	59:9-23	402; 403; F; SP; LC; EX; AF	111:4-112:4	[111:4-112:4] HRS; AMB; SPC; LFND; 403		
10/31/23	Kinast, Eric	60:8-61:5	402; 403; F; SP; LC; EX; AF	111:4-112:4	[111:4-112:4] HRS; AMB; SPC; LFND; 403		
10/31/23	Kinast, Eric	61:18-62:12	402; 403; F; SP; LC; EX; AF	111:4-112:4	[111:4-112:4] HRS; AMB; SPC; LFND; 403		
10/31/23	Kinast, Eric	63:3-23	402; 403; F; LC; EX; SP				
10/31/23	Kinast, Eric	64:7-65:11	402; 403; F; LC; EX; SP				
10/31/23	Kinast, Eric	69:4-70:18	F; SP				
10/31/23	Kinast, Eric	71:19-74:10	402; 403; F; SP; AF; M; H				
10/31/23	Kinast, Eric	74:19-75:1	402; 403; F; SP; AF; M; H				
10/31/23	Kinast, Eric	75:8-13	402; 403; F; SP; AF; M; H				
10/31/23	Kinast, Eric	75:22-76:14	402; 403; F; SP; AF; M; H				
10/31/23	Kinast, Eric	82:14-84:18	402; 403; F; SP; LC; EX; AF; AG	111:4-112:4	[111:4-112:4] HRS; AMB; SPC; LFND; 403		
10/31/23	Kinast, Eric	85:5-15	402; 403; F; SP; LC; EX; AF; AG	111:4-112:4	[111:4-112:4] HRS; AMB; SPC; LFND; 403		

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
10/31/23	Kinast, Eric	86:1-17	402; 403; F; SP; LC; EX; AF; AG	111:4-112:4	[111:4-112:4] HRS; AMB; SPC; LFND; 403		
10/31/23	Kinast, Eric	87:1-22	402; 403; F; SP; AF; AG; LC; EX; M				
10/31/23	Kinast, Eric	87:25-88:7	402; 403; F; SP; AF; AG; LC; EX; M				
10/31/23	Kinast, Eric	88:11-89:19	402; 403; F; SP; AF; AG; LC; EX; M				
10/31/23	Kinast, Eric	90:14-15	402; 403; F; SP; AF; AG; LC; EX; M				
10/31/23	Kinast, Eric	90:20-25	402; 403; F; SP; AF; AG; LC; EX; M				
10/31/23	Kinast, Eric	91:1-21	402; 403; F; SP; AF; AG; LC; EX; M				
10/31/23	Kinast, Eric	91:18-21	402; 403; F; SP				
10/31/23	Kinast, Eric	92:10-15	402; 403; F; SP				
10/31/23	Kinast, Eric	94:8-9	402; 403; F; SP; LC; EX				
10/31/23	Kinast, Eric	94:12-18	402; 403; F; SP; LC; EX				
10/31/23	Kinast, Eric	94:21-25	402; 403; F; SP; LC; EX				
10/31/23	Kinast, Eric	95:1-1	402; 403; F; SP; LC; EX				
10/31/23	Kinast, Eric	95:3-13	402; 403; F; SP; LC; EX				
10/31/23	Kinast, Eric	97:12-21 [withdrawn]	402; 403; F; SP				
10/31/23	Kinast, Eric	100:7-21		103:23-24; 104:2-7; 104:10-14	[103:23-24] CLC; SPC; IEXP; AMB; 403 [104:2-7] CLC; SPC; IEXP; AMB; 403 [104:10-14] CLC; SPC; IEXP; AMB; 403		
10/31/23	Kinast, Eric	101:1-15	402; 403; F; SP; LC; EX; AF	103:23-24; 104:2-7; 104:10-14	[103:23-24] CLC; SPC; IEXP; AMB; 403 [104:2-7] CLC; SPC; IEXP; AMB; 403 [104:10-14] CLC; SPC; IEXP; AMB; 403		
10/31/23	Kinast, Eric	102:2-5	402; 403; F; SP; LC; EX; AF	103:23-24; 104:2-7; 104:10-14	[103:23-24] CLC; SPC; IEXP; AMB; 403 [104:2-7] CLC; SPC; IEXP; AMB; 403 [104:10-14] CLC; SPC; IEXP; AMB; 403		
10/31/23	Kinast, Eric	102:24-25	402; 403; F; SP; LC; EX; AF	103:23-24; 104:2-7; 104:10-14	[103:23-24] CLC; SPC; IEXP; AMB; 403 [104:2-7] CLC; SPC; IEXP; AMB; 403 [104:10-14] CLC; SPC; IEXP; AMB; 403		
10/31/23	Kinast, Eric	103:3-4	402; 403; F; SP; LC; EX; AF	103:23-24; 104:2-7; 104:10-14	[103:23-24] CLC; SPC; IEXP; AMB; 403 [104:2-7] CLC; SPC; IEXP; AMB; 403 [104:10-14] CLC; SPC; IEXP; AMB; 403		
10/31/23	Kinast, Eric	103:7-9	402; 403; F; SP; LC; EX; AF	103:23-24; 104:2-7; 104:10-14	[103:23-24] CLC; SPC; IEXP; AMB; 403 [104:2-7] CLC; SPC; IEXP; AMB; 403 [104:10-14] CLC; SPC; IEXP; AMB; 403		
10/31/23	Kinast, Eric	107:15-18	402; 403; F; LC; EX; SP				
10/31/23	Kinast, Eric	108:1-8	402; 403; F; LC; EX; SP				
10/31/23	Kinast, Eric	113:8-22	AF	111:4-112:4	[111:4-112:4] HRS; AMB; SPC; LFND; 403		
11/07/23	Kokawa, Naoki	7:15-19					
11/07/23	Kokawa, Naoki	9:20-10:7		10:8-9; 11:24-12:1	[10:8-9] NREL; 403 [11:24-12:1] NREL; 403		
11/07/23	Kokawa, Naoki	12:2-5					
11/07/23	Kokawa, Naoki	12:16-18					
11/07/23	Kokawa, Naoki	13:13-14:15 [withdrawn]					
11/07/23	Kokawa, Naoki	17:22-18:1					
11/07/23	Kokawa, Naoki	18:5-13		18:14-20			
11/07/23	Kokawa, Naoki	18:24-19:2	F; SP				
11/07/23	Kokawa, Naoki	22:25-23:1		23:13-15	[23:13-15] NREL; 403	23:8-10	
11/07/23	Kokawa, Naoki	23:11-12		23:13-15	[23:13-15] NREL; 403	23:8-10	
11/07/23	Kokawa, Naoki	27:2-28:9	F; SP	28:13-14; 28:16-22; 28:24-24	[28:13-14] NREL; 403; AMB [28:16-22] NREL; 403; AMB; NR [28:24-24] CM; NREL; 403		
11/07/23	Kokawa, Naoki	31:11-19	F; SP; LC; EX; AG				
11/07/23	Kokawa, Naoki	32:1-2	F; SP; LC; EX; AG				
11/07/23	Kokawa, Naoki	32:4-10	F; SP; LC; EX; AG				
11/07/23	Kokawa, Naoki	32:12-18	F; SP; LC; EX; AG				
11/07/23	Kokawa, Naoki	32:20-22	F; SP; LC; EX; AG				
11/07/23	Kokawa, Naoki	33:12-34:3	F; SP; LC; EX; AG				
11/07/23	Kokawa, Naoki	34:7-9	402; 403; F; SP; AS; V; M				
11/07/23	Kokawa, Naoki	36:21-25	402; 403; F; SP; AS; V; M				
11/07/23	Kokawa, Naoki	37:1-3	402; 403; F; SP; AS; V; M				
11/07/23	Kokawa, Naoki	37:6-11	402; 403; F; SP; AS; V; M				
11/07/23	Kokawa, Naoki	37:14-17	402; 403; F; SP; AS; V; M				
11/07/23	Kokawa, Naoki	37:20-21	402; 403; F; SP; AS; V; M				
11/07/23	Kokawa, Naoki	37:24-25	402; 403; F; SP; AS; V; M				
11/07/23	Kokawa, Naoki	38:2-5	402; 403; F; SP; AS; V; M				
11/07/23	Kokawa, Naoki	38:8-11	402; 403; F; SP; AS; V; M				
11/07/23	Kokawa, Naoki	38:14-17	402; 403; F; SP; AS; V; M				
11/07/23	Kokawa, Naoki	38:20-23	402; 403; F; SP; AS; V; M				
11/07/23	Kokawa, Naoki	39:1-11	402; 403; F; SP; AS; V; M				

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
11/07/23	Kokawa, Naoki	39:14-14	402; 403; F; SP; AS; V; M				
11/07/23	Kokawa, Naoki	41:10-12	402; 403; F; SP; M; V; LC; EX	44:7-8; 44:10-11	[44:7-8] NREL; 403; OBJ [44:10-11] NR; NREL; 403; AMB; IEXP		
11/07/23	Kokawa, Naoki	41:19-24	402; 403; F; SP; M; V; LC; EX	44:7-8; 44:10-11	[44:7-8] NREL; 403; OBJ [44:10-11] NR; NREL; 403; AMB; IEXP		
11/07/23	Kokawa, Naoki	43:11-13	402; 403; F; SP; M; V; LC; EX	44:7-8; 44:10-11	[44:7-8] NREL; 403; OBJ [44:10-11] NR; NREL; 403; AMB; IEXP		
11/07/23	Kokawa, Naoki	43:17-21	402; 403; F; SP; M; V; LC; EX	44:7-8; 44:10-11	[44:7-8] NREL; 403; OBJ [44:10-11] NR; NREL; 403; AMB; IEXP		
11/07/23	Kokawa, Naoki	43:23-24	402; 403; F; SP; M; V; LC; EX	44:7-8; 44:10-11	[44:7-8] NREL; 403; OBJ [44:10-11] NR; NREL; 403; AMB; IEXP		
11/07/23	Kokawa, Naoki	44:2-5	402; 403; F; SP; M; V; LC; EX	44:7-8; 44:10-11	[44:7-8] NREL; 403; OBJ [44:10-11] NR; NREL; 403; AMB; IEXP		
11/07/23	Kokawa, Naoki	44:13-17	402; 403; F; SP; LC; EX; M; AG				
11/07/23	Kokawa, Naoki	44:20-21	402; 403; F; SP; LC; EX; M; AG				
11/07/23	Kokawa, Naoki	44:23-25	402; 403; F; SP; LC; EX; M; AG				
11/07/23	Kokawa, Naoki	45:1-3	402; 403; F; SP; LC; EX; M; AG				
11/07/23	Kokawa, Naoki	45:11-17	402; 403; F; SP; LC; EX; M; AG				
11/07/23	Kokawa, Naoki	45:19-21	402; 403; F; SP; LC; EX; M; AG				
11/07/23	Kokawa, Naoki	46:19-20	402; 403; F; SP; LC; EX; M; AG				
11/07/23	Kokawa, Naoki	46:22-22	402; 403; F; SP; LC; EX; M; AG				
11/07/23	Kokawa, Naoki	47:15-17	402; 403; F; SP; LC; EX; M; AG				
11/07/23	Kokawa, Naoki	47:19-19	402; 403; F; SP; LC; EX; M; AG				
11/07/23	Kokawa, Naoki	48:2-3	402; 403; F; SP; LC; EX; M; AG				
11/07/23	Kokawa, Naoki	48:5-6	402; 403; F; SP; LC; EX; M; AG				
11/07/23	Kokawa, Naoki	55:2-11	402; 403; F; SP; LC; EX; M; AG				
11/07/23	Kokawa, Naoki	56:1-3	402; 403; F; SP; LC; EX; M; AG				
11/07/23	Kokawa, Naoki	56:14-15	402; 403; F; SP; LC; EX; M; AG				
11/07/23	Kokawa, Naoki	56:17-18	402; 403; F; SP; LC; EX; M; AG				
11/07/23	Kokawa, Naoki	59:9-16	F; SP; LC; EX; V; AF	68:15-17; 68:19-20; 68:22-69:1; 69:4-5	[68:15-17] NREL; 403; BSD (OS); OBJ; MM [68:19-20] NREL; 403; MM; AMB; IEXP; LFND [68:22-69:1] BSD (OS); NREL; 403; MM; IEXP; NR [69:4-5] BSD (OS); NREL; 403; MM; AMB; IEXP	[68:15-17] 69:16-18; 69:21-22 [68:22-69:1] 69:16-18; 69:21-22 [68:19-20] 69:16-18; 69:21-22 [69:4-5] 69:16-18; 69:21-22	402; 403; F; SP; LC; EX
11/07/23	Kokawa, Naoki	59:19-24	F; SP; LC; EX; V; AF	68:15-17; 68:19-20; 68:22-69:1; 69:4-5	[68:15-17] NREL; 403; BSD (OS); OBJ; MM [68:19-20] NREL; 403; MM; AMB; IEXP; LFND [68:22-69:1] BSD (OS); NREL; 403; MM; IEXP; NR [69:4-5] BSD (OS); NREL; 403; MM; AMB; IEXP	[68:15-17] 69:16-18; 69:21-22 [68:22-69:1] 69:16-18; 69:21-22 [68:19-20] 69:16-18; 69:21-22 [69:4-5] 69:16-18; 69:21-22	402; 403; F; SP; LC; EX
11/07/23	Kokawa, Naoki	60:1-1	F; SP; LC; EX; V; AF	68:15-17; 68:19-20; 68:22-69:1; 69:4-5	[68:15-17] NREL; 403; BSD (OS); OBJ; MM [68:19-20] NREL; 403; MM; AMB; IEXP; LFND [68:22-69:1] BSD (OS); NREL; 403; MM; IEXP; NR [69:4-5] BSD (OS); NREL; 403; MM; AMB; IEXP	[68:15-17] 69:16-18; 69:21-22 [68:22-69:1] 69:16-18; 69:21-22 [68:19-20] 69:16-18; 69:21-22 [69:4-5] 69:16-18; 69:21-22	402; 403; F; SP; LC; EX
11/07/23	Kokawa, Naoki	61:7-10	F; SP; LC; EX; V; AF	68:15-17; 68:19-20; 68:22-69:1; 69:4-5	[68:15-17] NREL; 403; BSD (OS); OBJ; MM [68:19-20] NREL; 403; MM; AMB; IEXP; LFND [68:22-69:1] BSD (OS); NREL; 403; MM; IEXP; NR [69:4-5] BSD (OS); NREL; 403; MM; AMB; IEXP	[68:15-17] 69:16-18; 69:21-22 [68:22-69:1] 69:16-18; 69:21-22 [68:19-20] 69:16-18; 69:21-22 [69:4-5] 69:16-18; 69:21-22	402; 403; F; SP; LC; EX

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
11/07/23	Kokawa, Naoki	61:13-14	F; SP; LC; EX; V; AF	68:15-17; 68:19-20; 68:22-69:1; 69:4-5	[68:15-17] NREL; 403; BSD (OS); OBJ; MM [68:19-20] NREL; 403; MM; AMB; IEXP; LFND [68:22-69:1] BSD (OS); NREL; 403; MM; IEXP; NR [69:4-5] BSD (OS); NREL; 403; MM; AMB; IEXP	[68:15-17] 69:16-18; 69:21-22 [68:22-69:1] 69:16-18; 69:21-22 [68:19-20] 69:16-18; 69:21-22 [69:4-5] 69:16-18; 69:21-22	402; 403; F; SP; LC; EX
11/07/23	Kokawa, Naoki	61:20-23	F; SP; LC; EX; V; AF	68:15-17; 68:19-20; 68:22-69:1; 69:4-5	[68:15-17] NREL; 403; BSD (OS); OBJ; MM [68:19-20] NREL; 403; MM; AMB; IEXP; LFND [68:22-69:1] BSD (OS); NREL; 403; MM; IEXP; NR [69:4-5] BSD (OS); NREL; 403; MM; AMB; IEXP	[68:15-17] 69:16-18; 69:21-22 [68:22-69:1] 69:16-18; 69:21-22 [68:19-20] 69:16-18; 69:21-22 [69:4-5] 69:16-18; 69:21-22	402; 403; F; SP; LC; EX
11/07/23	Kokawa, Naoki	62:1-3	F; SP; LC; EX; V; AF	68:15-17; 68:19-20; 68:22-69:1; 69:4-5	[68:15-17] NREL; 403; BSD (OS); OBJ; MM [68:19-20] NREL; 403; MM; AMB; IEXP; LFND [68:22-69:1] BSD (OS); NREL; 403; MM; IEXP; NR [69:4-5] BSD (OS); NREL; 403; MM; AMB; IEXP	[68:15-17] 69:16-18; 69:21-22 [68:22-69:1] 69:16-18; 69:21-22 [68:19-20] 69:16-18; 69:21-22 [69:4-5] 69:16-18; 69:21-22	402; 403; F; SP; LC; EX
11/07/23	Kokawa, Naoki	62:5-6	F; SP; LC; EX; V; AF	68:19-20; 68:22-69:1; 69:4-5	[68:19-20] NREL; 403; MM; AMB; IEXP; LFND [68:22-69:1] BSD (OS); NREL; 403; MM; IEXP; NR [69:4-5] BSD (OS); NREL; 403; MM; AMB; IEXP	[68:22-69:1] 69:16-18; 69:21-22 [68:19-20] 69:16-18; 69:21-22 [69:4-5] 69:16-18; 69:21-22	402; 403; F; SP; LC; EX
11/07/23	Kokawa, Naoki	62:9-9	F; SP; LC; EX; V; AF	68:19-20; 68:22-69:1; 69:4-5	[68:19-20] NREL; 403; MM; AMB; IEXP; LFND [68:22-69:1] BSD (OS); NREL; 403; MM; IEXP; NR [69:4-5] BSD (OS); NREL; 403; MM; AMB; IEXP	[68:22-69:1] 69:16-18; 69:21-22 [68:19-20] 69:16-18; 69:21-22 [69:4-5] 69:16-18; 69:21-22	402; 403; F; SP; LC; EX
11/07/23	Kokawa, Naoki	63:15-16	F; SP; LC; EX; V; AF	68:15-17; 68:19-20; 68:22-69:1; 69:4-5	[68:15-17] NREL; 403; BSD (OS); OBJ; MM [68:19-20] NREL; 403; MM; AMB; IEXP; LFND [68:22-69:1] BSD (OS); NREL; 403; MM; IEXP; NR [69:4-5] BSD (OS); NREL; 403; MM; AMB; IEXP	[68:15-17] 69:16-18; 69:21-22 [68:22-69:1] 69:16-18; 69:21-22 [68:19-20] 69:16-18; 69:21-22 [69:4-5] 69:16-18; 69:21-22	402; 403; F; SP; LC; EX
11/07/23	Kokawa, Naoki	63:19-23	F; SP; LC; EX; V; AF	68:15-17; 68:19-20; 68:22-69:1; 69:4-5	[68:15-17] NREL; 403; BSD (OS); OBJ; MM [68:19-20] NREL; 403; MM; AMB; IEXP; LFND [68:22-69:1] BSD (OS); NREL; 403; MM; IEXP; NR [69:4-5] BSD (OS); NREL; 403; MM; AMB; IEXP	[68:15-17] 69:16-18; 69:21-22 [68:22-69:1] 69:16-18; 69:21-22 [68:19-20] 69:16-18; 69:21-22 [69:4-5] 69:16-18; 69:21-22	402; 403; F; SP; LC; EX
11/07/23	Kokawa, Naoki	63:25-25	F; SP; LC; EX; V; AF	68:15-17; 68:19-20; 68:22-69:1; 69:4-5	[68:15-17] NREL; 403; BSD (OS); OBJ; MM [68:19-20] NREL; 403; MM; AMB; IEXP; LFND [68:22-69:1] BSD (OS); NREL; 403; MM; IEXP; NR [69:4-5] BSD (OS); NREL; 403; MM; AMB; IEXP	[68:15-17] 69:16-18; 69:21-22 [68:22-69:1] 69:16-18; 69:21-22 [68:19-20] 69:16-18; 69:21-22 [69:4-5] 69:16-18; 69:21-22	402; 403; F; SP; LC; EX
11/07/23	Kokawa, Naoki	64:2-4	F; SP; LC; EX; V; AF	68:15-17; 68:19-20; 68:22-69:1; 69:4-5	[68:15-17] NREL; 403; BSD (OS); OBJ; MM [68:19-20] NREL; 403; MM; AMB; IEXP; LFND [68:22-69:1] BSD (OS); NREL; 403; MM; IEXP; NR [69:4-5] BSD (OS); NREL; 403; MM; AMB; IEXP	[68:15-17] 69:16-18; 69:21-22 [68:22-69:1] 69:16-18; 69:21-22 [68:19-20] 69:16-18; 69:21-22 [69:4-5] 69:16-18; 69:21-22	402; 403; F; SP; LC; EX

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
11/07/23	Kokawa, Naoki	64:6-7	F; SP; LC; EX; V; AF	68:15-17; 68:19-20; 68:22-69:1; 69:4-5	[68:15-17] NREL; 403; BSD (OS); OBJ; MM [68:19-20] NREL; 403; MM; AMB; IEXP; LFND [68:22-69:1] BSD (OS); NREL; 403; MM; IEXP; NR [69:4-5] BSD (OS); NREL; 403; MM; AMB; IEXP	[68:15-17] 69:16-18; 69:21-22 [68:22-69:1] 69:16-18; 69:21-22 [68:19-20] 69:16-18; 69:21-22 [69:4-5] 69:16-18; 69:21-22	402; 403; F; SP; LC; EX
11/07/23	Kokawa, Naoki	64:23-25	F; SP; LC; EX; V; AF	68:15-17; 68:19-20; 68:22-69:1; 69:4-5	[68:15-17] NREL; 403; BSD (OS); OBJ; MM [68:19-20] NREL; 403; MM; AMB; IEXP; LFND [68:22-69:1] BSD (OS); NREL; 403; MM; IEXP; NR [69:4-5] BSD (OS); NREL; 403; MM; AMB; IEXP	[68:15-17] 69:16-18; 69:21-22 [68:22-69:1] 69:16-18; 69:21-22 [68:19-20] 69:16-18; 69:21-22 [69:4-5] 69:16-18; 69:21-22	402; 403; F; SP; LC; EX
11/07/23	Kokawa, Naoki	65:3-3	F; SP; LC; EX; V; AF	68:15-17; 68:19-20; 68:22-69:1; 69:4-5	[68:15-17] NREL; 403; BSD (OS); OBJ; MM [68:19-20] NREL; 403; MM; AMB; IEXP; LFND [68:22-69:1] BSD (OS); NREL; 403; MM; IEXP; NR [69:4-5] BSD (OS); NREL; 403; MM; AMB; IEXP	[68:15-17] 69:16-18; 69:21-22 [68:22-69:1] 69:16-18; 69:21-22 [68:19-20] 69:16-18; 69:21-22 [69:4-5] 69:16-18; 69:21-22	402; 403; F; SP; LC; EX
11/07/23	Kokawa, Naoki	65:5-7	F; SP; LC; EX; V; AF	68:15-17; 68:19-20; 68:22-69:1; 69:4-5	[68:15-17] NREL; 403; BSD (OS); OBJ; MM [68:19-20] NREL; 403; MM; AMB; IEXP; LFND [68:22-69:1] BSD (OS); NREL; 403; MM; IEXP; NR [69:4-5] BSD (OS); NREL; 403; MM; AMB; IEXP	[68:15-17] 69:16-18; 69:21-22 [68:22-69:1] 69:16-18; 69:21-22 [68:19-20] 69:16-18; 69:21-22 [69:4-5] 69:16-18; 69:21-22	402; 403; F; SP; LC; EX
11/07/23	Kokawa, Naoki	65:10-12	F; SP; LC; EX; V; AF	68:15-17; 68:19-20; 68:22-69:1; 69:4-5	[68:15-17] NREL; 403; BSD (OS); OBJ; MM [68:19-20] NREL; 403; MM; AMB; IEXP; LFND [68:22-69:1] BSD (OS); NREL; 403; MM; IEXP; NR [69:4-5] BSD (OS); NREL; 403; MM; AMB; IEXP	[68:15-17] 69:16-18; 69:21-22 [68:22-69:1] 69:16-18; 69:21-22 [68:19-20] 69:16-18; 69:21-22 [69:4-5] 69:16-18; 69:21-22	402; 403; F; SP; LC; EX
11/07/23	Kokawa, Naoki	65:14-15	F; SP; LC; EX; V; AF	68:15-17; 68:19-20; 68:22-69:1; 69:4-5	[68:15-17] NREL; 403; BSD (OS); OBJ; MM [68:19-20] NREL; 403; MM; AMB; IEXP; LFND [68:22-69:1] BSD (OS); NREL; 403; MM; IEXP; NR [69:4-5] BSD (OS); NREL; 403; MM; AMB; IEXP	[68:15-17] 69:16-18; 69:21-22 [68:22-69:1] 69:16-18; 69:21-22 [68:19-20] 69:16-18; 69:21-22 [69:4-5] 69:16-18; 69:21-22	402; 403; F; SP; LC; EX
11/07/23	Kokawa, Naoki	65:17-17	F; SP; LC; EX; V; AF	68:15-17; 68:19-20; 68:22-69:1; 69:4-5	[68:15-17] NREL; 403; BSD (OS); OBJ; MM [68:19-20] NREL; 403; MM; AMB; IEXP; LFND [68:22-69:1] BSD (OS); NREL; 403; MM; IEXP; NR [69:4-5] BSD (OS); NREL; 403; MM; AMB; IEXP	[68:15-17] 69:16-18; 69:21-22 [68:22-69:1] 69:16-18; 69:21-22 [68:19-20] 69:16-18; 69:21-22 [69:4-5] 69:16-18; 69:21-22	402; 403; F; SP; LC; EX
11/07/23	Kokawa, Naoki	65:19-22	F; SP; LC; EX; V; AF	68:15-17; 68:19-20; 68:22-69:1; 69:4-5	[68:15-17] NREL; 403; BSD (OS); OBJ; MM [68:19-20] NREL; 403; MM; AMB; IEXP; LFND [68:22-69:1] BSD (OS); NREL; 403; MM; IEXP; NR [69:4-5] BSD (OS); NREL; 403; MM; AMB; IEXP	[68:15-17] 69:16-18; 69:21-22 [68:22-69:1] 69:16-18; 69:21-22 [68:19-20] 69:16-18; 69:21-22 [69:4-5] 69:16-18; 69:21-22	402; 403; F; SP; LC; EX



DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
11/07/23	Kokawa, Naoki	66:4-5	F; SP; LC; EX; V; AF	68:15-17; 68:19-20; 68:22-69:1; 69:4-5	[68:15-17] NREL; 403; BSD (OS); OBJ; MM [68:19-20] NREL; 403; MM; AMB; IEXP; LFND [68:22-69:1] BSD (OS); NREL; 403; MM; IEXP; NR [69:4-5] BSD (OS); NREL; 403; MM; AMB; IEXP	[68:15-17] 69:16-18; 69:21-22 [68:22-69:1] 69:16-18; 69:21-22 [68:19-20] 69:16-18; 69:21-22 [69:4-5] 69:16-18; 69:21-22	402; 403; F; SP; LC; EX
11/07/23	Kokawa, Naoki	66:17-22	F; SP; LC; EX; V; AF	68:15-17; 68:19-20; 68:22-69:1; 69:4-5	[68:15-17] NREL; 403; BSD (OS); OBJ; MM [68:19-20] NREL; 403; MM; AMB; IEXP; LFND [68:22-69:1] BSD (OS); NREL; 403; MM; IEXP; NR [69:4-5] BSD (OS); NREL; 403; MM; AMB; IEXP	[68:15-17] 69:16-18; 69:21-22 [68:22-69:1] 69:16-18; 69:21-22 [68:19-20] 69:16-18; 69:21-22 [69:4-5] 69:16-18; 69:21-22	402; 403; F; SP; LC; EX
11/07/23	Kokawa, Naoki	66:25-25	F; SP; LC; EX; V; AF	68:15-17; 68:19-20; 68:22-69:1; 69:4-5	[68:15-17] NREL; 403; BSD (OS); OBJ; MM [68:19-20] NREL; 403; MM; AMB; IEXP; LFND [68:22-69:1] BSD (OS); NREL; 403; MM; IEXP; NR [69:4-5] BSD (OS); NREL; 403; MM; AMB; IEXP	[68:15-17] 69:16-18; 69:21-22 [68:22-69:1] 69:16-18; 69:21-22 [68:19-20] 69:16-18; 69:21-22 [69:4-5] 69:16-18; 69:21-22	402; 403; F; SP; LC; EX
11/07/23	Kokawa, Naoki	67:2-7	F; SP; LC; EX; V; AF	68:15-17; 68:19-20; 68:22-69:1; 69:4-5	[68:15-17] NREL; 403; BSD (OS); OBJ; MM [68:19-20] NREL; 403; MM; AMB; IEXP; LFND [68:22-69:1] BSD (OS); NREL; 403; MM; IEXP; NR [69:4-5] BSD (OS); NREL; 403; MM; AMB; IEXP	[68:15-17] 69:16-18; 69:21-22 [68:22-69:1] 69:16-18; 69:21-22 [68:19-20] 69:16-18; 69:21-22 [69:4-5] 69:16-18; 69:21-22	402; 403; F; SP; LC; EX
11/07/23	Kokawa, Naoki	67:10-14	F; SP; LC; EX; V; AF	68:15-17; 68:19-20; 68:22-69:1; 69:4-5	[68:15-17] NREL; 403; BSD (OS); OBJ; MM [68:19-20] NREL; 403; MM; AMB; IEXP; LFND [68:22-69:1] BSD (OS); NREL; 403; MM; IEXP; NR [69:4-5] BSD (OS); NREL; 403; MM; AMB; IEXP	[68:15-17] 69:16-18; 69:21-22 [68:22-69:1] 69:16-18; 69:21-22 [68:19-20] 69:16-18; 69:21-22 [69:4-5] 69:16-18; 69:21-22	402; 403; F; SP; LC; EX
11/07/23	Kokawa, Naoki	67:16-18	F; SP; LC; EX; V; AF	68:15-17; 68:19-20; 68:22-69:1; 69:4-5	[68:15-17] NREL; 403; BSD (OS); OBJ; MM [68:19-20] NREL; 403; MM; AMB; IEXP; LFND [68:22-69:1] BSD (OS); NREL; 403; MM; IEXP; NR [69:4-5] BSD (OS); NREL; 403; MM; AMB; IEXP	[68:15-17] 69:16-18; 69:21-22 [68:22-69:1] 69:16-18; 69:21-22 [68:19-20] 69:16-18; 69:21-22 [69:4-5] 69:16-18; 69:21-22	402; 403; F; SP; LC; EX
11/07/23	Kokawa, Naoki	67:21-21	F; SP; LC; EX; V; AF	68:15-17; 68:19-20; 68:22-69:1; 69:4-5	[68:15-17] NREL; 403; BSD (OS); OBJ; MM [68:19-20] NREL; 403; MM; AMB; IEXP; LFND [68:22-69:1] BSD (OS); NREL; 403; MM; IEXP; NR [69:4-5] BSD (OS); NREL; 403; MM; AMB; IEXP	[68:15-17] 69:16-18; 69:21-22 [68:22-69:1] 69:16-18; 69:21-22 [68:19-20] 69:16-18; 69:21-22 [69:4-5] 69:16-18; 69:21-22	402; 403; F; SP; LC; EX
11/07/23	Kokawa, Naoki	67:25-68:1	F; SP; LC; EX; V; AF	68:15-17; 68:22-69:1; 69:4-5	[68:15-17] NREL; 403; BSD (OS); OBJ; MM [68:22-69:1] BSD (OS); NREL; 403; MM; IEXP; NR [69:4-5] BSD (OS); NREL; 403; MM; AMB; IEXP	[68:15-17] 69:16-18; 69:21-22 [68:22-69:1] 69:16-18; 69:21-22 [69:4-5] 69:16-18; 69:21-22	402; 403; F; SP; LC; EX
11/07/23	Kokawa, Naoki	68:4-4	F; SP; LC; EX; V; AF	68:15-17; 68:22-69:1; 69:4-5	[68:15-17] NREL; 403; BSD (OS); OBJ; MM [68:22-69:1] BSD (OS); NREL; 403; MM; IEXP; NR [69:4-5] BSD (OS); NREL; 403; MM; AMB; IEXP	[68:15-17] 69:16-18; 69:21-22 [68:22-69:1] 69:16-18; 69:21-22 [69:4-5] 69:16-18; 69:21-22	402; 403; F; SP; LC; EX

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
11/07/23	Kokawa, Naoki	69:24-70:10	F; SP; LC; EX; V				
11/07/23	Kokawa, Naoki	71:4-9	F; SP; LC; EX; V				
11/07/23	Kokawa, Naoki	71:12-17	F; SP; LC; EX; V				
11/07/23	Kokawa, Naoki	71:20-25	F; SP; LC; EX; V				
11/07/23	Kokawa, Naoki	72:1-1	F; SP; LC; EX; V				
11/07/23	Kokawa, Naoki	72:4-5	F; SP; LC; EX; V				
11/07/23	Kokawa, Naoki	73:2-4	F; SP; LC; EX; V				
11/07/23	Kokawa, Naoki	73:7-7	F; SP; LC; EX; V				
11/07/23	Kokawa, Naoki	73:17-20	F; SP; LC; EX; V				
11/07/23	Kokawa, Naoki	73:22-25	F; SP; LC; EX; V				
11/07/23	Kokawa, Naoki	74:1-2	F; SP; LC; EX; V				
11/07/23	Kokawa, Naoki	74:4-5	F; SP; LC; EX; V				
11/07/23	Kokawa, Naoki	75:11-13	F; SP; LC; EX; V				
11/07/23	Kokawa, Naoki	75:16-23	F; SP; LC; EX; V				
11/07/23	Kokawa, Naoki	76:1-2	F; SP; LC; EX; V				
11/07/23	Kokawa, Naoki	76:4-8	F; SP				
11/07/23	Kokawa, Naoki	76:22-77:3	F; SP; LC; EX; V				
11/07/23	Kokawa, Naoki	77:15-18	F; SP; LC; EX; V				
11/07/23	Kokawa, Naoki	77:21-24	F; SP; LC; EX; V				
11/07/23	Kokawa, Naoki	78:2-6	F; SP; LC; EX; V				
11/07/23	Kokawa, Naoki	78:9-18	F; SP; LC; EX; V				
11/07/23	Kokawa, Naoki	78:20-21	F; SP; LC; EX; V				
11/07/23	Kokawa, Naoki	80:5-6	F; SP; LC; EX; V				
11/07/23	Kokawa, Naoki	80:9-10	F; SP; LC; EX; V				
11/07/23	Kokawa, Naoki	82:19-20	402; 403; F; SP; LC; EX; V				
11/07/23	Kokawa, Naoki	82:22-24	402; 403; F; SP; LC; EX; V				
11/07/23	Kokawa, Naoki	83:24-25	F; SP; LC; EX; V; M				
11/07/23	Kokawa, Naoki	84:1-3	F; SP; LC; EX; V; M				
11/07/23	Kokawa, Naoki	84:6-7	F; SP; LC; EX; V; M				
11/07/23	Kokawa, Naoki	86:11-12	F; SP; LC; EX; V; M				
11/07/23	Kokawa, Naoki	86:15-18	F; SP; LC; EX; V; M				
11/07/23	Kokawa, Naoki	87:2-4	F; SP; LC; EX; V; M				
11/07/23	Kokawa, Naoki	91:13-18	F; SP; LC; EX; V	95:9-12; 95:16-18	[95:9-12] BSD (OS); NREL; 403; MM; OBJ [95:16-18] BSD (OS); NREL; 403; MM; IEXP	[95:16-18] 94:17-24; 95:2-5; 96:12-19; 96:23-97:1  [95:9-12] 94:17-24; 95:2-5; 96:12-19; 96:23-97:1	402; 403; F; SP; LC; EX
11/07/23	Kokawa, Naoki	92:15-25	F; SP; LC; EX; V	95:9-12; 95:16-18	[95:9-12] BSD (OS); NREL; 403; MM; OBJ [95:16-18] BSD (OS); NREL; 403; MM; IEXP	[95:16-18] 94:17-24; 95:2-5; 96:12-19; 96:23-97:1  [95:9-12] 94:17-24; 95:2-5; 96:12-19; 96:23-97:1	402; 403; F; SP; LC; EX
11/07/23	Kokawa, Naoki	93:1-1	F; SP; LC; EX; V	95:9-12; 95:16-18	[95:9-12] BSD (OS); NREL; 403; MM; OBJ [95:16-18] BSD (OS); NREL; 403; MM; IEXP	[95:16-18] 94:17-24; 95:2-5; 96:12-19; 96:23-97:1  [95:9-12] 94:17-24; 95:2-5; 96:12-19; 96:23-97:1	402; 403; F; SP; LC; EX
11/07/23	Kokawa, Naoki	99:22-100:20 [withdrawn]	F; SP; LC; EX; V				
11/07/23	Kokawa, Naoki	101:3-17	402; 403; F; SP; LC; EX; V; AG				
11/07/23	Kokawa, Naoki	101:21-102:5	402; 403; F; SP; LC; EX; V; AG				
11/07/23	Kokawa, Naoki	102:8-8	402; 403; F; SP; LC; EX; V; AG				
11/07/23	Kokawa, Naoki	102:10-104:3	402; 403; F; SP; LC; EX; V; AG				
11/07/23	Kokawa, Naoki	104:12-25	402; 403; F; SP; LC; EX; V; AG				
11/07/23	Kokawa, Naoki	105:1-1	402; 403; F; SP; LC; EX; V; AG				
11/07/23	Kokawa, Naoki	105:8-19	402; 403; F; SP; LC; EX; V; AG				
11/07/23	Kokawa, Naoki	105:23-110:21	402; 403; F; SP; LC; EX; V; AG				
11/07/23	Kokawa, Naoki	116:6-10	F; SP; LC; EX; V	119:14-17; 119:19-22	[119:14-17] NREL; 403; LFND [119:19-22] NREL; 403; LFND; AMB	[119:19-22] 26:20-27:1  [119:14-17] 26:20-27:1	402; 403
11/07/23	Kokawa, Naoki	116:17-24	F; SP; LC; EX; V	119:14-17; 119:19-22	[119:14-17] NREL; 403; LFND [119:19-22] NREL; 403; LFND; AMB	[119:19-22] 26:20-27:1  [119:14-17] 26:20-27:1	402; 403
11/07/23	Kokawa, Naoki	117:21-118:4	F; SP; LC; EX; V	119:14-17; 119:19-22	[119:14-17] NREL; 403; LFND [119:19-22] NREL; 403; LFND; AMB	[119:19-22] 26:20-27:1  [119:14-17] 26:20-27:1	402; 403
11/07/23	Kokawa, Naoki	118:12-119:13	F; SP; LC; EX; V	119:14-17; 119:19-22	[119:14-17] NREL; 403; LFND [119:19-22] NREL; 403; LFND; AMB	[119:19-22] 26:20-27:1  [119:14-17] 26:20-27:1	402; 403

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
11/07/23	Kokawa, Naoki	122:22-24	F; SP; LC; EX; V; AF				
11/07/23	Kokawa, Naoki	123:1-1	F; SP; LC; EX; V; AF				
11/08/23	Koo, Peter	10:14-11:6					
11/08/23	Koo, Peter	14:16-18 [withdrawn]					
11/08/23	Koo, Peter	16:19-17:15 [withdrawn]					
11/08/23	Koo, Peter	19:19-21:3 [withdrawn]					
11/08/23	Koo, Peter	21:16-25 [withdrawn]					
11/08/23	Koo, Peter	22:5-20 [withdrawn]					
11/08/23	Koo, Peter	26:11-27:10 [withdrawn]					
11/08/23	Koo, Peter	28:1-6 [withdrawn]					
11/08/23	Koo, Peter	37:12-39:22 [withdrawn]					
11/08/23	Koo, Peter	68:11-69:6					
11/08/23	Koo, Peter	69:14-20					
11/08/23	Koo, Peter	70:6-71:12					
11/08/23	Koo, Peter	74:8-75:3					
11/08/23	Koo, Peter	75:21-76:2					
11/08/23	Koo, Peter	76:11-25					
11/08/23	Koo, Peter	80:24-81:8					
11/08/23	Koo, Peter	81:10-82:19					
11/08/23	Koo, Peter	84:24-86:24					
11/08/23	Koo, Peter	88:22-89:4					
11/08/23	Koo, Peter	97:13-99:10 [withdrawn]		99:11-99:12; 100:10-100:16 - Keep Count	403; BSD (OS); NREL; OBJ	99:7-10; 100:18-19; 100:23-25	
11/08/23	Koo, Peter	113:15-114:9					
11/08/23	Koo, Peter	118:1-119:15 [withdrawn]					
11/08/23	Koo, Peter	120:21-121:1 [withdrawn]					
11/08/23	Koo, Peter	123:4-21					
11/08/23	Koo, Peter	135:2-9					
11/08/23	Koo, Peter	138:16-141:20					
11/08/23	Koo, Peter	145:9-146:19					
11/08/23	Koo, Peter	149:6-20					
11/08/23	Koo, Peter	152:10-153:4					
11/08/23	Koo, Peter	153:20-154:17					
11/08/23	Koo, Peter	158:12-159:15					
11/08/23	Koo, Peter	159:16-162:16					
11/08/23	Koo, Peter	164:6-169:10	402; 403; AG; F				
11/08/23	Koo, Peter	172:17-173:6					
11/08/23	Koo, Peter	174:14-24					
11/08/23	Koo, Peter	174:25-175:15					
11/08/23	Koo, Peter	177:10-178:17					
11/08/23	Koo, Peter	179:14-17					
11/08/23	Koo, Peter	180:4-25	AG; F				
11/08/23	Koo, Peter	181:1-182:2					
11/08/23	Koo, Peter	182:12-19					
11/08/23	Koo, Peter	183:4-15					
11/08/23	Koo, Peter	207:6-15 [withdrawn]					
11/08/23	Koo, Peter	208:2-6 [withdrawn]					
11/08/23	Koo, Peter	210:18-211:7 [withdrawn]					
11/08/23	Koo, Peter	213:22-214:17 [withdrawn]					
11/08/23	Koo, Peter	215:1-216:9 [withdrawn]	402; 403; AG; F				
11/08/23	Koo, Peter	225:19-227:10					
11/08/23	Koo, Peter	228:10-229:24					
11/08/23	Koo, Peter	240:14-241:20		241:21-241:25	[241:21-5] 403; NREL; OBJ	[241:21-5] 24:2-4; 24:6-25:1	OS; 402
11/08/23	Koo, Peter	242:2-15					
11/08/23	Koo, Peter	242:21-243:17					
11/08/23	Koo, Peter	244:14-245:5		245:6-245:14	[245:6-245:14] 403; BSD (OS); NREL		
11/08/23	Koo, Peter	245:25-248:7					
10/27/23	Kotcherha, Kyla	7:15-20					
10/27/23	Kotcherha, Kyla	8:3-9					
10/27/23	Kotcherha, Kyla	8:22-9:3 [withdrawn]					
10/27/23	Kotcherha, Kyla	9:10-14					
10/27/23	Kotcherha, Kyla	11:20-12:3	F; SP; LC; EX				
10/27/23	Kotcherha, Kyla	12:16-13:1	F; SP				
10/27/23	Kotcherha, Kyla	14:13-14					
10/27/23	Kotcherha, Kyla	14:20-16:11		16:12-15	[16:12-15] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Kotcherha, Kyla	17:2-10	F; SP				
10/27/23	Kotcherha, Kyla	18:15-19:1					
10/27/23	Kotcherha, Kyla	19:22-21:21	402; 403; LC; EX; AF				

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
10/27/23	Kotcherha, Kyla	24:16-19	402				
10/27/23	Kotcherha, Kyla	25:15-17 [withdrawn]					
10/27/23	Kotcherha, Kyla	26:2-25 [withdrawn]	402; F; SP; AF				
10/27/23	Kotcherha, Kyla	27:5-21 [withdrawn]	402				
10/27/23	Kotcherha, Kyla	29:7-22	402; F; LC; EX				
10/27/23	Kotcherha, Kyla	31:25-32:19 [withdrawn]	402; F; LC; EX	35:19-36:10	403; AG; AMB; SPC; HYP; LFND; MIS; NREL	36:13-25; 37-6-14	402; 403; F; SP
10/27/23	Kotcherha, Kyla	33:6-10	402; 403; F; LC; EX				
10/27/23	Kotcherha, Kyla	37:15-22	402; 403; AC; WP				
10/27/23	Kotcherha, Kyla	38:3-10 [withdrawn]	402; 403; AC; WP				
10/27/23	Kotcherha, Kyla	39:12-21 [withdrawn]					
10/27/23	Kotcherha, Kyla	49:7-20 [withdrawn]					
10/27/23	Kotcherha, Kyla	49:23-50:5					
10/27/23	Kotcherha, Kyla	50:8-13					
10/27/23	Kotcherha, Kyla	50:18-53:24	F; SP				
10/27/23	Kotcherha, Kyla	53:25-54:21					
10/27/23	Kotcherha, Kyla	55:4-16					
10/27/23	Kotcherha, Kyla	55:19-23		55:24-25; 56:3-4; 56:7-16; 57:14-20; 57:23-58:3	[55:24-25] AMB; AA; AG; LFND; MIS; NREL; 403 [56:3-4] AMB; AA; AG; LFND; MIS; NREL; 403 [56:7-16] AMB; AA; AG; LFND; MIS; NREL; 403 [57:14-20] AMB; AA; AG; LFND; MIS; NREL; 403; MM [57:23-58:3] AMB; AA; AG; LFND; MIS; NREL; 403; MM		
10/27/23	Kotcherha, Kyla	59:22-60:5	F; LC; EX				
10/27/23	Kotcherha, Kyla	60:8-18					
10/27/23	Kotcherha, Kyla	61:7-62:23					
10/27/23	Kotcherha, Kyla	63:5-8		63:9-10	[63:9-10] AMB; AA; AG; LFND; MIS; NREL; 403; MM		
10/27/23	Kotcherha, Kyla	63:11-64:2	F; SP				
10/27/23	Kotcherha, Kyla	73:18-78:6	F; LC; EX				
10/27/23	Kotcherha, Kyla	78:22-25		79:1-2	[79:1-2] AMB; AA; AG; LFND; MIS; NREL; 403; MM		
10/27/23	Kotcherha, Kyla	79:3-16	F; SP				
10/27/23	Kotcherha, Kyla	79:21-80:21		80:22-81:8	[80:22-81:8] AMB; AA; AG; LFND; MIS; NR; NREL; 403; MM		
10/27/23	Kotcherha, Kyla	81:9-82:11	F; SP				
10/27/23	Kotcherha, Kyla	83:3-6	F; LC; EX				
10/27/23	Kotcherha, Kyla	83:12-84:10	F; SP				
10/27/23	Kotcherha, Kyla	84:17-85:3	F; SP				
10/27/23	Kotcherha, Kyla	85:8-86:13	F; SP; LC; EX				
10/27/23	Kotcherha, Kyla	86:21-87:10	F; LC; EX				
10/27/23	Kotcherha, Kyla	87:16-88:12	F; SP				
10/27/23	Kotcherha, Kyla	90:3-9	F; SP; AF				
10/27/23	Kotcherha, Kyla	92:1-12	F; SP; AF				
10/27/23	Kotcherha, Kyla	93:13-22	F; SP; AF				
10/27/23	Kotcherha, Kyla	94:1-10	F; SP; AF				
10/27/23	Kotcherha, Kyla	94:22-95:3	F; SP; AF				
10/27/23	Kotcherha, Kyla	95:18-21	F; SP; AF				
10/27/23	Kotcherha, Kyla	96:1-6	F; SP; AF				
10/27/23	Kotcherha, Kyla	96:15-22	F; SP; AF				
10/27/23	Kotcherha, Kyla	97:10-16		97:17-19; 97:23-25	[97:17-25] AMB; AA; AG; LFND; LDG; MIS; NREL; 403	[97:17-19] 98:2-5	
			F; LC; EX			[97:23-25] 98:2-5	F; SP; LC; EX

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER- COUNTERS
10/27/23	Kotcherha, Kyla	98:14-101:23		98:6-13; 106:19-107:3; 107:11-108:4; 108:23-109:9; 109:12-13; 109:17-25; 110:3-3; 111:19-21; 111:23-112:8; 112:11-15	[98:6-13] AMB; AA; AG; LFND; LDG; MIS; NREL; 403 [106:19-107:3] AMB; AA; AG; BSD (OS); SPC; LFND; MIS; NREL; 403 [107:11-108:4] AMB; AA; AG; BSD (OS); SPC; IEXP; LFND; MIS; NP; NREL; 403 [108:23-109:9] AMB; AA; AG; BSD (OS); SPC; IEXP; LFND; LDG; MIS; NP; NREL; 403 [109:12-13] AMB; AA; AG; BSD (OS); SPC; IEXP; LFND; LDG; MIS; NP; NREL; 403 [109:17-25] AMB; AA; AG; BSD (OS); SPC; IEXP; LFND; MIS; NP; NREL; 403 [110:3-3] AMB; AA; AG; BSD (OS); SPC; IEXP; LFND; MIS; NP; NREL; 403 [111:19-21] AMB; AA; AG; BSD (OS); SPC; IEXP; LFND; MIS; NP; NREL; 403 [111:23-112:8] AMB; AA; AG; BSD (OS); SPC; IEXP; LFND; MIS; NP; NREL; 403 [112:11-15] AMB; AA; AG; BSD (OS); SPC; IEXP; LFND; MIS; NP; NREL; 403		
			F; SP; AF; LC; EX				
10/27/23	Kotcherha, Kyla	103:6-20	F; SP; AF				
10/27/23	Kotcherha, Kyla	104:9-19	F; SP				
10/27/23	Kotcherha, Kyla	105:16-23	F; SP				
10/27/23	Lodato, Franco	6:19-22	402				
10/27/23	Lodato, Franco	7:2-12					
10/27/23	Lodato, Franco	10:6-11 [withdrawn]	402, 403, F				
10/27/23	Lodato, Franco	12:23-13:12 [withdrawn]	402, 403, F				
10/27/23	Lodato, Franco	13:17-14:8 [withdrawn]	402, 403				
10/27/23	Lodato, Franco	15:17-22	402, 403, F, V				
10/27/23	Lodato, Franco	16:22-17:12 [withdrawn]	402, 403, V				
10/27/23	Lodato, Franco	17:21-23	402, 403				
10/27/23	Lodato, Franco	18:22-19:2	402, 403, F				
10/27/23	Lodato, Franco	21:18-22:4	402, 403, F				
10/27/23	Lodato, Franco	22:16-22	402, 403, F				
10/27/23	Lodato, Franco	23:12-14 [added]					
10/27/23	Lodato, Franco	25:2-4					
10/27/23	Lodato, Franco	31:14-21 [withdrawn]	402, 403, LC				
10/27/23	Lodato, Franco	41:7-9	402, 403, SP	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	42:5-9		44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	42:18-24		44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	43:7-10		44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	48:24-49:1	402, V, SP				
10/27/23	Lodato, Franco	51:22-52:10					
10/27/23	Lodato, Franco	53:19-54:11					
10/27/23	Lodato, Franco	55:1-2		44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	55:10-15	402, 403, V	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	55:19-21	402, 403, V	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	56:22-57:1		44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	58:10-16 [withdrawn]	402, 403, F				
10/27/23	Lodato, Franco	59:6-12	V, SP, F				
10/27/23	Lodato, Franco	60:3-24	V, SP, F				
10/27/23	Lodato, Franco	61:9-62:7 [withdrawn]	V, 402, 403	55:19-56:1; 44:16-25	[55:19-56:1] 403; AG; AMB; LFND; MIS [44:16-25] AMB; AG; LFND; MIS; NREL; 403	61:9-23	V, 402, 403
10/27/23	Lodato, Franco	62:17-23	402, 403	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	63:1-8	402, 403	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
10/27/23	Lodato, Franco	63:18-24	402, 403, M				
10/27/23	Lodato, Franco	64:8-18 [added]	402, 403, M, SP, F				
10/27/23	Lodato, Franco	66:12-67:10	402, 403, SP, V, LE	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	67:16-20	402, 403, SP, V, LE	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	69:1-4	402, 403	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	69:13-16	402, SP, F	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	70:4-20	402, SP, F	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	71:14-73:10	F, SP, V				
10/27/23	Lodato, Franco	76:20-77:2	F, SP, V	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	78:8-11	F, SP, V	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	81:4-13	M	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	82:11-83:20	SP, V, LE	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	84:6-18		44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	85:11-17	SP	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	86:20-87:2	SP, AF, V	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	87:20-89:19	SP, AF, V	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	91:6-25	402, 403				
10/27/23	Lodato, Franco	93:16-22	V, SP, M	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	94:20-95:2	402, CO, V	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	95:10-14	402, CO, V	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	95:15-97:4	402, CO, V, SP, LE	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	97:13-18	402, CO, V, SP, LE	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	99:22-24 [added]	402, V, SP, LE, F	44:16-25			
10/27/23	Lodato, Franco	100:22-101:8	M, LE, V				
10/27/23	Lodato, Franco	101:20-102:2 [withdrawn]					
10/27/23	Lodato, Franco	103:23-105:17	402, 403, M	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	106:7-13	402, 403, V	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	110:4-113:19 [withdrawn]	F, V, SP	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	115:11-18 [withdrawn]	M, V	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	117:1-22	F, SP				
10/27/23	Lodato, Franco	120:2-121:12	SP, V, I, LE	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	121:19-122:2	SP, V, I, LE	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	123:23-124:9	SP, V, I, LE	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	124:15-19	SP, V, I, LE	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	128:17-22	402, 403, M, SP, V, LE, F	44:16-25			
10/27/23	Lodato, Franco	129:10-18	SP	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	130:8-18		44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	132:16-133:15		44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
10/27/23	Lodato, Franco	134:15-135:3	AF, M, SP, V	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	135:11-15	AF, M, SP, V	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	138:6-15	AF, M, SP, V	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	141:12-23	AF, V, F	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	142:3-12	AF, V, F	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	143:17-144:15	V	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	145:8-21	V	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	148:15-21	AF, V				
10/27/23	Lodato, Franco	149:10-150:8	AF, V				
10/27/23	Lodato, Franco	150:18-151:17	SP, F, AF	44:16-25; 154:9-24	[44:16-25] AMB; AG; LFND; MIS; NREL; 403 [154:9-24] AMB; AG; LFND; LDG; MIS; NREL; 403	153:21-154:7	SP, F, AF
10/27/23	Lodato, Franco	151:21-153:2		44:16-25; 154:9-24	[44:16-25] AMB; AG; LFND; MIS; NREL; 403 [154:9-24] AMB; AG; LFND; LDG; MIS; NREL; 403	153:21-154:7	SP, F, AF
10/27/23	Lodato, Franco	155:1-11		44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	155:15-157:18	V, SP	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	157:23-24	SP, F	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	158:12-159:1	SP, F	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	159:19-160:10	SP, F	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	160:21-161:10	F, AF, V	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	162:8-15	F, AF, V	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	162:17-163:14	SP	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	163:17-164:13	AF, F, V, SP	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	165:2-166:1		44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	166:5-25		44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	167:3-11	402, 403, CO, F, SP	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	167:18-168:4	402, 403, CO, F, SP	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	168:8-19	402, 403, CO, F, SP	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	169:21-170:12	F, SP	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	170:18-22	F, SP	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	171:19-172:15	F, SP	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	173:4-22	AF, V	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	176:11-22	LE, V, SP, F	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	177:15-22 [withdrawn]		44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	178:2-179:7 [withdrawn]	F, SP, V	179:15-180:7; 44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	184:17-186:22 [withdrawn]	V, CO, SP	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
10/27/23	Lodato, Franco	188:1-8	LE, AG, V SP	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	188:20-189:22	LE, AG, V SP	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
10/27/23	Lodato, Franco	190:8-16	LE, AG, V SP	44:16-25	[44:16-25] AMB; AG; LFND; MIS; NREL; 403		
11/10/23	McClenahan, Tom	8:14-21					
11/10/23	McClenahan, Tom	9:8-14 [withdrawn]					
11/10/23	McClenahan, Tom	10:11-18					
11/10/23	McClenahan, Tom	15:12-21 [withdrawn]					
11/10/23	McClenahan, Tom	22:23-23:21 [withdrawn]					
11/10/23	McClenahan, Tom	25:16-26:10 [withdrawn]					
11/10/23	McClenahan, Tom		402/403	24:16-25:4	AMB; AG; LFND; BSD; NREL; 403	12:12-13:11; 26:2-6; 99:13-100:2; 101:22-102:6	V; SP; OS; 403; IH; AF
11/10/23	McClenahan, Tom	29:16-30:13 [withdrawn]					
11/10/23	McClenahan, Tom	36:16-20 [withdrawn]					
11/10/23	McClenahan, Tom	36:23-38:1					
11/10/23	McClenahan, Tom	42:2-4					
11/10/23	McClenahan, Tom	42:7-9					
11/10/23	McClenahan, Tom	42:14-14					
11/10/23	McClenahan, Tom	42:19-19					
11/10/23	McClenahan, Tom	44:14-24					
11/10/23	McClenahan, Tom	52:18-77:15 [withdrawn]					
11/10/23	McClenahan, Tom		402/403/A/M/AG/AC/AF/CO/LC	81:2-16, 81:17-82:1, 82:10-12, 84:1-84:8, 102:8-12	AMB; AG; LFND; BSD; NREL; 403; MIS; 1006		
11/10/23	McClenahan, Tom	92:2-4	402/403/M/F/LC/LW/AC/V/AG	102:8-12	[81:17-16] BSD (OS); CLC; SPC; 1006; NREL; 403 [102:8-12] BSD (OS); IMPs; MIS; NE; NREL; OBJ; 403		
11/03/23	Menawat, Devesh	6:16-17					
11/03/23	Menawat, Devesh	6:18-25					
11/03/23	Menawat, Devesh	7:1-5					
11/03/23	Menawat, Devesh	7:6-9:11					
11/03/23	Menawat, Devesh	9:14-17					
11/03/23	Menawat, Devesh	9:20-22					
11/03/23	Menawat, Devesh	9:24-10:3					
11/03/23	Menawat, Devesh	10:4-24					
11/03/23	Menawat, Devesh	11:2-5					
11/03/23	Menawat, Devesh	11:8-14					
11/03/23	Menawat, Devesh	11:18-12:23					
11/03/23	Menawat, Devesh	13:3-22					
11/03/23	Menawat, Devesh	13:23-23					
11/03/23	Menawat, Devesh	14:8-10					
11/03/23	Menawat, Devesh	15:10-12					
11/03/23	Menawat, Devesh	18:2-16					
11/03/23	Menawat, Devesh	18:23-25					
11/03/23	Menawat, Devesh	19:5-6					
11/03/23	Menawat, Devesh	23:5-25					
11/03/23	Menawat, Devesh	24:1-1					
11/03/23	Menawat, Devesh	24:3-17					
11/03/23	Menawat, Devesh	25:9-13					
11/03/23	Menawat, Devesh	27:6-25					
11/03/23	Menawat, Devesh	28:1-15					
11/03/23	Menawat, Devesh	28:16-18					
11/03/23	Menawat, Devesh	28:21-25	F; SP				
11/03/23	Menawat, Devesh	29:1-6					
11/03/23	Menawat, Devesh	29:22-23					
11/03/23	Menawat, Devesh	30:1-14					
11/03/23	Menawat, Devesh	30:20-25					
11/03/23	Menawat, Devesh	31:2-21					
11/03/23	Menawat, Devesh	32:12-25					
11/03/23	Menawat, Devesh	33:1-3					
11/03/23	Menawat, Devesh	33:6-16					
11/03/23	Menawat, Devesh	34:13-25					
11/03/23	Menawat, Devesh	35:2-25					
11/03/23	Menawat, Devesh	36:1-18					
11/03/23	Menawat, Devesh	36:20-25					
11/03/23	Menawat, Devesh	37:1-25					
11/03/23	Menawat, Devesh	38:1-12					
11/03/23	Menawat, Devesh	38:15-15					



DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER- COUNTERS
11/03/23	Menawat, Devesh	39:15-16					
11/03/23	Menawat, Devesh	39:18-18					
11/03/23	Menawat, Devesh	40:19-25					
11/03/23	Menawat, Devesh	41:3-7					
11/03/23	Menawat, Devesh	41:10-14	F				
11/03/23	Menawat, Devesh	41:17-25	F; AG				
11/03/23	Menawat, Devesh	42:2-2					
11/03/23	Menawat, Devesh	42:8-9	F; AG				
11/03/23	Menawat, Devesh	42:13-13					
11/03/23	Menawat, Devesh	42:15-18	F; SP				
11/03/23	Menawat, Devesh	42:24-25					
11/03/23	Menawat, Devesh	43:1-4					
11/03/23	Menawat, Devesh	43:8-8					
11/03/23	Menawat, Devesh	43:10-25	F; AG				
11/03/23	Menawat, Devesh	44:1-1	F; AG				
11/03/23	Menawat, Devesh	44:5-6	F; AG				
11/03/23	Menawat, Devesh	44:18-25					
11/03/23	Menawat, Devesh	45:1-1					
11/03/23	Menawat, Devesh	45:5-5					
11/03/23	Menawat, Devesh	53:7-8					
11/03/23	Menawat, Devesh	53:9-12					
11/03/23	Menawat, Devesh	53:22-23		53:24-54:3; 54:11-14	[53:24-54:3] AMB; SPC; NREL; 403 [54:11-14] AMB; SPC; NREL; 403	[53:24-54:3] 54:4-6 [54:11-14] 54:4-6	
11/03/23	Menawat, Devesh	54:4-6					
11/03/23	Menawat, Devesh	55:16-18	F; SP				
11/03/23	Menawat, Devesh	55:21-22					
11/03/23	Menawat, Devesh	55:24-24					
11/03/23	Menawat, Devesh	56:2-3					
11/03/23	Menawat, Devesh	56:5-10					
11/09/23	Muhsin, Bilal	16:22-24					
11/09/23	Muhsin, Bilal	63:24-24					
11/09/23	Muhsin, Bilal	64:3-7					
11/09/23	Muhsin, Bilal	64:16-65:5					
11/09/23	Muhsin, Bilal	65:10-13		68:24-69:2	[68:24-69:2] AMB; NREL; 403		
11/09/23	Muhsin, Bilal	71:21-72:5	402/403				
11/09/23	Muhsin, Bilal	72:11-73:11	402/403				
11/09/23	Muhsin, Bilal	73:21-74:4	402/403				
11/09/23	Muhsin, Bilal	74:8-25	F; SP				
11/09/23	Muhsin, Bilal	124:16-16	402/403	125:8-18	[125:8-18] INC; 403		
11/09/23	Muhsin, Bilal	124:20-125:7	402/403	125:8-18	[125:8-18] INC; 403		
11/09/23	Muhsin, Bilal	125:19-21	402/403	125:8-18	[125:8-18] INC; 403		
11/09/23	Muhsin, Bilal	125:24-126:2	402/403	125:8-18	[125:8-18] INC; 403		
11/09/23	Muhsin, Bilal	126:5-8	402/403	125:8-18	[125:8-18] INC; 403		
11/09/23	Muhsin, Bilal	126:11-17	402/403	125:8-18	[125:8-18] INC; 403		
11/09/23	Muhsin, Bilal	128:7-8					
11/09/23	Muhsin, Bilal	128:17-20		128:21-22; 128:21-129:1	[128:21-22] AMB; 403 [128:23-129:1] AMB; 403		
11/09/23	Muhsin, Bilal	142:18-23					
11/09/23	Muhsin, Bilal	146:4-147:6		147:7-11	[147:7-11] AMB; INC; NREL; 403	147:12-24	
11/09/23	Muhsin, Bilal	148:6-14					
11/09/23	Muhsin, Bilal	148:23-149:5	F; SP	149:16-150:2	[149:16-150:2] AMB; SPC; 403		
11/09/23	Muhsin, Bilal	150:14-15		150:18-20	[150:18-20] AMB; 403		
11/09/23	Muhsin, Bilal	150:21-23		150:24-151:3	[150:24-151:3] AMB; 403		
11/09/23	Muhsin, Bilal	151:4-8	F; SP	151:9-11	[151:9-11] AMB; 403		
11/09/23	Muhsin, Bilal	151:12-153:2	F; SP				
11/09/23	Muhsin, Bilal	182:4-5					
11/09/23	Muhsin, Bilal	182:9-184:13		184:14-16	[184:14-16] 403		
11/09/23	Muhsin, Bilal	184:17-185:3					
11/09/23	Muhsin, Bilal	185:6-186:10					
11/09/23	Muhsin, Bilal	186:25-187:3					
11/09/23	Muhsin, Bilal	187:7-21		187:22-23			
11/09/23	Muhsin, Bilal	187:24-188:7					
11/09/23	Muhsin, Bilal	188:18-189:23		189:24-190:4; 190:14-191:3	[189:24-190:4] AMB; AG; LFND; 403 [190:14-191:3] AMB; AG; LFND; 403		
11/09/23	Muhsin, Bilal	190:5-8		189:24-190:4; 190:14-191:3	[189:24-190:4] AMB; AG; LFND; 403 [190:14-191:3] AMB; AG; LFND; 403		
11/09/23	Muhsin, Bilal	222:17-25					

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
11/09/23	Muhsin, Bilal	223:1-9					
11/09/23	Muhsin, Bilal	226:10-25					
11/09/23	Muhsin, Bilal	227:1-6					
11/09/23	Muhsin, Bilal	257:14-15					
11/09/23	Muhsin, Bilal	257:19-21					
11/09/23	Muhsin, Bilal	257:23-24					
11/09/23	Muhsin, Bilal	258:2-9					
11/09/23	Muhsin, Bilal	258:20-23					
11/09/23	Muhsin, Bilal	259:4-7					
11/09/23	Muhsin, Bilal	260:11-16					
11/09/23	Muhsin, Bilal	260:23-261:2					
11/09/23	Muhsin, Bilal	261:18-20					
11/09/23	Muhsin, Bilal	261:25-262:2					
11/09/23	Muhsin, Bilal	264:23-23					
11/09/23	Muhsin, Bilal	265:3-24		265:25-266:7			
11/09/23	Muhsin, Bilal	266:10-12					
11/09/23	Muhsin, Bilal	272:12-22					
11/09/23	Muhsin, Bilal	274:6-8		274:9-17	[274:9-17] AMB; 403		
11/09/23	Muhsin, Bilal	277:15-15					
11/09/23	Muhsin, Bilal	277:19-278:12					
11/09/23	Muhsin, Bilal	278:16-24		278:25-279:2	[278:25-279:2] AMB; SPC; LFND; 403		
11/09/23	Muhsin, Bilal	282:9-15					
11/09/23	Muhsin, Bilal	282:19-283:1					
11/09/23	Muhsin, Bilal	283:7-14		283:15-16		283:17-19	F; SP
11/09/23	Muhsin, Bilal	289:17-19					
11/09/23	Muhsin, Bilal	289:22-22					
11/09/23	Muhsin, Bilal	289:24-290:12					
11/09/23	Muhsin, Bilal	290:15-16					
11/09/23	Muhsin, Bilal	291:3-10					
11/09/23	Muhsin, Bilal	291:14-292:1					
11/09/23	Muhsin, Bilal	292:3-14					
11/09/23	Muhsin, Bilal	292:20-24					
11/09/23	Muhsin, Bilal	293:9-13					
11/09/23	Muhsin, Bilal	294:24-295:5					
11/09/23	Muhsin, Bilal	295:9-22					
11/09/23	Muhsin, Bilal	295:24-24					
11/09/23	Muhsin, Bilal	296:2-297:4					
11/09/23	Muhsin, Bilal	297:15-21		297:22-298:16			
11/09/23	Muhsin, Bilal	298:17-299:13					
11/09/23	Muhsin, Bilal	307:14-16					
11/09/23	Muhsin, Bilal	307:20-21					
11/09/23	Muhsin, Bilal	307:24-308:9					
11/09/23	Muhsin, Bilal	308:14-309:6					
11/09/23	Muhsin, Bilal	329:24-330:6		329:20-23			
11/09/23	Muhsin, Bilal	330:8-16		330:17-17			
11/09/23	Muhsin, Bilal	331:13-19					
11/09/23	Muhsin, Bilal	337:7-11					
02/07/24	Muhsin, Bilal	7:20-25					
02/07/24	Muhsin, Bilal	8:1-8					
02/07/24	Muhsin, Bilal	10:11-11:1					
02/07/24	Muhsin, Bilal	11:15-21					
02/07/24	Muhsin, Bilal	159:20-160:21	402; 403	160:22-161:14	[160:22-161:14] AMB; IEXP; LFND; 403		
02/07/24	Muhsin, Bilal	161:15-20	402; 403	161:21-24	[161:21-24] AMB; IEXP; LFND; 403		
02/07/24	Muhsin, Bilal	168:19-23	402; 403	168:24-169:11	[168:24-169:11] AMB; AG; INC; LFND; 403	164:15-18	402; 403
02/07/24	Muhsin, Bilal	169:18-170:4	402; 403				
02/07/24	Muhsin, Bilal	236:2-17	402; 403				
02/07/24	Muhsin, Bilal	236:21-237:2	402; 403				
02/07/24	Muhsin, Bilal	237:11-13	402; 403	237:21-238:15	[237:21-238:15] AMB; AG; HRS; IEXP; LFND; NR; 403	238:16-239:9; 243:2-4	402; 403
02/07/24	Muhsin, Bilal	239:10-17	402; 403	239:18-23	[239:18-23] AMB; AG; HRS; LFND; NREL; 403	243:2-4	402; 403
02/07/24	Muhsin, Bilal	240:18-241:1	402; 403	241:13-20	[241:13-20] AMB; IEXP; LFND; NREL; 403	243:2-4	402; 403
02/07/24	Muhsin, Bilal	268:8-14	402; 403				
02/07/24	Muhsin, Bilal	327:24-328:9	402; 403				
02/07/24	Muhsin, Bilal	331:9-332:21	402; 403	328:12-329:1	[328:12-329:1] AMB; AG; IEXP; LFND; 403	329:8-11; 330:5-9	402; 403
08/19/22	Muhsin, Bilal (CDCA)	8:14-23		18:1-18	[18:1-18] AMB; 1006; INC; 403		
08/19/22	Muhsin, Bilal (CDCA)	9:3-8		18:1-18	[18:1-18] AMB; 1006; INC; 403		
08/19/22	Muhsin, Bilal (CDCA)	16:18-19		18:1-18	[18:1-18] AMB; 1006; INC; 403		

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
08/19/22	Muhsin, Bilal (CDCA)	16:22-24		18:1-18	[18:1-18] AMB; 1006; INC; 403		
08/19/22	Muhsin, Bilal (CDCA)	17:15-22		18:1-18	[18:1-18] AMB; 1006; INC; 403		
08/19/22	Muhsin, Bilal (CDCA)	139:22-24		138:21-139:18; 139:25-140:3	[138:21-139:18] AMB; AG; HRS; 1006; NR; NREL; 403 [139:25-140:3] AMB; NREL; 403	140:4-142:8	402; 403
08/19/22	Muhsin, Bilal (CDCA)	160:8-13		160:14-20	[160:14-20] AMB; INC; 403		
08/19/22	Muhsin, Bilal (CDCA)	161:20-24					
08/19/22	Muhsin, Bilal (CDCA)	215:16-216:10		161:25-162:3; 215:13-15; 216:11-217:6	[216:11-217:6] AMB; LFND; 403	[216:11-217:6] 217:15-19 [215:13-15] 217:15-19	
08/19/22	Muhsin, Bilal (CDCA)	218:12-25		219:1-5; 219:8-16			
08/19/22	Muhsin, Bilal (CDCA)	231:23-25	402; 403				
08/19/22	Muhsin, Bilal (CDCA)	232:1-12	402; 403				
08/19/22	Muhsin, Bilal (CDCA)	270:22-271:5	402; 403				
08/19/22	Muhsin, Bilal (CDCA)	276:9-22	402; 403				
08/19/22	Muhsin, Bilal (CDCA)	277:2-5	402; 403				
12/15/21	Muhsin, Bilal (ITC)	5:9-12					
12/15/21	Muhsin, Bilal (ITC)	49:18-20		49:21-50:12; 50:16-20; 50:25-51:4	[49:21-50:12] AMB; AG; 1006; INC; NR; NREL; 403 [50:16-20] AMB; AG; LA; NREL; 403 [50:25-51:4] AMB; NREL; 403		
12/15/21	Muhsin, Bilal (ITC)	53:24-54:11		53:17-23; 54:12-16	[53:17-23] AMB; NREL; 403 [54:12-16] AMB; NREL; 403		
12/15/21	Muhsin, Bilal (ITC)	60:22-25		61:3-6	[61:3-6] AMB; INC; LFND; 403		
12/15/21	Muhsin, Bilal (ITC)	157:15-16					
12/15/21	Muhsin, Bilal (ITC)	157:19-25					
12/15/21	Muhsin, Bilal (ITC)	158:8-10		158:11-22	[158:11-22] AMB; AG; NREL; 403	167:25-168:5	402; 403
12/15/21	Muhsin, Bilal (ITC)	158:23-159:2					
12/15/21	Muhsin, Bilal (ITC)	164:5-23	402; 403				
12/15/21	Muhsin, Bilal (ITC)	164:24-165:5	402; 403				
12/15/21	Muhsin, Bilal (ITC)	165:7-7	402; 403				
12/15/21	Muhsin, Bilal (ITC)	165:9-10	402; 403	165:11-166:1	[165:11-166:1] AMB; AG; NREL; 403		
12/15/21	Muhsin, Bilal (ITC)	166:21-167:2					
12/15/21	Muhsin, Bilal (ITC)	167:15-17		167:6-14; 167:18-24; 168:6-22; 169:6-8	[167:6-14] AMB; AG; LFND; NREL; 403 [167:18-24] AMB; LFND; NREL; 403 [168:6-22] AMB; 1006; LFND; NREL; 403	[167:6-14] 167:25-168:5 [167:18-24] 167:25-168:5 [168:6-22] 167:25-168:5 [169:6-8] 167:25-168:5	402; 403
12/15/21	Muhsin, Bilal (ITC)	184:16-18		184:19-185:15; 186:17-23	[184:19-185:15] AMB; AG; LFND; NREL; 403 [186:17-23] AMB; AG; LFND; NREL; 403	[184:19-185:15] 185:16-24 [186:17-23] 185:16-24	402; 403
02/22/22	Muhsin, Bilal (ITC)	8:16-17					
02/22/22	Muhsin, Bilal (ITC)	8:21-9:6					
02/22/22	Muhsin, Bilal (ITC)	13:16-18					
02/22/22	Muhsin, Bilal (ITC)	82:12-17					
02/22/22	Muhsin, Bilal (ITC)	87:6-7	F; SP				
02/22/22	Muhsin, Bilal (ITC)	87:10-24	F; SP	87:25-88:9	[87:25-88:9] AMB; INC; 403	88:10-89:21	402; 403
02/22/22	Muhsin, Bilal (ITC)	90:3-91:3					
02/22/22	Muhsin, Bilal (ITC)	109:18-110:3	402; 403				
10/09/23	Nakajima, Taïdo Lantz	6:9-14					
10/09/23	Nakajima, Taïdo Lantz	17:21-18:9		14:22-15:1; 28:3-12; 32:10-16	[14:22-15:1] AMB; NREL; 403 [28:3-12] AMB; NREL; 403	15:6-9	
10/09/23	Nakajima, Taïdo Lantz	18:14-19:1		14:22-15:1; 28:3-12; 32:10-16	[14:22-15:1] AMB; NREL; 403 [28:3-12] AMB; NREL; 403	15:6-9	
10/09/23	Nakajima, Taïdo Lantz	19:5-14		14:22-15:1; 28:3-12; 32:10-16	[14:22-15:1] AMB; NREL; 403 [28:3-12] AMB; NREL; 403	15:6-9	
10/09/23	Nakajima, Taïdo Lantz	19:18-20:14		14:22-15:1; 28:3-12; 32:10-16	[14:22-15:1] AMB; NREL; 403 [28:3-12] AMB; NREL; 403	15:6-9	
10/09/23	Nakajima, Taïdo Lantz	21:12-24:15		14:22-15:1; 28:3-12; 32:10-16	[14:22-15:1] AMB; NREL; 403 [28:3-12] AMB; NREL; 403	15:6-9	
10/09/23	Nakajima, Taïdo Lantz	26:14-27:6		14:22-15:1; 28:3-12; 32:10-16	[14:22-15:1] AMB; NREL; 403 [28:3-12] AMB; NREL; 403	15:6-9	
10/09/23	Nakajima, Taïdo Lantz	30:2-7					
10/09/23	Nakajima, Taïdo Lantz	37:22-38:3	402; 403				
10/09/23	Nakajima, Taïdo Lantz	38:8-39:11	402; 403				
10/09/23	Nakajima, Taïdo Lantz	47:12-49:4 [withdrawn]					

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
10/09/23	Nakajima, Taido Lantz	50:16-51:1 [withdrawn]					
10/09/23	Nakajima, Taido Lantz	51:6-53:13 [withdrawn]		53:14-53:15			
10/09/23	Nakajima, Taido Lantz	53:16-60:4 [withdrawn]		60:5-60:6, 61:4-61:10, 62:12-62:14			
10/09/23	Nakajima, Taido Lantz	63:17-20					
10/09/23	Nakajima, Taido Lantz	64:19-21					
10/09/23	Nakajima, Taido Lantz	76:21-78:6 [withdrawn]		78:7-78:16	403; CLC; IEXP; NREL	78:18-20	
10/09/23	Nakajima, Taido Lantz	79:13-80:2		154:7-18	[154:7-18] AMB; NREL; 403	155:14-17	
10/09/23	Nakajima, Taido Lantz	80:16-21		154:7-18	[154:7-18] AMB; NREL; 403	155:14-17	
10/09/23	Nakajima, Taido Lantz	86:20-89:13 [withdrawn]					
10/09/23	Nakajima, Taido Lantz	90:3-92:2 [withdrawn]					
10/09/23	Nakajima, Taido Lantz	92:17-93:8 [withdrawn]		93:17-94:3			
10/09/23	Nakajima, Taido Lantz	96:10-97:10 [withdrawn]		28:3-28:12, 99:11-100:1	AMB; NREL; 403; AA		
10/09/23	Nakajima, Taido Lantz	100:2-101:21 [withdrawn]					
10/09/23	Nakajima, Taido Lantz	104:17-105:11 [withdrawn]		104:12-104:16	AMB; NREL; 403; SPC		
10/09/23	Nakajima, Taido Lantz	106:6-107:2					
10/09/23	Nakajima, Taido Lantz	111:14-113:7 [withdrawn]					
10/09/23	Nakajima, Taido Lantz	115:18-119:1 [withdrawn]					
10/09/23	Nakajima, Taido Lantz	122:6-124:14 [withdrawn]					
10/09/23	Nakajima, Taido Lantz	126:21-127:20 [withdrawn]					
10/09/23	Nakajima, Taido Lantz	129:9-130:2 [withdrawn]		103:3-131:17	AMB; NREL; 403; OBJ		
10/09/23	Nakajima, Taido Lantz	132:9-136:19 [withdrawn]					
10/09/23	Nakajima, Taido Lantz	139:10-151:20 [withdrawn]	402; 403				
10/09/23	Nakajima, Taido Lantz	139:10-151:20 [withdrawn]					
10/09/23	Nakajima, Taido Lantz	153:17-154:6					
10/09/23	Nakajima, Taido Lantz	166:16-167:22					
10/09/23	Nakajima, Taido Lantz	168:4-13					
10/09/23	Nakajima, Taido Lantz	173:12-174:7					
10/09/23	Nakajima, Taido Lantz	179:5-180:12					
10/09/23	Nakajima, Taido Lantz	181:4-182:2					
10/09/23	Nakajima, Taido Lantz	185:5-17					
10/31/23	Park, Linus	10:8-14					
10/31/23	Park, Linus	11:23-25					
10/31/23	Park, Linus	12:1-25					
10/31/23	Park, Linus	13:1-25					
10/31/23	Park, Linus	14:1-10					
10/31/23	Park, Linus	15:8-22					
10/31/23	Park, Linus	17:4-25					
10/31/23	Park, Linus	17:8-20:5					
10/31/23	Park, Linus	18:1-25					
10/31/23	Park, Linus	19:1-7					
10/31/23	Park, Linus	21:18-20					
10/31/23	Park, Linus	96:18-98:10	402; 403				
10/31/23	Park, Linus	98:20-99:1	402; 403	99:3-22; 101:19-102:6; 102:23-103:4	[99:3-22] AMB; AG; HRS; LFND; NREL; 403 [101:19-102:6] AMB; AG; HRS; LFND; NREL; OBJ; 403 [102:23-103:4] AMB; AG; LFND; NREL; 403; MIL	[99:3-22] 100:25-101:2; 101:6-9; 101:12-13; 101:15-17 [101:19-102:6] 100:25-101:2; 101:6-9; 101:12-13; 101:15-17 [102:23-103:4] 100:25-101:2; 101:6-9; 101:12-13; 101:15-17	402; 403
10/31/23	Park, Linus	105:1-4					
10/31/23	Park, Linus	117:16-17					
10/31/23	Park, Linus	117:25-25					
10/31/23	Park, Linus	118:1-25					
10/31/23	Park, Linus	119:1-12					
10/31/23	Park, Linus	195:23-199:5					
10/31/23	Park, Linus	199:24-201:6	402; 403				
01/30/24	Priddell, Richard	7:13-21					
01/30/24	Priddell, Richard	8:13-24		8:25-9:5; 9:20-22	[8:25-9:5] NREL; 403 [9:20-22] NREL; 403	[8:25-9:5] 10:1-13 [9:20-22] 10:1-13	
01/30/24	Priddell, Richard	10:14-22					
01/30/24	Priddell, Richard	11:7-25		11:2-6	[11:2-6] NREL; 403; MIL		
01/30/24	Priddell, Richard	12:2-15					
01/30/24	Priddell, Richard	13:14-14:2		14:3-12	[14:3-12] NREL; 403	24:6-11	
01/30/24	Priddell, Richard	14:13-17:3					

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
01/30/24	Priddell, Richard	17:9-11					
01/30/24	Priddell, Richard	18:2-4					
01/30/24	Priddell, Richard	22:1-4		22:5-8; 22:17-20	[22:5-8] NREL; 403 [22:17-20] NREL; 403	[22:17-20] 24:6-11 [22:5-8] 24:6-11	
01/30/24	Priddell, Richard	60:1-14					
01/30/24	Priddell, Richard	206:13-207:12					
04/30/24	Priddell, Richard	6:7-20		6:21-7:1	[6:21-7:1] NREL; 403	7:11-17; 7:24-8:4	402; 403; I
04/30/24	Priddell, Richard	6:18-18					
04/30/24	Priddell, Richard	9:18-22	F; SP	9:23-10:3	[9:23-10:3] NREL; 403	7:11-17; 7:24-8:4	402; 403; I
04/30/24	Priddell, Richard	11:11-25		11:8-10; 12:1-6; 12:7-16	[11:8-10] NREL; 403 [12:1-6] NREL; 403 [12:7-16] NREL; 403	[11:8-10] 7:11-17; 7:24-8:4; 16:2-7; 27:7-15; 38:3-7 [12:7-16] 16:2-7; 27:7-15; 38:3-7 [12:1-6] 16:2-7; 27:7-15; 38:3-7	402; 403; I
04/30/24	Priddell, Richard	12:17-25					
04/30/24	Priddell, Richard	13:3-8		13:9-21	[13:9-21] NREL; 403	16:2-7; 27:7-15; 38:3-7	402; 403; I
04/30/24	Priddell, Richard	15:23-16:1		16:10-20	[16:10-20] NREL; 403	16:2-7; 27:7-15; 38:3-7	402; 403; I
04/30/24	Priddell, Richard	17:6-9		17:10-25	[17:10-25] NREL; 403	16:2-7; 27:7-15; 38:3-7	402; 403; I
04/30/24	Priddell, Richard	18:4-15		18:16-19	[18:16-19] NREL; 403	16:2-7; 27:7-15; 38:3-7	402; 403; I
04/30/24	Priddell, Richard	18:20-25					
04/30/24	Priddell, Richard	19:3-25					
04/30/24	Priddell, Richard	20:2-7					
04/30/24	Priddell, Richard	20:15-18					
04/30/24	Priddell, Richard	21:2-15		21:21-22:8	[21:21-22:8] BSD (OS); NREL; 403	16:2-7; 27:7-15; 38:3-7	402; 403; I
04/30/24	Priddell, Richard	22:24-23:18		23:19-24	[23:19-24] NREL; 403; BSD (OS)	16:2-7; 27:7-15; 38:3-7	402; 403; I
04/30/24	Priddell, Richard	24:15-23		24:5-14; 24:24-25:10; 25:11-16; 25:17-20	[24:5-14] NREL; 403 [24:24-25:10] BSD (OS); NREL; 403 [25:11-16] NREL; 403 [25:17-20] NREL; 403	[24:5-14] 16:2-7; 27:7-15; 38:3-7 [24:24-25:10] 16:2-7; 27:7-15; 38:3-7 [25:11-16] 16:2-7; 27:7-15; 38:3-7 [25:17-20] 16:2-7; 27:7-15; 38:3-7	402; 403; I
04/30/24	Priddell, Richard	26:4-23		27:21-28:7	[27:21-28:7] BSD (OS); NREL; 403	16:2-7; 27:7-15; 38:3-7	402; 403; I
04/30/24	Priddell, Richard	29:23-31:10		31:17-32:17	[31:17-32:17] BSD (OS); NREL; 403	16:2-7; 27:7-15; 38:3-7	402; 403; I
04/30/24	Priddell, Richard	33:18-34:4					
04/30/24	Priddell, Richard	34:20-35:11					
04/30/24	Priddell, Richard	40:5-41:6		38:22-39:4; 39:5-9	[38:22-39:4] BSD (OS); NREL; 403 [39:5-9] BSD (OS); NREL; 403	[38:22-39:4] 16:2-7; 27:7-15; 38:3-7 [39:5-9] 16:2-7; 27:7-15; 38:3-7	402; 403; I
04/30/24	Priddell, Richard	42:6-43:8					
04/30/24	Priddell, Richard	43:21-24					
04/30/24	Priddell, Richard	44:12-23					
04/30/24	Priddell, Richard	45:9-46:11		47:19-25	[47:19-25] BSD (OS); NREL; 403	16:2-7; 27:7-15; 38:3-7	402; 403; I
04/30/24	Priddell, Richard	48:25-49:13					
04/30/24	Priddell, Richard	49:20-52:3					
10/20/23	Priddell, Richard	9:10-10					
10/20/23	Priddell, Richard	9:11-11					
10/20/23	Priddell, Richard	9:12-12					
10/20/23	Priddell, Richard	9:13-13					
10/20/23	Priddell, Richard	12:17-17					
10/20/23	Priddell, Richard	12:18-18					
10/20/23	Priddell, Richard	12:19-19					
10/20/23	Priddell, Richard	12:20-20					
10/20/23	Priddell, Richard	12:21-21					
10/20/23	Priddell, Richard	13:15-15	402; 403				
10/20/23	Priddell, Richard	13:21-21 [withdrawn]	402; 403				
10/20/23	Priddell, Richard	13:23-23 [withdrawn]	402; 403				
10/20/23	Priddell, Richard	13:24-24 [withdrawn]	402; 403				
10/20/23	Priddell, Richard	13:25-25 [withdrawn]	402; 403				
10/20/23	Priddell, Richard	14:1-10 [withdrawn]	402; 403				
10/20/23	Priddell, Richard	14:14-21 [withdrawn]	402; 403				
10/20/23	Priddell, Richard	15:16-22					
10/20/23	Priddell, Richard	15:23-16:13		16:25-17:2; 17:5-7	[16:25-17:2] NREL; 403 [17:5-7] NREL; 403	[16:25-17:2] 16:17-23 [17:5-7] 16:17-23	

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
10/20/23	Priddell, Richard	16:23-23 [withdrawn]		16:25-17:2, 17:5-7	[16:25-17:2] NREL; 403 [17:5-7] NREL; 403	[16:25-17:2] 16:17-23 [17:5-7] 16:17-23	
10/20/23	Priddell, Richard	20:6-13 [withdrawn]					
10/20/23	Priddell, Richard	20:14-16 [withdrawn]					
10/20/23	Priddell, Richard	20:20-21:7					
10/20/23	Priddell, Richard	21:22-24 [withdrawn]	F; SP				
10/20/23	Priddell, Richard	22:2-5 [withdrawn]	F; SP				
10/20/23	Priddell, Richard	22:18-20 [withdrawn]	F; SP				
10/20/23	Priddell, Richard	22:22-22 [withdrawn]	F; SP				
10/20/23	Priddell, Richard	22:24-23:17 [withdrawn]	F; SP				
10/20/23	Priddell, Richard	23:19-25 [withdrawn]	F; SP				
10/20/23	Priddell, Richard	24:4-10		25:22-25; 26:2-4; 26:6-11	[25:22-25] NREL; 403 [26:2-4] LFND; OBJ; 403 [26:6-11] LFND; NREL; 403	[25:22-25] 228:6-229:19; 230:11-231:11 [26:2-4] 228:6-229:19; 230:11-231:11 [26:6-11] 228:6-229:19; 230:11-231:11	402; 403
10/20/23	Priddell, Richard	24:23-25:9	F; SP	25:22-25; 26:2-4; 26:6-11	[25:22-25] NREL; 403 [26:2-4] LFND; OBJ; 403 [26:6-11] LFND; NREL; 403	[25:22-25] 228:6-229:19; 230:11-231:11 [26:2-4] 228:6-229:19; 230:11-231:11 [26:6-11] 228:6-229:19; 230:11-231:11	402; 403
10/20/23	Priddell, Richard	26:12-27:14 [withdrawn]					
10/20/23	Priddell, Richard	28:11-16					
10/20/23	Priddell, Richard	29:4-6					
10/20/23	Priddell, Richard	29:13-23					
10/20/23	Priddell, Richard	30:7-9					
10/20/23	Priddell, Richard	30:11-13					
10/20/23	Priddell, Richard	30:19-21					
10/20/23	Priddell, Richard	31:12-18					
10/20/23	Priddell, Richard	33:9-11 [new]					F; SP; LC; EX; OS
10/20/23	Priddell, Richard	33:13-16	F; SP; LC; EX				
10/20/23	Priddell, Richard	33:18-34:2	F; SP; LC; EX				
10/20/23	Priddell, Richard	34:21-23	F; SP; LC; EX				
10/20/23	Priddell, Richard	34:25-35:1	F; SP; LC; EX				
10/20/23	Priddell, Richard	35:5-7	F; SP; LC; EX				
10/20/23	Priddell, Richard	35:9-23	F; SP; LC; EX				
10/20/23	Priddell, Richard	36:1-2	F; SP; LC; EX				
10/20/23	Priddell, Richard	36:10-15 [withdrawn]	F; SP; LC; EX				
10/20/23	Priddell, Richard	36:21-25	F; SP; LC; EX				
10/20/23	Priddell, Richard	37:4-11 [withdrawn]	F; SP; LC; EX				
10/20/23	Priddell, Richard	37:13-38:24 [withdrawn]	F; SP; LC; EX				
10/20/23	Priddell, Richard	39:4-6	F; SP				
10/20/23	Priddell, Richard	39:11-18 [withdrawn]	F; SP				
10/20/23	Priddell, Richard	39:20-24 [withdrawn]	F; SP				
10/20/23	Priddell, Richard	40:19-23	F; SP				
10/20/23	Priddell, Richard	42:10-17	F; SP				
10/20/23	Priddell, Richard	42:22-24	F; SP				
10/20/23	Priddell, Richard	44:2-6	F; SP				
10/20/23	Priddell, Richard	44:25-45:8	402; F; SP; LC; EX				
10/20/23	Priddell, Richard	45:14-17 [withdrawn]	402; F; SP; LC; EX				
10/20/23	Priddell, Richard	45:21-46:3 [withdrawn]	402; F; SP; LC; EX				
10/20/23	Priddell, Richard	46:9-11					
10/20/23	Priddell, Richard	46:17-22	402; F; SP; LC; EX	46:13-16	[46:13-16] NREL; 403		
10/20/23	Priddell, Richard	47:7-15	402; F; SP; LC; EX	46:13-16	[46:13-16] NREL; 403		
10/20/23	Priddell, Richard	47:20-21	402; F; SP; LC; EX				
10/20/23	Priddell, Richard	47:23-24	402; F; SP; LC; EX				
10/20/23	Priddell, Richard	48:1-2	402; F; SP; LC; EX				
10/20/23	Priddell, Richard	48:13-22	402; F; SP; LC; EX				
10/20/23	Priddell, Richard	49:3-3	402; F; SP; LC; EX				
10/20/23	Priddell, Richard	49:10-20	402; F; SP; LC; EX				

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
10/20/23	Priddell, Richard	49:24-50:3	402; F; SP; LC; EX				
10/20/23	Priddell, Richard	50:7-8	402; F; SP; LC; EX				
10/20/23	Priddell, Richard	50:13-16 [withdrawn]	402; F; SP; LC; EX				
10/20/23	Priddell, Richard	50:23-51:8	402; F; SP; LC; EX				
10/20/23	Priddell, Richard	52:1-2	402; F; SP; LC; EX				
10/20/23	Priddell, Richard	52:4-8	402; F; SP; LC; EX				
10/20/23	Priddell, Richard	52:11-15	402; F; SP; LC; EX				
10/20/23	Priddell, Richard	52:18-19	402; F; SP; LC; EX				
10/20/23	Priddell, Richard	53:5-14	402; F; SP; LC; EX				
10/20/23	Priddell, Richard	54:3-4	402; F; SP; LC; EX				
10/20/23	Priddell, Richard	54:7-11	402; F; SP; LC; EX				
10/20/23	Priddell, Richard	54:13-14	402; F; SP; LC; EX				
10/20/23	Priddell, Richard	55:4-9 [withdrawn]	402; F; SP; LC; EX				
10/20/23	Priddell, Richard	55:18-56:2	402; F; SP; LC; EX				
10/20/23	Priddell, Richard	56:19-23	402; F; SP; LC; EX				
10/20/23	Priddell, Richard	57:1-5	402; F; SP; LC; EX				
10/20/23	Priddell, Richard	57:7-8	402; F; SP; LC; EX				
10/20/23	Priddell, Richard	57:14-14 [withdrawn]	402; F; SP; LC; EX				
10/20/23	Priddell, Richard	57:25-58:4					
10/20/23	Priddell, Richard	58:7-18	402; F; SP; LC; EX				
10/20/23	Priddell, Richard	58:22-24	402; F; SP; LC; EX				
10/20/23	Priddell, Richard	59:7-13 [withdrawn]	402; F; SP; LC; EX				
10/20/23	Priddell, Richard	59:16-17 [withdrawn]	402; F; SP; LC; EX				
10/20/23	Priddell, Richard	60:9-9 [withdrawn]	F; SP; AF; V				
10/20/23	Priddell, Richard	60:10-10 [withdrawn]	F; SP; AF; V				
10/20/23	Priddell, Richard	60:17-17 [withdrawn]					
10/20/23	Priddell, Richard	60:19-22 [withdrawn]	F; SP; AF; V; I				
10/20/23	Priddell, Richard	71:8-15	F; SP; AF				
10/20/23	Priddell, Richard	72:3-9					
10/20/23	Priddell, Richard	72:14-17					
10/20/23	Priddell, Richard	73:23-25					
10/20/23	Priddell, Richard	74:1-2					
10/20/23	Priddell, Richard	74:13-19					
10/20/23	Priddell, Richard	75:19-24		75:5-10	403; BSD; NREL	60:1-6	402; 403
10/20/23	Priddell, Richard	76:7-10		75:5-10	403; BSD; NREL	60:1-6	402; 403
10/20/23	Priddell, Richard	76:13-18					
10/20/23	Priddell, Richard	76:20-22					
10/20/23	Priddell, Richard	77:2-12					
10/20/23	Priddell, Richard	77:16-16 [withdrawn]					
10/20/23	Priddell, Richard	77:18-22		77:23-78:14; 78:21-25	[77:23-78:14] NREL; 403; BSD (OS) [78:21-25] NREL; 403	[77:23-78:14] 79:12-15 [78:21-25] 79:12-15	
10/20/23	Priddell, Richard	79:6-11		79:18-21	[79:18-21] NREL; 403	79:12-15	
10/20/23	Priddell, Richard	82:19-21		82:22-83:1	[82:22-83:1] BSD (OS); LFND; NREL; 403		
10/20/23	Priddell, Richard	91:13-21					
10/20/23	Priddell, Richard	92:4-7					
10/20/23	Priddell, Richard	96:8-14		96:15-19; 96:22-23	[96:15-19] BSD (OS); SPC; HRS; NREL; 403 [96:22-23] SPC; HRS; NREL; 403	[96:15-19] 98:14-19 [96:22-23] 98:14-19	402; 403; F; SP
10/20/23	Priddell, Richard	101:8-10 [withdrawn]					
10/20/23	Priddell, Richard	101:19-21					
10/20/23	Priddell, Richard	101:25-102:3					
10/20/23	Priddell, Richard	104:2-5					
10/20/23	Priddell, Richard	104:8-11					
10/20/23	Priddell, Richard	104:14-105:4					
10/20/23	Priddell, Richard	105:24-106:7					
10/20/23	Priddell, Richard	108:14-17					
10/20/23	Priddell, Richard	108:23-109:1					
10/20/23	Priddell, Richard	123:9-16					
10/20/23	Priddell, Richard	123:20-124:3					
10/20/23	Priddell, Richard	124:15-23		125:10-17; 125:18-19; 125:22-24	[125:10-17] NREL; 403 [125:18-19] NREL; 403 [125:22-24] NREL; 403	[125:10-17] 124:24-125:9; 139:10-12; 139:17-22 [125:22-24] 124:24-125:9; 139:10-12; 139:17-22 [125:18-19] 124:24-125:9; 139:10-12; 139:17-22	402; 403; I

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
10/20/23	Priddell, Richard	131:16-133:2	AF	131:10-13; 133:3-5; 133:8-10; 133:12-13	[131:10-13] NREL; 403 [133:3-5] NREL; 403 [133:8-10] NREL; 403 [133:12-13] BSD (OS); NREL; 403	[131:10-13] 135:13-17; 139:10-12; 139:17-22  [133:8-10] 135:13-17; 139:10-12; 139:17-22  [133:12-13] 135:13-17; 139:10-12; 139:17-22  [133:3-5] 135:13-17; 139:10-12; 139:17-22	402; 403; I
10/20/23	Priddell, Richard	133:14-17		133:18-21	[133:18-21] CM; NREL; 403	135:13-17; 139:10-12; 139:17-22	402; 403; I
10/20/23	Priddell, Richard	134:4-6 [withdrawn]		134:2, 134:7, 134:25-135:2, 135:5-7, 135:9-11	403; CM; NREL	135:13-17; 139:10-12; 139:17-22	402; 403; I
10/20/23	Priddell, Richard	135:13-136:2 [withdrawn]	F; SP; LC; EX				
10/20/23	Priddell, Richard	136:5-11 [withdrawn]	F; SP; LC; EX				
10/20/23	Priddell, Richard	136:13-19 [withdrawn]	F; SP; LC; EX				
10/20/23	Priddell, Richard	136:22-137:4 [withdrawn]	F; SP; LC; EX				
10/20/23	Priddell, Richard	137:10-23	402				
10/20/23	Priddell, Richard	138:10-11					
10/20/23	Priddell, Richard	139:10-12 [withdrawn]		139:13-16	[139:13-16] BSD (OS); NREL; 403	139:10-12; 139:17-22	402; 403; I
10/20/23	Priddell, Richard	139:23-25	I	139:13-16; 142:4-15	[139:13-16] BSD (OS); NREL; 403	139:10-12; 139:17-22	402; 403; I
10/20/23	Priddell, Richard	142:16-19					
10/20/23	Priddell, Richard	142:20-23					
10/20/23	Priddell, Richard	143:6-20 [withdrawn]	F; SP; AF				
10/20/23	Priddell, Richard	143:22-144:16					
10/20/23	Priddell, Richard	144:20-145:25					
10/20/23	Priddell, Richard	146:16-147:1					
10/20/23	Priddell, Richard	147:12-17					
10/20/23	Priddell, Richard	147:25-149:14					
10/20/23	Priddell, Richard	150:12-15					
10/20/23	Priddell, Richard	150:16-23					
10/20/23	Priddell, Richard	151:13-24		152:15-18; 152:20-20; 152:22-24	[152:15-18] NREL; 403 [152:20-20] BSD (OS); NREL; 403 [152:22-24] AMB; BSD (OS); CM; NREL; 403	[152:20-20] 158:9-23  [152:15-18] 158:9-23  [152:22-24] 158:9-23	402; 403; F; SP; LC; EX
10/20/23	Priddell, Richard	153:14-18		152:15-18; 152:20-20; 152:22-24		[152:20-20] 158:9-23  [152:15-18] 158:9-23  [152:22-24] 158:9-23	402; 403; F; SP; LC; EX
10/20/23	Priddell, Richard	155:13-13 [withdrawn]					
10/20/23	Priddell, Richard	155:15-18 [withdrawn]					
10/20/23	Priddell, Richard	155:20-157:1 [withdrawn]					
10/20/23	Priddell, Richard	158:24-159:4	F; SP; LC; EX	157:13-15; 157:17-19	[157:13-15] CM; NREL; 403 [157:17-19] CM; NREL; 403	[157:13-15] 158:9-23  [157:17-19] 158:9-23	402; 403; F; SP; LC; EX
10/20/23	Priddell, Richard	159:7-11					
10/20/23	Priddell, Richard	159:23-160:20 [withdrawn]	F; SP; LC; EX	157:17-19	[157:17-19] CM; NREL; 403	[157:17-19] 158:9-23	402; 403; F; SP; LC; EX
10/20/23	Priddell, Richard	161:3-7 [withdrawn]					
10/20/23	Priddell, Richard	161:8-18 [withdrawn]					
10/20/23	Priddell, Richard	162:14-15 [withdrawn]	AC	162:18-18	403; BSD; NREL	166:21-24	402; 403
10/20/23	Priddell, Richard	162:22-23 [withdrawn]					
10/20/23	Priddell, Richard	162:24-164:2 [withdrawn]					
10/20/23	Priddell, Richard	164:19-165:1 [withdrawn]					
10/20/23	Priddell, Richard	165:4-9 [withdrawn]					
10/20/23	Priddell, Richard	165:22-25 [withdrawn]		165:19-21	403; NREL	166:21-24	402; 403
10/20/23	Priddell, Richard	166:5-5 [withdrawn]					
10/20/23	Priddell, Richard	166:21-24 [withdrawn]		166:17-20	403; NREL	166:21-24	402; 403
10/20/23	Priddell, Richard	167:10-13 [withdrawn]					
10/20/23	Priddell, Richard	167:20-21 [withdrawn]					
10/20/23	Priddell, Richard	167:23-168:8 [withdrawn]	402				
10/20/23	Priddell, Richard	168:15-169:13	F; SP				
10/20/23	Priddell, Richard	169:22-170:5	F; SP				
10/20/23	Priddell, Richard	170:19-171:14					
10/20/23	Priddell, Richard	171:21-172:16					



DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
10/20/23	Priddell, Richard	173:10-13					
10/20/23	Priddell, Richard	174:15-20	F; SP	177:24-25; 178:3-6	[177:24-25] SPC; NREL; 403; MM [178:3-6] SPC; NREL; 403; MM		
10/20/23	Priddell, Richard	174:24-25	F; SP	177:24-25; 178:3-6	[177:24-25] SPC; NREL; 403; MM [178:3-6] SPC; NREL; 403; MM		
10/20/23	Priddell, Richard	175:1-2	F; SP	177:24-25; 178:3-6	[177:24-25] SPC; NREL; 403; MM [178:3-6] SPC; NREL; 403; MM		
10/20/23	Priddell, Richard	175:15-20	F; SP	177:24-25; 178:3-6	[177:24-25] SPC; NREL; 403; MM [178:3-6] SPC; NREL; 403; MM		
10/20/23	Priddell, Richard	175:22-25	F; SP	177:24-25; 178:3-6	[177:24-25] SPC; NREL; 403; MM [178:3-6] SPC; NREL; 403; MM		
10/20/23	Priddell, Richard	176:1-1	F; SP	177:24-25; 178:3-6	[177:24-25] SPC; NREL; 403; MM [178:3-6] SPC; NREL; 403; MM		
10/20/23	Priddell, Richard	176:3-5	F; SP	177:24-25; 178:3-6	[177:24-25] SPC; NREL; 403; MM [178:3-6] SPC; NREL; 403; MM		
10/20/23	Priddell, Richard	176:8-25	F; SP	177:24-25; 178:3-6	[177:24-25] SPC; NREL; 403; MM [178:3-6] SPC; NREL; 403; MM		
10/20/23	Priddell, Richard	177:8-23	F; SP	177:24-25; 178:3-6	[177:24-25] SPC; NREL; 403; MM [178:3-6] SPC; NREL; 403; MM		
10/20/23	Priddell, Richard	178:8-9	F; SP; LC; EX				
10/20/23	Priddell, Richard	178:12-15	F; SP; LC; EX	178:17-23	[178:17-23] NREL; 403		
10/20/23	Priddell, Richard	179:2-5	F; SP				
10/20/23	Priddell, Richard	179:10-25	F; SP				
10/20/23	Priddell, Richard	182:11-19	402; 403; F; SP; LC; EX				
10/20/23	Priddell, Richard	182:22-24	402; 403; F; SP; LC; EX				
10/20/23	Priddell, Richard	183:1-5	402; 403; F; SP; LC; EX				
10/20/23	Priddell, Richard	183:24-184:2	402; 403; F; SP; LC; EX				
10/20/23	Priddell, Richard	184:17-19	402; 403; F; SP; LC; EX				
10/20/23	Priddell, Richard	184:21-22	402; 403; F; SP; LC; EX				
10/20/23	Priddell, Richard	185:3-6	402; 403; F; SP; LC; EX				
10/20/23	Priddell, Richard	186:22-25	402; 403; F; SP; LC; EX				
10/20/23	Priddell, Richard	187:23-25	402; 403; F; SP; LC; EX				
10/20/23	Priddell, Richard	188:11-20	402; 403; F; SP; LC; EX				
10/20/23	Priddell, Richard	189:14-19	402; 403; F; SP; LC; EX				
10/20/23	Priddell, Richard	189:22-23	402; 403; F; SP; LC; EX				
10/20/23	Priddell, Richard	189:25-190:2	402; 403; F; SP; LC; EX				
10/20/23	Priddell, Richard	190:10-191:7	402; 403; F; SP; LC; EX				
10/20/23	Priddell, Richard	200:14-16	402; 403; F; SP; LC; EX	206:8-17; 209:5-11; 209:14-17	[206:8-17] NREL; 403; MM [209:5-11] BSD (OS); NREL; 403 [209:14-17] BSD (OS); NREL; 403		
10/20/23	Priddell, Richard	201:11-24	402; 403; F; SP; LC; EX	206:8-17; 209:5-11; 209:14-17	[206:8-17] NREL; 403; MM [209:5-11] BSD (OS); NREL; 403 [209:14-17] BSD (OS); NREL; 403		
10/20/23	Priddell, Richard	202:17-203:14	402; 403; F; SP; LC; EX	206:8-17; 209:5-11; 209:14-17	[206:8-17] NREL; 403; MM [209:5-11] BSD (OS); NREL; 403 [209:14-17] BSD (OS); NREL; 403		
10/20/23	Priddell, Richard	205:2-25	402; 403; F; SP; LC; EX	206:8-17; 209:5-11; 209:14-17	[206:8-17] NREL; 403; MM [209:5-11] BSD (OS); NREL; 403 [209:14-17] BSD (OS); NREL; 403		
10/20/23	Priddell, Richard	206:18-25					
10/20/23	Priddell, Richard	207:14-22					
10/20/23	Priddell, Richard	208:2-25					
10/20/23	Priddell, Richard	210:4-7		213:11-18; 213:19-19; 213:23-214:2	[213:11-18] BSD (OS); NREL; 403 [213:19-19] NREL; 403 [213:23-214:2] BSD (OS); NREL; 403		
10/20/23	Priddell, Richard	210:12-15	402; 403; F; SP; LC; EX	213:11-18; 213:19-19; 213:23-214:2	[213:11-18] BSD (OS); NREL; 403 [213:19-19] NREL; 403 [213:23-214:2] BSD (OS); NREL; 403		
10/20/23	Priddell, Richard	210:24-211:7	402; 403; F; SP; LC; EX	213:11-18; 213:19-19; 213:23-214:2	[213:11-18] BSD (OS); NREL; 403 [213:19-19] NREL; 403 [213:23-214:2] BSD (OS); NREL; 403		
10/20/23	Priddell, Richard	211:20-212:4	402; 403; F; SP; LC; EX	213:11-18; 213:19-19; 213:23-214:2	[213:11-18] BSD (OS); NREL; 403 [213:19-19] NREL; 403 [213:23-214:2] BSD (OS); NREL; 403		
10/20/23	Priddell, Richard	212:18-21	402; 403; F; SP; LC; EX	213:11-18; 213:19-19; 213:23-214:2	[213:11-18] BSD (OS); NREL; 403 [213:19-19] NREL; 403 [213:23-214:2] BSD (OS); NREL; 403		

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
10/20/23	Priddell, Richard	212:24-213:1	402; 403; F; SP; LC; EX	213:11-18; 213:19-19; 213:23-214:2	[213:11-18] BSD (OS); NREL; 403 [213:19-19] NREL; 403 [213:23-214:2] BSD (OS); NREL; 403		
10/20/23	Priddell, Richard	214:6-11		214:12-15	[214:12-15] NREL; 403	214:16-16; 214:19-21	F; SP; LC; EX
10/20/23	Priddell, Richard	215:12-18	402; 403; F; SP; LC; EX	217:16-19; 218:2-3; 218:6-8	[217:16-19] BSD (OS); NREL; 403; MM [218:2-3] BSD (OS); NREL; 403; MM [218:6-8] BSD (OS); NREL; 403; MM	[217:16-19] 217:3-15 [218:2-3] 217:3-15 [218:6-8] 217:3-15	402; 403; F; SP
10/20/23	Priddell, Richard	216:8-8	402; 403; F; SP; LC; EX	217:16-19; 218:2-3; 218:6-8	[217:16-19] BSD (OS); NREL; 403; MM [218:2-3] BSD (OS); NREL; 403; MM [218:6-8] BSD (OS); NREL; 403; MM	[217:16-19] 217:3-15 [218:2-3] 217:3-15 [218:6-8] 217:3-15	402; 403; F; SP
10/20/23	Priddell, Richard	216:12-13	402; 403; F; SP; LC; EX	217:16-19; 218:2-3; 218:6-8	[217:16-19] BSD (OS); NREL; 403; MM [218:2-3] BSD (OS); NREL; 403; MM [218:6-8] BSD (OS); NREL; 403; MM	[217:16-19] 217:3-15 [218:2-3] 217:3-15 [218:6-8] 217:3-15	402; 403; F; SP
10/20/23	Priddell, Richard	216:21-22	402; 403; F; SP; LC; EX	217:16-19; 218:2-3; 218:6-8	[217:16-19] BSD (OS); NREL; 403; MM [218:2-3] BSD (OS); NREL; 403; MM [218:6-8] BSD (OS); NREL; 403; MM	[217:16-19] 217:3-15 [218:2-3] 217:3-15 [218:6-8] 217:3-15	402; 403; F; SP
10/20/23	Priddell, Richard	216:24-217:1	402; 403; F; SP; LC; EX	217:16-19; 218:2-3; 218:6-8	[217:16-19] BSD (OS); NREL; 403; MM [218:2-3] BSD (OS); NREL; 403; MM	[217:16-19] 217:3-15 [218:2-3] 217:3-15	402; 403; F; SP
10/20/23	Priddell, Richard	219:10-17	402; 403; F; SP; LC; EX				
10/20/23	Priddell, Richard	220:2-5	402; 403; F; SP; LC; EX				
10/20/23	Priddell, Richard	220:20-25	402; 403; F; SP; LC; EX				
10/20/23	Priddell, Richard	229:24-230:17 [withdrawn]					
10/20/23	Priddell, Richard	237:7-248:17 [withdrawn]	F; SP	237:5-6	403; BSD; NREL		
10/20/23	Priddell, Richard	248:18-252:6 [withdrawn]	F; SP				
10/20/23	Priddell, Richard	252:24-257:3 [withdrawn]	F; SP				
10/20/23	Priddell, Richard	257:4-18 [withdrawn]					
10/13/23	Russell-Clarke, Peter	7:19-21					
10/13/23	Russell-Clarke, Peter	8:6-8					
10/13/23	Russell-Clarke, Peter	13:3-15		12:22-13:2			
10/13/23	Russell-Clarke, Peter	14:10-19		14:21-15:4			
10/13/23	Russell-Clarke, Peter	15:10-16:4					
10/13/23	Russell-Clarke, Peter	17:20-18:12		43:2-4; 43:7-10; 43:12-15; 44:7-14; 44:19-21; 45:4-5; 45:8-13	[44:7-21] AMB; AA; CLC; NREL; 403 [45:4-13] AMB; AA; CLC; NREL; 403		
10/13/23	Russell-Clarke, Peter	19:8-20		19:22-20:2; 20:5-5; 43:2-4; 43:7-10; 43:12-15; 44:7-14; 44:19-21; 45:4-5; 45:8-13	[19:22-20:5] AMB; AA; CLC; NREL; 403 [44:7-21] AMB; AA; CLC; NREL; 403 [45:4-13] AMB; AA; CLC; NREL; 403		
10/13/23	Russell-Clarke, Peter	20:16-21:1					
10/13/23	Russell-Clarke, Peter	22:3-13					
10/13/23	Russell-Clarke, Peter	22:15-23:2					
10/13/23	Russell-Clarke, Peter	23:4-13					
10/13/23	Russell-Clarke, Peter	23:15-24:4					
10/13/23	Russell-Clarke, Peter	25:18-26:9					
10/13/23	Russell-Clarke, Peter	26:11-18					
10/13/23	Russell-Clarke, Peter	27:5-10 [withdrawn]					
10/13/23	Russell-Clarke, Peter	27:11-28:5					
10/13/23	Russell-Clarke, Peter	30:14-22					
10/13/23	Russell-Clarke, Peter	32:2-14		32:16-19	[32:16-19] AMB; CLC; NREL; 403		
10/13/23	Russell-Clarke, Peter	32:20-33:15					
10/13/23	Russell-Clarke, Peter	33:17-34:16					
10/13/23	Russell-Clarke, Peter	35:3-20					
10/13/23	Russell-Clarke, Peter	37:5-18		39:3-8; 39:12-40:1; 40:3-42:2; 42:14-16; 42:19-22; 43:2-4; 43:7-10; 43:12-15; 44:7-14; 44:19-21; 45:4-5; 45:8-13	[39:3-40:1] AMB; AA; CLC; MIS; NREL; 403 [40:3-42:2] AMB; PRV; CLC; SPC; NREL; 403 [42:14-43:15] AMB; AA; CLC; NREL; 403 [44:7-21] AMB; AA; CLC; NREL; 403 [45:4-13] AMB; AA; CLC; NREL; 403		

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
10/13/23	Russell-Clarke, Peter	38:6-39:1		39:3-8; 39:12-40:1; 40:3-42:2; 42:14-16; 42:19-22; 43:2-4; 43:7-10; 43:12-15; 44:7-14; 44:19-21; 45:4-5; 45:8-13	[39:3-40:1] AMB; AA; CLC; MIS; NREL; 403 [40:3-42:2] AMB; PRV; CLC; SPC; NREL; 403 [42:14-43:15] AMB; AA; CLC; NREL; 403 [44:7-21] AMB; AA; CLC; NREL; 403 [45:4-13] AMB; AA; CLC; NREL; 403		
10/13/23	Russell-Clarke, Peter	42:4-12 [withdrawn]		42:14-16, 42:19-22, 43:2-4, 43:7-10, 43:12-15, 44:7-14, 44:19-21, 45:4-5, 45:8-13	AMB; AA; CLC; NREL; 403		
10/13/23	Russell-Clarke, Peter	46:7-22		49:6-8; 49:10-21; 64:22-65:2; 65:5-8; 70:16-19; 70:22-22; 71:17-19; 72:1-7	[49:6-18] AMB; AA; CLC; NREL; 403		
10/13/23	Russell-Clarke, Peter	48:4-6		49:6-8; 49:10-21; 50:3-7; 64:22-65:2; 65:5-8; 70:16-19; 70:22-22; 71:17-19; 72:1-7	[49:6-18] AMB; AA; CLC; NREL; 403 [49:19-50:7] AMB; CLC; IEXP; NREL; 403		
10/13/23	Russell-Clarke, Peter	51:22-52:8		49:10-21; 50:3-7; 53:1-3; 53:6-10; 53:15-17; 53:20-20; 58:13-59:4	[49:19-50:7] AMB; CLC; IEXP; NREL; 403 [53:1-3] AMB; CLC; NREL; 403 [53:6-10] AMB; CLC; NREL; 403 [53:15-17] AMB; SPC; NREL; 403 [53:20-20] AMB; SPC; NREL; 403		
10/13/23	Russell-Clarke, Peter	57:10-58:12		58:13-59:4			
10/13/23	Russell-Clarke, Peter	59:13-60:13		58:13-59:4			
10/13/23	Russell-Clarke, Peter	78:21-80:13 [withdrawn]					
10/13/23	Russell-Clarke, Peter	81:19-82:17		87:16-17; 87:20-20	[87:16-17] AMB; NREL; 403 [87:20-20] AMB; NREL; 403		
10/13/23	Russell-Clarke, Peter	82:19-83:14 [withdrawn]	AS	49:6-8, 49:10-21, 50:3-7, 64:22-65:2, 65:5-8, 70:16-19, 70:22, 71:17-19, 72:1-7	AMB; AA; CLC; NREL; 403; IEXP; LFND; BSD		
10/13/23	Russell-Clarke, Peter	83:16-84:8		86:7-9; 86:12-14; 86:16-87:2; 87:3-7	[86:7-9] AMB; SPC; LFND; NREL; 403 [86:12-14] AMB; SPC; LFND; NREL; 403 [86:16-87:2] AMB; NREL; 403 [87:3-7] AMB; NREL; 403		
10/13/23	Russell-Clarke, Peter	84:21-86:5		86:7-9; 86:12-14; 86:16-87:2; 87:3-7	[86:7-9] AMB; SPC; LFND; NREL; 403 [86:12-14] AMB; SPC; LFND; NREL; 403 [86:16-87:2] AMB; NREL; 403 [87:3-7] AMB; NREL; 403		
10/13/23	Russell-Clarke, Peter	90:17-19		86:7-9; 86:12-14; 89:13-15; 89:18-20; 107:5-108:9	[86:7-9] AMB; SPC; LFND; NREL; 403 [86:12-14] AMB; SPC; LFND; NREL; 403 [89:13-15] AMB; NREL; 403 [89:18-20] AMB; NREL; 403 [107:5-108:9] AMB; CLC; IEXP; NREL; 403		
10/13/23	Russell-Clarke, Peter	91:1-6		89:13-15; 89:18-20; 107:5-108:9	[89:13-15] AMB; NREL; 403 [89:18-20] AMB; NREL; 403 [107:5-108:9] AMB; CLC; IEXP; NREL; 403		
10/13/23	Russell-Clarke, Peter	94:13-96:17		97:1-4; 97:7-8; 97:20-22; 98:6-7; 107:5-108:9	[97:1-4] AMB; NREL; 403 [97:7-8] AMB; NREL; 403 [97:20-22] AMB; NREL; 403 [98:6-7] AMB; NREL; 403 [107:5-108:9] AMB; CLC; IEXP; NREL; 403		
10/13/23	Russell-Clarke, Peter	98:20-99:12		98:11-13; 98:17-18; 101:2-3	[98:11-13] AMB; NREL; 403 [98:17-18] AMB; NREL; 403 [101:2-3] AMB; NREL; 403		
10/13/23	Russell-Clarke, Peter	99:14-18 [withdrawn]		143:13-18, 143:21-144:15	AA; AMB		
10/13/23	Russell-Clarke, Peter	99:20-100:21 [withdrawn]		101:2-3, 143:13-18, 143:21-144:15, 150:10-12, 150:15-151:3, 151:10-11, 151:14-16	AA; AMB; NREL		
10/13/23	Russell-Clarke, Peter	101:7-102:9		150:10-12; 150:15-151:3; 151:10-11; 151:14-16			
10/13/23	Russell-Clarke, Peter	103:11-104:6 [withdrawn]	I, V				
10/13/23	Russell-Clarke, Peter	110:15-111:5					
10/13/23	Russell-Clarke, Peter	112:13-22		111:7-9; 111:14-18; 123:16-18	[111:7-9] AMB; CLC; IEXP; NREL; 403 [111:14-18] AMB; CLC; IEXP; NREL; 403 [123:16-18] AMB; NREL; 403		

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTERS
10/13/23	Russell-Clarke, Peter	113:2-16		123:16-18; 123:20-124:6	[123:16-18] AMB; NREL; 403 [123:20-124:6] AMB; NREL; 403		
10/13/23	Russell-Clarke, Peter	113:18-114:9		123:16-18; 123:20-124:6	[123:16-18] AMB; NREL; 403 [123:20-124:6] AMB; NREL; 403		
10/13/23	Russell-Clarke, Peter	114:11-115:8		123:16-18; 123:20-124:6	[123:16-18] AMB; NREL; 403 [123:20-124:6] AMB; NREL; 403		
10/13/23	Russell-Clarke, Peter	115:10-15		119:20-21; 120:2-2	[119:20-21] AMB; SPC; NREL; 403 [120:2-2] AMB; SPC; NREL; 403		
10/13/23	Russell-Clarke, Peter	116:22-117:20					
10/13/23	Russell-Clarke, Peter	123:6-12		123:16-18; 123:20-124:6; 127:13-13	[123:16-18] AMB; NREL; 403 [123:20-124:6] AMB; NREL; 403 [127:13-13] AMB; CLC; IEXP; NREL; 403		
10/13/23	Russell-Clarke, Peter	126:13-127:7		127:8-9	[127:8-9] AMB; CLC; IEXP; NREL; 403		
10/13/23	Russell-Clarke, Peter	134:14-135:6		131:9-15; 133:9-12; 133:14-16; 133:21-22; 134:10-13; 138:3-5; 138:8-12; 138:14-17; 138:19-21; 139:2-4; 139:6-8; 139:10-12; 139:16-18	[133:9-12] AMB; NREL; 403 [133:14-16] AMB; NREL; 403 [133:21-22] AMB; NREL; 403 [134:10-13] AMB; NREL; 403		
10/13/23	Russell-Clarke, Peter	135:8-136:10		131:9-15; 133:9-12; 133:14-16; 133:21-22; 134:10-13; 138:3-5; 138:8-12; 138:14-17; 138:19-21; 139:2-4; 139:6-8; 139:10-12; 139:16-18	[133:9-12] AMB; NREL; 403 [133:14-16] AMB; NREL; 403 [133:21-22] AMB; NREL; 403 [134:10-13] AMB; NREL; 403		
10/13/23	Russell-Clarke, Peter	136:11-21		131:9-15; 133:9-12; 133:14-16; 133:21-22; 134:10-13; 138:3-5; 138:8-12; 138:14-17; 138:19-21; 139:2-4; 139:6-8; 139:10-12; 139:16-18	[133:9-12] AMB; NREL; 403 [133:14-16] AMB; NREL; 403 [133:21-22] AMB; NREL; 403 [134:10-13] AMB; NREL; 403		
10/13/23	Russell-Clarke, Peter	137:3-14		131:9-15; 133:9-12; 133:14-16; 133:21-22; 134:10-13; 138:3-5; 138:8-12; 138:14-17; 138:19-21; 139:2-4; 139:6-8; 139:10-12; 139:16-18	[133:9-12] AMB; NREL; 403 [133:14-16] AMB; NREL; 403 [133:21-22] AMB; NREL; 403 [134:10-13] AMB; NREL; 403		
10/13/23	Russell-Clarke, Peter	139:20-140:8	402, 403, F, SP	131:9-15; 133:9-12; 133:14-16; 133:21-22; 134:10-13; 138:3-5; 138:8-12; 138:14-17; 138:19-21; 139:2-4; 139:6-8; 139:10-12; 139:16-18; 140:11-13; 140:16-18	[133:9-12] AMB; NREL; 403 [133:14-16] AMB; NREL; 403 [133:21-22] AMB; NREL; 403 [134:10-13] AMB; NREL; 403 [140:11-13] AMB; CLC; IEXP; NREL; 403 [140:16-18] AMB; CLC; IEXP; NREL; 403		
10/13/23	Russell-Clarke, Peter	141:7-142:22	402, 403, F, SP	128:8-10; 128:13-16; 129:6-9; 129:12-16; 143:13-18; 143:21-144:15	[128:8-10] AMB; CLC; IEXP; NREL; 403 [128:13-16] AMB; CLC; IEXP; NREL; 403 [129:6-9] AMB; NREL; 403; MIS [129:12-16] AMB; MIS; NREL; 403		
10/13/23	Russell-Clarke, Peter	217:14-222:3 [withdrawn]		222:12-223:13, 229:7-8, 229:12-15, 230:1-2, 230:4-18	403; AMB; LFND; NREL; BSD; SPC		
10/13/23	Russell-Clarke, Peter	238:7-239:16	402, 403, AA				
10/13/23	Russell-Clarke, Peter	239:22-242:3	402, 403, AA				
08/23/22	Russell-Clarke, Peter (CDCA)	7:4-7					
08/23/22	Russell-Clarke, Peter (CDCA)	8:2-4					
08/23/22	Russell-Clarke, Peter (CDCA)	8:13-9-9					
08/23/22	Russell-Clarke, Peter (CDCA)	10:12-17					
08/23/22	Russell-Clarke, Peter (CDCA)	13:13-20	F, SP	11:3-5; 11:7-9; 11:11-13; 11:15-16; 11:18-12:3; 12:12-15; 12:17-18; 14:10-12; 14:14-15; 15:19-16:1	[11:3-9] AMB; CPD; SPC [11:11-16] AMB; SPC [11:18-12:3] AMB; NREL [12:12-18] AMB; NREL [14:10-15] AMB; NREL [15:19-16:1] AMB; NREL	[11:7-9] 13:13-20 [11:18-12:3] 13:13-20 [11:15-16] 13:13-20 [11:11-13] 13:13-20 [12:12-15] 13:13-20 [12:17-18] 13:13-20	F, SP
08/23/22	Russell-Clarke, Peter (CDCA)	16:3-19	402, 403	16:20-22; 17:2-11; 19:8-21; 29:4-7	[16:20-17:11] AMB; NREL [19:8-21] AMB; NREL; INC	[17:2-11] 17:12-18:1 [19:8-21] 17:12-18:1	402, 403
08/23/22	Russell-Clarke, Peter (CDCA)	28:11-19	I	28:4-10; 28:21-29:2; 29:4-7	[28:4-10] AMB; NREL; 403 [28:21-29:7] AMB; NREL; 403		
11/17/23	Smith, Daniel	5:6-9					

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
11/17/23	Smith, Daniel	5:15-17					
11/17/23	Smith, Daniel	7:12-15					
11/17/23	Smith, Daniel	13:9-14					
11/17/23	Smith, Daniel	14:7-11					
11/17/23	Smith, Daniel	17:12-18:22					
11/17/23	Smith, Daniel	19:6-14					
11/17/23	Smith, Daniel	20:12-18					
11/17/23	Smith, Daniel	25:21-27:5	402, 403				
11/17/23	Smith, Daniel	27:14-16					
11/17/23	Smith, Daniel	29:13-19					
11/17/23	Smith, Daniel	30:3-10					
11/17/23	Smith, Daniel	30:16-18					
11/17/23	Smith, Daniel	31:19-32:2					
11/17/23	Smith, Daniel	34:6-16	402, 403				
11/17/23	Smith, Daniel	36:22-37:2	402, 403				
11/17/23	Smith, Daniel	45:8-19					
11/17/23	Smith, Daniel	53:12-54:8	402, 403				
11/17/23	Smith, Daniel	60:12-17	402, 403				
11/17/23	Smith, Daniel	83:17-84:10	402, 403				
11/17/23	Smith, Daniel	109:9-12					
11/17/23	Smith, Daniel	109:16-19					
08/18/22	Smith, Robert (CDCA)	6:14-7:16					
08/18/22	Smith, Robert (CDCA)	8:2-13					
08/18/22	Smith, Robert (CDCA)	8:16-9:5					
08/18/22	Smith, Robert (CDCA)	10:2-4					
08/18/22	Smith, Robert (CDCA)	10:9-19					
08/18/22	Smith, Robert (CDCA)	11:9-13:12					
08/18/22	Smith, Robert (CDCA)	15:18-22					
08/18/22	Smith, Robert (CDCA)	15:25-16:3					
08/18/22	Smith, Robert (CDCA)	16:9-19					
08/18/22	Smith, Robert (CDCA)	72:4-20	402, 403, M, F	46:17-23; 46:25-47:22	[46:17-23] AMB; INC; 403 [46:25-47:22] AMB; INC; NR; 403		
08/18/22	Smith, Robert (CDCA)	72:23-73:3	402, 403, M, F				
08/18/22	Smith, Robert (CDCA)	73:9-74:2	402, 403, M, F	74:3-12	[74:3-12] AMB; 403		
08/18/22	Smith, Robert (CDCA)	74:13-75:9	402, 403, M, F	75:10-12; 75:15-15; 75:17-18; 75:20-22	[75:15-15] AMB; 403 [75:20-22] AMB; 403		
08/18/22	Smith, Robert (CDCA)	75:24-25	402, 403, M, F				
08/18/22	Smith, Robert (CDCA)	76:2-8	402, 403, M, F	76:9-10	[76:9-10] AMB; INC; NR; 403		
08/18/22	Smith, Robert (CDCA)	76:11-13	402, 403, M, F	76:14-15; 76:18-18	[76:18-18] AMB; 403		
08/18/22	Smith, Robert (CDCA)	76:20-22	402, 403, M, F	76:23-24; 77:2-2; 77:4-6	[77:2-2] AMB; 403 [77:4-6] AMB; 403		
08/18/22	Smith, Robert (CDCA)	77:7-12	402, 403, M, F				
08/18/22	Smith, Robert (CDCA)	77:15-16	402, 403, M, F				
08/18/22	Smith, Robert (CDCA)	77:18-22	402, 403, M, F	77:23-78:17; 78:20-79:7	[77:23-78:17] AMB; NR; 403 [78:20-79:7] AMB; NR; NREL; 403		
11/21/23	Stephens, Nicholas	11:13-12:3					
11/21/23	Stephens, Nicholas	14:20-15:1					
11/21/23	Stephens, Nicholas	36:11-19					
11/21/23	Stephens, Nicholas	37:5-9					
11/21/23	Stephens, Nicholas	40:18-41:19					
11/21/23	Stephens, Nicholas	43:9-44:19					
11/21/23	Stephens, Nicholas	45:2-49:5					
11/21/23	Stephens, Nicholas	50:10-51:6					
11/21/23	Stephens, Nicholas	53:5-12	402, 403				
11/21/23	Stephens, Nicholas	76:17-77:17					
11/21/23	Stephens, Nicholas	77:20-78:14					
11/21/23	Stephens, Nicholas	90:3-91:12	402, 403, F, SP	91:14-93:6	[91:14-93:6] AMB; NREL; 403		
11/21/23	Stephens, Nicholas	110:8-18					
11/21/23	Stephens, Nicholas	137:2-14	402, 403				
11/02/23	Tripodi, Anthony Blair	8:17-19					
11/02/23	Tripodi, Anthony Blair	10:11-15 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	11:11-15					
11/02/23	Tripodi, Anthony Blair	12:2-10					
11/02/23	Tripodi, Anthony Blair	14:7-21 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	15:13-15					
11/02/23	Tripodi, Anthony Blair	15:17-19					
11/02/23	Tripodi, Anthony Blair	15:21-16:3					
11/02/23	Tripodi, Anthony Blair	16:5-5					

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
11/02/23	Tripodi, Anthony Blair	16:7-8 [added]					
11/02/23	Tripodi, Anthony Blair	16:10-10 [added]					
11/02/23	Tripodi, Anthony Blair	16:12-24 [added]					
11/02/23	Tripodi, Anthony Blair	17:1-3 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	17:2-9 [added]					
11/02/23	Tripodi, Anthony Blair	22:25-23:13 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	25:14-24 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	26:1-1 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	26:22-25 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	27:2-23 [withdrawn]	F; SP				
11/02/23	Tripodi, Anthony Blair	29:3-9 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	29:16-25 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	30:24-31:9 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	31:14-16 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	32:10-24 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	35:4-12 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	37:12-18 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	38:1-11 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	41:11-42:7 [added]					
11/02/23	Tripodi, Anthony Blair	46:23-47:8 [added]					
11/02/23	Tripodi, Anthony Blair	48:15-21 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	49:19-21 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	49:23-25 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	50:7-19 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	51:2-10 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	51:19-19 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	51:21-22 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	51:24-52:4 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	52:11-21 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	53:9-25 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	54:1-13 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	54:14-55:3 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	55:6-9 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	58:5-13 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	59:20-60:2 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	60:4-13 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	66:7-68:17 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	68:19-69:10 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	69:21-70:18 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	71:16-22 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	73:3-7 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	73:9-11 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	73:13-14 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	74:8-19 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	74:22-75:4 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	75:23-76:2					
11/02/23	Tripodi, Anthony Blair	76:11-77:17					
11/02/23	Tripodi, Anthony Blair	80:5-18 [added]					
11/02/23	Tripodi, Anthony Blair	83:14-84:3					
11/02/23	Tripodi, Anthony Blair	87:19-22					
11/02/23	Tripodi, Anthony Blair	88:1-21 [added]					
11/02/23	Tripodi, Anthony Blair	90:4-13					
11/02/23	Tripodi, Anthony Blair	91:24-92:17 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	93:5-18 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	93:22-94:2 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	96:15-97:8 [added]					
11/02/23	Tripodi, Anthony Blair	104:13-105:1 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	105:14-25 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	113:2-114:14 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	114:23-115:3 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	115:17-22 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	115:25-116:6 [withdrawn]		117:16-24; 118:8-9 [Withdraw]	403; AMB; BER; SPC; HRS; LFND; NREL	113:2-13; 117:9-15; 118:10-15	
11/02/23	Tripodi, Anthony Blair	117:9-14 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	125:6-126:6					
11/02/23	Tripodi, Anthony Blair	127:1-4 [added]					
11/02/23	Tripodi, Anthony Blair	128:9-20 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	132:11-133:5 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	138:8-139:16 [added]					

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER- COUNTERS
11/02/23	Tripodi, Anthony Blair	141:21-142:5 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	143:18-144:1					
11/02/23	Tripodi, Anthony Blair	144:7-146:1					
11/02/23	Tripodi, Anthony Blair	146:3-4					
11/02/23	Tripodi, Anthony Blair	146:6-17					
11/02/23	Tripodi, Anthony Blair	147:24-148:8					
11/02/23	Tripodi, Anthony Blair	148:19-149:3 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	149:5-11 [withdrawn]	I				
11/02/23	Tripodi, Anthony Blair	152:7-16 [added]					
11/02/23	Tripodi, Anthony Blair	163:20-164:10 [added]					
11/02/23	Tripodi, Anthony Blair	168:2-11 [added]					
11/02/23	Tripodi, Anthony Blair	168:14-15 [added]					
11/02/23	Tripodi, Anthony Blair	172:20-22 [added]					
11/02/23	Tripodi, Anthony Blair	173:10-14 [added]					
11/02/23	Tripodi, Anthony Blair	173:17-174:5 [added]					
11/02/23	Tripodi, Anthony Blair	182:21-25 [added]					
11/02/23	Tripodi, Anthony Blair	183:3-9 [added]					
11/02/23	Tripodi, Anthony Blair	183:11-11 [added]					
11/02/23	Tripodi, Anthony Blair	183:13-14 [added]					
11/02/23	Tripodi, Anthony Blair	183:18-25 [added]					
11/02/23	Tripodi, Anthony Blair	189:19-190:8					
11/02/23	Tripodi, Anthony Blair	190:12-15					
11/02/23	Tripodi, Anthony Blair	190:19-20					
11/02/23	Tripodi, Anthony Blair	190:25-191:3					
11/02/23	Tripodi, Anthony Blair	191:5-6					
11/02/23	Tripodi, Anthony Blair	191:9-13					
11/02/23	Tripodi, Anthony Blair	204:16-206:24 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	209:7-14 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	209:16-23 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	210:6-8 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	210:25-211:14 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	211:16-18 [withdrawn]	F				
11/02/23	Tripodi, Anthony Blair	211:20-212:3 [withdrawn]	I				
11/02/23	Tripodi, Anthony Blair	212:19-24 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	213:1-1 [withdrawn]	I				
11/02/23	Tripodi, Anthony Blair	213:3-4 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	213:6-13 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	215:11-216:2					
11/02/23	Tripodi, Anthony Blair	213:15-214:5 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	217:3-12 [added]					
11/02/23	Tripodi, Anthony Blair	221:23-222:5 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	222:7-7 [withdrawn]					
11/02/23	Tripodi, Anthony Blair	222:9-21					
11/02/23	Tripodi, Anthony Blair	222:23-23					
11/02/23	Tripodi, Anthony Blair	222:25-223:5					
11/02/23	Tripodi, Anthony Blair	223:7-8					
11/02/23	Tripodi, Anthony Blair	223:14-14 [withdrawn]		223:16-18 Keep; also responds to 222:25	403; AMB; LFND; NREL	223-10:14	
11/02/23	Tripodi, Anthony Blair	223:19-22					
11/02/23	Tripodi, Anthony Blair	223:24-25					
11/02/23	Tripodi, Anthony Blair	224:2-4 [added]					
11/02/23	Tripodi, Anthony Blair	224:6-6					
11/02/23	Tripodi, Anthony Blair	225:19-226:2					
11/02/23	Tripodi, Anthony Blair	226:5-8					
11/02/23	Tripodi, Anthony Blair	226:11-11 [added]					
11/02/23	Wei, Crystal	9:21-22					
11/02/23	Wei, Crystal	10:1-12					
11/02/23	Wei, Crystal	10:22-24					
11/02/23	Wei, Crystal	12:15-13:10					
11/02/23	Wei, Crystal	13:16-24					
11/02/23	Wei, Crystal	14:17-20					
11/02/23	Wei, Crystal	15:16-21					
11/02/23	Wei, Crystal	16:16-19					
11/02/23	Wei, Crystal	17:19-24					
11/02/23	Wei, Crystal	18:9-22					
11/02/23	Wei, Crystal	22:4-8					
11/02/23	Wei, Crystal	22:11-17					
11/02/23	Wei, Crystal	30:18-31:16					
11/02/23	Wei, Crystal	32:8-25					

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
11/02/23	Wei, Crystal	33:1-15					
11/02/23	Wei, Crystal	35:4-6	402/403	35:24-36:3; 36:18-21; 37:1-3; 37:5-11; 37:16-17			
11/02/23	Wei, Crystal	36:4-4	402/403/C	35:24-36:3; 36:18-21; 37:1-3; 37:5-11; 37:16-17			
11/02/23	Wei, Crystal	38:3-25	402/403	35:24-36:3; 36:18-21; 37:1-3; 37:5-11; 37:16-17			
11/02/23	Wei, Crystal	39:1-7	402/403	35:24-36:3; 36:18-21; 37:1-3; 37:5-11; 37:16-17			
11/02/23	Wei, Crystal	40:13-41:25	402/403				
11/02/23	Wei, Crystal	42:4-11	402/403				
11/02/23	Wei, Crystal	43:11-20	402/403				
11/02/23	Wei, Crystal	43:22-44:4	402/403				
11/02/23	Wei, Crystal	44:21-45:9	402/403				
11/02/23	Wei, Crystal	45:13-23	402/403				
11/02/23	Wei, Crystal	46:3-3	402/403				
11/02/23	Wei, Crystal	46:25-47:3	402/403				
11/02/23	Wei, Crystal	47:10-12	402/403				
11/02/23	Wei, Crystal	47:18-48:17	402/403				
11/02/23	Wei, Crystal	49:1-17	402/403				
11/02/23	Wei, Crystal	53:6-12	402/403				
11/02/23	Wei, Crystal	53:14-54:11	402/403				
11/02/23	Wei, Crystal	55:17-25	402/403				
11/02/23	Wei, Crystal	56:1-2	402/403				
11/02/23	Wei, Crystal	56:8-8	402/403				
11/02/23	Wei, Crystal	56:10-20	402/403				
11/02/23	Wei, Crystal	56:22-57:13	402/403				
11/02/23	Wei, Crystal	57:15-21	402/403				
11/02/23	Wei, Crystal	58:7-19	402/403				
11/02/23	Wei, Crystal	59:8-14	402/403				
11/02/23	Wei, Crystal	60:3-10	402/403				
11/02/23	Wei, Crystal	60:12-19	402/403				
11/02/23	Wei, Crystal	61:1-22	402/403				
11/02/23	Wei, Crystal	61:24-62:11	402/403				
11/02/23	Wei, Crystal	62:13-19	402/403				
11/02/23	Wei, Crystal	64:12-22					
11/02/23	Wei, Crystal	72:16-19					
11/02/23	Wei, Crystal	79:14-82:13		85:24-86:6			
11/02/23	Wei, Crystal	82:22-83:22		85:24-86:6			
11/02/23	Wei, Crystal	88:9-89:7		85:24-86:6			
11/02/23	Wei, Crystal	107:24-110:9					
11/02/23	Wei, Crystal	114:22-116:10	402/403	117:18-21			
11/02/23	Wei, Crystal	117:13-16	402/403	117:18-21			
11/02/23	Wei, Crystal	138:8-10	402/403	150:11-15			
11/02/23	Wei, Crystal	139:11-18	402/403	150:11-15			
11/02/23	Wei, Crystal	142:1-12	402/403	150:11-15			
11/02/23	Wei, Crystal	142:16-143:11	402/403	150:11-15			
11/02/23	Wei, Crystal	143:14-15	402/403	150:11-15			
11/02/23	Wei, Crystal	143:17-144:1	402/403	150:11-15			
11/02/23	Wei, Crystal	148:5-149:5	402/403	150:11-15			
11/02/23	Wei, Crystal	165:20-166:9	402/403				
11/02/23	Wei, Crystal	174:23-175:3					
11/02/23	Wei, Crystal	175:12-15					
11/02/23	Wei, Crystal	179:12-25					
11/02/23	Wei, Crystal	180:1-1					
11/02/23	Wei, Crystal	194:6-22					
11/02/23	Wei, Crystal	196:2-7					
11/02/23	Wei, Crystal	198:9-21					
11/02/23	Wei, Crystal	205:3-8					
11/02/23	Wei, Crystal	206:7-208:5					
11/02/23	Wei, Crystal	208:15-25					
11/02/23	Wei, Crystal	211:17-212:11					
11/02/23	Wei, Crystal	212:22-213:17					
11/02/23	Wei, Crystal	215:7-22					
11/02/23	Wei, Crystal	216:3-217:1					
11/02/23	Wei, Crystal	217:13-15					
11/02/23	Wei, Crystal	217:23-218:2					
11/02/23	Wei, Crystal	218:11-21					



DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER- COUNTERS
11/02/23	Wei, Crystal	219:10-22		219:4-10; 219:24-220:5			
11/02/23	Wei, Crystal	220:7-11		219:4-10; 219:24-220:5			
11/02/23	Wei, Crystal	220:23-221:16					
11/02/23	Wei, Crystal	221:22-222:9					
11/02/23	Wei, Crystal	270:1-9					
08/25/22	Wei, Crystal (CDCA)	7:9-11					
08/25/22	Wei, Crystal (CDCA)	7:20-21					
08/25/22	Wei, Crystal (CDCA)	9:13-19					
08/25/22	Wei, Crystal (CDCA)	10:1-19					
08/25/22	Wei, Crystal (CDCA)	11:8-12:7					
08/25/22	Wei, Crystal (CDCA)	14:23-15:15					
08/25/22	Wei, Crystal (CDCA)	16:3-6					
08/25/22	Wei, Crystal (CDCA)	17:21-24					
08/25/22	Wei, Crystal (CDCA)	25:20-27:17	402/403	28:14-16; 29:5-12; 31:17-20; 32:7-18	[28:14-16] AMB; NREL; 403 [29:5-12] AMB; NREL; 403 [31:17-20] AMB; NREL; 403 [32:7-18] AMB; NREL; 403		
08/25/22	Wei, Crystal (CDCA)	46:20-23	402/403	28:14-16; 29:5-12; 31:17-20; 32:7-18	[28:14-16] AMB; NREL; 403 [29:5-12] AMB; NREL; 403 [31:17-20] AMB; NREL; 403 [32:7-18] AMB; NREL; 403		
08/25/22	Wei, Crystal (CDCA)	50:8-13	402/403	28:14-16; 29:5-12; 31:17-20; 32:7-18	[28:14-16] AMB; NREL; 403 [29:5-12] AMB; NREL; 403 [31:17-20] AMB; NREL; 403 [32:7-18] AMB; NREL; 403		
08/25/22	Wei, Crystal (CDCA)	50:14-18	402/403	28:14-16; 29:5-12; 31:17-20; 32:7-18	[28:14-16] AMB; NREL; 403 [29:5-12] AMB; NREL; 403 [31:17-20] AMB; NREL; 403 [32:7-18] AMB; NREL; 403		
08/25/22	Wei, Crystal (CDCA)	51:10-53:8	402/403	28:14-16; 29:5-12; 31:17-20; 32:7-18	[28:14-16] AMB; NREL; 403 [29:5-12] AMB; NREL; 403 [31:17-20] AMB; NREL; 403 [32:7-18] AMB; NREL; 403		
08/25/22	Wei, Crystal (CDCA)	59:2-6	402/403				
08/25/22	Wei, Crystal (CDCA)	59:11-25	402/403				
08/25/22	Wei, Crystal (CDCA)	60:1-63:5	402/403				
08/25/22	Wei, Crystal (CDCA)	64:13-16	402/403				
08/25/22	Wei, Crystal (CDCA)	64:22-70:8	402/403				
08/25/22	Wei, Crystal (CDCA)	71:18-73:2	402/403				
08/25/22	Wei, Crystal (CDCA)	77:2-82:21					
08/25/22	Wei, Crystal (CDCA)	82:24-25					
08/25/22	Wei, Crystal (CDCA)	83:7-91:13					
08/25/22	Wei, Crystal (CDCA)	116:6-123:16					
08/25/22	Wei, Crystal (CDCA)	123:18-125:5	402/403/LC/AC	125:7-13			
08/25/22	Wei, Crystal (CDCA)	126:4-15	402/403	125:7-13			
11/01/23	Wilson, William	7:15-19					
11/01/23	Wilson, William	8:23-25					
11/01/23	Wilson, William	9:1-3					
11/01/23	Wilson, William	9:19-10:19					
11/01/23	Wilson, William	13:1-15					
11/01/23	Wilson, William	167:16-22					
11/01/23	Wilson, William	168:5-10		168:11-23	[168:11-23] AMB; NREL; OBJ; 403	168:24-25; 169:2-3	
11/01/23	Wilson, William	168:24-25					
11/01/23	Wilson, William	169:2-3					
11/01/23	Wilson, William	169:5-5					
11/01/23	Wilson, William	169:7-14					
03/28/24	Yorke, Jacqueline	7:9-12					
03/28/24	Yorke, Jacqueline	7:16-18					
03/28/24	Yorke, Jacqueline	7:19-8:3					
03/28/24	Yorke, Jacqueline	8:11-9:22	402; 403				
03/28/24	Yorke, Jacqueline	10:7-11:5	402; 403				
03/28/24	Yorke, Jacqueline	11:19-12:10	402; 403	11:13-18	[11:13-18] NREL; 403	11:19-24	402; 403
03/28/24	Yorke, Jacqueline	12:13-13:11	402; 403				
03/28/24	Yorke, Jacqueline	13:15-17	402; 403				
03/28/24	Yorke, Jacqueline	13:20-15:10	402; 403				
03/28/24	Yorke, Jacqueline	15:18-16:13		16:14-15; 16:18-18	[16:14-18] AMB; SPC; LFND; NREL; 403		
03/28/24	Yorke, Jacqueline	17:9-12					
03/28/24	Yorke, Jacqueline	17:15-23					

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
03/28/24	Yorke, Jacqueline	18:7-18		18:19-20; 18:23-24	[18:19-24] AMB; AA; LDG; NREL; OBJ; 403		
03/28/24	Yorke, Jacqueline	18:25-19:20		19:21-21; 19:23-20:1	[19:21-20:1] AMB; SPC; LFND; NREL; 403		
03/28/24	Yorke, Jacqueline	20:2-21:8		21:9-11; 21:22-24; 22:2-3; 22:5-8; 22:10-11; 22:22-22; 23:1-6; 25:6-11; 38:7-9; 38:13-18; 41:9-15; 41:16-42:3; 42:4-7; 42:14-43:3; 43:22-25; 46:6-8; 47:9-17; 47:19-48:6; 48:9-13; 49:4-6; 50:1-9; 50:23-51:2; 51:4-4; 57:10-58:5; 58:11-19; 59:1-9; 59:21-60:3; 61:12-16; 61:17-62:4; 62:24-63:1; 63:23-24; 64:2-2; 64:6-7; 64:10-11; 66:23-67:2; 67:6-7; 73:14-19; 73:22-22	[21:9-11] AMB; LFND; NREL; 403 [21:22-22:11] AMB; SPC; LFND; LDG; NREL; 403 [22:22-23:6] AMB; AA; HRS; INC; LFND; NREL; 403 [25:6-11] AMB; SPC; LFND; NREL; 403 [38:7-18] AMB; ARG; LFND; LDG; NR; NREL; BSD (OS); 403 [41:9-15] AMB; NREL; 403 [41:16-42:3] AMB; NREL; 403 [42:4-7] AMB; NREL; 403 [42:14-43:3] AMB; SPC; NREL; 403 [43:22-25] AMB; NREL; 403 [46:6-8] AMB; LFND; NREL; 403 [47:9-48:13] AMB; LFND; LDG; NREL; 403 [49:4-6] SPC; NREL; 403; BSD (OS) [50:1-9] BER; BSD (OS); HRS; LDG; NREL; 403 [50:23-51:4] AMB; SPC; LFND; LDG; NREL; 403 [57:10-58:5] AMB; SPC; LFND; NREL; 403 [58:11-19] AMB; SPC; LFND; NREL; 403 [59:1-9] AMB; LFND; LDG; NREL; 403 [59:21-60:3] AMB; AA; SPC; LFND; LDG; NREL; 403 [61:12-62:4] AMB; BSD (OS); SPC; LFND; LDG; NREL; 403 [62:24-63:1] BSD (OS); LFND; LA; NREL; OBJ; 403; NP	[21:9-11] 21:12-21; 22:18-21; 51:10-18; 51:10-18 [21:22-24] 21:12-21; 22:18-21; 51:10-18; 51:10-18 [22:5-8] 21:12-21; 22:18-21; 51:10-18; 51:10-18 [22:10-11] 21:12-21; 22:18-21; 51:10-18; 51:10-18 [22:2-3] 21:12-21; 22:18-21; 51:10-18; 51:10-18 [25:6-11] 25:12-26:2; 51:10-18; 51:10-18 [38:13-18] 35:1-7; 51:10-18; 51:10-18 [38:7-9] 35:1-7; 51:10-18; 51:10-18 [47:19-48:6] 35:1-7 [47:9-17] 35:1-7 [48:9-13] 35:1-7	
03/28/24	Yorke, Jacqueline	25:12-26:8	402; 403	21:9-11; 21:22-24; 22:2-3; 22:5-8; 22:10-11; 22:22-22; 23:1-6; 25:6-11; 38:7-9; 38:13-18; 41:9-15; 41:16-42:3; 42:4-7; 42:14-43:3; 43:22-25; 46:6-8; 47:9-17; 47:19-48:6; 48:9-13; 49:4-6; 50:1-9; 50:23-51:2; 51:4-4; 57:10-58:5; 58:11-19; 59:1-9; 59:21-60:3; 61:12-16; 61:17-62:4; 62:24-63:1; 63:23-24; 64:2-2; 64:6-7; 64:10-11; 66:23-67:2; 67:6-7; 73:14-19; 73:22-22	[21:9-11] AMB; LFND; NREL; 403 [21:22-22:11] AMB; SPC; LFND; LDG; NREL; 403 [22:22-23:6] AMB; AA; HRS; INC; LFND; NREL; 403 [25:6-11] AMB; SPC; LFND; NREL; 403 [38:7-18] AMB; ARG; LFND; LDG; NR; NREL; BSD (OS); 403 [41:9-15] AMB; NREL; 403 [41:16-42:3] AMB; NREL; 403 [42:4-7] AMB; NREL; 403 [42:14-43:3] AMB; SPC; NREL; 403 [43:22-25] AMB; NREL; 403 [46:6-8] AMB; LFND; NREL; 403 [47:9-48:13] AMB; LFND; LDG; NREL; 403 [49:4-6] SPC; NREL; 403; BSD (OS) [50:1-9] BER; BSD (OS); HRS; LDG; NREL; 403 [50:23-51:4] AMB; SPC; LFND; LDG; NREL; 403 [57:10-58:5] AMB; SPC; LFND; NREL; 403 [58:11-19] AMB; SPC; LFND; NREL; 403 [59:1-9] AMB; LFND; LDG; NREL; 403 [59:21-60:3] AMB; AA; SPC; LFND; LDG; NREL; 403 [61:12-62:4] AMB; BSD (OS); SPC; LFND; LDG; NREL; 403 [62:24-63:1] BSD (OS); LFND; LA; NREL; OBJ; 403; NP	[21:9-11] 21:12-21; 22:18-21; 51:10-18; 51:10-18 [21:22-24] 21:12-21; 22:18-21; 51:10-18; 51:10-18 [22:5-8] 21:12-21; 22:18-21; 51:10-18; 51:10-18 [22:10-11] 21:12-21; 22:18-21; 51:10-18; 51:10-18 [22:2-3] 21:12-21; 22:18-21; 51:10-18; 51:10-18 [25:6-11] 25:12-26:2; 51:10-18; 51:10-18 [38:13-18] 35:1-7; 51:10-18; 51:10-18 [38:7-9] 35:1-7; 51:10-18; 51:10-18 [47:19-48:6] 35:1-7 [47:9-17] 35:1-7 [48:9-13] 35:1-7	402; 403; F; SP; I
03/28/24	Yorke, Jacqueline	30:16-31:1		31:16-16	[31:13-16] AMB; SPC; LFND; NREL; 403	[22:22-22] 51:10-18; 51:10-18	402; 403; F; SP; I
03/28/24	Yorke, Jacqueline	31:10-12		31:13-14	[31:13-16] AMB; SPC; LFND; NREL; 403	31:17-18; 31:24-32:7	402; 403; F; SP
03/28/24	Yorke, Jacqueline	32:23-34:8					

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
03/28/24	Yorke, Jacqueline	35:1-7	402; 403; F; SP	35:19-21; 35:24-36:1	[35:19-36:1] AMB; LFND; NREL; 403	[35:19-21] 35:1-7; 51:10-18; 51:10-18 [35:24-36:1] 35:1-7; 51:10-18; 51:10-18	402; 403; F; SP
03/28/24	Yorke, Jacqueline	36:24-38:6	402; 403	21:9-11; 21:22-24; 22:2-3; 22:5-8; 22:10-11; 22:22-22; 23:1-6; 25:6-11; 38:7-9; 38:13-18; 41:9-15; 41:16-42:3; 42:4-7; 42:14-43:3; 43:22-25; 46:6-8; 47:9-17; 47:19-48:6; 48:9-13; 49:4-6; 50:23-51:2; 51:4-4; 57:10-58:5; 58:11-19; 59:1-9; 59:21-60:3; 61:12-16; 61:17-62:4; 62:24-63:1; 63:23-24; 64:2-2; 64:6-7; 64:10-11; 66:23-67:2; 67:6-7; 73:14-19; 73:22-22	[21:9-11] AMB; LFND; NREL; 403 [21:22-22:11] AMB; SPC; LFND; LDG; NREL; 403 [22:22-23:6] AMB; AA; HRS; INC; LFND; NREL; 403 [25:6-11] AMB; SPC; LFND; NREL; 403 [38:7-18] AMB; ARG; LFND; LDG; NR; NREL; BSD (OS); 403 [41:9-15] AMB; NREL; 403 [41:16-42:3] AMB; NREL; 403 [42:4-7] AMB; NREL; 403 [42:14-43:3] AMB; SPC; NREL; 403 [43:22-25] AMB; NREL; 403 [46:6-8] AMB; LFND; NREL; 403 [47:9-48:13] AMB; LFND; LDG; NREL; 403 [49:4-6] SPC; NREL; 403; BSD (OS) [50:23-51:4] AMB; SPC; LFND; LDG; NREL; 403 [57:10-58:5] AMB; SPC; LFND; NREL; 403 [58:11-19] AMB; SPC; LFND; NREL; 403 [59:1-9] AMB; LFND; LDG; NREL; 403 [59:21-60:3] AMB; AA; SPC; LFND; LDG; NREL; 403 [61:12-62:4] AMB; BSD (OS); SPC; LFND; LDG; NREL; 403 [62:24-63:1] BSD (OS); LFND; LA; NREL; OBJ; 403; NP [63:23-64:11] AMB; BSD (OS); SPC; LFND; NP; NREL; 403	[21:9-11] 21:12-21; 22:18-21; 51:10-18; 51:10-18 [21:22-24] 21:12-21; 22:18-21; 51:10-18; 51:10-18 [22:5-8] 21:12-21; 22:18-21; 51:10-18; 51:10-18 [22:10-11] 21:12-21; 22:18-21; 51:10-18; 51:10-18 [22:2-3] 21:12-21; 22:18-21; 51:10-18; 51:10-18 [25:6-11] 25:12-26:2; 51:10-18; 51:10-18 [38:13-18] 35:1-7; 51:10-18; 51:10-18 [38:7-9] 35:1-7; 51:10-18; 51:10-18 [47:19-48:6] 35:1-7 [47:9-17] 35:1-7 [48:9-13] 35:1-7	402; 403; F; SP; I
03/28/24	Yorke, Jacqueline	38:19-40:7	402; 403	21:9-11; 21:22-24; 22:5-8; 22:10-11; 22:22-22; 23:1-6; 25:6-11; 38:7-9; 41:9-15; 41:16-42:3; 42:4-7; 42:14-43:3; 43:22-25; 46:6-8; 47:9-17; 47:19-48:6; 48:9-13; 49:4-6; 50:1-9; 50:23-51:2; 51:4-4; 57:10-58:5; 58:11-19; 59:1-9; 59:21-60:3; 61:12-16; 61:17-62:4; 62:24-63:1; 63:23-24; 64:2-2; 64:6-7; 64:10-11; 66:23-67:2; 67:6-7; 73:14-19; 73:22-22	[21:9-11] AMB; LFND; NREL; 403 [21:22-22:11] AMB; SPC; LFND; LDG; NREL; 403 [22:22-23:6] AMB; AA; HRS; INC; LFND; NREL; 403 [25:6-11] AMB; SPC; LFND; NREL; 403 [38:7-18] AMB; ARG; LFND; LDG; NR; NREL; BSD (OS); 403 [41:9-15] AMB; NREL; 403 [41:16-42:3] AMB; NREL; 403 [42:4-7] AMB; NREL; 403 [42:14-43:3] AMB; SPC; NREL; 403 [43:22-25] AMB; NREL; 403 [46:6-8] AMB; LFND; NREL; 403 [47:9-48:13] AMB; LFND; LDG; NREL; 403 [49:4-6] SPC; NREL; 403; BSD (OS) [50:1-9] BER; BSD (OS); HRS; LDG; NREL; 403 [50:23-51:4] AMB; SPC; LFND; LDG; NREL; 403 [57:10-58:5] AMB; SPC; LFND; NREL; 403 [58:11-19] AMB; SPC; LFND; NREL; 403 [59:1-9] AMB; LFND; LDG; NREL; 403 [59:21-60:3] AMB; AA; SPC; LFND; LDG; NREL; 403 [61:12-62:4] AMB; BSD (OS); SPC; LFND; LDG; NREL; 403 [62:24-63:1] BSD (OS); LFND; LA; NREL; OBJ; 403; NP	[21:9-11] 21:12-21; 22:18-21; 51:10-18; 51:10-18 [21:22-24] 21:12-21; 22:18-21; 51:10-18; 51:10-18 [22:5-8] 21:12-21; 22:18-21; 51:10-18; 51:10-18 [22:10-11] 21:12-21; 22:18-21; 51:10-18; 51:10-18 [25:6-11] 25:12-26:2; 51:10-18; 51:10-18 [38:7-9] 35:1-7; 51:10-18; 51:10-18 [47:19-48:6] 35:1-7 [47:9-17] 35:1-7 [48:9-13] 35:1-7 [22:22-22] 51:10-18; 51:10-18 [23:1-6] 51:10-18; 51:10-18 [50:23-51:2] 51:10-18; 51:10-18	402; 403; F; SP; I
11/21/23	Young, Micah	13:5-24					
11/21/23	Young, Micah	14:5-8	402, 403, I				
11/21/23	Young, Micah	15:25-25 [withdrawn]	402, 403, I				
11/21/23	Young, Micah	16:2-4	402, 403				
11/21/23	Young, Micah	16:6-6	402, 403				

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
11/21/23	Young, Micah	16:10-17:20	402, 403				
11/21/23	Young, Micah	17:25-18:13	402, 403				
11/21/23	Young, Micah	19:1-25 [withdrawn]	402, 403, I				
11/21/23	Young, Micah	20:1-4 [withdrawn]	402, 403, I				
11/21/23	Young, Micah	20:9-25 [withdrawn]	402, 403, I				
11/21/23	Young, Micah	21:1-2 [withdrawn]	402, 403, I				
11/21/23	Young, Micah	21:8-14 [withdrawn]	402, 403, I				
11/21/23	Young, Micah	21:16-16 [withdrawn]	402, 403, I				
11/21/23	Young, Micah	21:18-19 [withdrawn]	402, 403, I				
11/21/23	Young, Micah	21:25-22:14	402, 403				
11/21/23	Young, Micah	23:19-22	402, 403				
11/21/23	Young, Micah	24:1-6 [withdrawn]	402, 403, I				
11/21/23	Young, Micah	24:7-25 [withdrawn]	402, 403, I				
11/21/23	Young, Micah	25:1-25 [withdrawn]	402, 403, I				
11/21/23	Young, Micah	26:1-20 [withdrawn]	402, 403, I				
11/21/23	Young, Micah	27:4-5 [withdrawn]	402, 403, I				
11/21/23	Young, Micah	27:9-14	402, 403				
11/21/23	Young, Micah	28:8-12	402, 403				
11/21/23	Young, Micah	29:2-4 [withdrawn]	402, 403, I				
11/21/23	Young, Micah	29:6-8	402, 403				
11/21/23	Young, Micah	29:17-22	402, 403				
11/21/23	Young, Micah	30:8-10	402, 403				
11/21/23	Young, Micah	31:1-3 [withdrawn]	402, 403, AG, I				
11/21/23	Young, Micah	33:8-12	402, 403, F, SP				
11/21/23	Young, Micah	34:25-25 [withdrawn]	402, 403, I				
11/21/23	Young, Micah	35:1-11 [withdrawn]	402, 403, I				
11/21/23	Young, Micah	36:7-10	402, 403				
11/21/23	Young, Micah	36:14-37:20	402, 403				
11/21/23	Young, Micah	38:2-8	402, 403				
11/21/23	Young, Micah	38:16-25 [withdrawn]	402, 403, I				
11/21/23	Young, Micah	39:1-3 [withdrawn]	402, 403, I				
11/21/23	Young, Micah	39:10-17	402, 403				
11/21/23	Young, Micah	40:3-8 [added]	402, 403				
11/21/23	Young, Micah	41:11-17	402, 403, I				
11/21/23	Young, Micah	42:10-12	402, 403				
11/21/23	Young, Micah	43:16-44:1	402, 403				
11/21/23	Young, Micah	44:4-7	402, 403				
11/21/23	Young, Micah	44:12-22	402, 403				
11/21/23	Young, Micah	45:19-46:8	402, 403, I, F, SP				
11/21/23	Young, Micah	46:24-25 [withdrawn]	402, 403, I, F, SP				
11/21/23	Young, Micah	47:1-4 [withdrawn]	402, 403, I, F, SP				
11/21/23	Young, Micah	50:13-25 [withdrawn]	402, 403, I, F, SP				
11/21/23	Young, Micah	51:1-4 [withdrawn]	402, 403, I, F, SP				
11/21/23	Young, Micah	52:23-53:6	402, 403, F, SP	53:7-8	[53:7-8] LDG		
11/21/23	Young, Micah	53:9-15	402, 403, F, SP				
11/21/23	Young, Micah	53:25-25 [withdrawn]	402, 403, I				
11/21/23	Young, Micah	54:4-16 [withdrawn]	402, 403, I				
11/21/23	Young, Micah	54:17-22 [withdrawn]	402, 403, I				
11/21/23	Young, Micah	55:7-25 [withdrawn]	402, 403, I				
11/21/23	Young, Micah	56:1-1 [withdrawn]	402, 403, I				
11/21/23	Young, Micah	60:4-6 [withdrawn]	402, 403				
11/21/23	Young, Micah	69:5-22					
11/21/23	Young, Micah	70:22-71:2					
11/21/23	Young, Micah	72:1-11 [withdrawn]	402, 403, A, I				
11/21/23	Young, Micah	72:14-25 [withdrawn]	402, 403, A, I				
11/21/23	Young, Micah	73:1-10 [withdrawn]	402, 403, A, I				
11/21/23	Young, Micah	73:17-23	402, 403, A, I				
11/21/23	Young, Micah	76:7-77:1 [withdrawn]	402, 403, A, I, F, SP				
11/21/23	Young, Micah	77:2-4 [withdrawn]	402, 403, A, I, F, SP				
11/21/23	Young, Micah	77:18-24 [withdrawn]	402, 403, A, AG, I				
11/21/23	Young, Micah	80:21-25 [withdrawn]	402, 403, I, O				
11/21/23	Young, Micah	81:1-11 [withdrawn]	402, 403, I, O				
11/21/23	Young, Micah	82:23-83:1	402, 403, O				
11/21/23	Young, Micah	83:18-20 [withdrawn]	402, 403, A, I				
11/21/23	Young, Micah	83:24-25 [withdrawn]	402, 403, A, I				
11/21/23	Young, Micah	84:1-7 [withdrawn]	402, 403, A, I				
11/21/23	Young, Micah	84:8-18 [withdrawn]	402, 403, A, I				

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
11/21/23	Young, Micah	85:2-4 [withdrawn]	402, 403, I				
11/21/23	Young, Micah	85:12-19 [withdrawn]	402, 403, A, I, O				
11/21/23	Young, Micah	85:23-25 [withdrawn]	402, 403, A, I				
11/21/23	Young, Micah	86:1-1 [withdrawn]	402, 403, A, I				
11/21/23	Young, Micah	88:18-25 [withdrawn]	402, 403, A, I				
11/21/23	Young, Micah	89:2-6 [withdrawn]	402, 403, A, I				
11/21/23	Young, Micah	89:8-16 [withdrawn]	402, 403, A, I				
11/21/23	Young, Micah	89:18-18 [withdrawn]	402, 403, I				
11/21/23	Young, Micah	90:15-25 [withdrawn]	402, 403, F, I, SP				
11/21/23	Young, Micah	91:1-5 [withdrawn]	402, 403, F, I, SP				
11/21/23	Young, Micah	91:6-8 [withdrawn]	402, 403, F, I, SP				
11/21/23	Young, Micah	91:9-20 [withdrawn]	402, 403, A, F, I, SP				
11/21/23	Young, Micah	92:22-25 [withdrawn]	402, 403, AF, I				
11/21/23	Young, Micah	93:17-94:12	402, 403				
11/21/23	Young, Micah	94:22-24	402, 403, I				
11/21/23	Young, Micah	95:1-1	402, 403, I				
11/21/23	Young, Micah	95:12-14	402, 403, I				
11/21/23	Young, Micah	107:14-16	402, 403				
11/21/23	Young, Micah	107:24-25 [withdrawn]	402, 403, I				
11/21/23	Young, Micah	108:1-1 [withdrawn]	402, 403, I				
11/21/23	Young, Micah	108:3-5 [withdrawn]	402, 403, I				
11/21/23	Young, Micah	108:12-25	402, 403, F, O, SP				
11/21/23	Young, Micah	109:11-110:24	402, 403, F, O, SP				
11/21/23	Young, Micah	117:11-17 [withdrawn]	402, 403, F, I, O, SP, V				
11/21/23	Young, Micah	120:18-24 [withdrawn]	402, 403				
11/21/23	Young, Micah	121:11-13 [withdrawn]	402, 403				
11/21/23	Young, Micah	126:3-5 [added]	402, 403				
11/21/23	Young, Micah	127:3-8 [added]	402, 403				
11/21/23	Young, Micah	129:19-22 [withdrawn]	402, 403, A, I				
11/21/23	Young, Micah	130:1-12 [withdrawn]	402, 403, A, I				
11/21/23	Young, Micah	131:4-24 [withdrawn]	402, 403, A, I				
11/21/23	Young, Micah	133:1-3 [withdrawn]	402, 403, A, I				
11/21/23	Young, Micah	133:4-25 [withdrawn]	402, 403, A, I				
11/21/23	Young, Micah	134:12-17	402, 403, O				
11/21/23	Young, Micah	145:7-8 [added]	402, 403				
11/21/23	Young, Micah	145:16-146:7 [added]	402, 403				
11/21/23	Young, Micah	154:17-20 [added]	402, 403				
11/21/23	Young, Micah	154:24-155:14 [added]	402, 403				
11/21/23	Young, Micah	159:5-6 [added]	402, 403, A, H				
11/21/23	Young, Micah	159:10-17 [added]	402, 403, A, H				
11/21/23	Young, Micah	162:17-163:3	402, 403				
11/21/23	Young, Micah	167:5-6	402, 403				
11/21/23	Young, Micah	167:10-12	402, 403				
11/21/23	Young, Micah	168:1-1 [withdrawn]	402, 403, H, I				
11/21/23	Young, Micah	169:5-13	402, 403				
11/21/23	Young, Micah	169:15-19	402, 403				
06/30/22	Young, Micah (CDCA)	8:25-25					
06/30/22	Young, Micah (CDCA)	9:1-2					
06/30/22	Young, Micah (CDCA)	11:6-11					
06/30/22	Young, Micah (CDCA)	11:24-12:6					
06/30/22	Young, Micah (CDCA)	24:24-25:12					
06/30/22	Young, Micah (CDCA)	25:20-26:1	402, 403				
06/30/22	Young, Micah (CDCA)	27:14-16					
06/30/22	Young, Micah (CDCA)	181:2-7	402, 403, AF, F, SP				
06/30/22	Young, Micah (CDCA)	181:8-14	402, 403, AF, F, SP				
06/30/22	Young, Micah (CDCA)	181:15-16	402, 403, AF, F, SP				
06/30/22	Young, Micah (CDCA)	186:8-187:4	402, 403, AG, CO, O				
06/30/22	Young, Micah (CDCA)	187:5-25	402, 403, AG, CO, O				
06/30/22	Young, Micah (CDCA)	188:1-189:1	402, 403, AG, CO, O				
02/23/22	Young, Micah (ITC)	8:13-24					
02/23/22	Young, Micah (ITC)	9:5-18					
02/23/22	Young, Micah (ITC)	9:22-24					
02/23/22	Young, Micah (ITC)	10:9-25					
02/23/22	Young, Micah (ITC)	11:1-9					
02/23/22	Young, Micah (ITC)	282:9-14	402, 403				
02/23/22	Young, Micah (ITC)	283:2-25	402, 403, A, F, SP				
02/23/22	Young, Micah (ITC)	284:1-21	402, 403, A, F, SP				

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
02/23/22	Young, Micah (ITC)	285:6-25	402, 403, A, F, SP				
02/23/22	Young, Micah (ITC)	286:1-8	402, 403, A, F, SP				
02/23/22	Young, Micah (ITC)	286:13-16	402, 403, A, F, SP				
02/23/22	Young, Micah (ITC)	289:23-25	402, 403, A				
02/23/22	Young, Micah (ITC)	290:1-1	402, 403, A				
02/23/22	Young, Micah (ITC)	290:8-8	402, 403, A				
02/23/22	Young, Micah (ITC)	290:10-25	402, 403				
11/07/23	Zorkendorfer, Rico	7:14-17					
11/07/23	Zorkendorfer, Rico	15:13-16:1		16:14-17:1; 18:2-7; 18:9-10			
11/07/23	Zorkendorfer, Rico	16:5-13		16:14-17:1; 18:2-7; 18:9-10			
11/07/23	Zorkendorfer, Rico	25:11-13		25:14-17; 25:20-20	[25:14-20] AMB; CLC; NREL; 403		
11/07/23	Zorkendorfer, Rico	26:14-17					
11/07/23	Zorkendorfer, Rico	27:2-28:2					
11/07/23	Zorkendorfer, Rico	28:3-17					
11/07/23	Zorkendorfer, Rico	28:18-20					
11/07/23	Zorkendorfer, Rico	28:22-29:2					
11/07/23	Zorkendorfer, Rico	29:16-19					
11/07/23	Zorkendorfer, Rico	29:21-30:1					
11/07/23	Zorkendorfer, Rico	30:11-16					
11/07/23	Zorkendorfer, Rico	32:14-33:5					
11/07/23	Zorkendorfer, Rico	33:18-20					
11/07/23	Zorkendorfer, Rico	34:1-6					
11/07/23	Zorkendorfer, Rico	35:1-8					
11/07/23	Zorkendorfer, Rico	41:5-7					
11/07/23	Zorkendorfer, Rico	45:14-22		44:14-18; 44:21-45:4; 45:6-9; 46:1-2; 46:4-6	[44:14-45:9] AMB; CLC; NREL; 403; IEXP; LFND [46:1-2] AMB; CLC; NREL; 403; AA; ARG; LFND [46:4-6] AMB; NREL; 403	[44:21-45:4] 46:7-13 [44:14-18] 46:7-13 [45:6-9] 46:7-13 [46:1-2] 46:7-13 [46:4-6] 46:7-13	
11/07/23	Zorkendorfer, Rico	46:18-47:6		47:7-9; 47:12-12	[47:7-9] AMB; ARG; MIS; NREL; 403; AA; CM; LFND [47:12-12] AMB; MIS; NREL; 403		
11/07/23	Zorkendorfer, Rico	57:4-19					
11/07/23	Zorkendorfer, Rico	58:19-61:22		62:15-17; 62:19-19; 62:20-63:3; 63:5-19; 63:22-64:3; 64:6-8; 66:13-18; 66:21-21; 67:7-10; 67:12-18; 68:20-69:1; 69:3-8; 69:11-15; 69:17-19; 69:20-70:1; 70:3-5; 74:1-3	[62:15-19] AMB; AG; SPC; LFND; NREL; 403 [66:13-21] AMB; CPD; 1006; NREL; OBJ; 403 [67:7-18] AMB; AA; CPD; 1006; MIS; NREL; 403 [67:7-10] AMB; NREL; 403 [67:12-18] AMB; NREL; 403		
11/07/23	Zorkendorfer, Rico	64:9-22		64:6-8; 66:13-18; 66:21-21; 67:7-10; 67:12-18; 68:20-69:1; 69:3-8; 69:11-15; 69:17-19; 69:20-70:1; 70:3-5	[66:13-21] AMB; CPD; 1006; NREL; OBJ; 403 [67:7-18] AMB; AA; CPD; 1006; MIS; NREL; 403 [67:7-10] AMB; NREL; 403 [67:12-18] AMB; NREL; 403		
11/07/23	Zorkendorfer, Rico	64:9-22		64:6-8; 66:13-18; 66:21-21; 67:7-10; 67:12-18; 68:20-69:1; 69:3-8; 69:11-15; 69:17-19; 69:20-70:1; 70:3-5	[66:13-21] AMB; CPD; 1006; NREL; OBJ; 403 [67:7-18] AMB; AA; CPD; 1006; MIS; NREL; 403 [67:7-10] AMB; NREL; 403 [67:12-18] AMB; NREL; 403		
11/07/23	Zorkendorfer, Rico	65:1-12		64:6-8; 66:13-18; 66:21-21; 67:7-10; 67:12-18; 68:20-69:1; 69:3-8; 69:11-15; 69:17-19; 69:20-70:1; 70:3-5	[66:13-21] AMB; CPD; 1006; NREL; OBJ; 403 [67:7-18] AMB; AA; CPD; 1006; MIS; NREL; 403 [67:7-10] AMB; NREL; 403 [67:12-18] AMB; NREL; 403		

DATE	WITNESS	APPLE AFFIRMATIVES	MASIMO OBJECTIONS TO APPLE AFFIRMATIVES	MASIMO COUNTERS TO APPLE AFFIRMATIVES	APPLE OBJECTIONS TO MASIMO COUNTERS	APPLE COUNTERS TO MASIMO COUNTERS	MASIMO OBJECTIONS TO APPLE COUNTER-COUNTERS
11/07/23	Zorkendorfer, Rico	78:3-79:2		77:8-10; 77:14-19; 78:1-2	[77:8-10] AMB; CLC; IEXP; HYP; NREL; 403 [77:14-19] AMB; CLC; IEXP; HYP; NREL; 403 [78:1-2] AMB; CLC; IEXP; HYP; NREL; 403		
11/07/23	Zorkendorfer, Rico	80:10-21		79:12-15; 79:19-22; 81:16-17; 81:22-82:4; 82:6-9; 82:17-22	[79:12-15] AMB; CLC; IEXP; HYP; NREL; 403 [79:19-22] AMB; CLC; IEXP; HYP; NREL; 403 [81:16-82:4] AMB; CLC; IEXP; HYP; NREL; 403 [82:6-9] AMB; CLC; IEXP; HYP; NREL; 403 [82:17-22] AMB; CLC; IEXP; HYP; NREL; 403		
11/07/23	Zorkendorfer, Rico	81:10-15		79:12-15; 79:19-22; 81:16-17; 81:22-82:4; 82:6-9; 82:17-22	[79:12-15] AMB; CLC; IEXP; HYP; NREL; 403 [79:19-22] AMB; CLC; IEXP; HYP; NREL; 403 [81:16-82:4] AMB; CLC; IEXP; HYP; NREL; 403 [82:6-9] AMB; CLC; IEXP; HYP; NREL; 403 [82:17-22] AMB; CLC; IEXP; HYP; NREL; 403		
11/07/23	Zorkendorfer, Rico	111:19-113:4	F, SP, LC, EX				
11/07/23	Zorkendorfer, Rico	148:20-155:14	402, 403, LC, LE, LW, EX, IH, F, SP	156:4-8; 157:7-22; 158:6-20	[157:7-22] AMB; PRV; NREL; 403 [158:6-20] AMB; PRV; NREL; 403		

# **EXHIBIT 11**



**Masimo's Deposition Designations and  
Apple's Objections and Counter Designations**

Ueyn Block – July 21, 2022					
Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
8:25-9:1	[8:25-9:1] AMB				
12:7-12:13	[12:7-13] AMB; AG; CLC; 403	198:9-17; 207:4-10; 207:4-10	[207:4-10] 402, 403, F, SP, V, OS		
32:14-32:19	[32:14-19] ATH; LFND; LA; NREL	34:17-35:4; 39:24- 40:24; 42:12-22; 207:4-10; 207:4-10	[207:4-10] 402, 403, F, SP, V, OS		
32:25-33:5	[32:25-33:5] AMB; ATH; NREL; 403	34:17-35:4; 39:24- 40:24; 42:12-22; 207:4-10; 207:4-10	[207:4-10] 402, 403, F, SP, V, OS		
33:11-34:16	[33:11-34:16] AMB; AG; ATH; BSD; SPC; IDSCR; LFND; LA; NREL; 403	34:17-35:4; 39:24- 40:24; 42:12-22; 207:4-10; 207:4-10	[207:4-10] 402, 403, F, SP, V, OS		
38:23-39:10	[38:23-39:10] AG; ATH; BSD; IDSCR; LFND; LA; NREL; 403	34:17-35:4; 39:24- 40:24; 42:12-22; 207:4-10; 207:4-10	[207:4-10] 402, 403, F, SP, V, OS		
39:12-39:15	[39:12-15] AMB; AG; ATH; BSD; SPC; IDSCR; LFND; LA; NREL; 403	34:17-35:4; 39:24- 40:24; 42:12-22; 207:4-10; 207:4-10	[207:4-10] 402, 403, F, SP, V, OS		
39:17-39:23	[39:17-23] AMB; AG; ATH; BSD; SPC; IDSCR;	34:17-35:4; 39:24- 40:24; 42:12-22; 207:4-10; 207:4-10	[207:4-10] 402, 403, F, SP, V, OS		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
	LFND; LA; NREL; 403				
42:25-44:17	[42:25-44:17] AMB; ARG; AG; ATH; BSD; CLC; SPC; IDSCR; LFND; LA; NREL; 403	34:17-35:4; 39:24-40:24; 42:12-22; 207:4-10; 207:4-10	[207:4-10] 402, 403, F, SP, V, OS		
44:20-44:24	[44:20-24] ATH; LFND; LA; NREL	39:24-40:24; 42:12-22; 207:4-10; 207:4-10	[207:4-10] 402, 403, F, SP, V, OS		
45:4-45:6	[45:4-6] ATH; LA; NREL	39:24-40:24; 42:12-22; 207:4-10; 207:4-10	[207:4-10] 402, 403, F, SP, V, OS		
46:10-46:21	[46:10-21] AMB; AG; ATH; BSD; SPC; LFND; LA; NREL; 403	34:17-35:4; 39:24-40:24; 42:12-22; 46:22-47:5; 207:4-10; 207:4-10	[207:4-10] 402, 403, F, SP, V, OS		
47:6-47:12	[47:6-12] AMB; AG; ATH; BSD; SPC; LFND; LA; NREL; 403	34:17-35:4; 39:24-40:24; 42:12-22; 207:4-10; 207:4-10	[207:4-10] 402, 403, F, SP, V, OS		
58:14-58:18	[58:14-18] ATH; IDSCR; LFND; LA; NREL	39:24-40:24; 42:12-22; 207:4-10; 207:4-10	[207:4-10] 402, 403, F, SP, V, OS		
59:12-59:16	[59:12-16] ATH; LA; NREL	34:17-35:4; 39:24-40:24; 42:12-22; 207:4-10; 207:4-10	[207:4-10] 402, 403, F, SP, V, OS		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
60:3-60:15	[60:3-15] AMB; AG; ATH; BSD; SPC; LFND; LA; NREL; 403	34:17-35:4; 39:24- 40:24; 42:12-22; 207:4-10; 207:4-10	[207:4-10] 402, 403, F, SP, V, OS		
70:23-71:9	[70:23-71:9] AG; ATH; BSD; SPC; IDSCR; LA; MIS; NREL; 403	71:10-14; 71:21-24; 207:4-10; 207:4-10	[207:4-10] 402, 403, F, SP, V, OS		
72:6-73:3	[72:6-73:3] AMB; AG; ATH; BSD; SPC; IDSCR; LA; MIS; NREL; 403	34:17-35:4; 39:24- 40:24; 42:12-22; 71:10-14; 71:21-24; 207:4-10; 207:4-10	[207:4-10] 402, 403, F, SP, V, OS		

Ueyn Block – October 24, 2023					
Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
7:15-7:19	[17:3-9] AMB; AG; MIS; NREL; 403	16:9-12; 17:10-12; 215:22-216:13; 218:8-14; 218:16-219:2	[215:22-216:33] 402, 403, OS	219:4-10, 219:14-17, 220:7-11, 220:15-18	AMB, AG, NREL, 403, MIL
16:13-16:17	[16:13-17] AMB; AG; 403	16:9-12; 17:10-12; 215:22-216:13; 218:8-14; 218:16-219:2	[215:22-216:33] 402, 403, OS	219:4-10, 219:14-17, 220:7-11, 220:15-18	AMB, AG, NREL, 403, MIL
17:3-17:9		17:10-12; 90:13-14; 90:18-20; 91:6-13; 118:22-119:19; 123:10-13; 130:7-11; 168:2-170:1; 170:2-19; 172:14-173:12; 174:2-10; 174:13-16; 184:8-10; 184:13-185:2; 185:4-6; 185:9-21; 185:22-186:16; 211:10-10; 211:14-22; 212:1-9; 213:6-8; 215:22-216:13; 218:8-14; 218:16-219:2	[91:6-13] I, V [118:22-119:19] F, SP [168:2-170:1] I, V [215:22-216:33] 402, 403, OS	123:6-9, 165:1, 176:14-15, 186:17-19, 186:22-187:2, 211:6-9, 213:9-11, 213:13-17, 219:4-10, 219:14-17, 220:7-11, 220:15-18	AMB, AG, CLC, IEXP, NREL, 403, MIL

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
18:9-18:16	[18:9-16] AMB; AG; CLC; MIS; NREL; 403	16:9-12; 90:13-14; 90:18-20; 91:6-13; 118:22-119:19; 123:10-13; 129:13- 130:1; 130:7-11; 168:2-170:1; 170:2- 19; 172:14-173:12; 174:2-10; 174:13- 16; 184:8-10; 184:13-185:2; 185:4-6; 185:9-21; 185:22-186:16; 211:10-10; 211:14- 22; 212:1-9; 213:6- 8; 215:22-216:13; 218:8-14; 218:16- 219:2	[91:6-13] I, V  [118:22-119:19] F, SP  [168:2-170:1] I, V  [215:22-216:33] 402, 403, OS	123:6-9, 165:1, 176:14-15, 186:17- 19, 186:22-187:2, 211:6-9, 213:9-11, 213:13-17, 219:4- 10, 219:14-17, 220:7-11, 220:15-18	AMB, AG, CLC, IEXP, NREL, 403, MIL
86:17-87:7	[86:17-87:7] AMB; AG; BSD; CLC; SPC; IEXP; MIS; NREL; 403	90:13-14; 90:18-20; 91:6-13; 118:22- 119:19; 123:10-13; 129:13-130:1; 130:7-11; 168:2- 170:1; 170:2-19; 172:14-173:12; 174:2-10; 174:13- 16; 184:8-10; 184:13-185:2; 185:4-6; 185:9-21;	[91:6-13] I, V  [118:22-119:19] F, SP  [168:2-170:1] I, V		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		185:22-186:16; 211:10-10; 211:14-22; 212:1-9; 213:6-8			
89:9-90:11	[89:9-90:11] AMB; AG; BSD; CLC; SPC; IEXP; LFND; MIS; NREL; 403	90:13-14; 90:18-20; 91:6-13; 118:22-119:19; 123:10-13; 129:13-130:1; 130:7-11; 168:2-170:1; 170:2-19; 172:14-173:12; 174:2-10; 174:13-16; 184:8-10; 184:13-185:2; 185:4-6; 185:9-21; 185:22-186:16; 211:10-10; 211:14-22; 212:1-9; 213:6-8	[91:6-13] I, V  [118:22-119:19] F, SP  [168:2-170:1] I, V		
89:9-90:11	[91:15-92:4] AMB; AG; BSD; CLC; SPC; IEXP; LFND; MIS; NREL; 403	90:13-14; 90:18-20; 91:6-13; 118:22-119:19; 123:10-13; 129:13-130:1; 130:7-11; 168:2-170:1; 170:2-19; 172:14-173:12; 174:2-10; 174:13-16; 184:8-10;	[91:6-13] I, V  [118:22-119:19] F, SP  [168:2-170:1] I, V		

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
		184:13-185:2; 185:4-6; 185:9-21; 185:22-186:16; 211:10-10; 211:14-22; 212:1-9; 213:6-8			
91:15-92:4	[92:5-14] AMB; AG; BSD; CLC; SPC; IEXP; LFND; MIS; NREL; 403	90:13-14; 90:18-20; 91:6-13; 118:22-119:19; 123:10-13; 129:13-130:1; 130:7-11; 168:2-170:1; 170:2-19; 172:14-173:12; 174:2-10; 174:13-16; 184:8-10; 184:13-185:2; 185:4-6; 185:9-21; 185:22-186:16; 211:10-10; 211:14-22; 212:1-9; 213:6-8	[91:6-13] I, V  [118:22-119:19] F, SP  [168:2-170:1] I, V		
92:5-92:14	[93:4-10] AMB; AG; CLC; IEXP; LFND; NREL; 403	90:13-14; 90:18-20; 91:6-13; 118:22-119:19; 123:10-13; 129:13-130:1; 130:7-11; 168:2-170:1; 170:2-19; 172:14-173:12;	[91:6-13] I, V  [118:22-119:19] F, SP  [168:2-170:1] I, V		

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
		174:2-10; 174:13-16; 184:8-10; 184:13-185:2; 185:4-6; 185:9-21; 185:22-186:16; 211:10-10; 211:14-22; 212:1-9; 213:6-8			
93:4-93:10	[96:17-97:5] AMB; AG; BSD; CLC; SPC; IEXP; MIS; NREL; 403	90:13-14; 90:18-20; 91:6-13; 118:22-119:19; 123:10-13; 129:13-130:1; 130:7-11; 168:2-170:1; 170:2-19; 172:14-173:12; 174:2-10; 174:13-16; 184:8-10; 184:13-185:2; 185:4-6; 185:9-21; 185:22-186:16; 211:10-10; 211:14-22; 212:1-9; 213:6-8	[91:6-13] I, V  [118:22-119:19] F, SP  [168:2-170:1] I, V		
96:17-97:5	[98:10-99:5] AMB; AG; BSD; CLC; SPC; IEXP; MIS; NREL; 403	90:13-14; 90:18-20; 91:6-13; 118:22-119:19; 123:10-13; 129:13-130:1; 130:7-11; 168:2-	[91:6-13] I, V  [118:22-119:19] F, SP		



<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		170:1; 170:2-19; 172:14-173:12; 174:2-10; 174:13-16; 184:8-10; 184:13-185:2; 185:4-6; 185:9-21; 185:22-186:16; 211:10-10; 211:14-22; 212:1-9; 213:6-8	[168:2-170:1] I, V		
98:10-99:5	[100:18-101:2] AMB; AG; BSD; CLC; SPC; IEXP; MIS; NREL; 403	90:13-14; 90:18-20; 91:6-13; 118:22-119:19; 123:10-13; 129:13-130:1; 130:7-11; 168:2-170:1; 170:2-19; 172:14-173:12; 174:2-10; 174:13-16; 184:8-10; 184:13-185:2; 185:4-6; 185:9-21; 185:22-186:16; 211:10-10; 211:14-22; 212:1-9; 213:6-8	[91:6-13] I, V  [118:22-119:19] F, SP  [168:2-170:1] I, V		
100:18-101:2	[104:7-17] AMB; AG; BSD; CLC;	90:13-14; 90:18-20; 91:6-13; 118:22-119:19; 123:10-13;	[91:6-13] I, V  [118:22-119:19]		

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
	SPC; IEXP; HYP; MIS; NREL; 403	129:13-130:1; 130:7-11; 168:2-170:1; 170:2-19; 172:14-173:12; 174:2-10; 174:13-16; 184:8-10; 184:13-185:2; 185:4-6; 185:9-21; 185:22-186:16; 211:10-10; 211:14-22; 212:1-9; 213:6-8	F, SP [168:2-170:1] I, V		
104:7-104:17	[110:6-19] AMB; AG; BSD; CLC; SPC; MIS; NREL; 403	90:13-14; 90:18-20; 91:6-13; 118:22-119:19; 123:10-13; 129:13-130:1; 130:7-11; 168:2-170:1; 170:2-19; 172:14-173:12; 174:2-10; 174:13-16; 184:8-10; 184:13-185:2; 185:4-6; 185:9-21; 185:22-186:16; 211:10-10; 211:14-22; 212:1-9; 213:6-8	[91:6-13] I, V [118:22-119:19] F, SP [168:2-170:1] I, V		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
110:6-110:19	[111:12-112:1] AMB; AG; BSD; CLC; MIS; NREL; 403	90:13-14; 90:18-20; 91:6-13; 118:22- 119:19; 123:10-13; 129:13-130:1; 130:7-11; 168:2- 170:1; 170:2-19; 172:14-173:12; 174:2-10; 174:13- 16; 184:8-10; 184:13-185:2; 185:4-6; 185:9-21; 185:22-186:16; 211:10-10; 211:14- 22; 212:1-9; 213:6- 8	[91:6-13] I, V  [118:22-119:19] F, SP  [168:2-170:1] I, V		
111:12-112:1	[112:15-113:5] AMB; AG; BSD; CLC; LFND; MIS; NREL; 403	90:13-14; 90:18-20; 91:6-13; 118:22- 119:19; 123:10-13; 129:13-130:1; 130:7-11; 168:2- 170:1; 170:2-19; 172:14-173:12; 174:2-10; 174:13- 16; 184:8-10; 184:13-185:2; 185:4-6; 185:9-21; 185:22-186:16; 211:10-10; 211:14-	[91:6-13] I, V  [118:22-119:19] F, SP  [168:2-170:1] I, V  [213:19-20, 214:1- 6] F, SP		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		22; 212:1-9; 213:6-8; 213:19-20; 214:1-6			
112:15-113:5	[117:14-118:20] AMB; ARG; AG; BSD; CLC; SPC; LFND; MIS; NREL; 403	90:13-14; 90:18-20; 91:6-13; 118:22-119:19; 123:10-13; 129:13-130:1; 130:7-11; 168:2-170:1; 170:2-19; 172:14-173:12; 174:2-10; 174:13-16; 184:8-10; 184:13-185:2; 185:4-6; 185:9-21; 185:22-186:16; 211:10-10; 211:14-22; 212:1-9; 213:6-8; 213:19-20; 214:1-6	[91:6-13] I, V  [118:22-119:19] F, SP  [168:2-170:1] I, V  [213:19-20, 214:1-6] F, SP		
117:14-118:20	[119:21-120:11] AMB; AG; BSD; CLC; SPC; LFND; NREL; 403	90:13-14; 90:18-20; 91:6-13; 118:22-119:19; 123:10-13; 129:13-130:1; 130:7-11; 168:2-170:1; 170:2-19; 172:14-173:12; 174:2-10; 174:13-16; 184:8-10;	[91:6-13] I, V  [118:22-119:19] F, SP  [168:2-170:1] I, V		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		184:13-185:2; 185:4-6; 185:9-21; 185:22-186:16; 211:10-10; 211:14-22; 212:1-9; 213:6-8			
119:21-120:11	[122:9-123:2] AMB; AA; AG; BSD; CLC; SPC; LFND; MIS; NREL; 403	90:13-14; 90:18-20; 91:6-13; 118:22-119:19; 123:10-13; 129:13-130:1; 130:7-11; 168:2-170:1; 170:2-19; 172:14-173:12; 174:2-10; 174:13-16; 184:8-10; 184:13-185:2; 185:4-6; 185:9-21; 185:22-186:16; 211:10-10; 211:14-22; 212:1-9; 213:6-8	[91:6-13] I, V [118:22-119:19] F, SP [168:2-170:1] I, V		
122:9-123:2	[153:6-8] ATH; LFND; NREL; 403	90:13-14; 90:18-20; 91:6-13; 118:22-119:19; 123:10-13; 129:13-130:1; 130:7-11; 168:2-170:1; 170:2-19; 172:14-173:12;	[91:6-13] I, V [118:22-119:19] F, SP [168:2-170:1] I, V	123:6-9	AMB, AG, NREL, 403

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
		174:2-10; 174:13-16; 184:8-10; 184:13-185:2; 185:4-6; 185:9-21; 185:22-186:16; 211:10-10; 211:14-22; 212:1-9; 213:6-8			
153:6-153:8	[153:13-154:11] AMB; AG; BSD; CLC; SPC; LFND; NREL; 403	90:13-14; 90:18-20; 91:6-13; 118:22-119:19; 123:10-13; 129:13-130:1; 130:7-11; 168:2-170:1; 170:2-19; 172:14-173:12; 174:2-10; 174:13-16; 184:8-10; 184:13-185:2; 185:4-6; 185:9-21; 185:22-186:16; 211:10-10; 211:14-22; 212:1-9; 213:6-8	[91:6-13] I, V  [118:22-119:19] F, SP  [168:2-170:1] I, V		
153:13-154:11	[154:15-155:20] AMB; AG; BSD; MIS; NREL; 403	90:13-14; 90:18-20; 91:6-13; 118:22-119:19; 123:10-13; 129:13-130:1; 130:7-11; 168:2-	[91:6-13] I, V  [118:22-119:19] F, SP		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		170:1; 170:2-19; 172:14-173:12; 174:2-10; 174:13-16; 184:8-10; 184:13-185:2; 185:4-6; 185:9-21; 185:22-186:16; 211:10-10; 211:14-22; 212:1-9; 213:6-8; 213:19-20; 214:1-6	[168:2-170:1] I, V  [213:19-20, 214:1-6] F, SP		
154:15-155:20	[155:21-156:11] AMB; AG; BSD; MIS; NREL; 403	90:13-14; 90:18-20; 91:6-13; 118:22-119:19; 123:10-13; 129:13-130:1; 130:7-11; 168:2-170:1; 170:2-19; 172:14-173:12; 174:2-10; 174:13-16; 184:8-10; 184:13-185:2; 185:4-6; 185:9-21; 185:22-186:16; 211:10-10; 211:14-22; 212:1-9; 213:6-8	[91:6-13] I, V  [118:22-119:19] F, SP  [168:2-170:1] I, V		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
155:21-156:11	[156:21-157:10] AMB; AG; BSD; MIS; NREL; 403	90:13-14; 90:18-20; 91:6-13; 118:22- 119:19; 123:10-13; 129:13-130:1; 130:7-11; 168:2- 170:1; 170:2-19; 172:14-173:12; 174:2-10; 174:13- 16; 184:8-10; 184:13-185:2; 185:4-6; 185:9-21; 185:22-186:16; 211:10-10; 211:14- 22; 212:1-9; 213:6- 8; 213:19-20; 214:1-6	[91:6-13] I, V  [118:22-119:19] F, SP  [168:2-170:1] I, V  [213:19-20, 214:1- 6] F, SP		
156:21-157:10	[157:13-158:1] AMB; AG; BSD; MIS; NREL; 403	90:13-14; 90:18-20; 91:6-13; 118:22- 119:19; 123:10-13; 129:13-130:1; 130:7-11; 168:2- 170:1; 170:2-19; 172:14-173:12; 174:2-10; 174:13- 16; 184:8-10; 184:13-185:2; 185:4-6; 185:9-21; 185:22-186:16;	[91:6-13] I, V  [118:22-119:19] F, SP  [168:2-170:1] I, V		



<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		211:10-10; 211:14-22; 212:1-9; 213:6-8			
157:13-158:1	[158:17-159:16] AMB; AG; BSD; SPC; IEXP; LFND; MIS; NREL; 403	90:13-14; 90:18-20; 91:6-13; 118:22-119:19; 123:10-13; 129:13-130:1; 130:7-11; 168:2-170:1; 170:2-19; 172:14-173:12; 174:2-10; 174:13-16; 184:8-10; 184:13-185:2; 185:4-6; 185:9-21; 185:22-186:16; 211:10-10; 211:14-22; 212:1-9; 213:6-8	[91:6-13] I, V  [118:22-119:19] F, SP  [168:2-170:1] I, V		
158:17-159:16	[159:18-160:11] AMB; AG; BSD; NREL; 403	90:13-14; 90:18-20; 91:6-13; 118:22-119:19; 123:10-13; 129:13-130:1; 130:7-11; 168:2-170:1; 170:2-19; 172:14-173:12; 174:2-10; 174:13-16; 184:8-10; 184:13-185:2;	[91:6-13] I, V  [118:22-119:19] F, SP  [168:2-170:1] I, V		

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
		185:4-6; 185:9-21; 185:22-186:16; 211:10-10; 211:14-22; 212:1-9; 213:6-8			
159:18-160:11	[162:19-164:16] AMB; AG; BSD; SPC; IEXP; MIS; NREL; 403	90:13-14; 90:18-20; 91:6-13; 118:22-119:19; 123:10-13; 129:13-130:1; 130:7-11; 168:2-170:1; 170:2-19; 172:14-173:12; 174:2-10; 174:13-16; 184:8-10; 184:13-185:2; 185:4-6; 185:9-21; 185:22-186:16; 211:10-10; 211:14-22; 212:1-9; 213:6-8	[91:6-13] I, V  [118:22-119:19] F, SP  [168:2-170:1] I, V		
162:19-164:16	[164:21-22] ATH; LA; NREL	90:13-14; 90:18-20; 91:6-13; 118:22-119:19; 123:10-13; 129:13-130:1; 130:7-11; 168:2-170:1; 170:2-19; 172:14-173:12; 174:2-10; 174:13-	[91:6-13] I, V  [118:22-119:19] F, SP  [168:2-170:1] I, V		

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
		16; 184:8-10; 184:13-185:2; 185:4-6; 185:9-21; 185:22-186:16; 211:10-10; 211:14-22; 212:1-9; 213:6-8			
164:21-164:22	[165:7-9] AMB; ATH; LA; NREL	90:13-14; 90:18-20; 91:6-13; 118:22-119:19; 123:10-13; 129:13-130:1; 130:7-11; 168:2-170:1; 170:2-19; 172:14-173:12; 174:2-10; 174:13-16; 175:10-176:1; 184:8-10; 184:13-185:2; 185:4-6; 185:9-21; 185:22-186:16; 211:10-10; 211:14-22; 212:1-9; 213:6-8	[91:6-13] I, V  [118:22-119:19] F, SP  [168:2-170:1] I, V	165:1	AMB; ATH; LA; NREL
165:7-165:9	[166:18-167:5] AMB; AG; BSD; SPC; LA; NREL; 403	90:13-14; 90:18-20; 91:6-13; 118:22-119:19; 123:10-13; 129:13-130:1; 130:7-11; 168:2-170:1; 170:2-19;	[91:6-13] I, V  [118:22-119:19] F, SP  [168:2-170:1] I, V	165:1	AMB; ATH; LA; NREL

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
		172:14-173:12; 174:2-10; 174:13-16; 175:10-176:1; 184:8-10; 184:13-185:2; 185:4-6; 185:9-21; 185:22-186:16; 211:10-10; 211:14-22; 212:1-9; 213:6-8			
166:18-167:5	[176:3-9] AMB; AG; BSD; MIS; NREL; 403	90:13-14; 90:18-20; 91:6-13; 118:22-119:19; 123:10-13; 129:13-130:1; 130:7-11; 168:2-170:1; 170:2-19; 172:14-173:12; 174:2-10; 174:13-16; 175:10-176:1; 184:8-10; 184:13-185:2; 185:4-6; 185:9-21; 185:22-186:16; 211:10-10; 211:14-22; 212:1-9; 213:6-8	[91:6-13] I, V  [118:22-119:19] F, SP  [168:2-170:1] I, V		
176:3-176:9	[176:12-13] AMB; AG; ATH; LA; NREL; 403	90:13-14; 90:18-20; 91:6-13; 118:22-119:19; 123:10-13; 129:13-130:1;	[91:6-13] I, V  [118:22-119:19] F, SP		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		130:7-11; 168:2-170:1; 170:2-19; 172:14-173:12; 174:2-10; 174:13-16; 184:8-10; 184:13-185:2; 185:4-6; 185:9-21; 185:22-186:16; 211:10-10; 211:14-22; 212:1-9; 213:6-8	[168:2-170:1] I, V		
176:12-176:13	[176:18-177:4] AG; ATH; BSD; LA; NREL; 403	90:13-14; 90:18-20; 91:6-13; 118:22-119:19; 123:10-13; 129:13-130:1; 130:7-11; 168:2-170:1; 170:2-19; 172:14-173:12; 174:2-10; 174:13-16; 184:8-10; 184:13-185:2; 185:4-6; 185:9-21; 185:22-186:16; 211:10-10; 211:14-22; 212:1-9; 213:6-8	[91:6-13] I, V  [118:22-119:19] F, SP  [168:2-170:1] I, V	176:14-15	ATH; BSD; LA; NREL; 403
176:18-177:4	[183:9-184:6] AMB; AG; ATH;	90:13-14; 90:18-20; 91:6-13; 118:22-	[91:6-13] I, V	176:14-15	ATH; BSD; LA; NREL; 403

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
	BSD; CLC; SPC; IEXP; MIS; NREL; 403	119:19; 123:10-13; 129:13-130:1; 130:7-11; 168:2- 170:1; 170:2-19; 172:14-173:12; 174:2-10; 174:13- 16; 184:8-10; 184:13-185:2; 185:4-6; 185:9-21; 185:22-186:16; 211:10-10; 211:14- 22; 212:1-9; 213:6- 8	[118:22-119:19] F, SP  [168:2-170:1] I, V		
183:9-184:6	[189:16-190:3] AMB; AG; BSD; MIS; NREL; 403	90:13-14; 90:18-20; 91:6-13; 118:22- 119:19; 123:10-13; 129:13-130:1; 130:7-11; 168:2- 170:1; 170:2-19; 172:14-173:12; 174:2-10; 174:13- 16; 184:8-10; 184:13-185:2; 185:4-6; 185:9-21; 185:22-186:16; 211:10-10; 211:14- 22; 212:1-9; 213:6- 8	[91:6-13] I, V  [118:22-119:19] F, SP  [168:2-170:1] I, V	186:17-19, 186:22- 187:2	AMB; AG; BSD; CLC; MIS; NREL; 403

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
189:16-190:3	[212:10-213:1] AMB; AG; BSD; MIS; NREL; 403	90:13-14; 90:18-20; 91:6-13; 118:22- 119:19; 123:10-13; 129:13-130:1; 130:7-11; 168:2- 170:1; 170:2-19; 172:14-173:12; 174:2-10; 174:13- 16; 184:8-10; 184:13-185:2; 185:4-6; 185:9-21; 185:22-186:16; 211:10-10; 211:14- 22; 212:1-9; 213:6- 8	[91:6-13] I, V  [118:22-119:19] F, SP  [168:2-170:1] I, V		
212:10-213:1	[217:21-218:6] AMB; AG; BSD; CLC; MIS; NREL; 403	16:9-12; 90:13-14; 90:18-20; 91:6-13; 118:22-119:19; 123:10-13; 129:13- 130:1; 130:7-11; 168:2-170:1; 170:2- 19; 172:14-173:12; 174:2-10; 174:13- 16; 184:8-10; 184:13-185:2; 185:4-6; 185:9-21; 185:22-186:16; 211:10-10; 211:14-	[91:6-13] I, V  [118:22-119:19] F, SP  [168:2-170:1] I, V	211:6-9, 213:9-11, 213:13-17	AMB; AG; BSD; CLC; MIS; NREL; 1006; 403

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		22; 212:1-9; 213:6-8			
217:21-218:6	[17:3-9] AMB; AG; MIS; NREL; 403	16:9-12; 17:10-12; 215:22-216:13; 218:8-14; 218:16-219:2	[215:22-216:33] 402, 403, OS	219:4-10, 219:14-17, 220:7-11, 220:15-18	AMB; AG; BSD; CLC; LFND; MIS; NREL; 403



Steven Cardinali – September 21, 2023					
Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
5:15-5:16					
10:9-10:13		9:22-10:8			
14:3-14:14	[14:3-14] CLC; 403; NREL; INC	13:20-14:2; 14:15- 15:9			
19:1-19:12	[19:1-12] NREL; 403; CLC; SPC; IEXP	14:15-15:9; 14:15- 15:9			
19:15-19:21	[19:15-21] AMB; 403; CLC; NREL	14:15-15:9; 14:15- 15:9			
20:1-20:7	[20:1-7] AMB; NREL; 403; CLC; LDG	14:15-15:9			
20:9-20:13	[20:9-13] AMB; NREL; 403; AA; CLC; LDG; MM	14:15-15:9			
20:16-20:22	[20:16-22] NREL; 403; AMB; IEXP; AA; CLC; LDG; MM	14:15-15:9			
21:3-21:9	[21:3-9] NREL; 403; LDG	14:15-15:9			
27:20-27:22	[27:20-22] LFND; NREL; 403; LDG; AMB				
28:3-28:11	[28:3-11] CLC; NREL; 403; LDG	28:12-16; 29:11-18			

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
32:1-32:2					
32:6-32:8					
32:21-33:6					

**Adam Clavelle – September 7, 2023**

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
7:13-7:15		67:4-10			
12:4-13:6	[12:4-13:6] CLC; IEXP; 403	13:14-16; 13:18-14:5; 14:17-15:16; 15:19-22:15; 24:21-25:3; 25:17-26:14; 33:13-36:5; 46:21-47:21; 60:22-61:8; 61:10-62:1; 62:4-6; 67:11-68:11	402; 403; F; SP; LC; EX	25:4-15	NREL; 403; BSD; SPC; LFND
47:22-48:1		48:13-22; 52:4-5; 52:7-13; 60:22-61:8; 61:10-62:1; 62:4-6; 68:12-70:6	402; 403; F; SP; LC; EX		
48:7-48:12	[48:7-12] HRS; LDG; NREL; 403	48:13-22; 52:4-5; 52:7-13; 60:22-61:8; 61:10-62:1; 62:4-6; 68:12-70:6	402; 403; F; SP; LC; EX		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
49:1-50:10	[49:1-50:10] HRS; LDG; NREL; 403	24:21-25:3; 48:13-22; 50:11-13; 50:16-19; 52:4-5; 52:7-13; 60:22-61:8; 61:10-62:1; 62:4-6; 68:12-70:6	402; 403; F; SP; LC; EX	25:4-15	NREL; 403; BSD; SPC; LFND
64:16-64:20	[64:16-20] CLC; NREL; 403; LFND; SPC; AMB	65:4-6; 65:9-11		65:13-15	CLC; NREL; 403; LFND; SPC; AMB
65:1-65:2		65:4-6; 65:9-11		65:13-15	CLC; NREL; 403; LFND; SPC; AMB
65:21-66:11	[65:21-66:11] CLC; LDG; NREL; 403	65:4-6; 65:9-11			

Erik De Jong – September 19, 2023					
Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
6:20-6:21					
24:12-25:6	[24:12-25:6] IEXP; CLC; SPC; 403; NREL	25:21-26:15; 98:5- 103:3	402; 403; F; SP; LC; EX	33:4-18; 34:6-35:1 43:1-7 45:12-15 45:18-46:2 46:8-10 46:12-47:22 49:1-5 49:13-50:9 103:18-20 104:1-6 104:8 104:18-105:4 105:7-14 105:22-106:11 106:14-22 107:3-11 ("98:5 counters")	[33:4-18] NREL; 403; IMP; [34:6- 35:1] NREL; 403; IMP; [43:1-7] NREL; 403; [45:12- 15] NREL; 403; LFND; SPC; [45:18-46:2] NREL; 403; LFND; SPC; [46:8-10] IEXP; CLC; SPC; 403; NREL [46:12- 47:22] IEXP; CLC; SPC; 403; NREL [49:1-5] IEXP; CLC; SPC; 403; NREL [49:13-50:9] IEXP; CLC; SPC; 403; NREL [103:18-20] IEXP; CLC; SPC; 403; NREL; AMB [104:1-6] IEXP; CLC; SPC; 403; NREL; AMB

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					[104:8] IEXP; CLC; SPC; 403; NREL; AMB [104:18-105:4] IEXP; CLC; SPC; 403; NREL; AMB [105:7-14] IEXP; CLC; SPC; 403; NREL; AMB [105:22-106:11] IEXP; CLC; SPC; 403; NREL; AMB [106:14-22] IEXP; CLC; SPC; 403; NREL; AMB; MIS [107:3-11] IEXP; CLC; SPC; 403; NREL; AMB; MIS
25:8-25:19	[25:8-19] IEXP; CLC; SPC; 403; NR; NREL	25:21-26:15; 98:5-103:3	402; 403; F; SP; LC; EX	See 98:5 counters	[33:4-18] NREL; 403; IMP; [34:6-35:1] NREL; 403; IMP; [43:1-7] NREL; 403; [45:12-15] NREL; 403; LFND; SPC; [45:18-46:2] NREL; 403; LFND; SPC; [46:8-10] IEXP; CLC; SPC; 403;

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
					NREL [46:12-47:22] IEXP; CLC; SPC; 403; NREL [49:1-5] IEXP; CLC; SPC; 403; NREL [49:13-50:9] IEXP; CLC; SPC; 403; NREL [103:18-20] IEXP; CLC; SPC; 403; NREL; AMB [104:1-6] IEXP; CLC; SPC; 403; NREL; AMB [104:8] IEXP; CLC; SPC; 403; NREL; AMB [104:18-105:4] IEXP; CLC; SPC; 403; NREL; AMB [105:7-14] IEXP; CLC; SPC; 403; NREL; AMB [105:22-106:11] IEXP; CLC; SPC; 403; NREL; AMB [106:14-22] IEXP; CLC; SPC; 403; NREL; AMB; MIS

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					[107:3-11] IEXP; CLC; SPC; 403; NREL; AMB; MIS
43:1-43:7	[43:1-7] 403; NREL				
45:12-45:15	[45:12-15] LFND; NREL; SPC; 403	46:4-7			
45:18-46:2	[45:18-46:2] LFND; NREL; SPC; 403	46:4-7			
46:8-46:10	[46:8-10] IEXP; CLC; SPC; NREL; 403	42:9-16; 48:5-17; 98:5-103:3	402; 403; F; SP; LC; EX	See 98:5 counters	[33:4-18] NREL; 403; IMP; [34:6-35:1] NREL; 403; IMP; [43:1-7] NREL; 403; [45:12-15] NREL; 403; LFND; SPC; [45:18-46:2] NREL; 403; LFND; SPC; [46:8-10] IEXP; CLC; SPC; 403; NREL [46:12-47:22] IEXP; CLC; SPC; 403; NREL [49:1-5] IEXP; CLC; SPC; 403; NREL [49:13-50:9] IEXP; CLC; SPC; 403; NREL [103:18-20] IEXP;

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					CLC; SPC; 403; NREL; AMB [104:1-6] IEXP; CLC; SPC; 403; NREL; AMB [104:8] IEXP; CLC; SPC; 403; NREL; AMB [104:18-105:4] IEXP; CLC; SPC; 403; NREL; AMB [105:7-14] IEXP; CLC; SPC; 403; NREL; AMB [105:22-106:11] IEXP; CLC; SPC; 403; NREL; AMB [106:14-22] IEXP; CLC; SPC; 403; NREL; AMB; MIS [107:3-11] IEXP; CLC; SPC; 403; NREL; AMB; MIS
46:12-47:22	[46:12-47:22] NREL; 403; IEXP; CLC; SPC	42:9-16; 48:5-17; 98:5-103:3	402; 403; F; SP; LC; EX	See 98:5 counters	[33:4-18] NREL; 403; IMP; [34:6-35:1] NREL; 403; IMP; [43:1-7] NREL; 403; [45:12-15] NREL; 403;



Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					LFND; SPC; [45:18-46:2] NREL; 403; LFND; SPC; [46:8-10] IEXP; CLC; SPC; 403; NREL [46:12- 47:22] IEXP; CLC; SPC; 403; NREL [49:1-5] IEXP; CLC; SPC; 403; NREL [49:13-50:9] IEXP; CLC; SPC; 403; NREL [103:18-20] IEXP; CLC; SPC; 403; NREL; AMB [104:1-6] IEXP; CLC; SPC; 403; NREL; AMB [104:8] IEXP; CLC; SPC; 403; NREL; AMB [104:18- 105:4] IEXP; CLC; SPC; 403; NREL; AMB [105:7-14] IEXP; CLC; SPC; 403; NREL; AMB [105:22-106:11]

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					IEXP; CLC; SPC; 403; NREL; AMB [106:14-22] IEXP; CLC; SPC; 403; NREL; AMB; MIS [107:3-11] IEXP; CLC; SPC; 403; NREL; AMB; MIS
49:1-49:5	[49:1-5] IEXP; CLC; SPC; NREL; 403	42:9-16; 48:5-17; 98:5-103:3	402; 403; F; SP; LC; EX	See 98:5 counters	[33:4-18] NREL; 403; IMP; [34:6-35:1] NREL; 403; IMP; [43:1-7] NREL; 403; [45:12-15] NREL; 403; LFND; SPC; [45:18-46:2] NREL; 403; LFND; SPC; [46:8-10] IEXP; CLC; SPC; 403; NREL [46:12-47:22] IEXP; CLC; SPC; 403; NREL [49:1-5] IEXP; CLC; SPC; 403; NREL [49:13-50:9] IEXP; CLC; SPC; 403; NREL [103:18-20] IEXP;

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					CLC; SPC; 403; NREL; AMB [104:1-6] IEXP; CLC; SPC; 403; NREL; AMB [104:8] IEXP; CLC; SPC; 403; NREL; AMB [104:18-105:4] IEXP; CLC; SPC; 403; NREL; AMB [105:7-14] IEXP; CLC; SPC; 403; NREL; AMB [105:22-106:11] IEXP; CLC; SPC; 403; NREL; AMB [106:14-22] IEXP; CLC; SPC; 403; NREL; AMB; MIS [107:3-11] IEXP; CLC; SPC; 403; NREL; AMB; MIS
49:13-50:9	[49:13-50:9] NREL; 403; IEXP; CLC; SPC	42:9-16; 48:5-17; 98:5-103:3	402; 403; F; SP; LC; EX	<i>See</i> 98:5 counters	[33:4-18] NREL; 403; IMP; [34:6-35:1] NREL; 403; IMP; [43:1-7] NREL; 403; [45:12-15] NREL; 403;

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					LFND; SPC; [45:18-46:2] NREL; 403; LFND; SPC; [46:8-10] IEXP; CLC; SPC; 403; NREL [46:12- 47:22] IEXP; CLC; SPC; 403; NREL [49:1-5] IEXP; CLC; SPC; 403; NREL [49:13-50:9] IEXP; CLC; SPC; 403; NREL [103:18-20] IEXP; CLC; SPC; 403; NREL; AMB [104:1-6] IEXP; CLC; SPC; 403; NREL; AMB [104:8] IEXP; CLC; SPC; 403; NREL; AMB [104:18- 105:4] IEXP; CLC; SPC; 403; NREL; AMB [105:7-14] IEXP; CLC; SPC; 403; NREL; AMB [105:22-106:11]

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
					IEXP; CLC; SPC; 403; NREL; AMB [106:14-22] IEXP; CLC; SPC; 403; NREL; AMB; MIS [107:3-11] IEXP; CLC; SPC; 403; NREL; AMB; MIS
60:19-61:2	[60:19-61:2] 403; HYP; LFND; NREL; SPC				
61:5-61:8	[61:5-8] LFND; NREL; 403				

**Javis Demeulenaere (Fossil) – November 13, 2023**

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
8:12-9:5		10:20-11:4	402; 403		
10:7-10:19	[10:7-19] NREL; 403	10:20-11:4	402; 403		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
11:10-11:21	[11:10-21] CLC  [11:10-21] LFND; SPC; 403; NREL; OS				
12:3-12:8	[12:3-8] SPC; NREL; 403	12:18-22; 14:5- 15:3; 19:14-19; 20:6-21:9; 22:22- 23:6; 28:7-32:12	402; 403	33:6-33:17	403; AMB; HRS; LFND; NREL; OBJ; SPC
12:12-12:14	[12:12-14] AMB; SPC; LFND; NREL; 403	12:18-22; 14:5- 15:3; 19:14-19; 20:6-21:9; 22:22- 23:6; 28:7-32:12	402; 403	33:6-33:17	403; AMB; HRS; LFND; NREL; OBJ; SPC
15:15-16:4	[15:15-16:4] 403; LFND; SPC; NREL	12:18-22; 14:5- 15:3; 19:14-19; 20:6-21:9; 22:22- 23:6; 28:7-32:12	402; 403	33:6-33:17	403; AMB; HRS; LFND; NREL; OBJ; SPC
16:10-17:3	[16:10-17:3] ATH; SPC; LFND; LDG; OBJ; BER; 403; NREL	12:18-22; 14:5- 15:3; 17:19-18:1; 18:11-16; 19:14-19; 20:6-21:9; 22:22- 23:6; 26:11-27:8; 28:7-32:12; 32:17- 33:4	402; 403	33:6-33:17	403; AMB; HRS; LFND; NREL; OBJ; SPC
17:10-17:15	[17:10-15] NREL; 403; AMB; AA; ATH; SPC; CM; LFND; LDG; BER	12:18-22; 14:5- 15:3; 17:19-18:1; 18:11-16; 19:14-19; 20:6-21:9; 22:22-	402; 403	33:6-33:17	403; AMB; HRS; LFND; NREL; OBJ; SPC

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		23:6; 26:11-27:8; 28:7-32:12; 32:17-33:4			
18:3-18:10	[18:3-10] 403; NREL; LFND; AMB; ATH; LDG; BER	12:18-22; 14:5-15:3; 17:19-18:1; 18:11-16; 19:14-19; 20:6-21:9; 22:22-23:6; 26:11-27:8; 28:7-32:12; 32:17-33:4	402; 403	33:6-33:17	403; AMB; HRS; LFND; NREL; OBJ; SPC
18:18-18:20	[18:18-20] NREL; 403; AG; ATH; BSD; LFND	12:18-22; 14:5-15:3; 17:19-18:1; 18:11-16; 19:14-19; 20:6-21:9; 22:22-23:6; 26:11-27:8; 28:7-32:12; 32:17-33:4	402; 403	33:6-33:17	403; AMB; HRS; LFND; NREL; OBJ; SPC
19:1-19:4	[19:1-4] BER; SPC; LFND; LDG; NREL; 403	12:18-22; 14:5-15:3; 17:19-18:1; 18:11-16; 19:14-19; 20:6-21:9; 22:22-23:6; 26:11-27:8; 28:7-32:12; 32:17-33:4	402; 403	33:6-33:17	403; AMB; HRS; LFND; NREL; OBJ; SPC
21:17-21:19	[21:17-19] SPC; LFND; LDG; NREL; 403	12:18-22; 14:5-15:3; 17:19-18:1; 18:11-16; 19:14-19; 20:6-21:9; 22:22-	402; 403	33:6-33:17	403; AMB; HRS; LFND; NREL; OBJ; SPC

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		23:6; 26:11-27:8; 28:7-32:12; 32:17-33:4			
21:22-22:5	[21:22-22:5] AA; SPC; LFND; LDG; NREL; 403	12:18-22; 14:5-15:3; 17:19-18:1; 18:11-16; 19:14-19; 20:6-21:9; 22:22-23:6; 26:11-27:8; 28:7-32:12; 32:17-33:4	402; 403	33:6-33:17	403; AMB; HRS; LFND; NREL; OBJ; SPC
22:7-22:11	[22:7-11] SPC; LFND; LDG; NREL; 403	12:18-22; 14:5-15:3; 17:19-18:1; 18:11-16; 19:14-19; 20:6-21:9; 22:22-23:6; 26:11-27:8; 28:7-32:12; 32:17-33:4	402; 403	33:6-33:17	403; AMB; HRS; LFND; NREL; OBJ; SPC
22:14-22:14	[22:14-14] SPC; LFND; LDG; NREL; 403	12:18-22; 14:5-15:3; 17:19-18:1; 18:11-16; 19:14-19; 20:6-21:9; 22:22-23:6; 26:11-27:8; 28:7-32:12; 32:17-33:4	402; 403	33:6-33:17	403; AMB; HRS; LFND; NREL; OBJ; SPC
22:16-22:21	[22:16-21] BER; AMB; SPC; LFND; NREL; 403	12:18-22; 14:5-15:3; 17:19-18:1; 18:11-16; 19:14-19; 20:6-21:9; 22:22-	402; 403	33:6-33:17	403; AMB; HRS; LFND; NREL; OBJ; SPC



<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		23:6; 26:11-27:8; 28:7-32:12; 32:17-33:4			
23:8-23:13	[23:8-13] SPC; LFND; LDG; NREL; 403; BER	12:18-22; 14:5-15:3; 17:19-18:1; 18:11-16; 19:14-19; 20:6-21:9; 22:22-23:6; 26:11-27:8; 28:7-32:12; 32:17-33:4	402; 403	33:6-33:17	403; AMB; HRS; LFND; NREL; OBJ; SPC
23:16-24:5	[23:16-24:5] ATH; SPC; LFND; LDG; NREL; OBJ; 403; BER	12:18-22; 14:5-15:3; 19:14-19; 20:6-21:9; 26:11-27:8; 28:7-32:12	402; 403	33:6-33:17	403; AMB; HRS; LFND; NREL; OBJ; SPC
24:8-24:18	[24:8-18] BER; SPC; LFND; LDG; NREL; 403	12:18-22; 14:5-15:3; 19:14-19; 20:6-21:9; 26:11-27:8; 28:7-32:12	402; 403	33:6-33:17	403; AMB; HRS; LFND; NREL; OBJ; SPC
24:21-25:3	[24:21-25:3] ATH; BER; SPC; LFND; LDG; NREL; 403	12:18-22; 14:5-15:3; 19:14-19; 20:6-21:9; 26:11-27:8; 28:7-32:12	402; 403	33:6-33:17	403; AMB; HRS; LFND; NREL; OBJ; SPC
25:6-25:6	[24:21-25:3] ATH; BER; SPC; LFND; LDG; NREL; 403	12:18-22; 14:5-15:3; 19:14-19; 20:6-21:9; 26:11-27:8; 28:7-32:12	402; 403	33:6-33:17	403; AMB; HRS; LFND; NREL; OBJ; SPC

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
25:10-25:16	[25:10-16] AMB; AA; BER; SPC; CM; LFND; LDG; NREL; OBJ; 403	12:18-22; 14:5- 15:3; 19:14-19; 20:6-21:9; 26:11- 27:8; 28:7-32:12	402; 403	33:6-33:17	403; AMB; HRS; LFND; NREL; OBJ; SPC
25:19-25:22	[25:10-16] AMB; AA; BER; SPC; CM; LFND; LDG; NREL; OBJ; 403  [25:19-22] AMB; AG; SPC; LFND; LDG; MIS	12:18-22; 14:5- 15:3; 19:14-19; 20:6-21:9; 26:11- 27:8; 28:7-32:12	402; 403	33:6-33:17	403; AMB; HRS; LFND; NREL; OBJ; SPC
26:2-26:2	[25:10-16] AMB; AA; BER; SPC; CM; LFND; LDG; NREL; OBJ; 403	12:18-22; 14:5- 15:3; 19:14-19; 20:6-21:9; 26:11- 27:8; 28:7-32:12	402; 403	33:6-33:17	403; AMB; HRS; LFND; NREL; OBJ; SPC
26:5-26:7	[25:10-16] AMB; AA; BER; SPC; CM; LFND; LDG; NREL; OBJ; 403	12:18-22; 14:5- 15:3; 19:14-19; 20:6-21:9; 26:11- 27:8; 28:7-32:12	402; 403	33:6-33:17	403; AMB; HRS; LFND; NREL; OBJ; SPC
26:10-26:10	[25:10-16] AMB; AA; BER; SPC; CM; LFND; LDG; NREL; OBJ; 403	12:18-22; 14:5- 15:3; 19:14-19; 20:6-21:9; 26:11- 27:8; 28:7-32:12	402; 403	33:6-33:17	403; AMB; HRS; LFND; NREL; OBJ; SPC

Elisabeth Dickinson (Mio) – November 13, 2023					
Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
6:15-6:18		8:7-9; 33:7-18; 33:7-18; 34:1- 35:14; 34:1-35:14	402; 403	8:10-8:15	403; AMB; NREL
8:17-8:18	[8:17-18] AMB; BER; SPC; LDG; NREL; 403	8:7-9; 33:7-18; 33:7-18; 34:1- 35:14; 34:1-35:14	402; 403	8:10-8:15	403; AMB; NREL
9:3-9:11	[8:17-18] AMB; BER; SPC; LDG; NREL; 403	8:7-9; 33:7-18; 33:7-18; 34:1- 35:14; 34:1-35:14; 36:18-38:1; 38:13- 39:20; 40:11-41:11; 45:3-12; 45:14-18; 45:14-18; 46:9-11; 46:18-47:13	402; 403; M; OS	8:10-8:15	403; AMB; NREL
10:1-11:16	[8:17-18] AMB; BER; SPC; LDG; NREL; 403	8:7-9; 33:7-18; 33:7-18; 34:1- 35:14; 34:1-35:14; 36:18-38:1; 38:13- 39:20; 40:11-41:11; 45:3-12; 45:14-18; 45:14-18; 46:9-11; 46:18-47:13	402; 403; M; OS	8:10-8:15	403; AMB; NREL
16:13-17:2	[16:13-17:2] AMB; ATH; BER; SPC; LFND; LDG; NREL; OBJ; 403	8:7-9; 33:7-18; 33:7-18; 34:1- 35:14; 34:1-35:14; 36:18-38:1; 38:13-	402; 403; M; OS	8:10-8:15	403; AMB; NREL

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		39:20; 40:11-41:11; 43:8-16; 44:16-20; 44:16-20; 45:1-2; 45:3-12; 45:14-18; 45:14-18; 46:9-11; 46:18-47:13			
17:10-18:2	[16:13-17:2] AMB; ATH; BER; SPC; LFND; LDG; NREL; OBJ; 403	8:7-9; 18:3-8; 33:7-18; 33:7-18; 34:1-35:14; 34:1-35:14; 36:18-38:1; 38:13-39:20; 40:11-41:11; 43:8-16; 44:16-20; 44:16-20; 45:1-2; 45:3-12; 45:14-18; 45:14-18; 46:9-11; 46:18-47:13	402; 403; M; I; OS	8:10-8:15	403; AMB; NREL
18:9-18:21	[18:9-21] AMB; ATH; BER; SPC; LFND; LDG; NREL; OBJ; 403; HRS	8:7-9; 18:3-8; 33:7-18; 33:7-18; 34:1-35:14; 34:1-35:14; 36:18-38:1; 38:13-39:20; 40:11-41:11; 43:8-16; 44:16-20; 44:16-20; 45:1-2; 45:3-12; 45:14-18; 45:14-18; 46:9-11; 46:18-47:13	402; 403; M; I; OS	8:10-8:15	403; AMB; NREL
19:1-19:8	[19:1-8] AMB; ATH; BER; SPC;	8:7-9; 18:3-8; 33:7-18; 33:7-18; 34:1-	402; 403; M; I	8:10-8:15	403; AMB; NREL

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
	HRS; LFND; LDG; NREL; OBJ; 403	35:14; 34:1-35:14; 43:8-16; 44:16-20; 44:16-20; 45:1-2; 45:3-12; 45:14-18; 45:14-18			
19:11-20:10	[19:1-8] AMB; ATH; BER; SPC; HRS; LFND; LDG; NREL; OBJ; 403	8:7-9; 18:3-8; 33:7-18; 33:7-18; 34:1-35:14; 34:1-35:14; 43:8-16; 44:16-20; 44:16-20; 45:1-2; 45:3-12; 45:14-18; 45:14-18	402; 403; M; I	8:10-8:15	403; AMB; NREL
20:13-20:16	[19:1-8] AMB; ATH; BER; SPC; HRS; LFND; LDG; NREL; OBJ; 403	8:7-9; 18:3-8; 33:7-18; 33:7-18; 34:1-35:14; 34:1-35:14; 43:8-16; 44:16-20; 44:16-20; 45:1-2; 45:3-12; 45:14-18; 45:14-18	402; 403; M; I	8:10-8:15	403; AMB; NREL
20:19-20:22	[19:1-8] AMB; ATH; BER; SPC; HRS; LFND; LDG; NREL; OBJ; 403	8:7-9; 18:3-8; 33:7-18; 33:7-18; 34:1-35:14; 34:1-35:14; 43:8-16; 44:16-20; 44:16-20; 45:1-2; 45:3-12; 45:14-18; 45:14-18	402; 403; M; I	8:10-8:15	403; AMB; NREL

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
21:2-21:5	[21:2-5] AMB; SPC; LFND; LDG; NREL; 403	8:7-9; 18:3-8; 33:7-18; 33:7-18; 34:1-35:14; 34:1-35:14; 43:8-16; 44:16-20; 44:16-20; 45:1-2; 45:3-12; 45:14-18; 45:14-18	402; 403; M; I	8:10-8:15	403; AMB; NREL
21:7-21:17	[21:2-5] AMB; SPC; LFND; LDG; NREL; 403	8:7-9; 18:3-8; 33:7-18; 33:7-18; 34:1-35:14; 34:1-35:14; 43:8-16; 44:16-20; 44:16-20; 45:1-2; 45:3-12; 45:14-18; 45:14-18	402; 403; M; I	8:10-8:15	403; AMB; NREL
21:19-22:1	[21:2-5] AMB; SPC; LFND; LDG; NREL; 403	8:7-9; 18:3-8; 33:7-18; 33:7-18; 34:1-35:14; 34:1-35:14; 43:8-16; 44:16-20; 44:16-20; 45:1-2; 45:3-12; 45:14-18; 45:14-18	402; 403; M; I	8:10-8:15	403; AMB; NREL
22:3-22:6	[21:2-5] AMB; SPC; LFND; LDG; NREL; 403	8:7-9; 18:3-8; 33:7-18; 33:7-18; 34:1-35:14; 34:1-35:14; 43:8-16; 44:16-20; 44:16-20; 45:1-2; 45:3-12; 45:14-18; 45:14-18	402; 403; M; I	8:10-8:15	403; AMB; NREL

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
22:8-22:11	[21:2-5] AMB; SPC; LFND; LDG; NREL; 403	8:7-9; 18:3-8; 33:7-18; 33:7-18; 34:1-35:14; 34:1-35:14; 43:8-16; 44:16-20; 44:16-20; 45:1-2; 45:3-12; 45:14-18; 45:14-18	402; 403; M; I	8:10-8:15	403; AMB; NREL
22:13-23:2	[21:2-5] AMB; SPC; LFND; LDG; NREL; 403	8:7-9; 18:3-8; 33:7-18; 33:7-18; 34:1-35:14; 34:1-35:14; 43:8-16; 44:16-20; 44:16-20; 45:1-2; 45:3-12; 45:14-18; 45:14-18	402; 403; M; I	8:10-8:15	403; AMB; NREL
24:1-24:3	[24:1-3] AMB; SPC; LDG; NREL; 403	8:7-9; 33:7-18; 33:7-18; 34:1-35:14; 34:1-35:14; 43:8-16; 44:16-20; 44:16-20; 45:1-2; 45:3-12; 45:14-18; 45:14-18	402; 403; M	8:10-8:15	403; AMB; NREL
24:5-24:11	[24:1-3] AMB; SPC; LDG; NREL; 403	8:7-9; 33:7-18; 33:7-18; 34:1-35:14; 34:1-35:14; 43:8-16; 44:16-20; 44:16-20; 45:1-2; 45:3-12; 45:14-18; 45:14-18	402; 403; M	8:10-8:15	403; AMB; NREL

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
24:14-25:15	[24:1-3] AMB; SPC; LDG; NREL; 403	8:7-9; 33:7-18; 33:7-18; 34:1-35:14; 34:1-35:14; 43:8-16; 44:16-20; 44:16-20; 45:1-2; 45:3-12; 45:14-18; 45:14-18	402; 403; M	8:10-8:15	403; AMB; NREL
25:17-26:11	[24:1-3] AMB; SPC; LDG; NREL; 403  [25:17-26:11] AMB; SPC; LFND; LDG; NREL; 403	8:7-9; 33:7-18; 33:7-18; 34:1-35:14; 34:1-35:14; 43:8-16; 44:16-20; 44:16-20; 45:1-2; 45:3-12; 45:14-18; 45:14-18	402; 403; M; V	8:10-8:15	403; AMB; NREL
26:13-27:8	[25:17-26:11] AMB; SPC; LFND; LDG; NREL; 403	8:7-9; 33:7-18; 33:7-18; 34:1-35:14; 34:1-35:14; 36:18-38:1; 38:13-39:20; 40:11-41:11; 43:8-16; 44:16-20; 44:16-20; 45:1-2; 45:3-12; 45:14-18; 45:14-18; 46:9-11; 46:18-47:13	402; 403; M; V	8:10-8:15	403; AMB; NREL
27:10-27:17	[25:17-26:11] AMB; SPC; LFND; LDG; NREL; 403	8:7-9; 33:7-18; 33:7-18; 34:1-35:14; 34:1-35:14; 36:18-38:1; 38:13-	402; 403; M; V	8:10-8:15	403; AMB; NREL



<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		39:20; 40:11-41:11; 45:3-12; 45:14-18; 45:14-18; 46:9-11; 46:18-47:13			
27:20-28:22	[25:17-26:11] AMB; SPC; LFND; LDG; NREL; 403	8:7-9; 33:7-18; 33:7-18; 34:1- 35:14; 34:1-35:14; 46:18-47:13	402; 403; V	8:10-8:15	403; AMB; NREL
29:4-29:7	[29:4-7] AMB; SPC; LFND; LDG; NREL; 403; MM	8:7-9; 33:7-18; 33:7-18; 34:1- 35:14; 34:1-35:14	402; 403; V	8:10-8:15	403; AMB; NREL
29:10-29:18	[29:4-7] AMB; SPC; LFND; LDG; NREL; 403; MM	8:7-9; 33:7-18; 33:7-18; 34:1- 35:14; 34:1-35:14	402; 403; V	8:10-8:15	403; AMB; NREL
30:21-30:22	[30:21-22] AMB; SPC; LFND; LDG; NREL; 403	8:7-9; 33:7-18; 33:7-18; 34:1- 35:14; 34:1-35:14; 40:11-41:11; 46:18- 47:13	402; 403; V	8:10-8:15	403; AMB; NREL
31:3-31:4	[30:21-22] AMB; SPC; LFND; LDG; NREL; 403	8:7-9; 33:7-18; 33:7-18; 34:1- 35:14; 34:1-35:14; 40:11-41:11; 46:18- 47:13	402; 403; V	8:10-8:15	403; AMB; NREL
38:2-38:6	[38:2-6] INC	8:7-9; 33:7-18; 33:7-18; 34:1- 35:14; 34:1-35:14; 36:18-38:1; 38:7-8	402; 403	8:10-8:15	403; AMB; NREL

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
39:22-40:10	[39:22-40:10] ATH; BER; SPC; LFND; NREL; 403	8:7-9; 33:7-18; 33:7-18; 34:1- 35:14; 34:1-35:14; 36:18-38:1; 38:13- 39:20; 40:11-41:11; 45:3-12; 45:14-18; 45:14-18; 46:9-11; 46:18-47:13	402; 403; V	8:10-8:15	403; AMB; NREL
41:12-41:16	[41:12-16] AMB; NREL; 403	8:7-9; 33:7-18; 33:7-18; 34:1- 35:14; 34:1-35:14	402; 403	8:10-8:15	403; AMB; NREL
42:6-42:15	[42:6-15] AMB; SPC; LFND; NREL; 403	8:7-9; 33:7-18; 33:7-18; 34:1- 35:14; 34:1-35:14; 43:8-16; 44:16-20; 44:16-20; 45:1-2; 45:3-12; 45:14-18; 45:14-18	402; 403; V	8:10-8:15	403; AMB; NREL
43:4-43:7	[43:4-7] AMB; LFND; NREL; 403	8:7-9; 33:7-18; 33:7-18; 34:1- 35:14; 34:1-35:14; 43:8-16; 44:16-20; 44:16-20; 45:1-2; 45:3-12; 45:14-18; 45:14-18	402; 403; V	8:10-8:15	403; AMB; NREL
43:17-43:19	[43:17-19] AMB; SPC; LFND; NREL; 403	8:7-9; 33:7-18; 33:7-18; 34:1- 35:14; 34:1-35:14;	402; 403; V	8:10-8:15	403; AMB; NREL

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		43:8-16; 44:16-20; 44:16-20; 45:1-2; 45:3-12; 45:14-18; 45:14-18			
43:22-44:1	[43:17-19] AMB; SPC; LFND; NREL; 403	8:7-9; 33:7-18; 33:7-18; 34:1- 35:14; 34:1-35:14; 43:8-16; 44:16-20; 44:16-20; 45:1-2; 45:3-12; 45:14-18; 45:14-18	402; 403; V	8:10-8:15	403; AMB; NREL
44:3-44:4	[43:17-19] AMB; SPC; LFND; NREL; 403	8:7-9; 33:7-18; 33:7-18; 34:1- 35:14; 34:1-35:14; 43:8-16; 44:16-20; 44:16-20; 45:1-2; 45:3-12; 45:14-18; 45:14-18	402; 403; V	8:10-8:15	403; AMB; NREL
44:6-44:14	[43:17-19] AMB; SPC; LFND; NREL; 403	8:7-9; 33:7-18; 33:7-18; 34:1- 35:14; 34:1-35:14; 43:8-16; 44:16-20; 44:16-20; 45:1-2; 45:3-12; 45:14-18; 45:14-18	402; 403; V	8:10-8:15	403; AMB; NREL
45:20-46:8	[45:20-46:8] AMB; SPC; LFND; NREL; 403	8:7-9; 33:7-18; 33:7-18; 34:1-	402; 403; V	8:10-8:15	403; AMB; NREL

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		35:14; 34:1-35:14; 46:9-11			
46:12-46:17		8:7-9; 33:7-18; 33:7-18; 34:1- 35:14; 34:1-35:14; 46:9-11	402; 403; V	8:10-8:15	403; AMB; NREL

Chinsan Han – August 18, 2022					
Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
8:2-8:4					
8:17-8:18		8:19-9:2; 9:11-10:7; 10:11-16			
11:6-11:17		221:14-18; 221:20-222:9; 221:20-222:9; 223:15-20; 223:22-226:16; 223:22-226:16	402, 403, LE, OS		
12:19-12:20		221:14-18; 221:20-222:9; 221:20-222:9; 223:15-20; 223:22-226:16; 223:22-226:16	402, 403, LE, OS		
13:9-14:13	[13:9-14:13] NREL; 403	15:19-16:2; 16:6-10; 16:12-17:4; 53:9-54:3; 54:10-14; 67:3-4; 67:6-14; 67:22-68:21; 69:1-70:13; 70:15-71:8; 71:12-73:8; 221:14-18; 221:20-222:9; 221:20-222:9; 223:15-20; 223:22-226:16; 223:22-226:16	402, 403, V, OS, SP, F, LE		

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
47:15-48:8	[47:15-48:8] AMB; LDG; NREL; 403	15:19-16:2; 16:6-10; 16:12-17:4; 53:9-54:3; 54:10-14; 67:3-4; 67:6-14; 67:22-68:21; 69:1-70:13; 70:15-71:8; 71:12-73:8; 221:14-18; 221:20-222:9; 221:20-222:9; 223:15-20; 223:22-226:16; 223:22-226:16	402, 403, V, OS, LE		
50:6-51:9	[50:6-51:9] AMB; ATH; NREL; 403; LFND	221:14-18; 221:20-222:9; 221:20-222:9; 223:15-20; 223:22-226:16; 223:22-226:16	402, 403, V, OS, LE		
59:8-59:19	[59:8-19] AMB; NREL; 403	15:19-16:2; 16:6-10; 16:12-17:4; 53:9-54:3; 54:10-14; 67:3-4; 67:6-14; 67:22-68:21; 69:1-70:13; 70:15-71:8; 71:12-73:8; 221:14-18; 221:20-222:9; 221:20-222:9; 223:15-20; 223:22-	402, 403, V, OS, LE		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		226:16; 223:22-226:16			
60:11-60:16	[60:11-16] AMB; NREL; 403	15:19-16:2; 16:6-10; 16:12-17:4; 53:9-54:3; 54:10-14; 67:3-4; 67:6-14; 67:22-68:21; 69:1-70:13; 70:15-71:8; 71:12-73:8; 221:14-18; 221:20-222:9; 221:20-222:9; 223:15-20; 223:22-226:16; 223:22-226:16	402, 403, V, OS, LE		
61:10-61:19	[61:10-19] AMB; SPC; LFND; LDG; NR; NREL; 403	15:19-16:2; 16:6-10; 16:12-17:4; 53:9-54:3; 54:10-14; 63:6-17; 67:3-4; 67:6-14; 67:22-68:21; 69:1-70:13; 70:15-71:8; 71:12-73:8; 221:14-18; 221:20-222:9; 221:20-222:9; 223:15-20; 223:22-226:16; 223:22-226:16	402, 403, V, OS, I, LE	63:19-64:4; 64:13-65:9	403; AMB; LDG; SPC; LFND; NREL; 403

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
74:16-74:22	[74:16-22] AMB; NREL; OBJ; 403	15:19-16:2; 16:6-10; 16:12-17:4; 53:9-54:3; 54:10-14; 67:3-4; 67:6-14; 67:22-68:21; 69:1-70:13; 70:15-71:8; 71:12-73:8; 221:14-18; 221:20-222:9; 221:20-222:9; 223:15-20; 223:22-226:16; 223:22-226:16	402, 403, V, OS, LE		
83:21-83:22	[83:21-22] NREL; OBJ; 403	221:14-18; 221:20-222:9; 221:20-222:9; 223:15-20; 223:22-226:16; 223:22-226:16	402, 403, LE, OS		
84:18-84:21	[83:21-22] NREL; OBJ; 403	86:1-2; 86:4-11; 86:22-87:1; 87:4-22; 221:14-18; 221:20-222:9; 221:20-222:9; 223:15-20; 223:22-226:16; 223:22-226:16	402, 403, V, SP, F, OS, LE		
85:12-85:22	[85:12-22] BER; HRS; NREL; 403	86:1-2; 86:4-11; 86:22-87:1; 87:4-22; 221:14-18;	402, 403, V, SP, F, OS, LE		



Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
		221:20-222:9; 221:20-222:9; 223:15-20; 223:22- 226:16; 223:22- 226:16			
96:1-96:7	[96:1-7] AMB; MIS; NREL; 403	53:9-54:3; 54:10- 14; 67:3-4; 67:6-14; 67:22-68:21; 69:1- 70:13; 70:15-71:8; 71:12-73:8; 221:14- 18; 221:20-222:9; 221:20-222:9; 223:15-20; 223:22- 226:16; 223:22- 226:16	402, 403, V, OS, LE		
97:4-97:6	[97:4-6] BER; NREL; 403	221:14-18; 221:20- 222:9; 221:20- 222:9; 223:15-20; 223:22-226:16; 223:22-226:16	402, 403, LE, OS		
98:15-99:8	[98:15-99:8] AMB; HRS; LDG; NREL; 403	15:19-16:2; 16:6- 10; 16:12-17:4; 53:9-54:3; 54:10- 14; 67:3-4; 67:6-14; 67:22-68:21; 69:1- 70:13; 70:15-71:8; 71:12-73:8; 95:4- 22; 221:14-18;	402, 403, V, SP, F, OS, I, LE	94:13-19	NREL; 403

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		221:20-222:9; 221:20-222:9; 223:15-20; 223:22- 226:16; 223:22- 226:16			
103:15-103:16	[103:15-16] BER; NREL; 403	221:14-18; 221:20- 222:9; 221:20- 222:9; 223:15-20; 223:22-226:16; 223:22-226:16	402, 403, LE, OS		
105:12-105:16	[105:12-16] AMB; BER; HRS; NREL; 403	107:9-108:3; 221:14-18; 221:20- 222:9; 221:20- 222:9; 223:15-20; 223:22-226:16; 223:22-226:16	402, 403, V, SP, F, I, LE, OS	106:3-14	AMB; BER; LDG; NREL; 403
105:21-106:2	[105:12-16] AMB; BER; HRS; NREL; 403	107:9-108:3; 221:14-18; 221:20- 222:9; 221:20- 222:9; 223:15-20; 223:22-226:16; 223:22-226:16	402, 403, V, SP, F, I, LE, OS	106:3-14	AMB; BER; LDG; NREL; 403
106:20-107:2	[105:12-16] AMB; BER; HRS; NREL; 403	107:9-108:3; 221:14-18; 221:20- 222:9; 221:20- 222:9; 223:15-20; 223:22-226:16; 223:22-226:16	402, 403, V, SP, F, I, LE, OS	106:3-14	AMB; BER; LDG; NREL; 403

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
108:5-108:6	[108:5-6] BER; NREL; OBJ; OS; 403	67:3-4; 67:6-14; 67:22-68:21; 69:1-70:13; 70:15-71:8; 71:12-73:8; 221:14-18; 221:20-222:9; 221:20-222:9; 223:15-20; 223:22-226:16; 223:22-226:16	402, 403, V, OS, LE		
108:13-108:16	[108:5-6] BER; NREL; OBJ; OS; 403	67:3-4; 67:6-14; 67:22-68:21; 69:1-70:13; 70:15-71:8; 71:12-73:8; 221:14-18; 221:20-222:9; 221:20-222:9; 223:15-20; 223:22-226:16; 223:22-226:16	402, 403, V, OS, LE		
109:6-109:8	[109:6-8] AMB; BER; HRS; LDG; NREL; OBJ; 403	15:19-16:2; 16:6-10; 53:9-54:3; 54:10-14; 67:3-4; 67:6-14; 67:22-68:21; 69:1-70:13; 70:15-71:8; 71:12-73:8; 110:12-22; 221:14-18; 221:20-222:9; 221:20-222:9; 223:15-20;	402, 403, V, OS, F, SP, LE		

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
		223:22-226:16; 223:22-226:16			
109:14-110:11	[109:6-8] AMB; BER; HRS; LDG; NREL; OBJ; 403	16:12-17:4; 53:9- 54:3; 54:10-14; 67:3-4; 67:6-14; 67:22-68:21; 69:1- 70:13; 70:15-71:8; 71:12-73:8; 110:12- 22; 221:14-18; 221:20-222:9; 221:20-222:9; 223:15-20; 223:22- 226:16; 223:22- 226:16	402, 403, V, OS, F, SP, LE		
112:1-112:16	[112:1-16] AMB; BER; HRS; LDG; NREL; OS; 403	53:9-54:3; 54:10- 14; 67:3-4; 67:6-14; 67:22-68:21; 69:1- 70:13; 70:15-71:8; 71:12-73:8; 221:14- 18; 221:20-222:9; 221:20-222:9; 223:15-20; 223:22- 226:16; 223:22- 226:16	402, 403, V, OS, LE		
133:21-134:3	[133:21-134:3] AMB; BER; LFND; LDG; NREL; 403	15:19-16:2; 16:6- 10; 16:12-17:4; 53:9-54:3; 54:10- 14; 67:3-4; 67:6-14;	402, 403, V, OS, SP, F, LE		

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
		67:22-68:21; 69:1-70:13; 70:15-71:8; 71:12-73:8; 136:8-17; 136:8-137:11; 221:14-18; 221:20-222:9; 221:20-222:9; 223:15-20; 223:22-226:16; 223:22-226:16			
134:18-136:7	[133:21-134:3] AMB; BER; LFND; LDG; NREL; 403	15:19-16:2; 16:6-10; 16:12-17:4; 53:9-54:3; 54:10-14; 67:3-4; 67:6-14; 67:22-68:21; 69:1-70:13; 70:15-71:8; 71:12-73:8; 136:8-17; 136:8-137:11; 221:14-18; 221:20-222:9; 221:20-222:9; 223:15-20; 223:22-226:16; 223:22-226:16	402, 403, V, OS, SP, F, LE		

Evans Hankey – November 9, 2023					
Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
10:7-10:16					
29:21-30:9	[29:21-30:9] AMB; LFND; NREL; 403				
68:10-68:15	[68:10-15] AMB; CLC; SPC; LFND; NREL; 403				
68:17-68:21					
82:5-82:19	[82:5-19] AMB; LFND; NREL; 403				
84:8-86:5					
86:15-88:15					
89:19-90:12					
95:6-95:9	[95:6-9] AMB; LFND; NREL; 403	95:10-13	402, 403		
100:18-101:5	[100:18-101:5] AMB; LFND; NREL; 403				
101:17-101:22	[101:17-22] AMB; LFND; NREL; 403				
104:16-104:21	[104:16-105:7] AMB; LFND; NREL; 403	116:13-17			
104:22-105:7		106:16-107:12; 116:13-17	[106:16-107:12] 402, 403	104:16-104:21; 104:22-105:7; 105:14-19	[104:16-104:21] AMB; BSD; SPC; CPD; HYP; LFND; NREL; 403;

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
					[104:22-105:7] AMB; BSD; SPC; CPD; HYP; LFND; NREL; 403; [105:14-19] AMB; BSD; SPC; CPD; HYP; LFND; NREL; 403;
110:21-111:9	[110:21-111:9] AMB; LFND; NREL; 403	116:13-17			
117:11-117:17	[117:11-17] AMB; SPC; LFND; NREL; 403				
118:2-118:5					
120:6-120:10		121:17-122:7		100:18-101:1; 120:6-10; 122:8-13	[100:18-101:1] AMB; AG; SPC; LFND; LDG; MIS; NREL; 403; [120:6-10] AMB; AG; SPC; LFND; LDG; MIS; NREL; 403; [122:8-13] AMB; AG; SPC; LFND; LDG; MIS; NREL; 403;

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
122:8-122:13		122:14-22		100:18-101:1; 120:6-10; 121:17- 122:13	[100:18-101:1] AMB; AG; SPC; LFND; LDG; MIS; NREL; 403; [120:6-10] AMB; AG; SPC; LFND; LDG; MIS; NREL; 403; [121:17-122:13] AMB; AG; SPC; LFND; LDG; MIS; NREL; 403;
124:10-124:15	[124:10-15] AMB; LFND; NREL; 403				
126:17-126:21	[126:17-21] AMB; LFND; NREL; 403				
136:1-136:3					
137:4-137:8	[137:4-8] AMB; LFND; NREL; 403				
137:19-138:1	[137:19-138:1] AMB; LFND; NREL; 403				
139:18-140:4	[139:18-140:4] AMB; LFND; NREL; 403				
147:4-147:7	[147:4-7] AMB				
147:15-147:18	[147:15-18] AMB; LFND; NREL; 403				



Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
151:19-151:22	[151:19-22] AMB; LFND; NREL; 403				
152:11-152:15	[152:11-15] AMB; LFND; NREL; 403				
160:5-160:9	[160:5-9] AMB; LFND; NREL; 403				
162:18-162:22					
164:3-164:11		165:5-15	SP	100:18-101:1; 120:6-10; 121:17-122:13; 164:3-11; 168:20-169:6; [1]69:8-14; 172:4-12	[100:18-101:1] AMB; AG; SPC; LFND; LDG; MIS; NREL; 403; [120:6-10] AMB; AG; SPC; LFND; LDG; MIS; NREL; 403; [121:17-122:13] AMB; AG; SPC; LFND; LDG; MIS; NREL; 403; [164:3-11] AMB; ARG; AA; AG; CLC; SPC; LFND; LDG; MIS; NREL; 403 [168:20-169:6] AMB; ARG; AA; AG; CLC; SPC;

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					LFND; LDG; MIS; NREL; 403 [169:8-14] AMB; ARG; AA; AG; CLC; SPC; LFND; LDG; MIS; NREL; 403 [172:4-12] AMB; ARG; AA; AG; CLC; SPC; LFND; LDG; MIS; NREL; 403
167:4-167:9					
170:1-170:5					
172:4-172:12		177:15-178:5	SP	100:18-101:1; 120:6-10; 121:17-122:13; 164:3-11; 168:20-169:6; 169:8-14; 172:4-12	[100:18-101:1] AMB; AG; SPC; LFND; LDG; MIS; NREL; 403; [120:6-10] AMB; AG; SPC; LFND; LDG; MIS; NREL; 403; [121:17-122:13] AMB; AG; SPC; LFND; LDG; MIS; NREL; 403; [164:3-11] AMB; ARG; AA; AG;

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					CLC; SPC; LFND; LDG; MIS; NREL; 403 [168:20-169:6] AMB; ARG; AA; AG; CLC; SPC; LFND; LDG; MIS; NREL; 403 [169:8-14] AMB; ARG; AA; AG; CLC; SPC; LFND; LDG; MIS; NREL; 403 [172:4-12] AMB; ARG; AA; AG; CLC; SPC; LFND; LDG; MIS; NREL; 403
178:15-179:5	[178:15-179:5] AMB; LFND; MIS; NREL; 403				
179:14-179:17	[179:14-17] AMB; LFND; NREL; 403				
184:10-184:13	[184:10-13] AMB; LFND; NREL; 403				
188:2-188:6	[188:2-6] AMB; LFND; NREL; 403				

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
191:9-191:14	[191:9-14] AMB; LFND; NREL; 403				
192:20-192:22					
193:1-193:16	[193:1-16] AMB; AG; LFND; NREL; 403				
194:10-194:15	[194:10-15] AMB; LFND; NREL; 403				
200:15-200:19	[200:15-19] AMB; LFND; NREL; 403				
205:17-205:20	[205:17-20] AMB; LFND; NREL; 403				
209:4-209:8	[209:4-8] AMB; LFND; NREL; 403				
215:17-215:20	[215:17-20] AMB; LFND; NREL; 403				
218:4-218:13	[218:4-13] AMB; AA; LFND; NREL; 403				
219:6-219:9	[219:6-9] AMB; LFND; NREL; 403				
236:4-236:10	[236:4-10] AMB; LFND; NREL; 403				

Tobias Harrison-Noonan – October 6, 2023					
Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
6:17-6:20					
9:8-9:13					
11:10-11:11		26:11-15; 36:7-16; 36:7-16	I, OS	26:4-5, 26:8-9, 26:16-17	[26:4-5] 403; NREL; IEXP; CLC [26:8-9] 403; NREL; IEXP; CLC [26:16-17] 403; NREL; IEXP; CLC
11:14-11:16		26:11-15; 36:7-16; 36:7-16	I, OS	26:4-5, 26:8-9, 26:16-17	[26:4-5] 403; NREL; IEXP; CLC [26:8-9] 403; NREL; IEXP; CLC [26:16-17] 403; NREL; IEXP; CLC
11:18-11:21		26:11-15; 36:7-16; 36:7-16	I, OS	26:4-5, 26:8-9, 26:16-17	[26:4-5] 403; NREL; IEXP; CLC [26:8-9] 403; NREL; IEXP; CLC [26:16-17] 403; NREL; IEXP; CLC
12:5-12:7		26:11-15; 36:7-16; 36:7-16	I, OS	26:4-5, 26:8-9, 26:16-17	[26:4-5] 403; NREL; IEXP; CLC [26:8-9] 403; NREL; IEXP; CLC

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
					[26:16-17] 403; NREL; IEXP; CLC
12:13-15:2		26:11-15; 36:7-16; 36:7-16	I, OS	26:4-5, 26:8-9, 26:16-17	[26:4-5] 403; NREL; IEXP; CLC [26:8-9] 403; NREL; IEXP; CLC [26:16-17] 403; NREL; IEXP; CLC
23:11-23:12		26:11-15; 36:7-16; 36:7-16	I, OS	26:4-5, 26:8-9, 26:16-17	[26:4-5] 403; NREL; IEXP; CLC [26:8-9] 403; NREL; IEXP; CLC [26:16-17] 403; NREL; IEXP; CLC
23:17-23:19	[23:17-19] IEXP; NREL	26:11-15; 36:7-16; 36:7-16	I, OS	26:4-5, 26:8-9, 26:16-17	[26:4-5] 403; NREL; IEXP; CLC [26:8-9] 403; NREL; IEXP; CLC [26:16-17] 403; NREL; IEXP; CLC
23:22-24:4	[23:22-24:4] ARG; IEXP; NREL	12:13-15:2; 26:11-15; 36:7-16; 36:7-16	I, OS	26:4-5, 26:8-9, 26:16-17	[26:4-5] 403; NREL; IEXP; CLC [26:8-9] 403; NREL; IEXP; CLC

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
					[26:16-17] 403; NREL; IEXP; CLC
24:6-24:8	[24:6-8] IEXP; MIS; NREL	26:11-15; 36:7-16; 36:7-16	I, OS	26:4-5, 26:8-9, 26:16-17	[26:4-5] 403; NREL; IEXP; CLC [26:8-9] 403; NREL; IEXP; CLC [26:16-17] 403; NREL; IEXP; CLC
24:11-24:15	[24:11-15] IEXP; MIS; NREL	12:13-15:2; 26:11- 15; 36:7-16; 36:7- 16	I, OS	26:4-5, 26:8-9, 26:16-17	[26:4-5] 403; NREL; IEXP; CLC [26:8-9] 403; NREL; IEXP; CLC [26:16-17] 403; NREL; IEXP; CLC
24:17-25:5	[24:17-25:5] IEXP; NREL	12:13-15:2; 26:11- 15; 36:7-16; 36:7- 16	I, OS	26:4-5, 26:8-9, 26:16-17	[26:4-5] 403; NREL; IEXP; CLC [26:8-9] 403; NREL; IEXP; CLC [26:16-17] 403; NREL; IEXP; CLC
25:7-25:18	[25:7-18] IEXP; NREL	12:13-15:2; 26:11- 15; 36:7-16; 36:7- 16	I, OS	26:4-5, 26:8-9, 26:16-17	[26:4-5] 403; NREL; IEXP; CLC [26:8-9] 403; NREL; IEXP; CLC

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
					[26:16-17] 403; NREL; IEXP; CLC
27:13-27:19	[27:13-19] IEXP; NREL	26:11-15; 36:7-16; 36:7-16	I, OS	26:4-5, 26:8-9, 26:16-17	[26:4-5] 403; NREL; IEXP; CLC [26:8-9] 403; NREL; IEXP; CLC [26:16-17] 403; NREL; IEXP; CLC
32:10-32:12	[32:10-12] NREL; INC	26:11-15; 36:7-16; 36:7-16	I, OS	26:4-5, 26:8-9, 26:16-17, 32:14-21	[26:4-5] 403; NREL; IEXP; CLC [26:8-9] 403; NREL; IEXP; CLC [26:16-17] 403; NREL; IEXP; CLC [32:14-21] AMB; 403; NREL; IMP; MIS
35:20-36:5		26:11-15; 36:7-16; 36:7-16	I, OS	26:4-5, 26:8-9, 26:16-17	[26:4-5] 403; NREL; IEXP; CLC [26:8-9] 403; NREL; IEXP; CLC [26:16-17] 403; NREL; IEXP; CLC



Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
38:2-38:9	[38:2-9] NREL	26:11-15; 36:7-16; 36:7-16	I, OS	26:4-5, 26:8-9, 26:16-17	[26:4-5] 403; NREL; IEXP; CLC [26:8-9] 403; NREL; IEXP; CLC [26:16-17] 403; NREL; IEXP; CLC
47:9-48:1	[47:9-48:1] NREL	46:1-12; 48:2-12			
49:8-49:13	[49:8-13] IEXP; NREL	46:1-12; 52:16- 53:14			
50:7-51:4	[50:7-51:4] IEXP; NREL	46:1-12; 52:16- 53:14			
51:7-51:12	[51:7-12] IEXP; NREL; AA	46:1-12; 52:16- 53:14			
52:1-52:10	[52:1-10] IEXP; NREL	46:1-12; 52:16- 53:14			
53:21-54:5	[53:21-54:5] IEXP; NREL	46:1-12; 52:16- 53:14			

**Quin Hoellwarth – November 3, 2023**

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
5:14-5:20					

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
10:15-10:17					
12:10-12:14					
26:14-26:18					
27:8-27:13					
39:17-39:21	[39:17-21] AMB; LFND; NREL; 403	139:20-141:12	OS, L, F, SP, LC, V, 402, 403	38:22-39:6	[38:22-39:6] AMB; AG; PRV; BSD; SPC; LFND; MIS; NREL; 403
40:10-40:13	[40:10-13] AMB; LFND; NREL; 403	139:20-141:12	OS, L, F, SP, LC, V, 402, 403	38:22-39:6	[38:22-39:6] AMB; AG; PRV; SPC; LFND; MIS; NREL; 403
50:20-51:10		139:20-141:12	OS, L, F, SP, LC, V, 402, 403		
51:11-52:5	[51:11-52:5] AMB; LFND; NREL; 403; PRV	139:20-141:12	OS, L, F, SP, LC, V, 402, 403		
56:19-57:19	[56:19-57:19] AMB; LFND; NREL; 403	60:16-22; 139:20- 141:12	OS, L, F, SP, LC, V, 402, 403	60:6-9, 60:13-14	[60:6-9] AMB; ARG; AA; AG; PRV; BSD; CLC; SPC; IMP; INC; LFND; MIS; NREL; OBJ; 403; [60:13-14] AMB; ARG; AA; AG; PRV; BSD; CLC; SPC; IMP; INC;

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					LFND; MIS; NREL; OBJ; 403;
68:1-69:1	[68:1-69:1] AMB; LFND; NREL; 403	139:20-141:12	OS, L, F, SP, LC, V, 402, 403		
69:9-69:16		139:20-141:12	OS, L, F, SP, LC, V, 402, 403		
69:17-69:19		73:11-18; 85:20- 87:2; 87:16-88:14; 89:5-18; 91:3-92:2	F, AS	87:6-15, 88:15-89:4	[87:6-15] AMB; ARG; AA; AG; PRV; BSD; CLC; SPC; IMP; INC; LFND; MIS; NREL; OBJ; 403; [88:15-89:4] AMB; ARG; AA; AG; PRV; BSD; CLC; SPC; IMP; INC; LFND; MIS; NREL; OBJ; 403;
71:5-71:8		71:12-20	F, AS		
75:3-75:5		75:6-76:8	F, AS		
76:15-77:2		77:4-7	F, SP		
78:2-78:7					
85:4-85:9					
92:4-92:8	[92:4-8] AMB; LFND; NREL; 403				
92:15-92:15					

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
150:20-151:3		151:4-10		151:14-21, 152:1-5, 152:8-10, 152:22-153:1, 153:4-9	[151:14-21] AMB; ARG; AA; AG; CLC; SPC; LFND; MIS; NREL; OBJ; 403; [152:1-5] AMB; ARG; AA; AG; CLC; SPC; LFND; MIS; NREL; OBJ; 403; [152:8-10] AMB; ARG; AA; AG; CLC; SPC; LFND; MIS; NREL; OBJ; 403; [152:22-153:1] AMB; ARG; AA; AG; CLC; SPC; LFND; MIS; NREL; OBJ; 403; [153:4-9] AMB; ARG; AA; AG; CLC; SPC; LFND; MIS; NREL; OBJ; 403;
153:15-154:3	[153:15-154:3] AMB; AA; LFND; NREL; 403	148:5-10	OS, 402, 403	151:14-21, 152:1-5, 152:8-10, 152:22-153:1, 153:4-9	[151:14-21] AMB; ARG; AA; AG; CLC; SPC; LFND;

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
					MIS; NREL; OBJ; 403; [152:1-5] AMB; ARG; AA; AG; CLC; SPC; LFND; MIS; NREL; OBJ; 403; [152:8-10] AMB; ARG; AA; AG; CLC; SPC; LFND; MIS; NREL; OBJ; 403; [152:22-153:1] AMB; ARG; AA; AG; CLC; SPC; LFND; MIS; NREL; OBJ; 403; [153:4-9] AMB; ARG; AA; AG; CLC; SPC; LFND; MIS; NREL; OBJ; 403;

Steven Hotelling – August 2, 2022					
Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
9:12-9:14					
13:17-14:6					
27:15-27:16	[27:15-20] AMB; LFND; NREL; 403				
27:18-27:20					
36:19-37:6	[36:19-37:6] AMB; LFND; NREL; 403				
41:15-41:18	[41:15-18] AMB; LFND; NREL; 403				
42:11-42:15	[42:11-15] AMB; LFND; NREL; 403				
44:19-45:3	[44:19-46:3] AMB; LFND; NREL; 403; SPC				
45:5-45:7					
45:9-45:17					
45:19-46:3		46:20-47:13			
47:21-48:20	[47:21-48:20] AMB; LFND; NREL; 403				
49:6-49:13	[49:6-13] AMB; LFND; NREL; 403	50:16-51:3	I	50:6-15	[50:6-15] AMB; ARG; AA; AG; BSD; SPC; INC; LFND; MIS; NREL; 403; MIL

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
52:2-52:22	[52:2-22] AMB; LFND; NREL; 403				
53:2-53:9	[53:2-9] AMB; LFND; NREL; 403				
53:18-53:22	[53:18-22] AMB; LFND; NREL; 403				
55:1-55:3					
55:19-56:4					
56:15-57:10	[56:15-57:10] AMB; SPC; LFND; NREL; 403				
58:1-58:4	[58:1-4] AMB; SPC; LFND; NREL; 403				
62:6-63:3	[62:6-63:3] AMB; SPC; LFND; NREL; 403				
63:12-64:4	[63:12-64:4] AMB; SPC; LFND; NREL; 403	64:5-16			
65:16-66:17	[65:16-66:17] AMB; SPC; LFND; NREL; 403				
67:8-68:2	[67:8-68:2] AMB; SPC; LFND; NREL; 403	68:3-14	I	68:15-20, 69:1-4	[68:15-20] AMB; ARG; AA; AG; BSD; SPC; INC; LFND; MIS; NREL; 403; MIL;

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					[69:1-4] AMB; ARG; AA; AG; BSD; SPC; INC; LFND; MIS; NREL; 403; MIL;
74:15-74:18	[74:15-18] AMB; LFND; NREL; 403				
75:1-75:6	[75:1-6] AMB; LFND; NREL; 403				
75:17-76:1	[75:17-76:1] AMB; LFND; NREL; 403				
77:20-78:2	[77:20-78:2] AMB; LFND; NREL; 403				
83:17-84:2	[83:17-85:7] AMB; LFND; NREL; 403				
84:4-84:6					
84:12-84:18					
84:20-84:22					
85:2-85:7		85:8-13			
85:14-85:17	[85:14-17] AMB; LFND; NREL; 403				
86:3-86:17	[86:3-17] AMB; LFND; NREL; 403				
88:5-88:15	[88:5-15] AMB; LFND; NREL; 403				
89:11-91:1	[89:11-91:1] AMB; LFND; NREL; 403				



<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
91:22-93:1		93:8-15	402, 403, F, SP		
96:16-97:4					
97:13-98:4		98:14-20			
99:4-99:11	[99:4-14] AMB; LFND; NREL; 403				
99:13-99:14					
109:11-109:12	[109:11-110:18] AMB; LFND; NREL; 403				
109:18-110:18					
111:19-111:22					
112:16-112:20	[112:16-113:7] AMB; LFND; NREL; 403; SPC				
112:21-112:21					
113:2-113:7		219:6-13	402, 403, F, SP, LC, I, OS		
113:22-114:8	[113:22-114:8] AMB; SPC; LFND; NREL; 403	114:9-115:6; 219:6- 13	402, 403, F, SP, I, OS	115:18-19, 115:21- 116:8	[115:18-19] AMB; ARG; AA; AG; BSD; SPC; INC; LFND; MIS; NREL; 403; MIL; [115:21-116:8] AMB; ARG; AA; AG; BSD; SPC; INC; LFND; MIS; NREL; 403; MIL;

Steven Hotelling – November 3, 2023					
Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
30:19-31:1		31:2-9; 33:2-18		34:6-9, 171:6-172:4	[34:6-9] AMB; LFND; SPC; LDG; NREL; 403 [171:6-172:4] AMB; LFND; SPC; LDG; NREL; 403
31:10-32:5		33:2-18		34:6-9, 171:6-172:4	[34:6-9] AMB; LFND; SPC; LDG; NREL; 403 [171:6-172:4] AMB; LFND; SPC; LDG; NREL; 403
33:19-34:4	[33:19-34:4] AMB; LFND; NREL; 403				
35:9-35:20	[35:9-20] AMB; LFND; NREL; OS; 403	34:16-35:3		35:4-8, 171:6-172:4	[35:4-8] AMB; LFND; SPC; LDG; NREL; 403 [171:6-172:4] AMB; LFND; SPC; LDG; NREL; 403
36:11-36:17					
36:21-37:4					
37:14-38:3	[37:14-38:3] AMB; LFND; NREL; 403				

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
39:20-40:4	[39:20-40:4] AMB; LFND; NREL; 403				
53:3-53:12	[53:3-12] AMB; LFND; NREL; OS; 403	54:1-13		52:2-8	[52:2-8] AMB; BSD; LFND; SPC; NREL; 403
54:15-54:21	[54:15-21] AMB; LFND; NREL; OS; 403				
59:18-59:19	[59:18-19] NREL				
60:2-60:10	[60:2-10] NREL				
61:13-61:14	[61:13-14] NREL; AMB; LFND; OS; 403				
61:20-62:6	[61:20-62:6] AMB; LFND; NREL; OS; 403				
62:15-62:22	[62:15-22] AMB; LFND; NREL; OS; 403				
63:3-63:4	[63:3-4] AMB; LFND; NREL; OS; 403				
63:14-64:15	[63:14-64:15] AMB; LFND; NREL; OS; 403				
64:21-65:11	[64:21-65:11] AMB; LFND; NREL; OS; 403	65:21-66:5			

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
67:12-69:1	[67:12-69:5] AMB; LFND; NREL; OS; 403				
69:2-69:5					
69:9-69:12	[69:9-12] AMB; LFND; NREL; OS; 403	200:8-17	402, 403	204:18-21, 205:1, 206:3-6, 206:8-15, 206:3-15, 207:20- 21, 208:1-4, 209:3-5	[204:18-21] AMB; ARG; AG; PRV; ATH; BER; BSD; CLC; SPC; CPD; HRS; IMP; INC; LFND; LDG; MIS; NE; NP; NREL; 403; MIL; [205:1] AMB; ARG; AG; PRV; ATH; BER; BSD; CLC; SPC; CPD; HRS; IMP; INC; LFND; LDG; MIS; NE; NP; NREL; 403; MIL; [206:3-6] AMB; ARG; AG; PRV; ATH; BER; BSD; CLC; SPC; CPD; HRS; IMP; INC; LFND; LDG; MIS; NE; NP; NREL; 403; MIL;

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					<p>[206:8-15] AMB; ARG; AG; PRV; ATH; BER; BSD; CLC; SPC; CPD; HRS; IMP; INC; LFND; LDG; MIS; NE; NP; NREL; 403; MIL;</p> <p>[206:3-15] AMB; ARG; AG; PRV; ATH; BER; BSD; CLC; SPC; CPD; HRS; IMP; INC; LFND; LDG; MIS; NE; NP; NREL; 403; MIL;</p> <p>[207:20-21] AMB; ARG; AG; PRV; ATH; BER; BSD; CLC; SPC; CPD; HRS; IMP; INC; LFND; LDG; MIS; NE; NP; NREL; 403; MIL;</p> <p>[208:1-4] AMB; ARG; AG; PRV; ATH; BER; BSD; CLC; SPC; CPD;</p>

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
					HRS; IMP; INC; LFND; LDG; MIS; NE; NP; NREL; 403; MIL; [209:3-5] AMB; ARG; AG; PRV; ATH; BER; BSD; CLC; SPC; CPD; HRS; IMP; INC; LFND; LDG; MIS; NE; NP; NREL; 403; MIL;
69:17-73:15		193:3-194:3; 200:8-17	402, 403	204:18-21, 205:1, 206:3-6, 206:8-15, 206:3-15, 207:20-21, 208:1-4, 209:3-5	[204:18-21] AMB; ARG; AG; PRV; ATH; BER; BSD; CLC; SPC; CPD; HRS; IMP; INC; LFND; LDG; MIS; NE; NP; NREL; 403; MIL; [205:1] AMB; ARG; AG; PRV; ATH; BER; BSD; CLC; SPC; CPD; HRS; IMP; INC; LFND; LDG; MIS; NE; NP; NREL; 403; MIL;

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					<p>[206:3-6] AMB; ARG; AG; PRV; ATH; BER; BSD; CLC; SPC; CPD; HRS; IMP; INC; LFND; LDG; MIS; NE; NP; NREL; 403; MIL;</p> <p>[206:8-15] AMB; ARG; AG; PRV; ATH; BER; BSD; CLC; SPC; CPD; HRS; IMP; INC; LFND; LDG; MIS; NE; NP; NREL; 403; MIL;</p> <p>[206:3-15] AMB; ARG; AG; PRV; ATH; BER; BSD; CLC; SPC; CPD; HRS; IMP; INC; LFND; LDG; MIS; NE; NP; NREL; 403; MIL;</p> <p>[207:20-21] AMB; ARG; AG; PRV; ATH; BER; BSD; CLC; SPC; CPD;</p>

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
					HRS; IMP; INC; LFND; LDG; MIS; NE; NP; NREL; 403; MIL; [208:1-4] AMB; ARG; AG; PRV; ATH; BER; BSD; CLC; SPC; CPD; HRS; IMP; INC; LFND; LDG; MIS; NE; NP; NREL; 403; MIL; [209:3-5] AMB; ARG; AG; PRV; ATH; BER; BSD; CLC; SPC; CPD; HRS; IMP; INC; LFND; LDG; MIS; NE; NP; NREL; 403; MIL;
74:19-76:8		76:9-16; 193:3-194:3	402, 403, F, SP, I	76:18-21	[76:18-21] AMB; ARG; AG; BSD; SPC; CPD; LFND; LDG; MIS; NREL; 403; MIL;
76:22-77:10	[76:22-77:10] AMB; LFND; NREL; OS; 403	193:3-194:3; 200:8-17	402, 403	204:18-21, 205:1, 206:3-6, 206:8-15,	[204:18-21] AMB; ARG; AG; PRV; ATH; BER; BSD;



<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
				206:3-15, 207:20-21, 208:1-4, 209:3-5	CLC; SPC; CPD; HRS; IMP; INC; LFND; LDG; MIS; NE; NP; NREL; 403; MIL; [205:1] AMB; ARG; AG; PRV; ATH; BER; BSD; CLC; SPC; CPD; HRS; IMP; INC; LFND; LDG; MIS; NE; NP; NREL; 403; MIL; [206:3-6] AMB; ARG; AG; PRV; ATH; BER; BSD; CLC; SPC; CPD; HRS; IMP; INC; LFND; LDG; MIS; NE; NP; NREL; 403; MIL; [206:8-15] AMB; ARG; AG; PRV; ATH; BER; BSD; CLC; SPC; CPD; HRS; IMP; INC; LFND; LDG; MIS;

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					NE; NP; NREL; 403; MIL; [206:3-15] AMB; ARG; AG; PRV; ATH; BER; BSD; CLC; SPC; CPD; HRS; IMP; INC; LFND; LDG; MIS; NE; NP; NREL; 403; MIL; [207:20-21] AMB; ARG; AG; PRV; ATH; BER; BSD; CLC; SPC; CPD; HRS; IMP; INC; LFND; LDG; MIS; NE; NP; NREL; 403; MIL; [208:1-4] AMB; ARG; AG; PRV; ATH; BER; BSD; CLC; SPC; CPD; HRS; IMP; INC; LFND; LDG; MIS; NE; NP; NREL; 403; MIL; [209:3-5] AMB; ARG; AG; PRV;

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
					ATH; BER; BSD; CLC; SPC; CPD; HRS; IMP; INC; LFND; LDG; MIS; NE; NP; NREL; 403; MIL;
77:12-79:8	[77:12-79:8] AMB; LFND; NREL; OS; 403	193:3-194:3; 200:8-17	402, 403	204:18-21, 205:1, 206:3-6, 206:8-15, 206:3-15, 207:20-21, 208:1-4, 209:3-5	[204:18-21] AMB; ARG; AG; PRV; ATH; BER; BSD; CLC; SPC; CPD; HRS; IMP; INC; LFND; LDG; MIS; NE; NP; NREL; 403; MIL; [205:1] AMB; ARG; AG; PRV; ATH; BER; BSD; CLC; SPC; CPD; HRS; IMP; INC; LFND; LDG; MIS; NE; NP; NREL; 403; MIL; [206:3-6] AMB; ARG; AG; PRV; ATH; BER; BSD; CLC; SPC; CPD; HRS; IMP; INC; LFND; LDG; MIS;

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					NE; NP; NREL; 403; MIL; [206:8-15] AMB; ARG; AG; PRV; ATH; BER; BSD; CLC; SPC; CPD; HRS; IMP; INC; LFND; LDG; MIS; NE; NP; NREL; 403; MIL; [206:3-15] AMB; ARG; AG; PRV; ATH; BER; BSD; CLC; SPC; CPD; HRS; IMP; INC; LFND; LDG; MIS; NE; NP; NREL; 403; MIL; [207:20-21] AMB; ARG; AG; PRV; ATH; BER; BSD; CLC; SPC; CPD; HRS; IMP; INC; LFND; LDG; MIS; NE; NP; NREL; 403; MIL; [208:1-4] AMB; ARG; AG; PRV;

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
					ATH; BER; BSD; CLC; SPC; CPD; HRS; IMP; INC; LFND; LDG; MIS; NE; NP; NREL; 403; MIL; [209:3-5] AMB; ARG; AG; PRV; ATH; BER; BSD; CLC; SPC; CPD; HRS; IMP; INC; LFND; LDG; MIS; NE; NP; NREL; 403; MIL;
79:14-79:18	[79:14-18] AMB; LFND; NREL; OS; 403	193:3-194:3; 200:8-17	402, 403	204:18-21, 205:1, 206:3-6, 206:8-15, 206:3-15, 207:20-21, 208:1-4, 209:3-5	[204:18-21] AMB; ARG; AG; PRV; ATH; BER; BSD; CLC; SPC; CPD; HRS; IMP; INC; LFND; LDG; MIS; NE; NP; NREL; 403; MIL; [205:1] AMB; ARG; AG; PRV; ATH; BER; BSD; CLC; SPC; CPD; HRS; IMP; INC; LFND; LDG; MIS;

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
					NE; NP; NREL; 403; MIL; [206:3-6] AMB; ARG; AG; PRV; ATH; BER; BSD; CLC; SPC; CPD; HRS; IMP; INC; LFND; LDG; MIS; NE; NP; NREL; 403; MIL; [206:8-15] AMB; ARG; AG; PRV; ATH; BER; BSD; CLC; SPC; CPD; HRS; IMP; INC; LFND; LDG; MIS; NE; NP; NREL; 403; MIL; [206:3-15] AMB; ARG; AG; PRV; ATH; BER; BSD; CLC; SPC; CPD; HRS; IMP; INC; LFND; LDG; MIS; NE; NP; NREL; 403; MIL; [207:20-21] AMB; ARG; AG; PRV;

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
					ATH; BER; BSD; CLC; SPC; CPD; HRS; IMP; INC; LFND; LDG; MIS; NE; NP; NREL; 403; MIL; [208:1-4] AMB; ARG; AG; PRV; ATH; BER; BSD; CLC; SPC; CPD; HRS; IMP; INC; LFND; LDG; MIS; NE; NP; NREL; 403; MIL; [209:3-5] AMB; ARG; AG; PRV; ATH; BER; BSD; CLC; SPC; CPD; HRS; IMP; INC; LFND; LDG; MIS; NE; NP; NREL; 403; MIL;
82:13-83:6	[82:13-83:6] AMB; LFND; NREL; OS; 403	193:3-194:3			
84:5-84:11	[84:5-11] AMB; LFND; NREL; OS; 403	193:3-194:3			

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
89:7-91:12	[89:7-91:12] AMB; LFND; NREL; OS; 403	193:3-194:3			
92:3-94:21	[92:3-94:21] AMB; LFND; NREL; OS; 403	193:3-194:3			
98:10-98:14		194:18-195:7			
99:10-99:13	[99:10-13] AMB; LFND; NREL; OS; 403				
99:17-100:8	[99:17-100:8] AMB; LFND; NREL; OS; 403				
113:22-114:12	[113:22-114:12] AMB; LFND; NREL; OS; 403				
117:3-118:1	[117:3-118:7] AMB; LFND; NREL; OS; 403				
118:2-118:7					
119:3-119:13	[119:3-13] AMB; LFND; NREL; OS; 403	121:16-122:17	I	122:18-20, 122:22-123:1, 123:8-12	[122:18-20] AMB; ARG; AG; BSD; SPC; CPD; LFND; LDG; MIS; NREL; 403; MIL; [122:22-123:1] AMB; ARG; AG; BSD; SPC; CPD;



Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					LFND; LDG; MIS; NREL; 403; MIL; [123:8-12] AMB; ARG; AG; BSD; SPC; CPD; LFND; LDG; MIS; NREL; 403; MIL;
142:17-142:20					
143:20-144:2	[143:20-144:2] AMB; LFND; NREL; OS; 403				
144:10-144:13	[144:10-13] AMB; LFND; MIS; NREL; OS; 403				
144:16-148:20	[144:16-148:20] AMB; LFND; MIS; NREL; OS; 403				
149:14-149:19	[149:14-19] AMB; AG; LFND; MIS; NREL; OS; 403	194:18-195:7			
149:22-150:6	[149:22-150:6] AMB; AG; LFND; MIS; NREL; OS; 403	150:8-15	402, 403, F, SP, I	150:16-150:22, 151:3, 151:14-17, 151:19-22	[150:16-22] AMB; ARG; AG; BSD; SPC; CPD; LFND; LDG; MIS; NREL; 403; MIL; [151:3] AMB; ARG; AG; BSD; SPC; CPD; LFND;

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					LDG; MIS; NREL; 403; MIL; [151:14-17] AMB; ARG; AG; BSD; SPC; CPD; LFND; LDG; MIS; NREL; 403; MIL; [151:19-22] AMB; ARG; AG; BSD; SPC; CPD; LFND; LDG; MIS; NREL; 403; MIL;
152:17-153:8	[152:17-153:8] AMB; AA; AG; HYP; LFND; MIS; NREL; OS; 403	150:8-15	402, 403, F, SP, I	150:16-150:22, 151:3, 151:14-17, 151:19-22	[150:16-22] AMB; ARG; AG; BSD; SPC; CPD; LFND; LDG; MIS; NREL; 403; MIL; [151:3] AMB; ARG; AG; BSD; SPC; CPD; LFND; LDG; MIS; NREL; 403; MIL; [151:14-17] AMB; ARG; AG; BSD; SPC; CPD; LFND; LDG; MIS; NREL; 403; MIL;

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
					[151:19-22] AMB; ARG; AG; BSD; SPC; CPD; LFND; LDG; MIS; NREL; 403; MIL;
163:12-164:2		164:6-15			
170:16-171:5	[170:16-171:5] AMB; LFND; MIS; NREL; 403				
176:14-176:18					
176:19-177:5					
177:21-178:5					
189:8-189:15	[189:8-15] AMB; LFND; NREL; 403				
191:1-191:11					

Richard Howarth – October 20, 2023					
Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
12:10-12:13		121:8-125:15	402, LE, OS		
28:13-28:22	[28:13-22] AMB; LFND; NREL; 403	23:5-20; 29:1-21; 121:8-125:15	[23:5-20; 29:1-21] AS; [121:8-125:15] 402, LE, OS		
35:21-36:12	[35:21-36:12] AMB; AA; LFND; NREL; 403; CLC	38:20-39:14; 121:8- 125:15	[38:20-39:14] AS; [121:8-125:15] 402, LE, OS		
46:8-46:19	[46:8-19] AMB; AA; CLC; LFND; NREL; 403	46:20-47:6; 121:8- 125:15	[46:20-47:6] AS, [121:8-125:15] 402, LE, OS		
47:7-47:14	[47:7-14] AMB; AA; CLC; LFND; NREL; 403	121:8-125:15	402, LE, OS		
66:1-66:7	[66:1-7] AMB; LFND; NREL; 403	18:1-11; 121:8- 125:15	[18:1-11] AS, [121:8-125:15] 402, LE, OS		
66:20-67:11	[66:20-67:11] AMB; LFND; NREL; 403	121:8-125:15	402, LE, OS		
67:15-67:20	[67:15-20] AMB; LFND; NREL; 403	121:8-125:15	402, LE, OS		
71:1-71:17	[71:1-17] AMB; LFND; NREL; 403	73:6-74:7; 121:8- 125:15	[73:6-74:7] AS, [121:8-125:15] 402, LE, OS	74:8-11; 74:14-75:1	[74:8-11] AMB; AA; AG; SPC; LFND; MIS; NREL; 403

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
					[74:14-75:1] AMB; AA; AG; SPC; LFND; MIS; NREL; 403
77:8-77:14	[77:8-14] AMB; LFND; NREL; 403	77:20-79:6; 80:7-17; 121:8-125:15	[77:20-79:6] AS, V; [80:7-17] AS; [121:8-125:15] 402, LE, OS	77:15-19	[74:15-19] AMB; AA; AG; SPC; LFND; MIS; NREL; 403
80:18-81:12	[80:18-81:12] AMB; LFND; NREL; 403	121:8-125:15	402, LE, OS		
82:8-82:18	[82:8-18] AMB; AG; LFND; NREL; 403	121:8-125:15	402, LE, OS		
83:16-84:4	[83:16-84:4] AMB; CLC; LFND; NREL; 403	121:8-125:15	402, LE, OS		
84:17-85:6	[84:17-85:6] AMB; AG; LFND; NREL; 403	121:8-125:15	402, LE, OS		
85:21-86:3	[89:9-19] AMB; SPC; LFND; NREL; 403	88:11-19; 121:8-125:15	[88:11-19] AS; [121:8-125:15] 402, LE, OS		
89:9-89:19		90:13-91:6; 121:8-125:15	[90:13-91:6] AS; [121:8-125:15] 402, LE, OS		
92:7-92:12	[92:7-12] AMB; LFND; NREL; 403	121:8-125:15	402, LE, OS		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
97:4-97:19	[97:4-19] AMB; AA; LFND; NREL; 403	121:8-125:15	402, LE, OS		
98:10-98:19	[98:10-19] AMB; LFND; NREL; 403	121:8-125:15	402, LE, OS		
101:14-101:19		102:12-19; 121:8- 125:15	[121:8-125:15] 402, LE, OS		
104:19-105:6	[104:19-105:6] AMB; LFND; NREL; 403	121:8-125:15	402, LE, OS		
111:19-112:5	[111:19-112:5] AMB; LFND; NREL; 403	121:8-125:15	402, LE, OS		
115:2-115:14	[115:2-14] AMB; LFND; NREL; 403	121:8-125:15	402, LE, OS		

Eric Jue – October 25, 2023					
Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
8:6-8:8		32:9-33:17	OS, 402, 403	36:4-12	NREL; SPC; BSD
9:4-9:12		32:9-33:17	OS, 402, 403	36:4-12	NREL; SPC; BSD
28:18-29:6		29:7-18; 32:9-33:17; 43:19-46:16; 114:7-115:16  50:7-10; 50:13-21; 51:3-22	OS, 402, 403, F, SP, V, I	36:4-12, 47:17-20, 47:22-48:1, 48:3-5, 48:7-17, 48:20-49:4, 49:7-20, 50:1-5	403; NREL; SPC; BSD; AMB; AA; INC; LFND; HRS
53:9-53:20	[53:9-20] HRS; NREL; 403	43:19-46:16	402, 403, F, SP	47:17-20, 47:22-48:1, 48:3-5, 48:7-17, 48:20-49:4, 49:7-20, 50:1-5	403; NREL; SPC; BSD; AMB; AA; LFND; HRS;
54:15-55:21	[54:15-55:21] AMB; HRS; NREL; 403	43:19-46:16	402, 403, F, SP	47:17-20, 47:22-48:1, 48:3-5, 48:7-17, 48:20-49:4, 49:7-20, 50:1-5, 56:9-10	403; NREL; SPC; BSD; AMB; AA; LFND; HRS; INC
56:12-56:14	[56:12-14] AMB; SPC; LFND; NREL; 403	43:19-46:16	402, 403, F, SP	47:17-20, 47:22-48:1, 48:3-5, 48:7-17, 48:20-49:4, 49:7-20, 50:1-5	403; NREL; SPC; BSD; AMB; AA; LFND; HRS
56:16-56:18		43:19-46:16	402, 403, F, SP	47:17-20, 47:22-48:1, 48:3-5, 48:7-17, 48:20-49:4, 49:7-20, 50:1-5	403; NREL; SPC; BSD; AMB; AA; LFND; HRS

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
87:20-88:20	[87:20-88:20] AMB; BSD; SPC; LFND; NREL; 403	90:11-91:3; 94:3-95:14	402, 403, F, SP, LW, EX	36:4-12, 47:17-20, 47:22-48:1, 48:3-5, 48:7-17, 48:20- 49:4, 49:7-20, 50:1- 5, 93:21-94:2, 96:13-98:11, 100:5- 7, 100:9-15, 100:17- 19, 103:8-15	403; NREL; SPC; BSD; AMB; AA; LFND; HRS; IMP; INC; IEXP
89:1-90:8	[89:1-90:8] AMB; BSD; SPC; LFND; NREL; 403	90:11-91:3	402, 403, F, SP	36:4-12, 47:17-20, 47:22-48:1, 48:3-5, 48:7-17, 48:20- 49:4, 49:7-20, 50:1- 5	403; NREL; SPC; BSD; AMB; AA; LFND; HRS
103:16-104:1	[103:16-104:1] AMB; SPC; LFND; NREL; 403	43:19-46:16; 94:3- 95:14; 104:2-19; 279:3-280:7  280:9-281:8; 281:11-15; 281:18- 22	402, 403, F, SP, LW, EX, V, L	36:4-12, 47:17-20, 47:22-48:1, 48:3-5, 48:7-17, 48:20- 49:4, 49:7-20, 50:1- 5, 93:21-94:2, 96:13-98:11, 100:5- 7, 100:9-15, 100:17- 19, 103:8-15, 317:12-318:5, 318:7-11, 318:14-21	403; NREL; SPC; BSD; AMB; AA; LFND; HRS; IMP; INC; IEXP
105:5-105:10	[105:5-10] AMB; BSD; SPC; LFND; NREL; 403	43:19-46:16; 94:3- 95:14; 106:10-13; 279:3-280:7	402, 403, F, SP, LW, EX, V, L	36:4-12, 47:17-20, 47:22-48:1, 48:3-5, 48:7-17, 48:20- 49:4, 49:7-20, 50:1- 5, 93:21-94:2,	403; NREL; SPC; BSD; AMB; AA; LFND; HRS; IMP; INC; IEXP



<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
				96:13-98:11, 100:5-7, 100:9-15, 100:17-19, 103:8-15, 317:12-318:5, 318:7-11, 318:14-21	
105:11-106:8	[105:11-106:8] AMB; BSD; SPC; LFND; NREL; 403	43:19-46:16; 106:10-13; 279:3-280:7	402, 403, F, SP, LW, EX, V, L	36:4-12, 47:17-20, 47:22-48:1, 48:3-5, 48:7-17, 48:20-49:4, 49:7-20, 50:1-5, 93:21-94:2, 96:13-98:11, 100:5-7, 100:9-15, 100:17-19, 103:8-15, 317:12-318:5, 318:7-11, 318:14-21	403; NREL; SPC; BSD; AMB; AA; LFND; HRS; IMP; INC; IEXP
113:20-114:6	[113:20-114:6] 403; LFND; OS	43:19-46:16; 106:10-13; 114:7-115:16	402, 403, F, SP, V, I	36:4-12, 47:17-20, 47:22-48:1, 48:3-5, 48:7-17, 48:20-49:4, 49:7-20, 50:1-5	403; NREL; SPC; BSD; AMB; AA; LFND; HRS

Eugene Kim – July 29, 2022					
Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
8:19-8:21					
13:16-14:1		14:7-14			
14:21-15:8		14:7-14; 15:9-10; 15:19-21			
16:7-16:13	[16:7-13] AMB; MIS; 403; LDG	14:7-14; 18:4-21:3	402, 403, SP, F, OS		
60:20-61:1	[60:20-61:1] BER; HRS; NREL; 403; INC; LFND	14:7-14; 18:4-21:3; 64:14-15; 64:17-21	402, 403, SP, F, OS		
62:7-62:9	[60:20-61:1] BER; HRS; NREL; 403; INC; LFND  [62:7-9] SPC; LDG; NREL	14:7-14; 18:4-21:3; 62:13-18; 64:14-15; 64:17-21	402, 403, SP, F, OS		
62:19-63:5	[60:20-61:1] BER; HRS; NREL; 403; INC; LFND  [62:19-63:5] AMB; SPC; HRS; LDG; NREL; 403	14:7-14; 18:4-21:3; 62:13-18; 64:14-15; 64:17-21	402, 403, SP, F, OS		
64:3-64:13	[60:20-61:1] BER; HRS; NREL; 403; INC; LFND	14:7-14; 18:4-21:3; 64:14-15; 64:17-21	402, 403, SP, F, OS		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
	[64:3-13] AMB; LDG; NREL; 403				
69:17-69:19	[69:17-19] AMB; BER; HRS; LFND; NREL; 403	14:7-14; 18:4-21:3; 72:10-21; 73:21- 74:8	402, 403, SP, F, OS		
70:7-70:17	[69:17-19] AMB; BER; HRS; LFND; NREL; 403  [70:7-17] AMB; HRS; NREL; 403	14:7-14; 18:4-21:3; 72:10-21; 73:21- 74:8	402, 403, SP, F, OS		
71:4-71:7	[69:17-19] AMB; BER; HRS; LFND; NREL; 403  [71:4-7] AMB; HRS; NREL; 403	14:7-14; 18:4-21:3; 72:10-21; 73:21- 74:8	402, 403, SP, F, OS		
71:22-72:9	[69:17-19] AMB; BER; HRS; LFND; NREL; 403  [71:22-72:9] AMB; NREL; 403	14:7-14; 18:4-21:3; 72:10-21; 73:21- 74:8	402, 403, SP, F, OS		
72:22-73:5	[69:17-19] AMB; BER; HRS; LFND; NREL; 403  [72:22-73:5] AMB;	14:7-14; 18:4-21:3; 72:10-21; 73:21- 74:8	402, 403, SP, F, OS		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
	BER; HRS; IEXP; LFND; LDG; MIS; NREL; 403				

Eric Kinast – October 31, 2023					
Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
8:19-8:20					
9:21-9:25					
10:25-11:3		12:21-13:2; 14:13-18; 23:7-16; 49:19-22; 50:17-23; 52:12-21; 54:15-19; 55:1-20	F, H, M, SP, AF, LC, EX, 402, 403	11:9-12:2, 21:20-22:6, 22:20-23:6, 25:9-11, 52:9-11	[11:9-12:2] 403; NREL; AMB; LFND [21:20-22:6] 403; NREL; AMB; LFND; SPC [22:20-23:6] 403; NREL; AMB; LFND; SPC [25:9-11] 403; NREL; AMB; LFND; SPC [52:9-11] LDG; NREL; 403
12:7-12:20	[12:7-20] 403; LA; INC	12:21-13:2; 14:13-18; 23:7-16; 49:19-22; 50:17-23; 52:12-21; 54:15-19; 55:1-20	F, H, M, SP, AF, LC, EX, 402, 403	11:9-12:2, 21:20-22:6, 22:20-23:6, 25:9-11, 52:9-11	[11:9-12:2] 403; NREL; AMB; LFND [21:20-22:6] 403; NREL; AMB; LFND; SPC [22:20-23:6] 403; NREL; AMB; LFND; SPC [25:9-11] 403; NREL; AMB; LFND; SPC [52:9-11] LDG; NREL; 403

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
47:20-47:22		12:21-13:2; 14:13-18; 23:7-16; 49:19-22; 50:17-23; 52:12-21; 54:15-19; 55:1-20	F, H, M, SP, AF, LC, EX, 402, 403	11:9-12:2, 21:20-22:6, 22:20-23:6, 25:9-11, 52:9-11	[11:9-12:2] 403; NREL; AMB [21:20-22:6] AMB; LFND; SPC [22:20-23:6] 403; NREL; AMB; LFND; SPC [25:9-11] 403; NREL [52:9-11] NREL; 403
48:16-48:20	[48:16-20] 403; INC	12:21-13:2; 14:13-18; 23:7-16; 49:19-22; 50:17-23; 52:12-21; 54:15-19; 55:1-20	F, H, M, SP, AF, LC, EX, 402, 403	11:9-12:2, 21:20-22:6, 22:20-23:6, 25:9-11, 52:9-11	[11:9-12:2] 403; NREL; AMB [21:20-22:6] AMB; LFND; SPC [22:20-23:6] 403; NREL; AMB; LFND; SPC [25:9-11] 403; NREL [52:9-11] NREL; 403
48:25-49:8	[48:25-49:8] 403; INC	12:21-13:2; 14:13-18; 23:7-16; 49:19-22; 50:17-23; 52:12-21; 54:15-19; 55:1-20	F, H, M, SP, AF, LC, EX, 402, 403	11:9-12:2, 21:20-22:6, 22:20-23:6, 25:9-11, 52:9-11	[11:9-12:2] 403; NREL; AMB [21:20-22:6] AMB; LFND; SPC [22:20-23:6] 403; NREL; AMB; LFND; SPC [25:9-11] 403; NREL [52:9-11] NREL; 403

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
49:23-50:1		12:21-13:2; 14:13-18; 23:7-16; 49:19-22; 50:17-23; 52:12-21; 54:15-19; 55:1-20	F, H, M, SP, AF, LC, EX, 402, 403	11:9-12:2, 21:20-22:6, 22:20-23:6, 25:9-11, 52:9-11	[11:9-12:2] 403; NREL; AMB [21:20-22:6] AMB; LFND; SPC [22:20-23:6] 403; NREL; AMB; LFND; SPC [25:9-11] 403; NREL [52:9-11] NREL; 403
50:7-50:16	[50:7-16] 403; LFND; NREL; SPC; LA	12:21-13:2; 14:13-18; 23:7-16; 49:19-22; 50:17-23; 52:12-21; 54:15-19; 55:1-20	F, H, M, SP, AF, LC, EX, 402, 403	11:9-12:2, 21:20-22:6, 22:20-23:6, 25:9-11, 52:9-11	[11:9-12:2] 403; NREL; AMB [21:20-22:6] AMB; LFND; SPC [22:20-23:6] 403; NREL; AMB; LFND; SPC [25:9-11] 403; NREL [52:9-11] NREL; 403
52:2-52:8		12:21-13:2; 14:13-18; 23:7-16; 49:19-22; 50:17-23; 52:12-21; 54:15-19; 55:1-20	F, H, M, SP, AF, LC, EX, 402, 403	11:9-12:2, 21:20-22:6, 22:20-23:6, 25:9-11, 52:9-11	[11:9-12:2] 403; NREL; AMB [21:20-22:6] AMB; LFND; SPC [22:20-23:6] 403; NREL; AMB; LFND; SPC [25:9-11] 403; NREL [52:9-11] NREL; 403

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
53:20-54:5	[53:20-54:5] 403; LA; INC	12:21-13:2; 14:13-18; 23:7-16; 49:19-22; 50:17-23; 52:12-21; 54:15-19; 55:1-20	F, H, M, SP, AF, LC, EX, 402, 403	11:9-12:2, 21:20-22:6, 22:20-23:6, 25:9-11, 52:9-11	[11:9-12:2] 403; NREL; AMB [21:20-22:6] AMB; LFND; SPC [22:20-23:6] 403; NREL; AMB; LFND; SPC [25:9-11] 403; NREL [52:9-11] NREL; 403
54:23-54:25	[54:23-25] 403; LA; INC	12:21-13:2; 14:13-18; 23:7-16; 49:19-22; 50:17-23; 52:12-21; 54:15-19; 55:1-20	F, H, M, SP, AF, LC, EX, 402, 403	11:9-12:2, 21:20-22:6, 22:20-23:6, 25:9-11, 52:9-11	[11:9-12:2] 403; NREL; AMB [21:20-22:6] AMB; LFND; SPC [22:20-23:6] 403; NREL; AMB; LFND; SPC [25:9-11] 403; NREL [52:9-11] NREL; 403
56:20-57:1	[56:20-57:1] 403; LA; INC	12:21-13:2; 14:13-18; 23:7-16; 49:19-22; 50:17-23; 52:12-21; 54:15-19; 55:1-20	F, H, M, SP, AF, LC, EX, 402, 403	11:9-12:2, 21:20-22:6, 22:20-23:6, 25:9-11, 52:9-11	[11:9-12:2] 403; NREL; AMB [21:20-22:6] AMB; LFND; SPC [22:20-23:6] 403; NREL; AMB; LFND; SPC [25:9-11] 403; NREL [52:9-11] NREL; 403





Erno Klaassen – October 11, 2023					
Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
7:19-7:21		9:14-20; 52:2-11			
9:4-9:10	[9:4-10] AMB; NREL	9:14-20; 52:2-11			
10:7-10:20	[10:7-20] AMB; AG; LA; NREL; 403	9:14-20; 11:17- 12:5; 52:2-11			
11:7-11:15	[11:7-15] AMB; AG; CPD; LA; MIS; NREL; 403	9:14-20; 11:17- 12:5; 52:2-11			
12:6-12:10	[12:6-10] AMB; AG; MIS; NREL; 403	9:14-20; 11:17- 12:5; 52:2-11			
31:2-31:3	[31:2-3] AMB; ATH; IDSCR; LFND; LA; NREL; 403	9:14-20; 11:17- 12:5; 52:2-11			
40:4-40:11	[40:4-11] AMB; AG; BSD; SPC; IEXP; HYP; NREL; 403; ATH; LFND	9:14-20; 11:17- 12:5; 52:2-11			
41:9-41:17	[41:9-17] AMB; AG; ATH; BSD; SPC; IEXP; HYP; LFND; NREL; 403	9:14-20; 11:17- 12:5; 52:2-11			
50:3-50:10	[50:3-10] AMB; ARG; AG; ATH;	9:14-20; 11:17- 12:5; 52:2-11			

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
	BSD; SPC; IEXP; HYP; LFND; NREL; 403				
51:18-52:1	[51:18-52:1] AMB; ARG; AG; ATH; BSD; SPC; IEXP; HYP; LFND; NREL; 403	52:2-11			

Marcelo Lamego – July 12, 2022					
Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
9:7-9:9					
69:13-69:19	[69:13-19] AMB; LA; MIS; NREL; 403	22:18-23:1; 23:16- 24:3; 24:7-12; 49:9- 19; 49:23-50:10; 50:17-51:21; 52:4- 17; 54:19-21; 55:2- 3; 55:5-5; 56:7-12; 56:14-19; 63:4-7; 69:20-70:1; 72:2- 17; 82:4-13; 86:21- 22; 87:11-18; 90:24-91:10; 91:13- 14; 91:16-18; 98:10-12; 98:14-14; 98:23-99:5; 99:12- 100:10; 100:12-15; 100:18-19; 100:21- 22; 101:2-102:10; 102:13-13; 102:15- 17; 102:19-19; 106:23-107:6; 107:15-20; 107:23- 25; 108:1-13	402, 403, OS, LE, V, F, H, SP, I, LC	107:7-14, 107:21- 22, 393:3-16, 394:17-395:1, 417:17-436:7	AMB; AG; HRS; LFND; INC; SPC; NREL, ATH; NR; 403; MIL
71:20-71:25	[71:20-25] AMB; LA; MIS; NREL; 403	22:18-23:1; 23:16- 24:3; 24:7-12; 49:9- 19; 49:23-50:10;	402, 403, OS, LE, V, F, H, SP, I, LC	107:7-14, 107:21- 22, 393:3-16,	AMB; AG; HRS; LFND; INC; SPC;

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		50:17-51:21; 52:4-17; 54:19-21; 55:2-3; 55:5-5; 56:7-12; 56:14-19; 63:4-7; 69:20-70:1; 72:2-17; 82:4-13; 86:21-22; 87:11-18; 90:24-91:10; 91:13-14; 91:16-18; 98:10-12; 98:14-14; 98:23-99:5; 99:12-100:10; 100:12-15; 100:18-19; 100:21-22; 101:2-102:10; 102:13-13; 102:15-17; 102:19-19; 106:23-107:6; 107:15-20; 107:23-25; 108:1-13		394:17-395:1, 417:17-436:7	NREL, ATH; NR; 403; MIL
80:19-82:3	[80:19-82:3] AMB; AG; ATH; SPC; LFND; LA; MIS; NREL; 403	23:16-24:3; 24:7-12; 49:9-19; 49:23-50:10; 50:17-51:21; 52:4-17; 54:19-21; 55:2-3; 55:5-5; 56:7-12; 56:14-19; 63:4-7; 69:20-70:1; 72:2-17; 82:4-13;	402, 403, OS, LE, V, F, H, SP, I, LC	107:7-14, 107:21-22, 393:3-16, 394:17-395:1, 417:17-436:7	AMB; AG; HRS; LFND; INC; SPC; NREL, ATH; NR; 403; MIL

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		86:21-22; 87:11-18; 90:24-91:10; 91:13-14; 91:16-18; 98:10-12; 98:14-14; 98:23-99:5; 99:12-100:10; 100:12-15; 100:18-19; 100:21-22; 101:2-102:10; 102:13-13; 102:15-17; 102:19-19; 106:23-107:6; 107:15-20; 107:23-25; 108:1-13			

**Marcelo Lamego – July 13, 2022**

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
218:22-219:13	[218:22-219:13] AMB; AG; ATH; BSD; HRS; IDSCR; INC; LA; MIS; NREL; 403; LFND	219:14-221:2; Marcelo Lamego July 12, 2022 Deposition Tr. (22:18-23:1; 23:16-24:3; 24:7-12; 49:9-19; 49:23-50:10;	402, 403, OS, LE, V, F, H, SP, I, LC	107:7-14, 107:21-22, 393:3-16, 394:17-395:1, 417:17-436:7	AMB; AG; HRS; LFND; INC; SPC; NREL, ATH; NR; 403; MIL

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		50:17-51:21; 52:4-17; 54:19-21; 55:2-3; 55:5-5; 56:7-12; 56:14-19; 63:4-7; 69:20-70:1; 72:2-17; 82:4-13; 86:21-22; 87:11-18; 90:24-91:10; 91:13-14; 91:16-18; 98:10-12; 98:14-14; 98:23-99:5; 99:12-100:10; 100:12-15; 100:18-19; 100:21-22; 101:2-102:10; 102:13-13; 102:15-17; 102:19-19; 106:23-107:6; 107:15-20; 107:23-25; 108:1-13)			
224:13-224:20	[224:13-20] AMB; AG; ATH; BSD; IDSCR; INC; LFND; LA; MIS; NREL; 403	Marcelo Lamego July 12, 2022 Deposition Tr. (22:18-23:1; 23:16-24:3; 24:7-12; 49:9-19; 49:23-50:10; 50:17-51:21; 52:4-17; 54:19-21; 55:2-3; 55:5-5; 56:7-12;	402, 403, OS, LE, V, F, H, SP, I, LC	107:7-14, 107:21-22, 393:3-16, 394:17-395:1, 417:17-436:7	AMB; AG; HRS; LFND; INC; SPC; NREL, ATH; NR; 403; MIL

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		56:14-19; 63:4-7; 69:20-70:1; 72:2- 17; 82:4-13; 86:21- 22; 87:11-18; 90:24-91:10; 91:13- 14; 91:16-18; 98:10-12; 98:14-14; 98:23-99:5; 99:12- 100:10; 100:12-15; 100:18-19; 100:21- 22; 101:2-102:10; 102:13-13; 102:15- 17; 102:19-19; 106:23-107:6; 107:15-20; 107:23- 25; 108:1-13)			



Brian Land – April 18, 2023 (California Trial)					
Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
61:23-62:1					
68:17-68:21	LA; LDG; NREL; 403				
103:6-103:13	AMB; SPC; MIS; NREL; OBJ; 403	Brian Land Oct. 19, 2023 deposition transcript (45:21-46:10; 48:5-49:1; 49:5-50:1; 51:3-52:6; 58:8-20; 94:4-14)	402, 403, OS, Improper designation	See counter-counters in Brian Land Oct. 19, 2023 deposition below	[39:11-21] NREL; 403; OBJ; IMP; BSD [50:7] NREL; 403; OBJ; IMP; BSD [50:21-51:2] NREL; 403 [52:7-10] NREL; 403; AMB; SPC [52:17-18] NREL; 403; OBJ; IMP; BSD [53:2-4] NREL; 403; OBJ; IMP; BSD [60:14-15] NREL; 403; OBJ; IMP; BSD [75:18-20] NREL; 403; OBJ; IMP; BSD [96:20-22] AMB; NREL; 403 [97:5-8] AMB; NREL; 403

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>

<b>Brian Land – October 19, 2023</b>
--------------------------------------

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
6:16-6:18					
9:22-10:12	[9:22-10:12] SPC; NREL; 403; AMB; AG	94:4-14			
12:4-12:6	[12:4-6] NREL; 403; AMB; AG				
20:12-20:15	[20:12-15] AG; LFND; NREL; AMB; 403	45:21-46:10; 48:5- 49:1; 51:3-52:6; 58:8-20; 94:4-14			
39:22-40:1	[39:22-40:1] AG; HRS; LFND; NREL; SPC; 403; AMB	45:21-46:10; 48:5- 49:1; 51:3-52:6; 58:8-20; 94:4-14		39:11-21	[39:11-21] NREL; 403; OBJ; IMP; BSD
43:15-44:4	[43:15-44:4] AG; LFND; SPC; NREL; 403; AMB	45:21-46:10; 48:5- 49:1; 51:3-52:6; 58:8-20; 94:4-14			
44:19-45:1	[44:19-45:1] NREL; SPC; 403; AMB	45:21-46:10; 48:5- 49:1; 51:3-52:6; 58:8-20; 94:4-14			

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
46:11-46:18	[46:11-18] AG; HRS; NREL; SPC; 403	45:21-46:10; 48:5-49:1; 51:3-52:6; 58:8-20; 94:4-14		39:11-21	[39:11-21] NREL; 403; OBJ; IMP; BSD
47:2-48:3	[47:2-48:3] AMB; HRS; NREL; 403; INC; AG	45:21-46:10; 48:5-49:1; 51:3-52:6; 58:8-20; 94:4-14			
49:2-49:4	[49:2-4] AMB; NREL; 403; AG; INC	45:21-46:10; 48:5-49:1; 49:5-50:1; 51:3-52:6; 58:8-20; 94:4-14			
50:2-50:4	[50:2-4] NREL; INC; 403	45:21-46:10; 48:5-49:1; 51:3-52:6; 58:8-20; 94:4-14			
50:5-50:6	[50:5-6] NREL; 403; HRS; OBJ	45:21-46:10; 48:5-49:1; 51:3-52:6; 58:8-20; 94:4-14		50:7, 50:21-51:2, 52:7-10	[50:7] NREL; 403; OBJ; IMP; BSD [50:21-51:2] NREL; 403 [52:7-10] NREL; 403; AMB; SPC
50:11-50:13	[50:11-13] NREL; 403; HRS; SPC; LFND	45:21-46:10; 48:5-49:1; 51:3-52:6; 58:8-20; 94:4-14		50:7, 50:21-51:2, 52:7-10	[50:7] NREL; 403; OBJ; IMP; BSD [50:21-51:2] NREL; 403 [52:7-10] NREL; 403; AMB; SPC
53:17-53:19	[53:17-19] NREL; 403; HRS; LFND; MIS; AMB	45:21-46:10; 48:5-49:1; 51:3-52:6; 58:8-20; 94:4-14		52:17-18, 53:2-4	[52:17-18] NREL; 403; OBJ; IMP; BSD [53:2-4]

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
					NREL; 403; OBJ; IMP; BSD
54:5-54:18	[54:5-18] AG; LFND; NREL; SPC; 403; HRS; AMB	45:21-46:10; 48:5-49:1; 51:3-52:6; 58:8-20; 94:4-14		52:17-18, 53:2-4	[52:17-18] NREL; 403; OBJ; IMP; BSD [53:2-4] NREL; 403; OBJ; IMP; BSD
57:15-58:7	[57:15-58:7] AG; LFND; NREL; SPC; 403; HRS; AMB; INC	45:21-46:10; 48:5-49:1; 51:3-52:6; 58:8-20; 94:4-14			
58:22-58:22	[58:22-22] NREL; 403; HRS; OBJ; AMB	45:21-46:10; 48:5-49:1; 51:3-52:6; 58:8-20; 94:4-14			
59:5-59:12	[59:5-12] HRS; NREL; 403; AMB; AG; LFND	45:21-46:10; 48:5-49:1; 51:3-52:6; 58:8-20; 94:4-14			
59:13-59:20	[59:13-20] NREL; 403; HRS; AMB; SPC; LFND	45:21-46:10; 48:5-49:1; 51:3-52:6; 58:8-20; 94:4-14			
60:22-61:3	[60:22-61:3] NREL; 403; IDSCR; HRS; AG; LFND; LA	45:21-46:10; 48:5-49:1; 51:3-52:6; 58:8-20; 94:4-14		60:14-15	[60:14-15] NREL; 403; OBJ; IMP; BSD
61:12-61:18	[61:12-18] AMB; SPC; MIS; NREL; 403; HRS; AG; LFND	45:21-46:10; 48:5-49:1; 51:3-52:6; 58:8-20; 94:4-14		60:14-15	[60:14-15] NREL; 403; OBJ; IMP; BSD

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
69:21-70:4	[69:21-70:4] SPC; HRS; NREL; 403; AMB; LA	45:21-46:10; 48:5- 49:1; 51:3-52:6; 58:8-20; 94:4-14			
70:21-71:8	[70:21-71:8] SPC; HRS; NREL; 403; AG; AMB; LA	45:21-46:10; 48:5- 49:1; 51:3-52:6; 58:8-20; 94:4-14			
76:6-76:18	[76:6-18] HRS; LFND; NREL; 403; AMB; AG; SPC	45:21-46:10; 48:5- 49:1; 51:3-52:6; 58:8-20; 76:19- 77:7; 94:4-14		75:18-20	[75:18-20] NREL; 403; OBJ; IMP; BSD
77:8-78:11	[77:8-78:11] HRS; 403; LFND; NR; NREL; SPC; AMB	45:21-46:10; 48:5- 49:1; 51:3-52:6; 58:8-20; 78:12-19; 94:4-14		75:18-20	[75:18-20] NREL; 403; OBJ; IMP; BSD
91:20-92:4	[91:20-92:4] NREL; 403; AMB; LA	45:21-46:10; 48:5- 49:1; 51:3-52:6; 58:8-20; 94:4-14		96:20-22, 97:5-8	[96:20-22] AMB; NREL; 403 [97:5-8] AMB; NREL; 403
92:5-92:13	[92:5-13] LFND; NREL; SPC; 403; AMB; AA	45:21-46:10; 48:5- 49:1; 51:3-52:6; 58:8-20; 94:4-14; 94:4-14		96:20-22, 97:5-8	[96:20-22] AMB; NREL; 403 [97:5-8] AMB; NREL; 403
92:21-93:5	[92:21-93:5] 403; LFND; NREL; SPC; AMB; AA; AG	45:21-46:10; 48:5- 49:1; 51:3-52:6; 58:8-20; 94:4-14		96:20-22, 97:5-8	[96:20-22] AMB; NREL; 403 [97:5-8] AMB; NREL; 403
102:17-103:12	[102:17-103:12] AG; LFND; NREL; SPC; 403; AMB	45:21-46:10; 48:5- 49:1; 51:3-52:6; 58:8-20; 94:4-14		96:20-22, 97:5-8	[96:20-22] AMB; NREL; 403 [97:5-8] AMB; NREL; 403

**Paul Mannheimer – November 7, 2023**

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
8:3-8:5		12:4-6			
59:3-59:13	[59:3-13] NREL; 403	12:4-6; 58:18-18; 58:21-59:1			

**Bob Mansfield – August 11, 2022**

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
7:9-7:11					
9:16-10:2					
12:13-12:19					
21:10-21:19	[21:10-19] BER; NREL; 403	22:1-5; 22:13-18; 38:6-19; 49:16- 50:18	402, 403, LE, OS, AF		
22:6-22:12	[22:6-12] ATH; BER; HRS; INC; NREL; 403	22:1-5; 22:13-18; 38:6-19; 49:16- 50:18	402, 403, LE, OS, AF		
30:18-30:20	[30:18-20] BER; NREL; 403	31:16-32:8; 33:5-8; 34:3-9; 35:22-37:9; 38:6-19; 50:19- 51:12	402, 403, F, SP, LE, OS, AF		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
31:2-31:4	[31:2-4] BER; NREL; 403	31:16-32:8; 33:5-8; 34:3-9; 35:22-37:9; 38:6-19; 50:19-51:12	402, 403, F, SP, LE, OS, AF		
31:5-31:8	[31:5-8] BER; NREL; 403	31:16-32:8; 33:5-8; 34:3-9; 35:22-37:9; 38:6-19; 50:19-51:12	402, 403, F, SP, LE, OS, AF		
31:14-31:15	[31:14-15] ATH; BER; INC; NREL; 403	31:16-32:8; 33:5-8; 34:3-9; 35:22-37:9; 38:6-19; 50:19-51:12	402, 403, F, SP, LE, OS, AF		
32:13-33:4	[32:13-33:4] BER; HRS; NREL; 403	31:16-32:8; 33:5-8; 34:3-9; 35:22-37:9; 38:6-19; 50:19-51:12	402, 403, F, SP, LE, OS, AF		
33:9-34:2	[33:9-34:2] BER; SPC; HRS; NREL; 403	31:16-32:8; 33:5-8; 34:3-9; 35:22-37:9; 38:6-19; 50:19-51:12	402, 403, F, SP, LE, OS, AF		
35:11-35:21	[35:11-21] AMB; BER; HRS; LDG; NREL; 403	31:16-32:8; 33:5-8; 34:3-9; 35:22-37:9; 38:6-19; 50:19-51:12	402, 403, F, SP, LE, OS, AF		
40:9-40:12		38:6-19; 42:12-14; 42:16-16; 50:19-51:12	402, 403, LE, OS, AF		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
41:1-41:17		38:6-19; 42:12-14; 42:16-16; 50:19-51:12	402, 403, LE, OS, AF		

**Saahil Mehra – October 5, 2023**

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
7:12-7:14					
10:2-10:19	[10:2-19] AMB; OBJ; NREL	9:7-18; 9:20-22; 15:13-15; 33:16-17; 33:20-34:2; 34:20-21; 35:2-4; 50:11-21	402, 403, F, M, V	37:21-38:2, 38:4-10, 48:13-16	AMB; SPC; LFND; NREL; 403
11:2-11:5		9:7-18; 9:20-22; 15:13-15; 33:16-17; 33:20-34:2; 34:20-21; 35:2-4; 50:11-21	402, 403, F, M, V	37:21-38:2, 38:4-10, 48:13-16	AMB; SPC; LFND; NREL; 403
34:4-34:7	[34:4-7] AMB; NREL	33:16-17; 33:20-34:2; 34:20-21; 35:2-4; 41:13-42:7; 50:11-21	402, 403, F, M, V	37:21-38:2, 38:4-10, 45:22-46:2, 46:4-5, 48:13-16	AMB; SPC; LFND; NREL; 403
35:6-35:13	[35:6-13] AMB; CLC; NREL; OBJ; 403	15:13-15; 33:16-17; 33:20-34:2; 34:20-21; 35:2-4; 41:13-42:7; 50:11-21	402, 403, F, M, V	37:21-38:2, 38:4-10, 45:22-46:2, 46:4-5, 48:13-16	AMB; SPC; LFND; NREL; 403



<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
36:6-37:8	[36:6-37:8] AMB; CLC; NREL; 403; OBJ; AG	33:16-17; 33:20-34:2; 34:20-21; 35:2-4; 41:13-42:7; 45:15-18; 45:20-20; 50:11-21	402, 403, F, M, V	37:21-38:2, 38:4-10, 45:22-46:2, 46:4-5, 48:13-16	AMB; SPC; LFND; NREL; 403
38:12-39:1	[38:12-39:1] AMB; CLC; MIS; NREL; 403; AA; OBJ	33:16-17; 33:20-34:2; 34:20-21; 35:2-4; 39:3-14; 41:13-42:7; 45:15-18; 45:20-20; 50:11-21	402, 403, F, M, V	37:21-38:2, 38:4-10, 39:15-40:3, 40:5-6, 45:22-46:2, 46:4-5, 48:13-16	AMB; SPC; LFND; NREL; 403; LDG
40:18-41:11	[40:18-41:11] AMB; CLC; MIS; NREL; 403; AA; OBJ	15:13-15; 33:16-17; 33:20-34:2; 34:20-21; 35:2-4; 41:13-42:7; 43:14-44:10; 45:15-18; 45:20-20; 50:11-21	402, 403, F, M, V	37:21-38:2, 38:4-10, 45:22-46:2, 46:4-5, 48:13-16	AMB; SPC; LFND; NREL; 403
42:9-42:16	[42:9-16] AMB; CLC; NREL; 403; OBJ	15:13-15; 33:16-17; 33:20-34:2; 34:20-21; 35:2-4; 41:13-42:7; 42:18-20; 43:1-8; 50:11-21	402, 403, F, M, V	37:21-38:2, 38:4-10, 45:22-46:2, 46:4-5, 48:13-16	AMB; SPC; LFND; NREL; 403
44:11-44:18	[44:11-18] AMB; CLC; CPD; NREL; 403	33:16-17; 33:20-34:2; 34:20-21; 35:2-4; 41:13-42:7; 50:11-21	402, 403, F, M, V	37:21-38:2, 38:4-10, 45:22-46:2, 46:4-5, 48:13-16	AMB; SPC; LFND; NREL; 403

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
47:13-47:20	[47:13-20] AMB; BER; NREL; 403; LFND; AG; SPC; INC; LDG	33:16-17; 33:20- 34:2; 34:20-21; 35:2-4; 47:21-48:5; 50:11-21	402, 403, F, M, V	37:21-38:2, 38:4- 10, 47:7-12, 48:13- 16	AMB; SPC; LFND; NREL; 403; IDSCR; LDG; OBJ
48:6-48:11	[48:6-11] AMB; LFND; LDG; NR; NREL; 403; ATH; SPC	33:16-17; 33:20- 34:2; 34:20-21; 35:2-4; 47:21-48:5; 50:11-21	402, 403, F, M, V	37:21-38:2, 38:4- 10, 48:13-16	AMB; SPC; LFND; NREL; 403

Kathy Mester (Epson) – November 8, 2023					
Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
9:9-9:13					
10:2-10:8					
12:10-12:20	[12:10-20] LFND	80:12-81:15			
13:16-14:17	[13:16-14:17] LFND; NREL; 403	29:6-13; 29:17-18; 30:15-31:15; 42:12-14; 42:16-16; 48:21-49:1; 49:7-11; 49:13-19; 53:16-54:7; 57:13-58:16; 80:12-81:15			
15:11-15:14	[15:11-14] LFND; NREL; 403	29:6-13; 29:17-18; 30:15-31:15; 42:12-14; 42:16-16; 48:21-49:1; 49:7-11; 49:13-19; 53:16-54:7; 57:13-58:16; 80:12-81:15			
25:4-25:22	[25:4-22] BER; NREL; 403; LFND	26:8-8; 26:11-11; 27:11-13; 27:16-16; 30:15-31:15; 48:21-49:1; 80:12-81:15; 84:1-17	402; 403		
26:2-26:2	[26:2-2] BER; LFND; NREL; 403	26:8-8; 26:11-11; 27:11-13; 27:16-16; 30:15-31:15; 48:21-	402; 403		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		49:1; 80:12-81:15; 84:1-17			
26:13-26:13	[26:13-13] SPC; LFND; NREL; 403	26:8-8; 26:11-11; 27:11-13; 27:16-16; 30:15-31:15; 48:21- 49:1; 80:12-81:15; 84:1-17	402; 403		
26:16-26:19	[26:16-19] SPC; LFND; NREL; 403	26:8-8; 26:11-11; 27:11-13; 27:16-16; 30:15-31:15; 48:21- 49:1; 80:12-81:15; 84:1-17	402; 403		
26:22-27:6	[26:22-27:6] AMB; SPC; LFND; NREL; 403	26:8-8; 26:11-11; 27:11-13; 27:16-16; 30:15-31:15; 48:21- 49:1; 80:12-81:15; 84:1-17	402; 403		
27:9-27:9	[27:9-9] AMB; SPC; LFND; NREL; 403	26:8-8; 26:11-11; 27:11-13; 27:16-16; 30:15-31:15; 48:21- 49:1; 80:12-81:15; 84:1-17	402; 403		
29:3-29:5	[29:3-5] AMB; NREL; 403	29:6-13; 29:17-18; 30:15-31:15; 42:12- 14; 42:16-16; 48:21-49:1; 80:12- 81:15			

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
29:20-30:2	[29:20-30:2] AMB; LFND; NREL; 403	30:15-31:15; 42:12-14; 42:16-16; 48:21-49:1; 80:12-81:15			
30:5-30:9	[30:5-9] AMB; LFND; NREL; 403	29:6-13; 29:17-18; 30:15-31:15; 42:12-14; 42:16-16; 48:21-49:1; 80:12-81:15			
31:18-32:7	[31:18-32:7] LFND; NREL; OBJ; 403	33:7-8; 33:11-13; 33:16-22; 48:21-49:1; 80:12-81:15			
32:10-32:17	[32:10-17] AMB; LFND; LDG; NREL; 403	33:7-8; 33:11-13; 33:16-22; 48:21-49:1; 80:12-81:15			
32:20-32:21	[32:20-21] CLC; SPC; LFND; NREL; 403	33:7-8; 33:11-13; 33:16-22; 48:21-49:1; 80:12-81:15			
33:2-33:6	[33:2-6] CLC; SPC; LFND; NREL; 403	33:7-8; 33:11-13; 33:16-22; 48:21-49:1; 80:12-81:15			
35:3-35:5	[35:3-5] SPC; LFND; MIS; NREL; 403	33:7-8; 33:11-13; 33:16-22; 48:21-49:1; 80:12-81:15			
35:7-35:11	[35:7-11] AMB; SPC; LFND; LDG; MIS; NREL; 403	33:7-8; 33:11-13; 33:16-22; 48:21-49:1; 80:12-81:15			

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
35:14-36:19	[35:14-36:19] SPC; LFND; NREL; OBJ; 403	26:8-8; 26:11-11; 27:11-13; 27:16-16; 30:15-31:15; 33:7-8; 33:11-13; 33:16-22; 39:4-6; 42:12-14; 42:16-16; 48:21-49:1; 80:12-81:15; 84:1-17			
36:21-37:4	[36:21-37:4] AMB; LFND; NP; NREL; 403; SPC	39:4-6; 42:12-14; 42:16-16; 48:21-49:1; 80:12-81:15			
37:6-37:10	[37:6-10] AMB; SPC; LFND; NREL; 403	39:4-6; 42:12-14; 42:16-16; 48:21-49:1; 80:12-81:15			
37:13-37:17	[37:13-17] CLC; SPC; LFND; NREL; 403	39:4-6; 42:12-14; 42:16-16; 48:21-49:1; 80:12-81:15			
37:20-37:21	[37:20-21] CLC; SPC; LFND; NREL; 403	39:4-6; 42:12-14; 42:16-16; 48:21-49:1; 80:12-81:15			
38:2-38:2	[38:2-2] CLC; SPC; LFND; NREL; 403	39:4-6; 42:12-14; 42:16-16; 48:21-49:1; 80:12-81:15			
38:4-38:10	[38:4-10] CLC; SPC; LFND; NREL; 403	39:4-6; 42:12-14; 42:16-16; 48:21-49:1; 80:12-81:15			

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
42:17-43:7	[42:17-43:7] SPC; LFND; NREL; OBJ; 403	43:17-44:12; 48:21- 49:1; 49:7-11; 49:13-19; 53:16- 54:7; 57:13-58:16; 80:12-81:15			
43:10-43:16	[43:10-16] SPC; LFND; NREL; 403	43:17-44:12; 48:21- 49:1; 49:7-11; 49:13-19; 53:16- 54:7; 57:13-58:16; 80:12-81:15			
44:22-45:15	[44:22-45:15] BER; LFND; NREL; 403	48:21-49:1; 49:7- 11; 49:13-19; 53:16-54:7; 57:13- 58:16; 80:12-81:15			
46:14-46:15	[46:14-15] SPC; LFND; LDG; NREL; 403	29:6-13; 29:17-18; 30:15-31:15; 42:12- 14; 42:16-16; 48:21-49:1; 49:7- 11; 49:13-19; 53:16-54:7; 57:13- 58:16; 80:12-81:15			
46:17-46:17	[46:17-17] SPC; LFND; LDG; NREL; 403	29:6-13; 29:17-18; 30:15-31:15; 42:12- 14; 42:16-16; 48:21-49:1; 49:7- 11; 49:13-19; 53:16-54:7; 57:13- 58:16; 80:12-81:15			

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
46:21-47:2	[46:21-47:2] SPC; LFND; NREL; 403	29:6-13; 29:17-18; 30:15-31:15; 42:12-14; 42:16-16; 48:21-49:1; 49:7-11; 49:13-19; 53:16-54:7; 57:13-58:16; 80:12-81:15			
51:9-51:11	[51:9-11] AMB; LFND; NREL; 403; SPC	29:6-13; 29:17-18; 30:15-31:15; 42:12-14; 42:16-16; 48:21-49:1; 49:7-11; 49:13-19; 53:16-54:7; 57:13-58:16; 80:12-81:15			
51:13-51:14	[51:13-14] AMB; SPC; LFND; NREL; 403	29:6-13; 29:17-18; 30:15-31:15; 42:12-14; 42:16-16; 48:21-49:1; 49:7-11; 49:13-19; 53:16-54:7; 57:13-58:16; 80:12-81:15			
54:9-54:11	[54:9-11] CLC; SPC; LFND; NREL; 403	48:21-49:1; 49:7-11; 49:13-19; 53:16-54:7; 56:2-6; 56:9-9; 57:13-58:16; 80:12-81:15			



<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
54:13-55:7	[54:13-55:7] CLC; SPC; LFND; NREL; 403	48:21-49:1; 49:7-11; 49:13-19; 53:16-54:7; 56:2-6; 56:9-9; 57:13-58:16; 80:12-81:15			
55:14-56:1	[55:14-56:1] NREL; 403	48:21-49:1; 49:7-11; 49:13-19; 53:16-54:7; 56:2-6; 56:9-9; 57:13-58:16; 80:12-81:15			
58:21-59:3	[58:21-59:3] LFND; LDG; MIS; NREL; 403	48:21-49:1; 49:7-11; 49:13-19; 53:16-54:7; 57:13-58:16; 59:4-6; 59:12-16; 80:12-81:15			
59:7-59:11	[59:7-11] SPC; LFND; NREL; 403	48:21-49:1; 49:7-11; 49:13-19; 53:16-54:7; 57:13-58:16; 59:4-6; 59:12-16; 80:12-81:15			
60:6-60:13	[60:6-13] LFND; NREL; 403	48:21-49:1; 60:15-22; 62:18-21; 63:2-2; 80:12-81:15			
68:6-68:21	[68:6-21] SPC; LFND; NREL; 403	48:21-49:1; 75:6-17; 76:3-12; 80:12-81:15; 81:21-83:22	402; 403; V; M; SP		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
69:2-69:7	[69:2-7] AMB; CLC; SPC; LFND; NREL; 403	48:21-49:1; 75:6- 17; 76:3-12; 80:12- 81:15; 81:21-83:22	402; 403; V; M; SP		
69:9-69:9	[69:9-9] AMB; CLC; SPC; LFND; NREL; 403	48:21-49:1; 75:6- 17; 76:3-12; 80:12- 81:15; 81:21-83:22	402; 403; V; M; SP		
69:13-70:2	[69:13-70:2] LFND; NREL; 403	48:21-49:1; 75:6- 17; 76:3-12; 80:12- 81:15; 81:21-83:22	402; 403; V; M; SP		
70:9-73:3	[70:9-73:3] AMB; HRS; LFND; LDG; NREL; 403	48:21-49:1; 73:4-6; 75:6-17; 76:3-12; 80:12-81:15; 81:21- 83:22	402; 403; V; M; SP		
73:7-74:7	[73:7-74:7] AMB; SPC; HRS; LFND; LDG; NREL; 403; BER	48:21-49:1; 75:6- 17; 76:3-12; 80:12- 81:15; 81:21-83:22	402; 403; V; M; SP		
74:9-74:12	[74:9-12] AMB; BER; SPC; HRS; LFND; LDG; NREL; 403	48:21-49:1; 75:6- 17; 76:3-12; 80:12- 81:15; 81:21-83:22	402; 403; V; M; SP		
77:4-77:7	[77:4-7] AMB; SPC; LFND; NREL; 403	48:21-49:1; 75:6- 17; 76:3-12; 80:12- 81:15; 81:21-83:22	402; 403; V; M; SP		

Taido Nakajima – October 9, 2023					
Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
6:11-6:14		18:15-19:8; 19:11-20:14; 20:19-21; 20:19-21; 21:5-24:15	OS; 402		
10:4-10:6	[10:4-6] NREL; 403	17:21-18:9; 18:15-19:8; 19:11-20:14; 20:19-21; 20:19-21; 21:5-24:15; 79:13-80:2; 185:5-17	OS; 402	185:18-186:2; 186:4-14	[185:18-186:2] AMB; NREL; 403; CLC; SPC; IEXP [186:4-14] AMB; NREL; 403; CLC; SPC; IEXP
64:19-64:22	[64:19-22] AMB; CLC; NREL; 403	17:21-18:9; 18:15-19:8; 19:11-20:14; 20:19-21; 20:19-21; 21:5-24:15; 77:5-19; 79:13-80:2; 185:5-17	OS; 402; 403; AS	185:18-186:2; 186:4-14	[185:18-186:2] AMB; NREL; 403; CLC; SPC; IEXP [186:4-14] AMB; NREL; 403; CLC; SPC; IEXP
65:4-65:7	[65:4-7] AMB; CLC; NREL; 403	17:21-18:9; 18:15-19:8; 19:11-20:14; 20:19-21; 20:19-21; 21:5-24:15; 77:5-19; 79:13-80:2; 95:18-96:8; 185:5-17	OS; 402; 403; AS	185:18-186:2; 186:4-14	[185:18-186:2] AMB; NREL; 403; CLC; SPC; IEXP [186:4-14] AMB; NREL; 403; CLC; SPC; IEXP
65:9-65:13	[65:9-13] AMB; CLC; NREL; 403	17:21-18:9; 18:15-19:8; 19:11-20:14; 20:19-21; 20:19-21;	OS; 402; 403; AS	185:18-186:2; 186:4-14	[185:18-186:2] AMB; NREL; 403; CLC; SPC; IEXP

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		21:5-24:15; 77:5-19; 79:13-80:2; 95:18-96:8; 185:5-17			[186:4-14] AMB; NREL; 403; CLC; SPC; IEXP
80:3-80:8	[80:3-8] AMB; SPC; LFND; NREL; 403	18:15-19:8; 19:11-20:14; 20:19-21; 20:19-21; 21:5-24:15; 50:1-6; 79:13-80:2; 185:5-17	OS; 402; 403; AS	185:18-186:2; 186:4-14	[185:18-186:2] AMB; NREL; 403; CLC; SPC; IEXP [186:4-14] AMB; NREL; 403; CLC; SPC; IEXP
95:4-95:7		17:21-18:9; 18:15-19:8; 19:11-20:14; 20:19-21; 20:19-21; 21:5-24:15; 77:5-19; 79:13-80:2; 185:5-17	OS; 402; 403; AS	185:18-186:2; 186:4-14	[185:18-186:2] AMB; NREL; 403; CLC; SPC; IEXP [186:4-14] AMB; NREL; 403; CLC; SPC; IEXP
95:12-95:17	[95:12-17] AMB; NREL; 403	17:21-18:9; 18:15-19:8; 19:11-20:14; 20:19-21; 20:19-21; 21:5-24:15; 77:5-19; 79:13-80:2; 185:5-17	OS; 402; 403; AS	185:18-186:2; 186:4-14	[185:18-186:2] AMB; NREL; 403; CLC; SPC; IEXP [186:4-14] AMB; NREL; 403; CLC; SPC; IEXP
104:12-104:16	[104:12-16] AMB; SPC; NREL; 403	21:5-24:15; 155:14-17; 166:16-167:22; 168:4-13; 168:4-13; 173:12-174:7; 174:19-175:5; 175:6-14; 176:5-13;	OS; 402; 403	185:18-186:2; 186:4-14	[185:18-186:2] AMB; NREL; 403; CLC; SPC; IEXP [186:4-14] AMB; NREL; 403; CLC; SPC; IEXP

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		178:6-8; 179:5-15; 179:18-180:12; 181:4-182:10; 185:5-17			
105:2-105:11	[105:2-11] AMB; SPC; NREL; 403	21:5-24:15; 155:14-17; 166:16-167:22; 168:4-13; 168:4-13; 173:12-174:7; 174:19-175:5; 175:6-14; 176:5-13; 178:6-8; 179:5-15; 179:18-180:12; 181:4-182:10; 185:5-17	OS; 402; 403	185:18-186:2; 186:4-14	[185:18-186:2] AMB; NREL; 403; CLC; SPC; IEXP [186:4-14] AMB; NREL; 403; CLC; SPC; IEXP
164:10-164:13	[164:10-13] AMB; SPC; NREL; 403	21:5-24:15; 155:14-17; 166:16-167:22; 168:4-13; 168:4-13; 173:12-174:7; 174:19-175:5; 175:6-14; 176:5-13; 178:6-8; 179:5-15; 179:18-180:12; 181:4-182:10; 185:5-17	OS; 402; 403	185:18-186:2; 186:4-14	[185:18-186:2] AMB; NREL; 403; CLC; SPC; IEXP [186:4-14] AMB; NREL; 403; CLC; SPC; IEXP
165:5-165:12	[165:5-12] AMB; NREL; 403; LFND	21:5-24:15; 155:14-17; 166:16-167:22; 168:4-13; 168:4-13; 173:12-174:7;	OS; 402; 403		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		174:19-175:5; 175:6-14; 176:5-13; 178:6-8; 179:5-15; 179:18-180:12; 181:4-182:10; 185:5-17			
186:15-187:3	[186:15-187:3] AMB; SPC; NREL; 403	21:5-24:15; 155:14-17; 166:16-167:22; 168:4-13; 168:4-13; 173:12-174:7; 174:19-175:5; 175:6-14; 176:5-13; 178:6-8; 179:5-15; 179:18-180:12; 181:4-182:10; 185:5-17	OS; 402; 403	185:18-186:2; 186:4-14	[185:18-186:2] AMB; NREL; 403; CLC; SPC; IEXP [186:4-14] AMB; NREL; 403; CLC; SPC; IEXP

Michael O'Reilly – September 22, 2022					
Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
13:10-13:13					
285:13-286:16	[285:13-286:16] AMB; AG; LA; NREL; 403	16:10-17:1; 17:16-21; 287:16-17; 344:20-345:1; 345:4-17; 391:20-392:5; 393:14-394:7; 394:13-14; 394:18-395:17; 396:21-397:14; 397:22-398:9	402, 403, F, OS, I	345:19-22, 346:10-347:1, 347:21-348:2, 348:4-9, 348:12-15, 349:6-12	AMB; AG; LA; HYP; MIS; CLC; SPC; NREL; 403; MIL
285:13-287:13	[285:13-287:13] AMB; AG; LA; NREL; 403	16:10-17:1; 17:16-21; 287:16-17; 344:20-345:1; 345:4-17; 391:20-392:5; 393:14-394:7; 394:13-14; 394:18-395:17; 396:21-397:14; 397:22-398:9	402, 403, F, OS, I	345:19-22, 346:10-347:1, 347:21-348:2, 348:4-9, 348:12-15, 349:6-12	AMB; AG; LA; HYP; MIS; CLC; SPC; NREL; 403; MIL
307:8-307:10	[307:8-10] AMB; LA; NREL; 403	16:10-17:1; 17:16-21; 344:20-345:1; 345:4-17; 391:20-392:5; 393:14-394:7; 394:13-14; 394:18-395:17;	402, 403, F, OS, I	345:19-22, 346:10-347:1, 347:21-348:2, 348:4-9, 348:12-15, 349:6-12	AMB; AG; LA; HYP; MIS; CLC; SPC; NREL; 403; MIL

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		396:21-397:14; 397:22-398:9			
315:4-315:6	[315:4-6] AMB; ARG; AG; BSD; LA; NREL; 403	16:10-17:1; 17:16- 21; 344:20-345:1; 345:4-17; 394:13- 14; 394:18-395:17; 397:22-398:9	402, 403, F, OS, I	345:19-22, 346:10- 347:1, 347:21- 348:2, 348:4-9, 348:12-15, 349:6-12	AMB; AG; LA; HYP; MIS; CLC; SPC; NREL; 403; MIL
315:9-316:5	[315:9-316:5] AMB; AG; ATH; BSD; LA; NREL; 403	16:10-17:1; 17:16- 21; 343:7-19; 344:20-345:1; 345:4-17; 391:20- 392:5; 393:14- 394:7; 394:13-14; 394:18-395:17; 396:21-397:14; 397:22-398:9	402, 403, F, OS, I	345:19-22, 346:10- 347:1, 347:21- 348:2, 348:4-9, 348:12-15, 349:6-12	AMB; AG; LA; HYP; MIS; CLC; SPC; NREL; 403; MIL
316:9-317:4	[316:9-317:4] AMB; AG; ATH; BSD; HRS; LA; NREL; 403	16:10-17:1; 17:16- 21; 317:5-10; 317:17-318:8; 343:7-19; 344:20- 345:1; 345:4-17	402, 403, SP, I, F, OS	317:11-16, 321:20- 322:14, 322:16- 322:22, 345:19-22, 346:10-347:1, 347:21-348:2, 348:4-9, 348:12-15, 349:6-12	AMB; AG; LA; LFND; HYP; MIS; CLC; SPC; INC; NREL; 403; MIL
323:22-324:12	[323:22-324:12] AMB; AG; ATH; BSD; LA; NREL; 403	16:10-17:1; 17:16- 21; 344:20-345:1; 345:4-17	402, 403, F, OS, I	345:19-22, 346:10- 347:1, 347:21- 348:2, 348:4-9, 348:12-15, 349:6-12	AMB; AG; LA; HYP; MIS; CLC; SPC; NREL; 403; MIL



<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
324:16-324:20	[324:16-20] AMB; AG; ATH; BSD; HRS; LA; NREL; 403	16:10-17:1; 17:16-21; 324:21-325:8; 325:11-18; 344:20-345:1; 345:4-17; 393:14-394:7	402, 403, F, OS, I	325:19-326:6, 345:19-22, 346:10-347:1, 347:21-348:2, 348:4-9, 348:12-15, 349:6-12	AMB; AG; LA; HRS; HYP; MIS; CLC; SPC; NREL; 403; MIL
326:8-326:21	[326:8-21] AMB; AG; ATH; BSD; LA; NREL; 403	16:10-17:1; 17:16-21; 344:20-345:1; 345:4-17	402, 403, F, OS, I	345:19-22, 346:10-347:1, 347:21-348:2, 348:4-9, 348:12-15, 349:6-12	AMB; AG; LA; HYP; MIS; CLC; SPC; NREL; 403; MIL
327:3-327:6	[327:3-6] AG; ATH; BSD; LA; NREL; 403	16:10-17:1; 17:16-21; 327:11-16; 344:20-345:1; 345:4-17	402, 403, F, OS, I	345:19-22, 346:10-347:1, 347:21-348:2, 348:4-9, 348:12-15, 349:6-12	AMB; AG; LA; HYP; MIS; CLC; SPC; NREL; 403; MIL
327:17-328:10	[327:17-328:10] AMB; AG; ATH; BSD; LA; NREL; 403	16:10-17:1; 17:16-21; 344:20-345:1; 345:4-17; 393:14-394:7	402, 403, F, OS, I	345:19-22, 346:10-347:1, 347:21-348:2, 348:4-9, 348:12-15, 349:6-12	AMB; AG; LA; HYP; MIS; CLC; SPC; NREL; 403; MIL
328:12-329:8	[328:12-329:8] AMB; AG; ATH; BSD; LA; NREL; 403	16:10-17:1; 17:16-21; 343:7-19; 344:20-345:1; 345:4-17; 393:14-394:7	402, 403, F, OS, I	345:19-22, 346:10-347:1, 347:21-348:2, 348:4-9, 348:12-15, 349:6-12	AMB; AG; LA; HYP; MIS; CLC; SPC; NREL; 403; MIL
329:12-330:2	[329:12-330:2] AG; ATH; BSD; LA; NREL; 403	16:10-17:1; 17:16-21; 344:20-345:1; 345:4-17	402, 403, F, OS, I	345:19-22, 346:10-347:1, 347:21-348:2, 348:4-9, 348:12-15, 349:6-12	AMB; AG; LA; HYP; MIS; CLC; SPC; NREL; 403; MIL

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
331:12-331:18	[331:12-18] AMB; HRS; LA; NREL; 403	16:10-17:1; 17:16-21; 331:3-11; 344:20-345:1; 345:4-17; 391:20-392:5; 393:14-394:7; 394:13-14; 394:18-395:17; 396:21-397:14; 397:22-398:9	402, 403, I, OS, F	330:10-13, 330:19-331:2, 345:19-22, 346:10-347:1, 347:21-348:2, 348:4-9, 348:12-15, 349:6-12	AMB; AG; LA; LFND; ARG; HYP; MIS; CLC; SPC; NREL; 403; MIL
332:6-332:17	[332:6-17] AG; ATH; BSD; LFND; LA; NREL; 403	16:10-17:1; 17:16-21; 344:20-345:1; 345:4-17; 394:18-395:17	402, 403, F, OS, I	345:19-22, 346:10-347:1, 347:21-348:2, 348:4-9, 348:12-15, 349:6-12	AMB; AG; LA; HYP; MIS; CLC; SPC; NREL; 403; MIL
333:7-333:12	[333:7-12] AMB; AG; ATH; HRS; LFND; LA; NREL; 403	16:10-17:1; 17:16-21; 331:3-11; 333:13-13; 333:15-21; 335:20-336:11; 344:20-345:1; 345:4-17; 391:20-392:5; 393:14-394:7; 394:13-14; 394:18-395:17; 396:21-397:14; 397:22-398:9	402, 403, I, F, OS	332:21-333:6, 345:19-22, 346:10-347:1, 347:21-348:2, 348:4-9, 348:12-15, 349:6-12	AMB; AG; LA; HRS; INC; HYP; MIS; CLC; SPC; NREL; 403; MIL
334:1-334:9	[334:1-9] AMB; BSD; SPC; LFND; LA; NREL; 403	16:10-17:1; 17:16-21; 344:20-345:1; 345:4-17; 391:20-392:5; 393:14-	402, 403, F, OS, I	345:19-22, 346:10-347:1, 347:21-348:2, 348:4-9, 348:12-15, 349:6-12	AMB; AG; LA; HYP; MIS; CLC; SPC; NREL; 403; MIL

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		394:7; 394:13-14; 394:18-395:17; 396:21-397:14; 397:22-398:9			
334:10-334:17	[334:10-17] AG; ATH; BSD; LFND; LA; NREL; 403	16:10-17:1; 17:16- 21; 344:20-345:1; 345:4-17; 391:20- 392:5; 393:14- 394:7; 394:13-14; 394:18-395:17; 396:21-397:14; 397:22-398:9	402, 403, F, OS, I	345:19-22, 346:10- 347:1, 347:21- 348:2, 348:4-9, 348:12-15, 349:6-12	AMB; AG; LA; HYP; MIS; CLC; SPC; NREL; 403; MIL
334:21-335:6	[334:21-335:6] AMB; AG; ATH; BSD; HRS; LA; NREL; 403	16:10-17:1; 17:16- 21; 344:20-345:1; 345:4-17; 391:20- 392:5; 393:14- 394:7; 394:13-14; 394:18-395:17; 397:22-398:9	402, 403, F, OS, I	345:19-22, 346:10- 347:1, 347:21- 348:2, 348:4-9, 348:12-15, 349:6-12	AMB; AG; LA; HYP; MIS; CLC; SPC; NREL; 403; MIL
340:6-340:16	[340:6-16] AG; ATH; BSD; LA; NREL; 403	16:10-17:1; 17:16- 21; 344:20-345:1; 345:4-17; 391:20- 392:5; 393:14- 394:7; 394:13-14; 394:18-395:17; 396:21-397:14; 397:22-398:9	402, 403, F, OS, I	345:19-22, 346:10- 347:1, 347:21- 348:2, 348:4-9, 348:12-15, 349:6-12	AMB; AG; LA; HYP; MIS; CLC; SPC; NREL; 403; MIL

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
342:4-342:15	[342:4-15] AG; ATH; BSD; HRS; LA; NREL; 403	16:10-17:1; 17:16- 21; 342:21-343:5; 343:7-19; 344:20- 345:1; 345:4-17; 391:20-392:5; 393:14-394:7; 394:13-14; 394:18- 395:17; 396:21- 397:14; 397:22- 398:9	402, 403, F, SP, I, OS	343:20-344:2, 344:5-344:13, 344:16, 345:19-22, 346:10-347:1, 347:21-348:2, 348:4-9, 348:12-15, 349:6-12	AMB; ARG; AG; LA; HYP; MIS; CLC; SPC; INC; NREL; 403; MIL

Sameer Pandya – September 15, 2023					
Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
9:11-9:12					
13:21-14:12	[13:21-14:12] IEXP; NREL	14:20-16:14; 22:17-23:2; 25:14-20; 25:14-20; 67:2-12; 67:13-68:2; 68:3-22; 69:1-18; 69:19-21; 69:22-70:13	402; 403; F; SP; LC; EX; I	70:18-20; 71:1-7; 71:10-17; 71:20-72:5; 72:8-19	[70:18-20] NREL; 403; IEXP; CLC [71:1-7] NREL; 403; IEXP; CLC [71:10-17] NREL; 403; IEXP; CLC; MIS [71:20-72:5] NREL; 403; IEXP; CLC; MIS [72:8-19] NREL; 403; IEXP; CLC
14:15-14:18	[14:15-18] IEXP; NREL	14:20-16:14; 22:17-23:2; 25:14-20; 25:14-20; 67:2-12; 67:13-68:2; 68:3-22; 69:1-18; 69:19-21; 69:22-70:13	402; 403; F; SP; LC; EX; I	70:18-20; 71:1-7; 71:10-17; 71:20-72:5; 72:8-19	[70:18-20] NREL; 403; IEXP; CLC [71:1-7] NREL; 403; IEXP; CLC [71:10-17] NREL; 403; IEXP; CLC; MIS [71:20-72:5] NREL; 403; IEXP; CLC; MIS [72:8-19] NREL; 403; IEXP; CLC
25:21-26:3	[25:21-26:3] IEXP; NREL	22:17-23:2; 25:14-20; 25:14-20; 26:16-27:7; 26:16-	402; 403; F; SP; LC; EX; I	70:18-20; 71:1-7; 71:10-17; 71:20-72:5; 72:8-19	[70:18-20] NREL; 403; IEXP; CLC [71:1-7] NREL;

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
		27:7; 67:2-12; 67:13-68:2; 68:3- 22; 69:1-18; 69:19- 21; 69:22-70:13			403; IEXP; CLC [71:10-17] NREL; 403; IEXP; CLC; MIS [71:20-72:5] NREL; 403; IEXP; CLC; MIS [72:8- 19] NREL; 403; IEXP; CLC
26:13-26:15	[26:13-15] IEXP; NREL	22:17-23:2; 25:14- 20; 25:14-20; 26:16-27:7; 26:16- 27:7; 67:2-12; 67:13-68:2; 68:3- 22; 69:1-18; 69:19- 21; 69:22-70:13	402; 403; F; SP; LC; EX; I	70:18-20; 71:1-7; 71:10-17; 71:20- 72:5; 72:8-19	[70:18-20] NREL; 403; IEXP; CLC [71:1-7] NREL; 403; IEXP; CLC [71:10-17] NREL; 403; IEXP; CLC; MIS [71:20-72:5] NREL; 403; IEXP; CLC; MIS [72:8- 19] NREL; 403; IEXP; CLC
27:13-27:17	[27:13-17] IEXP; NREL	22:17-23:2; 25:14- 20; 25:14-20; 26:16-27:7; 26:16- 27:7; 67:2-12; 67:13-68:2; 68:3- 22; 69:1-18; 69:19- 21; 69:22-70:13			
28:7-28:12	[28:7-12] IEXP; NREL	22:17-23:2; 25:14- 20; 25:14-20;			

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		26:16-27:7; 26:16-27:7; 67:2-12; 67:13-68:2; 68:3-22; 69:1-18; 69:19-21; 69:22-70:13			
37:3-38:3	[37:3-38:3] SPC; HRS; NREL	67:2-12; 67:13-68:2; 68:3-22; 69:1-18; 69:19-21; 69:22-70:13			
38:12-38:17	[38:12-17] SPC; NREL	67:2-12; 67:13-68:2; 68:3-22; 69:1-18; 69:19-21; 69:22-70:13			
39:13-40:1	[39:13-40:1] SPC; NREL	67:2-12; 67:13-68:2; 68:3-22; 69:1-18; 69:19-21; 69:22-70:13			
46:20-46:21		67:2-12; 67:13-68:2; 68:3-22; 69:1-18; 69:19-21; 69:22-70:13			
47:3-47:4		67:2-12; 67:13-68:2; 68:3-22; 69:1-18; 69:19-21; 69:22-70:13			
47:6-47:10		67:2-12; 67:13-68:2; 68:3-22; 69:1-			

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		18; 69:19-21; 69:22-70:13			
48:9-48:10	[48:9-10] 403; NREL; HRS	67:2-12; 67:13- 68:2; 68:3-22; 69:1- 18; 69:19-21; 69:22-70:13			
48:12-48:16	[48:12-16] 403; SPC; NREL; HRS	67:2-12; 67:13- 68:2; 68:3-22; 69:1- 18; 69:19-21; 69:22-70:13			
48:22-49:3	[48:22-49:3] SPC; NREL; HRS; 403	67:2-12; 67:13- 68:2; 68:3-22; 69:1- 18; 69:19-21; 69:22-70:13			
49:11-49:12	[49:11-12] SPC; NREL; 403; HRS	67:2-12; 67:13- 68:2; 68:3-22; 69:1- 18; 69:19-21; 69:22-70:13			
49:14-50:3	[49:14-50:3] HRS; 403; SPC; LFND; NREL	67:2-12; 67:13- 68:2; 68:3-22; 69:1- 18; 69:19-21; 69:22-70:13			
51:2-51:5	[51:2-5] SPC; LFND; MIS; NREL; 403	67:2-12; 67:13- 68:2; 68:3-22; 69:1- 18; 69:19-21; 69:22-70:13			



<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
51:8-51:14	[51:8-14] SPC; LFND; MIS; 403; NREL	67:2-12; 67:13- 68:2; 68:3-22; 69:1- 18; 69:19-21; 69:22-70:13			
51:16-52:3	[51:16-52:3] 403; HRS; SPC; LFND; MIS; NREL	67:2-12; 67:13- 68:2; 68:3-22; 69:1- 18; 69:19-21; 69:22-70:13			
54:13-54:14	[54:13-14] HRS; NREL; 403	54:17-55:6; 67:2- 12; 67:13-68:2; 68:3-22; 69:1-18; 69:19-21; 69:22- 70:13			
55:7-55:11	[55:7-11] 403; HRS; NREL	67:2-12; 67:13- 68:2; 68:3-22; 69:1- 18; 69:19-21; 69:22-70:13			
55:19-56:19	[55:19-56:19] 403; HRS; SPC; LFND; MIS; NREL	67:2-12; 67:13- 68:2; 68:3-22; 69:1- 18; 69:19-21; 69:22-70:13			
56:22-57:3	[56:22-57:3] SPC; LFND; MIS; NREL; 403	67:2-12; 67:13- 68:2; 68:3-22; 69:1- 18; 69:19-21; 69:22-70:13			

Adrian Perica – August 12, 2022					
Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
7:14-7:17					
8:12-8:18					
56:21-57:5	[56:21-57:5] AMB				
64:14-64:17	[64:14-17] AMB; LFND; NREL; 403	79:21-80:17	AS, OS, SP, F, I	80:19-81:1	[80:19-81:1] AMB; LFND; NREL; 403
64:22-65:3					
65:16-66:7	[65:16-66:7] AMB; LFND; NREL; 403				
67:3-67:20	[67:3-20] AMB; NREL; 403				
77:19-78:5	[77:19-78:5] AMB; NREL; 403	79:21-80:17	AS, OS, SP, F, I	80:19-81:1	[80:19-81:1] AMB; LFND; NREL; 403
82:4-82:7	[82:4-7] AMB; LFND; NREL; 403				
82:11-82:18	[82:11-18] AMB; NREL; 403	87:10-18			
87:19-88:4	[87:19-88:4] AMB; NREL; 403	88:5-89:12	AS, F, SP		
89:14-90:9	[89:14-90:9] AMB; NREL; 403				
90:11-90:14	[90:11-14] AMB; NREL; 403				
90:21-91:10	[90:21-91:10] AMB; NREL; 403	241:16-243:12	402, 403, I, LE	248:18-249:9, 249:12-16, 251:12- 13, 251:16-19	[248:18-249:9] AMB; LFND; NREL; 403; MIL;

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
					[249:12-16] AMB; LFND; NREL; 403; MIL; [251:12-13] AMB; LFND; NREL; 403; MIL; [251:16-19] AMB; LFND; NREL; 403; MIL;
94:16-95:4	[94:16-95:4] AMB; NREL; 403	95:5-96:10; 100:11-101:2; 241:16-243:12	AS, F, SP, I, 402, 403, LE	100:5-10, 248:18-249:9, 249:12-16, 251:12-13, 251:16-19	[100:5-10] AMB; LFND; NREL; 403; MIL; [248:18-249:9] AMB; LFND; NREL; 403; MIL; [249:12-16] AMB; LFND; NREL; 403; MIL; [251:12-13] AMB; LFND; NREL; 403; MIL; [251:16-19] AMB; LFND; NREL; 403; MIL;
101:4-101:9	[101:4-9] AMB; NREL; 403	241:16-243:12	402, 403, I, LE	248:18-249:9, 249:12-16, 251:12-13, 251:16-19	[248:18-249:9] AMB; LFND; NREL; 403; MIL;

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					[249:12-16] AMB; LFND; NREL; 403; MIL; [251:12-13] AMB; LFND; NREL; 403; MIL; [251:16-19] AMB; LFND; NREL; 403; MIL;
104:12-104:16	[104:12-16] AMB; NREL; 403	241:16-243:12	402, 403, I, LE	248:18-249:9, 249:12-16, 251:12- 13, 251:16-19	[248:18-249:9] AMB; LFND; NREL; 403; MIL; [249:12-16] AMB; LFND; NREL; 403; MIL; [251:12-13] AMB; LFND; NREL; 403; MIL; [251:16-19] AMB; LFND; NREL; 403; MIL;
105:7-105:19	[105:7-19] AMB; NREL; 403	241:16-243:12	402, 403, I, LE	248:18-249:9, 249:12-16, 251:12- 13, 251:16-19	[248:18-249:9] AMB; LFND; NREL; 403; MIL; [249:12-16] AMB; LFND; NREL; 403; MIL;

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					[251:12-13] AMB; LFND; NREL; 403; MIL; [251:16-19] AMB; LFND; NREL; 403; MIL;
106:8-106:17	[106:8-17] AMB; NREL; 403	107:18-108:15; 241:16-243:12	AS, 402, 403, F, SP, I, LE	110:9-11, 248:18-249:9, 249:12-16, 251:12-13, 251:16-19	[110:9-11] AMB; LFND; NREL; 403; MIL; [248:18-249:9] AMB; LFND; NREL; 403; MIL; [249:12-16] AMB; LFND; NREL; 403; MIL; [251:12-13] AMB; LFND; NREL; 403; MIL; [251:16-19] AMB; LFND; NREL; 403; MIL;
111:12-112:13	[111:12-112:13] AMB; NREL; 403	112:18-113:8; 113:19-114:15; 116:9-22; 241:16-243:12	AS, 402, 403, F, SP, I, LE	110:9-11, 248:18-249:9, 249:12-16, 251:12-13, 251:16-19	[110:9-11] AMB; LFND; NREL; 403; MIL; [248:18-249:9] AMB; LFND; NREL; 403; MIL;

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					[249:12-16] AMB; LFND; NREL; 403; MIL; [251:12-13] AMB; LFND; NREL; 403; MIL; [251:16-19] AMB; LFND; NREL; 403; MIL;
119:18-120:7	[119:18-120:7] AMB; NREL; 403	120:8-19; 120:20-121:7; 241:16-243:12	AS, 402, 403, F, SP, I, LE	110:9-11, 248:18-249:9, 249:12-16, 251:12-13, 251:16-19	[110:9-11] AMB; LFND; NREL; 403; MIL; [248:18-249:9] AMB; LFND; NREL; 403; MIL; [249:12-16] AMB; LFND; NREL; 403; MIL; [251:12-13] AMB; LFND; NREL; 403; MIL; [251:16-19] AMB; LFND; NREL; 403; MIL;
122:6-122:10	[122:6-10] AMB; NREL; 403	123:6-19; 124:17-125:3; 241:16-243:12	402, 403, F, SP, I, LE	125:5-11, 125:19-21, 126:1-126:14, 126:16-127:1, 248:18-249:9,	[125:5-11] AMB; LFND; NREL; 403; MIL; [125:19-21]

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
				249:12-16, 251:12-13, 251:16-19	AMB; LFND; NREL; 403; MIL; [126:1-126:14] AMB; LFND; NREL; 403; MIL; [126:16-127:1] AMB; LFND; NREL; 403; MIL; [248:18-249:9] AMB; LFND; NREL; 403; MIL; [249:12-16] AMB; LFND; NREL; 403; MIL; [251:12-13] AMB; LFND; NREL; 403; MIL; [251:16-19] AMB; LFND; NREL; 403; MIL;
127:3-127:10	[127:3-10] AMB; NREL; 403	127:11-128:13; 241:16-243:12	AS, 402, 403, F, SP, I, LE	125:5-11, 125:19-21, 126:1-126:14, 126:16-127:1, 248:18-249:9, 249:12-16, 251:12-13, 251:16-19	[125:5-11] AMB; LFND; NREL; 403; MIL; [125:19-21] AMB; LFND; NREL; 403; MIL; [126:1-126:14]

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					AMB; LFND; NREL; 403; MIL; [126:16-127:1] AMB; LFND; NREL; 403; MIL; [248:18-249:9] AMB; LFND; NREL; 403; MIL; [249:12-16] AMB; LFND; NREL; 403; MIL; [251:12-13] AMB; LFND; NREL; 403; MIL; [251:16-19] AMB; LFND; NREL; 403; MIL;
132:18-132:19	[132:18-19] AMB; NREL; 403	241:16-243:12	402, 403, I, LE	248:18-249:9, 249:12-16, 251:12- 13, 251:16-19	[248:18-249:9] AMB; LFND; NREL; 403; MIL; [249:12-16] AMB; LFND; NREL; 403; MIL; [251:12-13] AMB; LFND; NREL; 403; MIL;



<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
					[251:16-19] AMB; LFND; NREL; 403; MIL;
133:3-133:4	[133:3-4] AMB; NREL; 403	241:16-243:12	402, 403, I, LE	248:18-249:9, 249:12-16, 251:12-13, 251:16-19	[248:18-249:9] AMB; LFND; NREL; 403; MIL; [249:12-16] AMB; LFND; NREL; 403; MIL; [251:12-13] AMB; LFND; NREL; 403; MIL; [251:16-19] AMB; LFND; NREL; 403; MIL;
134:9-135:12	[134:9-135:12] AMB; NREL; 403	136:11-17; 138:5-16; 241:16-243:12	402, 403, F, SP, I, LE	139:9-22, 248:18-249:9, 249:12-16, 251:12-13, 251:16-19	[139:9-22] AMB; LFND; NREL; 403; MIL; [248:18-249:9] AMB; LFND; NREL; 403; MIL; [249:12-16] AMB; LFND; NREL; 403; MIL; [251:12-13] AMB; LFND; NREL; 403; MIL;

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
					[251:16-19] AMB; LFND; NREL; 403; MIL;

Adrian Perica – October 13, 2023					
Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
7:16-7:17					
8:13-8:18					
10:11-10:14	[10:11-14] AMB; NREL; 403				
10:19-10:22	[10:19-22] AMB; NREL; 403	11:8-16			
11:20-12:10	[11:20-12:10] No objection basis				
12:18-12:21	[12:18-21] AMB; NREL; 403				
13:3-13:6	[13:3-11] AMB; NREL; 403				
13:7-13:11					
13:20-14:5	[13:20-14:5] AMB; NREL; 403				
23:17-23:22	[23:17-22] AMB; NREL; 403				
25:3-25:7	[25:3-7] AMB; NREL; 403				
30:6-30:14	[30:6-14] AMB; NREL; 403	31:10-32:7	AS, I, V	32:9-12	[32:9-12] AMB; NREL; 403
30:16-30:22	[30:16-22] AMB; NREL; 403				
31:2-31:8	[31:2-8] AMB; NREL; 403	36:19-37:7			

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
37:8-37:11	[37:8-11] AMB; NREL; 403				
37:16-38:8	[37:16-38:8] AMB; NREL; 403				
39:8-39:14	[39:8-16] AMB; NREL; 403	39:18-40:15; 41:14- 43:3	F, SP, I, 402, 403	43:4-7, 43:9-12	[43:4-7] AMB; NREL; 403; MIL; [43:9-12] AMB; NREL; 403; MIL
39:16-39:16		39:18-40:15; 41:14- 43:3	F, SP, I, 402, 403	43:4-7, 43:9-12	[43:4-7] AMB; NREL; 403; MIL; [43:9-12] AMB; NREL; 403; MIL
41:6-41:13	[41:6-13] AMB; NREL; 403	41:14-43:3	F, SP, I, 402, 403	43:4-7, 43:9-12	[43:4-7] AMB; NREL; 403; MIL; [43:9-12] AMB; NREL; 403; MIL
43:14-43:16	[43:14-44:1] No objection basis				
43:18-44:1					
45:17-45:20	[45:17-20] AMB; NREL; 403				
46:3-46:5	[46:3-5] AMB; NREL; 403				
46:17-47:11	[46:17-47:16] AMB; NREL; 403	47:18-21			
47:13-47:14		47:18-21			
47:16-47:16					

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
48:10-48:12	[48:10-12] AMB; NREL; 403				
48:14-48:18	[48:14-18] AMB; NREL; 403	53:17-54:7			
49:13-49:15	[49:13-50:10] AMB; NREL; 403	53:17-54:7			
49:17-50:10		50:11-51:5; 53:17- 54:7	AS, I	51:7-8, 51:10-22	[51:7-8] AMB; NREL; 403; MIL; [51:10-22] AMB; NREL; 403; MIL
54:9-54:13	[54:9-13] AMB; NREL; 403				
55:18-55:19	[55:18-56:2] AMB; NREL; 403				
55:21-56:2		56:4-57:16	I	57:17-18, 57:20- 58:4	[57:17-18] AMB; NREL; 403; [57:20-58:4] AMB; NREL; 403;
58:8-58:10	[58:8-59:2] AMB; NREL; 403				
58:12-59:2					
59:9-59:13	[59:9-13] AMB; NREL; 403				
59:15-59:20	[59:15-20] AMB; NREL; 403				
60:2-60:13	[60:2-13] AMB; NREL; 403	60:14-21	I, AS	61:1-6	[61:1-6] AMB; NREL; 403;

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
62:18-62:21	[62:18-21] AMB; NREL; 403				
63:3-63:5	[63:3-5] AMB; NREL; 403				
64:2-64:15	[64:2-18] AMB; NREL; 403				
64:17-64:18					
65:9-66:1	[65:9-66:1] AMB; NREL; 403	66:3-7			

**Cameron Pilling – October 24, 2023**

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
6:14-6:15					
7:10-7:15					
62:17-62:21	[62:17-21] AMB; LFND; NREL; 403	65:9-22; 66:15- 67:11	V, I	66:2-9	[66:2-9] AMB; AA; AG; PRV; BSD; SPC; LFND; MIS; NREL; 403
64:8-64:13	[64:8-13] AMB; LFND; NREL; 403	65:9-22; 66:15- 67:11	V, I	66:2-9	[66:2-9] AMB; AA; AG; PRV; BSD; SPC; LFND; MIS; NREL; 403

Steven "Colin" Roach – September 21, 2023					
Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
7:18-7:19		41:15-42:11			
11:17-11:19		23:20-22; 41:15-42:11			
16:8-16:10	[16:8-10] NREL; 403	11:20-12:19; 41:15-42:11	402; 403; F; SP; LC; EX		
17:4-17:11	[17:4-11] CLC; SPC; NREL; 403	11:20-12:19; 41:15-42:11	402; 403; F; SP; LC; EX		
17:12-17:14	[17:12-14] AMB; CLC; SPC; NREL; 403	11:20-12:19; 41:15-42:11	402; 403; F; SP; LC; EX		
17:16-17:21	[17:16-21] AMB; CLC; SPC; NREL; 403	11:20-12:19; 41:15-42:11	402; 403; F; SP; LC; EX		
24:1-24:9	[24:1-9] AMB; SPC; NREL; 403	41:15-42:11			
24:19-25:12	[24:19-25:12] AMB; SPC; NREL; 403	23:20-22; 41:15-42:11			
25:14-25:14	[25:14-14] AMB; SPC; NREL; 403	23:20-22; 41:15-42:11			
25:21-26:1	[25:21-26:1] AMB; SPC; NREL; 403	23:20-22; 41:15-42:11			
26:3-26:4	[26:3-4] AMB; SPC; NREL; 403	23:20-22; 41:15-42:11			
26:6-26:9	[26:6-9] AMB; SPC; NREL; 403	23:20-22; 41:15-42:11			

Peter Russell-Clarke – October 13, 2023					
Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
12:22-13:4					
14:10-15:4					
32:20-33:15					
33:17-34:16		35:3-20			
42:4-42:12					
58:13-59:4	[58:13-59:4] AMB; PRV; LFND; NREL; 403	59:13-60:13		49:6-8; 49:10-21; 50:3-7; 58:13-59:4; 64:22-65:2; 65:5-8; 70:16-19; 70:22; 71:17-19; 72:1-7	[49:6-8] AMB; AA; CLC; NREL; 403; [49:10-21] AMB; AA; CLC; NREL; 403; [50:3-7] AMB; AA; CLC; NREL; 403; [58:13-59:4] AMB; PRV; LFND; NREL; 403;



Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					[64:22-65:2] AMB; CLC; LFND; NREL; 403; [65:5-8] AMB; CLC; LFND; NREL; 403; [70:16-19] AMB; CLC; LFND; NREL; 403; OS [70:22] AMB; CLC; LFND; NREL; 403; OS [71:17-19] AMB; CLC; LFND; NREL; 403; OS; SPC; [72:1-7] AMB; CLC; LFND; NREL; 403; OS; SPC
64:22-65:8	[64:22-65:8] AMB; CLC; SPC; LFND; NREL; 403	65:10-66:12		49:6-8; 49:10-21; 50:3-7; 64:22-65:2; 65:5-8; 66:14-15; 70:16-19; 70:22; 71:17-19; 72:1-7	[49:6-8] AMB; AA; CLC; NREL; 403; [49:10-21] AMB; AA; CLC; NREL; 403; [50:3-7] AMB; AA; CLC; NREL; 403;

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					[58:13-59:4] AMB; PRV; LFND; NREL; 403; [64:22-65:2] AMB; CLC; LFND; NREL; 403; [65:5-8] AMB; CLC; LFND; NREL; 403; [70:16-19] AMB; CLC; LFND; NREL; 403; OS [70:22] AMB; CLC; LFND; NREL; 403; OS [71:17-19] AMB; CLC; LFND; NREL; 403; OS; SPC; [72:1-7] AMB; CLC; LFND; NREL; 403; OS; SPC
70:16-70:22	[70:16-22] AMB; CLC; SPC; LFND; NREL; OS; 403				

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
71:17-72:7	[71:17-72:7] AMB; CLC; SPC; LFND; NREL; OS; 403	72:9-73:1	AS	49:6-8, 49:10-21, 50:3-7, 64:22-65:2, 65:5-8, 70:16-19, 70:22, 71:17-19, 72:1-7	[49:6-8] AMB; AA; CLC; NREL; 403; [49:10-21] AMB; AA; CLC; NREL; 403; [50:3-7] AMB; AA; CLC; NREL; 403; [58:13-59:4] AMB; PRV; LFND; NREL; 403; [64:22-65:2] AMB; CLC; LFND; NREL; 403; [65:5-8] AMB; CLC; LFND; NREL; 403; [70:16-19] AMB; CLC; LFND; NREL; 403; OS [70:22] AMB; CLC; LFND; NREL; 403; OS [71:17-19] AMB; CLC; LFND; NREL; 403; OS; SPC; [72:1-7] AMB; CLC; LFND;

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
					NREL; 403; OS; SPC
134:14-135:6					
138:3-138:12	[138:3-12] AMB; LFND; MIS; NREL; 403	137:16-138:2		138:14-17; 138:19-139:4; 139:6-12; 139:16-18	[138:14-17] AMB; LFND; NREL; 403; [138:19-139:4] AMB; LFND; NREL; 403; [139:6-12] AMB; LFND; NREL; 403; [139:16-18] AMB; LFND; NREL; 403;
138:14-139:18	[138:14-139:18] AMB; LFND; NREL; 403	137:16-138:2		138:3-5; 138:8-12	[138:3-5] AMB; LFND; MIS; NREL; 403; [138:8-12] AMB; LFND; MIS; NREL; 403
143:2-143:9					
143:13-144:15	[143:13-144:15] AMB; AA				
150:10-151:3	[150:10-151:3] AMB; AG				
151:5-151:16	[151:5-16] AMB; AG; CLC; OS				
159:5-159:6	[159:5-6] AMB; LFND; NREL; 403	160:2-3	402, 403		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
159:12-159:22	[159:12-22] AMB; LFND; NREL; 403	160:2-3	402, 403		
165:21-165:22	[165:21-22] AMB; LFND; NREL; 403				
166:5-166:18	[166:5-18] AMB; LFND; NREL; 403				
174:21-174:22	[174:21-22] AMB; LFND; NREL; 403				
175:5-175:11	[175:5-11] AMB; LFND; NREL; 403				
176:4-176:10	[176:4-10] AMB; LFND; NREL; 403				
185:10-185:14	[185:10-14] AMB; LFND; NREL; 403				
185:21-186:3	[185:21-186:3] AMB; LFND; NREL; 403				
188:14-188:15	[188:14-15] AMB; LFND; NREL; 403				
188:21-189:6	[188:21-189:6] AMB; LFND; NREL; 403				
189:21-190:9	[189:21-190:9] AMB; LFND; NREL; 403				
191:14-192:5	[191:14-192:5] AMB; LFND; NREL; 403				

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
195:7-195:8	[195:7-8] AMB; LFND; NREL; 403				
195:15-195:21	[195:15-21] AMB; LFND; NREL; 403				
201:1-201:4	[201:1-4] AMB; LFND; NREL; 403				
201:8-201:12	[201:8-12] AMB; LFND; NREL; 403				
203:21-204:2	[203:21-204:2] AMB; LFND; NREL; 403				
205:12-205:13	[205:12-13] AMB; LFND; NREL; 403				
205:19-206:4	[205:19-206:4] AMB; LFND; NREL; 403				
217:14-217:18					
218:21-219:2					
219:17-219:19					
220:7-220:18					
221:13-222:3					
222:12-223:13					
229:7-229:15	[229:7-15] AMB; SPC; LFND; NREL; OS; 403				

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
230:1-230:18	[230:1-18] AMB; SPC; LFND; NREL; OS; 403				
231:14-231:18					

Denby Sellers – December 15, 2021					
Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
8:3-8:8					
20:5-20:11					
76:7-76:19	NREL, SPC, LFND, 403, HRS	78:22-79-13; 79:16-79-17; 80:17-81-5; 83:14-83:18	402, 403, F, SP, I	82:9-15, 85:17-86:13	NREL; 403; SPC; LFND; AG; HRS; BSD; IMP; MIL
78:15-78:21	NREL, 403, SPC, LFND, AG	78:22-79-13; 79:16-79-17; 80:17-81-5; 83:14-83:18	402, 403, F, SP, I	82:9-15, 85:17-86:13	NREL; 403; SPC; LFND; AG; HRS; BSD; IMP; MIL
80:6-80:9	NREL, 403, HRS, LFND, AMB	78:22-79-13; 79:16-79-17; 80:17-81-5; 83:14-83:18	402, 403, F, SP, I	82:9-15, 85:17-86:13	NREL; 403; SPC; LFND; AG; HRS; BSD; IMP; MIL
80:12-80:15	NREL, 403, HRS, LFND, AMB	78:22-79-13; 79:16-79-17; 80:17-81-5; 83:14-83:18	402, 403, F, SP, I	82:9-15, 85:17-86:13	NREL; 403; SPC; LFND; AG; HRS; BSD; IMP; MIL
129:1-129:7	HRS, NREL, 403, NP, AMB,	131:18-132:4; 132:16-133:2; 133:7-133:10; 134:2-134:4; 134:7; 134:9-134:18; 134:21	402, 403, F, SP, V, I	135:2-3, 135:5-8	NREL; 403; SPC; HRS; LFND; AG; BSD; IMP; MIL
132:5-132:12	HRS, LFND, NREL, 403	131:18-132:4; 132:16-133:2; 133:7-133:10; 134:2-134:4; 134:7; 134:9-134:18; 134:21	402, 403, F, SP, V, I	135:2-3, 135:5-8	NREL; 403; SPC; LFND; AG; HRS; BSD; IMP; MIL



<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
180:7-180:12	HRS, NREL, 403, NP	183:15-184:1; 191:12-192:3; 191:12-192:3; 192:22-193:14	402, 403, F, SP, I	182:12-22, 191:3-11, 195:1-13	NREL; 403; HRS; MIL; LFND; SPC; BSD; IMP; AG
180:16-180:20	HRS, NREL, 403, AMB	183:15-184:1; 191:12-192:3; 192:22-193:14	402, 403, F, SP, I	182:12-22, 191:3-11, 195:1-13	NREL; 403; HRS; MIL; LFND; SPC; BSD; IMP; AG
183:8-183:14	HRS, NREL, 403, AG, LFND	183:15-184:1; 191:12-192:3; 192:22-193:14	402, 403, F, SP, I	182:12-22, 191:3-11, 195:1-13	NREL; 403; HRS; MIL; LFND; SPC; BSD; IMP; AG
189:3-191:2	SPC, LFND, LDG, NREL, 403, HRS, AMB,	183:15-184:1; 191:12-192:3; 192:22-193:14	402, 403, F, SP, I	182:12-22, 191:3-11, 195:1-13	NREL; 403; HRS; MIL; LFND; SPC; BSD; IMP; AG
192:4-192:20	HRS, NREL, 403, SPC, LFND, CPD, AMB, MIS	183:15-184:1; 191:12-192:3; 192:22-193:14	402, 403, F, SP, I	182:12-22, 191:3-11, 195:1-13	NREL; 403; HRS; MIL; LFND; SPC; BSD; IMP; AG
221:11-221:15	HRS, NREL, 403, NP	224:7-224:9; 224:12-224:17; 224:20-225:5	402, 403, F, SP, I	225:7-12, 225:15-226:1	NREL; 403; MIL; SPC; LFND; AMB; AG; BSD; IMP; HRS; HYP
221:19-222:1	HRS, NREL, 403, LDG, LFND, AMB, AG,	224:7-224:9; 224:12-224:17; 224:20-225:5	402, 403, F, SP, I	225:7-12, 225:15-226:1	NREL; 403; MIL; SPC; LFND; AMB; AG; BSD; IMP; HRS; HYP
223:8-223:13	HRS, NREL, 403, SPC, AMB, AG, LFND	224:7-224:9; 224:12-224:17; 224:20-225:5	402, 403, F, SP, I	225:7-12, 225:15-226:1	NREL; 403; MIL; SPC; LFND; AMB; AG; BSD; IMP; HRS; HYP

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
223:18-224:6	HRS, NREL, 403, SPC, LFND, MIS	224:7-224:9; 224:12-224:17; 224:20-225:5	402, 403, F, SP, I	225:7-12, 225:15-226:1	NREL; 403; MIL; SPC; LFND; AMB; AG; BSD; IMP; HRS; HYP
282:14-282:18	HRS, NREL, 403, NP				
283:3-283:6	HRS, NREL, 403, LDG, LFND, AMB, MIS				
306:7-306:11	HRS, NREL, 403, NP				
306:13-306:21	HRS, NREL, 403, LDG, SPC, MIS, AMB				

Denby Sellers – June 24, 2022					
Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
6:14-6:17		184:21-191:19			
49:21-50:3	[49:21-50:3] HRS; NREL; 403; OBJ	184:21-191:19			
50:21-51:2	[50:21-51:2] HRS; NREL; 403; AMB; LFND; INC	67:2-11; 68:5-17; 69:3-70:18; 184:21- 191:19			
67:12-67:15	[67:12-15] SPC; LFND; LDG; NREL; 403; AMB; MIS; INC	67:2-11; 68:5-17; 69:3-70:18; 184:21- 191:19			
67:17-68:4	[67:17-68:4] NREL; 403; AMB; SPC; LFND; INC	67:2-11; 68:5-17; 69:3-70:18; 184:21- 191:19			
71:19-72:1	[71:19-72:1] HRS; NREL; 403; OBJ	184:21-191:19			
75:3-75:5	[75:3-5] HRS; LDG; NREL; 403; AMB; LA	184:21-191:19			
75:17-75:22	[75:17-22] HRS; LDG; NREL; 403; AMB; LA	184:21-191:19			
173:9-173:12	[173:9-12] HRS; NREL; 403; OBJ	177:13-178:6; 178:12-21			
173:22-174:2	[173:22-174:2] HRS; NREL; 403;	177:13-178:6; 178:12-21			

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
	AMB; AG; LFND; LA				
177:9-177:12	[177:9-12] HRS; NREL; 403; AMB; LFND; LA; INC	177:13-178:6; 178:12-21			
178:7-178:11	[178:7-11] HRS; LDG; NREL; 403; AMB; LFND; INC	177:13-178:6; 178:12-21			

Benjamin Shaffer – October 19, 2023					
Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
9:13-9:15		7:3-8:17; 9:4-7; 9:16-10:14; 11:12- 22; 20:4-22:11; 24:15-25:5; 26:15- 27:7	[7:3-8:17] 402, OS; [26:15-27:7] 402		
22:21-23:12	[22:21-23:12] AMB; CLC; LFND; NREL; 403	23:13-24:2; 24:15- 25:5; 26:15-27:7	[26:15-27:7] 402		
27:21-28:9	[27:21-28:9] AMB; LFND; NREL; 403	26:15-27:7; 28:18- 29:7; 30:12-31:9	[26:15-27:7] 402	29:19-30:2	[29:19-30:2] AMB; AA; SPC; CPD; LFND; MIS; NREL; 403
31:17-32:1	[31:17-32:1] AMB; LFND; NREL; 403	26:15-27:7; 30:12- 31:9	[26:15-27:7] 402	29:19-30:2	[29:19-30:2] AMB; AA; SPC; CPD; LFND; MIS; NREL; 403
33:18-33:19	[33:18-19] AMB; CLC; LFND; NREL; 403				
33:20-34:8	[33:20-34:8] AMB; CLC; LFND; NREL; 403	35:16-37:2			
44:9-44:13	[44:9-13] AMB; SPC; LFND; NREL; OS; 403				

**Gregor Simeonov (Innominds) – November 8, 2023**

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
9:12-9:19		97:20-98:19	403	11:6-11:7; 11:16-11:16	AMB; LDG; NREL; 403
10:19-10:22	[10:19-22] AMB; NREL; 403	97:20-98:19	403	11:6-11:7; 11:16-11:16	AMB; LDG; NREL; 403
11:21-12:2		97:20-98:19	403	11:6-11:7; 11:16-11:16	AMB; LDG; NREL; 403
13:13-14:13	[13:13-14:13] AMB; NREL; 403	97:20-98:19	403	11:6-11:7; 11:16-11:16	AMB; LDG; NREL; 403
14:15-14:16	[14:15-16] AMB; NREL; 403	97:20-98:19	403	11:6-11:7; 11:16-11:16	AMB; LDG; NREL; 403
15:15-15:16	[15:15-16] AMB; LFND; LDG; NREL; 403; SPC	97:20-98:19	403	11:6-11:7; 11:16-11:16	AMB; LDG; NREL; 403
15:19-15:22	[15:19-22] AMB; SPC; LFND; LDG; NREL; 403	97:20-98:19	403	11:6-11:7; 11:16-11:16	AMB; LDG; NREL; 403
16:9-16:10	[16:9-10] AMB; BSD; LFND; LDG; MIS; NREL; 403	97:20-98:19	403	11:6-11:7; 11:16-11:16	AMB; LDG; NREL; 403
16:16-17:6	[16:16-17:6] AMB; BSD; LFND; LDG; MIS; NREL; 403	97:20-98:19	403	11:6-11:7; 11:16-11:16	AMB; LDG; NREL; 403
17:11-18:2	[17:11-18:2] AMB; BSD; LFND; LDG; MIS; NREL; 403	97:20-98:19	403	11:6-11:7; 11:16-11:16	AMB; LDG; NREL; 403

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
26:21-27:6	[26:21-27:6] BER; LFND; NREL; OBJ; 403	30:7-31:1; 31:13-14; 31:17-19; 34:4-6; 35:5-6; 35:10-11; 97:20-98:19; 101:20-21; 102:2-4; 103:2-3; 103:7-8	402; 403; AA; LC; OS	30:3-30:6; 35:13-35:13; 35:17-35:19	AMB; SPC; LFND; NREL; 403
29:20-30:2	[29:20-30:2] LFND; NREL; 403	30:7-31:1; 31:13-14; 31:17-19; 34:4-6; 35:5-6; 35:10-11; 97:20-98:19; 101:20-21; 102:2-4; 103:2-3; 103:7-8	402; 403; AA; LC; OS	30:3-30:6; 35:13-35:13; 35:17-35:19	AMB; SPC; LFND; NREL; 403
31:21-31:22	[31:21-22] AMB; BER; SPC; LFND; NREL; 403	30:7-31:1; 31:13-14; 31:17-19; 34:4-6; 35:5-6; 35:10-11; 97:20-98:19; 101:20-21; 102:2-4; 103:2-3; 103:7-8	402; 403; AA; LC; OS	30:3-30:6; 35:13-35:13; 35:17-35:19	AMB; SPC; LFND; NREL; 403
32:3-32:13	[32:3-13] AMB; BER; SPC; LFND; NREL; 403	30:7-31:1; 31:13-14; 31:17-19; 34:4-6; 35:5-6; 35:10-11; 97:20-98:19; 101:20-21; 102:2-4; 103:2-3; 103:7-8	402; 403; AA; LC; OS	30:3-30:6; 35:13-35:13; 35:17-35:19	AMB; SPC; LFND; NREL; 403
34:20-34:21	[34:20-21] AMB; SPC; LFND; LDG; NREL; 403	30:7-31:1; 31:13-14; 31:17-19; 34:4-6; 35:5-6; 35:10-11; 97:20-98:19;	402; 403; AA; LC; OS	30:3-30:6; 35:13-35:13; 35:17-35:19	AMB; SPC; LFND; NREL; 403

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		101:20-21; 102:2-4; 103:2-3; 103:7-8			
35:2-35:2	[35:2-2] AMB; SPC; LFND; LDG; NREL; 403	30:7-31:1; 31:13-14; 31:17-19; 34:4-6; 35:5-6; 35:10-11; 97:20-98:19; 101:20-21; 102:2-4; 103:2-3; 103:7-8	402; 403; AA; LC; OS	30:3-30:6; 35:13-35:13; 35:17-35:19	AMB; SPC; LFND; NREL; 403
35:21-35:22	[35:21-22] AMB; SPC; LFND; NREL; 403	97:20-98:19	402; 403	11:6-11:7; 11:16-11:16	AMB; LDG; NREL; 403
36:2-36:22	[36:2-22] AMB; SPC; LFND; NREL; 403	97:20-98:19	402; 403	11:6-11:7; 11:16-11:16	AMB; LDG; NREL; 403
37:2-37:2	[37:2-2] AMB; SPC; LFND; NREL; 403	39:13-17; 39:19-40:11; 40:19-20; 41:2-5; 41:10-11; 46:10-12; 46:14-21; 47:3-7; 47:12-12; 48:22-49:12; 76:21-77:1; 77:4-14; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 97:20-98:19	402; 403; OS		
37:5-37:17	[37:5-17] AMB; SPC; LFND; NREL; 403; LDG	39:13-17; 39:19-40:11; 40:19-20; 41:2-5; 41:10-11; 46:10-12; 46:14-21;	402; 403; OS		



<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		47:3-7; 47:12-12; 48:22-49:12; 76:21- 77:1; 77:4-14; 77:4- 14; 77:17-22; 78:4- 8; 78:11-11; 97:20- 98:19			
37:19-37:19	[37:19-19] AMB; SPC; LFND; LDG; NREL; 403	39:13-17; 39:19- 40:11; 40:19-20; 41:2-5; 41:10-11; 46:10-12; 46:14-21; 47:3-7; 47:12-12; 48:22-49:12; 76:21- 77:1; 77:4-14; 77:4- 14; 77:17-22; 78:4- 8; 78:11-11; 97:20- 98:19	402; 403; OS		
37:21-37:21	[37:21-21] AMB; SPC; LFND; LDG; NREL; 403	39:13-17; 39:19- 40:11; 40:19-20; 41:2-5; 41:10-11; 46:10-12; 46:14-21; 47:3-7; 47:12-12; 48:22-49:12; 76:21- 77:1; 77:4-14; 77:4- 14; 77:17-22; 78:4- 8; 78:11-11; 97:20- 98:19	402; 403; OS		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
38:2-38:3	[38:2-3] AMB; SPC; LFND; LDG; NREL; 403	39:13-17; 39:19-40:11; 40:19-20; 41:2-5; 41:10-11; 46:10-12; 46:14-21; 47:3-7; 48:22-49:12; 76:21-77:1; 77:4-14; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 97:20-98:19	402; 403; OS		
38:5-38:11	[38:5-11] AMB; SPC; LFND; LDG; NREL; 403	39:13-17; 39:19-40:11; 40:19-20; 41:2-5; 41:10-11; 46:10-12; 46:14-21; 47:3-7; 47:12-12; 48:22-49:12; 76:21-77:1; 77:4-14; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 97:20-98:19	402; 403; OS		
38:13-39:3	[38:13-39:3] AMB; SPC; LFND; NREL; 403	39:13-17; 39:19-40:11; 40:19-20; 41:2-5; 41:10-11; 46:10-12; 46:14-21; 47:3-7; 47:12-12; 48:22-49:12; 76:21-77:1; 77:4-14; 77:4-14; 77:17-22; 78:4-	402; 403; OS		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		8; 78:11-11; 97:20-98:19			
39:6-39:11	[39:6-11] AMB; SPC; LFND; NREL; 403	39:13-17; 39:19-40:11; 40:19-20; 41:2-5; 41:10-11; 46:10-12; 46:14-21; 47:3-7; 47:12-12; 48:22-49:12; 76:21-77:1; 77:4-14; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 97:20-98:19	402; 403; OS		
40:12-40:13	[40:12-13] AMB; SPC; LFND; NREL; 403	39:13-17; 39:19-40:11; 40:19-20; 41:2-5; 41:10-11; 46:10-12; 46:14-21; 47:3-7; 47:12-12; 48:22-49:12; 76:21-77:1; 77:4-14; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 97:20-98:19	402; 403; OS		
40:16-40:17	[40:16-17] AMB; SPC; LFND; NREL; 403	39:13-17; 39:19-40:11; 40:19-20; 41:2-5; 41:10-11; 46:10-12; 46:14-21; 47:3-7; 47:12-12; 48:22-49:12; 76:21-	402; 403; OS		

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
		77:1; 77:4-14; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 97:20-98:19			
41:13-41:14	[41:13-14] AMB; SPC; LFND; LDG; NREL; 403	39:13-17; 39:19-40:11; 40:19-20; 41:2-5; 41:10-11; 46:10-12; 46:14-21; 47:3-7; 47:12-12; 48:22-49:12; 76:21-77:1; 77:4-14; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 97:20-98:19	402; 403; OS		
41:19-41:22	[41:19-22] AMB; SPC; LFND; LDG; NREL; 403	39:13-17; 39:19-40:11; 40:19-20; 41:2-5; 41:10-11; 46:10-12; 46:14-21; 47:3-7; 47:12-12; 48:22-49:12; 76:21-77:1; 77:4-14; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 97:20-98:19	402; 403; OS		
44:16-44:19	[44:16-19] AMB; SPC; LFND; LDG; NREL; 403	39:13-17; 39:19-40:11; 40:19-20; 41:2-5; 41:10-11; 46:10-12; 46:14-21;	402; 403; OS		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		47:3-7; 47:12-12; 48:22-49:12; 76:21- 77:1; 77:4-14; 77:4- 14; 77:17-22; 78:4- 8; 78:11-11; 97:20- 98:19			
45:2-45:7	[45:2-7] AMB; SPC; LFND; LDG; NREL; 403	39:13-17; 39:19- 40:11; 40:19-20; 41:2-5; 41:10-11; 46:10-12; 46:14-21; 47:3-7; 47:12-12; 48:22-49:12; 76:21- 77:1; 77:4-14; 77:4- 14; 77:17-22; 78:4- 8; 78:11-11; 97:20- 98:19	402; 403; OS		
45:10-45:21	[45:10-21] AMB; SPC; LFND; LDG; NREL; 403	39:13-17; 39:19- 40:11; 40:19-20; 41:2-5; 41:10-11; 46:10-12; 46:14-21; 47:3-7; 47:12-12; 48:22-49:12; 76:21- 77:1; 77:4-14; 77:4- 14; 77:17-22; 78:4- 8; 78:11-11; 97:20- 98:19	402; 403; OS		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
46:2-46:4	[46:2-4] AMB; SPC; LFND; LDG; MIS; NREL; 403	39:13-17; 39:19-40:11; 40:19-20; 41:2-5; 41:10-11; 46:10-12; 46:14-21; 47:3-7; 47:12-12; 48:22-49:12; 76:21-77:1; 77:4-14; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 97:20-98:19	402; 403; OS		
46:8-46:8	[46:8-8] AMB; SPC; LFND; LDG; MIS; NREL; 403	39:13-17; 39:19-40:11; 40:19-20; 41:2-5; 41:10-11; 46:10-12; 46:14-21; 47:3-7; 47:12-12; 48:22-49:12; 76:21-77:1; 77:4-14; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 97:20-98:19	402; 403; OS		
47:14-47:15	[47:14-15] CLC; LFND; NREL; 403	48:22-49:12; 54:18-55:2; 76:21-77:1; 77:4-14; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 97:20-98:19; 108:5-8	402; 403; I; OS		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
47:18-48:21	[47:18-48:21] AMB; SPC; LFND; NREL; 403	48:22-49:12; 54:18-55:2; 76:21-77:1; 77:4-14; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 97:20-98:19; 108:5-8	402; 403; I; OS		
49:20-49:21	[49:20-21] LFND; NREL; OBJ; 403	48:22-49:12; 49:13-18; 54:18-55:2; 57:18-19; 57:22-58:6; 65:5-9; 65:15-66:5; 66:7-8; 76:21-77:1; 77:4-14; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 97:20-98:19; 108:5-8	402; 403; I; OS		
50:5-50:10	[50:5-10] LFND; NREL; OBJ; 403	48:22-49:12; 49:13-18; 54:18-55:2; 57:18-19; 57:22-58:6; 65:5-9; 65:15-66:5; 66:7-8; 76:21-77:1; 77:4-14; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 97:20-98:19; 108:5-8	402; 403; I; OS		
52:3-52:9	[52:3-9] SPC; LFND; NREL; 403	48:22-49:12; 54:18-55:2; 57:18-19; 57:22-58:6; 65:5-9; 65:15-66:5; 66:7-8;	402; 403; I; OS		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		76:21-77:1; 77:4-14; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 97:20-98:19; 108:5-8			
54:3-54:4	[54:3-4] AMB; LFND; NREL; 403	48:22-49:12; 54:18-55:2; 57:18-19; 57:22-58:6; 65:5-9; 65:15-66:5; 66:7-8; 76:21-77:1; 77:4-14; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 97:20-98:19; 108:5-8	402; 403; I; OS		
54:7-54:17	[54:7-17] AMB; LFND; NREL; 403	48:22-49:12; 54:18-55:2; 57:18-19; 57:22-58:6; 65:5-9; 65:15-66:5; 66:7-8; 76:21-77:1; 77:4-14; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 97:20-98:19; 108:5-8	402; 403; I; OS		
55:16-55:19	[55:16-19] BER; NREL; 403	48:22-49:12; 57:18-19; 57:22-58:6; 65:5-9; 65:15-66:5; 66:7-8; 76:21-77:1; 77:4-14; 77:4-14;	402; 403; I; OS		



<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		77:17-22; 78:4-8; 78:11-11; 97:20-98:19; 108:5-8			
55:22-56:2	[55:22-56:2] BER; NREL; 403	48:22-49:12; 57:18-19; 57:22-58:6; 65:5-9; 65:15-66:5; 66:7-8; 76:21-77:1; 77:4-14; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 97:20-98:19; 108:5-8	402; 403; I; OS		
56:14-56:17	[56:14-17] SPC; LFND; LDG; MIS; NREL; 403	48:22-49:12; 57:18-19; 57:22-58:6; 65:5-9; 65:15-66:5; 66:7-8; 76:21-77:1; 77:4-14; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 97:20-98:19; 108:5-8	402; 403; I; OS		
56:20-56:20	[56:20-20] SPC; LFND; LDG; MIS; NREL; 403	48:22-49:12; 57:18-19; 57:22-58:6; 65:5-9; 65:15-66:5; 66:7-8; 76:21-77:1; 77:4-14; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 97:20-98:19; 108:5-8	402; 403; I; OS		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
58:7-59:1	[58:7-59:1] AMB; BER; LDG; NREL; 403	48:22-49:12; 57:18-19; 57:22-58:6; 65:5-9; 65:15-66:5; 66:7-8; 76:21-77:1; 77:4-14; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 97:20-98:19; 108:5-8	402; 403; I; OS		
59:7-59:21	[59:7-21] AMB; SPC; LFND; NREL; 403	48:22-49:12; 57:18-19; 57:22-58:6; 65:5-9; 65:15-66:5; 66:7-8; 76:21-77:1; 77:4-14; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 97:20-98:19; 108:5-8	402; 403; I; OS		
60:2-60:9	[60:2-9] AMB; BER; LFND; NREL; 403	48:22-49:12; 57:18-19; 57:22-58:6; 65:5-9; 66:7-8; 76:21-77:1; 77:4-14; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 97:20-98:19; 108:5-8	402; 403; I; OS		
60:11-61:12	[60:11-61:12] AMB; BER; NREL; 403	48:22-49:12; 57:18-19; 57:22-58:6; 65:5-9; 65:15-66:5; 66:7-8; 76:21-77:1;	402; 403; I; OS		

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
		77:4-14; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 97:20- 98:19; 108:5-8			
62:2-62:3	[62:2-3] BER; LFND; NREL; 403	57:18-19; 57:22- 58:6; 65:5-9; 65:15- 66:5; 66:7-8; 76:21- 77:1; 77:4-14; 77:4- 14; 77:17-22; 78:4- 8; 78:11-11; 97:20- 98:19; 108:5-8	402; 403		
62:8-62:15	[62:8-15] BER; NREL; 403	57:18-19; 57:22- 58:6; 65:5-9; 65:15- 66:5; 66:7-8; 76:21- 77:1; 77:4-14; 77:4- 14; 77:17-22; 78:4- 8; 78:11-11; 97:20- 98:19; 108:5-8	402; 403		
62:20-63:5	[62:20-63:5] BER; LFND; LDG; NREL; 403	57:18-19; 57:22- 58:6; 65:5-9; 65:15- 66:5; 66:7-8; 76:21- 77:1; 77:4-14; 77:4- 14; 77:17-22; 78:4- 8; 78:11-11; 97:20- 98:19; 108:5-8	402; 403		
63:7-63:9	[63:7-9] AMB; AA; LFND; LDG; NREL; 403	57:18-19; 57:22- 58:6; 65:5-9; 65:15- 66:5; 66:7-8; 76:21-	402; 403		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		77:1; 77:4-14; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 97:20-98:19; 108:5-8			
63:11-63:17	[63:11-17] AMB; BER; CLC; SPC; LFND; NREL; 403	57:18-19; 57:22-58:6; 65:5-9; 65:15-66:5; 66:7-8; 76:21-77:1; 77:4-14; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 97:20-98:19; 108:5-8	402; 403		
63:20-63:21	[63:20-21] AMB; BER; CLC; SPC; LFND; NREL; 403	57:18-19; 57:22-58:6; 65:5-9; 65:15-66:5; 66:7-8; 76:21-77:1; 77:4-14; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 97:20-98:19; 108:5-8	402; 403		
64:2-64:17	[64:2-17] SPC; LFND; LDG; NREL; 403	57:18-19; 57:22-58:6; 65:5-9; 65:15-66:5; 66:7-8; 76:21-77:1; 77:4-14; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 97:20-98:19; 108:5-8	402; 403		
66:10-66:14	[66:10-14] AMB; BSD; SPC; LFND; NREL; 403	57:18-19; 57:22-58:6; 65:5-9; 65:15-66:5; 66:7-8; 76:21-	402; 40		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		77:1; 77:4-14; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 97:20-98:19; 108:5-8			
66:17-66:20	[66:17-20] BSD; SPC; LFND; NREL; 403	57:18-19; 57:22-58:6; 65:5-9; 65:15-66:5; 66:7-8; 76:21-77:1; 77:4-14; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 97:20-98:19; 108:5-8	402; 403		
67:1-67:7	[67:1-7] BSD; SPC; LFND; NREL; 403	49:13-18; 54:18-55:2; 57:18-19; 57:22-58:6; 65:5-9; 65:15-66:5; 66:7-8; 76:21-77:1; 77:4-14; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 97:20-98:19; 108:5-8	402; 403		
67:10-67:14	[67:10-14] BSD; SPC; LFND; NREL; 403	49:13-18; 54:18-55:2; 57:18-19; 57:22-58:6; 76:21-77:1; 77:4-14; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 97:20-98:19; 108:5-8	402; 403		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
67:17-67:21	[67:17-21] LFND; NREL; 403	71:7-10; 74:2-3; 74:6-18; 74:21- 75:5; 75:8-12; 75:15-20; 76:21- 77:1; 77:4-14; 77:4- 14; 77:17-22; 78:4- 8; 78:11-11; 97:20- 98:19	402; 40		
68:13-68:14	[68:13-14] AA; LFND; NREL; 403	71:7-10; 74:2-3; 74:6-18; 74:21- 75:5; 75:8-12; 75:15-20; 76:21- 77:1; 77:4-14; 77:4- 14; 77:17-22; 78:4- 8; 78:11-11; 97:20- 98:19	402; 403		
68:19-69:4	[68:19-69:4] LFND; MIS; NREL; 403	69:5-9; 71:7-10; 74:2-3; 74:6-18; 74:21-75:5; 75:8- 12; 75:15-20; 76:21-77:1; 77:4- 14; 77:4-14; 77:17- 22; 78:4-8; 78:11- 11; 97:20-98:19	402; 40		
70:12-70:18	[70:12-18] AMB; SPC; LFND; NREL; 403	71:7-10; 74:2-3; 74:6-18; 74:21- 75:5; 75:8-12; 75:15-20; 76:21-	402; 403		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		77:1; 77:4-14; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 97:20-98:19			
70:21-71:6	[70:21-71:6] LFND; NREL; 403	71:7-10; 74:2-3; 74:6-18; 74:21-75:5; 75:8-12; 75:15-20; 76:21-77:1; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 97:20-98:19	402; 403		
71:18-72:18	[71:18-72:18] LFND; NREL; 403	74:2-3; 74:6-18; 74:21-75:5; 75:8-12; 75:15-20; 76:21-77:1; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 97:20-98:19	402; 403		
76:10-76:12	[76:10-12] AMB; SPC; LFND; LDG; NREL; 403	74:2-3; 74:6-18; 74:21-75:5; 75:8-12; 75:15-20; 76:21-77:1; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 97:20-98:19	402; 403		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
76:14-76:16	[76:14-16] AMB; SPC; LFND; LDG; NREL; 403	74:2-3; 74:6-18; 74:21-75:5; 75:8-12; 75:15-20; 76:21-77:1; 77:4-14; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 97:20-98:19	402; 403		
78:13-78:14	[78:13-14] SPC; LFND; NREL; 403	74:2-3; 74:6-18; 74:21-75:5; 75:8-12; 75:15-20; 76:21-77:1; 77:4-14; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 80:14-81:14; 81:16-82:1; 82:3-22; 97:20-98:19	402; 403		
78:17-80:13	[78:17-80:13] SPC; LFND; LDG; NREL; 403	74:2-3; 74:6-18; 74:21-75:5; 75:8-12; 75:15-20; 76:21-77:1; 77:4-14; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 80:14-81:14; 81:16-82:1; 82:3-22; 97:20-98:19	402; 403		
83:2-83:15	[83:2-15] LDG; MIS; NREL; OBJ; 403	74:2-3; 74:6-18; 74:21-75:5; 75:8-12; 75:15-20;	402; 403		



Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
		76:21-77:1; 77:4-14; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 80:14-81:14; 81:16-82:1; 82:3-22; 97:20-98:19			
84:21-85:2	[84:21-85:2] SPC; LFND; NREL; 403	74:2-3; 74:6-18; 74:21-75:5; 75:8-12; 75:15-20; 76:21-77:1; 77:4-14; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 80:14-81:14; 81:16-82:1; 82:3-22; 97:20-98:19	402; 403		
86:5-86:9	[86:5-9] SPC; LFND; NREL; 403	74:2-3; 74:6-18; 74:21-75:5; 75:8-12; 75:15-20; 76:21-77:1; 77:4-14; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 80:14-81:14; 81:16-82:1; 82:3-22; 97:20-98:19	402; 403		
86:12-86:18	[86:12-18] SPC; LFND; NREL; 403	74:2-3; 74:6-18; 74:21-75:5; 75:8-12; 75:15-20; 76:21-77:1; 77:4-	402; 403		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		14; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 80:14-81:14; 81:16-82:1; 82:3-22; 97:20-98:19			
86:21-86:21	[86:21-21] SPC; LFND; NREL; 403	74:2-3; 74:6-18; 74:21-75:5; 75:8-12; 75:15-20; 76:21-77:1; 77:4-14; 77:4-14; 77:17-22; 78:4-8; 78:11-11; 80:14-81:14; 81:16-82:1; 82:3-22; 97:20-98:19	402; 403		
88:17-88:18	[88:17-18] LFND; NP; NREL; 403	90:7-8; 90:11-21; 91:2-3; 93:21-22; 95:5-6; 95:9-14; 95:19-22; 96:3-8; 97:20-98:19	402; 403; I	91:5-91:7	AMB; SPC; LFND; NREL; 403
89:2-90:6	[89:2-90:6] BER; LFND; NP; NREL; 403	90:7-8; 90:11-21; 91:2-3; 93:21-22; 95:5-6; 95:9-14; 95:19-22; 96:3-8; 97:20-98:19	402; 403; I	91:5-91:7	AMB; SPC; LFND; NREL; 403
91:8-92:14	[91:8-92:14] NP; NREL; OBJ; 403	90:7-8; 90:11-21; 91:2-3; 93:21-22; 95:5-6; 95:9-14;	402; 403; I	91:5-91:7	AMB; SPC; LFND; NREL; 403

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		95:19-22; 96:3-8; 97:20-98:19			
92:16-93:20	[92:16-93:20] NP; NREL; OBJ; 403	90:7-8; 90:11-21; 91:2-3; 93:21-22; 95:5-6; 95:9-14; 95:19-22; 96:3-8; 97:20-98:19	402; 403; I	91:5-91:7	AMB; SPC; LFND; NREL; 403
94:1-94:8	[94:1-8] BER; LFND; NP; NREL; 403	90:7-8; 90:11-21; 91:2-3; 93:21-22; 95:5-6; 95:9-14; 95:19-22; 96:3-8; 97:20-98:19	402; 403; I	91:5-91:7	AMB; SPC; LFND; NREL; 403
94:10-95:4	[94:10-95:4] NP; NREL; OBJ; 403	90:7-8; 90:11-21; 91:2-3; 93:21-22; 95:5-6; 95:9-14; 95:19-22; 96:3-8; 97:20-98:19	402; 403; I	91:5-91:7	AMB; SPC; LFND; NREL; 403
103:10-103:11	[103:10-11] AMB; LFND; NREL; 403	97:20-98:19; 101:20-21; 102:2-4; 103:2-3; 103:7-8	402; 403; OS		
103:14-104:1	[103:14-104:1] AMB; LFND; NREL; 403	97:20-98:19; 101:20-21; 102:2-4; 103:2-3; 103:7-8	402; 403; OS		

David Tom – November 3, 2022					
Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
5:20-6:1					
7:1-7:5	[7:1-5] HRS; NREL; 403; OBJ	28:10-21; 29:19-31:9; 61:3-8; 61:10-21	402, 403, F, SP, AS, I, LE	28:7-9, 31:10-19, 32:17-22, 33:1-9, 62:16-63:10	SPC; NREL; 403; HRS; MIL; AMB; LFND; AG; BSD
8:16-8:16		28:10-21; 29:19-31:9; 61:3-8; 61:10-21	402, 403, F, SP, AS, I, LE	28:7-9, 31:10-19, 32:17-22, 33:1-9, 62:16-63:10	SPC; NREL; 403; HRS; MIL; AMB; LFND; AG; BSD
8:20-9:1	[8:20-9:1] HRS; NREL; 403; AMB; AG; SPC; LFND	28:10-21; 29:19-31:9; 61:3-8; 61:10-21	402, 403, F, SP, AS, I, LE	28:7-9, 31:10-19, 32:17-22, 33:1-9, 62:16-63:10	SPC; NREL; 403; HRS; MIL; AMB; LFND; AG; BSD
9:15-9:20	[9:15-20] HRS; NREL; 403; AMB; INC	28:4-6; 28:10-21; 29:19-31:9; 61:3-8; 61:10-21	402, 403, F, SP, AS, I, LE	28:7-9, 31:10-19, 32:17-22, 33:1-9, 62:16-63:10	SPC; NREL; 403; HRS; MIL; AMB; LFND; AG; BSD
11:9-12:6	[11:9-12:6] NREL; 403; AMB; INC	28:4-6; 28:10-21; 29:19-31:9; 61:3-8; 61:10-21	402, 403, F, SP, AS, I, LE	28:7-9, 31:10-19, 32:17-22, 33:1-9, 62:16-63:10	SPC; NREL; 403; HRS; MIL; AMB; LFND; AG; BSD
21:8-22:4	[21:8-22:4] SPC; LFND; NREL; 403; AMB	28:10-21; 29:19-31:9; 61:3-8; 61:10-21	402, 403, F, SP, AS, I, LE	28:7-9, 31:10-19, 32:17-22, 33:1-9, 62:16-63:10	SPC; NREL; 403; HRS; MIL; AMB; LFND; AG; BSD
32:10-32:16	[32:10-16] SPC; HRS; LFND; NREL; 403; AG	28:10-21; 29:19-31:9; 61:3-8; 61:10-21	402, 403, F, SP, AS, I, LE	28:7-9, 31:10-19, 32:17-22, 33:1-9, 62:16-63:10	SPC; NREL; 403; HRS; MIL; AMB; LFND; AG; BSD

Meng Tong (Contec) – October 18, 2023					
Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
5:15-5:20					
6:9-6:19	[6:9-19] HRS; LFND; NREL; 403				
7:2-7:4		7:5-7			
7:14-7:15					
8:5-8:19	[8:5-19] LFND; NREL; 403; HRS				
9:3-9:8	[9:3-8] HRS; LFND; NREL; 403				
14:1-15:6	[14:1-15:6] AMB; SPC; HRS; LFND; NREL; 403	16:6-8; 16:11-11	I; LC; LW; EX; 403	17:8-9; 17:12- 17:17; 17:21-17:22; 18:7-18:12	AMB; BER; HRS; LFND; LDG; NREL; OBJ; 403
15:10-15:19	[15:10-19] AMB; AG; LFND; NREL; 403; HRS	16:6-8; 16:11-11	I; LC; LW; EX; 403	17:8-9; 17:12- 17:17; 17:21-17:22; 18:7-18:12	AMB; BER; HRS; LFND; LDG; NREL; OBJ; 403
16:1-16:5	[16:1-5] SPC; HRS; LFND; NREL; 403	16:6-8; 16:11-11	I; LC; LW; EX; 403	17:8-9; 17:12- 17:17; 17:21-17:22; 18:7-18:12	AMB; BER; HRS; LFND; LDG; NREL; OBJ; 403
16:15-17:7	[16:15-17:7] BER; LFND; NREL; 403; HRS	30:13-15; 30:18-21; 31:5-12	OS; 402; 403; AG; L		
18:14-18:22	[18:14-22] SPC; LFND; NREL; 403; HRS	30:13-15; 30:18-21; 31:5-12	OS; 402; 403; AG; L		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
19:1-19:11	[19:1-11] BER; HRS; LFND; NREL; 403	30:13-15; 30:18-21; 31:5-12	OS; 402; 403; AG; L		
19:13-19:13	[19:13-13] BER; HRS; LFND; NREL; 403	30:13-15; 30:18-21; 31:5-12	OS; 402; 403; AG; L		
19:15-20:1	[19:15-20:1] AG; BER; HRS; LFND; NREL; 403	30:13-15; 30:18-21; 31:5-12	OS; 402; 403; AG; L		
20:6-20:9	[20:6-9] LFND; NREL; 403; HRS	30:13-15; 30:18-21; 31:5-12	OS; 402; 403; AG; L		
20:16-20:18	[20:16-18] AMB; SPC; HRS; LFND; NREL; 403	30:13-15; 30:18-21; 31:5-12	OS; 402; 403; AG; L		
21:16-21:16	[21:16-16] AMB; SPC; HRS; LFND; NREL; 403	30:13-15; 30:18-21; 31:5-12	OS; 402; 403; AG; L		
21:17-21:19	[21:17-19] LFND; NREL; 403; HRS	30:13-15; 30:18-21; 31:5-12	OS; 402; 403; AG; L		
22:1-22:3	[22:1-3] LFND; NREL; 403; HRS	30:13-15; 30:18-21; 31:5-12	OS; 402; 403; AG; L		
22:7-22:14	[22:7-14] LFND; NREL; 403; HRS	23:3-5; 23:7-7; 32:21-33:5; 33:8-9; 33:11-11; 33:19-20; 34:1-1; 34:11-12; 34:14-22; 35:2-2; 35:12-14; 35:17-17	402; 403	9:18-9:22; 10- 1:10:12; 10:16- 10:22; 11:3-11:9	AMB; BER; HRS; IDSCR; LFND; LDG; NREL; OBJ; 403

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
22:18-23:2	[22:18-23:2] BER; LFND; NREL; 403; HRS	23:3-5; 23:7-7; 32:21-33:5; 33:8-9; 33:11-11; 33:19-20; 34:1-1; 34:11-12; 34:14-22; 35:2-2; 35:12-14; 35:17-17	402; 403	9:18-9:22; 10- 1:10:12; 10:16- 10:22; 11:3-11:9	AMB; BER; HRS; IDSCR; LFND; LDG; NREL; OBJ; 403
24:5-24:9	[24:5-9] AMB; LFND; NREL; 403; HRS	23:3-5; 23:7-7; 32:21-33:5; 33:8-9; 33:11-11; 33:19-20; 34:1-1; 34:11-12; 34:14-22; 35:2-2; 35:12-14; 35:17-17	402; 403	9:18-9:22; 10- 1:10:12; 10:16- 10:22; 11:3-11:9	AMB; BER; HRS; IDSCR; LFND; LDG; NREL; OBJ; 403
24:16-24:18	[24:16-18] BER; HRS; LFND; NREL; 403	23:3-5; 23:7-7; 32:21-33:5; 33:8-9; 33:11-11; 33:19-20; 34:1-1; 34:11-12; 34:14-22; 35:2-2; 35:12-14; 35:17-17	402; 403	9:18-9:22; 10- 1:10:12; 10:16- 10:22; 11:3-11:9	AMB; BER; HRS; IDSCR; LFND; LDG; NREL; OBJ; 403
24:20-24:21	[24:20-21] BER; HRS; LFND; NREL; 403	23:3-5; 23:7-7; 32:21-33:5; 33:8-9; 33:11-11; 33:19-20; 34:1-1; 34:11-12; 34:14-22; 35:2-2; 35:12-14; 35:17-17	402; 403	9:18-9:22; 10- 1:10:12; 10:16- 10:22; 11:3-11:9	AMB; BER; HRS; IDSCR; LFND; LDG; NREL; OBJ; 403
25:1-25:10	[25:1-10] BER; HRS; LFND; LDG; NREL; 403	23:3-5; 23:7-7; 32:21-33:5; 33:8-9; 33:11-11; 33:19-20; 34:1-1; 34:11-12;	402; 403	9:18-9:22; 10- 1:10:12; 10:16- 10:22; 11:3-11:9	AMB; BER; HRS; IDSCR; LFND; LDG; NREL; OBJ; 403

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		34:14-22; 35:2-2; 35:12-14; 35:17-17			
Video time stamp: 45:23-46:06	[25:12-12] BER; HRS; LFND; LDG; NREL; 403	23:3-5; 23:7-7; 32:21-33:5; 33:8-9; 33:11-11; 33:19-20; 34:1-1; 34:11-12; 34:14-22; 35:2-2; 35:12-14; 35:17-17	402; 403	9:18-9:22; 10- 1:10:12; 10:16- 10:22; 11:3-11:9	AMB; BER; HRS; IDSCR; LFND; LDG; NREL; OBJ; 403
25:12-25:12	[28:19-29:8] AMB; AA; LFND; LDG; NREL; 403; HRS	30:13-15; 30:18-21; 31:5-12	402; 403	9:18-9:22; 10- 1:10:12; 10:16- 10:22; 11:3-11:9	AMB; BER; HRS; IDSCR; LFND; LDG; NREL; OBJ; 403
28:19-29:8	[31:13-14] LFND; NREL; 403; HRS	30:13-15; 30:18-21; 31:5-12	402; 403	9:18-9:22; 10- 1:10:12; 10:16- 10:22; 11:3-11:9	AMB; BER; HRS; IDSCR; LFND; LDG; NREL; OBJ; 403
31:13-31:14	[31:17-18] LFND; NREL; 403; HRS	30:13-15; 30:18-21; 31:5-12	402; 403	9:18-9:22; 10- 1:10:12; 10:16- 10:22; 11:3-11:9	AMB; BER; HRS; IDSCR; LFND; LDG; NREL; OBJ; 403
31:17-31:18	[31:20-21] LFND; NREL; 403; HRS	30:13-15; 30:18-21; 31:5-12	402; 403	9:18-9:22; 10- 1:10:12; 10:16- 10:22; 11:3-11:9	AMB; BER; HRS; IDSCR; LFND; LDG; NREL; OBJ; 403
31:20-31:21	[32:2-3] LFND; NREL; 403; HRS	30:13-15; 30:18-21; 31:5-12	402; 403	9:18-9:22; 10- 1:10:12; 10:16- 10:22; 11:3-11:9	AMB; BER; HRS; IDSCR; LFND; LDG; NREL; OBJ; 403



<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
32:2-32:3					

William "Mac" Tyler – October 20, 2023					
Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
5:15-5:17					
13:13-13:21		13:22-15:10; 79:5-20			
16:5-16:7					
17:3-17:5					
20:5-20:9		49:4-10; 51:8-20; 76:10-15	402		
20:14-20:22	[20:14-22] CLC; AMB; 403; IEXP; NREL	79:21-80:4	402		
24:8-24:11	[24:8-11] CLC; NREL; 403	24:12-16; 25:3-26:2	402; F; LC; EX		
24:19-24:22	[24:19-22] NREL; 403; LDG; CLC	25:3-26:2	402; F; LC; EX		
25:1-25:2	[25:1-2] NREL; 403	25:3-26:2	402; F; LC; EX		
27:20-28:6	[27:20-28:6] NREL; 403; MM; IEXP; CLC; SPC; LFND; LDG	26:12-20	F; LC; EX		
28:18-28:22	[28:18-22] NREL; 403; CLC; SPC; IEXP	26:12-20	F; LC; EX		
29:8-29:15	[29:8-15] IEXP; NREL; 403; CLC; SPC; LDG; MM	26:12-20	F; LC; EX		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
44:10-44:22	[44:10-22] NREL; 403; CLC; IEXP; LFND; LDG	21:1-6	F; LC; EX		
45:1-45:21	[45:1-21] CLC; LDG; LFND; NREL; 403; IEXP	22:4-9	F; LC; EX	22:14-16	CLC; LFND; NREL; 403; IEXP
46:15-46:22	[46:15-22] LDG; NREL; 403	55:10-14	F; LC; EX	55:15-16; 55:19	CLC; LFND; NREL; 403; IEXP
67:20-67:22	[67:20-22] SPC; CLC; LDG; LFND; IEXP; NREL; 403	54:19-55:9; 56:7-9; 58:6-21; 67:7-19; 68:20-22; 72:18-73:6; 75:5-11	402; 403; F; LC; EX	55:21-56:6; 56:10-13; 56:20-22; 57:5-14; 73:7-12	CLC; LFND; NREL; 403; IEXP; SPC; AMB; BSD
69:13-70:1	[69:13-70:1] CLC; LDG; NREL; 403; IEXP	35:22-36:3; 36:10-14; 54:19-55:9; 56:7-9; 58:6-21; 67:7-19; 68:20-22; 72:18-73:6; 75:5-11	402; 403; F; LC; EX	55:21-56:6; 56:10-13; 56:20-22; 57:5-14; 73:7-12	CLC; LFND; NREL; 403; IEXP; SPC; AMB; BSD
70:17-70:18	[70:17-18] NREL; 403; SPC; LDG; IEXP; CLC; LFND	54:19-55:9; 56:7-9; 58:6-21; 67:7-19; 68:20-22; 72:18-73:6; 75:5-11	402; 403; F; LC; EX	55:21-56:6; 56:10-13; 56:20-22; 57:5-14; 73:7-12	CLC; LFND; NREL; 403; IEXP; SPC; AMB; BSD
70:21-70:21		54:19-55:9; 56:7-9; 58:6-21; 67:7-19; 68:20-22; 72:18-73:6; 75:5-11	402; 403; F; LC; EX	55:21-56:6; 56:10-13; 56:20-22; 57:5-14; 73:7-12	CLC; LFND; NREL; 403; IEXP; SPC; AMB; BSD
71:1-71:8	[71:1-8] CLC; LDG; MM; SPC;	35:22-36:3; 36:10-14; 54:19-55:9; 56:7-9; 58:6-21;	402; 403; F; LC; EX	55:21-56:6; 56:10-13; 56:20-22; 57:5-14; 73:7-12	CLC; LFND; NREL; 403; IEXP; SPC; AMB; BSD

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
	IEXP; NREL; 403; LFND	67:7-19; 68:20-22; 72:18-73:6; 75:5-11			
71:22-72:13	[71:22-72:13] IEXP; NREL; 403; LDG; MM; CLC; SPC; LFND	35:22-36:3; 36:10-14; 54:19-55:9; 56:7-9; 58:6-21; 67:7-19; 68:20-22; 72:18-73:6; 75:5-11	402; 403; F; LC; EX	55:21-56:6; 56:10-13; 56:20-22; 57:5-14; 73:7-12	CLC; LFND; NREL; 403; IEXP; SPC; AMB; BSD

Vivek Venugopal – October 20, 2023					
Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
11:19-11:20					
103:11-103:15	[103:11-15] NREL; 403; AMB; LFND; INC; SPC	111:11-112:2	OS		
106:13-106:20	[106:13-20] SPC; IEXP; NREL; 403; LFND				
111:1-111:10	[111:1-10] NREL; 403; AMB; LFND; INC	148:11-16; 149:6-9	402, 403, OS	146:18-147:16, 148:5-6	NREL; OBJ; 403; BSD; PRV; IMP
112:3-112:18	[112:3-18] NREL; 403; AMB; AG; INC	148:11-16	402, 403, OS	146:18-147:16, 148:5-6	NREL; OBJ; 403; BSD; PRV; IMP
114:12-114:17	[114:12-17] NREL; 403; AMB; INC	118:13-120:10; 148:11-16; 149:6-9	402, 403, OS	146:18-147:16, 148:5-6	NREL; OBJ; 403; BSD; PRV; IMP
118:5-118:11	[118:5-11] LDG; NREL; 403; AMB; SPC; INC; OS				
120:12-120:18	[120:12-18] AMB; SPC; LFND; NREL; 403; INC				
122:13-122:19	[122:13-19] HRS; NREL; 403; AMB; LFND; LDG	133:19-134:8	I, V	133:9-17	NREL; 403; HRS

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
123:10-123:18	[123:10-18] SPC; HRS; LFND; NREL; 403; AMB	133:19-134:8	I, V	133:9-17	NREL; 403; HRS
124:10-125:2	[124:10-125:2] AMB; SPC; HRS; LFND; NREL; 403; INC	133:19-134:8	I, V	133:9-17	NREL; 403; HRS
132:4-132:18	[132:4-18] AMB; SPC; HRS; LFND; NREL; 403	133:19-134:8	I, V	133:9-17	NREL; 403; HRS
134:9-134:21	[134:9-21] SPC; LFND; NREL; 403; AMB	133:19-134:8	I, V	133:9-17	NREL; 403; HRS
135:22-136:1	[135:22-136:1] NREL; 403; OBJ	136:16-137:9; 137:11-22			
136:6-136:15	[136:6-15] HRS; NREL; 403; SPC; AMB	136:16-137:9; 137:11-22			
138:2-138:7	[138:2-7] AMB; SPC; HRS; LFND; NREL; 403; LA	137:11-22		140:2-6	NREL; 403; HRS
140:15-141:9	[140:15-141:9] SPC; HRS; LFND; MIS; NREL; 403; AMB	137:11-22		140:2-6	NREL; 403; HRS

**Steven Waydo – August 11, 2022**

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
8:14-8:16					
77:7-78:16	[77:7-78:16] AMB; LFND; NREL; 403				
100:15-100:17	[100:15-17] AMB; LFND; NREL; 403				
100:20-103:1	[100:20-103:1] AMB; LFND; NREL; 403				
126:16-127:7	[126:16-127:7] AMB; LFND; NREL; 403	127:8-128:5		117:20-118:12, 128:6-129:4	[117:20-118:12] AMB; LFND; NREL; 403; [128:6-129:4] AMB; LFND; NREL; 403

**Steven Waydo – October 27, 2023**

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
8:8-8:10		193:13-194:17; 195:17-196:16	F, LE, M, V, 402, 403	197:3-4, 199:20- 200:9, 200:11-18, 201:13-202:12, 202:13-15, 203:1-3, 203:6-7, 203:9-11,	[197:3-4] AMB; NREL; 403; MIL; [199:20-200:9] AMB; NREL; 403; MIL;

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
				203:14-204:1, 204:18-205:5	[200:11-18] AMB; NREL; 403; MIL; [201:13-202:12] AMB; NREL; 403; MIL; [202:13-15] AMB; NREL; 403; MIL; [203:1-3] AMB; NREL; 403; MIL; [203:6-7] AMB; NREL; 403; MIL; [203:9-11] AMB; NREL; 403; MIL; [203:14-204:1] AMB; NREL; 403; MIL; [204:18-205:5] AMB; NREL; 403; MIL;
86:16-86:18	[86:16-18] AMB; LFND; NREL; 403	193:13-194:17; 195:17-196:16	F, LE, M, V, 402, 403	197:3-4, 199:20- 200:9, 200:11-18, 201:13-202:12, 202:13-15, 203:1-3, 203:6-7, 203:9-11, 203:14-204:1, 204:18-205:5	[197:3-4] AMB; NREL; 403; MIL; [199:20-200:9] AMB; NREL; 403; MIL; [200:11-18] AMB; NREL; 403; MIL;



<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
					[201:13-202:12] AMB; NREL; 403; MIL; [202:13-15] AMB; NREL; 403; MIL; [203:1-3] AMB; NREL; 403; MIL; [203:6-7] AMB; NREL; 403; MIL; [203:9-11] AMB; NREL; 403; MIL; [203:14-204:1] AMB; NREL; 403; MIL; [204:18-205:5] AMB; NREL; 403; MIL;
87:1-87:12	[87:1-12] AMB; LFND; NREL; 403	193:13-194:17; 195:17-196:16	F, LE, M, V, 402, 403	197:3-4, 199:20-200:9, 200:11-18, 201:13-202:12, 202:13-15, 203:1-3, 203:6-7, 203:9-11, 203:14-204:1, 204:18-205:5	[197:3-4] AMB; NREL; 403; MIL; [199:20-200:9] AMB; NREL; 403; MIL; [200:11-18] AMB; NREL; 403; MIL; [201:13-202:12] AMB; NREL; 403; MIL;

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
					[202:13-15] AMB; NREL; 403; MIL; [203:1-3] AMB; NREL; 403; MIL; [203:6-7] AMB; NREL; 403; MIL; [203:9-11] AMB; NREL; 403; MIL; [203:14-204:1] AMB; NREL; 403; MIL; [204:18-205:5] AMB; NREL; 403; MIL;
87:13-87:15	[87:13-15] AMB; LFND; NREL; 403	193:13-194:17; 195:17-196:16	F, LE, M, V, 402, 403	197:3-4, 199:20-200:9, 200:11-18, 201:13-202:12, 202:13-15, 203:1-3, 203:6-7, 203:9-11, 203:14-204:1, 204:18-205:5	[197:3-4] AMB; NREL; 403; MIL; [199:20-200:9] AMB; NREL; 403; MIL; [200:11-18] AMB; NREL; 403; MIL; [201:13-202:12] AMB; NREL; 403; MIL; [202:13-15] AMB; NREL; 403; MIL; [203:1-3] AMB; NREL; 403; MIL;

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					[203:6-7] AMB; NREL; 403; MIL; [203:9-11] AMB; NREL; 403; MIL; [203:14-204:1] AMB; NREL; 403; MIL; [204:18-205:5] AMB; NREL; 403; MIL;
88:7-88:22	[88:7-22] AMB; LFND; NREL; 403	193:13-194:17; 195:17-196:16	F, LE, M, V, 402, 403	197:3-4, 199:20-200:9, 200:11-18, 201:13-202:12, 202:13-15, 203:1-3, 203:6-7, 203:9-11, 203:14-204:1, 204:18-205:5	[197:3-4] AMB; NREL; 403; MIL; [199:20-200:9] AMB; NREL; 403; MIL; [200:11-18] AMB; NREL; 403; MIL; [201:13-202:12] AMB; NREL; 403; MIL; [202:13-15] AMB; NREL; 403; MIL; [203:1-3] AMB; NREL; 403; MIL; [203:6-7] AMB; NREL; 403; MIL; [203:9-11] AMB; NREL; 403; MIL;

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
					[203:14-204:1] AMB; NREL; 403; MIL; [204:18-205:5] AMB; NREL; 403; MIL;
89:3-89:14	[89:3-14] AMB; LFND; NREL; 403	193:13-194:17; 195:17-196:16	F, LE, M, V, 402, 403	197:3-4, 199:20-200:9, 200:11-18, 201:13-202:12, 202:13-15, 203:1-3, 203:6-7, 203:9-11, 203:14-204:1, 204:18-205:5	[197:3-4] AMB; NREL; 403; MIL; [199:20-200:9] AMB; NREL; 403; MIL; [200:11-18] AMB; NREL; 403; MIL; [201:13-202:12] AMB; NREL; 403; MIL; [202:13-15] AMB; NREL; 403; MIL; [203:1-3] AMB; NREL; 403; MIL; [203:6-7] AMB; NREL; 403; MIL; [203:9-11] AMB; NREL; 403; MIL; [203:14-204:1] AMB; NREL; 403; MIL;

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
					[204:18-205:5] AMB; NREL; 403; MIL;
89:17-90:5	[89:17-90:5] AMB; LFND; NREL; 403	193:13-194:17; 195:17-196:16	F, LE, M, V, 402, 403	197:3-4, 199:20-200:9, 200:11-18, 201:13-202:12, 202:13-15, 203:1-3, 203:6-7, 203:9-11, 203:14-204:1, 204:18-205:5	[197:3-4] AMB; NREL; 403; MIL; [199:20-200:9] AMB; NREL; 403; MIL; [200:11-18] AMB; NREL; 403; MIL; [201:13-202:12] AMB; NREL; 403; MIL; [202:13-15] AMB; NREL; 403; MIL; [203:1-3] AMB; NREL; 403; MIL; [203:6-7] AMB; NREL; 403; MIL; [203:9-11] AMB; NREL; 403; MIL; [203:14-204:1] AMB; NREL; 403; MIL; [204:18-205:5] AMB; NREL; 403; MIL;

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
94:16-95:3		193:13-194:17; 195:17-196:16	F, LE, M, V, 402, 403	197:3-4, 199:20- 200:9, 200:11-18, 201:13-202:12, 202:13-15, 203:1-3, 203:6-7, 203:9-11, 203:14-204:1, 204:18-205:5	[197:3-4] AMB; NREL; 403; MIL; [199:20-200:9] AMB; NREL; 403; MIL; [200:11-18] AMB; NREL; 403; MIL; [201:13-202:12] AMB; NREL; 403; MIL; [202:13-15] AMB; NREL; 403; MIL; [203:1-3] AMB; NREL; 403; MIL; [203:6-7] AMB; NREL; 403; MIL; [203:9-11] AMB; NREL; 403; MIL; [203:14-204:1] AMB; NREL; 403; MIL; [204:18-205:5] AMB; NREL; 403; MIL;
94:16-95:3		193:13-194:17; 195:17-196:16	F, LE, M, V, 402, 403	197:3-4, 199:20- 200:9, 200:11-18, 201:13-202:12, 202:13-15, 203:1-3,	[197:3-4] AMB; NREL; 403; MIL;

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
				203:6-7, 203:9-11, 203:14-204:1, 204:18-205:5	[199:20-200:9] AMB; NREL; 403; MIL; [200:11-18] AMB; NREL; 403; MIL; [201:13-202:12] AMB; NREL; 403; MIL; [202:13-15] AMB; NREL; 403; MIL; [203:1-3] AMB; NREL; 403; MIL; [203:6-7] AMB; NREL; 403; MIL; [203:9-11] AMB; NREL; 403; MIL; [203:14-204:1] AMB; NREL; 403; MIL; [204:18-205:5] AMB; NREL; 403; MIL;
95:21-95:21	[96:1-19] AMB; LFND; NREL; 403	193:13-194:17; 195:17-196:16	F, LE, M, V, 402, 403	197:3-4, 199:20-200:9, 200:11-18, 201:13-202:12, 202:13-15, 203:1-3, 203:6-7, 203:9-11,	[197:3-4] AMB; NREL; 403; MIL; [199:20-200:9] AMB; NREL; 403; MIL;

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
				203:14-204:1, 204:18-205:5	[200:11-18] AMB; NREL; 403; MIL; [201:13-202:12] AMB; NREL; 403; MIL; [202:13-15] AMB; NREL; 403; MIL; [203:1-3] AMB; NREL; 403; MIL; [203:6-7] AMB; NREL; 403; MIL; [203:9-11] AMB; NREL; 403; MIL; [203:14-204:1] AMB; NREL; 403; MIL; [204:18-205:5] AMB; NREL; 403; MIL;
95:21-95:21	[111:5-112:12] AMB; LFND; NREL; 403	193:13-194:17; 195:17-196:16	F, LE, M, V, 402, 403	197:3-4, 199:20- 200:9, 200:11-18, 201:13-202:12, 202:13-15, 203:1-3, 203:6-7, 203:9-11, 203:14-204:1, 204:18-205:5	[197:3-4] AMB; NREL; 403; MIL; [199:20-200:9] AMB; NREL; 403; MIL; [200:11-18] AMB; NREL; 403; MIL;



Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					[201:13-202:12] AMB; NREL; 403; MIL; [202:13-15] AMB; NREL; 403; MIL; [203:1-3] AMB; NREL; 403; MIL; [203:6-7] AMB; NREL; 403; MIL; [203:9-11] AMB; NREL; 403; MIL; [203:14-204:1] AMB; NREL; 403; MIL; [204:18-205:5] AMB; NREL; 403; MIL;
96:1-96:19	[114:2-10] AMB; LFND; NREL; 403	193:13-194:17; 195:17-196:16	F, LE, M, V, 402, 403	197:3-4, 199:20-200:9, 200:11-18, 201:13-202:12, 202:13-15, 203:1-3, 203:6-7, 203:9-11, 203:14-204:1, 204:18-205:5	[197:3-4] AMB; NREL; 403; MIL; [199:20-200:9] AMB; NREL; 403; MIL; [200:11-18] AMB; NREL; 403; MIL; [201:13-202:12] AMB; NREL; 403; MIL;

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					[202:13-15] AMB; NREL; 403; MIL; [203:1-3] AMB; NREL; 403; MIL; [203:6-7] AMB; NREL; 403; MIL; [203:9-11] AMB; NREL; 403; MIL; [203:14-204:1] AMB; NREL; 403; MIL; [204:18-205:5] AMB; NREL; 403; MIL;
111:5-112:12	[115:22-116:9] AMB; LFND; NREL; 403; HRS	193:13-194:17; 195:17-196:16	F, LE, M, V, 402, 403	197:3-4, 199:20-200:9, 200:11-18, 201:13-202:12, 202:13-15, 203:1-3, 203:6-7, 203:9-11, 203:14-204:1, 204:18-205:5	[197:3-4] AMB; NREL; 403; MIL; [199:20-200:9] AMB; NREL; 403; MIL; [200:11-18] AMB; NREL; 403; MIL; [201:13-202:12] AMB; NREL; 403; MIL; [202:13-15] AMB; NREL; 403; MIL; [203:1-3] AMB; NREL; 403; MIL;

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
					[203:6-7] AMB; NREL; 403; MIL; [203:9-11] AMB; NREL; 403; MIL; [203:14-204:1] AMB; NREL; 403; MIL; [204:18-205:5] AMB; NREL; 403; MIL;
114:2-114:10	[119:11-120:11] AMB; LFND; NREL; 403	193:13-194:17; 195:17-196:16	F, LE, M, V, 402, 403	197:3-4, 199:20-200:9, 200:11-18, 201:13-202:12, 202:13-15, 203:1-3, 203:6-7, 203:9-11, 203:14-204:1, 204:18-205:5	[197:3-4] AMB; NREL; 403; MIL; [199:20-200:9] AMB; NREL; 403; MIL; [200:11-18] AMB; NREL; 403; MIL; [201:13-202:12] AMB; NREL; 403; MIL; [202:13-15] AMB; NREL; 403; MIL; [203:1-3] AMB; NREL; 403; MIL; [203:6-7] AMB; NREL; 403; MIL; [203:9-11] AMB; NREL; 403; MIL;

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					[203:14-204:1] AMB; NREL; 403; MIL; [204:18-205:5] AMB; NREL; 403; MIL;
115:22-116:9	[121:15-122:2] AMB; LFND; NREL; 403	193:13-194:17; 195:17-196:16	F, LE, M, V, 402, 403	197:3-4, 199:20-200:9, 200:11-18, 201:13-202:12, 202:13-15, 203:1-3, 203:6-7, 203:9-11, 203:14-204:1, 204:18-205:5	[197:3-4] AMB; NREL; 403; MIL; [199:20-200:9] AMB; NREL; 403; MIL; [200:11-18] AMB; NREL; 403; MIL; [201:13-202:12] AMB; NREL; 403; MIL; [202:13-15] AMB; NREL; 403; MIL; [203:1-3] AMB; NREL; 403; MIL; [203:6-7] AMB; NREL; 403; MIL; [203:9-11] AMB; NREL; 403; MIL; [203:14-204:1] AMB; NREL; 403; MIL;

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
					[204:18-205:5] AMB; NREL; 403; MIL;
119:11-120:11		193:13-194:17; 195:17-196:16	F, LE, M, V, 402, 403	197:3-4, 199:20-200:9, 200:11-18, 201:13-202:12, 202:13-15, 203:1-3, 203:6-7, 203:9-11, 203:14-204:1, 204:18-205:5	[197:3-4] AMB; NREL; 403; MIL; [199:20-200:9] AMB; NREL; 403; MIL; [200:11-18] AMB; NREL; 403; MIL; [201:13-202:12] AMB; NREL; 403; MIL; [202:13-15] AMB; NREL; 403; MIL; [203:1-3] AMB; NREL; 403; MIL; [203:6-7] AMB; NREL; 403; MIL; [203:9-11] AMB; NREL; 403; MIL; [203:14-204:1] AMB; NREL; 403; MIL; [204:18-205:5] AMB; NREL; 403; MIL;

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
121:15-122:2	[86:16-18] AMB; LFND; NREL; 403	193:13-194:17; 195:17-196:16	F, LE, M, V, 402, 403	197:3-4, 199:20- 200:9, 200:11-18, 201:13-202:12, 202:13-15, 203:1-3, 203:6-7, 203:9-11, 203:14-204:1, 204:18-205:5	[197:3-4] AMB; NREL; 403; MIL; [199:20-200:9] AMB; NREL; 403; MIL; [200:11-18] AMB; NREL; 403; MIL; [201:13-202:12] AMB; NREL; 403; MIL; [202:13-15] AMB; NREL; 403; MIL; [203:1-3] AMB; NREL; 403; MIL; [203:6-7] AMB; NREL; 403; MIL; [203:9-11] AMB; NREL; 403; MIL; [203:14-204:1] AMB; NREL; 403; MIL; [204:18-205:5] AMB; NREL; 403; MIL;

Steven Waydo – July 9, 2024					
Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
8:21-9:1		100:8-102:12	OS		
33:17-34:4		34:15-36:2; 36:15-37:3; 100:8-102:12	OS	34:7-14, 326:20-327:2, 327:4-9, 339:7-340:2	[34:7-14] AMB; LFND; NREL; [326:20-327:2] AMB; LFND; NREL; [327:4-9] AMB; LFND; NREL; [339:7-340:2] AMB; LFND; NREL;
36:3-36:14	[36:3-14] AMB; SPC; LFND; NREL; OS; 403	34:15-36:2; 36:15-37:3; 100:8-102:12	OS	34:7-14, 326:20-327:2, 327:4-9, 339:7-340:2	[34:7-14] AMB; LFND; NREL; [326:20-327:2] AMB; LFND; NREL; [327:4-9] AMB; LFND; NREL; [339:7-340:2] AMB; LFND; NREL;
96:4-97:11	[96:4-97:11] AMB; SPC; LFND; NREL; OS; 403	97:12-98:7; 100:8-102:12		102:13-19, 326:20-327:2, 327:4-9, 339:7-340:2	[102:13-19] AMB; LFND; NREL; [326:20-327:2] AMB; LFND; NREL;

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
					[327:4-9] AMB; LFND; NREL; [339:7-340:2] AMB; LFND; NREL;
98:12-99:7	[98:12-99:7] AMB; SPC; LFND; NREL; OS; 403	100:8-102:12		102:13-19, 326:20- 327:2, 327:4-9, 339:7-340:2	[102:13-19] AMB; LFND; NREL; [326:20-327:2] AMB; LFND; NREL; [327:4-9] AMB; LFND; NREL; [339:7-340:2] AMB; LFND; NREL;
333:6-333:16	[333:6-16] AMB; SPC; LFND; NREL; OS; 403	333:17-334:9	402, 403	332:19-333:3, 338:18-21, 339:7- 340:2	[332:19-333:3] AMB; LFND; NREL; [338:18-21] AMB; LFND; NREL; [339:7-340:2] AMB; LFND; NREL;



Steven Waydo – June 9, 2022 (ITC Hearing, Vol. IV)					
Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
918:22-919:2	HRS; NREL, 403; SPC; LFND; CPD; AMB; MIS	927:10-928:8; 949:6-16	I, V, OS	943:8-13	[943:8-13] AMB; LFND; NREL;
926:23-927:9	HRS; NREL, 403; SPC; LFND; CPD; AMB; MIS	927:10-928:8; 949:6-16	I, V, OS	943:8-13	[943:8-13] AMB; LFND; NREL;

Jeff Williams – August 9, 2023					
Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
10:13-10:15		296:17-297:9; 297:10-298:16; 300:2-20; 310:2-7; 310:10-16	402, 403, OS, LE		
11:11-12:3	[11:11-12:3] AMB; NREL; 403	296:17-297:9; 297:10-298:16; 300:2-20; 310:2-7; 310:10-16	402, 403, OS, LE		
50:22-51:1	[50:22-51:1] AG; ATH; IDSCR; LFND; NREL; OBJ; 403	52:5-13; 53:7-12; 54:3-6; 58:6-13; 58:14-20; 58:21- 59:7; 302:21-303:18	402, 403, F, SP, OS, I, LE	59:8-60:4	AMB; AG; BSD; SPC; HYP; LFND; INC; MIS; NREL; 403; MIL
51:19-52:1	[51:19-52:1] AMB; AG; ATH; BSD; SPC; LFND; LA; NREL; OBJ; 403	52:5-13; 296:17- 297:9; 297:10- 298:16; 300:2-20; 310:2-7; 310:10-16	402, 403, F, SP, OS, I, LE	59:8-60:4	AMB; AG; BSD; SPC; HYP; LFND; INC; MIS; NREL; 403; MIL
52:14-52:17	[52:14-17] AMB; AG; ATH; BSD; SPC; LFND; LA; NREL; 403	53:7-12; 54:3-6; 58:6-13; 58:14-20; 58:21-59:7; 302:21- 303:18	402, 403, F, SP, OS, I, LE	59:8-60:4	AMB; AG; BSD; SPC; HYP; LFND; INC; MIS; NREL; 403; MIL
101:19-102:7	[101:19-102:7] AMB; AG; ATH; SPC; LFND; LA; NREL; 403	53:7-12; 54:3-6; 58:6-13; 58:14-20; 58:21-59:7; 102:14- 18; 103:22-104:6; 104:20-105:1; 105:18-106:11;	402, 403, F, SP, OS, I, LE	59:8-60:4, 102:19- 103:4, 106:14- 107:2, 107:5-7, 108:17-21	AMB; AG; BSD; SPC; HYP; LFND; INC; MIS; NREL; 403; ATH; HRS; MIL

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		107:8-15; 108:9-16; 302:21-303:18			
103:14-103:21	[103:14-21] AMB; AG; ATH; BSD; 1006; IDSCR; LFND; LA; NREL; 403	53:7-12; 54:3-6; 58:6-13; 58:14-20; 58:21-59:7; 102:14- 18; 103:22-104:6; 104:20-105:1; 105:18-106:11; 107:8-15; 108:9-16; 302:21-303:18	402, 403, F, SP, OS, I, LE	59:8-60:4, 102:19- 103:4, 106:14- 107:2, 107:5-7, 108:17-21	AMB; AG; BSD; SPC; HYP; LFND; INC; MIS; NREL; 403; ATH; HRS; MIL
105:7-105:17	[105:7-17] AMB; AG; ATH; BSD; 1006; IDSCR; LFND; LA; NREL; 403	53:7-12; 54:3-6; 58:6-13; 58:14-20; 58:21-59:7; 102:14- 18; 103:22-104:6; 104:20-105:1; 105:18-106:11; 107:8-15; 108:9-16; 302:21-303:18	402, 403, F, SP, OS, I, LE	59:8-60:4, 102:19- 103:4, 106:14- 107:2, 107:5-7, 108:17-21	AMB; AG; BSD; SPC; HYP; LFND; INC; MIS; NREL; 403; ATH; HRS; MIL
108:3-108:8	[108:3-8] AMB; AG; ATH; BSD; LFND; LA; NREL; 403	53:7-12; 54:3-6; 58:6-13; 58:14-20; 58:21-59:7; 105:18- 106:11; 107:8-15; 108:9-16; 302:21- 303:18	402, 403, F, SP, OS, I, LE	59:8-60:4, 102:19- 103:4, 106:14- 107:2, 107:5-7, 108:17-21	AMB; AG; BSD; SPC; HYP; LFND; INC; MIS; NREL; 403; ATH; HRS; MIL
245:18-247:9	[245:18-247:9] AMB; AG; BSD; CLC; SPC; IEXP;	58:6-13; 58:14-20; 58:21-59:7; 247:10- 20; 296:17-297:9; 297:10-298:16;	402, 403, F, SP, OS, I, LE	59:8-60:4, 247:21- 248:5	AMB; AG; BSD; SPC; HYP; LFND; INC; MIS; NREL; 403; MIL

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
	LFND; LA; MIS; NREL; 403	300:2-20; 302:21- 303:18; 303:21- 304:11; 304:13-14; 304:21-305:1; 310:2-7			

Michael Wittenberg – November 7, 2023					
Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
5:16-5:18					
8:15-8:18		115:14-21			
13:22-14:1		115:14-21			
14:16-14:21		115:14-21			
16:17-17:2	[16:17-17:2] CLC; IEXP; LDG; NREL; 403	18:17-19:12; 20:9-14; 20:17-17; 21:14-22; 22:15-23:6; 24:2-13; 24:2-13; 27:18-28:21; 32:5-33:13; 34:15-16; 34:18-35:2; 43:3-4; 43:6-16; 44:4-46:4; 115:14-21	402; 403; F; SP; LC; EX	20:19-20; 21:1-2; 23:7-9; 23:12; 23:14-15; 23:18; 24:14-16	SPC; CLC; LFND; 403; NREL; IEXP; BSD
17:3-17:16		17:17-18:7; 18:17-19:12; 20:9-14; 20:17-17; 21:14-22; 22:15-23:6; 24:2-13; 24:2-13; 27:18-28:21; 32:5-33:13; 34:15-16; 34:18-35:2; 43:3-4; 43:6-16; 44:4-46:4; 115:14-21	402; 403; F; SP; LC; EX	20:19-20; 21:1-2; 23:7-9; 23:12; 23:14-15; 23:18; 24:14-16	SPC; CLC; LFND; 403; NREL; IEXP; BSD

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
18:8-18:9	[18:8-9] CLC; IEXP; LDG; NREL; 403	17:17-18:7; 18:17-19:12; 20:9-14; 20:17-17; 21:14-22; 22:15-23:6; 24:2-13; 24:2-13; 27:18-28:21; 32:5-33:13; 34:15-16; 34:18-35:2; 43:3-4; 43:6-16; 44:4-46:4; 115:14-21	402; 403; F; SP; LC; EX	20:19-20; 21:1-2; 23:7-9; 23:12; 23:14-15; 23:18; 24:14-16	SPC; CLC; LFND; 403; NREL; IEXP; BSD
18:13-18:15		17:17-18:7; 18:17-19:12; 20:9-14; 20:17-17; 21:14-22; 22:15-23:6; 24:2-13; 24:2-13; 27:18-28:21; 32:5-33:13; 34:15-16; 34:18-35:2; 43:3-4; 43:6-16; 115:14-21	402; 403; F; SP; LC; EX	20:19-20; 21:1-2; 23:7-9; 23:12; 23:14-15; 23:18; 24:14-16	SPC; CLC; LFND; 403; NREL; IEXP; BSD
19:13-20:8		17:17-18:7; 18:17-19:12; 20:9-14; 20:17-17; 21:14-22; 22:15-23:6; 24:2-13; 24:2-13; 27:18-28:21; 32:5-33:13; 34:15-16; 34:18-35:2; 43:3-4; 43:6-16; 44:4-46:4	402; 403; F; SP; LC; EX	20:19-20; 21:1-2; 23:7-9; 23:12; 23:14-15; 23:18; 24:14-16	SPC; CLC; LFND; 403; NREL; IEXP; BSD

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
21:3-21:13	[21:3-13] LFND; NREL; 403	17:17-18:7; 18:17- 19:12; 20:9-14; 20:17-17; 21:14-22; 22:15-23:6; 24:2- 13; 24:2-13; 27:18- 28:21; 32:5-33:13; 34:15-16; 34:18- 35:2; 43:3-4; 43:6- 16; 44:4-46:4; 63:11-13	402; 403; F; SP; LC; EX	20:19-20; 21:1-2; 23:7-9; 23:12; 23:14-15; 23:18; 24:14-16	SPC; CLC; LFND; 403; NREL; IEXP; BSD
26:6-26:11	[26:6-11] CLC; SPC; LFND; NREL; 403	24:2-13; 24:2-13; 27:18-28:21; 32:5- 33:13; 34:15-16; 34:18-35:2; 43:3-4; 43:6-16; 44:4-46:4	402; 403; F; SP; LC; EX	20:19-20; 21:1-2; 23:7-9; 23:12; 23:14-15; 23:18; 24:14-16	SPC; CLC; LFND; 403; NREL; IEXP; BSD
35:4-35:20	[35:4-20] CLC; SPC; IEXP; LFND; LDG; NREL; 403; AMB	32:5-33:13; 34:15- 16; 34:18-35:2; 43:3-4; 43:6-16; 44:4-46:4	402; 403; F; SP; LC; EX	20:19-20; 21:1-2; 23:7-9; 23:12; 23:14-15; 23:18; 24:14-16	SPC; CLC; LFND; 403; NREL; IEXP; BSD
35:22-36:17	[35:22-36:17] AA; NREL; 403; CLC	32:5-33:13; 34:15- 16; 34:18-35:2; 43:3-4; 43:6-16; 44:4-46:4	402; 403; F; SP; LC; EX	20:19-20; 21:1-2; 23:7-9; 23:12; 23:14-15; 23:18; 24:14-16	SPC; CLC; LFND; 403; NREL; IEXP; BSD
36:21-37:8	[36:21-37:8] CLC; SPC; IEXP; NREL; 403	32:5-33:13; 34:15- 16; 34:18-35:2; 43:3-4; 43:6-16; 44:4-46:4	402; 403; F; SP; LC; EX	20:19-20; 21:1-2; 23:7-9; 23:12; 23:14-15; 23:18; 24:14-16	SPC; CLC; LFND; 403; NREL; IEXP; BSD

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
37:13-37:14		37:17-38:20; 43:3-4; 43:6-16; 44:4-46:4	402; 403; F; SP; LC; EX	20:19-20; 21:1-2; 23:7-9; 23:12; 23:14-15; 23:18; 24:14-16	SPC; CLC; LFND; 403; NREL; IEXP; BSD
38:21-39:3	[38:21-39:3] CLC; LDG; NREL; 403	37:17-38:20; 43:3-4; 43:6-16; 44:4-46:4	402; 403; F; SP; LC; EX	20:19-20; 21:1-2; 23:7-9; 23:12; 23:14-15; 23:18; 24:14-16	SPC; CLC; LFND; 403; NREL; IEXP; BSD
56:1-56:11	[56:1-11] CLC; IEXP; NREL; 403				
61:16-62:13	[61:16-62:13] AMB; CLC; CPD; IEXP; NREL; 403	63:11-13; 63:17-64:5	402; 403; F; SP; LC; EX	63:1-10; 63:14-16	SPC; CLC; LFND; 403; NREL; IEXP; AMB
62:16-62:21		63:11-13; 63:17-64:5	402; 403; F; SP; LC; EX	63:1-10; 63:14-16	SPC; CLC; LFND; 403; NREL; IEXP; AMB
64:6-64:8	[64:6-8] AMB; CLC; SPC; NREL; 403	63:17-64:5	402; 403; F; SP; LC; EX	63:1-10; 63:14-16	SPC; CLC; LFND; 403; NREL; IEXP; AMB
64:11-64:16	[64:11-16] AMB; CLC; SPC; NREL; 403	63:17-64:5	402; 403; F; SP; LC; EX	63:1-10; 63:14-16	SPC; CLC; LFND; 403; NREL; IEXP; AMB
64:18-64:22	[64:18-22] AMB; CLC; SPC; NREL; 403	63:17-64:5	402; 403; F; SP; LC; EX	63:1-10; 63:14-16	SPC; CLC; LFND; 403; NREL; IEXP; AMB
65:2-65:7	[65:2-7] AMB; CLC; SPC; NREL; 403	63:17-64:5	402; 403; F; SP; LC; EX	63:1-10; 63:14-16	SPC; CLC; LFND; 403; NREL; IEXP; AMB



<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
65:9-65:14	[65:9-14] AMB; CLC; SPC; NREL; 403	63:17-64:5	402; 403; F; SP; LC; EX	63:1-10; 63:14-16	SPC; CLC; LFND; 403; NREL; IEXP; AMB
65:16-65:22	[65:16-22] AMB; CLC; SPC; NREL; 403	63:17-64:5	402; 403; F; SP; LC; EX	63:1-10; 63:14-16	SPC; CLC; LFND; 403; NREL; IEXP; AMB
66:3-66:9	[66:3-9] AMB; CLC; SPC; NREL; 403	63:11-13; 63:17- 64:5	402; 403; F; SP; LC; EX	63:1-10; 63:14-16	SPC; CLC; LFND; 403; NREL; IEXP; AMB
66:13-67:13	[66:13-67:13] AMB; NREL; 403	63:11-13; 63:17- 64:5	402; 403; F; SP; LC; EX	63:1-10; 63:14-16	SPC; CLC; LFND; 403; NREL; IEXP; AMB
89:19-89:22	[89:19-22] AMB; CLC; SPC; IEXP; LFND; LDG; NREL; 403	90:20-91:16; 91:19- 92:17; 93:11-96:6; 99:3-100:22; 101:14-103:14; 103:19-105:10; 107:4-20	402; 403; F; SP; LC; EX	92:18-93:1; 93:5; 96:7-14; 97:19-22; 101:7-13; 103:15- 18; 105:11-15; 106:14-16; 106:19- 20	403; NREL; AMB; CLC; SPC; IEXP; LFND; LDG; BSD
90:15-90:19	[90:15-19] AMB; CLC; SPC; IEXP; LDG; NREL; 403	90:20-91:16; 91:19- 92:17; 93:11-96:6; 99:3-100:22; 101:14-103:14; 103:19-105:10; 107:4-20	402; 403; F; SP; LC; EX	92:18-93:1; 93:5; 96:7-14; 97:19-22; 101:7-13; 103:15- 18; 105:11-15; 106:14-16; 106:19- 20	403; NREL; AMB; CLC; SPC; IEXP; LFND; LDG; BSD
93:7-93:10	[93:7-10] AMB; CLC; SPC; IEXP; LFND; LDG; NREL; 403	90:20-91:16; 91:19- 92:17; 93:11-96:6; 99:3-100:22; 101:14-103:14;	402; 403; F; SP; LC; EX	92:18-93:1; 93:5; 96:7-14; 97:19-22; 101:7-13; 103:15- 18; 105:11-15;	403; NREL; AMB; CLC; SPC; IEXP; LFND; LDG; BSD

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		103:19-105:10; 107:4-20		106:14-16; 106:19-20	
106:22-107:3	[106:22-107:3] CLC; SPC; IEXP; LFND; LDG; NREL; 403	90:20-91:16; 91:19-92:17; 93:11-96:6; 99:3-100:22; 101:14-103:14; 103:19-105:10; 107:4-20	402; 403; F; SP; LC; EX	92:18-93:1; 93:5; 96:7-14; 97:19-22; 101:7-13; 103:15-18; 105:11-15; 106:14-16; 106:19-20	403; NREL; AMB; CLC; SPC; IEXP; LFND; LDG; BSD
120:7-120:7	[120:7-7] INC			120:2-4	403; NREL; AMB; CLC; SPC; IEXP; LFND; LDG; BSD

Jacqueline Yorke (Transperfect) – March 28, 2024					
Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
7:11-7:12		36:24-38:6; 38:19-39:21; 40:1-7	402; 403		
8:11-8:22		9:9-12; 9:16-22; 13:20-15:10; 20:24-21:8; 25:12-26:2; 36:24-38:6; 38:19-39:21; 40:1-7	402; 403		
9:6-9:8	[9:6-8] NREL; 403	9:9-12; 9:16-22; 13:20-15:10; 20:24-21:8; 25:12-26:2; 36:24-38:6; 38:19-39:21; 40:1-7	402; 403		
15:18-15:21	[15:18-21] NREL; 403	13:20-15:10; 16:7-13; 20:24-21:8; 25:12-26:2; 36:24-38:6; 38:19-39:21; 40:1-7	402; 403		
15:24-16:5	[15:24-16:5] NREL; 403	13:20-15:10; 16:7-13; 20:24-21:8; 25:12-26:2; 36:24-38:6; 38:19-39:21; 40:1-7	402; 403		
20:2-20:6		13:20-15:10; 20:24-21:8; 25:12-26:2; 36:24-38:6; 38:19-39:21; 40:1-7	402; 403		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
20:9-20:9	[20:9-9] NREL; 403	13:20-15:10; 20:24-21:8; 25:12-26:2; 36:24-38:6; 38:19-39:21; 40:1-7	402; 403		
20:10-20:11	[20:10-11] NREL; 403	13:20-15:10; 20:24-21:8; 25:12-26:2; 36:24-38:6; 38:19-39:21; 40:1-7	402; 403		
20:17-20:23	[20:17-23] NREL; 403	13:20-15:10; 20:24-21:8; 25:12-26:2; 36:24-38:6; 38:19-39:21; 40:1-7	402; 403		
21:22-21:24	[21:22-24] LFND; NREL; 403	13:20-15:10; 20:24-21:8; 25:12-26:2; 36:24-38:6; 38:19-39:21; 40:1-7	402; 403		
22:2-22:3	[22:2-3] LFND; NREL; 403; SPC	13:20-15:10; 20:24-21:8; 25:12-26:2; 36:24-38:6; 38:19-39:21; 40:1-7	402; 403		
22:5-22:8	[22:5-8] LFND; NREL; 403	13:20-15:10; 20:24-21:8; 25:12-26:2; 36:24-38:6; 38:19-39:21; 40:1-7	402; 403		
22:10-22:11	[22:10-11] SPC; LFND; NREL; 403	13:20-15:10; 20:24-21:8; 25:12-26:2; 36:24-38:6; 38:19-39:21; 40:1-7	402; 403		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
30:16-30:19		13:20-15:10; 20:24-21:8; 25:12-26:2; 34:1-2; 34:5-8; 35:1-2; 35:5-7; 36:24-38:6; 38:19-39:21; 40:1-7	402; 403; F; SP		
30:22-31:1		13:20-15:10; 20:24-21:8; 25:12-26:2; 34:1-2; 34:5-8; 35:1-2; 35:5-7; 36:24-38:6; 38:19-39:21; 40:1-7	402; 403; F; SP		
35:19-35:21		13:20-15:10; 20:24-21:8; 25:12-26:2; 36:24-38:6; 38:19-39:21; 40:1-7	402; 403		
35:24-36:1		13:20-15:10; 20:24-21:8; 25:12-26:2; 36:24-38:6; 38:19-39:21; 40:1-7	402; 403		
38:7-38:9	[38:7-9] SPC; LFND; NREL; 403	13:20-15:10; 20:24-21:8; 25:12-26:2; 36:24-38:6; 38:19-39:21; 40:1-7	402; 403		
38:13-38:18	[38:13-18] SPC; LFND; NREL; 403	13:20-15:10; 20:24-21:8; 25:12-26:2; 36:24-38:6; 38:19-39:21; 40:1-7	402; 403		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
73:14-73:19	[73:14-19] SPC; LFND; LDG; MIS; NREL; 403	13:20-15:10; 20:24- 21:8; 25:12-26:2; 36:24-38:6; 38:19- 39:21; 40:1-7; 73:23-74:3	402; 403		
73:22-73:22	[73:22-22] SPC; LFND; LDG; MIS; NREL; 403	13:20-15:10; 20:24- 21:8; 25:12-26:2; 36:24-38:6; 38:19- 39:21; 40:1-7; 73:23-74:3	402; 403		

Zhepeng Zhang – September 29, 2023					
Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
7:5-7:11					
17:5-17:6		18:11-21; 21:1-3; 21:5-23:7; 33:18- 21; 34:2-6; 35:17- 36:2	402; 403; F; SP; LC; EX	24:2-4; 24:7-11	[24:2-4] 403; NREL; IEXP; CLC; AMB [24:7-11] 403; NREL; IEXP; CLC; AMB
17:16-17:17	[17:16-17] IEXP; NREL; 403; CLC	18:11-21; 21:1-3; 21:5-23:7; 33:18- 21; 34:2-6; 35:17- 36:2	402; 403; F; SP; LC; EX	24:2-4; 24:7-11	[24:2-4] 403; NREL; IEXP; CLC; AMB [24:7-11] 403; NREL; IEXP; CLC; AMB
17:20-18:2	[17:20-18:2] IEXP; NREL; 403; CLC	18:11-21; 21:1-3; 21:5-23:7; 33:18- 21; 34:2-6; 35:17- 36:2	402; 403; F; SP; LC; EX	24:2-4; 24:7-11	[24:2-4] 403; NREL; IEXP; CLC; AMB [24:7-11] 403; NREL; IEXP; CLC; AMB
28:6-28:7	[28:6-7] CLC; IEXP; NREL; 403	18:11-21; 21:1-3; 21:5-23:7; 33:18- 21; 34:2-6; 35:17- 36:2	402; 403; F; SP; LC; EX	24:2-4; 24:7-11	[24:2-4] 403; NREL; IEXP; CLC; AMB [24:7-11] 403; NREL; IEXP; CLC; AMB
28:10-28:11	[28:10-11] CLC; IEXP; NREL; 403	18:11-21; 21:1-3; 21:5-23:7; 33:18- 21; 34:2-6; 35:17- 36:2	402; 403; F; SP; LC; EX	24:2-4; 24:7-11	[24:2-4] 403; NREL; IEXP; CLC; AMB [24:7-11] 403; NREL; IEXP; CLC; AMB

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
28:13-28:15	[28:13-15] AA; CLC; IEXP; MIS; NREL; 403	18:11-21; 21:1-3; 21:5-23:7; 33:18- 21; 34:2-6; 35:17- 36:2	402; 403; F; SP; LC; EX	24:2-4; 24:7-11	[24:2-4] 403; NREL; IEXP; CLC; AMB [24:7-11] 403; NREL; IEXP; CLC; AMB
28:18-29:3	[28:18-29:3] AA; CLC; IEXP; MIS; NREL; 403	18:11-21; 21:1-3; 21:5-23:7; 33:18- 21; 34:2-6; 35:17- 36:2	402; 403; F; SP; LC; EX	24:2-4; 24:7-11	[24:2-4] 403; NREL; IEXP; CLC; AMB [24:7-11] 403; NREL; IEXP; CLC; AMB
29:6-29:9	[29:6-9] AA; CLC; IEXP; MIS; NREL; 403	18:11-21; 21:1-3; 21:5-23:7; 33:18- 21; 34:2-6; 35:17- 36:2	402; 403; F; SP; LC; EX	24:2-4; 24:7-11	[24:2-4] 403; NREL; IEXP; CLC; AMB [24:7-11] 403; NREL; IEXP; CLC; AMB
29:12-29:16	[29:12-16] AA; CLC; IEXP; MIS; NREL; 403	18:11-21; 21:1-3; 21:5-23:7; 33:18- 21; 34:2-6; 35:17- 36:2	402; 403; F; SP; LC; EX	24:2-4; 24:7-11	[24:2-4] 403; NREL; IEXP; CLC; AMB [24:7-11] 403; NREL; IEXP; CLC; AMB
29:18-30:6	[29:18-30:6] AA; CLC; IEXP; MIS; NREL; 403	18:11-21; 21:1-3; 21:5-23:7; 33:18- 21; 34:2-6; 35:17- 36:2	402; 403; F; SP; LC; EX	24:2-4; 24:7-11	[24:2-4] 403; NREL; IEXP; CLC; AMB [24:7-11] 403; NREL; IEXP; CLC; AMB
31:8-31:10	[31:8-10] AMB; AA; CLC; IEXP; MIS; NREL; 403	18:11-21; 21:1-3; 21:5-23:7; 33:18-	402; 403; F; SP; LC; EX	24:2-4; 24:7-11	[24:2-4] 403; NREL; IEXP; CLC; AMB [24:7-11]



Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
		21; 34:2-6; 35:17-36:2			403; NREL; IEXP; CLC; AMB
31:12-31:13	[31:12-13] AMB; AA; CLC; IEXP; MIS; NREL; 403	18:11-21; 21:1-3; 21:5-23:7; 33:18-21; 34:2-6; 35:17-36:2	402; 403; F; SP; LC; EX	24:2-4; 24:7-11	[24:2-4] 403; NREL; IEXP; CLC; AMB [24:7-11] 403; NREL; IEXP; CLC; AMB
31:15-31:22	[31:15-22] AMB; AA; CLC; IEXP; MIS; NREL; 403	18:11-21; 21:1-3; 21:5-23:7; 33:18-21; 34:2-6; 35:17-36:2	402; 403; F; SP; LC; EX	24:2-4; 24:7-11	[24:2-4] 403; NREL; IEXP; CLC; AMB [24:7-11] 403; NREL; IEXP; CLC; AMB
43:7-43:9	[43:7-9] SPC; NREL; 403				
43:12-44:6	[43:12-44:6] AMB; NREL; 403				
44:8-44:8	[44:8-8] AMB; NREL; 403				
44:17-45:6	[44:17-45:6] AMB; NREL; 403				
47:1-47:11	[47:1-11] SPC; LFND; NREL; 403	18:11-21; 21:5-23:7; 33:18-21; 34:2-6; 35:17-36:2; 47:12-22	402; 403; F; SP; LC; EX	24:2-4; 24:7-11	[24:2-4] 403; NREL; IEXP; CLC; AMB [24:7-11] 403; NREL; IEXP; CLC; AMB
79:10-79:20	[79:10-20] ARG; AA; CLC; NREL; 403	18:11-21; 21:1-3; 21:5-23:7; 33:18-	402; 403; F; SP; LC; EX	24:2-4; 24:7-11	[24:2-4] 403; NREL; IEXP; CLC; AMB [24:7-11]

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		21; 34:2-6; 35:17-36:2			403; NREL; IEXP; CLC; AMB
80:1-80:6	[80:1-6] ARG; AA; CLC; NREL; 403	18:11-21; 21:1-3; 21:5-23:7; 33:18-21; 34:2-6; 35:17-36:2	402; 403; F; SP; LC; EX	24:2-4; 24:7-11	[24:2-4] 403; NREL; IEXP; CLC; AMB [24:7-11] 403; NREL; IEXP; CLC; AMB
80:9-80:10	[80:9-10] ARG; AA; CLC; NREL; 403	21:1-3	I		

Rico Zorkendorfer – November 7, 2023					
Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
7:14-7:17					
16:11-16:13		30:2-10; 30:17-31:18; 60:15-22; 61:1-22; 64:9-65:12; 152:4-155:14	[152:4-155:14] 402, 403, LC, LE, LW, EX, IH, F, SP	43:1-3; 43:6-7; 43:8-10; 43:13-14; 43:15-18; 43:20-21; 43:22-44:3; 44:5-6; 62:15-17; 62:19; 62:20-63:3; 63:5-19; 63:22-64:3; 64:6-8; 66:13-18; 66:21; 67:7-10; 67:12-18; 68:20-69:1; 69:3-8; 69:11-15; 69:17-19; 69:20-70:1; 70:3-5; 74:1-3; 74:7	[43:1-3] 403; AA; AMB; LFND; NREL [43:6-7] 403; AA; AMB; LFND; NREL [43:8-10] 403; AA; AMB; NREL [43:13-14] 403; AA; AMB; NREL [43:15-18] 403; AA; AMB; NREL [43:20-21] 403; AA; AMB; NREL [43:22-44:3] 403; AA; AMB; NREL [44:5-6] 403; AA; AMB; NREL; [62:15-17] 403; AG; AMB; LFND; NREL; SPC [62:19] 403; AG; AMB; LFND; NREL; SPC [62:20-63:3] 403; AMB; CLC; LFND; NREL; MIS; SPC

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					[63:5-19] 403; AMB; CLC; LFND; NREL; MIS; SPC [63:22-64:3] 403; AMB; CLC; LFND; NREL; MIS; SPC [64:6-8] 403; AMB; CLC; LFND; NREL; MIS; SPC [66:13-18] 403; AMB; NREL; CPD; MIS [66:21] 403; AMB; NREL; CPD; MIS [67:7-10] 403; AMB; NREL [67:12-18] 403; AMB; NREL [68:20-69:1] 403; AMB; CLC; LFND; NREL; SPC [69:3-8] 403; AMB; CLC; LFND; NREL; MIS; SPC [69:11-15] 403; AMB; CLC; LFND; NREL; MIS; SPC

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					[69:17-19] 403; AMB; CLC; LFND; NREL; SPC [69:20-70:1] 403; AMB; CLC; LFND; NREL; SPC [70:3-5] 403; AMB; CLC; LFND; NREL; SPC [74:1-3] 403; AMB; CLC; IEXP; HYP; INC; LFND; NREL; SPC [74:7] 403; AMB; CLC; IEXP; HYP; INC; LFND; NREL; SPC
16:14-17:1	[16:14-17:1] AMB; CPD; NREL; 403; INC	30:2-10; 30:17-31:18; 60:15-22; 61:1-22; 64:9-65:12; 85:16-86:9; 85:16-86:9; 92:9-20; 152:4-155:14	[85:16-86:9; 92:9-20] AS; [92:9-20] LC, E, IH; [152:4-155:14] 402, 403, LC, LE, LW, EX, IH, F, SP	43:1-3; 43:6-7; 43:8-10; 43:13-14; 43:15-18; 43:20-21; 43:22-44:3; 44:5-6; 62:15-17; 62:19; 62:20-63:3; 63:5-19; 63:22-64:3; 64:6-8; 66:13-18; 66:21; 67:7-10; 67:12-18; 68:20-69:1; 69:3-8; 69:11-	[43:1-3] 403; AA; AMB; LFND; NREL [43:6-7] 403; AA; AMB; LFND; NREL [43:8-10] 403; AA; AMB; NREL [43:13-14] 403; AA; AMB; NREL [43:15-18] 403; AA; AMB;

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
				15; 69:17-19; 69:20-70:1; 70:3-5; 74:1-3; 74:7	NREL [43:20-21] 403; AA; AMB; NREL [43:22-44:3] 403; AA; AMB; NREL [44:5-6] 403; AA; AMB; NREL; [62:15-17] 403; AG; AMB; LFND; NREL; SPC [62:19] 403; AG; AMB; LFND; NREL; SPC [62:20-63:3] 403; AMB; CLC; LFND; NREL; MIS; SPC [63:5-19] 403; AMB; CLC; LFND; NREL; MIS; SPC [63:22-64:3] 403; AMB; CLC; LFND; NREL; MIS; SPC [64:6-8] 403; AMB; CLC; LFND; NREL; MIS; SPC [66:13-18] 403; AMB; NREL; CPD; MIS [66:21] 403;

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
					<p>AMB; NREL; CPD;  MIS [67:7-10] 403;  AMB; NREL  [67:12-18] 403;  AMB; NREL  [68:20-69:1] 403;  AMB; CLC; LFND;  NREL; SPC [69:3-8] 403; AMB;  CLC; LFND;  NREL; MIS; SPC  [69:11-15] 403;  AMB; CLC; LFND;  NREL; MIS; SPC  [69:17-19] 403;  AMB; CLC; LFND;  NREL; SPC [69:20-70:1] 403; AMB;  CLC; LFND;  NREL; SPC [70:3-5] 403; AMB;  CLC; LFND;  NREL; SPC [74:1-3] 403; AMB;  CLC; IEXP; HYP;  INC; LFND;</p>

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					NREL; SPC [74:7] 403; AMB; CLC; IEXP; HYP; INC; LFND; NREL; SPC
18:2-18:5	[18:2-5] AMB; CPD; NREL; 403; LA	30:2-10; 30:17-31:18; 60:15-22; 61:1-22; 64:9-65:12; 85:16-86:9; 85:16-86:9; 92:9-20; 152:4-155:14	[85:16-86:9; 92:9-20] AS; [92:9-20] LC, E, IH; [152:4-155:14] 402, 403, LC, LE, LW, EX, IH, F, SP	43:1-3; 43:6-7; 43:8-10; 43:13-14; 43:15-18; 43:20-21; 43:22-44:3; 44:5-6; 62:15-17; 62:19; 62:20-63:3; 63:5-19; 63:22-64:3; 64:6-8; 66:13-18; 66:21; 67:7-10; 67:12-18; 68:20-69:1; 69:3-8; 69:11-15; 69:17-19; 69:20-70:1; 70:3-5; 74:1-3; 74:7	[43:1-3] 403; AA; AMB; LFND; NREL [43:6-7] 403; AA; AMB; LFND; NREL [43:8-10] 403; AA; AMB; NREL [43:13-14] 403; AA; AMB; NREL [43:15-18] 403; AA; AMB; NREL [43:20-21] 403; AA; AMB; NREL [43:22-44:3] 403; AA; AMB; NREL [44:5-6] 403; AA; AMB; NREL; [62:15-17] 403; AG; AMB; LFND; NREL; SPC [62:19] 403; AG; AMB; LFND; NREL; SPC [62:20-63:3] 403;



Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					<p>AMB; CLC; LFND; NREL; MIS; SPC [63:5-19] 403;</p> <p>AMB; CLC; LFND; NREL; MIS; SPC [63:22-64:3] 403;</p> <p>AMB; CLC; LFND; NREL; MIS; SPC [64:6-8] 403;</p> <p>AMB; CLC; LFND; NREL; MIS; SPC [66:13-18] 403;</p> <p>AMB; NREL; CPD; MIS [66:21] 403;</p> <p>AMB; NREL; CPD; MIS [67:7-10] 403;</p> <p>AMB; NREL [67:12-18] 403;</p> <p>AMB; NREL [68:20-69:1] 403;</p> <p>AMB; CLC; LFND; NREL; SPC [69:3-8] 403; AMB; CLC; LFND; NREL; MIS; SPC [69:11-15] 403;</p>

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					AMB; CLC; LFND; NREL; MIS; SPC [69:17-19] 403; AMB; CLC; LFND; NREL; SPC [69:20-70:1] 403; AMB; CLC; LFND; NREL; SPC [70:3-5] 403; AMB; CLC; LFND; NREL; SPC [74:1-3] 403; AMB; CLC; IEXP; HYP; INC; LFND; NREL; SPC [74:7] 403; AMB; CLC; IEXP; HYP; INC; LFND; NREL; SPC
18:6-18:10	[18:6-10] AMB; NREL; 403; LDG; INC; LA	30:2-10; 30:17-31:18; 60:15-22; 61:1-22; 64:9-65:12; 85:16-86:9; 85:16-86:9; 92:9-20; 152:4-155:14	[85:16-86:9; 92:9-20] AS; [92:9-20] LC, E, IH; [152:4-155:14] 402, 403, LC, LE, LW, EX, IH, F, SP	43:1-3; 43:6-7; 43:8-10; 43:13-14; 43:15-18; 43:20-21; 43:22-44:3; 44:5-6; 62:15-17; 62:19; 62:20-63:3; 63:5-19; 63:22-64:3; 64:6-8; 66:13-18; 66:21; 67:7-10;	[43:1-3] 403; AA; AMB; LFND; NREL [43:6-7] 403; AA; AMB; LFND; NREL [43:8-10] 403; AA; AMB; NREL [43:13-14] 403; AA; AMB;

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
				67:12-18; 68:20-69:1; 69:3-8; 69:11-15; 69:17-19; 69:20-70:1; 70:3-5; 74:1-3; 74:7	NREL [43:15-18] 403; AA; AMB; NREL [43:20-21] 403; AA; AMB; NREL [43:22-44:3] 403; AA; AMB; NREL [44:5-6] 403; AA; AMB; NREL; [62:15-17] 403; AG; AMB; LFND; NREL; SPC [62:19] 403; AG; AMB; LFND; NREL; SPC [62:20-63:3] 403; AMB; CLC; LFND; NREL; MIS; SPC [63:5-19] 403; AMB; CLC; LFND; NREL; MIS; SPC [63:22-64:3] 403; AMB; CLC; LFND; NREL; MIS; SPC [64:6-8] 403; AMB; CLC; LFND; NREL; MIS; SPC [66:13-18] 403;

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					<p>AMB; NREL; CPD; MIS [66:21] 403; AMB; NREL; CPD; MIS [67:7-10] 403; AMB; NREL [67:12-18] 403; AMB; NREL [68:20-69:1] 403; AMB; CLC; LFND; NREL; SPC [69:3-8] 403; AMB; CLC; LFND; NREL; MIS; SPC [69:11-15] 403; AMB; CLC; LFND; NREL; MIS; SPC [69:17-19] 403; AMB; CLC; LFND; NREL; SPC [69:20-70:1] 403; AMB; CLC; LFND; NREL; SPC [70:3-5] 403; AMB; CLC; LFND; NREL; SPC [74:1-3] 403; AMB;</p>

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					CLC; IEXP; HYP; INC; LFND; NREL; SPC [74:7] 403; AMB; CLC; IEXP; HYP; INC; LFND; NREL; SPC
28:18-29:2	[28:18-29:2] NREL; 403; AMB; LFND; INC	30:2-10; 30:17-31:18; 60:15-22; 61:1-22; 64:9-65:12; 85:16-86:9; 85:16-86:9; 92:9-20; 152:4-155:14	[85:16-86:9; 92:9-20] AS; [92:9-20] LC, E, IH; [152:4-155:14] 402, 403, LC, LE, LW, EX, IH, F, SP	43:1-3; 43:6-7; 43:8-10; 43:13-14; 43:15-18; 43:20-21; 43:22-44:3; 44:5-6; 62:15-17; 62:19; 62:20-63:3; 63:5-19; 63:22-64:3; 64:6-8; 66:13-18; 66:21; 67:7-10; 67:12-18; 68:20-69:1; 69:3-8; 69:11-15; 69:17-19; 69:20-70:1; 70:3-5; 74:1-3; 74:7	[43:1-3] 403; AA; AMB; LFND; NREL [43:6-7] 403; AA; AMB; LFND; NREL [43:8-10] 403; AA; AMB; NREL [43:13-14] 403; AA; AMB; NREL [43:15-18] 403; AA; AMB; NREL [43:20-21] 403; AA; AMB; NREL [43:22-44:3] 403; AA; AMB; NREL [44:5-6] 403; AA; AMB; NREL; [62:15-17] 403; AG; AMB; LFND; NREL; SPC [62:19] 403; AG; AMB;

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
					LFND; NREL; SPC [62:20-63:3] 403; AMB; CLC; LFND; NREL; MIS; SPC [63:5-19] 403; AMB; CLC; LFND; NREL; MIS; SPC [63:22-64:3] 403; AMB; CLC; LFND; NREL; MIS; SPC [64:6-8] 403; AMB; CLC; LFND; NREL; MIS; SPC [66:13-18] 403; AMB; NREL; CPD; MIS [66:21] 403; AMB; NREL; CPD; MIS [67:7-10] 403; AMB; NREL [67:12-18] 403; AMB; NREL [68:20-69:1] 403; AMB; CLC; LFND; NREL; SPC [69:3-8] 403; AMB; CLC; LFND;

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					NREL; MIS; SPC [69:11-15] 403; AMB; CLC; LFND; NREL; MIS; SPC [69:17-19] 403; AMB; CLC; LFND; NREL; SPC [69:20-70:1] 403; AMB; CLC; LFND; NREL; SPC [70:3-5] 403; AMB; CLC; LFND; NREL; SPC [74:1-3] 403; AMB; CLC; IEXP; HYP; INC; LFND; NREL; SPC [74:7] 403; AMB; CLC; IEXP; HYP; INC; LFND; NREL; SPC
29:5-29:7	[29:5-7] AMB; CLC; SPC; NREL; 403; LFND; LA; OBJ	30:2-10; 30:17-31:18; 60:15-22; 61:1-22; 64:9-65:12; 85:16-86:9; 85:16-86:9; 92:9-20; 152:4-155:14	[85:16-86:9; 92:9-20] AS; [92:9-20] LC, E, IH; [152:4-155:14] 402, 403, LC, LE, LW, EX, IH, F, SP	43:1-3; 43:6-7; 43:8-10; 43:13-14; 43:15-18; 43:20-21; 43:22-44:3; 44:5-6; 62:15-17; 62:19; 62:20-63:3; 63:5-19; 63:22-64:3;	[43:1-3] 403; AA; AMB; LFND; NREL [43:6-7] 403; AA; AMB; LFND; NREL [43:8-10] 403; AA; AMB;

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
				64:6-8; 66:13-18; 66:21; 67:7-10; 67:12-18; 68:20-69:1; 69:3-8; 69:11-15; 69:17-19; 69:20-70:1; 70:3-5; 74:1-3; 74:7	NREL [43:13-14] 403; AA; AMB; NREL [43:15-18] 403; AA; AMB; NREL [43:20-21] 403; AA; AMB; NREL [43:22-44:3] 403; AA; AMB; NREL [44:5-6] 403; AA; AMB; NREL; [62:15-17] 403; AG; AMB; LFND; NREL; SPC [62:19] 403; AG; AMB; LFND; NREL; SPC [62:20-63:3] 403; AMB; CLC; LFND; NREL; MIS; SPC [63:5-19] 403; AMB; CLC; LFND; NREL; MIS; SPC [63:22-64:3] 403; AMB; CLC; LFND; NREL; MIS; SPC [64:6-8] 403; AMB; CLC; LFND;



<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
					NREL; MIS; SPC [66:13-18] 403; AMB; NREL; CPD; MIS [66:21] 403; AMB; NREL; CPD; MIS [67:7-10] 403; AMB; NREL [67:12-18] 403; AMB; NREL [68:20-69:1] 403; AMB; CLC; LFND; NREL; SPC [69:3-8] 403; AMB; CLC; LFND; NREL; MIS; SPC [69:11-15] 403; AMB; CLC; LFND; NREL; MIS; SPC [69:17-19] 403; AMB; CLC; LFND; NREL; SPC [69:20-70:1] 403; AMB; CLC; LFND; NREL; SPC [70:3-5] 403; AMB; CLC; LFND;

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					NREL; SPC [74:1-3] 403; AMB; CLC; IEXP; HYP; INC; LFND; NREL; SPC [74:7] 403; AMB; CLC; IEXP; HYP; INC; LFND; NREL; SPC
29:13-29:15	[29:13-15] AMB; CLC; SPC; MIS; NREL; 403; INC; HRS; LFND	30:2-10; 30:17-31:18; 60:15-22; 61:1-22; 64:9-65:12; 85:16-86:9; 85:16-86:9; 92:9-20; 152:4-155:14	[85:16-86:9; 92:9-20] AS; [92:9-20] LC, E, IH; [152:4-155:14] 402, 403, LC, LE, LW, EX, IH, F, SP	43:1-3; 43:6-7; 43:8-10; 43:13-14; 43:15-18; 43:20-21; 43:22-44:3; 44:5-6; 62:15-17; 62:19; 62:20-63:3; 63:5-19; 63:22-64:3; 64:6-8; 66:13-18; 66:21; 67:7-10; 67:12-18; 68:20-69:1; 69:3-8; 69:11-15; 69:17-19; 69:20-70:1; 70:3-5; 74:1-3; 74:7	[43:1-3] 403; AA; AMB; LFND; NREL [43:6-7] 403; AA; AMB; LFND; NREL [43:8-10] 403; AA; AMB; NREL [43:13-14] 403; AA; AMB; NREL [43:15-18] 403; AA; AMB; NREL [43:20-21] 403; AA; AMB; NREL [43:22-44:3] 403; AA; AMB; NREL [44:5-6] 403; AA; AMB; NREL; [62:15-17] 403; AG; AMB; LFND;

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					NREL; SPC [62:19] 403; AG; AMB; LFND; NREL; SPC [62:20-63:3] 403; AMB; CLC; LFND; NREL; MIS; SPC [63:5-19] 403; AMB; CLC; LFND; NREL; MIS; SPC [63:22-64:3] 403; AMB; CLC; LFND; NREL; MIS; SPC [64:6-8] 403; AMB; CLC; LFND; NREL; MIS; SPC [66:13-18] 403; AMB; NREL; CPD; MIS [66:21] 403; AMB; NREL; CPD; MIS [67:7-10] 403; AMB; NREL [67:12-18] 403; AMB; NREL [68:20-69:1] 403; AMB; CLC; LFND; NREL; SPC [69:3-

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
					8] 403; AMB; CLC; LFND; NREL; MIS; SPC [69:11-15] 403; AMB; CLC; LFND; NREL; MIS; SPC [69:17-19] 403; AMB; CLC; LFND; NREL; SPC [69:20-70:1] 403; AMB; CLC; LFND; NREL; SPC [70:3-5] 403; AMB; CLC; LFND; NREL; SPC [74:1-3] 403; AMB; CLC; IEXP; HYP; INC; LFND; NREL; SPC [74:7] 403; AMB; CLC; IEXP; HYP; INC; LFND; NREL; SPC
60:9-60:14	[60:9-14] AMB; SPC; NREL; 403; LFND; INC	30:2-10; 30:17-31:18; 60:15-22; 61:1-22; 64:9-65:12; 85:16-86:9;	[85:16-86:9; 92:9-20] AS; [92:9-20] LC, E, IH; [152:4-155:14] 402, 403,	43:1-3; 43:6-7; 43:8-10; 43:13-14; 43:15-18; 43:20-21; 43:22-44:3; 44:5-6;	[43:1-3] 403; AA; AMB; LFND; NREL [43:6-7] 403; AA; AMB; LFND;

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		85:16-86:9; 85:16-86:9; 92:9-20; 152:4-155:14	LC, LE, LW, EX, IH, F, SP	62:15-17; 62:19; 62:20-63:3; 63:5-19; 63:22-64:3; 64:6-8; 66:13-18; 66:21; 67:7-10; 67:12-18; 68:20-69:1; 69:3-8; 69:11-15; 69:17-19; 69:20-70:1; 70:3-5; 74:1-3; 74:7	NREL [43:8-10] 403; AA; AMB; NREL [43:13-14] 403; AA; AMB; NREL [43:15-18] 403; AA; AMB; NREL [43:20-21] 403; AA; AMB; NREL [43:22-44:3] 403; AA; AMB; NREL [44:5-6] 403; AA; AMB; NREL; [62:15-17] 403; AG; AMB; LFND; NREL; SPC [62:19] 403; AG; AMB; LFND; NREL; SPC [62:20-63:3] 403; AMB; CLC; LFND; NREL; MIS; SPC [63:5-19] 403; AMB; CLC; LFND; NREL; MIS; SPC [63:22-64:3] 403; AMB; CLC; LFND; NREL; MIS; SPC

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					[64:6-8] 403; AMB; CLC; LFND; NREL; MIS; SPC [66:13-18] 403; AMB; NREL; CPD; MIS [66:21] 403; AMB; NREL; CPD; MIS [67:7-10] 403; AMB; NREL [67:12-18] 403; AMB; NREL [68:20-69:1] 403; AMB; CLC; LFND; NREL; SPC [69:3-8] 403; AMB; CLC; LFND; NREL; MIS; SPC [69:11-15] 403; AMB; CLC; LFND; NREL; MIS; SPC [69:17-19] 403; AMB; CLC; LFND; NREL; SPC [69:20-70:1] 403; AMB; CLC; LFND; NREL; SPC [70:3-

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					5] 403; AMB; CLC; LFND; NREL; SPC [74:1-3] 403; AMB; CLC; IEXP; HYP; INC; LFND; NREL; SPC [74:7] 403; AMB; CLC; IEXP; HYP; INC; LFND; NREL; SPC
62:20-64:8	[62:20-64:8] AMB; CLC; SPC; LFND; MIS; NREL; 403	30:2-10; 30:17-31:18; 60:15-22; 61:1-22; 64:9-65:12; 85:16-86:9; 85:16-86:9; 92:9-20; 152:4-155:14	[85:16-86:9; 92:9-20] AS; [92:9-20] LC, E, IH; [152:4-155:14] 402, 403, LC, LE, LW, EX, IH, F, SP	43:1-3; 43:6-7; 43:8-10; 43:13-14; 43:15-18; 43:20-21; 43:22-44:3; 44:5-6; 62:15-17; 62:19; 62:20-63:3; 63:5-19; 63:22-64:3; 64:6-8; 66:13-18; 66:21; 67:7-10; 67:12-18; 68:20-69:1; 69:3-8; 69:11-15; 69:17-19; 69:20-70:1; 70:3-5; 74:1-3; 74:7	[43:1-3] 403; AA; AMB; LFND; NREL [43:6-7] 403; AA; AMB; LFND; NREL [43:8-10] 403; AA; AMB; NREL [43:13-14] 403; AA; AMB; NREL [43:15-18] 403; AA; AMB; NREL [43:20-21] 403; AA; AMB; NREL [43:22-44:3] 403; AA; AMB; NREL [44:5-6] 403; AA; AMB; NREL;

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					[62:15-17] 403; AG; AMB; LFND; NREL; SPC [62:19] 403; AG; AMB; LFND; NREL; SPC [62:20-63:3] 403; AMB; CLC; LFND; NREL; MIS; SPC [63:5-19] 403; AMB; CLC; LFND; NREL; MIS; SPC [63:22-64:3] 403; AMB; CLC; LFND; NREL; MIS; SPC [64:6-8] 403; AMB; CLC; LFND; NREL; MIS; SPC [66:13-18] 403; AMB; NREL; CPD; MIS [66:21] 403; AMB; NREL; CPD; MIS [67:7-10] 403; AMB; NREL [67:12-18] 403; AMB; NREL [68:20-69:1] 403;



<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
					<p>AMB; CLC; LFND; NREL; SPC [69:3-8] 403; AMB; CLC; LFND; NREL; MIS; SPC [69:11-15] 403; AMB; CLC; LFND; NREL; MIS; SPC [69:17-19] 403; AMB; CLC; LFND; NREL; SPC [69:20-70:1] 403; AMB; CLC; LFND; NREL; SPC [70:3-5] 403; AMB; CLC; LFND; NREL; SPC [74:1-3] 403; AMB; CLC; IEXP; HYP; INC; LFND; NREL; SPC [74:7] 403; AMB; CLC; IEXP; HYP; INC; LFND; NREL; SPC</p>

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
64:9-64:22	[64:9-22] AMB; SPC; LFND; NREL; 403	30:2-10; 30:17-31:18; 60:15-22; 61:1-22; 64:9-65:12; 85:16-86:9; 85:16-86:9; 92:9-20; 152:4-155:14	[85:16-86:9; 92:9-20] AS; [92:9-20] LC, E, IH; [152:4-155:14] 402, 403, LC, LE, LW, EX, IH, F, SP	43:1-3; 43:6-7; 43:8-10; 43:13-14; 43:15-18; 43:20-21; 43:22-44:3; 44:5-6; 62:15-17; 62:19; 62:20-63:3; 63:5-19; 63:22-64:3; 64:6-8; 66:13-18; 66:21; 67:7-10; 67:12-18; 68:20-69:1; 69:3-8; 69:11-15; 69:17-19; 69:20-70:1; 70:3-5; 74:1-3; 74:7	[43:1-3] 403; AA; AMB; LFND; NREL [43:6-7] 403; AA; AMB; LFND; NREL [43:8-10] 403; AA; AMB; NREL [43:13-14] 403; AA; AMB; NREL [43:15-18] 403; AA; AMB; NREL [43:20-21] 403; AA; AMB; NREL [43:22-44:3] 403; AA; AMB; NREL [44:5-6] 403; AA; AMB; NREL; [62:15-17] 403; AG; AMB; LFND; NREL; SPC [62:19] 403; AG; AMB; LFND; NREL; SPC [62:20-63:3] 403; AMB; CLC; LFND; NREL; MIS; SPC [63:5-19] 403; AMB; CLC; LFND;

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
					<p>NREL; MIS; SPC [63:22-64:3] 403; AMB; CLC; LFND; NREL; MIS; SPC [64:6-8] 403; AMB; CLC; LFND; NREL; MIS; SPC [66:13-18] 403; AMB; NREL; CPD; MIS [66:21] 403; AMB; NREL; CPD; MIS [67:7-10] 403; AMB; NREL [67:12-18] 403; AMB; NREL [68:20-69:1] 403; AMB; CLC; LFND; NREL; SPC [69:3-8] 403; AMB; CLC; LFND; NREL; MIS; SPC [69:11-15] 403; AMB; CLC; LFND; NREL; MIS; SPC [69:17-19] 403; AMB; CLC; LFND;</p>

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					NREL; SPC [69:20-70:1] 403; AMB; CLC; LFND; NREL; SPC [70:3-5] 403; AMB; CLC; LFND; NREL; SPC [74:1-3] 403; AMB; CLC; IEXP; HYP; INC; LFND; NREL; SPC [74:7] 403; AMB; CLC; IEXP; HYP; INC; LFND; NREL; SPC
68:20-69:19	[68:20-69:19] AMB; CLC; SPC; LFND; MIS; NREL; 403	30:2-10; 30:17-31:18; 60:15-22; 61:1-22; 64:9-65:12; 85:16-86:9; 85:16-86:9; 92:9-20; 152:4-155:14	[85:16-86:9; 92:9-20] AS; [92:9-20] LC, E, IH; [152:4-155:14] 402, 403, LC, LE, LW, EX, IH, F, SP	43:1-3; 43:6-7; 43:8-10; 43:13-14; 43:15-18; 43:20-21; 43:22-44:3; 44:5-6; 62:15-17; 62:19; 62:20-63:3; 63:5-19; 63:22-64:3; 64:6-8; 66:13-18; 66:21; 67:7-10; 67:12-18; 68:20-69:1; 69:3-8; 69:11-15; 69:17-19;	[43:1-3] 403; AA; AMB; LFND; NREL [43:6-7] 403; AA; AMB; LFND; NREL [43:8-10] 403; AA; AMB; NREL [43:13-14] 403; AA; AMB; NREL [43:15-18] 403; AA; AMB; NREL [43:20-21] 403; AA; AMB;

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
				69:20-70:1; 70:3-5; 74:1-3; 74:7	NREL [43:22-44:3] 403; AA; AMB; NREL [44:5-6] 403; AA; AMB; NREL; [62:15-17] 403; AG; AMB; LFND; NREL; SPC [62:19] 403; AG; AMB; LFND; NREL; SPC [62:20-63:3] 403; AMB; CLC; LFND; NREL; MIS; SPC [63:5-19] 403; AMB; CLC; LFND; NREL; MIS; SPC [63:22-64:3] 403; AMB; CLC; LFND; NREL; MIS; SPC [64:6-8] 403; AMB; CLC; LFND; NREL; MIS; SPC [66:13-18] 403; AMB; NREL; CPD; MIS [66:21] 403; AMB; NREL; CPD; MIS [67:7-10] 403;

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
					AMB; NREL [67:12-18] 403; AMB; NREL [68:20-69:1] 403; AMB; CLC; LFND; NREL; SPC [69:3-8] 403; AMB; CLC; LFND; NREL; MIS; SPC [69:11-15] 403; AMB; CLC; LFND; NREL; MIS; SPC [69:17-19] 403; AMB; CLC; LFND; NREL; SPC [69:20-70:1] 403; AMB; CLC; LFND; NREL; SPC [70:3-5] 403; AMB; CLC; LFND; NREL; SPC [74:1-3] 403; AMB; CLC; IEXP; HYP; INC; LFND; NREL; SPC [74:7] 403; AMB; CLC;

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					IEXP; HYP; INC; LFND; NREL; SPC
69:20-70:5	[69:20-70:5] AMB; SPC; LFND; MIS; NREL; 403	30:2-10; 30:17-31:18; 60:15-22; 61:1-22; 64:9-65:12; 85:16-86:9; 85:16-86:9; 92:9-20; 152:4-155:14	[85:16-86:9; 92:9-20] AS; [92:9-20] LC, E, IH; [152:4-155:14] 402, 403, LC, LE, LW, EX, IH, F, SP	43:1-3; 43:6-7; 43:8-10; 43:13-14; 43:15-18; 43:20-21; 43:22-44:3; 44:5-6; 62:15-17; 62:19; 62:20-63:3; 63:5-19; 63:22-64:3; 64:6-8; 66:13-18; 66:21; 67:7-10; 67:12-18; 68:20-69:1; 69:3-8; 69:11-15; 69:17-19; 69:20-70:1; 70:3-5; 74:1-3; 74:7	[43:1-3] 403; AA; AMB; LFND; NREL [43:6-7] 403; AA; AMB; LFND; NREL [43:8-10] 403; AA; AMB; NREL [43:13-14] 403; AA; AMB; NREL [43:15-18] 403; AA; AMB; NREL [43:20-21] 403; AA; AMB; NREL [43:22-44:3] 403; AA; AMB; NREL [44:5-6] 403; AA; AMB; NREL; [62:15-17] 403; AG; AMB; LFND; NREL; SPC [62:19] 403; AG; AMB; LFND; NREL; SPC [62:20-63:3] 403; AMB; CLC; LFND; NREL; MIS; SPC

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					[63:5-19] 403; AMB; CLC; LFND; NREL; MIS; SPC [63:22-64:3] 403; AMB; CLC; LFND; NREL; MIS; SPC [64:6-8] 403; AMB; CLC; LFND; NREL; MIS; SPC [66:13-18] 403; AMB; NREL; CPD; MIS [66:21] 403; AMB; NREL; CPD; MIS [67:7-10] 403; AMB; NREL [67:12-18] 403; AMB; NREL [68:20-69:1] 403; AMB; CLC; LFND; NREL; SPC [69:3-8] 403; AMB; CLC; LFND; NREL; MIS; SPC [69:11-15] 403; AMB; CLC; LFND; NREL; MIS; SPC



Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					[69:17-19] 403; AMB; CLC; LFND; NREL; SPC [69:20-70:1] 403; AMB; CLC; LFND; NREL; SPC [70:3-5] 403; AMB; CLC; LFND; NREL; SPC [74:1-3] 403; AMB; CLC; IEXP; HYP; INC; LFND; NREL; SPC [74:7] 403; AMB; CLC; IEXP; HYP; INC; LFND; NREL; SPC
74:1-74:7	[74:1-7] AMB; CLC; IEXP; HYP; NREL; 403; INC; LFND	30:2-10; 30:17-31:18; 60:15-22; 61:1-22; 64:9-65:12; 85:16-86:9; 85:16-86:9; 92:9-20; 152:4-155:14	[85:16-86:9; 92:9-20] AS; [92:9-20] LC, E, IH; [152:4-155:14] 402, 403, LC, LE, LW, EX, IH, F, SP	43:1-3; 43:6-7; 43:8-10; 43:13-14; 43:15-18; 43:20-21; 43:22-44:3; 44:5-6; 62:15-17; 62:19; 62:20-63:3; 63:5-19; 63:22-64:3; 64:6-8; 66:13-18; 66:21; 67:7-10; 67:12-18; 68:20-69:1; 69:3-8; 69:11-	[43:1-3] 403; AA; AMB; LFND; NREL [43:6-7] 403; AA; AMB; LFND; NREL [43:8-10] 403; AA; AMB; NREL [43:13-14] 403; AA; AMB; NREL [43:15-18] 403; AA; AMB;

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
				15; 69:17-19; 69:20-70:1; 70:3-5; 74:1-3; 74:7	NREL [43:20-21] 403; AA; AMB; NREL [43:22-44:3] 403; AA; AMB; NREL [44:5-6] 403; AA; AMB; NREL; [62:15-17] 403; AG; AMB; LFND; NREL; SPC [62:19] 403; AG; AMB; LFND; NREL; SPC [62:20-63:3] 403; AMB; CLC; LFND; NREL; MIS; SPC [63:5-19] 403; AMB; CLC; LFND; NREL; MIS; SPC [63:22-64:3] 403; AMB; CLC; LFND; NREL; MIS; SPC [64:6-8] 403; AMB; CLC; LFND; NREL; MIS; SPC [66:13-18] 403; AMB; NREL; CPD; MIS [66:21] 403;

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
					AMB; NREL; CPD; MIS [67:7-10] 403; AMB; NREL [67:12-18] 403; AMB; NREL [68:20-69:1] 403; AMB; CLC; LFND; NREL; SPC [69:3-8] 403; AMB; CLC; LFND; NREL; MIS; SPC [69:11-15] 403; AMB; CLC; LFND; NREL; MIS; SPC [69:17-19] 403; AMB; CLC; LFND; NREL; SPC [69:20-70:1] 403; AMB; CLC; LFND; NREL; SPC [70:3-5] 403; AMB; CLC; LFND; NREL; SPC [74:1-3] 403; AMB; CLC; IEXP; HYP; INC; LFND;

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					NREL; SPC [74:7] 403; AMB; CLC; IEXP; HYP; INC; LFND; NREL; SPC
85:1-85:9	[85:1-9] AMB; MIS; NREL; 403; AG; SPC; LFND	30:2-10; 30:17-31:18; 60:15-22; 61:1-22; 64:9-65:12; 85:16-86:9; 85:16-86:9; 92:9-20; 152:4-155:14	[85:16-86:9; 92:9-20] AS; [92:9-20] LC, E, IH; [152:4-155:14] 402, 403, LC, LE, LW, EX, IH, F, SP	43:1-3; 43:6-7; 43:8-10; 43:13-14; 43:15-18; 43:20-21; 43:22-44:3; 44:5-6; 62:15-17; 62:19; 62:20-63:3; 63:5-19; 63:22-64:3; 64:6-8; 66:13-18; 66:21; 67:7-10; 67:12-18; 68:20-69:1; 69:3-8; 69:11-15; 69:17-19; 69:20-70:1; 70:3-5; 74:1-3; 74:7	[43:1-3] 403; AA; AMB; LFND; NREL [43:6-7] 403; AA; AMB; LFND; NREL [43:8-10] 403; AA; AMB; NREL [43:13-14] 403; AA; AMB; NREL [43:15-18] 403; AA; AMB; NREL [43:20-21] 403; AA; AMB; NREL [43:22-44:3] 403; AA; AMB; NREL [44:5-6] 403; AA; AMB; NREL; [62:15-17] 403; AG; AMB; LFND; NREL; SPC [62:19] 403; AG; AMB; LFND; NREL; SPC [62:20-63:3] 403;

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					<p>AMB; CLC; LFND; NREL; MIS; SPC [63:5-19] 403; AMB; CLC; LFND; NREL; MIS; SPC [63:22-64:3] 403; AMB; CLC; LFND; NREL; MIS; SPC [64:6-8] 403; AMB; CLC; LFND; NREL; MIS; SPC [66:13-18] 403; AMB; NREL; CPD; MIS [66:21] 403; AMB; NREL; CPD; MIS [67:7-10] 403; AMB; NREL [67:12-18] 403; AMB; NREL [68:20-69:1] 403; AMB; CLC; LFND; NREL; SPC [69:3-8] 403; AMB; CLC; LFND; NREL; MIS; SPC [69:11-15] 403;</p>

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
					AMB; CLC; LFND; NREL; MIS; SPC [69:17-19] 403; AMB; CLC; LFND; NREL; SPC [69:20-70:1] 403; AMB; CLC; LFND; NREL; SPC [70:3-5] 403; AMB; CLC; LFND; NREL; SPC [74:1-3] 403; AMB; CLC; IEXP; HYP; INC; LFND; NREL; SPC [74:7] 403; AMB; CLC; IEXP; HYP; INC; LFND; NREL; SPC
91:13-91:14	[91:13-14] AMB; CLC; IEXP; HYP; NREL; 403; SPC; LFND; OBJ	30:2-10; 30:17-31:18; 60:15-22; 61:1-22; 64:9-65:12; 85:16-86:9; 85:16-86:9; 152:4-155:14	[85:16-86:9; 92:9-20] AS; [92:9-20] LC, E, IH; [152:4-155:14] 402, 403, LC, LE, LW, EX, IH, F, SP	43:1-3; 43:6-7; 43:8-10; 43:13-14; 43:15-18; 43:20-21; 43:22-44:3; 44:5-6; 62:15-17; 62:19; 62:20-63:3; 63:5-19; 63:22-64:3; 64:6-8; 66:13-18; 66:21; 67:7-10;	[43:1-3] 403; AA; AMB; LFND; NREL [43:6-7] 403; AA; AMB; LFND; NREL [43:8-10] 403; AA; AMB; NREL [43:13-14] 403; AA; AMB;

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
				67:12-18; 68:20-69:1; 69:3-8; 69:11-15; 69:17-19; 69:20-70:1; 70:3-5; 74:1-3; 74:7	NREL [43:15-18] 403; AA; AMB; NREL [43:20-21] 403; AA; AMB; NREL [43:22-44:3] 403; AA; AMB; NREL [44:5-6] 403; AA; AMB; NREL; [62:15-17] 403; AG; AMB; LFND; NREL; SPC [62:19] 403; AG; AMB; LFND; NREL; SPC [62:20-63:3] 403; AMB; CLC; LFND; NREL; MIS; SPC [63:5-19] 403; AMB; CLC; LFND; NREL; MIS; SPC [63:22-64:3] 403; AMB; CLC; LFND; NREL; MIS; SPC [64:6-8] 403; AMB; CLC; LFND; NREL; MIS; SPC [66:13-18] 403;

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
					<p>AMB; NREL; CPD; MIS [66:21] 403; AMB; NREL; CPD; MIS [67:7-10] 403; AMB; NREL [67:12-18] 403; AMB; NREL [68:20-69:1] 403; AMB; CLC; LFND; NREL; SPC [69:3-8] 403; AMB; CLC; LFND; NREL; MIS; SPC [69:11-15] 403; AMB; CLC; LFND; NREL; MIS; SPC [69:17-19] 403; AMB; CLC; LFND; NREL; SPC [69:20-70:1] 403; AMB; CLC; LFND; NREL; SPC [70:3-5] 403; AMB; CLC; LFND; NREL; SPC [74:1-3] 403; AMB;</p>



Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					CLC; IEXP; HYP; INC; LFND; NREL; SPC [74:7] 403; AMB; CLC; IEXP; HYP; INC; LFND; NREL; SPC
91:17-91:19	[91:17-19] AMB; CLC; IEXP; HYP; NREL; 403; SPC; LFND	30:17-31:18; 60:15-22; 61:1-22; 64:9-65:12; 85:16-86:9; 85:16-86:9; 152:4-155:14	[85:16-86:9; 92:9-20] AS; [92:9-20] LC, E, IH; [152:4-155:14] 402, 403, LC, LE, LW, EX, IH, F, SP	43:1-3; 43:6-7; 43:8-10; 43:13-14; 43:15-18; 43:20-21; 43:22-44:3; 44:5-6; 62:15-17; 62:19; 62:20-63:3; 63:5-19; 63:22-64:3; 64:6-8; 66:13-18; 66:21; 67:7-10; 67:12-18; 68:20-69:1; 69:3-8; 69:11-15; 69:17-19; 69:20-70:1; 70:3-5; 74:1-3; 74:7	[43:1-3] 403; AA; AMB; LFND; NREL [43:6-7] 403; AA; AMB; LFND; NREL [43:8-10] 403; AA; AMB; NREL [43:13-14] 403; AA; AMB; NREL [43:15-18] 403; AA; AMB; NREL [43:20-21] 403; AA; AMB; NREL [43:22-44:3] 403; AA; AMB; NREL [44:5-6] 403; AA; AMB; NREL; [62:15-17] 403; AG; AMB; LFND; NREL; SPC [62:19] 403; AG; AMB;

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
					LFND; NREL; SPC [62:20-63:3] 403; AMB; CLC; LFND; NREL; MIS; SPC [63:5-19] 403; AMB; CLC; LFND; NREL; MIS; SPC [63:22-64:3] 403; AMB; CLC; LFND; NREL; MIS; SPC [64:6-8] 403; AMB; CLC; LFND; NREL; MIS; SPC [66:13-18] 403; AMB; NREL; CPD; MIS [66:21] 403; AMB; NREL; CPD; MIS [67:7-10] 403; AMB; NREL [67:12-18] 403; AMB; NREL [68:20-69:1] 403; AMB; CLC; LFND; NREL; SPC [69:3-8] 403; AMB; CLC; LFND;

Masimo's Designations	Apple's Objections	Apple's Counter Designations	Masimo's Objections	Masimo's Counter-Counter Designations	Apple's Objections
					NREL; MIS; SPC [69:11-15] 403; AMB; CLC; LFND; NREL; MIS; SPC [69:17-19] 403; AMB; CLC; LFND; NREL; SPC [69:20-70:1] 403; AMB; CLC; LFND; NREL; SPC [70:3-5] 403; AMB; CLC; LFND; NREL; SPC [74:1-3] 403; AMB; CLC; IEXP; HYP; INC; LFND; NREL; SPC [74:7] 403; AMB; CLC; IEXP; HYP; INC; LFND; NREL; SPC
92:21-93:14	[92:21-93:14] AMB; CLC; CPD; NREL; 403; AG; INC; OBJ	106:21-107:4; 106:21-107:4; 108:22-109:6; 108:22-109:6; 109:22-110:8; 148:20-150:19;	[106:21-107:4] AS, LC, E; [109:22-110:8] V; [148:20-150:19; 152:4-155:14] 402, 403, LC, LE, LW, EX, IH, F, SP		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		148:20-150:19; 152:4-155:14			
93:18-93:21	[93:18-21] AMB; CLC; CPD; IEXP; NREL; 403; SPC; OBJ	106:21-107:4; 106:21-107:4; 108:22-109:6; 108:22-109:6; 109:22-110:8; 148:20-150:19; 148:20-150:19; 152:4-155:14	[106:21-107:4] AS, LC, E; [109:22- 110:8] V; [148:20- 150:19; 152:4- 155:14] 402, 403, LC, LE, LW, EX, IH, F, SP		
94:1-94:6	[94:1-6] AMB; CLC; CPD; IEXP; NREL; 403; SPC; LFND; LA	106:21-107:4; 106:21-107:4; 108:22-109:6; 108:22-109:6; 109:22-110:8; 148:20-150:19; 148:20-150:19; 152:4-155:14	[106:21-107:4] AS, LC, E; [109:22- 110:8] V; [148:20- 150:19; 152:4- 155:14] 402, 403, LC, LE, LW, EX, IH, F, SP		
94:8-95:4	[94:8-95:4] AMB; CLC; IEXP; NREL; 403; LFND	106:21-107:4; 106:21-107:4; 108:22-109:6; 108:22-109:6; 109:22-110:8; 148:20-150:19; 148:20-150:19; 152:4-155:14	[106:21-107:4] AS, LC, E; [109:22- 110:8] V; [148:20- 150:19; 152:4- 155:14] 402, 403, LC, LE, LW, EX, IH, F, SP		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
95:7-95:13	[95:7-13] AMB; CLC; IEXP; NREL; 403; SPC	106:21-107:4; 106:21-107:4; 108:22-109:6; 108:22-109:6; 109:22-110:8; 148:20-150:19; 148:20-150:19; 152:4-155:14	[106:21-107:4] AS, LC, E; [109:22- 110:8] V; [148:20- 150:19; 152:4- 155:14] 402, 403, LC, LE, LW, EX, IH, F, SP		
96:3-96:7	[96:3-7] AMB; CLC; IEXP; NREL; 403; SPC; CPD	106:21-107:4; 106:21-107:4; 108:22-109:6; 108:22-109:6; 109:22-110:8; 148:20-150:19; 148:20-150:19; 152:4-155:14	[106:21-107:4] AS, LC, E; [109:22- 110:8] V; [148:20- 150:19; 152:4- 155:14] 402, 403, LC, LE, LW, EX, IH, F, SP		
96:11-96:14	[96:11-14] AMB; CLC; IEXP; NREL; 403; LFND	106:21-107:4; 106:21-107:4; 108:22-109:6; 108:22-109:6; 109:22-110:8; 148:20-150:19; 148:20-150:19; 152:4-155:14	[106:21-107:4] AS, LC, E; [109:22- 110:8] V; [148:20- 150:19; 152:4- 155:14] 402, 403, LC, LE, LW, EX, IH, F, SP		
96:17-96:19	[96:17-19] AMB; CLC; IEXP; HYP; NREL; 403; LFND	106:21-107:4; 106:21-107:4; 108:22-109:6; 108:22-109:6;	[106:21-107:4] AS, LC, E; [109:22- 110:8] V; [148:20- 150:19; 152:4-		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		109:22-110:8; 148:20-150:19; 148:20-150:19; 152:4-155:14	155:14] 402, 403, LC, LE, LW, EX, IH, F, SP		
97:1-97:7	[97:1-7] AMB; CLC; IEXP; HYP; NREL; 403; SPC; LFND	106:21-107:4; 106:21-107:4; 108:22-109:6; 108:22-109:6; 109:22-110:8; 148:20-150:19; 148:20-150:19; 152:4-155:14	[106:21-107:4] AS, LC, E; [109:22- 110:8] V; [148:20- 150:19; 152:4- 155:14] 402, 403, LC, LE, LW, EX, IH, F, SP		
97:10-97:14	[97:10-14] AMB; CLC; IEXP; NREL; 403	106:21-107:4; 106:21-107:4; 108:22-109:6; 108:22-109:6; 109:22-110:8; 148:20-150:19; 148:20-150:19; 152:4-155:14	[106:21-107:4] AS, LC, E; [109:22- 110:8] V; [148:20- 150:19; 152:4- 155:14] 402, 403, LC, LE, LW, EX, IH, F, SP		
97:17-97:21	[97:17-21] AMB; CLC; IEXP; NREL; 403; LFND	106:21-107:4; 106:21-107:4; 108:22-109:6; 108:22-109:6; 109:22-110:8; 148:20-150:19; 148:20-150:19; 152:4-155:14	[106:21-107:4] AS, LC, E; [109:22- 110:8] V; [148:20- 150:19; 152:4- 155:14] 402, 403, LC, LE, LW, EX, IH, F, SP		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
98:1-98:15	[98:1-15] AMB; CLC; CPD; IEXP; NREL; 403; LFND; LA; OBJ	106:21-107:4; 106:21-107:4; 108:22-109:6; 108:22-109:6; 109:22-110:8; 148:20-150:19; 148:20-150:19; 152:4-155:14	[106:21-107:4] AS, LC, E; [109:22- 110:8] V; [148:20- 150:19; 152:4- 155:14] 402, 403, LC, LE, LW, EX, IH, F, SP		
98:19-99:1	[98:19-99:1] AMB; CLC; CPD; IEXP; NREL; 403; LFND	106:21-107:4; 106:21-107:4; 108:22-109:6; 108:22-109:6; 109:22-110:8; 148:20-150:19; 148:20-150:19; 152:4-155:14	[106:21-107:4] AS, LC, E; [109:22- 110:8] V; [148:20- 150:19; 152:4- 155:14] 402, 403, LC, LE, LW, EX, IH, F, SP		
99:4-99:6	[99:4-6] AMB; CLC; IEXP; NREL; 403; INC	106:21-107:4; 106:21-107:4; 108:22-109:6; 108:22-109:6; 109:22-110:8; 148:20-150:19; 148:20-150:19; 152:4-155:14	[106:21-107:4] AS, LC, E; [109:22- 110:8] V; [148:20- 150:19; 152:4- 155:14] 402, 403, LC, LE, LW, EX, IH, F, SP		
99:10-100:6	[99:10-100:6] AMB; CLC; IEXP; NREL; 403; LFND; LA	106:21-107:4; 106:21-107:4; 108:22-109:6; 108:22-109:6;	[106:21-107:4] AS, LC, E; [109:22- 110:8] V; [148:20- 150:19; 152:4-		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		109:22-110:8; 148:20-150:19; 148:20-150:19; 152:4-155:14	155:14] 402, 403, LC, LE, LW, EX, IH, F, SP		
100:10-101:4	[100:10-101:4] AMB; CLC; SPC; IEXP; LFND; NREL; 403; MIS	106:21-107:4; 106:21-107:4; 108:22-109:6; 108:22-109:6; 109:22-110:8; 148:20-150:19; 148:20-150:19; 152:4-155:14	[106:21-107:4] AS, LC, E; [109:22- 110:8] V; [148:20- 150:19; 152:4- 155:14] 402, 403, LC, LE, LW, EX, IH, F, SP		
101:8-101:10	[101:8-10] AMB; CLC; SPC; IEXP; LFND; NREL; 403; LDG	106:21-107:4; 106:21-107:4; 108:22-109:6; 108:22-109:6; 109:22-110:8; 148:20-150:19; 148:20-150:19; 152:4-155:14	[106:21-107:4] AS, LC, E; [109:22- 110:8] V; [148:20- 150:19; 152:4- 155:14] 402, 403, LC, LE, LW, EX, IH, F, SP		
101:14-102:6	[101:14-102:6] AMB; CLC; SPC; IEXP; LFND; NREL; 403	106:21-107:4; 106:21-107:4; 108:22-109:6; 108:22-109:6; 109:22-110:8; 148:20-150:19; 148:20-150:19; 152:4-155:14	[106:21-107:4] AS, LC, E; [109:22- 110:8] V; [148:20- 150:19; 152:4- 155:14] 402, 403, LC, LE, LW, EX, IH, F, SP		



<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
102:13-102:16	[102:13-16] AMB; MIS; NREL; 403	106:21-107:4; 106:21-107:4; 108:22-109:6; 108:22-109:6; 109:22-110:8; 148:20-150:19; 148:20-150:19; 152:4-155:14	[106:21-107:4] AS, LC, E; [109:22- 110:8] V; [148:20- 150:19; 152:4- 155:14] 402, 403, LC, LE, LW, EX, IH, F, SP		
102:19-102:22	[102:19-22] AMB; MIS; NREL; 403	106:21-107:4; 106:21-107:4; 108:22-109:6; 108:22-109:6; 109:22-110:8; 148:20-150:19; 148:20-150:19; 152:4-155:14	[106:21-107:4] AS, LC, E; [109:22- 110:8] V; [148:20- 150:19; 152:4- 155:14] 402, 403, LC, LE, LW, EX, IH, F, SP		
103:13-103:15	[103:13-15] IEXP; LFND; MIS; NREL; 403; AMB; CLC; SPC; OBJ	106:21-107:4; 106:21-107:4; 108:22-109:6; 108:22-109:6; 109:22-110:8; 148:20-150:19; 148:20-150:19; 152:4-155:14	[106:21-107:4] AS, LC, E; [109:22- 110:8] V; [148:20- 150:19; 152:4- 155:14] 402, 403, LC, LE, LW, EX, IH, F, SP		
103:20-103:21	[103:20-21] AMB; CLC; SPC; IEXP; LFND; MIS; NREL; 403	108:22-109:6; 108:22-109:6; 109:22-110:8; 148:20-150:19;	[109:22-110:8] V; [148:20-150:19; 152:4-155:14] 402,		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		148:20-150:19; 152:4-155:14	403, LC, LE, LW, EX, IH, F, SP		
104:2-104:8	[104:2-8] AMB; CLC; SPC; IEXP; LFND; MIS; NREL; 403	108:22-109:6; 108:22-109:6; 109:22-110:8; 148:20-150:19; 148:20-150:19; 152:4-155:14	[109:22-110:8] V; [148:20-150:19; 152:4-155:14] 402, 403, LC, LE, LW, EX, IH, F, SP		
104:12-104:17	[104:12-17] AMB; AA; CLC; SPC; IEXP; LFND; MIS; NREL; 403	108:22-109:6; 108:22-109:6; 109:22-110:8; 148:20-150:19; 148:20-150:19; 152:4-155:14	[109:22-110:8] V; [148:20-150:19; 152:4-155:14] 402, 403, LC, LE, LW, EX, IH, F, SP		
104:21-105:2	[104:21-105:2] AMB; AA; CLC; SPC; IEXP; LFND; MIS; NREL; 403	108:22-109:6; 108:22-109:6; 109:22-110:8; 148:20-150:19; 148:20-150:19; 152:4-155:14	[109:22-110:8] V; [148:20-150:19; 152:4-155:14] 402, 403, LC, LE, LW, EX, IH, F, SP		
105:4-105:16	[105:4-16] AMB; CLC; IEXP; NREL; 403	106:21-107:4; 106:21-107:4; 108:22-109:6; 108:22-109:6; 109:22-110:8; 148:20-150:19; 148:20-150:19; 152:4-155:14	[106:21-107:4] AS, LC, E; [109:22- 110:8] V; [148:20- 150:19; 152:4- 155:14] 402, 403, LC, LE, LW, EX, IH, F, SP		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
105:19-106:1	[105:19-106:1] AMB; AA; CLC; IEXP; NREL; 403; ARG	106:21-107:4; 106:21-107:4; 108:22-109:6; 108:22-109:6; 109:22-110:8; 148:20-150:19; 148:20-150:19; 152:4-155:14	[106:21-107:4] AS, LC, E; [109:22-110:8] V; [148:20-150:19; 152:4-155:14] 402, 403, LC, LE, LW, EX, IH, F, SP		
106:5-106:7	[106:5-7] AMB; CLC; IEXP; NREL; 403	106:21-107:4; 106:21-107:4; 108:22-109:6; 108:22-109:6; 109:22-110:8; 148:20-150:19; 148:20-150:19; 152:4-155:14	[106:21-107:4] AS, LC, E; [109:22-110:8] V; [148:20-150:19; 152:4-155:14] 402, 403, LC, LE, LW, EX, IH, F, SP		
106:9-106:10	[106:9-10] AMB; AA; CLC; IEXP; NREL; 403; LFND	106:21-107:4; 106:21-107:4; 108:22-109:6; 108:22-109:6; 109:22-110:8; 148:20-150:19; 148:20-150:19; 152:4-155:14	[106:21-107:4] AS, LC, E; [109:22-110:8] V; [148:20-150:19; 152:4-155:14] 402, 403, LC, LE, LW, EX, IH, F, SP		
109:14-109:21	[109:14-21] AMB; SPC; NREL; 403; CLC; AG; LFND	106:21-107:4; 106:21-107:4; 108:22-109:6; 108:22-109:6;	[106:21-107:4] AS, LC, E; [109:22-110:8] V; [148:20-150:19; 152:4-		

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
		109:22-110:8; 148:20-150:19; 148:20-150:19; 152:4-155:14	155:14] 402, 403, LC, LE, LW, EX, IH, F, SP		
113:10-113:22	[113:10-22] AMB; HRS; LFND; NREL; 403	152:4-155:14	402, 403, LC, LE, LW, EX, IH, F, SP		
119:16-119:19	[119:16-19] AMB; HRS; LFND; NREL; 403	152:4-155:14	402, 403, LC, LE, LW, EX, IH, F, SP		
120:2-120:5	[120:2-5] AMB; HRS; LFND; NREL; 403	152:4-155:14	402, 403, LC, LE, LW, EX, IH, F, SP		
125:13-125:19	[125:13-19] AMB; AG; SPC; LFND; NREL; 403	152:4-155:14	402, 403, LC, LE, LW, EX, IH, F, SP		
133:7-133:13	[133:7-13] AMB; HRS; LFND; NREL; 403	139:4-8; 152:4- 155:14	[152:4-155:14] 402, 403, LC, LE, LW, EX, IH, F, SP		
139:14-139:22	[139:14-22] AMB; SPC; HRS; LFND; NREL; 403	139:4-8; 152:4- 155:14	[152:4-155:14] 402, 403, LC, LE, LW, EX, IH, F, SP		
140:12-140:17	[140:12-17] AMB; SPC; HRS; LFND; NREL; 403	139:4-8; 152:4- 155:14	[152:4-155:14] 402, 403, LC, LE, LW, EX, IH, F, SP		
144:6-144:12	[144:6-12] AMB; SPC; HRS; LFND; NREL; 403	147:15-21; 150:20- 152:3; 152:4-155:14	[150:20-152:3; 152:4-155:14] 402,	144:16-145:18; 147:1-147:14; 147:22-148:4	[144:16-145:18] 403; AMB; HRS;

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
			403, LC, LE, LW, EX, IH, F, SP		LFND; NREL; MIS; SPC [147:1-147:14] 403; AMB; HRS; LFND; NREL; SPC [147:22-148:4] 403; AMB; HRS; LFND; NREL; MIS; SPC
144:16-145:18	[144:16-145:18] AMB; SPC; HRS; LFND; NREL; 403; MIS	146:10-22; 150:20-152:3; 152:4-155:14	[150:20-152:3; 152:4-155:14] 402, 403, LC, LE, LW, EX, IH, F, SP	144:6-144:12; 147:1-147:14; 147:22-148:4	[144:6-144:12] 403; AMB; HRS; LFND; NREL; SPC [147:1-147:14] 403; AMB; HRS; LFND; NREL; SPC [147:22-148:4] 403; AMB; HRS; LFND; NREL; MIS; SPC
147:1-147:14	[147:1-14] AMB; SPC; HRS; LFND; NREL; 403	146:10-22; 147:15-21; 150:20-152:3; 152:4-155:14	[150:20-152:3; 152:4-155:14] 402, 403, LC, LE, LW, EX, IH, F, SP	144:6-144:12; 144:16-145:18; 147:22-148:4	[144:6-144:12] 403; AMB; HRS; LFND; NREL; SPC [144:16-145:18] 403; AMB; HRS; LFND; NREL; MIS; SPC [147:22-148:4] 403; AMB; HRS; LFND; NREL; MIS; SPC

<b>Masimo's Designations</b>	<b>Apple's Objections</b>	<b>Apple's Counter Designations</b>	<b>Masimo's Objections</b>	<b>Masimo's Counter-Counter Designations</b>	<b>Apple's Objections</b>
147:22-148:4	[147:22-148:4] AMB; SPC; HRS; LFND; NREL; 403; MIS	146:10-22; 147:15- 21; 150:20-152:3; 152:4-155:14	[150:20-152:3; 152:4-155:14] 402, 403, LC, LE, LW, EX, IH, F, SP	144:6-144:12; 144:16-145:18; 147:1-147:14	[144:6-144:12] 403; AMB; HRS; LFND; NREL; SPC [144:16-145:18] 403; AMB; HRS; LFND; NREL; MIS; SPC [147:1- 147:14] 403; AMB; HRS; LFND; NREL; SPC

# **EXHIBIT 12**

**FILED UNDER SEAL**

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

APPLE INC.,

Plaintiff,

v.

MASIMO CORPORATION AND SOUND  
UNITED, LLC,

Defendants.

---

MASIMO CORPORATION AND CERCACOR  
LABORATORIES, INC.,

Counterclaim-Plaintiffs,

v.

APPLE INC.,

Counterclaim-Defendant.

---

C.A. No. 1:22-cv-1377-JLH

C.A. No. 1:22-cv-1378-JLH

**HIGHLY CONFIDENTIAL –  
ATTORNEYS EYES’ ONLY**

**FILED UNDER SEAL**

**PLAINTIFF APPLE INC.’S MOTION *IN LIMINE* NO. 1:  
TO PRECLUDE TESTIMONY, ARGUMENT, OR REFERENCE REGARDING  
THE PRESENCE OR ABSENCE OF ANY PARTY’S CORPORATE  
REPRESENTATIVE, EMPLOYEE, OR OTHER WITNESS AT TRIAL**



Masimo alleges *twenty-seven* Apple employees committed inequitable conduct in prosecuting Apple’s asserted patents, and at least [REDACTED] Apple engineers are unnamed inventors on Apple’s asserted patents. *See Apple Inc. v. Masimo Corp. et al.*, No. 1:22-cv-01377-JLH, D.I. 521 at 3-15 (D. Del. Feb. 21, 2024); Ex. 1 (Stoll Open. Rep.) at 29-40; Ex. 2 (Stoll Reply Rep.) at 12-54. Masimo admits Apple cannot call all these witnesses during a one-week trial to rebut Masimo’s spurious allegations. *See, e.g.*, Ex. 3 (email correspondence) at 5 (Masimo counsel stating, “Apple knows that it cannot present 28 fact witnesses in its half of a five-day trial.”). However, rather than agree not to reference the presence or absence of any witness at trial—a rule this Court previously called its “default rule” (*Arendi S.A.R.L. v. Google LLC*, No. 1:13-CV-00919-JLH, D.I. 502 at 58:24-59:14 (D. Del. Apr. 6, 2023) (Ex. 4))—Masimo refuses.<sup>1</sup>

Instead, Masimo intends to improperly impugn Apple and any of these [REDACTED] witnesses who are absent from trial—including many of whom Masimo declined to depose during fact discovery—in hopes that Apple’s unsurprising inability to present them all during a five-day trial will cause the jury to prejudicially infer that any absent witness would have given harmful testimony that Apple is allegedly hiding.<sup>2</sup> During the parties’ meet and confer, Masimo could not articulate any permissible reason to mention a witness’s absence. Masimo’s proposed argument or inference about witnesses who do not testify at trial has no relevance to any issue and would only serve to mislead and confuse the jury and unfairly prejudice Apple. *See* Fed. R. Evid. 401,

---

<sup>1</sup> Masimo also refuses to narrow its inequitable conduct and improper inventorship allegations, and intends to engage in trial by ambush. Masimo knows it cannot try all these allegations in a five-day trial, but, despite multiple requests, refuses to tell Apple which allegations it intends to try. *See* Ex. 3 at 1 (Apple counsel stating, “Masimo refuses to (1) identify the persons Masimo will contend committed inequitable conduct at trial and (2) identify the persons that Masimo will contend are omitted inventors at trial.”); *id.* (Apple counsel again requesting Masimo to identify which inequitable conduct and improper inventorship claims it intends to try).

<sup>2</sup> The parties took *one hundred and eighteen* depositions in this case, pointing up the absurdity of Masimo’s insistence that it can comment negatively on every witness absent from trial.

402, 403. Apple requests the Court preclude testimony, argument, or reference regarding the presence or absence of any party's corporate representative, employee, or other witness at trial.

**A. The Absence Of Witnesses Is Irrelevant To Any Issue In This Case.**

Whether or not a witness appears live at trial is irrelevant to any issue in dispute, and commenting on a witness's absence would only result in a sideshow that will mislead and confuse the jury. Thus, it should be excluded. *See* Fed. R. Evid. 401, 402, 403. This is especially true here, where Masimo's overbroad theories unjustifiably implicate over forty Apple witnesses.

First, nearly half of the current and former Apple employees accused of inequitable conduct or alleged to be unnamed inventors—namely, [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]. To the

best of Apple's knowledge, *none* of those [REDACTED] witnesses are within the Court's subpoena power. Apple cannot force these witnesses to come to trial, so their absence should not be held against Apple.

Second, even if Apple wanted to bring all [REDACTED] of these witnesses to trial, there is simply not enough time—a fact Masimo itself has repeatedly conceded. *See, e.g.*, Ex. 3 at 5. The Court should apply its default rule and prevent such commentary here. *See Arendi*, No. 1:13-CV-00919-JLH, D.I. 502 at 58:24-59:2 (Ex. 4) (“The default is going to be that neither side can reference the presence or absence of any parties’ corporate representative or employee or other witness....”); *IPA Techs. Inc. v. Microsoft Corp.*, 1:18-cv-00001-RGA-SRF, D.I. 344 (D. Del. Apr. 26, 2024) (Ex. 6) (granting MIL to preclude reference to missing witnesses); *Hillman Grp., Inc. v. KeyMe, LLC*, No. 2:19-CV-00209-JRG, 2021 WL 1248180, at \*6 (E.D. Tex. Mar. 30, 2021)

(same); *Intell. Ventures II LLC v. FedEx Corp.*, No. 2:16-CV-00980-JRG, 2018 WL 10638138, at \*4 (E.D. Tex. Apr. 26, 2018) (same Re: “absence of any of the Asserted Patents’ non-party inventors”).

**B. Any Supposed Probative Value Of Commenting On A Witness’s Absence Is Substantially Outweighed By A Danger Of Unfair Prejudice.**

Allowing testimony, argument, or reference to the absence of witnesses would also unfairly prejudice Apple by improperly encouraging the jury to infer that Apple is “hiding evidence.” *See Nunez v. Coloplast Corp.*, No. 19-CV-24000, 2020 WL 2315077, at \*14 (S.D. Fla. May 11, 2020) (holding that a party “cannot raise adverse inferences on who [a party] decides to call as a witness, and who it does not call”). Further, such insinuation would violate this Court’s Preliminary Jury Instructions: “Deposition testimony is entitled to the same consideration and is to be judged, insofar as possible, in the same way as if the witness had been present to testify.” *See, e.g., Arendi S.A.R.L. v. Google LLC*, No. 1:13-CV-00919-JLH, D.I. 478, at No. 8 (D. Del. Apr. 20, 2023) (Ex. 7) (“Court’s Preliminary Jury Instructions”). Masimo subpoenaed and deposed many of Apple’s witnesses during fact discovery, and it should not now be allowed to use its own failure to depose the others to encourage negative inferences about them. This Court’s Preliminary Jury Instructions also instruct the jury to “not speculate about what a witness might have said or what an exhibit might have shown,” but rather to “decide th[e] case based solely on the evidence presented in the Courtroom.” *See, e.g., id.* at Nos. 4, 12; Third Circuit Model Civil Jury Instructions at Nos. 1.5, 3.1 (June 2024) (Ex. 8) (similar). Masimo wants to violate these instructions as well, by impugning absent witnesses, thereby inviting the jury to speculate about what a witness “might have said” and why Apple did not call them live. Masimo should be prohibited from doing so under Federal Rule of Evidence 403.

Dated: September 4, 2024

OF COUNSEL:

John M. Desmarais  
Cosmin Maier  
Jordan N. Malz  
Kerri-Ann Limbeek  
**DESMARAIS LLP**  
230 Park Avenue  
New York, NY 10169  
Tel: (212) 351-3400  
jdesmarais@desmaraisllp.com

Peter C. Magic  
**DESMARAIS LLP**  
101 California Street  
San Francisco, CA 94111  
Tel: (415) 573-1900  
pmagic@desmaraisllp.com

Jennifer Milici  
Dominic Vote  
**WILMER CULTER PICKERING  
HALE AND DORR LLP**  
2100 Pennsylvania Avenue NW  
Washington, DC 20037  
Tel: (202) 663-6000

Mark A. Ford  
**WILMER CULTER PICKERING  
HALE AND DORR LLP**  
60 State Street  
Boston, MA 02109  
Tel: (617) 526-6423

By: /s/ David E. Moore  
David E. Moore (#3983)  
Bindu A. Palapura (#5370)  
Andrew M. Moshos (#6685)  
**POTTER ANDERSON & CORROON LLP**  
Hercules Plaza, 6th Floor  
1313 N. Market Street  
Wilmington, DE 19801  
Tel: (302) 984-6000  
dmoore@potteranderson.com  
bpalapura@potteranderson.com  
amoshos@potteranderson.com

*Attorneys for Plaintiff/Counter-Defendant  
Apple Inc.*

**CERTIFICATE OF SERVICE**

I hereby certify that a copy of Apple Inc.'s Motion *In Limine* No. 1 was served upon counsel of record for Masimo Corporation and Sound United, LLC on September 4, 2024.

/s/ Jamie L. Kringstein

Jamie L. Kringstein

Motion In Limine No. 1 Exhibits Table	
Exhibit No.	Description
1	Excerpts of Expert Report of Robert L. Stoll (11-22-2023)
2	Excerpts of Reply Expert Report of Robert L. Stoll (01-05-2024)
3	Email Correspondence between Counsel for Plaintiff Apple Inc. and Counsel for Defendants RE: Apple v Masimo (Del) - Apple Witness List / Deposition Designations (08-09-2024 - 08-30-2024)
4	Arendi S.A.R.L. v. Google LLC, No. 1:13-CV-00919-JLH, D.I. 502 (D. Del. Apr. 6, 2023)
5	Second Supplemental Initial Disclosures of Defendants Masimo Corporation and Sound United, LLC and Counter-Claimants Masimo Corporation and Cercacor Laboratories, Inc. (11-09-2023)
6	IPA Techs. Inc. v. Microsoft Corp., 1:18-cv-00001-RGA-SRF, D.I. 344 (D. Del. Apr. 26, 2024)
7	Arendi S.A.R.L. v. Google LLC, No. 1:13-CV-00919-JLH, D.I. 478 (D. Del. Apr. 20, 2023)
8	Third Circuit Model Civil Jury Instructions

**IN THE U.S. DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

APPLE INC.,  <i>Plaintiff,</i>  v.  MASIMO CORPORATION and SOUND UNITED, LLC,  <i>Defendants.</i>	C.A. No. 22-1377-JLH  <b>JURY TRIAL DEMANDED</b>
MASIMO CORPORATION,  <i>Counter-Claimant,</i>  v.  APPLE INC.  <i>Counter-Defendant.</i>	
APPLE INC.,  <i>Plaintiff,</i>  v.  MASIMO CORPORATION and SOUND UNITED, LLC,  <i>Defendants.</i>	C.A. No. 22-1378-JLH  <b>JURY TRIAL DEMANDED</b>
MASIMO CORPORATION and CERCACOR LABORATORIES, INC.,  <i>Counter-Claimants,</i>  v.  APPLE INC.  <i>Counter-Defendant.</i>	<b>CONFIDENTIAL – ATTORNEYS’ EYES ONLY FILED UNDER SEAL</b>

**DEFENDANTS MASIMO CORPORATION AND SOUND UNITED, LLC’S  
OPPOSITION TO APPLE INC.’S MOTION *IN LIMINE* NO. 1**

## **I. Apple Refuses To Narrow This Case For Trial**

Apple begins by complaining about the scope of Masimo's fraud and inequitable conduct allegations. Br. at 1. Apple ignores that Apple has not identified which of its ten patents, much less which of the 46 asserted utility patent claims, Apple will present at trial. Despite Apple likely having no more than 15 hours to present its case, Apple designated approximately 50 hours of deposition testimony—in addition to its live fact and expert witnesses. Apple has made no attempt to focus on claims it could reasonably present in a one-week trial. After Apple, as the plaintiff, identifies the patents and claims for trial, Masimo can evaluate narrowing its arguments.

Apple also complains about the number of people Masimo accuses of defrauding the Patent Office. Br. at 1. Apple ignores that this is because Apple names as inventors on all Apple design patents every member of its industrial design team (and only industrial designers). The Apple patent agent responsible for prosecuting the design patents, and the 26 named design inventors, concealed material information from, and made egregiously false assertions to, the Patent Office regarding inventorship and functionality.

Apple also exaggerates the number of omitted inventors. Masimo's experts focused on

Apple engineers who should have been named as inventors on the design patents.

## **II. Commenting On Absent Witnesses Under A Party's Control Is Appropriate**

Apple asserts that “Masimo intends to improperly impugn Apple” and that “argument or inference about witnesses who do not testify at trial has no relevance to any issue... .” Br. at 1. To the contrary, commenting on missing witnesses is both proper and relevant. The Supreme Court explained that, “if a party has it peculiarly within his power to produce witnesses whose testimony would elucidate the transaction, the fact that he does not do it creates the presumption that the testimony, if produced, would be unfavorable[.]” *Graves v. United States*, 150 U.S. 118,



121 (1893). The Third Circuit explained that “[t]he applicability of a ‘missing witness’ inference is based on the ‘simple proposition that if a party who has evidence which bears on the issues fails to present it, it must be presumed that such evidence would be detrimental to his cause.’” *United States v. Hines*, 470 F.2d 225, 230 (3d Cir. 1972) (quoting *United States v. Restrains*, 369 F.2d 544, 547 (3d Cir. 1966)). Accordingly, “[i]t is well-settled that a party’s failure to call a witness may permissibly support an inference that that witness’s testimony would have been adverse.” *Revson v. Cinque & Cinque, P.C.*, 221 F.3d 71, 81-82 (2d Cir. 2000).

Apple argues that some potential witnesses “no longer work for Apple.” Br. at 2. The predicate for a missing witness inference is a party’s ability to bring the witness to trial. *Graves*, 150 U.S. at 121. If Apple cannot bring a witness to trial, then no adverse inference would be appropriate. But Apple has identified no former employee it would be unable to bring to trial.<sup>1</sup> Moreover, the patent agent who defrauded the Patent Office and [REDACTED] Apple engineers who should have been named as inventors are current Apple employees.

### **III. There Is No Risk Of Unfair Prejudice**

Apple asserts that this Court has expressed a “default rule” that parties may not “reference the presence or absence of any witness at trial.” Br. at 1. The transcript Apple cites does not support Apple’s argument. The “main concern” in *Arendi* revolved around a third-party witness. Ex. 4 at 57:15-58:3. The parties disputed whether he was under party control. *Id.* at 57:15-58:8. Apple ignores the Court stated it would address the issue on a witness-by-witness basis. If a party wanted to pursue a missing witness inference, the Court would consider “whether or not the other

---

<sup>1</sup> [REDACTED]

side had control of that person and whether you could have subpoenaed them.” *Id.* at 59:3-10. The Court stated that, “[i]f they couldn’t have subpoenaed them either, I’m not going to let you make that argument.” *Id.* at 59:10-12. The Court’s observation suggests the converse is also true; if a party could have brought a witness, the jury may infer the testimony would have been negative.

Apple cites other district court cases that generally recognize the same distinction between witnesses a party does and does not control. *See Hillman Grp., Inc. v. KeyMe, LLC*, 2021 WL 1248180, at \*6 (E.D. Tex. Mar. 30, 2021) (allowing parties to raise any “factual and legal basis to believe that an absent witness is subject to the sole control of the other party”). Any Texas cases holding otherwise would be contrary to Third Circuit precedent. *See United States v. Ugwu*, 539 F. App’x 35, at \*7 (3d Cir. 2013) (“Asking or permitting the jury to draw the conclusion that, had an available but uncalled witness been called by the defense, his testimony would have been harmful, is permissible”); *United States v. Atwell*, 71 F.R.D. 357, 360 (D. Del. 1976) (commenting on the non-appearance of presumably favorable witnesses is permitted “in this Circuit”).

Moreover, nothing requires that the jury draw an adverse inference. Apple can argue there is an innocent explanation and the jury can draw its own conclusions.

#### **IV. Drawing Adverse Inferences Is Consistent With The Jury Instructions**

Apple asserts that a missing witness inference is inconsistent with giving deposition testimony the same weight as trial testimony. Br. at 3. Apple is wrong. The jury can infer that Apple did not bring a witness to answer additional questions at trial because Apple expected the testimony would be unfavorable to Apple without discounting the deposition testimony presented.

Finally, Apple asserts that drawing an inference is inconsistent with deciding the case on the evidence presented. Br. at 3. The cases disagree. *Graves*, 150 U.S. at 121; *Hines*, 470 F.2d at 230; *Restrained*, 369 F.2d at 547; *Revson*, 221 F.3d at 81–82.

September 18, 2024

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

By: /s/ Kendall M. Loebbaka

Joseph R. Re  
Stephen C. Jensen  
Stephen W. Larson  
Benjamin A. Katzenellenbogen  
Edward M. Cannon  
Brian C. Claassen  
Jared C. Bunker  
Mark Lezama  
Kendall M. Loebbaka  
Douglas B. Wentzel  
Knobbe, Martens, Olson & Bear, LLP  
2040 Main Street, 14th Floor  
Irvine, CA 92614  
(949) 760-0404 Telephone  
(949) 760-9502 Facsimile  
joe.re@knobbe.com  
steve.jensen@knobbe.com  
stephen.larson@knobbe.com  
ben.katzenellenbogen@knobbe.com  
ted.cannon@knobbe.com  
brian.claassen@knobbe.com  
jared.bunker@knobbe.com  
mark.lezama@knobbe.com  
kendall.loebbaka@knobbe.com  
douglas.wentzel@knobbe.com

Brian Horne  
Knobbe, Martens, Olson & Bear, LLP  
1925 Century Park East, Suite 600  
Los Angeles, CA 90067  
(310) 551-3450 Telephone  
(310) 551-3458 Facsimile  
brian.horne@knobbe.com  
Adam Powell  
Daniel P. Hughes  
Knobbe, Martens, Olson & Bear, LLP  
3579 Valley Centre Drive, Suite 300  
San Diego, CA 92130  
(858) 707-4000 Telephone  
(858) 707-4001 Facsimile

adam.powell@knobbe.com  
Daniel.hughes@knobbe.com

Carol M. Pitzel Cruz  
Knobbe, Martens, Olson & Bear, LLP  
925 4th Ave., #2500  
Seattle, WA 98104  
206-405-2000 Telephone  
206-405-2001 Facsimile  
carol.pitzelcruz@knobbe.com

PHILLIPS MCLAUGHLIN & HALL, P.A.  
John C. Phillips, Jr. (No. 110)  
Megan C. Haney (No. 5016)  
1200 North Broom Street  
Wilmington, DE 19806  
(302) 655-4200 Telephone  
(302) 655-4210 Fax  
jcp@pmhdelaw.com  
mch@pmhdelaw.com

*Counsel for Defendant and Counter-Claimant  
Masimo Corporation; Defendant Sound United,  
LLC; and Counter-Claimant Cercacor  
Laboratories, Inc.*

### CERTIFICATE OF SERVICE

I hereby certify that on September 18, 2024, a true and correct copy of the foregoing document was served on the following counsel of record at the addresses and in the manner indicated:

***VIA ELECTRONIC MAIL:***

David E. Moore Bindu A. Palapura Andrew L. Brown Hercules Plaza, 6th Floor 1313 N. Market Street Wilmington, DE 19801 dmoore@potteranderson.com bpalapura@potteranderson.com abrown@potteranderson.com	John M. Desmarais Kerri-Ann Limbeek Cosmin Maier Jordan N. Malz Benjamin N. Luehrs Joze Welsh Jamie L. Kringstein Jennifer M. Przybylski Carson Olsheski Jeffrey Scott Seddon, II Amy I. Wann Raymond N. Habbaz Lee Matalon Taeg Sang Cho Eli Balsam Patrick Reilly Marie Weisfeiler Ryan G. Thorne Paul A. Bondor Desmarais LLP 230 Park Avenue, 26th Floor New York, NY 10169 jdesmarais@desmaraisllp.com klimbeek@desmaraisllp.com cmaier@desmaraisllp.com jmalz@desmaraisllp.com bluehrs@desmaraisllp.com jwelsh@desmaraisllp.com jkringstein@desmaraisllp.com jprzybylski@desmaraisllp.com colsheski@desmaraisllp.com jseddon@desmaraisllp.com awann@desmaraisllp.com rhabbaz@desmaraisllp.com lmatalon@desmaraisllp.com tcho@desmaraisllp.com
--	--

	<p>ebalsam@desmaraisllp.com  preilly@desmaraisllp.com  mweisfeiler@desmaraisllp.com  rthorne@desmaraisllp.com  pbondor@desmaraisllp.com</p>
<p>Peter C. Magic  Kyle Curry  Maria Tartakovsky  DESMARAIS LLP  101 California Street  San Francisco, CA 94111  pmagic@desmaraisllp.com  kcurry@desmaraisllp.com  mtartakovsky@desmaraisllp.com</p>	<p>Jennifer Milici  Dominic Vote  Leon B. Greenfield  Heath Brooks  John O'Toole  Wilmer Cutler Pickering Hale and Dorr LLP  2100 Pennsylvania Avenue NW  Washington, DC 20037  jennifer.milici@wilmerhale.com  dominic.vote@wilmerhale.com  leon.greenfield@wilmerhale.com  heath.brooks@wilmerhale.com  john.otoole@wilmerhale.com</p>
<p>Mark A. Ford  Vinita Ferrera  Wilmer Cutler Pickering Hale and Dorr LLP  60 State Street  Boston, MA 02109  mark.ford@wilmerhale.com  vinita.ferrera@wilmerhale.com</p>	<p>David J. Cho  David J. Shaw  Desmarais LLP  1899 Pennsylvania Avenue NW, Suite 400  Washington, DC 20006  dcho@desmaraisllp.com  dshaw@desmaraisllp.com</p>
<p>Lydia Turnage  Wilmer Cutler Pickering Hale and Dorr LLP  7 World Trade Center  250 Greenwich Street  New York, NY 10007  lydia.turnage@wilmerhale.com</p>	<p>Bethany Stevens  Hannah Cannom  Walker Stevens Cannom LLP  500 Molino Street, Suite 118  Los Angeles, CA 90013  bstevens@wscllp.com  hcannom@wscllp.com</p>
<p>Lauren Ige  Cristina Salcedo  Wilmer Cutler Pickering Hale and Dorr LLP  250 South Grand Avenue, Suite 2400  Los Angeles, CA 90071  lauren.ige@wilmerhale.com  cristina.salcedo@wilmerhale.com</p>	<p>IPservice@potteranderson.com</p>
<p>AppleMasimoService@desmaraisllp.com</p>	<p>whmasimoantitrustservice@wilmerhale.com</p>

September 18, 2024

/s/ Kendall M. Loebbaka  
Kendall M. Loebbaka

**Masimo's Opposition to Apple Inc.'s Motion *in Limine* No. 1**

**TABLE OF EXHIBITS**

<b>Exhibit</b>	<b>Description</b>
M1	Email from Benjamin Luehrs to Kendall Loebbaka on October 31, 2023.
M2	Excerpts of the November 7, 2023 Deposition of Rico Zorkendorfer.

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

APPLE INC.,

Plaintiff,

v.

MASIMO CORPORATION AND SOUND  
UNITED, LLC,

Defendants.

---

MASIMO CORPORATION AND CERCACOR  
LABORATORIES, INC.,

Counterclaim-Plaintiffs,

v.

APPLE INC.,

Counterclaim-Defendant.

---

C.A. No. 1:22-cv-1377-JLH

C.A. No. 1:22-cv-1378-JLH

**HIGHLY CONFIDENTIAL –  
ATTORNEYS EYES’ ONLY**

**FILED UNDER SEAL**

**APPLE’S REPLY BRIEF IN SUPPORT OF ITS MOTION *IN LIMINE* NO. 1:  
TO PRECLUDE TESTIMONY, ARGUMENT, OR REFERENCE REGARDING THE  
PRESENCE OR ABSENCE OF ANY PARTY’S CORPORATE REPRESENTATIVE,  
EMPLOYEE, OR OTHER WITNESS AT TRIAL**



Masimo’s complaints about the number of asserted claims and deposition designations are irrelevant to Apple’s MIL No. 1, which seeks to prevent Masimo from pointing to an absent witness to abdicate its clear and convincing burden for inequitable conduct and inventorship. Masimo’s long list of targets ensures that no matter which witnesses Apple brings to trial, Masimo can point to others who did not appear, and claim their absence “support[s] an inference that the witness’s testimony would have been adverse.” Opp. at 2 (citing *Revson*). That is contrary to Federal Circuit law. See *Therasense, Inc. v. Becton, Dickinson & Co.*, 649 F.3d 1276, 1296 (Fed. Cir. 2011) (“a patentee need not offer any good faith explanation”).

Masimo’s case law is inapposite. *Graves* (a 130-year-old criminal case) did not permit commentary on a witness’s absence. *Graves*, 150 U.S. at 121. And in *Hines*, an unfavorable inference based on a missing witness was not justified. *Hines*, 470 F.2d at 230. *Revson*, *Ugwu*, and *Atwell* each involved one “missing witness.” *Revson*, 221 F.3d at 81; *Ugwu*, 539 F. App’x at \*39; *Atwell*, 71 F.R.D. at 358. Here, Masimo’s sweeping inequitable conduct theories name dozens of witnesses, and Masimo has not offered a shred of evidence that any one of them has testimony that would “elucidate the transaction” such that commentary on their absences would be appropriate.<sup>1</sup> *Graves*, 150 U.S. at 121. Masimo *knows* that Apple cannot call all these witnesses in a time constrained trial to rebut Masimo’s speculation about their purported intent to deceive the PTO—in fact, Masimo is counting on it. Exs. 3, 5. Moreover, Masimo’s assertion that it cannot narrow its inequitable conduct allegations until Apple narrows its asserted claims is also incorrect. Masimo asserts the same theory against all four asserted design patents, accusing the largely overlapping set of 25+ inventors of inequitable conduct for each patent. Even if Apple narrowed the case to one asserted design claim, Masimo would still accuse over twenty people.

---

<sup>1</sup> Masimo chose not to depose most of these inventors and must live with its failure of proof.

Dated: September 25, 2024

OF COUNSEL:

John M. Desmarais  
Cosmin Maier  
Jordan N. Malz  
Kerri-Ann Limbeek  
**DESMARAIS LLP**  
230 Park Avenue  
New York, NY 10169  
Tel: (212) 351-3400  
jdesmarais@desmaraisllp.com

Peter C. Magic  
**DESMARAIS LLP**  
101 California Street  
San Francisco, CA 94111  
Tel: (415) 573-1900  
pmagic@desmaraisllp.com

Jennifer Milici  
Dominic Vote  
**WILMER CULTER PICKERING  
HALE AND DORR LLP**  
2100 Pennsylvania Avenue NW  
Washington, DC 20037  
Tel: (202) 663-6000

Mark A. Ford  
**WILMER CULTER PICKERING  
HALE AND DORR LLP**  
60 State Street  
Boston, MA 02109  
Tel: (617) 526-6423

By: /s/ Bindu A. Palapura  
David E. Moore (#3983)  
Bindu A. Palapura (#5370)  
Andrew M. Moshos (#6685)  
**POTTER ANDERSON & CORROON LLP**  
Hercules Plaza, 6th Floor  
1313 N. Market Street  
Wilmington, DE 19801  
Tel: (302) 984-6000  
dmoore@potteranderson.com  
bpalapura@potteranderson.com  
amoshos@potteranderson.com

*Attorneys for Plaintiff/Counter-Defendant  
Apple Inc.*

**CERTIFICATE OF SERVICE**

I hereby certify that a copy of Apple's Reply Brief In Support Of Its Motion *In Limine* No. 1 was served upon counsel of record for Masimo Corporation and Sound United, LLC on September 25, 2024.

/s/ Jamie L. Kringstein

Jamie L. Kringstein

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

APPLE INC.,

Plaintiff,

v.

MASIMO CORPORATION AND SOUND  
UNITED, LLC,

Defendants.

---

MASIMO CORPORATION AND CERCACOR  
LABORATORIES, INC.,

Counterclaim-Plaintiffs,

v.

APPLE INC.,

Counterclaim-Defendant.

---

C.A. No. 1:22-cv-1377-JLH

C.A. No. 1:22-cv-1378-JLH

**HIGHLY CONFIDENTIAL –  
ATTORNEYS EYES’ ONLY**

**FILED UNDER SEAL**

**PLAINTIFF APPLE INC.’S MOTION *IN LIMINE* NO. 2:  
TO PRECLUDE EVIDENCE AND ARGUMENT INVOLVING  
PEJORATIVE CHARACTERIZATIONS OF A PARTY OR PERSON**

Masimo intends to bias the jury against Apple by offering irrelevant and unfairly prejudicial anecdotes disparaging Apple and its current or former employees and executives. For example, Masimo's exhibit list includes: (1) a blog titled "These are all the ideas Apple stole from other companies, or people, and sold for billions" (Ex. A (DTX 2873)), (2) a law review article titled "'Efficient' Infringement and Other Lies" that purports to characterize alleged patent infringement by large companies like Apple as "predatory" (Exs. B, I (DTX 2927, 3025)), (3) a statement allegedly made by a former Apple employee (after he left Apple) likening "efficient infringement" to a "fiduciary responsibility" (Exs. C, J (DTX 2934, 3052)), (4) a blog titled "How Apple uses its App Store to copy the best ideas" (Ex. D (DTX 2939)), (5) a book titled "Dying for an iPhone" that purports to describe working conditions at Apple's contract manufacturers' factories (Ex. E (DTX 2940)), (6) an article titled "Apple Bans Phone Story Game That Exposes Seedy Side of Smartphone Creation" (Ex. G (DTX 2865)), (7) an article discussing "How Apple Became a Trillion-Dollar Company and Lost Its Soul" (Ex. K (DTX 2938)), (8) statements calling Apple a thief (Ex. F (DTX 2933)), and (9) an article suggesting Apple "silenced" medical experts (Ex. H (DTX 0346)). When the parties met and conferred, Masimo said it would offer this evidence to impugn Apple's business ethics, particularly if Apple pursued its well-pled copying allegations against Masimo. *See* D.I. 1, ¶ 3. These one-sided, wrong, hearsay upon hearsay anecdotes are irrelevant to any issue in dispute, and any probative value is substantially outweighed by the danger of unfair prejudice to Apple. *See* Fed. R. Evid. 401, 402, 403. This Court, like many before, should preclude evidence and argument referring to any other person or entity as "greedy," "corrupt," "evil," "rich," a "monopolist," a "bully," a "trillion-dollar company," or using any other pejorative term, and referring to statements allegedly attributed to current or former Apple employees about "efficient infringement," "sherlocking," or acting like a "pirate," and statements

allegedly relating to copying or stealing technology attributed to Apple.<sup>1</sup>

**A. The Court Should Preclude Pejorative References To Parties And People.**

The Court should preclude pejorative references to parties and people as “greedy,” “corrupt,” “evil,” “rich,” a “monopolist,” “bully,” a “trillion-dollar company” or other similarly inflammatory terms because those characterizations have no relevance to any issue in dispute. *Evolved Wireless, LLC v. Apple Inc.*, No. CV 15-542-JFB-SRF, 2019 WL 1100471, at \*1 (D. Del. Mar. 7, 2019) (excluding same quote offered by Masimo in DTX 2933 (Ex. F)). For example, Masimo intends to offer evidence purporting to “expose” a “seedy side of smartphone creation.” Ex. G (DTX 2865). This case, however, concerns Masimo’s willful infringement of Apple’s design and utility patents on *watches*—there is no rational connection between those issues and Apple’s smartphone development (*e.g.*, Ex. G (DTX 2865)), supposed labor issues (*e.g.*, Ex. E (DTX 2940)), or negative commentary on its wealth (*e.g.*, Ex. K (DTX 2938)). Even if Masimo’s pejoratives have some minimal relevance (they do not), the Court should exclude them under FRE 403. Masimo’s intended portrayal of Apple as a corrupt, greedy, rich, evil, bullying thief (*e.g.*, Exs. A, C, F) would unfairly suggest to jurors that its infringement of Apple’s patents is somehow justified and create a “trial-within-a-trial” where Apple would have to rebut Masimo’s irrelevant accusations, notwithstanding that Masimo, not Apple, is the accused infringer here.

**B. The Court Should Preclude Pejorative References To “Efficient Infringement,” “Sherlocking,” Or Acting Like A “Pirate.”**

The Court should preclude references to Apple engaging in “efficient infringement” or “sherlocking,”<sup>2</sup> acting like a “pirate,” or other similarly inflammatory accusations, because they

---

<sup>1</sup> This would not preclude a party from introducing factual evidence to support a claim of copying relevant to a jury issue (*e.g.*, infringement, secondary considerations, or willfulness). Nor would this preclude a party from appropriately attacking a witness’s credibility.

<sup>2</sup> *See, e.g.*, 1378 Case, D.I. 15, Counterclaims at ¶ 45 (referencing Ex. C).

are not true and have no relevance to any issue in dispute. Indeed, the Court in the parties' CDCA Case granted Apple's similar motion before trial last year. *See Masimo Corp. v. Apple Inc.*, No. 20-cv-0048, 2023 WL 3432126, at \*2-3 (C.D. Cal. Mar. 15, 2023) (excluding evidence of purported "efficient infringement" and "stealing"). Masimo failed to identify any witness who would testify regarding such a strategy, and has not tied any such strategy to Masimo's defenses. Therefore, any such references (*see, e.g.*, Exs. B, D, E) should be categorically excluded under FRE 402. Even if this material has some relevance (it does not), the Court should exclude it under FRE 403. Such references would, again, unfairly suggest that Masimo's infringement of Apple's intellectual property is somehow justified and create a "trial-within-a-trial."

**C. The Court Should Preclude Pejorative Statements Attributed To Apple Allegedly Relating To Copying Or Stealing Technology.**

Statements attributed to Apple or its former employees/executives allegedly relating to copying or stealing technology simply have no relevance to Masimo's infringement of Apple's patents, and the Court should preclude them. *See Evolved Wireless*, 2019 WL 1100471 at \*1. Masimo intends to offer remarks purportedly made by Apple's deceased former CEO Steve Jobs in the 1980s that "good artists copy, great artists steal." *See* Ex. F. Similarly, Masimo intends to offer remarks by bloggers purporting to identify "all the ideas Apple stole from other companies." *See* Ex. A. These are not relevant to any claim or defense, and any minimal relevance is outweighed by unfair prejudice. *See Masimo*, 2023 WL 3432126 at \*3 ("courts have routinely excluded the same, often-quoted statements by Steve Jobs, who died before the events at issue, as irrelevant or prejudicial"). Even if Apple alleges that Masimo copied Apple Watch, that does not make Apple's purported copying relevant, as Masimo argued during the parties' meet and confer.<sup>3</sup>

---

<sup>3</sup> To the extent any of Masimo's pejoratives touch on Masimo's counterclaims, those issues are not part of the October trial, and are thus irrelevant. 1378 Case, D.I. 671.

Dated: September 4, 2024

OF COUNSEL:

John M. Desmarais  
Cosmin Maier  
Jordan N. Malz  
Kerri-Ann Limbeek  
**DESMARAIS LLP**  
230 Park Avenue  
New York, NY 10169  
Tel: (212) 351-3400  
jdesmarais@desmaraisllp.com

Peter C. Magic  
**DESMARAIS LLP**  
101 California Street  
San Francisco, CA 94111  
Tel: (415) 573-1900  
pmagic@desmaraisllp.com

Jennifer Milici  
Dominic Vote  
**WILMER CULTER PICKERING  
HALE AND DORR LLP**  
2100 Pennsylvania Avenue NW  
Washington, DC 20037  
Tel: (202) 663-6000

Mark A. Ford  
**WILMER CULTER PICKERING  
HALE AND DORR LLP**  
60 State Street  
Boston, MA 02109  
Tel: (617) 526-6423

By: /s/ David E. Moore  
David E. Moore (#3983)  
Bindu A. Palapura (#5370)  
Andrew M. Moshos (#6685)  
**POTTER ANDERSON & CORROON LLP**  
Hercules Plaza, 6th Floor  
1313 N. Market Street  
Wilmington, DE 19801  
Tel: (302) 984-6000  
dmoore@potteranderson.com  
bpalapura@potteranderson.com  
amoshos@potteranderson.com

*Attorneys for Plaintiff/Counter-Defendant  
Apple Inc.*



**CERTIFICATE OF SERVICE**

I hereby certify that a copy of Apple Inc.'s Motion *In Limine* No. 2 was served upon  
counsel of record for Masimo Corporation and Sound United, LLC on September 4, 2024.

/s/ Jamie L. Kringstein

Jamie L. Kringstein

Motion In Limine No. 2 Exhibits Table				
Exhibit No.	DTX No.	Production BegBates No.	Production EndBates No.	Description
A	2873			"These are all the ideas Apple stole from other companies, or people, and sold for billions," Ashraf, October 28, 2012.
B	2927			Osenga, Kristen Jakobsen, "'Efficient' Infringement and Other Lies," Seton Hall Law Review, 2022, 52(4): 1085–1110
C	2934			"The Trouble With Patent-Troll Hunting," The Economist , December 14, 2019, <a href="https://www.economist.com/business/2019/12/14/the-trouble-with-patent-troll-hunting">https://www.economist.com/business/2019/12/14/the-trouble-with-patent-troll-hunting</a>
D	2939			Albergotti, Reed, "How Apple uses its App Store to copy the best ideas," The Washington Post, September 5, 2019.
E	2940			Chan, Jenny, Selden, Mark and Pun Ngai, "Dying for an iPhone: Apple, Foxconn, and The Lives of China's Workers," Haymarket Books, 2020.
F	2933			Denning, Steve, "The Lost Interview: Steve Jobs Tells Us What Really Matters," Forbes , November 17, 2011, available at <a href="https://www.forbes.com/sites/stevedenning/2011/11/17/the-lost-interview-steve-jobs-tells-us-what-really-matters/?sh=78be55fd6c3a">https://www.forbes.com/sites/stevedenning/2011/11/17/the-lost-interview-steve-jobs-tells-us-what-really-matters/?sh=78be55fd6c3a</a>
G	2865			Brown, Mark, "Apple Bans Phone Story Game That Exposes Seedy Side of Smartphone Creation," Wired.com, September 14, 2011, <a href="https://www.wired.com/2011/09/phone-story/">https://www.wired.com/2011/09/phone-story/</a> .
H	346			10/8/2021 Dodge, B., "Apple dreamed of making health care easy. Then it silenced its medical experts." Business Insider
I	3025	MASAD00032163	MASAD00032188	Osenga, Kristen Jakobsen, "'Efficient" Infringement and Other Lies," Seton Hall Law Review, 52:1085-1110 (2022)
J	3052	MASAD00238635	MASAD00238637	12/14/2019 The Economist, "The trouble with patent-troll-hunting"
K	2938			Mickle, Tripp, "After Steve - How Apple Became a Trillion-Dollar Company and Lost Its Soul," HarperCollins Publishers, May 3, 2022.

IN THE U.S. DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE

APPLE INC.,  <i>Plaintiff,</i>  v.  MASIMO CORPORATION and SOUND UNITED, LLC,  <i>Defendants.</i>	C.A. No. 22-1377-JLH  <b>JURY TRIAL DEMANDED</b>
MASIMO CORPORATION,  <i>Counter-Claimant,</i>  v.  APPLE INC.  <i>Counter-Defendant.</i>	
APPLE INC.,  <i>Plaintiff,</i>  v.  MASIMO CORPORATION and SOUND UNITED, LLC,  <i>Defendants.</i>	C.A. No. 22-1378-JLH  <b>JURY TRIAL DEMANDED</b>
MASIMO CORPORATION and CERCACOR LABORATORIES, INC.,  <i>Counter-Claimants,</i>  v.  APPLE INC.  <i>Counter-Defendant.</i>	<b>CONFIDENTIAL – ATTORNEYS’ EYES ONLY FILED UNDER SEAL</b>

**DEFENDANTS MASIMO CORPORATION AND SOUND UNITED, LLC’S  
OPPOSITION TO APPLE INC.’S MOTION *IN LIMINE* NO. 2**

Apple's MIL No. 2 would allow Apple to disparage Masimo without restriction, while preventing Masimo from responding. Apple's strategy is explicit: Apple asks the Court to preclude "statements allegedly relating to copying or stealing technology" by Apple, but allow Apple to introduce "evidence to support a claim of copying" by Masimo. MIL No. 2 at 1-2, 2 n.1. The Court should deny Apple's attempts to prevent Masimo from rebutting Apple's allegations that Apple is an innovator and Masimo is a freeriding copycat.

**A. The Court Should Reject Apple's One-Sided Rule on Pejorative References to Parties and People**

Apple has consistently referred to itself in a positive light while using inflammatory and pejorative language when referring to Masimo. For example, Apple's Complaints refer to the Apple Watch containing "cutting-edge technology with a beautiful design," and an "innovative, and appealing product." *See, e.g.*, No. -1378, D.I. 1 at ¶¶ 2 and 22. Apple then pejoratively refers to Masimo as "secretly copying" Apple Watch and "freeriding on Apple's hard work." *See, e.g., id.* at ¶¶ 22 and 34. One of Apple's experts casts Apple (who makes the Apple Watch in Asia) as an "innovative company" with a "strong reputation," while equating Masimo (which makes the accused products in the United States) with Chinese "shanzhai manufacturers," which he calls "the mountain bandits of technology." Ex. M1 at 6-10 and 71.

Apple has disparaged Masimo and its founder in several other ways, including by alleging: (1) "The COVID-19 pandemic made Mr. Kiani a billionaire;" (2) Masimo's products "contain technology and designs that were stolen from Apple"; (3) Masimo lacked "its own innovations and novel technologies"; (4) "Masimo is now flagrantly freeriding on Apple's hard work and innovation"; (5) "Masimo knowingly released inferior products with technology and designs misappropriated from Apple"; and (6) Masimo copied non-watch Apple products through the sale of other products not at issue. Ex. M2 at 7-8, 30-31. Apple's MIL No. 2 asserts such statements

are somehow “relevant to a jury issue,” while simultaneously seeking to prevent Masimo from introducing appropriate rebuttal evidence.

Apple intends to cast itself as an innovator wronged by “freeriding” Masimo to persuade the jury that Masimo infringed valid patents. This strategy puts at issue evidence of whether Apple is, in fact, the “innovator” it claims to be. Masimo should be permitted to introduce documents discussing Apple’s business practices—including those that contain negative statements about Apple—to rebut Apple’s false narrative that it is an innovator and Masimo is “freeriding on Apple’s hard work.” Introducing such evidence is not unfairly prejudicial simply because it undercuts Apple’s infringement and validity theories. The Court should reject Apple’s attempt to prevent a fair rebuttal to Apple’s false narrative that it is an innovator and Masimo is a copyist.

For similar reasons, Masimo should be allowed to introduce evidence that Apple has engaged in “efficient infringement” and “sherlocking,” to rebut Apple’s attempts to portray itself as an innovator wronged by Masimo. The exclusion of similar evidence in Masimo’s trade secret case against Apple in California does not control the result here. In California, the issue was whether such evidence might be considered prejudicial given Masimo’s allegations that Apple misappropriated Masimo’s trade secrets. But here, Apple is asserting patents against Masimo. Apple seeks to convince the jury that Masimo could not innovate as support for Apple’s allegations of infringement and validity. Apple’s narrative put its supposed “innovation” at issue and Masimo should be allowed to rebut Apple’s narrative with evidence of Apple’s failure to innovate.

Steve Jobs’s statement that “good artists copy, great artists steal,” is also potentially relevant rebuttal evidence. For example, at least one Apple trial witness testified at deposition that

[REDACTED]

[REDACTED] If Apple references Jobs to assert it has a reputation of innovation or [REDACTED]

[REDACTED], Masimo should be able to present Jobs's statement to paint a more complete picture. Apple witnesses should not be able to try to rely on Jobs's celebrity while shielding his own prior statements from the jury.

**B. The Specific Exhibits Apple References Are For Rebuttal**

For the specific exhibits referenced in MIL No. 2, ten of the eleven exhibits were relied on by Masimo expert Cleve Tyler in rebuttal to arguments made by Apple's expert, James Malackowski. If Malackowski disparages Masimo (e.g., by calling Masimo a shanzhai copyist as he did in his expert report) while portraying Apple as an innocent and moral innovator, these exhibits provide relevant rebuttal evidence. If, however, the Court grants Masimo's MIL No. 1 to preclude Malackowski's testimony, and Apple does not otherwise open the door, there should be no need for Masimo to introduce these exhibits during the jury trial. Although these exhibits are more relevant to injunctive relief, Apple has refused to stipulate that Malackowski will not open the door to such rebuttal during any jury trial.

September 18, 2024

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

By: /s/ Kendall M. Loebbaka

Joseph R. Re  
Stephen C. Jensen  
Stephen W. Larson  
Benjamin A. Katzenellenbogen  
Edward M. Cannon  
Brian C. Claassen  
Jared C. Bunker  
Mark Lezama  
Kendall M. Loebbaka  
Douglas B. Wentzel  
Knobbe, Martens, Olson & Bear, LLP  
2040 Main Street, 14th Floor  
Irvine, CA 92614  
(949) 760-0404 Telephone  
(949) 760-9502 Facsimile  
joe.re@knobbe.com  
steve.jensen@knobbe.com  
stephen.larson@knobbe.com  
ben.katzenellenbogen@knobbe.com  
ted.cannon@knobbe.com  
brian.claassen@knobbe.com  
jared.bunker@knobbe.com  
mark.lezama@knobbe.com  
kendall.loebbaka@knobbe.com  
douglas.wentzel@knobbe.com

Brian Horne  
Knobbe, Martens, Olson & Bear, LLP  
1925 Century Park East, Suite 600  
Los Angeles, CA 90067  
(310) 551-3450 Telephone  
(310) 551-3458 Facsimile  
brian.horne@knobbe.com  
Adam Powell  
Daniel P. Hughes  
Knobbe, Martens, Olson & Bear, LLP  
3579 Valley Centre Drive, Suite 300  
San Diego, CA 92130

(858) 707-4000 Telephone  
(858) 707-4001 Facsimile  
adam.powell@knobbe.com  
Daniel.hughes@knobbe.com

Carol M. Pitzel Cruz  
Knobbe, Martens, Olson & Bear, LLP  
925 4th Ave., #2500  
Seattle, WA 98104  
206-405-2000 Telephone  
206-405-2001 Facsimile  
carol.pitzelcruz@knobbe.com

PHILLIPS MCLAUGHLIN & HALL, P.A.  
John C. Phillips, Jr. (No. 110)  
Megan C. Haney (No. 5016)  
1200 North Broom Street  
Wilmington, DE 19806  
(302) 655-4200 Telephone  
(302) 655-4210 Fax  
jcp@pmhdelaw.com  
mch@pmhdelaw.com

*Counsel for Defendant and Counter-Claimant  
Masimo Corporation; Defendant Sound United,  
LLC; and Counter-Claimant Cercacor  
Laboratories, Inc.*



### CERTIFICATE OF SERVICE

I hereby certify that on September 18, 2024, a true and correct copy of the foregoing document was served on the following counsel of record at the addresses and in the manner indicated:

***VIA ELECTRONIC MAIL:***

David E. Moore Bindu A. Palapura Andrew L. Brown Hercules Plaza, 6th Floor 1313 N. Market Street Wilmington, DE 19801 dmoore@potteranderson.com bpalapura@potteranderson.com abrown@potteranderson.com	John M. Desmarais Kerri-Ann Limbeek Cosmin Maier Jordan N. Malz Benjamin N. Luehrs Joze Welsh Jamie L. Kringstein Jennifer M. Przybylski Carson Olsheski Jeffrey Scott Seddon, II Amy I. Wann Raymond N. Habbaz Lee Matalon Taeg Sang Cho Eli Balsam Patrick Reilly Marie Weisfeiler Ryan G. Thorne Paul A. Bondor Desmarais LLP 230 Park Avenue, 26th Floor New York, NY 10169 jdesmarais@desmaraisllp.com klimbeek@desmaraisllp.com cmaier@desmaraisllp.com jmalz@desmaraisllp.com bluehrs@desmaraisllp.com jwelsh@desmaraisllp.com jkringstein@desmaraisllp.com jprzybylski@desmaraisllp.com colsheski@desmaraisllp.com jseddon@desmaraisllp.com awann@desmaraisllp.com rhabbaz@desmaraisllp.com lmatalon@desmaraisllp.com tcho@desmaraisllp.com
--	--

	ebalsam@desmaraisllp.com preilly@desmaraisllp.com mweisfeiler@desmaraisllp.com rthorne@desmaraisllp.com pbondor@desmaraisllp.com
Peter C. Magic Kyle Curry Maria Tartakovsky DESMARAIS LLP 101 California Street San Francisco, CA 94111 pmagic@desmaraisllp.com kcurry@desmaraisllp.com mtartakovsky@desmaraisllp.com	Jennifer Milici Dominic Vote Leon B. Greenfield Heath Brooks John O'Toole Wilmer Cutler Pickering Hale and Dorr LLP 2100 Pennsylvania Avenue NW Washington, DC 20037 jennifer.milici@wilmerhale.com dominic.vote@wilmerhale.com leon.greenfield@wilmerhale.com heath.brooks@wilmerhale.com john.otoole@wilmerhale.com
Mark A. Ford Vinita Ferrera Wilmer Cutler Pickering Hale and Dorr LLP 60 State Street Boston, MA 02109 mark.ford@wilmerhale.com vinita.ferrera@wilmerhale.com	David J. Cho David J. Shaw Desmarais LLP 1899 Pennsylvania Avenue NW, Suite 400 Washington, DC 20006 dcho@desmaraisllp.com dshaw@desmaraisllp.com
Lydia Turnage Wilmer Cutler Pickering Hale and Dorr LLP 7 World Trade Center 250 Greenwich Street New York, NY 10007 lydia.turnage@wilmerhale.com	Bethany Stevens Hannah Cannom Walker Stevens Cannom LLP 500 Molino Street, Suite 118 Los Angeles, CA 90013 bstevens@wscllp.com hcannom@wscllp.com
Lauren Ige Cristina Salcedo Wilmer Cutler Pickering Hale and Dorr LLP 250 South Grand Avenue, Suite 2400 Los Angeles, CA 90071 lauren.ige@wilmerhale.com cristina.salcedo@wilmerhale.com	IPservice@potteranderson.com
AppleMasimoService@desmaraisllp.com	whmasimoantitrustservice@wilmerhale.com

September 18, 2024

/s/ Kendall M. Loebbaka  
Kendall M. Loebbaka

**Masimo's Opposition to Apple Inc.'s Motion *in Limine* No. 2**

**TABLE OF EXHIBITS**

<b>Exhibit</b>	<b>Description</b>
M1	Opening Expert Report of James E. Malackowski
M2	Apple's First Supplemental Objections and Responses to Defendants' Eighth Set of Interrogatories (Nos. 44, 45, 46, 47) dated November 9, 2023
M3	Excerpts of the October 10, 2023 Deposition of Fletcher Rothkopf

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

APPLE INC.,

Plaintiff,

v.

MASIMO CORPORATION AND SOUND  
UNITED, LLC,

Defendants.

---

MASIMO CORPORATION AND CERCACOR  
LABORATORIES, INC.,

Counterclaim-Plaintiffs,

v.

APPLE INC.,

Counterclaim-Defendant.

---

C.A. No. 1:22-cv-1377-JLH

C.A. No. 1:22-cv-1378-JLH

**HIGHLY CONFIDENTIAL –  
ATTORNEYS EYES’ ONLY**

**FILED UNDER SEAL**

**APPLE’S REPLY BRIEF IN SUPPORT OF ITS MOTION *IN LIMINE* NO. 2:  
TO PRECLUDE EVIDENCE AND ARGUMENT INVOLVING  
PEJORATIVE CHARACTERIZATIONS OF A PARTY OR PERSON**

Masimo's overarching claim that any evidence of innovation by Apple opens the door to gossip about Apple's alleged business practices is nothing more than a smear campaign that ignores Rules 401 and 403. *First*, Masimo's campaign to discredit Apple's innovation by making false accusations using statements of non-witnesses that cannot be challenged in court will unduly prejudice Apple. *See, e.g., Wonderland Switzerland AG v. Evenflo Co., Inc.*, No. 1:20-CV-00727-JPM, 2022 WL 20591121, at \*4 (D. Del. Dec. 29, 2022) (hearsay issues "further increase the potential unfair prejudice and confusion"). *Second*, Masimo's false accusations regarding Apple's supposed business practices have no bearing on the issues in this case: ***Masimo's copying and willful infringement***. *See Zimmer Surgical, Inc. v. Stryker Corp.*, No. CV 16-679-RGA, 2019 WL 9171205, at \*2 (D. Del. Mar. 13, 2019) (excluding defendant's evidence that defendant is also an innovator and that plaintiff also copied under Fed. R. Evid. 403, finding it not relevant to defendant's willful infringement, highly prejudicial, and would likely confuse the jury). *Third*, even if Masimo's false accusations and inflammatory documents had some minimal relevance—they do not—any probative value is substantially outweighed by the real danger of unfair prejudice to Apple. The only purpose of such information is to cast Apple in a negative light and invite the jury to render a verdict on an improper and unfounded emotional basis rather than the merits of Apple's claims and Masimo's defenses. *See VLSI Tech. LLC v. Intel Corp.*, No. CV 18-966-CFC-CJB, 2022 WL 2304112, at \*1 (D. Del. June 27, 2022) ("[A]ny conceivable probative value Intel's ... corporate culture... could have would be substantially outweighed by the danger of unfair prejudice."). *Finally*, Masimo is wrong that this MIL rises and falls with Masimo's MIL #1 to exclude actual evidence that Masimo copied, because Masimo's "copying is evidence of willful infringement," an actual issue in this case. *See State Indus., Inc. v. Mor-Flo Indus., Inc.*, 883 F.2d 1573, 1582 (Fed. Cir. 1989); *Read Corp. v. Portec, Inc.*, 970 F.2d 816, 826–27 (Fed. Cir. 1992).

Dated: September 25, 2024

OF COUNSEL:

John M. Desmarais  
Cosmin Maier  
Jordan N. Malz  
Kerri-Ann Limbeek  
**DESMARAIS LLP**  
230 Park Avenue  
New York, NY 10169  
Tel: (212) 351-3400  
jdesmarais@desmaraisllp.com

Peter C. Magic  
**DESMARAIS LLP**  
101 California Street  
San Francisco, CA 94111  
Tel: (415) 573-1900  
pmagic@desmaraisllp.com

Jennifer Milici  
Dominic Vote  
**WILMER CULTER PICKERING  
HALE AND DORR LLP**  
2100 Pennsylvania Avenue NW  
Washington, DC 20037  
Tel: (202) 663-6000

Mark A. Ford  
**WILMER CULTER PICKERING  
HALE AND DORR LLP**  
60 State Street  
Boston, MA 02109  
Tel: (617) 526-6423

By: /s/ Bindu A. Palapura  
David E. Moore (#3983)  
Bindu A. Palapura (#5370)  
Andrew M. Moshos (#6685)  
**POTTER ANDERSON & CORROON LLP**  
Hercules Plaza, 6th Floor  
1313 N. Market Street  
Wilmington, DE 19801  
Tel: (302) 984-6000  
dmoore@potteranderson.com  
bpalapura@potteranderson.com  
amoshos@potteranderson.com

*Attorneys for Plaintiff/Counter-Defendant  
Apple Inc.*

**CERTIFICATE OF SERVICE**

I hereby certify that a copy of Apple's Reply Brief In Support Of Its Motion *In Limine* No. 2 was served upon counsel of record for Masimo Corporation and Sound United, LLC on September 25, 2024.

/s/ Jamie L. Kringstein

Jamie L. Kringstein

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

APPLE INC.,

Plaintiff,

v.

MASIMO CORPORATION AND SOUND  
UNITED, LLC,

Defendants.

---

MASIMO CORPORATION AND CERCACOR  
LABORATORIES, INC.,

Counterclaim-Plaintiffs,

v.

APPLE INC.,

Counterclaim-Defendant.

---

C.A. No. 1:22-cv-1377-JLH

C.A. No. 1:22-cv-1378-JLH

**HIGHLY CONFIDENTIAL –  
ATTORNEYS EYES’ ONLY**

**FILED UNDER SEAL**

**PLAINTIFF APPLE INC.’S MOTION *IN LIMINE* NO. 3:  
TO PRECLUDE EVIDENCE, ARGUMENT, AND REFERENCE TO UNRELATED  
LITIGATIONS, PROCEEDINGS, CLAIMS, LEGAL REMEDIES, AND ALLEGATIONS  
NOT BEING ADJUDICATED IN THE OCTOBER 2024 JURY TRIAL**



Masimo has made it clear that it intends to distract the jury from Masimo's infringement of Apple's patents with irrelevant and unfairly prejudicial evidence relating to Masimo's unrelated (and false) allegations that Apple met with Masimo in 2013 feigning interest in acquiring Masimo, strategized to recruit Masimo's employees, stole Masimo's purported trade secrets, infringes Masimo's patents, and engages in false advertising and anticompetitive conduct. These allegations relate, not to Apple's patent infringement claims being tried in October, but instead to Masimo's trade secret, antitrust, unfair competition, false advertising, and patent claims in the ITC, Central District of California, and District of Delaware. Masimo also intends to reference the parties' other cases in the ITC and CDCA; PTAB proceedings on patents not set for trial in October; Masimo's prior litigations against third parties, such as Philips and Nellcor; the Department of Justice's case against Apple; and Apple's requests for legal remedies to be decided by the Court, not the jury, including Apple's request for an injunction for Masimo's infringement of Apple's patents. But none of these cases, claims, or allegations are set for trial before the jury in October 2024 in this Court. The October trial is the time for Apple to have its claims (and Masimo's defenses) decided.

The Court should preclude Masimo from prejudicing the jury with evidence, argument, and reference to allegations, claims, and proceedings that have no relevance to the issues the parties are trying in October—namely, whether Masimo willfully infringed Apple's asserted patents, whether those patents are valid, and, if Masimo's inequitable conduct claim survives summary judgment, whether certain patents are enforceable. 1378 Case, D.I. 671; FRE 402 (“Irrelevant evidence is not admissible.”). Masimo's strategy is a classic attempt to smear as a distraction from the issues set for trial, and should be excluded under Federal Rules of Evidence 401, 402, and 403.

The risk is not hypothetical. Masimo's exhibit list includes numerous exhibits regarding the parties' previous interactions—*e.g.*, documents regarding Apple meeting with Masimo in 2013

about the possibility of a business arrangement (Exs. 1–33). Masimo also identifies exhibits regarding Apple’s hiring of former Defendant employees, including Marcelo Lamago and Michael O’Reilly, who have been at the center of the CDCA litigation, as well as others which the CDCA court itself excluded as irrelevant and prejudicial, *Masimo Corp. v. Apple Inc.*, 2023 WL 3432126, at \*2 (C.D. Cal. Mar. 15, 2023)—*e.g.*, an email from Apple CEO Tim Cook about “smart recruiting [REDACTED]”; Apple’s CDCA interrogatory response about Apple hiring former Masimo employees (Ex. 35); Apple emails and documents regarding hiring former Masimo employees (Exs. 36–79); and documents and emails relating to Apple’s alleged misappropriation of Masimo’s purported trade secrets through hiring Mr. Lamago and Dr. O’Reilly (Exs. 80–206).

Masimo also identifies exhibits relating to its false advertising, antitrust, unfair competition, and willful infringement claims—*e.g.*, documents relating to Apple’s advertising (Exs. 207–250); Apple’s App Store, app review policy, and Masimo’s app submission (Exs. 251–280); and [REDACTED]

Masimo also designated testimony on each of the topics identified above. (Exs. 288–308.)

Finally, Masimo identifies unrelated PTAB filings (Exs. 309–336), Masimo’s asserted patents (Exs. 337–344), CDCA expert reports (Exs. 345–346), ITC filings (Exs. 347–394), and documents relating to Masimo’s litigations against third parties (Exs. 395–402) as exhibits.

During conferral, Masimo claimed this information is relevant to describing the parties’ history and Apple’s purported motivation for bringing this suit. But Masimo’s false storytelling is not probative of any issue set for trial and is extremely inflammatory. And none of it is among the facts that Masimo ever identified in this case as relevant to its defenses to any of Apple’s patent infringement claims. Masimo also failed to make any such connection during conferral. Masimo’s plan is to confuse the jury as to whose conduct is relevant, waste trial time by distracting from the

issues, and unfairly prejudice Apple. Masimo's tactics would also give rise to "trial within a trial" problems, as Apple would be required to put on otherwise-irrelevant evidence to contextualize Masimo's evidence. Tellingly, when the shoe was on the other foot in CDCA, Masimo argued that Apple's copying allegations in Delaware had no place in the CDCA trial. Ex. 403 (*Masimo Corp. v. Apple Inc.*, No. 8:20-cv-48, D.I. 1362 at 11 (C.D. Cal. Feb. 24, 2023)). Likewise, Masimo's allegations against Apple have no place in this trial.

"Courts routinely exclude evidence and argumentation relating to prior litigation because the risk of unfair prejudice substantially outweighs the probative value of any evidence." *IBM Corp. v. Zynga Inc.*, 2024 WL 3993290, at \*2 (D. Del. Aug. 29, 2024). Indeed, courts have excluded evidence relating to trade secret and antitrust claims in a patent trial. *See, e.g., Alarm.com, Inc. v. SecureNet Techs. LLC*, No. 1:15-cv-807, D.I. 242 at 1 (D. Del. Jan. 23, 2019) (Ex. 404) (finding antitrust positions "have virtually no probative value" in patent case); *Medtronic Vascular, Inc. v. Advanced Cardiovascular Sys., Inc.*, 2005 WL 67086, at \*1 (D. Del. Jan. 5, 2005) (granting MIL "to preclude Medtronic from introducing argument or evidence relating to its claim that ACS misappropriated trade secrets in the trial for the Boneau patent claim"). And courts have excluded evidence relating to a request for an injunction. *See, e.g., Evolved Wireless, LLC v. Apple Inc.*, 2019 WL 1100471, at \*6 (D. Del. Mar. 7, 2019). Faced with Apple's similar motion, the CDCA court ruled that "evidence, rulings, and dispositions of other cases will shed little, if any, probative value," and "risks danger of unfair prejudice, confusion of the issues, and misleading the jury." *Masimo*, 2023 WL 3432126, at \*1.

The Court should preclude Masimo from introducing evidence and argument regarding irrelevant proceedings, claims, and allegations, and referencing other proceedings, to avoid wasting time, misleading the jury as to the issues to be decided, and unfairly prejudicing Apple.

Dated: September 12, 2024

OF COUNSEL:

John M. Desmarais  
Cosmin Maier  
Jordan N. Malz  
Kerri-Ann Limbeek  
**DESMARAIS LLP**  
230 Park Avenue  
New York, NY 10169  
Tel: (212) 351-3400  
jdesmarais@desmaraisllp.com

Peter C. Magic  
**DESMARAIS LLP**  
101 California Street  
San Francisco, CA 94111  
Tel: (415) 573-1900  
pmagic@desmaraisllp.com

Jennifer Milici  
Dominic Vote  
**WILMER CULTER PICKERING  
HALE AND DORR LLP**  
2100 Pennsylvania Avenue NW  
Washington, DC 20037  
Tel: (202) 663-6000

Mark A. Ford  
**WILMER CULTER PICKERING  
HALE AND DORR LLP**  
60 State Street  
Boston, MA 02109  
Tel: (617) 526-6423

By: /s/ David E. Moore  
David E. Moore (#3983)  
Bindu A. Palapura (#5370)  
Andrew M. Moshos (#6685)  
**POTTER ANDERSON & CORROON LLP**  
Hercules Plaza, 6th Floor  
1313 N. Market Street  
Wilmington, DE 19801  
Tel: (302) 984-6000  
dmoore@potteranderson.com  
bpalapura@potteranderson.com  
amoshos@potteranderson.com

*Attorneys for Plaintiff/Counter-Defendant  
Apple Inc.*

**CERTIFICATE OF SERVICE**

I hereby certify that a copy of Apple Inc.'s Motion *In Limine* No. 3 was served upon counsel of record for Masimo Corporation and Sound United, LLC on September 12, 2024.

/s/ Jamie L. Kringstein

Jamie L. Kringstein

Motion In Limine No. 3 Exhibits Table					
Exhibit No.	DTX No.	Production BegBates No.	Production EndBates No.	Description	Deposition Designation Pages
1	58	APL-MAS_00399124	APL-MAS_00399125	[REDACTED]	
2	59	APL-MAS_02506931	APL-MAS_02506933	[REDACTED]	
3	159	MASA00203148	MASA00203149	[REDACTED]	
4	160	APL-MAS_01891934	APL-MAS_01891935	[REDACTED]	
5	161	APL-MAS_00676290	APL-MAS_00676290	[REDACTED]	
6	162	APL-MAS_00676497	APL-MAS_00676498	[REDACTED]	
7	166	APL_DEL01569131	APL_DEL01569135	[REDACTED]	
8	320	APL-MAS_01896101	APL-MAS_01896103	[REDACTED]	
9	393			[REDACTED]	
10	394			[REDACTED]	
11	395			[REDACTED]	
12	425	APL-MAS_02364484	APL-MAS_02364488	[REDACTED]	
13	480	APL-MAS_03077337	APL-MAS_03077341	[REDACTED]	
14	481	APL-MAS_00909102	APL-MAS_00909134	[REDACTED]	
15	483	APL-MAS_01853759	APL-MAS_01853795	[REDACTED]	
16	559	MASA03217800	MASA03217800	[REDACTED]	

Motion In Limine No. 3 Exhibits Table					
Exhibit No.	DTX No.	Production BegBates No.	Production EndBates No.	Description	Deposition Designation Pages
17	1022	APL-MAS_00414570	APL-MAS_00414570	[REDACTED]	
18	1073			[REDACTED]	
19	1160			[REDACTED]	
20	1189			[REDACTED]	
21	1190			[REDACTED]	
22	1201			[REDACTED]	
23	1202			[REDACTED]	
24	1212			[REDACTED]	
25	1221	MASA00203107	MASA00203110	[REDACTED]	
26	1222	MASA002456175	MASA002456175	[REDACTED]	
27	2985	APL-MAS_00433808	APL-MAS_00433810	[REDACTED]	
28	3005	APL-MAS_00403772	APL-MAS_00403784	[REDACTED]	
29	3010	APL-MAS_00676516	APL-MAS_00676517	[REDACTED]	
30	3272	APL-MAS_00233252	APL-MAS_00233253	[REDACTED]	
31	3293			[REDACTED]	
32	3317			[REDACTED]	
33	3510			[REDACTED]	
34	316	APL-MAS_00433706	APL-MAS_00433710	[REDACTED]	

Motion In Limine No. 3 Exhibits Table					
Exhibit No.	DTX No.	Production BegBates No.	Production EndBates No.	Description	Deposition Designation Pages
35	497			10/7/2022 Apple's Supplemental Objections and Responses to Masimo's Third Set of Interrogatories (Nos. 11-13) (Masimo v. Apple, No. 8:20-cv-00048)	
36	259	APL-MAS_00403772	APL-MAS_00403784	[REDACTED]	
37	392			[REDACTED]	
38	475	APL-MAS_00083085	APL-MAS_00083104	[REDACTED]	
39	476	APL-MAS_00083087	APL-MAS_00083087	[REDACTED]	
40	477	APL-MAS_00083940	APL-MAS_00083940	[REDACTED]	
41	478	APL-MAS_00083940	APL-MAS_00083940	[REDACTED]	
42	482	APL-TW_00000010	APL-TW_00000013	[REDACTED]	
43	484	APL-MAS_00359941	APL-MAS_00359941	[REDACTED]	
44	485	APL-MAS_00359928	APL-MAS_00359929	[REDACTED]	
45	486	APL-TW_00000720	APL-TW_00000721	[REDACTED]	
46	487	APL-MAS_00359988	APL-MAS_00359990	[REDACTED]	
47	488	APL-TW_00000439	APL-TW_00000439	[REDACTED]	
48	489	APL-MAS_00237567	APL-MAS_00237571	[REDACTED]	
49	492	APL-MAS_00241716	APL-MAS_00241727	[REDACTED]	
50	493	APL-MAS_00417705	APL-MAS_00417719	[REDACTED]	



Motion In Limine No. 3 Exhibits Table					
Exhibit No.	DTX No.	Production BegBates No.	Production EndBates No.	Description	Deposition Designation Pages
51	507			[REDACTED]	
52	762			[REDACTED]	
53	810			[REDACTED]	
54	1020	APL-MAS_00399304	APL-MAS_00399304	[REDACTED]	
55	1075			[REDACTED]	
56	1076			[REDACTED]	
57	1077			[REDACTED]	
58	1078			[REDACTED]	
59	1079			[REDACTED]	
60	1080			[REDACTED]	
61	1081			[REDACTED]	
62	1141			[REDACTED]	
63	1157			[REDACTED]	
64	1158			[REDACTED]	

Motion In Limine No. 3 Exhibits Table					
Exhibit No.	DTX No.	Production BegBates No.	Production EndBates No.	Description	Deposition Designation Pages
65	1173			[REDACTED]	
66	1206			[REDACTED]	
67	1213			[REDACTED]	
68	3017			[REDACTED]	
69	3335			[REDACTED]	
70	3516	APL-MAS_02469202	APL-MAS_02469203	[REDACTED]	
71	3517	APL-MAS_00335253	APL-MAS_00335255	[REDACTED]	
72	3518	APL-MAS_00926335	APL-MAS_00926338	[REDACTED]	
73	3519	APL-MAS_00432016	APL-MAS_00432017	[REDACTED]	
74	3520	APL-MAS_00314770	APL-MAS_00314770	[REDACTED]	
75	3521	APL-MAS_01595027	APL-MAS_01595031	[REDACTED]	
76	3522	APL-MAS_00242089	APL-MAS_00242089	[REDACTED]	
77	3523	APL-MAS_00285363	APL-MAS_00285363	[REDACTED]	
78	3524	APL-MAS_00300536	APL-MAS_00300537	[REDACTED]	
79	3530	APL-MAS_00362441	APL-MAS_00362441	[REDACTED]	
80	12	APL-MAS_00415341	APL-MAS_00415342	[REDACTED]	

Motion In Limine No. 3 Exhibits Table					
Exhibit No.	DTX No.	Production BegBates No.	Production EndBates No.	Description	Deposition Designation Pages
81	14	APL-MAS_01890890	APL-MAS_01890891	[REDACTED]	
82	23	APL-MAS_00067169	APL-MAS_00067172	[REDACTED]	
83	153	APL-MAS_00239842	APL-MAS_00239845	[REDACTED]	
84	154	APL-MAS_00240663	APL-MAS_00240674	[REDACTED]	
85	233	APL-MAS_01875995	APL-MAS_01876151	[REDACTED]	
86	238	APL-MAS_00498535	APL-MAS_00498536	[REDACTED]	
87	377			[REDACTED]	
88	411			[REDACTED]	
89	412			[REDACTED]	
90	415			[REDACTED]	
91	416			[REDACTED]	
92	490	APL-MAS_00233250	APL-MAS_00233251	[REDACTED]	
93	491	APL-MAS_00241566	APL-MAS_00241568	[REDACTED]	
94	494	APL-MAS_00429627	APL-MAS_00429629	[REDACTED]	

Motion In Limine No. 3 Exhibits Table					
Exhibit No.	DTX No.	Production BegBates No.	Production EndBates No.	Description	Deposition Designation Pages
95	495	APL-MAS_00233541	APL-MAS_00233542	[REDACTED]	
96	496	APL-MAS_00574476	APL-MAS_00574526	[REDACTED]	
97	528			[REDACTED]	
98	529			[REDACTED]	
99	541			[REDACTED]	
100	610			[REDACTED]	
101	614			[REDACTED]	
102	769			[REDACTED]	
103	777			[REDACTED]	
104	786			[REDACTED]	
105	780			[REDACTED]	
106	784			[REDACTED]	
107	808			[REDACTED]	
108	811			[REDACTED]	
109	827			[REDACTED]	

Motion In Limine No. 3 Exhibits Table					
Exhibit No.	DTX No.	Production BegBates No.	Production EndBates No.	Description	Deposition Designation Pages
110	828			[REDACTED]	
111	831			[REDACTED]	
112	832			[REDACTED]	
113	851			[REDACTED]	
114	859			[REDACTED]	
115	880			[REDACTED]	
116	881			[REDACTED]	
117	935			[REDACTED]	
118	936			[REDACTED]	
119	937			[REDACTED]	
120	1003	APL-MAS_00304771	APL-MAS_00304778	[REDACTED]	
121	1005	APL-MAS_00028917	APL-MAS_00029072	[REDACTED]	
122	1006	APL-MAS_00067173	APL-MAS_00067175	[REDACTED]	
123	1007	APL-MAS_00068732	APL-MAS_00068819	[REDACTED]	
124	1008	APL-MAS_00089399	APL-MAS_00089569	[REDACTED]	
125	1009	APL-MAS_00107160	APL-MAS_00107211	[REDACTED]	
126	1011	APL-MAS_00180415	APL-MAS_00180447	[REDACTED]	

Motion In Limine No. 3 Exhibits Table					
Exhibit No.	DTX No.	Production BegBates No.	Production EndBates No.	Description	Deposition Designation Pages
127	1012	APL-MAS_00180664	APL-MAS_00180679	[REDACTED]	
128	1015	APL-MAS_00239728	APL-MAS_00239733	[REDACTED]	
129	1016	APL-MAS_00241367	APL-MAS_00241369	[REDACTED]	
130	1018	APL-MAS_00310721	APL-MAS_00310722	[REDACTED]	
131	1019	APL-MAS_00360367	APL-MAS_00360368	[REDACTED]	
132	1021	APL-MAS_00413821	APL-MAS_00413837	[REDACTED]	
133	1023	APL-MAS_00414788	APL-MAS_00414793	[REDACTED]	
134	1024	APL-MAS_00414846	APL-MAS_00414846	[REDACTED]	
135	1025	APL-MAS_00414954	APL-MAS_00414955	[REDACTED]	
136	1026	APL-MAS_00415008	APL-MAS_00415009	[REDACTED]	
137	1027	APL-MAS_00415200	APL-MAS_00415201	[REDACTED]	
138	1028	APL-MAS_00420607	APL-MAS_00420611	[REDACTED]	
139	1029	APL-MAS_00433535	APL-MAS_00433538	[REDACTED]	
140	1031	APL-MAS_00826994	APL-MAS_00826997	[REDACTED]	

Motion In Limine No. 3 Exhibits Table					
Exhibit No.	DTX No.	Production BegBates No.	Production EndBates No.	Description	Deposition Designation Pages
141	1032	APL-MAS_01403427	APL-MAS_01403431	[REDACTED]	
142	1038	MASA00296750	MASA00296750	[REDACTED]	
143	1048			[REDACTED]	
144	1056			[REDACTED]	
145	1057			[REDACTED]	
146	1058			[REDACTED]	
147	1059			[REDACTED]	
148	1060			[REDACTED]	
149	1061			[REDACTED]	
150	1062			[REDACTED]	
151	1063			[REDACTED]	
152	1064			[REDACTED]	
153	1065			[REDACTED]	
154	1066			[REDACTED]	
155	1067			[REDACTED]	
156	1068			[REDACTED]	
157	1069			[REDACTED]	
158	1070			[REDACTED]	

Motion In Limine No. 3 Exhibits Table					
Exhibit No.	DTX No.	Production BegBates No.	Production EndBates No.	Description	Deposition Designation Pages
159	1071			[REDACTED]	
160	1072			[REDACTED]	
161	1084			[REDACTED]	
162	1085			[REDACTED]	
163	1090			[REDACTED]	
164	1092			[REDACTED]	
165	1094			[REDACTED]	
166	1099			[REDACTED]	
167	1100			[REDACTED]	
168	1103			[REDACTED]	
169	1105			US20060211924.pdf, MASA03054594-MASA03054653	
170	1106			US20100030040, MASA00026937-MASA00027024	
171	1108			[REDACTED]	
172	1109			[REDACTED]	
173	1110			[REDACTED]	
174	1111			[REDACTED]	



Motion In Limine No. 3 Exhibits Table					
Exhibit No.	DTX No.	Production BegBates No.	Production EndBates No.	Description	Deposition Designation Pages
175	1112			[REDACTED]	
176	1113			[REDACTED]	
177	1132			[REDACTED]	
178	1133			[REDACTED]	
179	1134			[REDACTED]	
180	1138			[REDACTED]	
181	1143			[REDACTED]	
182	1159			[REDACTED]	
183	1161			[REDACTED]	
184	1162			[REDACTED]	
185	1163			[REDACTED]	
186	1168			[REDACTED]	
187	1170			[REDACTED]	
188	1174			[REDACTED]	

Motion In Limine No. 3 Exhibits Table					
Exhibit No.	DTX No.	Production BegBates No.	Production EndBates No.	Description	Deposition Designation Pages
189	1184			[REDACTED]	
190	1187			[REDACTED]	
191	1188			[REDACTED]	
192	1191			[REDACTED]	
193	1197			[REDACTED]	
194	1199			[REDACTED]	
195	1204			[REDACTED]	
196	1205			[REDACTED]	
197	1207			[REDACTED]	
198	1208			[REDACTED]	
199	3004	APL-MAS_00239694	APL-MAS_00239698	[REDACTED]	
200	3006	APL-MAS_00432923	APL-MAS_00432924	[REDACTED]	
201	3183	APL-MAS_00197134	APL-MAS_00197135	[REDACTED]	
202	3421	APL-MAS_00432316	APL-MAS_00432317	[REDACTED]	
203	3429	APL-MAS_00414174	APL-MAS_00414175	[REDACTED]	

Motion In Limine No. 3 Exhibits Table					
Exhibit No.	DTX No.	Production BegBates No.	Production EndBates No.	Description	Deposition Designation Pages
204	3512			[REDACTED]	
205	3514	APL-MAS_00227728	APL-MAS_00227772	[REDACTED]	
206	3515	APL-MAS_00229732	APL-MAS_00229735	[REDACTED]	
207	39	APL-MAS_00819220	APL-MAS_00819222	[REDACTED]	
208	42			Video: Excerpt of Apple launch video	
209	43	APL_DEL01409991	APL_DEL010409992	[REDACTED]	
210	246	APL_DEL03699672	APL_DEL03699672	[REDACTED]	
211	431	APL-MAS_00631182	APL-MAS_00631183	[REDACTED]	
212	432	APL-MAS_00723491	APL-MAS_00723497	[REDACTED]	
213	433	APL_DEL00951868	APL_DEL00951891	[REDACTED]	
214	434	APL-MAS_00316530	APL-MAS_00316539	[REDACTED]	
215	435	APL_DEL02805523	APL_DEL02805545	[REDACTED]	
216	436	APL_DEL01858311	APL_DEL01858343	[REDACTED]	
217	437	APL-MAS_02364342	APL-MAS_02364349	[REDACTED]	
218	438	APL_DEL02691839	APL_DEL02691846	[REDACTED]	
219	445	APL-MAS_00171691	APL-MAS_00171696	[REDACTED]	
220	511	APL_DEL03893132	APL_DEL03893134	[REDACTED]	

Motion In Limine No. 3 Exhibits Table					
Exhibit No.	DTX No.	Production BegBates No.	Production EndBates No.	Description	Deposition Designation Pages
221	512	APL_DEL03978336	APL_DEL03978344	[REDACTED]	
222	513	APL_DEL03967232	APL_DEL03967235	[REDACTED]	
223	514	APL_DEL03910942	APL_DEL03910955	[REDACTED]	
224	515	APL_DEL03907424	APL_DEL03907426	[REDACTED]	
225	516	APL_DEL03902970	APL_DEL03902972	[REDACTED]	
226	517	APL_DEL03930994	APL_DEL03931036	[REDACTED]	
227	518	APL_DEL03980368	APL_DEL03980479	[REDACTED]	
228	519	APL_DEL03939857	APL_DEL03939862	[REDACTED]	
229	520	APL_DEL03963872	APL_DEL03963903	[REDACTED]	
230	521	APL_DEL03875661	APL_DEL03875675	[REDACTED]	
231	522	APL_DEL03971431	APL_DEL03971445	[REDACTED]	
232	523	APL_DEL03910469	APL_DEL03910473	[REDACTED]	

Motion In Limine No. 3 Exhibits Table					
Exhibit No.	DTX No.	Production BegBates No.	Production EndBates No.	Description	Deposition Designation Pages
233	524	APL_DEL03918242	APL_DEL03918243	[REDACTED]	
234	525	APL_DEL03947212	APL_DEL03947218	[REDACTED]	
235	526	APL_DEL03857014	APL_DEL03857017	[REDACTED]	
236	527	APL_DEL03875826	APL_DEL03875842	[REDACTED]	
237	3229			Masimo W1 White Paper: Hospital-Grade Continuous Monitoring of SpO2 and Other Parameters in a Consumer Watch	
238	3230			Article - MedPage Today, Anthony Pearson, Should You Trust the New Apple Watch on Blood Oxygen Readings	
239	3231			Washington Post, Geoffrey Fowler, The new Apple Watch says my lungs may be sick. Or perfect. It can't decide	
240	3234			CNet - Fitbit and Apple know their Smartwatches Arent Medical Devices	
241	3235			Engineering - Can the Apple Watch Series 6 Keep the Doctor Away	
242	3236			Inc - The New Apple Watch 6 May have a Problem	
243	3237			Input - The Apple Watch_s blood oxygen sensor is less accurate than you think	
244	3238			Verge - Apple Watch Blood Oxygen For Wellness Not Medicine	
245	3532	APL-MAS_00203385	APL-MAS_00203387	[REDACTED]	
246	3539	APL_MAS_ITC_01097560	APL_MAS_ITC_01097562	[REDACTED]	
247	3540	APL_MAS_ITC_00379631	APL_MAS_ITC_00379634	[REDACTED]	
248	3541	APL_MAS_ITC_00449343	APL_MAS_ITC_00449346	[REDACTED]	

Motion In Limine No. 3 Exhibits Table					
Exhibit No.	DTX No.	Production BegBates No.	Production EndBates No.	Description	Deposition Designation Pages
249	3542	APL_MAS_ITC_00449506	APL_MAS_ITC_00449510	[REDACTED]	
250	3547	MASITC_01399130	MASITC_01399134	Wyatt, K., et al., "Clinical evaluation and diagnostic yield following evaluation of abnormal pulse detected using Apple Watch", Journal of the American Medical Informatics Association, 27(9):1359-1363 (2020)	
251	441	APL_DEL02720065	APL_DEL02720068	[REDACTED]	
252	443	APL_DEL03677883	APL_DEL03677910	[REDACTED]	
253	447	APL_DEL02646321	APL_DEL02646400	[REDACTED]	
254	448	MASA03019103	MASA03019182	[REDACTED]	
255	449			[REDACTED]	
256	450	MASA03028081	MASA03028103	[REDACTED]	
257	451	APL_DEL01937094	APL_DEL01937115	[REDACTED]	
258	452	APL_DEL02646275	APL_DEL02646298	[REDACTED]	
259	453	APL_DEL03549605	APL_DEL03549631	[REDACTED]	
260	454	APL_DEL03070920	APL_DEL03070947	[REDACTED]	
261	455	APL_DEL01191547	APL_DEL01191576	[REDACTED]	
262	456	APL_DEL03855237	APL_DEL03855238	[REDACTED]	
263	457	APL_DEL03855615	APL_DEL03855619	[REDACTED]	
264	458	APL_DEL01191888	APL_DEL01191892	[REDACTED]	
265	459	APL_DEL03819782	APL_DEL03819782	[REDACTED]	
266	460	APL_DEL01189019	APL_DEL01189025	[REDACTED]	
267	461	APL_DEL01368829	APL_DEL01368830	[REDACTED]	
268	462	APL_DEL01191027	APL_DEL01191030	[REDACTED]	

Motion In Limine No. 3 Exhibits Table					
Exhibit No.	DTX No.	Production BegBates No.	Production EndBates No.	Description	Deposition Designation Pages
269	463	APL_DEL01191869	APL_DEL01191871	[REDACTED]	
270	464	APL_DEL01246610	APL_DEL01246613	[REDACTED]	
271	465	APL_DEL03827666	APL_DEL03827688	[REDACTED]	
272	466	APL_DEL03551662	APL_DEL03551666	[REDACTED]	
273	468	APL_DEL03125484	APL_DEL03125495	[REDACTED]	
274	469	APL_DEL01189965	APL_DEL01189969	[REDACTED]	
275	470	APL_DEL03827647	APL_DEL03827665	[REDACTED]	
276	471	APL_DEL01369591	APL_DEL01369592	[REDACTED]	
277	472	APL_DEL01369226	APL_DEL01369230	[REDACTED]	
278	473	APL_DEL03827784	APL_DEL03827794	[REDACTED]	
279	2865			Brown, Mark, "Apple Bans Phone Story Game That Exposes Seedy Side of Smartphone Creation," Wired.com, September 14, 2011, <a href="https://www.wired.com/2011/09/phone-story/">https://www.wired.com/2011/09/phone-story/</a> .	
280	2939			Albergotti, Reed, "How Apple uses its App Store to copy the best ideas," The Washington Post, September 5, 2019.	
281	1010	APL-MAS_00169370	APL-MAS_00169371	[REDACTED]	
282	1014	APL-MAS_00197637	APL-MAS_00197657	[REDACTED]	

Motion In Limine No. 3 Exhibits Table					
Exhibit No.	DTX No.	Production BegBates No.	Production EndBates No.	Description	Deposition Designation Pages
283	1017	APL-MAS_00290959	APL-MAS_00290962	[REDACTED]	
284	1034	APL-MAS_01860875	APL-MAS_01860888	[REDACTED]	
285	1046			[REDACTED]	
286	3012	APL-MAS_00226067	APL-MAS_00226071	[REDACTED]	
287	3016	APL-MAS_01831295	APL-MAS_01831295	[REDACTED]	
288				Excerpts of Masimo's Affirmative Deposition Designations of Transcript of Deposition of Ueyn Block (07-21-2022)	33-34, 42-44, 72-73
289				Excerpts of Masimo's Affirmative Deposition Designations of Transcript of Deposition of Chinsan Han (08-18-2022)	13-14, 47-48, 50-51, 59-61, 74, 83-85, 96-99, 103, 105-110, 112, 133-136
290				Excerpts of Masimo's Affirmative Deposition Designations of Transcript of Deposition of Evans Hankey (11-09-2023)	236
291				Excerpts of Masimo's Affirmative Deposition Designations of Transcript of Deposition of Steven Hotelling (08-02-2022)	27, 36-37, 41-42, 44-49, 52-53, 55-58, 62-68, 74-78, 83-86, 89-93, 96-99, 109-114
292				Excerpts of Masimo's Affirmative Deposition Designations of Transcript of Deposition of Steven Hotelling (11-03-2023)	59-65, 67-79, 82-84, 89-94, 98-100, 113-114, 117-119, 142-150, 152-153
293				Excerpts of Masimo's Affirmative Deposition Designations of Transcript of Deposition of Eugene Kim (07-29-2022)	60-64
294				Excerpts of Masimo's Affirmative Deposition Designations of Transcript of Deposition of Marcelo Lamego (07-12-2023)	69, 71, 80-82
295				Excerpts of Masimo's Affirmative Deposition Designations of Transcript of Deposition of Marcelo Lamego (07-13-2023)	218-19, 224



Motion In Limine No. 3 Exhibits Table					
Exhibit No.	DTX No.	Production BegBates No.	Production EndBates No.	Description	Deposition Designation Pages
296				Excerpts of Masimo's Affirmative Deposition Designations of Transcript of Deposition of Robert Mansfield (08-11-2022)	21-22
297				Excerpts of Masimo's Affirmative Deposition Designations of Transcript of Deposition of Michael O'Reilly (09-22-2022)	285-287, 307, 315-317, 323-324, 326-335, 340, 342
298				Excerpts of Masimo's Affirmative Deposition Designations of Transcript of Deposition of Adrian Perica (08-12-2022)	56-57, 64-67, 77-78, 82, 87-91, 94-95, 101, 104-106, 111-112, 119-120, 122, 127, 132-135
299				Excerpts of Masimo's Affirmative Deposition Designations of Transcript of Deposition of Adrian Perica (10-13-2023)	10-14, 30-31, 37-39, 41, 43-50, 54-56, 58-60, 62-66
300				Excerpts of Masimo's Affirmative Deposition Designations of Transcript of Deposition of Denby Sellers (12-15-2021)	20, 76, 78, 80, 129, 132, 180, 183, 189-192, 221-224, 282-283, 306.
301				Excerpts of Masimo's Affirmative Deposition Designations of Transcript of Deposition of Denby Sellers (06-24-2022)	49-51, 67-68, 71-72, 75, 173-174, 177-178
302				Excerpts of Masimo's Affirmative Deposition Designations of Transcript of Deposition of David Tom (08-11-2022)	7-9, 11-12, 21-22, 32
303				Excerpts of Masimo's Affirmative Deposition Designations of Transcript of Deposition of Jeff Williams (08-09-2022)	50-52, 101-103, 105, 108, 245-247
304				Excerpts of Masimo's Counter Deposition Designations of Transcript of Deposition of Bilal Muhsin (11-09-2023)	329
305				Excerpts of Masimo's Counter Deposition Designations of Transcript of Deposition of Linus Park (10-31-2023)	102-103
306				Excerpts of Masimo's Counter Deposition Designations of Transcript of Deposition of Steven Hotelling (11-03-2023)	206-209
307				Excerpts of Masimo's Counter Deposition Designations of Transcript of Deposition of Yassir Abdul-Hafiz (02-18-2022)	14-15
308				Excerpts of Masimo's Counter Deposition Designations of Transcript of Deposition of Evans Hankey (11-09-2023)	236
309	692			7/15/2022 Petition for Inter Partes Review of U.S. Patent No. 10,912,501 (Apple v. Masimo, IPR2022-01271)	
310	693			7/15/2022 Petition for Inter Partes Review of U.S. Patent No. 10,912,501 (Apple v. Masimo, IPR2022-01272)	

Motion In Limine No. 3 Exhibits Table					
Exhibit No.	DTX No.	Production BegBates No.	Production EndBates No.	Description	Deposition Designation Pages
311	694			7/15/2022 Petition for Inter Partes Review of U.S. Patent No. 10,912,502 (Apple v. Masimo, IPR2022-01273)	
312	695			7/15/2022 Petition for Inter Partes Review of U.S. Patent No. 10,912,502 (Apple v. Masimo, IPR2022-01274)	
313	696			7/15/2022 Petition for Inter Partes Review of U.S. Patent No. 10,945,648 (Apple v. Masimo, IPR2022-01275)	
314	697			7/15/2022 Petition for Inter Partes Review of U.S. Patent No. 10,945,648 (Apple v. Masimo, IPR2022-01276)	
315	700			9/30/2020 Petition for Inter Partes Review of U.S. Patent No. 10,624,564 (Apple v. Masimo, IPR2020-01713)	
316	701			9/30/2020 Petition for Inter Partes Review of U.S. Patent No. 10,631,765 (Apple v. Masimo, IPR2020-01714)	
317	702			9/30/2020 Petition for Inter Partes Review of U.S. Patent No. 10,631,765 (Apple v. Masimo, IPR2020-01715)	
318	703			6/9/2021 Petition for Inter Partes Review of U.S. Patent No. 9,572,499 (Apple v. AliveCor, IPR2021-00970)	
319	704			6/9/2021 Petition for Inter Partes Review of U.S. Patent No. 10,595,731 (Apple v. AliveCor, IPR2021-00971)	
320	705			6/9/2021 Petition for Inter Partes Review of U.S. Patent No. 10,638,941 (Apple v. AliveCor, IPR2021-00972)	
321	706			9/26/2022 Petition for Inter Partes Review of U.S. Patent No. 9,420,956 (Apple v. AliveCor, IPR2022-01560)	
322	707			9/26/2022 Petition for Inter Partes Review of U.S. Patent No. 10,159,415 (Apple v. AliveCor, IPR2022-01562)	
323	708			8/9/2021 Petitioner Apple's Power of Attorney in Post Grant Proceedings Before the Patent Trial and Appeal Board re USP 10,912,501	
324	709			8/9/2021 Petitioner Apple's Power of Attorney in Post Grant Proceedings Before the Patent Trial and Appeal Board re USP 10,912,501	
325	710			8/9/2021 Petitioner Apple's Power of Attorney in Post Grant Proceedings Before the Patent Trial and Appeal Board re USP 10,912,502	

Motion In Limine No. 3 Exhibits Table					
Exhibit No.	DTX No.	Production BegBates No.	Production EndBates No.	Description	Deposition Designation Pages
326	711			8/9/2021 Petitioner Apple's Power of Attorney in Post Grant Proceedings Before the Patent Trial and Appeal Board re USP 10,912,502	
327	712			8/9/2021 Petitioner Apple's Power of Attorney in Post Grant Proceedings Before the Patent Trial and Appeal Board re USP 10,945,648	
328	713			8/9/2021 Petitioner Apple's Power of Attorney in Post Grant Proceedings Before the Patent Trial and Appeal Board re USP 10,945,648	
329	714			5/6/2021 Petitioner Apple's Power of Attorney in Inter Partes Review Proceedings Before the Patent Trial and Appeal Board re USP 9,572,499	
330	715			5/6/2021 Petitioner Apple's Power of Attorney in Inter Partes Review Proceedings Before the Patent Trial and Appeal Board re USP 10,595,731	
331	716			5/6/2021 Petitioner Apple's Power of Attorney in Inter Partes Review Proceedings Before the Patent Trial and Appeal Board re USP 10,638,941	
332	717			8/12/2022 Petitioner Apple's Power of Attorney in Post Grant Proceedings Before the Patent Trial and Appeal Board re USP 9,420,956	
333	718			8/12/2022 Petitioner Apple's Power of Attorney in Post Grant Proceedings Before the Patent Trial and Appeal Board re USP 10,159,415	
334	2109			U.S. Application No. 17/028,655 and File History	
335	2118			U.S. Application No. 11/366,209 and File History	
336	2124			U.S. Application No. 11/367,033 and File History	
337	645			Exhibit A-5 - Final Invalidity Claim Chart for U.S. Patent No. 10,687,743, Apple Watch Series 0	
338	646			Exhibit B-5 - Final Invalidity Claim Chart of U.S. Patent No. 10,722,159 - Apple Watch Series 0	
339	1172	APL-MAS_02044086	APL-MAS_02044147	U.S. Patent No. 7,764,982	
340	1262			U.S. Pat. No. 10,912,501 ("501 Patent")	
341	1263			U.S. Pat. No. 10,912,502	
342	1264			U.S. Pat. No. 10,945,648	

Motion In Limine No. 3 Exhibits Table					
Exhibit No.	DTX No.	Production BegBates No.	Production EndBates No.	Description	Deposition Designation Pages
343	2151			U.S. Pat. No. 10,687,745 (Al-Ali)	
344	2361	MASAD04144984	MASAD04145010	U.S. Pat. No. 10,687,745	
345	1385			Expert Rebuttal Report of Shirley Webster dated November 17, 2022, No. 8:20-cv-00048 (C.D. Cal.)	
346	1386			Expert Rebuttal Report of Majid Sarrafzadeh dated November 4, 2022, No. 8:20-cv-00048 (C.D. Cal.)	
347	334	MASAD00438018	MASAD00438019	2/21/2023 Letter from Stephen Ruoss (Stanford School of Medicine) to the U.S. International Trade Commission re Apple Watch with blood oxygen saturation monitoring feature	
348	335	MASAD00437988	MASAD00437988	2/13/2023 Letter from Marianne S. Clancy (Cure HHT) to the U.S. International Trade Commission re Apple Watch	
349	336	MASAD00246202	MASAD00246203	2/14/2023 Letter from Robert M. Wachter (UCSF) to the U.S. International Trade Commission re Apple Watch	
350	1727			Apple Inc's Notice of Deposition to Complainants, November 3, 2021	
351	1986			Masimo Corp. et al. v. Apple Inc., Excerpts of Public Final Initial Determination on Violation of Section 337, ITC Inv. No 337-TA-1276	
352	1995			Masimo Corp. et al. v. Apple Inc., Apple's September 14, 2022 Public Second Corrected Post-Hearing Brief, ITC Inv. No 337-TA-1276	
353	2697			In the Matter of Certain Light-Based Physiological Measurement Devices and Components Thereof, "Final Initial Determination of Violation of Section 337," U.S. International Trade Commission, Inv. No. 337-TA-1276, issued January 10, 2023.	
354	2698			In the Matter of Certain Light-Based Physiological Measurement Devices and Components Thereof, "Cease and Desist Order," U.S. International Trade Commission, Inv. No. 337-TA-1276, issued October 26, 2023.	

Motion In Limine No. 3 Exhibits Table					
Exhibit No.	DTX No.	Production BegBates No.	Production EndBates No.	Description	Deposition Designation Pages
355	2699			In the Matter of Certain Light-Based Physiological Measurement Devices and Components Thereof, "Notice of the Commission's Final Determination Finding a Violation of Section 337; Issuance of a Limited Exclusion Order and a Cease and Desist Order; Termination of the Investigation," U.S. International Trade Commission, Inv. No. 337-TA-1276, October 26, 2023.	
356	2700			In the Matter of Certain Light-Based Physiological Measurement Devices and Components Thereof, "Commission Opinion," U.S. International Trade Commission, Inv. No. 337-TA-1276, issued November 14, 2023.	
357	2827			"US trade tribunal issues potential Apple Watch import ban in Masimo Patent Fight," Reuters, October 27, 2023, <a href="https://www.reuters.com/technology/us-trade-tribunal-issues-potential-apple-watch-import-ban-masimo-patent-fight-2023-10-26/">https://www.reuters.com/technology/us-trade-tribunal-issues-potential-apple-watch-import-ban-masimo-patent-fight-2023-10-26/</a>	
358	2866			Federal Register Notice 46275 / Vol. 86, No. 157, August 18, 2021.	
359	2921			Chris McCarthy Public Interest Statement, EDIS Doc. ID 789080, February 1, 2023	
360	2922			Medical Device Manufacturers Association Public Interest Statement., EDIS Doc. ID 791167, February 27, 2023, (citing <a href="https://www.verywellhealth.com/health-tracking-watches-masimo-vs-apple-7111935">https://www.verywellhealth.com/health-tracking-watches-masimo-vs-apple-7111935</a> ).	
361	2929			Peter Pronovost Public Interest Statement, EDIS Doc. ID 791162, February 26, 2023, (citing <a href="https://academic.oup.com/jamia/article/27/9/1359/5911974?login=false">https://academic.oup.com/jamia/article/27/9/1359/5911974?login=false</a> ).	
362	2930			Patient Safety Movement Foundation Public Interest Statement, EDIS Doc. ID 791175, February 27, 2023.	
363	2993	APL-MAS_02617587	APL-MAS_02617869	06/06/2022 ITC Investigation No. 337-TA-1276 - Transcript Volume I of Evidentiary Hearing in Certain Light-based Physiological Measurement Devices and Components Thereof (Full)	

Motion In Limine No. 3 Exhibits Table					
Exhibit No.	DTX No.	Production BegBates No.	Production EndBates No.	Description	Deposition Designation Pages
364	2994	APL-MAS_02623951	APL-MAS_02623997	02/18/2022 ITC Investigation No. 337-TA-1276 Transcript of Deposition of Stephen Waudo, PH.D.; 03/22/2022 Errata Sheet	
365	3198			1/31/2023 [789029] Public Interest Statement of Dr. Adam Waddell, MD in Support of Masimo	
366	3199			2/1/2023 [789080] Public Interest Statement of Chris McCarthy in Support of Masimo	
367	3200			2/3/2023 [789338] Public Interest Statement of Cynthia Persaud in Support of Masimo	
368	3201			2/22/2023 [790787] Letter from Josh Malone ISO ITC Enforcing Recommended Remedial Orders against Apple	
369	3202			2/22/2023 [790883] Public Interest Statement of Dr. David E. Albert, M.D. in Support of Masimo	
370	3203			2/22/2023 [790884] Public Interest Statement of Dr. Kevin Ward, M.D. in Support of Masimo	
371	3204			2/23/2023 [790943] Public Interest Statement of Medical Device Manufacturers Association (MDMA) in Support of Masimo	
372	3205			2/23/2023 [790962] Public Interest Statement of Bill Carpou of Octane in Support of Masimo	
373	3206			2/23/2023 [790980] Public Interest Statement of Dr. Michael Ramsay, M.D. of Patient Safety Movement Foundation (PSMF) in Support of Masimo	
374	3207			2/23/2023 [790986] Public Interest Statement of Dr. Mitchell Goldstein, M.D. in Support of Masimo	
375	3208			2/23/2023 [790991] Public Interest Statement of Ryan Drant of Questa Capital in Support of Masimo	
376	3209			2/23/2023 [791000] Public Interest Statement of Bobby Yazdani of Cota Capital in Support of Masimo	
377	3210			2/23/2023 [791006] Public Interest Statement of Mark Cooper of Consumer Federation of America	
378	3211			2/23/2023 [791012] Public Interest Statement of Mike Guerra of California Life Sciences (CLS) ISO Imposing Limited Exclusion Order	

Motion In Limine No. 3 Exhibits Table					
Exhibit No.	DTX No.	Production BegBates No.	Production EndBates No.	Description	Deposition Designation Pages
379	3212			2/23/2023 [791041] Public Interest Statement of Randy Landreneau of US Inventor in Support Remedial Orders	
380	3213			2/23/2023 [791047] Public Interest Statement of Congressman Ken Buck (along with Congressman Hank Johnson and Congresswoman Kate Porter) in Support of Masimo	
381	3214			2/23/2023 [791048] Public Interest Statement of Brian Pomper of Innovation Alliance in Support of Masimo	
382	3215			2/23/2023 [791050] Complainants' Statement on the Public Interest	
383	3216			2/23/2023 [791069] Public Interest Statement of Third Party Law Professors Adam Mossoff and Kristen Osenga	
384	3217			2/27/2023 [791162] Public Interest Statement of Non-Party Dr. Peter Pronovost, M.D. in Support of Masimo	
385	3218			2/27/2023 [791163] Public Interest Statement of Mark Cooper of Consumer Federation of America (CFA) of Masimo	
386	3219			2/27/2023 [791167] Public Interest Statement of Mark Leahey of Non-Party Medical Device Manufacturers Association (MDMA)	
387	3220			2/27/2023 [791175] Public Interest Statement of Dr. Michael Ramsay, M.D. of Non-Party Patient Safety Movement Foundation (PSMF)	
388	3221			2/27/2023 [791177] Public Interest Statement of Bobby Yazdani of Cota Capital in Support of Masimo	
389	3223			2/27/2023 [791179] Public Interest Statement of Dr. Mitchell Goldstein, M.D. from LLU School of Medicine in Support of Masimo	
390	3224			3/2/2023 [791567] Public Interest Statement of Frank Cullen of Council for Innovation Promotion (C4IP) ISO Exclusion Order	
391	3225			3/3/2023 [791674] Public Interest Statement of Robert P. Taylor of the Alliance for U.S. Startups and Inventors for Jobs (USIJ) in Support of Masimo	

Motion In Limine No. 3 Exhibits Table					
Exhibit No.	DTX No.	Production BegBates No.	Production EndBates No.	Description	Deposition Designation Pages
392	3226			3/3/2023 [791686] Public Interest Statement of David Dinielli and Michael Enseki-Frank	
393	3227			6/5/2023 [797854] Public Interest Statements of Frank Cullen of Council for Innovation Promotion (C4IP) in Support of Masimo	
394	3228			6/12/2023 [798257] Public Interest Statements of Professors Francisco J. Valero-Cuevas, PhD and Najmedin Meshkati, PhD, CPE of USC in Support of Masimo	
395	215			10/16/2017 Masimo - San Diego Bankruptcy Court Rules Sotera Employees Misappropriated Masimo Trade Secrets	
396	2755			<a href="https://www.biospace.com/article/releases/nellcor-and-masimo-corporation-announce-settlement-of-patent-litigation-/">https://www.biospace.com/article/releases/nellcor-and-masimo-corporation-announce-settlement-of-patent-litigation-/</a> .	
397	2756			<a href="https://www.sec.gov/Archives/edgar/data/937556/000119312507082880/dex1030.htm">https://www.sec.gov/Archives/edgar/data/937556/000119312507082880/dex1030.htm</a> .	
398	2915			Memorandum Opinion, Masimo Corporation v. Philips N. Am. Corp., 1:09-cv-00080-LPS, D.I. 997, (D. Del. May 18, 2015).	
399	2925			"Nellcor And Masimo Corporation Announce Settlement of Patent Litigation," BioSpace, January 24, 2006, available at <a href="https://www.biospace.com/article/releases/nellcor-and-masimo-corporation-announce-settlement-of-patent-litigation-/">https://www.biospace.com/article/releases/nellcor-and-masimo-corporation-announce-settlement-of-patent-litigation-/</a> .	
400	2931			"Settlement Agreement and Release of Claims," SEC, January 17, 2006, available at <a href="https://www.sec.gov/Archives/edgar/data/937556/000119312507082880/dex1030.htm">https://www.sec.gov/Archives/edgar/data/937556/000119312507082880/dex1030.htm</a> .	
401	3180	MASA11397116	MASA11397126	Masimo Corp. v. Philips Elec. North America Corp., No. 09-80-LPS, 2015 WL 2406061 (D. Del. May 18, 2015)	
402	3181	MASA11397127	MASA11397145	Masimo Corp. v. Philips Elec. North America Corp., No. 09-80-LPS, 2015 WL 2379485 (D. Del. May 18, 2015)	
403				Masimo Corp. v. Apple Inc., No. 8:20-cv-48, D.I. 1362 (C.D. Cal. Feb. 24, 2023)	
404				Alarm.com, Inc. v. SecureNet Techs. LLC, No. 1:15-cv-807, D.I. 242 (D. Del. Jan. 23, 2019)	



Motion In Limine No. 3 Exhibits Table					
Exhibit No.	DTX No.	Production BegBates No.	Production EndBates No.	Description	Deposition Designation Pages
405	3595			Apple Says Masimo Secretly Copied Watch Tech to Make a Rival	
406	3596			Apple lawsuits say health monitoring company Masimo copied Apple Watch _ Reuters	
407	3610			Apple Presentation titled "Direct Examination of Professor Steven Warren, Ph.D." dated June 10, 2022, from ITC Inv. No. 337-TA-1276	
408	3611			Apple Presentation titled "Apple's Opening Presentation" dated June 6, 2022, from ITC Inv. No. 337-TA-1276	
409	3612			Apple Inc.'s Second Corrected Post-Hearing Brief, dated September 2, 2022, from ITC Inv. No. 337-TA-1276	
410	3613			Excerpt of Expert Report of Steve Warren, Ph.D. Regarding Certain of Plaintiffs' Alleged Technical Trade Secrets, dated September 23, 2022, from Masimo Corp, et al. v. Apple Inc., No. 8:20-cv-00048 (C.D. Cal.)	
411				Excerpts of Masimo's Counter-Counter Deposition Designations of Transcript of Deposition of Ueyn Block (10-24-2023)	219-220
412				Excerpts of Masimo's Counter-Counter Deposition Designations of Transcript of Deposition of Steve Hotelling (08-02-2022)	50, 68-69, 115-116
413				Excerpts of Masimo's Counter-Counter Deposition Designations of Transcript of Deposition of Steve Hotelling (11-03-2023)	76, 122-123, 150-151, 204-209
414				Excerpts of Masimo's Counter-Counter Deposition Designations of Transcript of Deposition of Marcelo Lamago (07-12-2022)	107
415				Excerpts of Masimo's Counter-Counter Deposition Designations of Transcript of Deposition of Marcelo Lamago (07-13-2022)	393-395, 417-436
416				Excerpts of Masimo's Counter-Counter Deposition Designations of Transcript of Deposition of Michael O'Reilly (09-22-2022)	317, 321-322, 325-326, 330-333, 343-349

Motion In Limine No. 3 Exhibits Table					
Exhibit No.	DTX No.	Production BegBates No.	Production EndBates No.	Description	Deposition Designation Pages
417				Excerpts of Masimo's Counter-Counter Deposition Designations of Transcript of Deposition of Adrian Perica (08-12-2022)	110, 125-127, 139, 248-249, 251
418				Excerpts of Masimo's Counter-Counter Deposition Designations of Transcript of Deposition of Adrian Perica (10-13-2023)	32, 43, 51, 57-58, 61
419				Excerpts of Masimo's Counter-Counter Deposition Designations of Transcript of Deposition of Denby Sellers (12-15-2021)	82, 85-86, 135, 182, 191, 195, 225-226
420				Excerpts of Masimo's Counter-Counter Deposition Designations of Transcript of Deposition of David Tom (08-11-2022)	28, 31-33, 62-63
421				Excerpts of Masimo's Counter-Counter Deposition Designations of Transcript of Deposition of Stephen Waydo (10-27-2023)	200-205
422				Excerpts of Masimo's Counter-Counter Deposition Designations of Transcript of Deposition of Jeff Williams (08-09-2022)	59-60, 102-103, 106-108, 247-248

**IN THE U.S. DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

APPLE INC.,  <i>Plaintiff,</i>  v.  MASIMO CORPORATION and SOUND UNITED, LLC,  <i>Defendants.</i>	C.A. No. 22-1377-JLH  <b>JURY TRIAL DEMANDED</b>
MASIMO CORPORATION,  <i>Counter-Claimant,</i>  v.  APPLE INC.  <i>Counter-Defendant.</i>	
APPLE INC.,  <i>Plaintiff,</i>  v.  MASIMO CORPORATION and SOUND UNITED, LLC,  <i>Defendants.</i>	C.A. No. 22-1378-JLH  <b>JURY TRIAL DEMANDED</b>
MASIMO CORPORATION and CERCACOR LABORATORIES, INC.,  <i>Counter-Claimants,</i>  v.  APPLE INC.  <i>Counter-Defendant.</i>	<b>CONFIDENTIAL – ATTORNEYS’ EYES ONLY FILED UNDER SEAL</b>

**DEFENDANTS MASIMO CORPORATION AND SOUND UNITED, LLC’S  
OPPOSITION TO APPLE INC.’S MOTION *IN LIMINE* NO. 3**

Citations to Exhibit numbers without the “M” prefix correspond to those referenced in Apple’s Motion *in Limine* No. 3 Exhibits Table untimely served September 12, 2024. Apple timely served a different and much smaller Exhibits Table on September 4, 2024.

Apple's scattershot MIL No. 3 seeks to exclude hundreds of exhibits that are relevant to several disparate issues. Masimo cannot address the specific relevance of so many different exhibits and the issues to which they relate in three pages. The Court should thus deny MIL No. 3 as an unfair end-run around the limit on MILs. MIL No. 3 also fails for additional reasons below.

**A. Apple's Case Relies on Glorifying Its Capabilities and Products While Painting Masimo and its CEO as Inept, Unethical Copyists**

Apple argues its Complaint sets forth "well-pled copying allegations against Masimo" that it intends to pursue at trial. *See* Apple MIL No. 2 at 1. The Complaint alleges Apple first released the "revolutionary" Apple Watch in 2015 and "every Apple Watch since the first generation includes a biosensor module on the back." No. -1377, D.I. 1 ¶¶ 2, 16. The Complaint also alleges:

Apple worked for years to develop Apple Watch into a successful, innovative, and appealing product. In contrast, Masimo copied from Apple Watch and is freeriding on Apple's hard work. Rather than develop its own innovations to make its W1 attractive to consumers, Masimo copied Apple Watch and brought carefully timed lawsuits to try to kick Apple out of the market while Masimo ... launched the W1.

*Id.* ¶ 22. Apple alleges Masimo only recently intended to enter the "consumer" space. *Id.* ¶ 21. And Apple's interrogatory response disparages Masimo's CEO, Joe Kiani, by alleging he relies on "loyal yes-people" and brought the W1 to market "by any means necessary—including ... deceptive advertising and willful theft of Apple's intellectual property." Ex. M1 at 6-7.

**B. The Court Should Not Exclude Evidence of Apple Recognizing Masimo's Technical Expertise**

Apple seeks to exclude evidence that refutes Apple's story. Apple recognized Masimo as an innovator that could develop biosensors for consumer watches. Apple's "Rover" program sought a health company that Apple could use as a "stepping stone" to develop its watch. Ex. 14. Apple identified Masimo and Cercacor, both run by Kiani, as the two "standout" companies. Ex. 28. Apple recognized Kiani as having a "Steve Jobs" like reputation. Ex. 58. [REDACTED]

[REDACTED]

In May 2013, Apple contacted and met with Masimo to discuss integrating Masimo's technology in Apple's products. Ex. 3. Apple was very impressed and considered acquiring Masimo. Exs. 4, 6, 9-11, and 29. An Apple executive told Apple's CEO, Tim Cook, that Apple was "most clueless" in "non-invasive diagnostics" [REDACTED]

[REDACTED]

By Fall 2013, Apple concluded the Apple Watch sensor was on track to "fail" and "with it will go probably the most important feature of the device." Ex. M2. Apple started project "Everest" [REDACTED]

[REDACTED]. Apple hired Masimo's Chief Medical Officer, as well as Cercacor's Chief Technical Officer, and pursued a project to hire "the next level down" of Masimo employees. Exs. 37, 42, and 45-48.<sup>1</sup>

This and similar evidence debunks Apple's unfounded attacks on Masimo. The Court should not prevent Masimo from presenting its side of the story.<sup>2</sup>

### **C. Other Litigations Are Relevant**

Apple has put other lawsuits at issue. The Complaint discusses the parties' ITC litigation at length and accuses Masimo of copying Apple "while filing lawsuits to prevent sales of Apple Watch." After the Complaint, Apple even falsely accused Masimo's counsel of stealing

---

<sup>1</sup> Apple argues the California court excluded much of this evidence as prejudicial. MIL No. 3 at 2 (discussing Cook statements, hiring former employees, and documents regarding the hiring of Lamego and O'Reilly). The order said nothing about most of the exhibits that Apple claims it excluded. The order excluded evidence about some former employees, but the Court reversed the order at trial and let Masimo present evidence of Apple recruiting the "next level down."

<sup>2</sup> Apple asserts that Masimo took a contrary position in California by arguing Apple's "copying allegations" were not relevant when Masimo was the plaintiff. Br. at 3. Apple omits its response: that Masimo's alleged copying was relevant to rebut Masimo's claims. Ex. M3 at 12-13. Apple also omits that the Court did *not* prohibit Apple from introducing such evidence at trial. Regardless, Masimo's argument is not that Apple copied Masimo. Rather, Apple's recognition of Masimo as the technological leader rebuts the narrative Apple will tell at trial.

confidential information from the California case and giving it to Masimo to copy the Apple Watch. No. -1377, D.I. 7 at 2-3. Moreover, Apple accuses Masimo of copying Apple because royalty revenues from the Nellcor and Philips cases had supposedly “dried up.” No. -1377, D.I. 1 ¶¶ 26-27. Thus, Apple itself is relying on the very cases it now asserts are irrelevant. The lawsuits also rebut Apple’s pretense that it brought this case merely to stop Masimo’s alleged infringement.

The lawsuits also illustrate Masimo’s investments in innovation and respect for intellectual property rights. Such evidence rebuts Apple’s narrative that Masimo needed to steal from Apple. *See Sonos, Inc. v. D&M Holdings*, 2017 WL 5633204, \*1 (D. Del. Nov. 21, 2017) (allowing evidence of accused infringer’s own patents and countersuits if patentee argued “[accused infringer] lacks its own technology and therefore must rely on stealing”). Apple’s cited cases regarding exclusion of prior litigation (*IBM, Alarm.com, Medtronic*, and *Evolved*) do not compel a different result because none included analogous facts to those found here where a patentee’s theory is based on a narrative that the accused infringer had to copy because it was not innovative. Nor does the California court excluding evidence of other litigations in different circumstances.

#### **D. The Other Categories Identified by Apple Are Also Relevant**

Documents concerning the Apple Watch’s poor performance (Exs. 207-250) and public interest statements from the ITC (Exs. 365-394) are also relevant. These documents are relevant to corroborating that Masimo—a medical technology leader developing a medical-grade consumer watch—would not copy Apple’s inferior products. The evidence would also be relevant to rebut arguments that Apple is an innovator and its watch “saves lives” or improves public health.

The CDCA expert reports (Exs. 345-346) [REDACTED] that are directly relevant to noninfringement. And Masimo’s patents rebut Apple’s narrative that Masimo lacked the technical capabilities and needed to infringe Apple’s patents.

September 18, 2024

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

By: /s/ Kendall M. Loebbaka

Joseph R. Re  
Stephen C. Jensen  
Stephen W. Larson  
Benjamin A. Katzenellenbogen  
Edward M. Cannon  
Brian C. Claassen  
Jared C. Bunker  
Mark Lezama  
Kendall M. Loebbaka  
Douglas B. Wentzel  
Knobbe, Martens, Olson & Bear, LLP  
2040 Main Street, 14th Floor  
Irvine, CA 92614  
(949) 760-0404 Telephone  
(949) 760-9502 Facsimile  
joe.re@knobbe.com  
steve.jensen@knobbe.com  
stephen.larson@knobbe.com  
ben.katzenellenbogen@knobbe.com  
ted.cannon@knobbe.com  
brian.claassen@knobbe.com  
jared.bunker@knobbe.com  
mark.lezama@knobbe.com  
kendall.loebbaka@knobbe.com  
douglas.wentzel@knobbe.com

Brian Horne  
Knobbe, Martens, Olson & Bear, LLP  
1925 Century Park East, Suite 600  
Los Angeles, CA 90067  
(310) 551-3450 Telephone  
(310) 551-3458 Facsimile  
brian.horne@knobbe.com

Adam Powell  
Daniel P. Hughes  
Knobbe, Martens, Olson & Bear, LLP  
3579 Valley Centre Drive, Suite 300  
San Diego, CA 92130  
(858) 707-4000 Telephone

(858) 707-4001 Facsimile  
adam.powell@knobbe.com  
Daniel.hughes@knobbe.com

Carol M. Pitzel Cruz  
Knobbe, Martens, Olson & Bear, LLP  
925 4th Ave., #2500  
Seattle, WA 98104  
206-405-2000 Telephone  
206-405-2001 Facsimile  
carol.pitzelcruz@knobbe.com

PHILLIPS MCLAUGHLIN & HALL, P.A.  
John C. Phillips, Jr. (No. 110)  
Megan C. Haney (No. 5016)  
1200 North Broom Street  
Wilmington, DE 19806  
(302) 655-4200 Telephone  
(302) 655-4210 Fax  
jcp@pmhdelaw.com  
mch@pmhdelaw.com

*Counsel for Defendant and Counter-Claimant  
Masimo Corporation; Defendant Sound United,  
LLC; and Counter-Claimant Cercacor  
Laboratories, Inc.*



### CERTIFICATE OF SERVICE

I hereby certify that on September 18, 2024, a true and correct copy of the foregoing document was served on the following counsel of record at the addresses and in the manner indicated:

***VIA ELECTRONIC MAIL:***

David E. Moore Bindu A. Palapura Andrew L. Brown Hercules Plaza, 6th Floor 1313 N. Market Street Wilmington, DE 19801 dmoore@potteranderson.com bpalapura@potteranderson.com abrown@potteranderson.com	John M. Desmarais Kerri-Ann Limbeek Cosmin Maier Jordan N. Malz Benjamin N. Luehrs Joze Welsh Jamie L. Kringstein Jennifer M. Przybylski Carson Olsheski Jeffrey Scott Seddon, II Amy I. Wann Raymond N. Habbaz Lee Matalon Taeg Sang Cho Eli Balsam Patrick Reilly Marie Weisfeiler Ryan G. Thorne Paul A. Bondor Desmarais LLP 230 Park Avenue, 26th Floor New York, NY 10169 jdesmarais@desmaraisllp.com klimbeek@desmaraisllp.com cmaier@desmaraisllp.com jmalz@desmaraisllp.com bluehrs@desmaraisllp.com jwelsh@desmaraisllp.com jkringstein@desmaraisllp.com jprzybylski@desmaraisllp.com colsheski@desmaraisllp.com jseddon@desmaraisllp.com awann@desmaraisllp.com rhabbaz@desmaraisllp.com lmatalon@desmaraisllp.com tcho@desmaraisllp.com
--	--


	ebalsam@desmaraisllp.com preilly@desmaraisllp.com mweisfeiler@desmaraisllp.com rthorne@desmaraisllp.com pbondor@desmaraisllp.com
Peter C. Magic Kyle Curry Maria Tartakovsky DESMARAIS LLP 101 California Street San Francisco, CA 94111 pmagic@desmaraisllp.com kcurry@desmaraisllp.com mtartakovsky@desmaraisllp.com	Jennifer Milici Dominic Vote Leon B. Greenfield Heath Brooks John O'Toole Wilmer Cutler Pickering Hale and Dorr LLP 2100 Pennsylvania Avenue NW Washington, DC 20037 jennifer.milici@wilmerhale.com dominic.vote@wilmerhale.com leon.greenfield@wilmerhale.com heath.brooks@wilmerhale.com john.otoole@wilmerhale.com
Mark A. Ford Vinita Ferrera Wilmer Cutler Pickering Hale and Dorr LLP 60 State Street Boston, MA 02109 mark.ford@wilmerhale.com vinita.ferrera@wilmerhale.com	David J. Cho David J. Shaw Desmarais LLP 1899 Pennsylvania Avenue NW, Suite 400 Washington, DC 20006 dcho@desmaraisllp.com dshaw@desmaraisllp.com
Lydia Turnage Wilmer Cutler Pickering Hale and Dorr LLP 7 World Trade Center 250 Greenwich Street New York, NY 10007 lydia.turnage@wilmerhale.com	Bethany Stevens Hannah Cannom Walker Stevens Cannom LLP 500 Molino Street, Suite 118 Los Angeles, CA 90013 bstevens@wscllp.com hcannom@wscllp.com
Lauren Ige Cristina Salcedo Wilmer Cutler Pickering Hale and Dorr LLP 250 South Grand Avenue, Suite 2400 Los Angeles, CA 90071 lauren.ige@wilmerhale.com cristina.salcedo@wilmerhale.com	IPservice@potteranderson.com
AppleMasimoService@desmaraisllp.com	whmasimoantitrustservice@wilmerhale.com

September 18, 2024

/s/ Kendall M. Loebbaka  
Kendall M. Loebbaka

**Masimo's Opposition to Apple Inc.'s Motion *in Limine* No. 3**

**TABLE OF EXHIBITS**

<b>Exhibit</b>	<b>Description</b>
M1	Apple's First Supplemental Objections and Responses to Defendants' Eighth Set of Interrogatories (Nos. 44, 45, 46, 47) dated November 9, 2023
M2	 l.
M3	Apple's Reply Memorandum In Support Of Its Motion <i>In Limine</i> No. 1: Preclude References To Other Litigations And Proceedings (Redacted), <i>Masimo Corp. v. Apple Inc.</i> , No. 8:20-cv-48, D.I. 1384, Feb. 27, 2023

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

APPLE INC.,

Plaintiff,

v.

MASIMO CORPORATION AND SOUND  
UNITED, LLC,

Defendants.

---

MASIMO CORPORATION AND CERCACOR  
LABORATORIES, INC.,

Counterclaim-Plaintiffs,

v.

APPLE INC.,

Counterclaim-Defendant.

---

C.A. No. 1:22-cv-1377-JLH

C.A. No. 1:22-cv-1378-JLH

**HIGHLY CONFIDENTIAL –  
ATTORNEYS EYES’ ONLY**

**FILED UNDER SEAL**

**APPLE’S REPLY BRIEF IN SUPPORT OF ITS MOTION *IN LIMINE* NO. 3:  
TO PRECLUDE EVIDENCE, ARGUMENT, AND REFERENCE TO UNRELATED  
LITIGATIONS, PROCEEDINGS, CLAIMS, LEGAL REMEDIES, AND ALLEGATIONS  
NOT BEING ADJUDICATED IN THE OCTOBER 2024 JURY TRIAL**

Apple's MIL No. 3 seeks to prevent Masimo from confusing and prejudicing the jury with scattershot irrelevant factual allegations and litigations that are untethered to the claims set for trial in October. Masimo's infringement will be tried in October, not its allegations of Apple's infringement. Masimo's opposition confirms the only purpose for the arguments and evidence Apple seeks to exclude is to throw irrelevant mud at Apple. What Apple thought of Masimo is simply not relevant to any issue set for trial. Apple identified hundreds of exemplary exhibits and designations for exclusion (*e.g.*, Exs. 1-402, 405-422) because that is the extent to which Masimo intends to create a trial-within-a-trial on Masimo's allegations that are *not* set for trial this October.

Masimo argues it needs to present inflammatory arguments and evidence to rebut Apple's claim that it is an innovator and "to corroborat[e] Masimo [as] a medical technology leader." Opp. at 1, 3. But Masimo's legal defenses to Apple having innovative patented inventions is that those patents are allegedly invalid, not infringed, or unenforceable—the evidence and arguments Apple seeks to exclude are irrelevant to those defenses or Apple's claims. And Masimo fails to establish that its only way to show its purported technology leadership and to rebut Apple's technical capabilities is via prejudicial evidence.

Finally, Masimo fails to point to any evidence in Apple's pretrial disclosures for the purported "story" Masimo worries Apple will tell, instead repeatedly pointing to the Complaint and other filings that are not evidence. Masimo's assertion that Apple's interrogatory response disparages Masimo by alleging "willful theft of Apple's intellectual property" (*id.* at 1) is not "disparagement," but a precise recitation of Apple's legal claim that Masimo copied and willfully infringes. Masimo also argues "[t]he lawsuits also rebut Apple's pretense that it brought this case merely to stop Masimo's alleged infringement." *Id.* at 3. But why Apple brought this case is not a fact at issue and Apple does seek to stop Masimo's infringement.

Dated: September 25, 2024

OF COUNSEL:

John M. Desmarais  
Cosmin Maier  
Jordan N. Malz  
Kerri-Ann Limbeek  
**DESMARAIS LLP**  
230 Park Avenue  
New York, NY 10169  
Tel: (212) 351-3400  
jdesmarais@desmaraisllp.com

Peter C. Magic  
**DESMARAIS LLP**  
101 California Street  
San Francisco, CA 94111  
Tel: (415) 573-1900  
pmagic@desmaraisllp.com

Jennifer Milici  
Dominic Vote  
**WILMER CULTER PICKERING  
HALE AND DORR LLP**  
2100 Pennsylvania Avenue NW  
Washington, DC 20037  
Tel: (202) 663-6000

Mark A. Ford  
**WILMER CULTER PICKERING  
HALE AND DORR LLP**  
60 State Street  
Boston, MA 02109  
Tel: (617) 526-6423

By: /s/ Bindu A. Palapura  
David E. Moore (#3983)  
Bindu A. Palapura (#5370)  
Andrew M. Moshos (#6685)  
**POTTER ANDERSON & CORROON LLP**  
Hercules Plaza, 6th Floor  
1313 N. Market Street  
Wilmington, DE 19801  
Tel: (302) 984-6000  
dmoore@potteranderson.com  
bpalapura@potteranderson.com  
amoshos@potteranderson.com

*Attorneys for Plaintiff/Counter-Defendant  
Apple Inc.*

**CERTIFICATE OF SERVICE**

I hereby certify that a copy of Apple's Reply Brief In Support Of Its Motion *In Limine* No. 3 was served upon counsel of record for Masimo Corporation and Sound United, LLC on September 25, 2024.

/s/ Jamie L. Kringstein

Jamie L. Kringstein

# **EXHIBIT 13**

**FILED UNDER SEAL**



**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

APPLE INC.,  <i>Plaintiff,</i>  v.  MASIMO CORPORATION and SOUND UNITED, LLC,  <i>Defendants.</i>	C.A. No. 22-1377-JLH  <b>JURY TRIAL DEMANDED</b>
MASIMO CORPORATION,  <i>Counter-Claimant,</i>  v.  APPLE INC.  <i>Counter-Defendant.</i>	
APPLE INC.,  <i>Plaintiff,</i>  v.  MASIMO CORPORATION and SOUND UNITED, LLC,  <i>Defendants.</i>	C.A. No. 22-1378-JLH  <b>JURY TRIAL DEMANDED</b>
MASIMO CORPORATION and CERCACOR LABORATORIES, INC.,  <i>Counter-Claimants,</i>  v.  APPLE INC.  <i>Counter-Defendant.</i>	

**MASIMO’S MOTION *IN LIMINE* #1  
TO PRECLUDE EVIDENCE OR ARGUMENT FOR ANY MONETARY RELIEF  
BEYOND THE MINIMUM OF \$250 UNDER § 289 AND  
TO PRECLUDE TESTIMONY FROM JAMES MALACKOWSI**

All emphasis added unless otherwise noted.

The Court should preclude Apple from presenting any evidence or argument for any monetary remedy other than the statutory \$250 minimum under 35 U.S.C. § 289. Thus, the Court should preclude Apple from (1) seeking any monetary remedy under § 284 and (2) presenting any testimony from its damages expert, James Malackowski. Neither Apple nor Malackowski has ever disclosed the basis for damages under § 284, and Apple's claim for \$250 under § 289 requires no damages testimony. Malackowski's remaining opinions address an injunction and should not be presented at the liability trial.

### **I. BACKGROUND**

As Masimo explained when it moved for a bench trial (D.I. 598), Apple repeatedly failed to disclose the basis for § 284 damages during discovery. It made no such disclosure in its Initial Damages Model, interrogatory responses, or initial and supplemental initial disclosures. D.I. 599 at 2-3 (citing D.I. 600, Exs. 1-4). Rather than provide any damages contention, Apple deferred to its expert report. *Id.* But Malackowski's report devoted just two pages to Apple's financial remedy. D.I. 600, Ex. 5. In those two pages, Malackowski opined that Apple should recover the \$250 statutory minimum under § 289 and explicitly disclaimed any opinion under § 284:

Furthermore, while I have determined the amount of damages by reference to the statute applicable to design patents, the \$250 represents damages for infringement of both the Apple Asserted Design Patents and the Apple Asserted Utility Patents based on my understanding that a patentee ***may not recover both disgorgement*** of profits from infringement of a design patent, (or patents) ***and a reasonable royalty*** for infringement of a utility patent (patents) for an infringing sale of the same item.

*Id.* at 4 (citing D.I. 600, Ex. 5 at 63).

On March 20, 2024, the Court held a hearing on trial procedure. Apple's arguments at that hearing confirmed that it had not yet disclosed any methodology or calculation to recover damages under § 284. Apple first argued that "[t]he Freedom is in our expert reports, been accused of infringement of the design patents and the utility patents and ***we are seeking an injunction. It's***

*an injunction case. It's not a monetary case.*" D.I. 658, Ex. 6 at 20:18-21. Later in the hearing, the Court suggested that Apple might contend that it has a right to trial by jury by arguing Masimo would launch the Freedom in Summer 2024 "and that *there is going to be* a damages claim." *Id.* at 36:12-16. Apple did not contend it had disclosed any damages theory. Instead, Apple responded that it might assert a damages claim in the future: "Well, they have announced that they are launching the Freedom, so there certainly are *potential future damages.*" *Id.* at 36:17-19.

That hypothetical never came to pass. Masimo has not launched the Freedom. Apple did not supplement its initial disclosures or interrogatory responses regarding damages, and it did not serve a supplemental expert report offering an opinion that Apple could recover damages. Nevertheless, Apple's portion of the pretrial conference order asserts that:

Apple will seek damages pursuant to 35 U.S.C. § 289 for Defendants' infringement of Apple's Design Patents through trial. Apple will seek *damages* pursuant to 35 U.S.C. § ~~284~~ for Defendants' infringement of Apple's Utility Patents through trial. Apple contends that damages are available from the earliest date of known infringement through trial and will ask the jury to award damages of *at least* \$250.

PCO at ¶ \_\_\_\_.

## II. ARGUMENT

Apple never identified any basis to recover § 284 damages. Apple's failure is neither substantially justified nor harmless. Apple cannot possibly justify failing to disclose its theory in fact or expert discovery. And allowing Apple to ambush Masimo at trial would unfairly prejudice Masimo's ability to defend itself. When the parties conferred on this motion, Apple represented that it set forth its positions in its two briefs regarding trial logistics. But those briefs do not identify anywhere Apple disclosed its damages theory, they do not disclose a damages theory, and they do not defend Apple's failures. D.I. 659, 665. Therefore, Apple should not be allowed to pursue § 284 damages. *See* Fed. R. Civ. P. 37(c).

Apple argued that its expert "opined that \$250 would be appropriate damages for

infringement of [Apple’s utility patents].” D.I. 659 at 6. Apple’s argument is misleading at best. Malackowski stated that \$250 “represents” damages for both the design and utility patents because Apple “may not” recover a reasonable royalty (under § 284) for infringement of the utility patents.

Apple argued a damages case can be presented without expert testimony. *Id.* at 7. But Apple cannot do so because it never disclosed such a theory or any facts supporting such a theory in discovery. Apple asserts it “has consistently sought damages for infringement of its utility patents.” *Id.* Apple, however, cited merely to boilerplate statements that it was entitled to recover damages and the types of factors used to calculate damages. Apple cited nothing that identified its damages contentions.

Apple also argued that “there is no real dispute that \$250 is appropriate compensation for Masimo’s 1,702 infringing products.” *Id.* But Apple did not explain why \$250 would be appropriate under § 284, much less identify any legal theory under which it would seek such damages (e.g., lost profits or reasonable royalty). Apple states that neither Masimo nor its experts challenged “that \$250 was an appropriate amount.” *Id.* But Masimo never responded to a § 284 damages claim because Apple never disclosed such a claim. Apple’s sole claim was under § 289. Moreover, Apple now no longer limits its request to \$250. Apple’s portion of the pretrial conference order states that it seeks *at least* \$250.

Finally, Apple asserted that Masimo “cannot escape damages” by arguing Masimo has not fully released the Freedom. D.I. 665 at 2. Apple undermines its own position. At the March hearing, **Apple** argued it had not disclosed a damages theory *because* Masimo had not yet launched the Freedom. Apple now argues that it could have claimed damages for allegedly infringing acts concerning the Freedom. But Apple never did so. Therefore, the Court should preclude Apple from doing so at trial.

September 4, 2024

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

By: /s/ Kendall M. Loebbaka

Joseph R. Re  
Stephen C. Jensen  
Stephen W. Larson  
Benjamin A. Katzenellenbogen  
Edward M. Cannon  
Brian C. Claassen  
Jared C. Bunker  
Mark Lezama  
Kendall M. Loebbaka  
Douglas B. Wentzel  
Knobbe, Martens, Olson & Bear, LLP  
2040 Main Street, 14th Floor  
Irvine, CA 92614  
(949) 760-0404 Telephone  
(949) 760-9502 Facsimile  
joe.re@knobbe.com  
steve.jensen@knobbe.com  
stephen.larson@knobbe.com  
ben.katzenellenbogen@knobbe.com  
ted.cannon@knobbe.com  
brian.claassen@knobbe.com  
jared.bunker@knobbe.com  
mark.lezama@knobbe.com  
kendall.loebbaka@knobbe.com  
douglas.wentzel@knobbe.com

Brian Horne  
Knobbe, Martens, Olson & Bear, LLP  
1925 Century Park East, Suite 600  
Los Angeles, CA 90067  
(310) 551-3450 Telephone  
(310) 551-3458 Facsimile  
brian.horne@knobbe.com  
Adam Powell  
Daniel P. Hughes  
Knobbe, Martens, Olson & Bear, LLP  
3579 Valley Centre Drive, Suite 300  
San Diego, CA 92130

(858) 707-4000 Telephone  
(858) 707-4001 Facsimile  
adam.powell@knobbe.com  
Daniel.hughes@knobbe.com

Carol M. Pitzel Cruz  
Knobbe, Martens, Olson & Bear, LLP  
925 4th Ave., #2500  
Seattle, WA 98104  
206-405-2000 Telephone  
206-405-2001 Facsimile  
carol.pitzelcruz@knobbe.com

PHILLIPS MCLAUGHLIN & HALL, P.A.  
John C. Phillips, Jr. (No. 110)  
Megan C. Haney (No. 5016)  
1200 North Broom Street  
Wilmington, DE 19806  
(302) 655-4200 Telephone  
(302) 655-4210 Fax  
jcp@pmhdelaw.com  
mch@pmhdelaw.com

*Counsel for Defendant and Counter-Claimant  
Masimo Corporation; Defendant Sound United,  
LLC; and Counter-Claimant Cercacor  
Laboratories, Inc.*

### CERTIFICATE OF SERVICE

I hereby certify that on September 4, 2024, a true and correct copy of the foregoing document was served on the following counsel of record at the addresses and in the manner indicated:

***VIA ELECTRONIC MAIL:***

David E. Moore Bindu A. Palapura Andrew L. Brown Hercules Plaza, 6th Floor 1313 N. Market Street Wilmington, DE 19801 dmoore@potteranderson.com bpalapura@potteranderson.com abrown@potteranderson.com	John M. Desmarais Kerri-Ann Limbeek Cosmin Maier Jordan N. Malz Benjamin N. Luehrs Joze Welsh Jamie L. Kringstein Jennifer M. Przybylski Carson Olsheski Jeffrey Scott Seddon, II Amy I. Wann Raymond N. Habbaz Lee Matalon Taeg Sang Cho Eli Balsam Patrick Reilly Marie Weisfeiler Ryan G. Thorne Paul A. Bondor Desmarais LLP 230 Park Avenue, 26th Floor New York, NY 10169 jdesmarais@desmaraisllp.com klimbeek@desmaraisllp.com cmaier@desmaraisllp.com jmalz@desmaraisllp.com bluehrs@desmaraisllp.com jwelsh@desmaraisllp.com jkringstein@desmaraisllp.com jprzybylski@desmaraisllp.com colsheski@desmaraisllp.com jseddon@desmaraisllp.com awann@desmaraisllp.com rhabbaz@desmaraisllp.com lmatalon@desmaraisllp.com tcho@desmaraisllp.com
--	--

	<p>ebalsam@desmaraisllp.com  preilly@desmaraisllp.com  mweisfeiler@desmaraisllp.com  rthorne@desmaraisllp.com  pbondor@desmaraisllp.com</p>
<p>Peter C. Magic  Kyle Curry  Maria Tartakovsky  DESMARAIS LLP  101 California Street  San Francisco, CA 94111  pmagic@desmaraisllp.com  kcurry@desmaraisllp.com  mtartakovsky@desmaraisllp.com</p>	<p>Jennifer Milici  Dominic Vote  Leon B. Greenfield  Heath Brooks  John O'Toole  Wilmer Cutler Pickering Hale and Dorr LLP  2100 Pennsylvania Avenue NW  Washington, DC 20037  jennifer.milici@wilmerhale.com  dominic.vote@wilmerhale.com  leon.greenfield@wilmerhale.com  heath.brooks@wilmerhale.com  john.otoole@wilmerhale.com</p>
<p>Mark A. Ford  Vinita Ferrera  Wilmer Cutler Pickering Hale and Dorr LLP  60 State Street  Boston, MA 02109  mark.ford@wilmerhale.com  vinita.ferrera@wilmerhale.com</p>	<p>David J. Cho  David J. Shaw  Desmarais LLP  1899 Pennsylvania Avenue NW, Suite 400  Washington, DC 20006  dcho@desmaraisllp.com  dshaw@desmaraisllp.com</p>
<p>Lydia Turnage  Wilmer Cutler Pickering Hale and Dorr LLP  7 World Trade Center  250 Greenwich Street  New York, NY 10007  lydia.turnage@wilmerhale.com</p>	<p>Bethany Stevens  Hannah Cannom  Walker Stevens Cannom LLP  500 Molino Street, Suite 118  Los Angeles, CA 90013  bstevens@wscllp.com  hcannom@wscllp.com</p>
<p>Lauren Ige  Cristina Salcedo  Wilmer Cutler Pickering Hale and Dorr LLP  250 South Grand Avenue, Suite 2400  Los Angeles, CA 90071  lauren.ige@wilmerhale.com  cristina.salcedo@wilmerhale.com</p>	<p>IPservice@potteranderson.com</p>
<p>AppleMasimoService@desmaraisllp.com</p>	<p>whmasimoantitrustservice@wilmerhale.com</p>

September 4, 2024

/s/ Kendall M. Loebbaka

Kendall M. Loebbaka



**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

APPLE INC.,

Plaintiff,

v.

MASIMO CORPORATION AND SOUND  
UNITED, LLC,

Defendants.

---

MASIMO CORPORATION AND CERCACOR  
LABORATORIES, INC.,

Counterclaim-Plaintiffs,

v.

APPLE INC.,

Counterclaim-Defendant.

---

C.A. No. 1:22-cv-1377-JLH

C.A. No. 1:22-cv-1378-JLH

**HIGHLY CONFIDENTIAL –  
ATTORNEYS’ EYES ONLY**

**FILED UNDER SEAL**

**APPLE’S OPPOSITION TO MASIMO’S MOTION *IN LIMINE* #1:  
TO PRECLUDE EVIDENCE OR ARGUMENT FOR ANY MONETARY RELIEF  
BEYOND THE MINIMUM OF \$250 UNDER § 289 AND  
TO PRECLUDE TESTIMONY FROM JAMES MALACKOWSI**

Before trial, without consideration of any evidence, and without even one supporting case, Masimo asks the Court to make the substantive determination that Apple should be awarded zero damages under 35 U.S.C. § 284 for Masimo’s utility patent infringement. Masimo’s motion should be denied on multiple grounds. First, Masimo’s motion is wrong on the law—the Federal Circuit has repeatedly held that a finding of utility patent infringement requires damages. Second, Masimo is wrong on the facts. Apple’s discovery responses properly disclose the bases for its damages claim under § 284, as does the report of Apple’s expert, James Malackowski. Apple cannot be precluded from presenting properly disclosed evidence and testimony supporting damages. Finally, Masimo’s motion should also be denied because it violates the Court’s schedule as an untimely request for summary judgment on damages.

**A. Masimo Cannot Escape Liability For Damages Under 35 U.S.C. § 284.**

Masimo’s attempt to preclude Apple from seeking damages under 35 U.S.C. § 284 has no legal basis and cannot be reconciled with the statute or controlling precedent. The wording of the statute is mandatory—section 284 states that “the court *shall* award the claimant damages adequate to compensate for the infringement” upon a finding for the patentee. The Federal Circuit has confirmed that, if infringement is found, “the statute requires the court to award damages.” *See Apple Inc. v. Motorola, Inc.*, 757 F.3d 1286, 1327-28 (Fed. Cir. 2014), *overruled on other grounds by Williamson v. Citrix Online, LLC*, 792 F.3d 1339 (Fed. Cir. 2015). Indeed, the Federal Circuit has repeatedly held that “[t]he statute is unequivocal that the district court must award damages” where infringement is found, even without expert testimony. *See Dow Chem. Co. v. Mee Indus., Inc.*, 341 F.3d 1370, 1381 (Fed. Cir. 2003); *Lindemann Maschinenfabrik GmbH v. Am. Hoist & Derrick Co.*, 895 F.2d 1403, 1406 (Fed. Cir. 1990) (“the fact of infringement establishes the fact of damage”). Masimo’s attempt to escape liability for damages before trial thus must be denied.

Masimo argues that Apple should be limited to recovering damages under 35 U.S.C § 289

(see Br. at 1), but that makes no sense. Apple is asserting utility patents, not just design patents, and has a right to submit requests for damages on both to the jury. Indeed, the Federal Circuit has endorsed submitting both requests for damages under § 284 for utility patent infringement and damages under § 289 for design patent infringement to the jury. See *Catalina Lighting, Inc. v. Lamps Plus, Inc.*, 295 F.3d 1277, 1289-90 (Fed. Cir. 2002) (affirming jury determinations on both). To be sure, *Catalina* found that combining the jury awards *after trial* would be a double recovery, see *id.* at 1290-92, but that does not support Masimo’s attempt to zero out utility patent damages *before trial*. And Masimo’s request opens the door to tremendous inefficiencies in the event of a mixed verdict. For instance, if the jury finds Masimo infringes Apple’s utility patents but not any design patents, section 289 would not apply, yet damages would be required under § 284, see *Apple*, 757 F.3d at 1327-28, thus Masimo’s proposal would require a second trial on damages.

**B. Apple Properly Disclosed Supporting Factual Evidence And Expert Testimony.**

Masimo’s motion should also be denied because Apple disclosed its § 284 damages claim and supporting evidence in discovery and Malackowski’s expert report. Apple’s response to Masimo’s interrogatory on damages disclosed Apple’s request for damages under § 284 (see Ex. 1 at 14), and identified Masimo’s “sales of the instrumentalities at issue” (*id.* at 15); Masimo’s “manufacturing ... of the accused products” (*id.* at 17); Masimo’s “worldwide ... sales” of accused products made in the United States (*id.* at 15); “[u]nit cost, pricing, and sales volume ... for the accused products” (*id.* at 17); Masimo’s “sales and marketing strategies” (*id.* at 16); and “the effect of infringing features of the accused products on Defendants’ sales” (*id.* at 17) as supporting evidence. Apple cannot be barred from presenting factual evidence—e.g., deposition testimony (and accompanying exhibits) from Joseph Kiani, Bilal Muhsin, Blair Tripodi, and Micah Young, which were also identified in Apple’s discovery response (*id.* at 19)—on those topics.

Malackowski’s opinions provide further support for Apple’s § 284 damages claim for

utility patent infringement. Malackowski's report identifies key features in the accused products from Masimo's marketing (*see* Ex. 2 at 42-45); describes the relationship between certain features and Apple's utility patents (relying on technical experts) (*see id.* at 50-51); and determines that those features drive demand for Masimo's products (*id.* at 82-84)—a point that Masimo's expert does not dispute. *See, e.g.*, Ex. 3 at 189:1-7 (agreeing monitoring drives demand for Masimo's W1). Moreover, Malackowski analyzes manufactured units, U.S. sales, and profitability (Ex. 2 at 62-63) and opines that \$250 was appropriate damages (as of that date) for Masimo's infringement of Apple's utility patents as well as Apple's design patents. *See id.* at 63. Masimo chose not to respond to that damages claim, but cannot credibly deny its existence.

### **C. Masimo's Motion Is An Untimely Summary Judgment Motion**

Finally, Masimo's motion should be denied because it is an untimely summary judgment motion masquerading as a motion in limine. Masimo had full knowledge of Apple's disclosures by the close of expert discovery, yet chose not to move for summary judgment of no damages on Apple's utility patents and for good reason—it had no basis to do so. *See, e.g., Apple*, 757 F.3d at 1327-28 (“a judge may only award a zero royalty for infringement if there is no genuine issue of material fact that zero is the only reasonable royalty”). Masimo may not now disregard the Scheduling Order and seek the same substantive relief through abbreviated in limine briefing. *See, e.g., Brobst v. Columbus Servs. Int'l*, 761 F.2d 148, 154 (3d Cir. 1985) (reversing decision where “the district court’s procedure converted the in limine motion into one for summary judgment”); *Moon Express, Inc. v. Intuitive Machines, LLC*, No. 16-344, 2017 WL 6380750, at \*2 (D. Del. Dec. 14, 2017) (denying in limine motions seeking partial summary judgment); *Telcordia Techs., Inc. v. Lucent Techs., Inc.*, No. 04-875, 2007 WL 7076662, at \*8 (D. Del. Apr. 27, 2007) (same).

Dated: September 18, 2024

OF COUNSEL:

John M. Desmarais  
Cosmin Maier  
Jordan N. Malz  
Kerri-Ann Limbeek  
**DESMARAIS LLP**  
230 Park Avenue  
New York, NY 10169  
Tel: (212) 351-3400  
jdesmarais@desmaraisllp.com

Peter C. Magic  
**DESMARAIS LLP**  
101 California Street  
San Francisco, CA 94111  
Tel: (415) 573-1900  
pmagic@desmaraisllp.com

Jennifer Milici  
Dominic Vote  
**WILMER CULTER PICKERING  
HALE AND DORR LLP**  
2100 Pennsylvania Avenue NW  
Washington, DC 20037  
Tel: (202) 663-6000

Mark A. Ford  
**WILMER CULTER PICKERING  
HALE AND DORR LLP**  
60 State Street  
Boston, MA 02109  
Tel: (617) 526-6423

By: /s/ Bindu A. Palapura  
David E. Moore (#3983)  
Bindu A. Palapura (#5370)  
Andrew M. Moshos (#6685)  
**POTTER ANDERSON & CORROON LLP**  
Hercules Plaza, 6th Floor  
1313 N. Market Street  
Wilmington, DE 19801  
Tel: (302) 984-6000  
dmoore@potteranderson.com  
bpalapura@potteranderson.com  
amoshos@potteranderson.com

*Attorneys for Plaintiff/Counter-Defendant  
Apple Inc.*

**CERTIFICATE OF SERVICE**

I hereby certify that a copy of Apple Inc.'s Opposition to Masimo's Motion *In Limine* #1 was served upon counsel of record for Masimo Corporation and Sound United, LLC on September 18, 2024.

/s/ Jamie L. Kringstein

Jamie L. Kringstein

Apple's Opposition to Masimo's MIL No. 1 Exhibits Table		
Exhibit No.	PTX No.	Description
1		Excerpts of Apple's Fourth Supplemental Response to Defendants' Second Set of Interrogatories (Nos. 6-9, 11-15) (11-09-2023)
2	PTX-1577	Excerpts of Opening Expert Report of James E. Malackowski (11-22-2023)
3		Excerpts of Deposition Transcript of Cleve Tyler (09-13-2024)

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

<div>APPLE INC.,  <i>Plaintiff,</i>  v.  MASIMO CORPORATION and SOUND UNITED, LLC,  <i>Defendants.</i></div>	C.A. No. 22-1377-JLH  <b>JURY TRIAL DEMANDED</b>
<div>MASIMO CORPORATION,  <i>Counter-Claimant,</i>  v.  APPLE INC.  <i>Counter-Defendant.</i></div>	
<div>APPLE INC.,  <i>Plaintiff,</i>  v.  MASIMO CORPORATION and SOUND UNITED, LLC,  <i>Defendants.</i></div>	C.A. No. 22-1378-JLH  <b>JURY TRIAL DEMANDED</b>
<div>MASIMO CORPORATION and CERCACOR LABORATORIES, INC.,  <i>Counter-Claimants,</i>  v.  APPLE INC.  <i>Counter-Defendant.</i></div>	

**MASIMO’S REPLY SUPPORTING ITS MOTION *IN LIMINE* #1  
TO PRECLUDE EVIDENCE OR ARGUMENT FOR ANY MONETARY RELIEF  
BEYOND THE MINIMUM OF \$250 UNDER § 289 AND  
TO PRECLUDE TESTIMONY FROM JAMES MALACKOWSI**

All emphasis added unless otherwise noted.



**I. Apple Did Not Disclose Any Theory Under § 284**

As Apple’s brief shows, Apple’s interrogatory response merely listed types of evidence, such as Masimo’s sales, profits, and marketing strategies. Opp. at 2. But these are not specific facts, and the interrogatory response never explained how any fact supports a particular damages theory. Apple did not even disclose whether it would rely on these types of facts to establish a reasonable royalty or lost profits. Rather, Apple said that it “anticipates that an analysis of the impact of Defendants’ infringement” would consider these types of facts. Apple Ex. 1 at 15. Apple confirmed it had not disclosed any theory by explaining it “anticipates” an expert would later determine a royalty base and perform related calculations. *Id.*; *see also id.* at 14 (“Apple expects that its final requests for relief will be based at least in part on expert opinions”).

Malackowski’s report did not cure Apple’s failure to disclose a damages theory. Apple cites to facts in his report that might be used to support a theory. Opp. at 3. But Apple cites no damages opinion. In fact, Apple even resorts to citing Malackowski’s opinion on irreparable harm to support an injunction. Opp. at 2-3 (citing Malackowski at 82-84).

**II. The “Shall Award” Language of § 284 Does Not Rescue Apple**

Undisclosed damages claims can be struck under Rule 37. *See Trutek Corp. v. BlueWillow Biologics, Inc.*, 2023 WL 6130532, \*11-12 (E.D. Mich. Sept. 19, 2023). And a plaintiff can waive any right to collect a royalty. *Promega Corp. v. Life Techs. Corp.*, 875 F.3d 651, 660, 664-66 (Fed. Cir. 2017). A Plaintiff can also be awarded zero damages as a royalty. *See, e.g., TecSec, Inc. v. Adobe Inc.*, 978 F.3d 1278, 1291 (Fed. Cir. 2020). Finally, an award under § 289, which Apple seeks, “also constitutes ‘damages adequate to compensate for the infringement, but in no event less than a reasonable royalty ....’” *Catalina Lighting, Inc. v. Lamps Plus, Inc.*, 295 F.3d 1277, 1291 (Fed. Cir. 2002).

September 25, 2024

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

By: /s/ Kendall M. Loebbaka

Joseph R. Re  
Stephen C. Jensen  
Stephen W. Larson  
Benjamin A. Katzenellenbogen  
Edward M. Cannon  
Brian C. Claassen  
Jared C. Bunker  
Mark Lezama  
Kendall M. Loebbaka  
Douglas B. Wentzel  
Knobbe, Martens, Olson & Bear, LLP  
2040 Main Street, 14th Floor  
Irvine, CA 92614  
(949) 760-0404 Telephone  
(949) 760-9502 Facsimile  
joe.re@knobbe.com  
steve.jensen@knobbe.com  
stephen.larson@knobbe.com  
ben.katzenellenbogen@knobbe.com  
ted.cannon@knobbe.com  
brian.claassen@knobbe.com  
jared.bunker@knobbe.com  
mark.lezama@knobbe.com  
kendall.loebbaka@knobbe.com  
douglas.wentzel@knobbe.com

Brian Horne  
Knobbe, Martens, Olson & Bear, LLP  
1925 Century Park East, Suite 600  
Los Angeles, CA 90067  
(310) 551-3450 Telephone  
(310) 551-3458 Facsimile  
brian.horne@knobbe.com  
Adam Powell  
Daniel P. Hughes  
Knobbe, Martens, Olson & Bear, LLP  
3579 Valley Centre Drive, Suite 300  
San Diego, CA 92130  
(858) 707-4000 Telephone  
(858) 707-4001 Facsimile

adam.powell@knobbe.com  
Daniel.hughes@knobbe.com

Carol M. Pitzel Cruz  
Knobbe, Martens, Olson & Bear, LLP  
925 4th Ave., #2500  
Seattle, WA 98104  
206-405-2000 Telephone  
206-405-2001 Facsimile  
carol.pitzelcruz@knobbe.com

PHILLIPS MCLAUGHLIN & HALL, P.A.  
John C. Phillips, Jr. (No. 110)  
Megan C. Haney (No. 5016)  
1200 North Broom Street  
Wilmington, DE 19806  
(302) 655-4200 Telephone  
(302) 655-4210 Fax  
jcp@pmhdelaw.com  
mch@pmhdelaw.com

*Counsel for Defendant and Counter-Claimant  
Masimo Corporation; Defendant Sound United,  
LLC; and Counter-Claimant Cercacor  
Laboratories, Inc.*

### CERTIFICATE OF SERVICE

I hereby certify that on September 25, 2024, a true and correct copy of the foregoing document was served on the following counsel of record at the addresses and in the manner indicated:

***VIA ELECTRONIC MAIL:***

David E. Moore Bindu A. Palapura Andrew L. Brown Hercules Plaza, 6th Floor 1313 N. Market Street Wilmington, DE 19801 dmoore@potteranderson.com bpalapura@potteranderson.com abrown@potteranderson.com	John M. Desmarais Kerri-Ann Limbeek Cosmin Maier Jordan N. Malz Benjamin N. Luehrs Joze Welsh Jamie L. Kringstein Jennifer M. Przybylski Carson Olsheski Jeffrey Scott Seddon, II Amy I. Wann Raymond N. Habbaz Lee Matalon Taeg Sang Cho Eli Balsam Patrick Reilly Marie Weisfeiler Ryan G. Thorne Paul A. Bondor Desmarais LLP 230 Park Avenue, 26th Floor New York, NY 10169 jdesmarais@desmaraisllp.com klimbeek@desmaraisllp.com cmaier@desmaraisllp.com jmalz@desmaraisllp.com bluehrs@desmaraisllp.com jwelsh@desmaraisllp.com jkringstein@desmaraisllp.com jprzybylski@desmaraisllp.com colsheski@desmaraisllp.com jseddon@desmaraisllp.com awann@desmaraisllp.com rhabbaz@desmaraisllp.com lmatalon@desmaraisllp.com tcho@desmaraisllp.com
--	--

	<p>ebalsam@desmaraisllp.com  preilly@desmaraisllp.com  mweisfeiler@desmaraisllp.com  rthorne@desmaraisllp.com  pbondor@desmaraisllp.com</p>
<p>Peter C. Magic  Kyle Curry  Maria Tartakovsky  DESMARAIS LLP  101 California Street  San Francisco, CA 94111  pmagic@desmaraisllp.com  kcurry@desmaraisllp.com  mtartakovsky@desmaraisllp.com</p>	<p>Jennifer Milici  Dominic Vote  Leon B. Greenfield  Heath Brooks  John O'Toole  Wilmer Cutler Pickering Hale and Dorr LLP  2100 Pennsylvania Avenue NW  Washington, DC 20037  jennifer.milici@wilmerhale.com  dominic.vote@wilmerhale.com  leon.greenfield@wilmerhale.com  heath.brooks@wilmerhale.com  john.otoole@wilmerhale.com</p>
<p>Mark A. Ford  Vinita Ferrera  Wilmer Cutler Pickering Hale and Dorr LLP  60 State Street  Boston, MA 02109  mark.ford@wilmerhale.com  vinita.ferrera@wilmerhale.com</p>	<p>David J. Cho  David J. Shaw  Desmarais LLP  1899 Pennsylvania Avenue NW, Suite 400  Washington, DC 20006  dcho@desmaraisllp.com  dshaw@desmaraisllp.com</p>
<p>Lydia Turnage  Wilmer Cutler Pickering Hale and Dorr LLP  7 World Trade Center  250 Greenwich Street  New York, NY 10007  lydia.turnage@wilmerhale.com</p>	<p>Bethany Stevens  Hannah Cannom  Walker Stevens Cannom LLP  500 Molino Street, Suite 118  Los Angeles, CA 90013  bstevens@wscllp.com  hcannom@wscllp.com</p>
<p>Lauren Ige  Cristina Salcedo  Wilmer Cutler Pickering Hale and Dorr LLP  250 South Grand Avenue, Suite 2400  Los Angeles, CA 90071  lauren.ige@wilmerhale.com  cristina.salcedo@wilmerhale.com</p>	<p>IPservice@potteranderson.com</p>
<p>AppleMasimoService@desmaraisllp.com</p>	<p>whmasimoantitrustservice@wilmerhale.com</p>

September 25, 2024

/s/ Kendall M. Loebbaka  
Kendall M. Loebbaka

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

APPLE INC.,  <i>Plaintiff,</i>  v.  MASIMO CORPORATION and SOUND UNITED, LLC,  <i>Defendants.</i>	C.A. No. 22-1377-JLH  <b>JURY TRIAL DEMANDED</b>
MASIMO CORPORATION,  <i>Counter-Claimant,</i>  v.  APPLE INC.  <i>Counter-Defendant.</i>	
APPLE INC.,  <i>Plaintiff,</i>  v.  MASIMO CORPORATION and SOUND UNITED, LLC,  <i>Defendants.</i>	C.A. No. 22-1378-JLH  <b>JURY TRIAL DEMANDED</b>
MASIMO CORPORATION and CERCACOR LABORATORIES, INC.,  <i>Counter-Claimants,</i>  v.  APPLE INC.  <i>Counter-Defendant.</i>	

**MASIMO’S MOTION *IN LIMINE* #2  
TO PRECLUDE APPLE FROM PRESENTING EVIDENCE OR ARGUMENT  
REGARDING WILLFUL INFRINGEMENT OR COPYING**

All emphasis added unless otherwise noted.

Masimo moves *in limine* to preclude Apple from introducing legally irrelevant and unfairly prejudicial evidence or argument regarding either alleged willfulness or copying.

**I. NO EVIDENCE OR ARGUMENT ASSERTING WILLFUL INFRINGEMENT**

The Court should preclude Apple from asserting willful infringement because it would be irrelevant to Apple's requested recovery under 35 U.S.C. § 289.

**A. Enhanced Damages Are Not Available**

As explained in Masimo's Motion *in Limine* No. 1, Apple elected to seek recovery only under Section 289 (Apple disputes this for the utility patents but concedes it for the design patents). The Federal Circuit has explained that monetary recovery under Section 289 does not constitute "damages" that may be increased up to three times under Section 284. *Braun Inc. v. Dynamics Corp. of Am.*, 975 F.2d 815, 823-24 (Fed. Cir. 1992). Although courts may enhance damages sought under Section 284, nothing in Section 289 authorizes any enhancement. *Id.* at 823-24; *Catalina Lighting, Inc. v. Lamps Plus, Inc.*, 295 F. 3d 1277, 1291 (Fed. Cir. 2002) ("Section 289, however, has no provision for enhanced damages"). To the contrary, Section 289 "explicitly precludes" a patentee from seeking such enhanced recovery. *Braun*, 975 F.2d at 824 (citing *Bergstrom v. Sears, Roebuck and Co.*, 496 F. Supp. 476, 496 (D. Minn.1980)). In *Braun*, the Federal Circuit held that "the district court clearly exceeded its statutory authority" by enhancing an award under Section 289. *Id.* & n.17.

**B. Willfulness Is Irrelevant Because Enhanced Damages Are Not Available**

The issue of willfulness is not relevant to evaluating infringement. *Global-Tech Appliances, Inc. v. SEB S.A.*, 563 U.S. 754, 761 n.2 (2011) ("[A] direct infringer's knowledge or intent is irrelevant."). A finding of willfulness relates only to the Court's ability to enhance damages at its discretion. *Johns Hopkins Univ. v. CellPro, Inc.*, 152 F.3d 1342, 1364 (Fed. Cir.

1998); see *Halo Elecs., Inc. v. Pulse Elecs., Inc.*, 579 U.S. 93 (2016) (relaxing standard for awarding enhanced damages). As explained above, the Court cannot enhance any recovery for design patent infringement because Apple seeks monetary recovery under only Section 289. See *Braun*, 975 F.2d at 823-24. Therefore, willfulness is irrelevant.

The Court could consider willfulness when evaluating whether to award attorneys' fees. See 35 U.S.C. § 285. But that is an issue for the Court, not the jury. *Octane Fitness, LLC v. ICON Health & Fitness, Inc.*, 572 U.S. 545, 554 (2014). It would unnecessarily confuse the jury, and potentially prejudice Masimo, to present evidence or argument that could be relevant only to attorneys' fees. The parties should present such evidence or argument to the Court after the court has determined the prevailing party, or at least outside the presence of the jury.<sup>1</sup>

## **II. NO EVIDENCE OR ARGUMENT REGARDING COPYING**

Masimo also seeks an order excluding evidence of copying analogous to Judge Andrews' order in *Shure*; a case both parties have cited extensively as generally setting forth the law on design patent issues. In *Shure*, the defendant sought, as does Masimo, "to 'prevent any evidence of alleged "copying" until [plaintiff's] rebuttal case, in response to a [defendant's] assertion that [plaintiff's] asserted design patent is obvious.'" *Shure Inc. v. ClearOne, Inc.*, 2021 WL 4974001, at \*1 (D. Del. Oct. 26, 2021). The court held that evidence of copying is irrelevant to design patent infringement and inadmissible under Rule 402 because "'the inquiry is whether there is a feature that is similar between the designs, not whether the defendant tried to copy.'" *Id.* at \*1.

The court also found that, "even if copying were relevant in the way suggested by the Magistrate Judge, it would be far more prejudicial than probative." *Id.* at \*2 (citing *Finjan, Inc. v.*

---

<sup>1</sup> Apple intends to amplify that prejudice by having technical experts testify that certain evidence supports a willfulness finding. Such testimony should never be presented to the jury.



*Blue Coat Sys., Inc.*, 2015 WL 4129193, at \*6 (N.D. Cal. July 8, 2015)). The court explained that “there is significant prejudice associated with this evidence, as a jury may use evidence of copying to unfairly conclude that Defendant's products *infringe* the patents-in-suit.” *Id.* Accordingly, the court held that, “[i]n the alternative, therefore, copying evidence is excluded in Plaintiff’s case-in-chief pursuant to Rule 403.” *Id.*

In a prior case, Apple narrowly avoided exclusion of copying evidence and opinions under very different circumstances than here. *See Apple Inc. v. Samsung Elecs. Co.*, 2018 WL 1586276, at \*10 (N.D. Cal. Apr. 2, 2018). The district court had previously ruled that “‘the infringer’s intent in copying the patented design’ is not relevant to § 289.” *Id.* (citing earlier order). On remand from the Supreme Court, the court agreed with Apple that “copying testimony is relevant specifically to *the article of manufacture issue* and admissible under Rule 403 *when liability is no longer at issue*.” *Id.* Here, the “article of manufacture” is not at issue because there is no need to try to apportion Masimo’s profits attributable to the claimed design. Apple seeks the statutory remedy of \$ 250. More importantly, liability is still at issue. Judge Koh’s opinion appears to assume that where, as here, liability has yet to be decided, evidence of copying should be excluded.

For the utility patents, Apple’s copying arguments are irrelevant to secondary considerations of non-obviousness because Apple does not allege that Masimo copied a feature in the claims. Such evidence would be inadmissible because copying “requires the replication of a specific [patented] product.” *Iron Grip Barbell Co. v. USA Sports, Inc.*, 392 F.3d 1317, 1325 (Fed. Cir. 2004).

Accordingly, this Court should exclude evidence or argument of alleged copying Apple’s patented devices or designs (unless presented in rebuttal to design-patent obviousness).

September 4, 2024

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

By: /s/ Kendall M. Loebbaka

Joseph R. Re  
Stephen C. Jensen  
Stephen W. Larson  
Benjamin A. Katzenellenbogen  
Edward M. Cannon  
Brian C. Claassen  
Jared C. Bunker  
Mark Lezama  
Kendall M. Loebbaka  
Douglas B. Wentzel  
Knobbe, Martens, Olson & Bear, LLP  
2040 Main Street, 14th Floor  
Irvine, CA 92614  
(949) 760-0404 Telephone  
(949) 760-9502 Facsimile  
joe.re@knobbe.com  
steve.jensen@knobbe.com  
stephen.larson@knobbe.com  
ben.katzenellenbogen@knobbe.com  
ted.cannon@knobbe.com  
brian.claassen@knobbe.com  
jared.bunker@knobbe.com  
mark.lezama@knobbe.com  
kendall.loebbaka@knobbe.com  
douglas.wentzel@knobbe.com

Brian Horne  
Knobbe, Martens, Olson & Bear, LLP  
1925 Century Park East, Suite 600  
Los Angeles, CA 90067  
(310) 551-3450 Telephone  
(310) 551-3458 Facsimile  
brian.horne@knobbe.com  
Adam Powell  
Daniel P. Hughes  
Knobbe, Martens, Olson & Bear, LLP  
3579 Valley Centre Drive, Suite 300  
San Diego, CA 92130

(858) 707-4000 Telephone  
(858) 707-4001 Facsimile  
adam.powell@knobbe.com  
Daniel.hughes@knobbe.com

Carol M. Pitzel Cruz  
Knobbe, Martens, Olson & Bear, LLP  
925 4th Ave., #2500  
Seattle, WA 98104  
206-405-2000 Telephone  
206-405-2001 Facsimile  
carol.pitzelcruz@knobbe.com

PHILLIPS MCLAUGHLIN & HALL, P.A.  
John C. Phillips, Jr. (No. 110)  
Megan C. Haney (No. 5016)  
1200 North Broom Street  
Wilmington, DE 19806  
(302) 655-4200 Telephone  
(302) 655-4210 Fax  
jcp@pmhdelaw.com  
mch@pmhdelaw.com

*Counsel for Defendant and Counter-Claimant  
Masimo Corporation; Defendant Sound United,  
LLC; and Counter-Claimant Cercacor  
Laboratories, Inc.*

**CERTIFICATE OF SERVICE**

I hereby certify that on September 4, 2024, a true and correct copy of the foregoing document was served on the following counsel of record at the addresses and in the manner indicated:

***VIA ELECTRONIC MAIL:***

David E. Moore Bindu A. Palapura Andrew L. Brown Hercules Plaza, 6th Floor 1313 N. Market Street Wilmington, DE 19801 dmoore@potteranderson.com bpalapura@potteranderson.com abrown@potteranderson.com	John M. Desmarais Kerri-Ann Limbeek Cosmin Maier Jordan N. Malz Benjamin N. Luehrs Joze Welsh Jamie L. Kringstein Jennifer M. Przybylski Carson Olsheski Jeffrey Scott Seddon, II Amy I. Wann Raymond N. Habbaz Lee Matalon Taeg Sang Cho Eli Balsam Patrick Reilly Marie Weisfeiler Ryan G. Thorne Paul A. Bondor Desmarais LLP 230 Park Avenue, 26th Floor New York, NY 10169 jdesmarais@desmaraisllp.com klimbeek@desmaraisllp.com cmaier@desmaraisllp.com jmalz@desmaraisllp.com bluehrs@desmaraisllp.com jwelsh@desmaraisllp.com jkringstein@desmaraisllp.com jprzybylski@desmaraisllp.com colsheski@desmaraisllp.com jseddon@desmaraisllp.com awann@desmaraisllp.com rhabbaz@desmaraisllp.com lmatalon@desmaraisllp.com tcho@desmaraisllp.com
--	--

	<p>ebalsam@desmaraisllp.com  preilly@desmaraisllp.com  mweisfeiler@desmaraisllp.com  rthorne@desmaraisllp.com  pbondor@desmaraisllp.com</p>
<p>Peter C. Magic  Kyle Curry  Maria Tartakovsky  DESMARAIS LLP  101 California Street  San Francisco, CA 94111  pmagic@desmaraisllp.com  kcurry@desmaraisllp.com  mtartakovsky@desmaraisllp.com</p>	<p>Jennifer Milici  Dominic Vote  Leon B. Greenfield  Heath Brooks  John O'Toole  Wilmer Cutler Pickering Hale and Dorr LLP  2100 Pennsylvania Avenue NW  Washington, DC 20037  jennifer.milici@wilmerhale.com  dominic.vote@wilmerhale.com  leon.greenfield@wilmerhale.com  heath.brooks@wilmerhale.com  john.otoole@wilmerhale.com</p>
<p>Mark A. Ford  Vinita Ferrera  Wilmer Cutler Pickering Hale and Dorr LLP  60 State Street  Boston, MA 02109  mark.ford@wilmerhale.com  vinita.ferrera@wilmerhale.com</p>	<p>David J. Cho  David J. Shaw  Desmarais LLP  1899 Pennsylvania Avenue NW, Suite 400  Washington, DC 20006  dcho@desmaraisllp.com  dshaw@desmaraisllp.com</p>
<p>Lydia Turnage  Wilmer Cutler Pickering Hale and Dorr LLP  7 World Trade Center  250 Greenwich Street  New York, NY 10007  lydia.turnage@wilmerhale.com</p>	<p>Bethany Stevens  Hannah Cannom  Walker Stevens Cannom LLP  500 Molino Street, Suite 118  Los Angeles, CA 90013  bstevens@wscllp.com  hcannom@wscllp.com</p>
<p>Lauren Ige  Cristina Salcedo  Wilmer Cutler Pickering Hale and Dorr LLP  250 South Grand Avenue, Suite 2400  Los Angeles, CA 90071  lauren.ige@wilmerhale.com  cristina.salcedo@wilmerhale.com</p>	<p>IPservice@potteranderson.com</p>
<p>AppleMasimoService@desmaraisllp.com</p>	<p>whmasimoantitrustservice@wilmerhale.com</p>

September 4, 2024

/s/ Kendall M. Loebbaka  
Kendall M. Loebbaka

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

APPLE INC.,

Plaintiff,

v.

MASIMO CORPORATION AND SOUND  
UNITED, LLC,

Defendants.

---

MASIMO CORPORATION AND CERCACOR  
LABORATORIES, INC.,

Counterclaim-Plaintiffs,

v.

APPLE INC.,

Counterclaim-Defendant.

---

C.A. No. 1:22-cv-1377-JLH

C.A. No. 1:22-cv-1378-JLH

**HIGHLY CONFIDENTIAL –  
ATTORNEYS’ EYES ONLY**

**FILED UNDER SEAL**

**APPLE’S OPPOSITION TO MASIMO’S MOTION *IN LIMINE* #2:  
TO PRECLUDE APPLE FROM PRESENTING EVIDENCE OR ARGUMENT  
REGARDING WILLFUL INFRINGEMENT OR COPYING**

Since the day Apple filed this case, a central allegation was that Masimo willfully copied Apple Watch's patented designs and technologies. *See, e.g.*, -1377 D.I. 1 ¶¶ 3-4, 21-22, 34, 36, 40, 46, 53, 60, 67; Prayer for Relief ¶ B; -1378 D.I. 1 ¶¶ 3-4, 21-22, 34, 36, 40; Prayer for Relief ¶ B. Apple will prove those allegations at trial: the Masimo employees in charge of developing the W1 and Freedom [REDACTED]

[REDACTED]. Exs. 1-5. Masimo even copied Apple's charger. *E.g.*, -1377 D.I. 1 ¶ 3, 36, 67. Apple then filed this case. *Id.* Caught red-handed, Masimo kept selling its W1 but tried to cover-up the infringement by removing the relevant images from its website. Ex. 6. Masimo may disagree with those allegations, but it cannot hide them from the jury in the hopes of telling a false independent development story. Willfulness and copying are relevant to the October trial. Masimo's MIL, which is an untimely SJ motion, should be denied.

**First**, Apple seeks compensatory damages under § 284, which expressly allows enhanced damages. Masimo asks the Court to eliminate willfulness from the jury trial because it argues Apple might not later receive enhancement, but that places the cart before the horse. A trial judge's later enhancement decision is distinct from the "factual components" of willfulness, which must first be decided by a jury. *See, e.g., WBIP, LLC v. Kohler Co.*, 829 F.3d 1317, 1341 (Fed. Cir. 2016) ("We do not interpret *Halo* as changing the established law that the factual components of the willfulness question should be resolved by the jury."); *Power Integrations v. Fairchild Semiconductor Int'l*, 2019 WL 3290369, at \*7 (D. Del. July 22, 2019) ("The role of the jury in determining willfulness and the role of the judge in determining enhancement . . . are distinct.").

Masimo suggests that the Court may bifurcate willfulness into a separate post-verdict bench proceeding, but that is neither supported by any legal authority nor consistent with the Seventh Amendment. "Willfulness of behavior is a classical jury question of intent. When trial is

had to a jury, the issue should be decided by the jury.” *WBIP*, 829 F.3d at 1341 (quoting *Richardson v. Suzuki Motor Co.*, 868 F.2d 1226, 1250 (Fed. Cir. 1989)); *Power Integrations*, 2019 WL 3290369, at \*7 (“Certainly a judge cannot substitute his or her factual determination for a jury’s willfulness finding.”) (citation omitted). Masimo also never requested this in its fulsome trial-sequencing briefing or its motion for a bench trial. *See* -1377 D.I. 575-577, 635, 636, 645.

**Second**, Masimo cites *Shure* to argue that evidence of copying should be limited to Apple’s rebuttal to obviousness, but *Shure* did not even address willfulness. 2021 WL 4974001, at \*1-2 (D. Del. Oct. 25, 2021). In that case, the District Judge overruled a finding by the Magistrate Judge that copying was a component of the **ordinary observer test** for direct design patent infringement. *Id.* But Apple is not arguing that point. And since Masimo intends to present a development story of the “Masimo Watch,” Apple should be permitted to offer relevant, contextualizing evidence—such as that Masimo’s employees [REDACTED], Exs. 1-5—through its case-in-chief and on cross-examination. Courts regularly admit evidence of copying and willful infringement in similar circumstances. *See, e.g., Georgetown R. Equip. Co. v. Holland L.P.*, 867 F.3d 1229, 1245 (Fed. Cir. 2017) (affirming trial court allowing jury to hear “circumstantial evidence that [defendant] copied”); *Nox Med. Ehf v. Natus Neurology*, 2018 WL 6629704, at \*2 (D. Del. Apr. 12, 2018) (permitting the jury to hear that defendant copied plaintiff’s product and kept selling it after learning of plaintiff’s patent). Restricting such evidence to Apple’s rebuttal case is not only unfair to Apple’s case presentation, but highly inefficient and potentially confusing. Since Apple will sponsor the pertinent evidence through depositions and cross-examination, Masimo’s proposal would inevitably require the same fact witnesses to testify twice.

**Third**, evidence of copying and a verdict of willful infringement is relevant to matters besides non-obviousness and enhancement. For one, Masimo’s [REDACTED]



\_\_\_\_\_ directly undercuts Masimo’s invalidity argument that there is only one possible design for the relevant features. *See, e.g.*, Ex. 5. Willfulness also may be relevant to irreparable harm and the balance of hardships for injunctive relief. *See, e.g., Bio-Rad Labs. v. 10X Genomics*, 967 F.3d 1353, 1378 (Fed. Cir. 2020) (affirming court’s reliance on verdict of willful infringement to find irreparable harm); *W. Plastics v. DuBose Strapping*, 2020 WL 5709250, at \*3 (E.D.N.C. Sept. 24, 2020) (on hardships, “[i]f any party caused mischief, [defendant] did so by willfully infringing”). Other relevant examples, such as exceptional cases, are conceded in Masimo’s brief. Moreover, it is unfair of Masimo to seek to prevent the jury from hearing about its copying while simultaneously stating or implying to the jury that the amount of Apple’s damages ask or other facts indicate Apple has an ulterior motive for suing Masimo.

Masimo’s cases miss the mark. *Johns Hopkins v. CellPro* does not say that “a finding of willfulness **relates only** to” enhancement, as Masimo claims. *See* 152 F.3d 1342, 1365 (Fed. Cir. 1998) (“willful infringement **does not mandate** that the district court enhance damages; it **merely authorizes** the court to do so”). Next, Masimo cites a damages retrial in *Apple v. Samsung* and speculates that the judge might not have admitted evidence of copying if liability was still at issue. But the liability trial record shows that the judge allowed Apple to present willfulness and copying evidence there. *See, e.g.*, Ex. 7 (Opening Statements) at 323:6-12. The evidence here also conforms with *Iron Grip* (e.g., “internal documents,” “disassembling,” and “access . . . and substantial similarity,” 392 F.3d 1317, 1325 (Fed. Cir. 2004)) and confirms that Masimo copied specific patented features and designs practiced by Apple Watch. This MIL should be denied.

Finally, and independently, this MIL should be denied as “an untimely and improper motion for summary judgment” of no willfulness, contrary to the Scheduling Order and District practice. *E.g., DataCore Software v. Scale Computing*, 2024 WL 3823001, at \*2 (D. Del. Aug. 14, 2024).

Dated: September 18, 2024

OF COUNSEL:

John M. Desmarais  
Cosmin Maier  
Jordan N. Malz  
Kerri-Ann Limbeek  
**DESMARAIS LLP**  
230 Park Avenue  
New York, NY 10169  
Tel: (212) 351-3400  
jdesmarais@desmaraisllp.com

Peter C. Magic  
**DESMARAIS LLP**  
101 California Street  
San Francisco, CA 94111  
Tel: (415) 573-1900  
pmagic@desmaraisllp.com

Jennifer Milici  
Dominic Vote  
**WILMER CULTER PICKERING  
HALE AND DORR LLP**  
2100 Pennsylvania Avenue NW  
Washington, DC 20037  
Tel: (202) 663-6000

Mark A. Ford  
**WILMER CULTER PICKERING  
HALE AND DORR LLP**  
60 State Street  
Boston, MA 02109  
Tel: (617) 526-6423

By: /s/ Bindu A. Palapura  
David E. Moore (#3983)  
Bindu A. Palapura (#5370)  
Andrew M. Moshos (#6685)  
**POTTER ANDERSON & CORROON LLP**  
Hercules Plaza, 6th Floor  
1313 N. Market Street  
Wilmington, DE 19801  
Tel: (302) 984-6000  
dmoore@potteranderson.com  
bpalapura@potteranderson.com  
amoshos@potteranderson.com

*Attorneys for Plaintiff/Counter-Defendant  
Apple Inc.*

**CERTIFICATE OF SERVICE**

I hereby certify that a copy of Apple Inc.'s Opposition to Masimo's Motion *In Limine* #2 was served upon counsel of record for Masimo Corporation and Sound United, LLC on September 18, 2024.

/s/ Jamie L. Kringstein

Jamie L. Kringstein

Apple's Opposition to Masimo's MIL No. 2 Exhibits Table				
Exhibit No.	PTX No.	Production BegBates No.	Production EndBates No.	Description
1	PTX-1507			Defendants Masimo Corporation and Sound United, LLC's Second Supplemental Response to Apple Inc.'s First Set of Interrogatories (No. 2) (-1378) (08-10-2023)
2	PTX-1470	MASITC_01379392	MASITC_01379392	
3	PTX-1132	MASITC_01379391	MASITC_01379391	
4	PTX-0630	MASAD00995550	MASAD00995550	
5	PTX-1236	MASAD02496985	MASAD02496991	
6	PTX-0495	MASAD01984659	MASAD01984660	
7				<i>Apple Inc. v. Samsung Elecs. Co. Ltd.</i> , N.D. Cal. Case No. 5:11-cv-01846-LHK, D.I. 1547, Transcript of Jury Trial Held July 31, 2012 (Opening Statements) (08-02-2012)

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

APPLE INC.,  <i>Plaintiff,</i>  v.  MASIMO CORPORATION and SOUND UNITED, LLC,  <i>Defendants.</i>	C.A. No. 22-1377-JLH  <b>JURY TRIAL DEMANDED</b>
MASIMO CORPORATION,  <i>Counter-Claimant,</i>  v.  APPLE INC.  <i>Counter-Defendant.</i>	
APPLE INC.,  <i>Plaintiff,</i>  v.  MASIMO CORPORATION and SOUND UNITED, LLC,  <i>Defendants.</i>	C.A. No. 22-1378-JLH  <b>JURY TRIAL DEMANDED</b>
MASIMO CORPORATION and CERCACOR LABORATORIES, INC.,  <i>Counter-Claimants,</i>  v.  APPLE INC.  <i>Counter-Defendant.</i>	

**REPLY IN SUPPORT OF MASIMO’S MOTION *IN LIMINE* #2  
TO PRECLUDE APPLE FROM PRESENTING EVIDENCE OR ARGUMENT  
REGARDING WILLFUL INFRINGEMENT OR COPYING**

Apple concedes that evidence of purported copying is irrelevant to infringement. *See* Opp. at 2 (“Apple is not arguing that point.”). Apple also never disputes that it seeks recovery under only § 289 for its design patent claims, which cannot be enhanced. *Id.* at 1-3. Thus, Apple should not present to the jury evidence of purported copying of Apple’s designs.

Apple’s three main arguments are wrong. First, Apple asserts, without support, that it seeks damages under § 284 for its utility patent claims. Opp. at 1. Recovery under § 284 is not available. *See* Masimo’s MIL #1. Apple inaccurately asserts that Masimo suggested “the Court may bifurcate willfulness into a separate post-verdict bench proceeding[.]” Opp’n at 1. Masimo merely argued that, where, as here, the only monetary relief at issue is under § 289, evidence regarding willfulness would be relevant only to issues for the Court. Br. at 2. If Apple wants to avoid requiring “the same fact witnesses to testify twice” (Opp. at 2), the parties could present such evidence to the Court during trial away from the jury.

Second, Apple tries to distinguish *Shure*, which excluded evidence of copying in a design patent case. Opp. at 2. Apple asserts that “[c]ourts regularly admit evidence of copying and willful infringement in similar circumstances.” *Id.* But Apple cites only irrelevant utility patent cases where enhanced damages under § 284 were available. *See Georgetown R. Equip. Co. v. Holland L.P.*, 867 F.3d 1229, 1244 (Fed. Cir. 2017) (§ 284 damages may be enhanced); *Nox Med. Ehf v. Natus Neurology*, 2018 WL 6629704 (D. Del. Apr. 12, 2018) (denying MIL), *id.* at 2018 WL 6427686, at \*1-\*4 (D. Del. Dec. 7, 2018) (declining to enhance § 284 damages).

Third, Apple argues that evidence of copying could rebut “that there is only one possible design for the relevant features.” Opp. at 3. But Masimo never made any such argument. Apple also argues copying could be relevant to legal issues for the Court. *Id.* (“injunctive relief” and “exceptional cases”). But that does not support presenting such evidence to the jury.

September 25, 2024

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

By: /s/ Kendall M. Loebbaka

Joseph R. Re  
Stephen C. Jensen  
Stephen W. Larson  
Benjamin A. Katzenellenbogen  
Edward M. Cannon  
Brian C. Claassen  
Jared C. Bunker  
Mark Lezama  
Kendall M. Loebbaka  
Douglas B. Wentzel  
Knobbe, Martens, Olson & Bear, LLP  
2040 Main Street, 14th Floor  
Irvine, CA 92614  
(949) 760-0404 Telephone  
(949) 760-9502 Facsimile  
joe.re@knobbe.com  
steve.jensen@knobbe.com  
stephen.larson@knobbe.com  
ben.katzenellenbogen@knobbe.com  
ted.cannon@knobbe.com  
brian.claassen@knobbe.com  
jared.bunker@knobbe.com  
mark.lezama@knobbe.com  
kendall.loebbaka@knobbe.com  
douglas.wentzel@knobbe.com

Brian Horne  
Knobbe, Martens, Olson & Bear, LLP  
1925 Century Park East, Suite 600  
Los Angeles, CA 90067  
(310) 551-3450 Telephone  
(310) 551-3458 Facsimile  
brian.horne@knobbe.com  
Adam Powell  
Daniel P. Hughes  
Knobbe, Martens, Olson & Bear, LLP  
3579 Valley Centre Drive, Suite 300  
San Diego, CA 92130

(858) 707-4000 Telephone  
(858) 707-4001 Facsimile  
adam.powell@knobbe.com  
Daniel.hughes@knobbe.com

Carol M. Pitzel Cruz  
Knobbe, Martens, Olson & Bear, LLP  
925 4th Ave., #2500  
Seattle, WA 98104  
206-405-2000 Telephone  
206-405-2001 Facsimile  
carol.pitzelcruz@knobbe.com

PHILLIPS MCLAUGHLIN & HALL, P.A.  
John C. Phillips, Jr. (No. 110)  
Megan C. Haney (No. 5016)  
1200 North Broom Street  
Wilmington, DE 19806  
(302) 655-4200 Telephone  
(302) 655-4210 Fax  
jcp@pmhdelaw.com  
mch@pmhdelaw.com

*Counsel for Defendant and Counter-Claimant  
Masimo Corporation; Defendant Sound United,  
LLC; and Counter-Claimant Cercacor  
Laboratories, Inc.*



### CERTIFICATE OF SERVICE

I hereby certify that on September 25, 2024, a true and correct copy of the foregoing document was served on the following counsel of record at the addresses and in the manner indicated:

***VIA ELECTRONIC MAIL:***

David E. Moore Bindu A. Palapura Andrew L. Brown Hercules Plaza, 6th Floor 1313 N. Market Street Wilmington, DE 19801 dmoore@potteranderson.com bpalapura@potteranderson.com abrown@potteranderson.com	John M. Desmarais Kerri-Ann Limbeek Cosmin Maier Jordan N. Malz Benjamin N. Luehrs Joze Welsh Jamie L. Kringstein Jennifer M. Przybylski Carson Olsheski Jeffrey Scott Seddon, II Amy I. Wann Raymond N. Habbaz Lee Matalon Taeg Sang Cho Eli Balsam Patrick Reilly Marie Weisfeiler Ryan G. Thorne Paul A. Bondor Desmarais LLP 230 Park Avenue, 26th Floor New York, NY 10169 jdesmarais@desmaraisllp.com klimbeek@desmaraisllp.com cmaier@desmaraisllp.com jmalz@desmaraisllp.com bluehrs@desmaraisllp.com jwelsh@desmaraisllp.com jkringstein@desmaraisllp.com jprzybylski@desmaraisllp.com colsheski@desmaraisllp.com jseddon@desmaraisllp.com awann@desmaraisllp.com rhabbaz@desmaraisllp.com lmatalon@desmaraisllp.com tcho@desmaraisllp.com
--	--

	<p>ebalsam@desmaraisllp.com  preilly@desmaraisllp.com  mweisfeiler@desmaraisllp.com  rthorne@desmaraisllp.com  pbondor@desmaraisllp.com</p>
<p>Peter C. Magic  Kyle Curry  Maria Tartakovsky  DESMARAIS LLP  101 California Street  San Francisco, CA 94111  pmagic@desmaraisllp.com  kcurry@desmaraisllp.com  mtartakovsky@desmaraisllp.com</p>	<p>Jennifer Milici  Dominic Vote  Leon B. Greenfield  Heath Brooks  John O'Toole  Wilmer Cutler Pickering Hale and Dorr LLP  2100 Pennsylvania Avenue NW  Washington, DC 20037  jennifer.milici@wilmerhale.com  dominic.vote@wilmerhale.com  leon.greenfield@wilmerhale.com  heath.brooks@wilmerhale.com  john.otoole@wilmerhale.com</p>
<p>Mark A. Ford  Vinita Ferrera  Wilmer Cutler Pickering Hale and Dorr LLP  60 State Street  Boston, MA 02109  mark.ford@wilmerhale.com  vinita.ferrera@wilmerhale.com</p>	<p>David J. Cho  David J. Shaw  Desmarais LLP  1899 Pennsylvania Avenue NW, Suite 400  Washington, DC 20006  dcho@desmaraisllp.com  dshaw@desmaraisllp.com</p>
<p>Lydia Turnage  Wilmer Cutler Pickering Hale and Dorr LLP  7 World Trade Center  250 Greenwich Street  New York, NY 10007  lydia.turnage@wilmerhale.com</p>	<p>Bethany Stevens  Hannah Cannom  Walker Stevens Cannom LLP  500 Molino Street, Suite 118  Los Angeles, CA 90013  bstevens@wscllp.com  hcannom@wscllp.com</p>
<p>Lauren Ige  Cristina Salcedo  Wilmer Cutler Pickering Hale and Dorr LLP  250 South Grand Avenue, Suite 2400  Los Angeles, CA 90071  lauren.ige@wilmerhale.com  cristina.salcedo@wilmerhale.com</p>	<p>IPservice@potteranderson.com</p>
<p>AppleMasimoService@desmaraisllp.com</p>	<p>whmasimoantitrustservice@wilmerhale.com</p>

September 25, 2024

/s/ Kendall M. Loebbaka  
Kendall M. Loebbaka

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

APPLE INC.,  <i>Plaintiff,</i>  v.  MASIMO CORPORATION and SOUND UNITED, LLC,  <i>Defendants.</i>	C.A. No. 22-1377-JLH  <b>JURY TRIAL DEMANDED</b>
MASIMO CORPORATION,  <i>Counter-Claimant,</i>  v.  APPLE INC.  <i>Counter-Defendant.</i>	
APPLE INC.,  <i>Plaintiff,</i>  v.  MASIMO CORPORATION and SOUND UNITED, LLC,  <i>Defendants.</i>	C.A. No. 22-1378-JLH  <b>JURY TRIAL DEMANDED</b>
MASIMO CORPORATION and CERCACOR LABORATORIES, INC.,  <i>Counter-Claimants,</i>  v.  APPLE INC.  <i>Counter-Defendant.</i>	

**MASIMO’S MOTION *IN LIMINE* #3  
FOR DETERMINATION OF ADMISSIBILITY OF PATENT OFFICE DECISIONS**

Masimo respectfully requests an *in limine* ruling regarding the admissibility of Patent Office decisions in this case that would apply equally to both sides' patents.

## **I. BACKGROUND**

Masimo filed petitions with the Patent Office seeking *inter partes* review ("IPR") of Apple's asserted patents. Apple responded by filing IPR petitions against Masimo's asserted patents. The Patent Office rendered decisions in some of the challenged patents and, between now and the October 21 trial on Apple's patents, the Patent Office is expected to issue decisions regarding the rest of Apple's patents.

Both sides proposed potential motions *in limine* to admit or exclude aspects of Patent Office proceedings. Apple asserted the parties should be able to introduce evidence and argument regarding Patent Office rulings on Apple's patents that Apple regards as favorable. Masimo proposed the parties agree that Patent Office decisions regarding both sides' patents be treated the same. Apple refused.

Accordingly, Masimo seeks a ruling regarding the admissibility of Patent Office proceedings that applies to all patents in this case.

## **II. ARGUMENT**

The Court has discretion to admit or exclude evidence relating to IPR proceedings. *See, e.g., Siemens Mobility Inc. v. Westinghouse Air Brake Techs. Corp.*, 2019 WL 77046, at \*1 (D. Del. 2019) (admitting evidence developed in IPR proceeding).

### **A. Arguments To The Patent Office Should Be Admissible**

Masimo explained in its claim construction brief (D.I. 294) that a patent owner's arguments during IPR proceedings to establish patentability are part of the prosecution history and can be relevant to the scope of the claimed designs. *See, e.g., Aylus Networks, Inc. v. Apple Inc.*, 856 F.3d

1353, 1360-61 (Fed. Cir. 2017) (appropriate to consider statements made by a patent owner during an IPR proceeding for claim construction); *Apple, Inc. v. Samsung Elecs. Co.*, 2012 WL 3071477, at \*9 (N.D. Cal. 2012) (“*Egyptian Goddess*’s description of the use of prosecution history in determining the scope of a design patent . . . allows for statements made during prosecution to be considered as intrinsic evidence.”).

The parties do not appear to dispute that, at a minimum, the Court should allow the parties to introduce representations and arguments made by a party during Patent Office proceedings. This rule should apply to all patents and all trials in this case.

**B. Patent Office Decisions Must Be Treated Equally**

Masimo also requests an *in limine* ruling regarding whether the parties can introduce representations and arguments regarding Patent Office decisions. Any ruling regarding the Patent Office decisions (e.g., institution or denial of institution) should apply to all patents and all trials in this case.

Respectfully submitted,

September 4, 2024

KNOBBE, MARTENS, OLSON & BEAR, LLP

By: /s/ Kendall M. Loebbaka

Joseph R. Re  
Stephen C. Jensen  
Stephen W. Larson  
Benjamin A. Katzenellenbogen  
Edward M. Cannon  
Brian C. Claassen  
Jared C. Bunker  
Mark Lezama  
Kendall M. Loebbaka  
Douglas B. Wentzel  
Knobbe, Martens, Olson & Bear, LLP  
2040 Main Street, 14th Floor

Irvine, CA 92614  
(949) 760-0404 Telephone  
(949) 760-9502 Facsimile  
joe.re@knobbe.com  
steve.jensen@knobbe.com  
stephen.larson@knobbe.com  
ben.katzenellenbogen@knobbe.com  
ted.cannon@knobbe.com  
brian.claassen@knobbe.com  
jared.bunker@knobbe.com  
mark.lezama@knobbe.com  
kendall.loebbaka@knobbe.com  
douglas.wentzel@knobbe.com

Brian Horne  
Knobbe, Martens, Olson & Bear, LLP  
1925 Century Park East, Suite 600  
Los Angeles, CA 90067  
(310) 551-3450 Telephone  
(310) 551-3458 Facsimile  
brian.horne@knobbe.com  
Adam Powell  
Daniel P. Hughes  
Knobbe, Martens, Olson & Bear, LLP  
3579 Valley Centre Drive, Suite 300  
San Diego, CA 92130  
(858) 707-4000 Telephone  
(858) 707-4001 Facsimile  
adam.powell@knobbe.com  
Daniel.hughes@knobbe.com

Carol M. Pitzel Cruz  
Knobbe, Martens, Olson & Bear, LLP  
925 4th Ave., #2500  
Seattle, WA 98104  
206-405-2000 Telephone  
206-405-2001 Facsimile  
carol.pitzelcruz@knobbe.com

PHILLIPS MCLAUGHLIN & HALL, P.A.  
John C. Phillips, Jr. (No. 110)  
Megan C. Haney (No. 5016)  
1200 North Broom Street  
Wilmington, DE 19806  
(302) 655-4200 Telephone

(302) 655-4210 Fax  
jcp@pmhdelaw.com  
mch@pmhdelaw.com

*Counsel for Defendant and Counter-Claimant  
Masimo Corporation; Defendant Sound United,  
LLC; and Counter-Claimant Cercacor  
Laboratories, Inc.*

### CERTIFICATE OF SERVICE

I hereby certify that on September 4, 2024, a true and correct copy of the foregoing document was served on the following counsel of record at the addresses and in the manner indicated:

***VIA ELECTRONIC MAIL:***

David E. Moore Bindu A. Palapura Andrew L. Brown Hercules Plaza, 6th Floor 1313 N. Market Street Wilmington, DE 19801 dmoore@potteranderson.com bpalapura@potteranderson.com abrown@potteranderson.com	John M. Desmarais Kerri-Ann Limbeek Cosmin Maier Jordan N. Malz Benjamin N. Luehrs Joze Welsh Jamie L. Kringstein Jennifer M. Przybylski Carson Olsheski Jeffrey Scott Seddon, II Amy I. Wann Raymond N. Habbaz Lee Matalon Taeg Sang Cho Eli Balsam Patrick Reilly Marie Weisfeiler Ryan G. Thorne Paul A. Bondor Desmarais LLP 230 Park Avenue, 26th Floor New York, NY 10169 jdesmarais@desmaraisllp.com klimbeek@desmaraisllp.com cmaier@desmaraisllp.com jmalz@desmaraisllp.com bluehrs@desmaraisllp.com jwelsh@desmaraisllp.com jkringstein@desmaraisllp.com jprzybylski@desmaraisllp.com colsheski@desmaraisllp.com jseddon@desmaraisllp.com awann@desmaraisllp.com rhabbaz@desmaraisllp.com lmatalon@desmaraisllp.com tcho@desmaraisllp.com
--	--



	<p>ebalsam@desmaraisllp.com  preilly@desmaraisllp.com  mweisfeiler@desmaraisllp.com  rthorne@desmaraisllp.com  pbondor@desmaraisllp.com</p>
<p>Peter C. Magic  Kyle Curry  Maria Tartakovsky  DESMARAIS LLP  101 California Street  San Francisco, CA 94111  pmagic@desmaraisllp.com  kcurry@desmaraisllp.com  mtartakovsky@desmaraisllp.com</p>	<p>Jennifer Milici  Dominic Vote  Leon B. Greenfield  Heath Brooks  John O'Toole  Wilmer Cutler Pickering Hale and Dorr LLP  2100 Pennsylvania Avenue NW  Washington, DC 20037  jennifer.milici@wilmerhale.com  dominic.vote@wilmerhale.com  leon.greenfield@wilmerhale.com  heath.brooks@wilmerhale.com  john.otoole@wilmerhale.com</p>
<p>Mark A. Ford  Vinita Ferrera  Wilmer Cutler Pickering Hale and Dorr LLP  60 State Street  Boston, MA 02109  mark.ford@wilmerhale.com  vinita.ferrera@wilmerhale.com</p>	<p>David J. Cho  David J. Shaw  Desmarais LLP  1899 Pennsylvania Avenue NW, Suite 400  Washington, DC 20006  dcho@desmaraisllp.com  dshaw@desmaraisllp.com</p>
<p>Lydia Turnage  Wilmer Cutler Pickering Hale and Dorr LLP  7 World Trade Center  250 Greenwich Street  New York, NY 10007  lydia.turnage@wilmerhale.com</p>	<p>Bethany Stevens  Hannah Cannom  Walker Stevens Cannom LLP  500 Molino Street, Suite 118  Los Angeles, CA 90013  bstevens@wscllp.com  hcannom@wscllp.com</p>
<p>Lauren Ige  Cristina Salcedo  Wilmer Cutler Pickering Hale and Dorr LLP  250 South Grand Avenue, Suite 2400  Los Angeles, CA 90071  lauren.ige@wilmerhale.com  cristina.salcedo@wilmerhale.com</p>	<p>IPservice@potteranderson.com</p>
<p>AppleMasimoService@desmaraisllp.com</p>	<p>whmasimoantitrustservice@wilmerhale.com</p>

September 4, 2024

/s/ Kendall M. Loebbaka  
Kendall M. Loebbaka

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

APPLE INC.,

Plaintiff,

v.

MASIMO CORPORATION AND SOUND  
UNITED, LLC,

Defendants.

C.A. No. 1:22-cv-1377-JLH

C.A. No. 1:22-cv-1378-JLH

---

MASIMO CORPORATION AND CERCACOR  
LABORATORIES, INC.,

Counterclaim-Plaintiffs,

v.

APPLE INC.,

Counterclaim-Defendant.

---

**APPLE’S OPPOSITION TO MASIMO’S MOTION *IN LIMINE* #3:  
FOR DETERMINATION OF ADMISSIBILITY OF PATENT OFFICE DECISIONS**

Masimo's motion *in limine* #3 does not seek to exclude any evidence from the October trial. Instead, it seeks a preemptive ruling on the treatment of IPRs in a trial of Masimo's patents that is not yet scheduled. Masimo's request is accordingly premature. In the October trial, this District's well-established rules restricting the admissibility of evidence from IPRs should apply. However, if Masimo seeks to make the counter-factual argument that the PTO would have rejected Apple's design patent applications had it been presented with evidence allegedly showing that the designs are "functional"—a predicate argument to Masimo's *Walker Process* "fraud" allegations—then Apple should be permitted to present the evidence necessary to show the PTO has already concluded otherwise.

As a general rule, courts in this District routinely prohibit parties from telling the jury about the existence of IPRs, the nature of the proceedings, or the PTAB's conclusions on patentability. *See, e.g., Pac. Biosciences of Cal., Inc. v. Oxford Nanopore Techs., Inc.*, 2020 WL 954938, at \*2 (D. Del. Feb. 27, 2020) (ruling IPR petition and expert declaration "may properly be used to impeach ... witnesses, provided that the parties reference them as being related to 'another matter,' without disclosing the nature, details, or results of the IPR"); *Liqwd, Inc. v. L'Oreal USA, Inc.*, 2019 WL 2648008, at \*1 (D. Del. June 26, 2019) ("There will be no references to any of these [PGR] proceedings during trial."); *Siemens Mobility Inc. v. Westinghouse Air Brake Techs. Corp.*, 2019 WL 77046, at \*1 (D. Del. Jan. 2, 2019) ("The jury will not be told anything about the existence of the IPRs or other litigations between the parties."); *Alarm.com, Inc. v. SecureNet Techs. LLC*, No. 1:15-cv-807, D.I. 242 at 3 (D. Del. Jan. 23, 2019) (Ex. 1) (granting MIL to preclude reference to IPR petitions and institution decisions, but denying MIL "to the extent that a witness's prior sworn statements in these actions may be used for purposes of

impeachment”). That rule should stand here.<sup>1</sup>

Here, however, Masimo appears intent on unfairly leveraging that general rule to make counterfactual statements about what the PTO would have done had it been presented with certain evidence. Should it attempt to do so, the Court should deem Masimo to have opened the door to Apple referencing the PTAB’s decisions finding that Apple’s claimed designs are not dictated by function. This potential scenario arises in the context of Masimo’s arguments relating to its inequitable conduct and *Walker Process* claims (if they survive summary judgment).

Specifically, one of Masimo’s inequitable conduct and *Walker Process* theories is that an Apple patent agent and 26 inventors all intentionally defrauded the PTO during prosecution of three asserted Apple design patents by allegedly withholding material facts purportedly showing that each element of Apple’s claimed designs is functional. No. 22-1377, D.I. 138 at 11-42; Ex. 2 at 60-139; Ex. 3 at 34-39. According to Masimo, the withheld information shows that Apple’s asserted patented designs are invalid as dictated by function, and thus, that information was purportedly material to patentability. To prove its claim, Masimo must demonstrate that the allegedly withheld information was *material to patentability*, meaning that had the PTO been aware of that information, it would not have issued the design patents. If Masimo tells the jury that the PTO would have found the allegedly withheld information material to patentability, then Apple should be permitted to present the real-world evidence refuting it—namely, that the PTO actually rejected this same argument in the context of denying Masimo’s IPR petitions.

Masimo made the same functionality arguments that it seeks to make to the jury in its IPR

---

<sup>1</sup> Masimo’s assertion that “a patent owner’s arguments during IPR proceedings ... can be relevant to the scope of the claimed designs” (Br. at 1-2) does not allow Masimo to present such claim construction evidence at trial, because claim scope is a question for the Court, not the jury. *See Eon Corp. IP Holdings v. Silver Spring Networks*, 815 F.3d 1314, 1319 (Fed. Cir. 2016).

petitions (Ex. 4 at 16-35; Ex. 5 at 16-34; Ex. 6 at 16-31)—and the PTAB decided in denying those petitions that Apple’s claimed designs were not dictated by function. In its decisions denying Masimo’s IPR petitions, the PTAB determined “the record amply demonstrates that there are multiple alternative designs for the rear face or surface of an electronic device that present a distinct visual appearance ... significant[ly] undermining [Masimo]’s assertion that the ... patent design should be regarded largely, if not entirely, as including elements that are purely functional.” Ex. 7 at 12; Ex. 8 at 10-11; Ex. 9 at 10-11.

Therefore, if Masimo opens the door at trial by arguing that the PTO would have rejected Apple’s asserted design patent claims as dictated by function had it been aware of information allegedly showing that features covered by the claimed designs perform functions, then the PTAB’s determinations to the contrary in its decisions denying institution of IPR on the same claimed designs should be admissible to show that the PTO actually would *not* have found that information material because the PTAB (which decides examination appeals) rejected that exact same argument in Masimo’s IPR petitions. Apple would present any such evidence within the confines of this District’s well-established rules regarding IPR evidence—i.e., by redacting the PTAB’s decisions in a manner showing rejection of the relevant argument while not disclosing the nature or outcome of the proceeding. *See, e.g., Siemens*, 2019 WL 77046, at \*1 (“[E]vidence that has been developed in an IPR ... may be used at trial, provided that it is done without referencing the IPR.”); *Pac. Biosciences*, 2020 WL 954938, at \*2 (permitting redactions to IPR documents “to eliminate confusing or unfairly prejudicial references”).

Dated: September 18, 2024

OF COUNSEL:

John M. Desmarais  
Cosmin Maier  
Jordan N. Malz  
Kerri-Ann Limbeek  
**DESMARAIS LLP**  
230 Park Avenue  
New York, NY 10169  
Tel: (212) 351-3400  
jdesmarais@desmaraisllp.com

Peter C. Magic  
**DESMARAIS LLP**  
101 California Street  
San Francisco, CA 94111  
Tel: (415) 573-1900  
pmagic@desmaraisllp.com

Jennifer Milici  
Dominic Vote  
**WILMER CULTER PICKERING  
HALE AND DORR LLP**  
2100 Pennsylvania Avenue NW  
Washington, DC 20037  
Tel: (202) 663-6000

Mark A. Ford  
**WILMER CULTER PICKERING  
HALE AND DORR LLP**  
60 State Street  
Boston, MA 02109  
Tel: (617) 526-6423

By: /s/ Bindu A. Palapura  
David E. Moore (#3983)  
Bindu A. Palapura (#5370)  
Andrew M. Moshos (#6685)  
**POTTER ANDERSON & CORROON LLP**  
Hercules Plaza, 6th Floor  
1313 N. Market Street  
Wilmington, DE 19801  
Tel: (302) 984-6000  
dmoore@potteranderson.com  
bpalapura@potteranderson.com  
amoshos@potteranderson.com

*Attorneys for Plaintiff/Counter-Defendant  
Apple Inc.*

**CERTIFICATE OF SERVICE**

I hereby certify that a copy of Apple Inc.'s Opposition to Masimo's Motion *In Limine* #3 was served upon counsel of record for Masimo Corporation and Sound United, LLC on September 18, 2024.

/s/ Jamie L. Kringstein

Jamie L. Kringstein

Apple's Opposition to Masimo's MIL No. 3 Exhibits Table		
Exhibit No.	PTX No.	Description
1		Alarm.com, Inc. v. SecureNet Techs. LLC, No. 1:15-cv-00807, D.I. 242 (D. Del. Jan. 23, 2019)
2	PTX-1576	Opening Expert Report of Vijay K. Madisetti, Ph.D. (11-22-2023) (excluding appendices and exhibits)
3	PTX-0671	Opening Expert Report of Robert Stoll (11-22-2023) (excluding exhibits)
4	PTX-0946	Masimo v. Apple, PTAB Case No. IPR2023-00774, Decision Denying Institution of Inter Partes Review (09-27-2023)
5	PTX-0947	Masimo v. Apple, PTAB Case No. IPR2023-00702, Decision Denying Institution of Inter Partes Review (09-27-2023)
6	PTX-0948	Masimo v. Apple, PTAB Case No. IPR2023-00728, Decision Denying Institution of Inter Partes Review (09-18-2023)
7	PTX-0979	Masimo v. Apple, PTAB Case No. IPR2023-00702, Petition for Inter Partes Review of U.S. Patent No. D947,842 (03-09-2023)
8	PTX-0980	Masimo v. Apple, PTAB Case No. IPR2023-00728, Petition for Inter Partes Review of US Patent No. D962,936 (03-16-2023)
9	PTX-0981	Masimo v. Apple, PTAB Case No. IPR2023-00774, Petition for Inter Partes Review of U.S. Patent No. D883,279 (03-24-2023)



**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

APPLE INC.,  <i>Plaintiff,</i>  v.  MASIMO CORPORATION and SOUND UNITED, LLC,  <i>Defendants.</i>	C.A. No. 22-1377-JLH  <b>JURY TRIAL DEMANDED</b>
MASIMO CORPORATION,  <i>Counter-Claimant,</i>  v.  APPLE INC.  <i>Counter-Defendant.</i>	
APPLE INC.,  <i>Plaintiff,</i>  v.  MASIMO CORPORATION and SOUND UNITED, LLC,  <i>Defendants.</i>	C.A. No. 22-1378-JLH  <b>JURY TRIAL DEMANDED</b>
MASIMO CORPORATION and CERCACOR LABORATORIES, INC.,  <i>Counter-Claimants,</i>  v.  APPLE INC.  <i>Counter-Defendant.</i>	

**REPLY IN SUPPORT OF MASIMO’S MOTION *IN LIMINE* #3  
FOR DETERMINATION OF ADMISSIBILITY OF PATENT OFFICE DECISIONS**

Apple argues that Masimo's motion is "premature." Opp. at 1. It is not. The parties raised the admissibility of IPR proceedings. Apple offers no reason why the Court should treat IPRs on some patents differently from IPRs on other patents in the same case. The admissibility of Patent Office proceedings should be the same for all patents. Br. at 1-2.

Apple purports to argue the Court should exclude IPR proceedings, but asserts that Masimo's arguments regarding functionality of Apple's design patents will "open[] the door" for Apple to rely on the same IPR rulings Apple claims should be excluded. Opp. at 2-3. Apple is wrong legally because, in the IPR, Masimo could not argue unpatentability due to functionality. *See* 35 U.S.C § 311(b) (IPR limited to grounds based on patents or printed publications). Thus, the IPR could not have decided that functionality evidence is, or would have been, immaterial.

Apple is wrong factually because Masimo will not make "the same functionality arguments" in this case that it made in the IPRs. Opp. at 2-3. Masimo will present at trial [REDACTED]

[REDACTED] *See, e.g.*, Ex. 3 at 34-35; Ex. 2 at 75-80, 88-91, 95-99, 102-105, 138-139. Masimo did not and could not have presented this evidence in the IPR. Discovery is limited in IPR proceedings, and Apple produced the evidence in this case only after Masimo filed its IPR petitions.

Regardless of whether the parties can refer to IPR proceedings generally, the Court should prevent Apple from falsely asserting that the IPR decisions suggest the information Apple concealed is immaterial. Such arguments would mislead the jury and require the parties to attempt to explain the differences in the legal arguments and factual record between the IPR proceedings and this case. *See* Ex. 1 at 3 (excluding IPR non-institution decisions under Rule 403); *Interdigital Commc's v. Nokia*, 2014 WL 8104167, at \*1 (D. Del. 2014) (same).

September 25, 2024

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

By: /s/ Kendall M. Loebbaka

Joseph R. Re  
Stephen C. Jensen  
Stephen W. Larson  
Benjamin A. Katzenellenbogen  
Edward M. Cannon  
Brian C. Claassen  
Jared C. Bunker  
Mark Lezama  
Kendall M. Loebbaka  
Douglas B. Wentzel  
Knobbe, Martens, Olson & Bear, LLP  
2040 Main Street, 14th Floor  
Irvine, CA 92614  
(949) 760-0404 Telephone  
(949) 760-9502 Facsimile  
joe.re@knobbe.com  
steve.jensen@knobbe.com  
stephen.larson@knobbe.com  
ben.katzenellenbogen@knobbe.com  
ted.cannon@knobbe.com  
brian.claassen@knobbe.com  
jared.bunker@knobbe.com  
mark.lezama@knobbe.com  
kendall.loebbaka@knobbe.com  
douglas.wentzel@knobbe.com

Brian Horne  
Knobbe, Martens, Olson & Bear, LLP  
1925 Century Park East, Suite 600  
Los Angeles, CA 90067  
(310) 551-3450 Telephone  
(310) 551-3458 Facsimile  
brian.horne@knobbe.com  
Adam Powell  
Daniel P. Hughes  
Knobbe, Martens, Olson & Bear, LLP  
3579 Valley Centre Drive, Suite 300  
San Diego, CA 92130  
(858) 707-4000 Telephone  
(858) 707-4001 Facsimile

adam.powell@knobbe.com  
Daniel.hughes@knobbe.com

Carol M. Pitzel Cruz  
Knobbe, Martens, Olson & Bear, LLP  
925 4th Ave., #2500  
Seattle, WA 98104  
206-405-2000 Telephone  
206-405-2001 Facsimile  
carol.pitzelcruz@knobbe.com

PHILLIPS MCLAUGHLIN & HALL, P.A.  
John C. Phillips, Jr. (No. 110)  
Megan C. Haney (No. 5016)  
1200 North Broom Street  
Wilmington, DE 19806  
(302) 655-4200 Telephone  
(302) 655-4210 Fax  
jcp@pmhdelaw.com  
mch@pmhdelaw.com

*Counsel for Defendant and Counter-Claimant  
Masimo Corporation; Defendant Sound United,  
LLC; and Counter-Claimant Cercacor  
Laboratories, Inc.*

### CERTIFICATE OF SERVICE

I hereby certify that on September 25, 2024, a true and correct copy of the foregoing document was served on the following counsel of record at the addresses and in the manner indicated:

***VIA ELECTRONIC MAIL:***

David E. Moore Bindu A. Palapura Andrew L. Brown Hercules Plaza, 6th Floor 1313 N. Market Street Wilmington, DE 19801 dmoore@potteranderson.com bpalapura@potteranderson.com abrown@potteranderson.com	John M. Desmarais Kerri-Ann Limbeek Cosmin Maier Jordan N. Malz Benjamin N. Luehrs Joze Welsh Jamie L. Kringstein Jennifer M. Przybylski Carson Olsheski Jeffrey Scott Seddon, II Amy I. Wann Raymond N. Habbaz Lee Matalon Taeg Sang Cho Eli Balsam Patrick Reilly Marie Weisfeiler Ryan G. Thorne Paul A. Bondor Desmarais LLP 230 Park Avenue, 26th Floor New York, NY 10169 jdesmarais@desmaraisllp.com klimbeek@desmaraisllp.com cmaier@desmaraisllp.com jmalz@desmaraisllp.com bluehrs@desmaraisllp.com jwelsh@desmaraisllp.com jkringstein@desmaraisllp.com jprzybylski@desmaraisllp.com colsheski@desmaraisllp.com jseddon@desmaraisllp.com awann@desmaraisllp.com rhabbaz@desmaraisllp.com lmatalon@desmaraisllp.com tcho@desmaraisllp.com
--	--

	<p>ebalsam@desmaraisllp.com  preilly@desmaraisllp.com  mweisfeiler@desmaraisllp.com  rthorne@desmaraisllp.com  pbondor@desmaraisllp.com</p>
<p>Peter C. Magic  Kyle Curry  Maria Tartakovsky  DESMARAIS LLP  101 California Street  San Francisco, CA 94111  pmagic@desmaraisllp.com  kcurry@desmaraisllp.com  mtartakovsky@desmaraisllp.com</p>	<p>Jennifer Milici  Dominic Vote  Leon B. Greenfield  Heath Brooks  John O'Toole  Wilmer Cutler Pickering Hale and Dorr LLP  2100 Pennsylvania Avenue NW  Washington, DC 20037  jennifer.milici@wilmerhale.com  dominic.vote@wilmerhale.com  leon.greenfield@wilmerhale.com  heath.brooks@wilmerhale.com  john.otoole@wilmerhale.com</p>
<p>Mark A. Ford  Vinita Ferrera  Wilmer Cutler Pickering Hale and Dorr LLP  60 State Street  Boston, MA 02109  mark.ford@wilmerhale.com  vinita.ferrera@wilmerhale.com</p>	<p>David J. Cho  David J. Shaw  Desmarais LLP  1899 Pennsylvania Avenue NW, Suite 400  Washington, DC 20006  dcho@desmaraisllp.com  dshaw@desmaraisllp.com</p>
<p>Lydia Turnage  Wilmer Cutler Pickering Hale and Dorr LLP  7 World Trade Center  250 Greenwich Street  New York, NY 10007  lydia.turnage@wilmerhale.com</p>	<p>Bethany Stevens  Hannah Cannom  Walker Stevens Cannom LLP  500 Molino Street, Suite 118  Los Angeles, CA 90013  bstevens@wscllp.com  hcannom@wscllp.com</p>
<p>Lauren Ige  Cristina Salcedo  Wilmer Cutler Pickering Hale and Dorr LLP  250 South Grand Avenue, Suite 2400  Los Angeles, CA 90071  lauren.ige@wilmerhale.com  cristina.salcedo@wilmerhale.com</p>	<p>IPservice@potteranderson.com</p>
<p>AppleMasimoService@desmaraisllp.com</p>	<p>whmasimoantitrustservice@wilmerhale.com</p>

September 25, 2024

/s/ Kendall M. Loebbaka  
Kendall M. Loebbaka